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Regarding global warming issue, the scientific revolution has nowadays tended to reduce the use 
of non-renewable resources and to avoid the productions of chemical wastes and pollutants, 
which represent major environmental issues. Therefore, the development of sustainable 
chemistry has become a major goal for chemists. In 1998, Anastas and Warner published the 12 
Principles of Green Chemistry to diminish the impact of chemical processes on the environment 
and health, and to guide the development of green chemistry technologies.[1] Catalysis emerges 
as one of these principles in order to prevent stoichiometric transformations and reduce the 
amount of chemical waste. Thus, catalysis plays an important role in organic synthesis, with broad 
applications to academia as well as industries.[2] 
 
1.1 Transition Metal-Catalyzed C–H Functionalization 
A major breakthrough in modern organic synthesis over five decades has been represented by 
transition metal-catalyzed C–C and C–Het bond formations, allowing for the preparation and the 
synthetic modification of natural products and biological active compounds, among others.[3] 
Well-known transition metal catalyses, such as the Kumada-Corriu,[4] Mizoroki-Heck,[5] 
Sonogashira-Hagihara,[6] Negishi,[7] Stille,[8] Suzuki-Miyaura,[9] and Hiyama[10] cross-couplings 
afford new C–C bond formation for arylations, alkylations, alkenylations, and alkynylations. Due 
to these reactions emerging as a powerful toolbox for molecular synthesis with broad applications 
in crop protection, material sciences, and drug discovery,[11] these innovative transformations 
were recognized with the Nobel Prize in Chemistry in 2010 to R. F. Heck, E.-i. Negishi, and A. 
Suzuki.[12] 
Despite this revolution in synthesis, cross-coupling reactions still display a number of drawbacks. 
First, a pre-functionalization of both substrates is obligatory, not only for organic (pseudo-)halides, 
but also for the employed organometallic reagents, which usually require multistep syntheses. 
Moreover, some of the nucleophiles are highly reactive and difficult to handle organometallic 
compounds, e.g. organomagnesium (RMgX) or organozinc (R2Zn), and toxic organotin reagents 
(RSnR’3) (Scheme 1). In addition to these operational issues, a generation of environmentally 
problematic metal-waste constitutes a disadvantage of traditional cross-coupling reactions. To 
avoid the use of these organometallic reagents, transition metal-catalyzed selective C–H 
functionalization has evolved as a powerful and sustainable method over the last decades 
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(Scheme 1).[13] Since the pre-functionlization for organometallic coupling partners is not 
necessary, the catalytic C–H activation strategy proves to be a more atom- and step-economical 
process. Furthermore, ideal oxidative C–H/C–H activations allow for the formation of new C–C 
bonds (Scheme 1).[13h, 14] Although the dehydrogenative transformation formally generates an 
equivalent of H2 as the sole by-product, the oxidative process of the twofold C–H activations 
typically requires stoichiometric amounts of an oxidant, often silver(I) salts. 
 
 
Scheme 1: General methods for the formation of C–C and C–Het bonds. 
  
Since the C–H activation strategy has become more attractive, the nature of C–H bond cleavage 
has been extensively examined. Excluding radical-type outer-sphere mechanisms,[15] several 
modes of C–H bond activation have been categorized in five different pathways, depending on the 
electronic properties and the coordination environment of the metal center (Scheme 2).[16] The 
oxidative addition of a C–H bond is a typical reaction mechanism for electron-rich late transition 
metals in low oxidation states, such as ruthenium(0), rhodium(I), and palladium(0) (Scheme 2a). 
In contrast, most late transition metals in higher oxidation states act preferentially through an 
electrophilic substitution (Scheme 2b). The concerted pathway proceeding through four-centered 
transition state in which two -bond cleavage and two new -bond formation without any overall 
change in the oxidation state of the metal center is called -bond metathesis. This pathway is 
observed for early transition metals as well as lanthanides and actinides (Scheme 2c).[17] The 
1,2-addition usually takes place for early transition metals with an unsaturated M=X bond, mostly 
metal imido complexes (Scheme 2d).[18] Moreover, the base-assisted C–H metalation occurs with 
metal-carboxylate or -carbonate complexes, leading to the formation of a new M–R bond (Scheme 
2e).[16a, 19] 




Scheme 2: Mechanistic pathways for C–H activations. 
 
The base-assisted mechanism was further investigated and different transition states were 
identified (Figure 1). The concerted metalation-deprotonation (CMD)[20] and the ambiphilic metal 
ligand activation (AMLA),[21] which propose through a six-membered transition state, 
preferentially take place for electron-deficient substrates. A more strained four-membered 
transition state has been coined the internal electrophilic substitution (IES), which is mostly 
observed in C–H activations enabled by metal-alkoxy complexes.[22] Recently, the base-assisted 
internal electrophilic substitution (BIES) has been frequently observed through an electrophilic 
substitution-type pathway for electron-rich substrates.[23]  
 
 
Figure 1: Proposed transition states for base-assisted C–H metalation. 
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Since C–H bonds are omnipresent in organic compounds with similar bond dissociations energies, 
site-selective functionalization has become a key challenge wthin the C–H activations concept. To 
conquer the regioselectivity issues, three different methods have been established (Figure 2).[24] 
The difference in reactivity among C–H bonds in heterocyclic compounds is highly related to their 
kinetic acidity, which leads to selective C–H transformations (Figure 2a).[25] The use of sterically 
hindered substituents in the substrate prevents the C–H activation process in the neighboring 
position, resulting in the selective functionalization of the less hindered C–H bond (Figure 2b).[26] 
However, the electronic or steric biased methods require specific substrates, which are considered 
as one of their drawbacks. The basic concept of proximity-induced C–H activation is representative 
of a general strategy for selective C–H transformations by using a Lewis-basic group  (Figure 2c).[27] 
The chelation-assistance through directing groups (DG) brings the metal complex into close 
proximity to the desired C–H bond, typically at the ortho position. Over the years, a variety of 
N-heterocyclic compounds and Lewis basic functional groups have been identified as the directing 
groups in ortho-selective C–H activations (Figure 3). 
 
 




Figure 3: Selected examples of directing groups in C–H activation catalysis. 
 
1.2 Ruthenium-Catalyzed Direct ortho-C–H Functionalizations 
Over the last decade, transition metal-catalyzed C–H functionalization has gained significant 
momentum with notable achievements by means of 4d and 5d metal catalysis.[28] In addition to 
precious transition metals, ruthenium catalysis has emerged as an effective and inexpensive 
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alternative for several transformations.[19b, 29] In particular, site-selective C–H functionalizations on 
arenes have become more attractive. 
 
1.2.1 ortho-C–H Alkylations 
In 1986, the first ruthenium-catalyzed C–H alkylation of phenol (1) was reported by Lewis and 
Smith (Scheme 3).[30] A triphenylphosphite was proven to be a transient directing group in the 
catalytic alkylation of phenol (1) with ethylene (2), affording the mono- and diethylated products 
4 and 5 at the ortho position. The reaction was performed under high pressure and temperature 
of 6.6 bar and 177 °C, respectively. 
 
 
Scheme 3: Direct C–H alkylation of phenol (1) with ethylene (2). 
 
Afterwards, the group of Murai successfully developed a general method for the ortho-C–H 
alkylations using [RuH2(CO)(PPh3)3] as the catalyst precursor (Scheme 4).[31] This effective protocol 
was applicable to a variety of aromatic ketones 6 and alkenes 7, affording the desired alkylated 
ketones 8 with excellent levels of regioselectivity. In spite of no mechanistic studies, the in situ 
formed five-membered cyclometalated ruthenium complex 9 was proposed as an intermediate in 
the catalytic transformation, which undergoes olefin insertion followed by reductive elimination 





Scheme 4: Ruthenium-catalyzed hydroarylations of ketones 6.  
 
In contrast to hydroarylations via sensitive ruthenium hydrides,[32] the method for carboxylate-
assisted direct alkylation of alkyl halides 11 was first reported by the group of Ackermann in 2009 
(Scheme 5).[33] The catalytic alkylations were proven to be applicable to arylpyridines, 
arylpyrazoles, and arylimines. Moreover, the well-defined [Ru(O2CAd)2(p-cymene)] provided a 
catalytic efficacy comparable to the standard reaction conditions. 
 
 
Scheme 5: Ruthenium-catalyzed direct C–H alkylations with primary alkyl bromides 11. 
 
Later, the versatility of carboxylate-assisted ruthenium-catalyzed ortho-C–H functionalization was 
mirrored by the direct alkylation of ketimines 14, followed by reduction in one-pot fashion, 
affording the ortho-alkylated benzylamines 15 (Scheme 6).[34] Experiments with isotopically 
labeled substrates were indicative of a reversible carboxylate-assisted C–H bond cleavage to form 
ruthenacycle 18 (Scheme 7). Oxidative addition with alkyl halide 11 followed by reductive 
1.2 Ruthenium-Catalyzed Direct ortho-C–H Functionalizations 
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Scheme 6: Sequential direct C–H alkylations of ketimines 14 followed by reduction. 
 
 




1.2.2 ortho-C–H Benzylations 
In continuation of the previous study, the group of Ackermann further demonstrated the power 
of carboxylate-assisted ruthenium catalysis, enabling ortho-selective C–H benzylations (Scheme 
8).[35] In addition to pyridines and pyrazoles, transformative oxazolines were employed as the 
directing group in these direct C–H benzylations. 
 
 
Scheme 8: Ruthenium(II)-catalyzed direct benzylations. 
 
1.2.3 ortho-C–H Arylations 
The group of Oi/Inoue developed ruthenium-phosphine catalysis for the first direct arylations of 
phenylpyridines in 2001 (Scheme 9).[36] Afterwards, the ruthenium catalysis under the same 
reaction condition allowed for ortho-selective arylation of synthetically useful ketimines,[37] 
oxazolines, and imidazolines.[38] The catalytic arylations selectively occurred at the less sterically-
hindered ortho position when meta-substituted arenes were employed. It is noteworthy that 
impurities in NMP solvent exerted a major influence on the catalytic efficacy of ruthenium 
catalysis, leading to a lack of reproducibility.[39] 




Scheme 9: Ruthenium-catalyzed direct C–H arylations. 
 
In 2011, the modified direct arylation protocol with KOAc as the key additive enabled the 
formation of biaryl 27 on a multikilogram scale, as was demonstrated by the group of Ouellet 
(Scheme 10).[39] Oxazoline 27 was smoothly converted to benzyl alcohol 28, which is an 
intermediate in the synthesis of Anacetrapib (29), a CETP inhibitor.  
 
 




In addition to ruthenium-phosphine catalysis, a simple RuCl3·nH2O (30) catalyst allowed for 
ortho-selective C–H arylations under phosphine-free conditions, as was reported by the group of 
Ackermann in 2007 (Scheme 11).[40] The uncommon ruthenium(III)-catalyzed C–H activations were 
applicable to 2-alkenyl or 2-arylpyridines, 2-aryloxazoline, and arylpyrazoles. 
 
 
Scheme 11: Direct arylations by RuCl3·nH2O (30) as a catalyst. 
 
In 2008, the group of Ackermann disclosed the first general and robust method for ruthenium(II)-
catalyzed direct C–H arylations using carboxylic acids as additives (Scheme 12).[41] Sterically 
hindered MesCO2H (31) proved to be an efficient additive in nonpolar solvent, PhMe, whereas 
phosphines and NHC ligands provided low catalytic efficacy. The ruthenium-carboxylate catalysis 
verified to be applicable to various aromatic substrates 10. In particular, 1,2,3-triazoles, which are 
found in broad applications in drug discovery, crop protection, and material sciences, were simply 
converted to the ortho-arylated products 24.[42] Furthermore, the C–H bond cleavage process was 
proposed to occur through a base-assisted metalation, involving a six-membered cyclic transition 
state 32.    
 




Scheme 12: Ruthenium-carboxylate catalysis for direct arylations through transition state 32. 
 
Afterwards, mechanistic insights of ruthenium-catalyzed ortho-arylations were studied.[43] 
Stoichiometric experiments of [RuCl2(p-cymene)]2 and MesCO2H (31) led to the formation of the 
well-defined [Ru(O2CMes)2(p-cymene)] (33), which was highly effective for the catalytic arylations. 
Although ruthenium biscarboxylate complex 33 exhibited no reaction with aryl chloride, the 
reaction of complex 33 with 2-(4-methoxyphenyl)pyridine afforded the corresponding 
cyclometalated complex, which showed high catalytic efficacy in the arylation reactions. 
Furthermore, an observed H/D scrambling was indicative of a reversible, carboxylate-assisted       
C–H ruthenation, as shown in Scheme 13. Ruthenacycle 36 reacts with aryl halide 23 to form 
putative ruthenium(IV) intermediate 37, which finally undergoes reductive elimination to give the 





Scheme 13: Proposed catalytic cycle for direct arylations. 
 
Thereafter, the group of Ackermann reported on a modified ruthenium-carboxylate catalysis, 
which allowed for the direct arylations of aryltetrazoles 39 (Scheme 14a).[44] In addition to the 
commercially available carboxylic acids,[44b] the use of monoprotected amino acid (MPAA) 
Piv-Val-OH (41) in ruthenium catalysis smoothly afforded the corresponding biaryl tetrazoles 
42,[44a] which are core structures of angiotensin II receptor blockers (ARBs). In particular, the 
powerful C–H arylations enabled the concise synthesis of antihypertensive Valsartan (44), as 
illustrated in Scheme 14b.  




Scheme 14: Direct arylations of protected tetrazoles 39 using Piv-Val-OH (41) as a ligand and 
their application for synthesis of Valsartan (44). 
 
In 2017, the group of Larrosa reported on direct C–H arylations of benzoic acids 45 and aryl iodides 
46 using a cationic ruthenium(II) complex 47 (Scheme 15).[45] It is noteworthy that the addition of 
potassium perfluoro-tert-butoxide enhanced the catalytic efficacy. 
 
 




Subsequently, the cyclometalated ruthenium complex 49 allowed for the catalytic arylations at 
mild reaction temperature of 35–50 °C (Scheme 16).[46] In the presence of carboxylate salts, the 
power of the ruthenium catalysis was reflected by late-stage C–H arylations of relevant 
pharmaceuticals and natural products. 
 
 
Scheme 16: Late-stage direct arylations of pharmaceuticals and natural products. 
 
1.2.4 ortho-C–H Halogenations 
In addition to the new C–C bond formations, the protocol for ruthenium-catalyzed direct 
brominations and iodinations of tertiary amides 50 was illustrated by the group of Ackermann in 
2014 (Scheme 17).[47] Both experiments with 2,6-di-tert-butylpyridine and TEMPO were suggestive 
of a single-electron transfer mechanism for the catalytic C–H halogenations. 
 




Scheme 17: ortho-Selective C–H halogenations of amides 50. 
 
1.3 Ruthenium-Catalyzed Remote meta-C–H Functionalizations 
In contrast to a plethora of reports on ortho-C–H transformations, methods for the site-selective 
C–H bond activations at the meta position continue to be in high demand. Among those reports 
on meta-selective C–H functionalizations, they were classified into five categories (Figure 4).[48] 
First, the use of bulky substituents on the aromatic substrates can block the activation of C–H 
bonds in the adjacent positions,[49] leading to the C–H transformation at a less sterically-hindered 
meta position (Figure 4a).[50] However, this method is restricted to few transformations, mainly 
borylation or silylation. On the basis of chelation-assistance, the installation of a template on the 
arenes assists the coordination of the catalyst to come into close proximity to the targeted C–H 
bond at the meta or para position (Figure 4b).[51] Although the template assistance[52] is one of the 
favorite methods for remote functionalizations, the template design, installation, and subsequent 
removal require the number additional synthetic steps, which is addressed as the drawback of this 
strategy. The third method developed by Kuninobu/Kanai is a reversible hydrogen bonding linker, 
enabling C–H borylations at the meta position (Figure 4c).[53] However, the limitation to iridium 
catalysis and specific transformations is a weakness of this method. Inspired by the Catellani 
reaction,[54] norbornene and derivatives are employed as effective transient mediators to promote 
palladium-catalyzed meta-selective C–H transformations (Figure 4d).[55] Finally, the in situ formed 
cyclometalated ruthenium complexes by proximity-induced ortho-C–H metalation allow for the 
remote C–H functionalizations at the para position with respect to ruthenium (Figure 4e).[56] This 
phenomena is explained by the electronic bias of the ruthenacycles, identifying the Ru–C bond as 




Figure 4: Methodologies for remote meta-C–H activations. 
 
The inspiration for the ruthenium-catalyzed remote C–H functionalizations results from the 
reports on stoichiometric nitration of ruthenium aryl complexes by Roper/Wright in 1994 (Scheme 
18).[57] The C–H nitrations of o-tolyl ruthenium complex 53 selectively occurred at the position 
para to the ruthenium metal center (Scheme 18a). In contrast, the reaction of p-tolyl ruthenium 
complex 56 led to the formation of very stable five-membered ruthenacycle 57 (Scheme 18b). The 
results were presumably clarified by ortho/para-directing effect of the metal center. 
 
 
Scheme 18: Stoichiometric C–H nitrations. 
 
Later, the first chelation-assisted oxidative remote C–H/C–H functionalization was illustrated by 
the group of van Koten (Scheme 19).[58] The treatment of the cationic ruthenium complex 58 with 
CuCl2 furnished the formation of a binuclear complex 59 and small amounts of chlorinated 
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ruthenium complex 60. It is noteworthy that the reduced form of 59 strongly displayed electron 
resonance between the two metal centers through an ideally planar 4,4’-biphenyldiyl bridge. 
 
 
Scheme 19: Oxidative homocoupling of ruthenium complex 58. 
 
In addition, the group of Coudret reported on site-selective electrophilic C–H halogenations of 
cyclometalated ruthenium complex 61 at room temperature (Scheme 20a).[59] 
N-Bromosuccinimide (NBS, 62) proved to be an efficient brominating agent, whereas 
N-iodosuccinimide (NIS) led to complex degradation. The treatment of complex 61 with the 
combination of molecular iodine and PhI(OAc)2 smoothly delivered the desired iodinated 
ruthenacycle 63b. Afterwards, Roper and Wright disclosed highly selective C–H brominations of 
arenes on the ruthenium and osmium complexes 64 (Scheme 20b).[60] The electrophilic 
substitutions using operational-simple pyridinium perbromide and a catalytic amount of iron 
powder occurred at the para position with respect to metal centers. Furthermore, the same 
regioselectivity was observed in brominations of metallacycles 66, while no substitution occurred 
on the non-activated arene.[60a] This observation was suggestive of electronic directing effect of 




Scheme 20: Electrophilic C–H halogenations of cyclometalated complexes. 
 
1.3.1 meta-C–H Alkylations 
The first observation for catalytic remote C–H functionalization was reported by the group of 
Ackermann in 2011 (Scheme 21).[34] Chelation-assisted C–H alkylations with primary alkyl 
bromides typically furnished the ortho-alkylated products. However, the catalytic transformation 
of phenylpyridine 68a with 1-bromohexane (69) delivered the ortho-alkylated product 70 along 
with the unprecendented meta-decorated arene 70’, albeit in rather low yield. 
 
 
Scheme 21: Ruthenium-catalyzed C–H alkylation with n-hexyl bromide (69). 
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Inspired by the first observation, the group of Ackermann thereafter disclosed the methods for 
remote meta-C–H alkylations using secondary alkyl bromides 72 through an ortho-ruthenation 
strategy (Scheme 22).[61] The catalytic remote alkylations were applicable to pyridines, 
pyrimidines, and azoles as directing groups, leading to the formation of meta-alkylated arenes 73 
with excellent levels of position-selectivity (Scheme 22a). Detailed mechanistic studies of this 
remote functionalization were supportive of a reversible C–H ruthenation and a subsequent 
site-selective alkylation, which was rationalized by the strong electronic effect of the Ru–C(sp2) 
-bond. It is noteworthy that the enantiomerically-enriched alkyl bromide (s)-72a was converted 
to the racemic product 73a (Scheme 22b). 
 
 
Scheme 22: Remote meta-C–H alkylations with secondary alkyl bromides 72. 
 
In 2015, carboxylate-assisted ruthenium catalysis enabled tertiary meta-C–H alkylations was 
concurrently investigated by the group of Ackermann[62] and Frost[63] (Scheme 23). The highlight 
of Ackermann’s protocol was the use of monoprotected amino acids 41 (MPAA) as the carboxylate 
ligand for the first time in ruthenium-catalyzed C–H activation (Scheme 23a). Furthermore, the 
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power of the effective transformations was reflected by broadly applicable directing groups. 
Particularly, removable N-pyrimidyl anilines were efficiently converted to the corresponding 
products 75. Notably, the catalytic reactions with commercially available and less reactive tertiary 
alkyl chlorides 74a under Frost’s conditions provided the desired product 76 with high catalytic 
efficacy (Scheme 23b).  
 
 
Scheme 23: Remote C–H transformations with tertiary alkyl halides 74. 
 
Mechanistic experiments by Ackermann, such as reactions with radical scavengers, reactions with 
diastereomerically pure alkyl bromides, and radical clock experiments, were supportive of a 
radical mechanism.[62] Based on such findings, the following catalytic cycle was proposed by 
Ackermann (Scheme 24). The in situ generated ruthenium complex 77 initially undergoes a 
reversible C–H ruthenation to form cyclometalated ruthenium intermediate 78. Single-electron 
transfer from ruthenium(II) to alkyl halide 74 provides the corresponding radical 79, which attacks 
on the arene at the para position with respect to the Ru–C bond to form radical intermediate 80. 
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Then, rearomatization and hydrogen-atom abstraction afford the ruthenacycle intermediate 81. 
Finally, complex 81 undergoes protodemetalation, delivering the meta-alkylated product 82 and 
regenerating the catalytically active complex 77.  
 
 
Scheme 24: Proposed catalytic cycle for remote C–H alkylations via ortho-ruthenation. 
 
Since organofluorine compounds display an important role in agrochemicals, pharmaceuticals, 
and material sciences,[64] the installation of fluorine-containing groups has been of interest during 
the past decade.[65] In 2017, the group of Ackermann reported on the first remote meta-C–H 
mono- and difluoromethylations by the cooperative action of phosphine and carboxylate ligands 
in ruthenium(II) catalysis (Scheme 25a).[66] Later, the group of Wang disclosed a dual ruthenium 




Scheme 25: Ruthenium catalysis for remote mono- and difluoromethylations. 
 
1.3.2 meta-C–H Benzylations 
Although the benzyl radical is more stable than the alkyl radicals, the ruthenium catalysis of 
primary benzyl chlorides enabled direct ortho-C–H benzylations.[35] Taking into account atom- and 
step economical C–H/C–H activations[14] for the formation of new C–C bonds, oxidative 
ruthenium-catalyzed remote C–H benzylations of toluene derivatives 87 using 
di-tert-butylperoxide (DTBP) as a radical initiator were illustrated by the group of Shi/Zhao 
(Scheme 26a).[68] Even though the pre-functionalized substrates are not obligatory for the                
C–H/C–H activations, an excess of toluene derivative 87 is mandatory in the catalytic benzylations. 
Ru(PPh3)3Cl2 catalyst provided the direct benzylated products 88 without additional ligands. 
Among the additive ligands, the combination between RuCl3 and (±)-BNDHP was the most 
effective catalytic system, switching the site-selectivity of the oxidative C–H/C–H benzylations 
from ortho (88) to meta (89). Simultaneously, the group of Shi also reported on oxidative 
benzylations using perfluoroisopropyl iodide as a radical generator (Scheme 26b).[69]  




Scheme 26: Oxidative ruthenium-catalyzed C–H/C–H benzylations with toluene derivatives 87. 
 
1.3.3 meta-C–H Carboxylations 
Carboxylation reactions are powerful methods for introducing a C-1 moiety into target 
molecules.[70] In 2017, the group of Greaney disclosed meta-selective carboxylation through a 
single-electron transfer process (Scheme 27).[71] Ruthenium-catalyzed meta-C–C bond formation 
followed by methanolysis was applicable to various arylheteroarenes, such as 2-arylpyridines 
(68b), 2-arylpyrimidines, and 6-arylpurines, thus affording meta-decorated arenes 92. 
 
 
Scheme 27: Ruthenium-catalyzed remote C–H carboxylation with CBr4. 
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1.3.4 meta-C–H Acylation 
Recently, the group of Wang demonstrated a protocol for oxidative meta-C–H acylations, as 
shown in Scheme 28.[72] In the presence of a silver salt and a persulfate oxidant, the ketoacids 93 
underwent oxidative decarboxylation to furnish an acyl radical, which is the key intermediate in 
the remote transformations. Radical intermediate selectively attacked on the arene of the in situ 
formed cyclometalated ruthenium complexes, leading to the formation of new meta-C–C bonds. 
 
 
Scheme 28: Remote C–H acylations via oxidative decarboxylation. 
 
1.3.5 meta-C–H Sulfonylation 
In addition to C–C bond, site-selective C–Het bond formation reactions have gained considerable 
attention over the last decade.[73] On the basis of remote functionalizations of ruthenacycles, the 
group of Frost first reported on a meta-selective C–H sulfonylation of 2-arylpyridines 68 and 
arylsulfonyl chlorides 95 in 2011 (Scheme 29).[74] Chelation-assisted C–H ruthenation led to the 
formation of a Ru–C bond, which exerts a strong para-directing effect for the subsequent 
proposed electrophilic sulfonylation. 
 




Scheme 29: meta-C–H Sulfonylations of phenylpyridines 68 with sulfonyl chlorides 95. 
 
Afterwards, mechanistic experiments of meta-C–H sulfonylations were studied in more detail to 
unravel the catalyst working mode of such remote transformations.[75] It is noteworthy that the 
yields for the meta-sulfonylation of 2-phenylpyridine (68b) with p-tosyl chloride (95a) in the latter 
report[75] remarkably dropped from 80% to 50%, compared to the identical reaction conditions 
published earlier.[74] Among a series of well-defined cyclometalated ruthenium complexes in the 
catalytic sulfonylations, p-cymene-free ruthenacycle 98 provided a similar catalytic efficacy.[75] 
Moreover, dissociation of the p-cymene was observed during the course of the reaction by 
1H-NMR spectroscopy, which suggested cyclometalated complex 98 to be an active catalyst for 
this reaction. Reactions with various sulfonating agents and an experiment with radical scavenger 
TEMPO revealed that the catalytic sulfonylations likely proceeded via a radical mechanism, 
whereas a previously proposed electrophilic pathway could be ruled out. This is in good 
agreement with single-electron transfer (SET) mechanism for ruthenium-catalyzed 
meta-alkylation, which was earlier reported by the group of Ackermann.[62] On the basis of their 
findings, the catalytic cycle for remote sulfonylations was proposed,[75] which commences by C–H 
ruthenation followed by decoordination of p-cymene to form cationic cyclometalated complex 98 
(Scheme 30). Sulfonyl radical 99, which is generated from SET process from ruthenium(II), attacks 
at the position para to the Ru–C bond to form intermediate 100. Rearomatization followed by 
ligand replacement furnish cationic ruthenium 102, which undergoes demetalation and C–H 




Scheme 30: Proposed catalytic cycle for meta-sulfonylation. 
 
1.3.6 meta-C–H Brominations 
Since aryl halides are typically used as starting materials for arylation reactions, a number of 
methods for direct C–H halogenation have been reported.[76] However, general methods for 
meta-selective halogenations continue to be scarce. In 2015, the group of Greaney disclosed 
ruthenium-catalyzed meta-C–H brominations of 2-phenylpyridine (68b) (Scheme 31a).[77] 
Tetrabutylammonium tribromide (103) was proven to be the most effective for remote 
brominations in Greaney’s protocol. The synthetic utility of meta-brominations was reflected by 
late-stage transformations of the obtained adducts by Suzuki-Miyaura and Heck reactions in 
one-pot fashion, furnishing the meta-arylated product 105 or meta-alkenylated product 106, 
respectively (Scheme 31b). 




Scheme 31: Remote C–H brominations and sequential transformations. 
 
Concurrently, the group of Huang also reported on remote C–H brominations using 
N-bromosuccinimide (NBS, 62) as a bromine source (Scheme 32a).[78] In addition to 
palladium-catalyzed coupling reactions, the power of meta-brominations was highlighted by the 
concise synthesis of anti-cancer drug Vismodegib (109), as shown in Scheme 32b. The sequential 
meta-bromination followed by ortho-chlorination in one-pot fashion delivered the desired 
intermediate 107, which underwent copper-catalyzed amidation and substituent replacement to 
furnish the target molecule Vismodegib (109). Moreover, the cross-over H/D scrambling 
experiment suggested biscyclometalated complex as the key intermediate in the catalytic 
brominations. Remote meta-bromination was fully inhibited by the addition of radical scavenger 





Scheme 32: Ruthenium-catalyzed meta-brominations and synthesis of Vismodegib (109). 
 
1.3.7 meta-C–H Nitrations 
The nitro group is a strongly electron-withdrawing group, which is frequently found in drug and 
material sciences.[79] Therefore, site-selective nitrations are in high demand.[80] The group of Zhang 
reported for the first time on a ruthenium-catalyzed meta-C–H nitration using Cu(NO3)2·3H2O 
(110) (Scheme 33a).[81] The protocol for meta-nitrations was applicable to various directing group, 
such as pyridines, pyrimidines, pyrazoles, and ketoximes. Transformations of the obtained product 
111a led to the concise synthetic pathway of a marketed drug, Vismodegib (109), and a CDK/CK1 
dual inhibitor (R)-DRF053 (115) (Scheme 33b). On the basis of their mechanistic findings, a 
plausible mechanism commences by the formation of biscyclometalated ruthenium complex 116 
(Scheme 34). Nitrogen dioxide radical, which is generated from anion exchange and a 
silver-mediated radical process, attacks on the arene at para to Ru–C bond, providing ruthenium 
intermediate 117. Afterwards, oxidative rearomatization and ligand exchange afford the desired 
product 111a and regenerate the active catalyst 116.  









Scheme 34: Proposed catalytic cycle for ruthenium-catalyzed meta-nitrations. 
 
Later, the group of Zhang improved the remote nitration protocol for transformable ketoximes 
119 by using PhI(TFA)2 as oxidant under an oxygen atmosphere (Scheme 35a).[82] Under the 
standard conditions, a monomeric octahedral ruthenium(II) complex 122 was isolated and 
confirmed by X-ray crystallography. Catalytic and stoichiometric reactions as well as DFT 
calculations prove ruthenacycle 122 to be an active intermediate in the catalytic nitration. 
Thereafter, a modified method using sterically hindered trimesitylphosphine was shown to be 
effective for the meta-nitration of 6-arylpurines 123a and nucleosides (Scheme 35b).[83] 




Scheme 35: Ruthenium-catalyzed remote C–H nitrations of ketoximes 119 and purines 123a. 
 
1.4 Ruthenium-Catalyzed Remote para-C–H Functionalizations 
In contrast to the significant progress in meta-selective C–H transformations, challenging     
para-C–H functionalizations remain scarce. According to transition metal catalysis for 
para-selectivity, it can be achieved by three possible methodologies (Figure 5).[48b, 48c] The use of 
bulky ligand coordinated with iridium catalyst allowed for para-C–H borylations (Figure 5a).[84] It 
is noteworthy that the site-selectivity at the para position increased when sterically hindered 
substituents on the arene were employed. Moreover, cation/anion pairing can prevent meta-C–H 
activation, leading to C–H bond cleavage at the para position.[85] Nevertheless, this strategy is 
limited to iridium-catalyzed borylations. On the basis of proximity-induced C–H activation, the 
designed templates were installed to the target molecules, guiding the metal catalyst to be close 
to the desired C–H bond (Figure 5b).[51a, 86] The positional selectivity is directly controlled by the 
shape of the design template, enabling remote meta- or para-functionalizations. In addition, the 
electronic bias at the arene ring of cyclometalated ruthenium complexes leads to remote C–H 




Figure 5: Methodologies for remote para-C–H activations. 
 
In 2017, the groups of Frost disclosed a ruthenium-catalyzed para-C–H functionalizations, leading 
to remote alkylations of α-bromo esters 126 (Scheme 36).[87] To avoid the second remote 
alkylation on the pyrimidine ring, chloro-substituent pyrimidine 125a was employed in the remote 
transformations, smoothly delivering the corresponding para-alkylated adduct 127. Mechanistic 
insights by experiments and DFT calculations were suggestive of a four-membered ruthenacycle 
128 as the key intermediate. 
 
 
Scheme 36: Ruthenium-catalyzed para-C–H alkylations with α-bromo esters 126. 
 
Thereafter, ruthenium-catalyzed para-C–H fluoroalkylations of anilides 129 with α-bromo esters 
84a were demonstrated by Zhao/Lan (Scheme 37a).[88] The combination between AgNTf2 and 
carboxylic acid additive 12 under harsh reaction conditions of 120 °C selectively afforded the 
desired products 130. Under the standard reaction conditions, 2-phenylpyridine (68b) was 
converted to the meta-difluoromethylated product, whereas the site-selectivity of 
phenylpyrazoles was controlled by the electron density of pyrazole rings. These findings were 
indicative of the electronic influence of the cyclometallic C–N bond on the para position. 
Moreover, the same group later employed similar reaction conditions for remote transformations 
of ketoximes 119 (Scheme 37b).[89] It is noteworthy that the well-defined monocylometalated 
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ruthenium complex 132 was proven to be the active intermediate by catalytic and stoichiometric 
experiments as well as DFT calculations.  
 
 





On the basis of sustainable chemistry, transition metal-catalyzed C–H activation has been 
recognized as a powerful platform in organic synthesis, accessing the selective formations of C–C 
and C–Het bonds.[13, 90] Control of site-selectivity is one of the key challenges for synthetically 
useful C–H transformations.[24a] Thus, the concept of chelation-assistance unravels the positional 
selectivity, enabling the functionalization of arenes at the ortho position.[27a, 27b] 
Beside precious transition metals, ruthenium offers a highly reactive and cost-effective catalyst, 
with broadly transformative applications. Due to the distinctive character of the cyclometalated 
complexes, ruthenium catalysis accomplished the selective C–H transformations of arenes at the 
ortho,[29e] meta,[56b] or para positions.[87-89] However, the reports on ruthenium-catalyzed remote 
meta-C–H activations are limited to alkylations, sulfonylation, and nitrations. Since aryl halides are 
typically employed as starting materials in several catalytic transformations, a protocol for a 
meta-selective C–H bromination should be investigated (Scheme 38). 
 
 
Scheme 38: Ruthenium-catalyzed romote meta-C–H brominations of purines 123. 
 
In addition, efficient protocols for ruthenium-catalyzed remote alkylations are generally restricted 
to strongly-coordinating directing groups, such as pyridines, pyrimidines, and pyrazoles.[61, 63] 
Inspired by the report from the group of Ackermann on remote alkylations of removable 
N-pyrimidyl anilines,[62] transformable ketimines 135 should be studied in remote meta-C–H 
functionalization (Scheme 39). Additionally, further modifications of the obtained products 137 






Scheme 39: Remote C–H alkylations of ketimines 135 and further transformations. 
 
Typically, methods for remote C–H transformations require high reaction temperature of           
100–120 °C.[56b] The synergistic ruthenium catalysis with phosphine ligands furnishing remote 
meta-C–H mono- or difluoromethylations at lower temperature of 60 °C, was demonstrated by 
the group of Ackermann.[66] Thus, the power of carboxylate-phosphine ruthenium catalysis should 
be further explored with α-bromo carbonyl compounds 140 and benzyl chlorides 142 (Scheme 
40). Furthermore, detailed mechanistic insights should be investigated to rationalize the site-
selectivity of C–C bond formations and to better understand the reaction mechanism. 
 
 
Scheme 40: Carboxylate-phosphine ruthenium catalysis for remote alkylation and benzylation. 
 
Besides numerous reports on C–H functionalizations, a ruthenium-catalyzed decarbamoylative 
arylation of aromatic amides was illustrated by the group of Ackermann.[91] Therefore, a concept 
of ruthenium-catalyzed C–C activation should be applied for site-selective alkylations of primary, 




Scheme 41: Ruthenium catalysis for decarboxylative alkylations. 
 
Since unprecedented ortho-alkylations of bromocyclohexane and bromonorbornane were 
observed in decarboxylative reactions, ruthenium-catalyzed C–H transformations of pyrazole 
derivatives 147 with a variety of secondary alkyl bromides 148 should be explored (Scheme 42). 
Moreover, mechanistic experiments should be conducted to elucidate the mechanistic pathway 
for ortho-selective alkylations. 
 
 
Scheme 42: Site-selective C–H alkylation of secondary alkyl bromides. 
 
Inspired by reports on photo-induced ruthenium-catalyzed remote C–H alkylations at room 
temperature,[92] the photoredox concept should be applied to direct C–H arylations to avoid the 
requirement of high reaction temperature of 100–140 °C (Scheme 43). In addition, mechanistic 








3 Results and Discussion 
3.1 Ruthenium-Catalyzed meta-Selective Bromination 
Aryl halides have played an important role in several organic transformations, especially in 
coupling reactions.[93] The electrophilic halogenation on arenes is a powerful transformation 
among direct C─H activations. However, the drawbacks of this method were reflected by multiple 
halogenated products. Moreover, halogenations at the benzylic position tend to be more efficient 
than at aromatic C─H bonds in the presence of light. Consequently, site-selective halogenation has 
been highly demanded in the synthetic methodology. Chelation-assistance has not allowed only 
for ortho-C─H halogenations,[47, 76] but also more challenging meta-C─H halogenations. However, 
the protocols were limited to pyridines, pyrimidines, and pyrazoles as directing groups.[77-78] 
Due to a number of biologically active unnatural nucleosides,[94] late-stage transformations of 
nucleosides became more attractive in molecular syntheses. Although the most acidic C─H bond 
on purine ring is at the C8 position, a meta-selective C─H bromination on arene 123 using purine 
as the directing group was achieved by Dr. D. J. Burns in the Ackermann group (Scheme 44).[95] 
 
 
Scheme 44: Remote C─H bromination in the homogeneous system. 
 
3.1.1 Optimization Studies 
Having identified DMA as a good choice for the solvent (Table 1, entries 1─2),[95] some 
investigations concerning the nature of the catalyst and its loading were performed. A reduced 
catalytic loading significantly decreased the obtained yields of the meta-brominated product 133a 
(entries 3─4). To reduce the metal waste, heterogeneous remote C─H bromination using 
ruthenium-sol-gel catalysts 152 was accomplished by Dr. S. Warratz (entry 5). In contrast to the 
homogeneous catalyst, a slight decrease of the product yields was observed in the reaction with 
lower catalytic loading (entries 6─7). Moreover, it was highlighted that the catalyst 152 could be 
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recovered and reused for 4─5 times without loss of catalytic efficacy.[95] In terms of sustainability, 
the heterogeneous catalyst 152 was therefore chosen to explore the scope of the meta-
bromination.  
 
Table 1: Ruthenium-catalyzed meta-bromination of purine 123a with various catalytic loading.[a] 
 
Entry cat. [Ru] 133a (%) 
1 RuCl3·nH2O (30, 10 mol %) 77[b] 
2 30 (10 mol %) ---[c] 
3 30 (5 mol %) 25 
4 30 (2.5 mol %) 6 
5 Ru@SiO2 (152, 10 mol %) 63 (70)[d] 
6 152 (5 mol %) 68 
7 152 (2.5 mol %) 50 
[a] Reaction conditions: 123a (0.25 mmol), NBS (62, 0.50 mmol), [Ru] (x mol %), DMA (0.5 mL), 40 °C, 20 h, under N2; 
yield of isolated products. [b] Reaction was performed by Dr. D. J. Burns. [c] DMA:H2O (1:1). [d] Reaction was performed 
by Dr. S. Warratz. 
 
3.1.2 Scope of the meta-Selective C─H Bromination  
With the optimized catalytic system in hand, the versatility of heterogeneous remote C─H 
bromination was explored with various N-substituents of purine 123 (Scheme 45). Even though 
the meta-brominated adducts 133 were observed in excellent level of site-selectivity, the scope 
of purines in the heterogeneous ruthenium catalysis was limited to substituents on the aromatic 
motif.  
The heterogeneous meta-bromination was not restricted to the assistance of purines 123, but 
pyridines[95] and pyrimidines 139 were also efficiently converted to the desired products 153 
(Scheme 46). The reaction of 2-(o-tolyl)pyrimidine (139d) delivered the monobrominated product 
153c as the major product in 62% yield and the dibrominated arene 153c’ as a side product in 
13%. Moreover, the bromination of bromo-substituted pyrazole 147b gave 23% of the 
corresponding adduct 153d. 




Scheme 45: Scope of meta-bromination in heterogeneous system. 
 
 
Scheme 46: meta-Bromination of different heteroarenes. 
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3.2 Ruthenium(II)-Catalyzed Remote meta-C–H Alkylation of Ketimines 
During the past decade, full control of positional selectivity in C─H functionalization reactions has 
been identified as a major challenge.[24a] To achieve the selectivity, chelation-assistance has thus 
proven to be valuable for proximity-induced C─H functionalization.[27b] Unlike other ortho-
metalations, ortho-C─H ruthenation process allowed not only for ortho-C─H transformations,[29e] 
but also more challenging meta-C─H functionalizations.[56b] In the early progress from the groups 
of Ackermann[61] and Frost,[63] pyridines and azoles were employed as the directing groups in the 
meta-C─H alkylations. The utility of these directing groups was limited, as they are difficult to 
modify or remove. The first report on the remote meta-alkylation of removable 
N-pyrimidylanilines was achieved by the group of Ackermann.[62] 
 
3.2.1 Optimization Studies 
To expand the versatility of ruthenium catalysis, Dr. J. Li in the Ackermann group developed a 
remote meta-C─H alkylation of ketimine 135 using [RuCl2(p-cymene)]2 catalyst, 
1-adamantanecarboxylic acid (1-AdCO2H, 12) as an additive in toluene as the solvent (Table 2, 
entry 1).[96] Then acid additives as the ligand of the ruthenium catalyst were tested. While pivalic 
acid showed similar efficacy to acid 12 (entry 2), MPAAs gave lower conversions (entries 3─4). 
However, the drawback of toluene is the radical-sensitive benzylic proton, resulting in the 
formation of ortho-benzylated adducts as a side product. To prevent the side reaction, Dr. S. De 
Sarkar found tert-butylbenzene (PhCMe3) could be employed as the solvent instead of toluene 
and the twofold catalytic efficacy was observed (entry 5). After probing the additives and solvents 
(entries 6─10), the optimized reaction condition was to use a catalytic amount of acid 12 in 
PhCMe3 (entry 7). In addition, it was found that carboxylic acid additive was essential in the 
ruthenium-catalyzed C─H activation (entry 11). Moreover, arenes on ruthenium complexes did 
not exert influence on the catalytic efficacy (entries 12─17). RuCl3 catalysts failed to give any 
conversion (entries 18─19). Due to a reduced electronic density of imine, the reaction of 
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Table 2: Optimization studies for the ruthenium(II)-catalyzed meta-alkylation of ketimine 135a.[a] 
 
Entry cat. [Ru] Additive Solvent 154aa (%) 
1 [RuCl2(p-cymene)]2 1-AdCO2H (12) PhMe 58[b] 
2 [RuCl2(p-cymene)]2 PivOH PhMe 62 
3 [RuCl2(p-cymene)]2 Piv-Val-OH (41) PhMe 17 
4 [RuCl2(p-cymene)]2 Piv-Ile-OH (155) PhMe 33[c] 
5 [RuCl2(p-cymene)]2 155 PhCMe3 64[c] 
6 [RuCl2(p-cymene)]2 AcOH PhCMe3 14 
7 [RuCl2(p-cymene)]2 12 PhCMe3 73 
8 [RuCl2(p-cymene)]2 12 PhH 54 
9 [RuCl2(p-cymene)]2 12 PhF 42 
10 [RuCl2(p-cymene)]2 12 PhCF3 52 
11 [RuCl2(p-cymene)]2 --- PhCMe3 --- 
12 [RuCl2(C6H6)]2 12 PhCMe3 73 
13 [RuCl2(PhCMe3)]2 12 PhCMe3 67 
14 [RuCl2(C6H6)]2 12 1,4-dioxane 51 
15 [RuCl2(p-cymene)]2 12 1,4-dioxane 52[b] 
16 [RuCl2(p-cymene)]2 MesCO2H (31) 1,4-dioxane 30 
17 [RuCl2(PhCMe3)]2 12 1,4-dioxane 48 
18 RuCl3 155 PhCMe3 --- 
19 RuCl3·nH2O (30) 155 PhCMe3 --- 
20 [RuCl2(p-cymene)]2 155 PhCMe3 44[d] 
[a] Reaction conditions: 135a (0.50 mmol), 136a (1.50 mmol), [Ru] (10 mol %), additive (30 mol %), K2CO3 
(1.00 mmol), solvent (2.0 mL), 120 °C, 20 h, under N2, then hydrolysis by 2 N HCl, 3 h; yield of isolated products.             
[b] Reactions were performed by Dr. J. Li. [c] Reactions were performed by Dr. S. De Sarkar. [d] 4-Methoxyphenyl (PMP) 
instead of TMP. TMP = 3,4,5-trimethoxyphenyl. 
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3.2.2 Scope of the meta-Selective C─H Alkylation of Ketimines 
Having identified the optimal catalytic system, the versatility of ruthenium(II)-catalyzed remote 
meta-alkylation of ketimines 135 and tertiary alkyl bromides 136 was investigated (Scheme 47). 
In all cases, the ruthenium(II) biscarboxylate catalyst proved to be more effective than the 
ruthenium catalyst derived from Piv-Ile-OH (155). Acyclic and cyclic tertiary alkyl bromides 136 
were smoothly reacted under the remote alkylation conditions. It is noteworthy that the less 
reactive alkyl chloride also furnished the desired meta-decorated arene 154ab with similar 
catalytic efficacy, in contrast to tert-butyl iodide.[96] Moreover, the reaction of tertiary alkyl 
bromide 136f containing a reactive primary alkyl chloride motif delivered the meta-alkylated 
ketone 154af with excellent levels of chemo- and site-selectivity. Additionally, 3,4,5-
trimethoxyphenylamine (TMP-NH2) was recovered in a sustainable fashion in high yield after 
acidic hydrolysis, which could possibly be reused in further transformations.[96] However, strong 
electron-withdrawing substituents on the arenes 135k─135m gave unsatisfactory results (154kb–
154mb) under the optimized reaction conditions. Furthermore, ketimines 135n and 135o 
decorated with cyclic amine, methylenedioxy (135p), naphthalene (135q), and thiophene (135r) 
poorly reacted with tert-butyl bromide (136b). Steric hinderance of ketimines 135s and 135t 
changed the equilibrium to the inactive Z-isomer, resulting in inefficiency in the ruthenium 
catalysis.  
In addition to tertiary alkyl bromides 136a–136g, the applicability of the remote C─H 
functionalization procedure was reflected by efficient meta-alkylation with various secondary 
alkyl bromides 136h–136q (Scheme 48). A range of electronically different ketimines 135 
performed efficiently with cyclic alkyl bromides 136h–136k. The highly effective remote alkylation 
proved to be broadly applicable, tolerating a wealth of functional groups, including chlorides 
(154ch), esters (154kh), nitriles (154lh), and amines.[96] Unlike tertiary alkyl bromides, ketimines 
derived from amino-subtituted acetophenones (135n and 135o) and 2-acetylnaphthalene (135q) 
were effortlessly reacted with both cyclic and acyclic secondary alkyl bromides. While the reaction 
of 4-bromopiperidine (136p) and 4-bromotetrahydropyran (136q) delivered the corresponding 
ketones 154qp, 154ap, and 154aq in moderate yields, 3-bromotetrahydrofuran (136r) gave low 
yield of the corresponding product 154ar. Moreover, the reaction of nitro-substituted ketimine 
135m failed to provide any conversion. 
 




Scheme 47: Remote meta-C─H alkylation with tertiary alkyl bromides. 
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Scheme 48: Remote meta-C─H alkylation with secondary alkyl bromides. 
 
3.2.3 Mechanistic Studies 
In order to delineate the working mode of the ruthenium(II)-catalyzed remote C─H activation, 
experimental mechanistic studies were conducted. To this end, intermolecular competition 
experiments highlighted electron-deficient arene to be conducted more preferentially (Scheme 
3.2 Ruthenium(II)-Catalyzed Remote meta-C–H Alkylation of Ketimines 
 
45 
49). Similarly, the meta-C─H alkylation of ketimine 135w favorably occurred on the arene with 
fluorine substituent, delivering the monoalkylated product 154wh as well as the dialkylated 
product (Scheme 50). It is noteworthy that the monoalkylated product on unsubstituted arene 
moiety was not observed even though the E/Z isomeric mixture of 135w was employed. To 
rationalize this phenomenon, NOESY experiment was performed. According to the 2D-spectrum, 
the interconversion between E- and Z-isomer was observed even at ambient temperature with 
kinetic conversion rate kBA>kAB (Figure 6). 
 
 
Scheme 49: Intermolecular competition experiments for remote C─H alkylation. The conversion 
was determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard. 
 
 
Scheme 50: Intramolecular competition experiments for remote C─H alkylation. 
 




Figure 6: NOESY 2D-spectrum for isomeric mixture of ketimine 135w. 
 
To understand the nature of the C─X bond cleavage, the reaction was performed in the presence 
of radical scavengers (Scheme 51a). While BHT did not exert influence on the catatytic potency, 
the addition of the typically used radical trap TEMPO completely inhibited the catalytic C─H 
transformation. The TEMPO adduct 156 was isolated, which supported a homolytic C─X bond 
cleavage. Moreover, the reactions with enantiomerically enriched substrate (S)-136o and 
diasteromerically pure alkyl bromides 136s delivered the isomeric mixtures 154ao and  154as, 












Scheme 51: Support for a radical-type mechanism of meta-C─H alkylation. 
 
3.2.4 Late-Stage Diversification 
Finally, the power of efficient remote meta-C─H alkylation was illustrated by late-stage 
diversification of the thus obtained meta-alkylated arenes as depicted in Scheme 52. First, facile 
reduction of the obtained meta-alkylated ketimines in a one-pot fashion furnished benzylamine 
derivatives 157. Second, the sequential twofold meta-/ortho-C─H functionalizations, performed 
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by Dr. T. Rogge, provided the approach for densely-tetrasubstituted arenes 158a and 158b 
without any additional catalysts. Moreover, the synthetic utilization of the meta-decorated arenes 
154 was mirrored by transformative oxidation[97] to form valuable carboxylic acid 159 and Fischer 
indole synthesis (162) (Scheme 53). Since phenols and anilines are strong ortho-/para-directors in 
the electrophilic aromatic substitutions, the classical Friedel-Crafts reaction fails to provide 
meta-C─H transformations. Notably, classically transformative Baeyer-Villiger oxidation and 
Beckmann rearrangement[98] of ketones 154 impressively accessed to meta-alkylated phenols 160 
and anilines 161, respectively. 
 
 
Scheme 52: Sequential transformations in a one-pot fashion. 




Scheme 53: Late-stage diversifications of the meta-alkylated arenes. 
 
3.3 Sequential meta-/ortho-C–H Functionalizations by One-Pot Ruthenium(II/III) 
Catalysis 
Since the earlier protocols for ruthenium(II)-catalyzed remote C─H secondary and tertiary 
alkylations,[61-63] sulfonylations,[74] brominations,[77-78] and nitrations[81] were performed at high 
reaction temperatures, the development of milder remote C─H transformations have been highly 
demanded in order to access to biorthogonal late-stage diversifications of biorelevant molecules 
and expand the range of tolerated functional groups. Further development in remote alkylations 
was achieved by Dr. Z. Ruan in the Ackermann group using a ruthenium(II) biscarboxylate complex 
cooperated with phosphine ligands.[66] The synergistic ruthenium catalysis was first accomplished 
meta-C─H mono- and difluoromethylation under milder conditions. 
Acetic acid and propionic acid are important structural moieties of biologically and 
pharmaceutically active compounds, namely nonsteroidal anti-inflammatory drugs (NSAIDs), as 
depicted in Figure 7.[99] Among them, Ketoprofen, Flurbiprofen, and Fenoprofen contain 
meta-substituted pattern of arenes. Therefore, the remote meta-alkylations of α-halocarbonyl 
compounds have been of interest. In 2017, the group of Frost demonstrated protocols for the 
remote alkylation of α-halo esters and ketones. However, the reactions were still conducted at 
high reaction temperature of 120 °C.[100] 
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Figure 7: Selected nonsteroidal anti-inflammatory drugs (NSAIDs). 
 
3.3.1 Optimization Studies 
Initially, the remote alkylations were optimized by probing various reaction conditions for the 
transformation of 2-phenylpyrimidine (139a) with alkyl bromide 140a (Table 3). It was found that 
a PPh3 had a great influence on the formation of meta-alkylated product 141a (entries 1─2). 
Moreover, the lower reaction temperatures significantly increased the catalytic efficacy (entries 
2–6). Among the inorganic bases, K2CO3 proved to be most effective (entries 5─11). 
 
Table 3: Bases and reaction temperatures for the remote meta-C–H alkylation.[a] 
 
Entry Base T (°C) 141a (%) 
1 K2CO3 120 30[b] 
2 K2CO3 120 54 
3 K2CO3 80 71 
4 K2CO3 60 77 
5 K2CO3 40 82 
6 K2CO3 23 78 
7 KOAc 40 70 
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Entry Base T (°C) 141a (%) 
8 K3PO4 40 69 
9 Li2CO3 40 (9) 
10 Na2CO3 40 72 
11 Cs2CO3 40 (3) 
[a] Reaction conditions: 139a (0.5 mmol), 140a (1.5 mmol), [Ru(O2CMes)2(p-cymene)] (33, 10 mol %), PPh3 (10 mol %), 
base (1.0 mmol), 1,4-dioxane (2.0 mL), 20 h, under N2; yield of isolated products. The yield in parentheses was 
determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard. [b] Without PPh3. 
 
Among a variety of substituents on triarylphosphines, the cost-effective and commercially 
available PPh3 was found as the optimal ligand for the remote meta-alkylations (Table 4, entry 3). 
Sterically-hindered triarylphosphines (entries 7─10), trialkylphosphines (entries 11─13) and 
phosphine oxides (entries 14–15) gave less satisfactory results. In addition, bidentate phosphine 
ligands failed to give any formation of 141a (entries 16─17). It is noteworthy that chiral 
phosphoramidite ligand was also effective in the catalytic remote meta-alkylation. However, a 
racemic mixture of 141a was observed by analytical HPLC (entry 18). 
 
Table 4: Screening of different phosphine ligands for the remote meta-C–H alkylation.[a] 
 
Entry Phosphine 141a (%) Entry Phosphine 141a (%) 
1 P(4-MeOC6H4)3 67 13 P(n-Bu)3 (4) 
2 P(4-MeC6H4)3 79 14 O=PPh3 --- 
3 PPh3 82 15 HPOPh2 (4) 
4 P(4-FC6H4)3 76 16 rac-BINAP --- 





6 P(2-furyl)3 73 
7 P(2-MeC6H4)3 --- 
8 P(2,4,6-(MeO)3C6H2)3 --- 
9 P(2,4,6-Me3C6H2)3 --- 
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Entry Phosphine 141a (%) Entry Phosphine 141a (%) 





11 P(1-Ad)2n-Bu --- 
12 PCy3 (6) 
   
[a] Reaction conditions: 139a (0.5 mmol), 140a (1.5 mmol), [Ru(O2CMes)2(p-cymene)] (33, 10 mol %), phosphine 
(10 mol %), K2CO3 (1.0 mmol), 1,4-dioxane (2.0 mL), 40 °C, 20 h, under N2; yield of isolated products. The yield in 
parentheses was determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard.          
[b] Enantiomerical excess (ee) was determined by chiral HPLC with n-hexane:i-PrOH (90:10). 
 
Then carboxylate assistance was found to be of key importance to enable the remote meta-C─H 
alkylations, with the best results using [Ru(O2CAd)2(p-cymene)] (163) as the catalyst (Table 5, 
entry 3), while N. Kaplaneris found [Ru(O2CMes)2(p-cymene)] (33) performed more effectively in 
the remote transformations of imidates.[101] Other ruthenium sources fell short of the formation 
of meta-decorated arene 141a (entries 7─9). Moreover, among other solvents, 1,4-dioxane 
proved to be the most efficient in the catalytic transformations (entries 10─13).  
 
Table 5: Probing of ruthenium catalysts and solvents for the remote meta-C–H alkylation.[a] 
 
Entry cat. [Ru] Solvent 141a (%) 
1 [Ru(OAc)2(p-cymene)] 1,4-dioxane 76 
2 [Ru(O2CMes)2(p-cymene)] (33) 1,4-dioxane 82 
3 [Ru(O2CAd)2(p-cymene)] (163) 1,4-dioxane 85 
4 [RuCl2(p-cymene)]2 1,4-dioxane ---[b] 
5 [RuCl2(p-cymene)]2 1,4-dioxane (3)[b, c] 
6 [RuCl2(p-cymene)]2 1,4-dioxane (1)[b, d] 
7 RuCl3·nH2O (30) 1,4-dioxane ---[e] 
8 [Ru(t-BuCN)6][BF4]2 1,4-dioxane ---[e] 
9 RuCl2(PPh3)3 1,4-dioxane (2)[e, f] 
10 163 2-MeTHF 77 
11 163 cyclopentyl methyl ether 69 
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Entry cat. [Ru] Solvent 141a (%) 
12 163 PhMe 71 
13 163 1,2-DCE 72 
[a] Reaction conditions: 139a (0.5 mmol), 140a (1.5 mmol), [Ru] (10 mol %), PPh3 (10 mol %), K2CO3 (1.0 mmol), 
solvent (2.0 mL), 40 °C, 20 h, under N2; yield of isolated products. The yield in parentheses was determined by 
1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard. [b] 5.0 mol %. [c] Piv-Ile-OH (155, 
30 mol %). [d] Piv-Phe-OH (30 mol %). [e] MesCO2H (31, 30 mol %). [f] Without PPh3. 
 
3.3.2 Scope of the meta-Selective C─H Alkylation with α-bromo carbonyl compounds 
With the optimized ruthenium(II) biscarboxylate catalyst in hand, the robustness in the remote 
meta-alkylation of α-bromo carbonyl compounds 140 was explored (Scheme 54). Notably, the 
potent remote alkylation proved to be generally applicable, tolerating a wealth of functional 
groups, including halides, esters, ketones, and amides. In addition to 2-arylpyrimidines, the 
developed procedure was appropriate to transformable imidates (141f), removable pyrazoles 
(141g─141i), and purines (141j). It was highlighted that α-bromo-substituted esters, ketones, and 
amides were efficiently converted into the meta-alkylated arenes 141 with excellent levels of 
positional selectivity. Moreover, the reaction of methyl 2-bromoacetate (140b) afforded the 
desired meta-alkylated product 141k, which is unlike ruthenium-catalyzed ortho-C–H alkylations 
with primary alkyl bromides.[33] 
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Scheme 54: Remote meta-alkylation under the synergistic ruthenium catalysis. 
 
The synergistic ruthenium-catalyzed meta-C–H alkylation was also effective with arylketimines 
135, providing the meta-alkylated ketone 164 after acid hydrolysis (Scheme 55). Therefore, this 
protocol was applied for a step-economical synthesis of Ketoprofen derivatives 164b and 164c. 




Scheme 55: Remote alkylation of ketimines 135 followed by acid hydrolysis. 
 
In spite of the efficacy, robustness, and versatility of the ruthenium catalysis, N-pyrimidyl anilines, 
triazoles, tetrazoles, and acyclic imidates failed to give any conversion under the optimized 
ruthenium catalysis (Figure 8). Moreover, ineffective alkyl bromides are listed in Figure 8.  
 
 
Figure 8: Inefficient directing groups and alkyl bromides in the synergistic ruthenium catalysis. 
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3.3.3 Scope of the Sequential meta-C─H Alkylation/ortho-C─H Arylation in One-Pot 
The potential of the synergistic ruthenium catalysis was explored through sequential meta-C–H 
alkylations followed by ortho-C–H arylations in a one-pot fashion. The operationally simple 
addition of the electrophilic aryl bromides 165 after completion of the meta-C–H 
functionalizations allowed for the twofold one-pot C–H transformations (Scheme 56). The 
sequential meta-C–H/ortho-C–H functionalizations under the synergistic ruthenium catalysis were 
applicable for removable pyrazoles (166a–166d) in excellent levels of positional selectivity. In 




Scheme 56: Sequential one-pot meta-alkylation followed by ortho-arylation under the 
carboxylate-phosphine ruthenium catalysis. 
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Due to the different reactivities of alkyl bromides 140 and aryl bromides 165, a temperature-
controlled sequential meta-C–H/ortho-C–H functionalization in a one-pot reaction of alkyl 
bromide 140a and aryl halides 165 led to the formation of the corresponding products 166 with 
excellent levels of chemo- and positional selectivities (Scheme 57). This protocol was efficiently 




Scheme 57: Temperature controlled chemo-selective twofold C–H functionalizations. 
 
3.3.4 Mechanistic Studies 
To understand its mode of action, the H/D exchange and KIE experiments were conducted by 
N. Kaplaneris.[101] The obtained results indicated that the C–H bond cleavage is a reversible 
process. 
To delineate C–X bond cleavage event of the meta-C–H transformations, experiments with radical 
scavengers were conducted. The catalytic C–H activation was completely inhibited by the addition 
of TEMPO (Scheme 58a). The isolated TEMPO adduct 167 was supportive of the homolytic C–X 
bond cleavage. In addition, the stereochemically well-defined substrate 140j was converted under 
the catalytic transformation to the diastereomeric mixtures 141r and 141s, which is again in good 
agreement with a single-electron transfer promoted C–X bond cleavage (Scheme 58b). Further 
strong support for a radical mechanism was obtained by EPR spectroscopic studies, in 
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collaboration with Dr. A. C. Stückl. Hence, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) was 
employed as a spin-trap label to indicate the in situ generation of an alkyl radical (Scheme 59). 
 
 

















Scheme 59: EPR spectroscopic evidence for the in situ generation of an alkyl radical in 
ruthenium-catalyzed meta-alkylations. 
 
3.3.5 Proposed Catalytic Cycle 
On the basis of the experimental and computational studies,[101] a plausible catalytic cycle 
commences with a reversible, carboxylate-assisted C─H ruthenation of arene 139h (Scheme 60). 
Subsequently, single-electron transfer occurs from ruthenacycle 170 to alkyl halides 140, forming 
the ruthenium(III) intermediate 171 and the alkyl radical 172. Radical attack on the aromatic 
moiety at the position para to ruthenium generates ruthenacycle intermediate 173. 
Rearomatization followed by protodemetalation delivers the desired meta-substituted product 
141 and regenerates the catalytically active ruthenium(II) complex 169. 
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Scheme 60: Proposed catalytic cycle for the remote meta-alkylation. 
 
3.3.6 Late-Stage Diversification 
Finally, the potential of the sequential meta-C─H/ortho-C─H functionalization strategy was 
reflected by the facile late-stage modification of the thus obtained arenes 141a and 166g (Scheme 
61). The saponification of the ester group afforded the corresponding carboxylic acids 175 in high 
yields. Then, decarboxylative reduction under photoredox catalysis at room temperature[102] 
efficiently provided the meta-alkylated products 177. Notably, carboxylic acid derivative 178, 
which was modified by hydrolysis of adduct 141f, underwent through a visible-light photoredox 
catalysis reduction manifold, leading to the chemo-selective decarboxylation of the aliphatic 
carboxylic acids. 




Scheme 61: Late-stage modification of the obtained meta-alkylated products. 
 
3.3.7 Preliminary Studies on para-Selective C─H Alkylation 
With respect to Frost’s report on ruthenium-catalyzed para-C─H alkylation,[87] the synergistic 
ruthenium catalyst was examined on para-C─H functionalization (Table 6). The reaction between 
N-pyrimidyl aniline (125b) and alkyl bromide 140k provided promising results in m-xylene as 
solvent (entries 1–3). Moreover, different electronic influence on phosphine ligand gave the 
similar results (entries 4–6). In addition to the corresponding product 180a, the twofold alkylation 
of aniline 125b was observed at the position para to NH group on both the phenyl and pyrimidine 
rings. 
 
Table 6: Screening of phosphine ligands and solvents for the remote para-alkylation of 125b.[a] 
 
Entry Phosphine Solvent 180a (%) 
1 PPh3 1,4-dioxane trace[b, c] 
2 PPh3 1,4-dioxane 12 (di 15)[b] 
3 PPh3 m-xylene 33[b] 
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Entry Phosphine Solvent 180a (%) 
4 PPh3 PhCMe3 26 (di 23) 
5 P(4-FC6H4)3 m-xylene 28 (di 23) 
6 P(4-MeC6H4)3 m-xylene 26 (di 19) 
[a] Reaction conditions: 125b (0.25 mmol), 140k (0.75 mmol), [Ru(O2CMes)2(p-cymene)] (33, 10 mol %), phosphine 
(10 mol %), K2CO3 (0.50 mmol), solvent (1.0 mL), 120 °C, 20 h, under N2; yield of isolated products. [b] Reactions were 
performed by N. Kaplaneris. [c] 60 °C. 
 
To avoid the formation of the dialkylated product, 4-chloropyrimidine 125a was employed in the 
para-C─H alkylation (Table 7). The synergistic ruthenium catalysis with a phosphine ligand proved 
to be more powerful than the reaction without phosphine (entries 1–3). Different carboxylates on 
ruthenium precatalysts slightly dropped the yield of the corresponding product 180b        
(entries 4–5), while the reaction of [RuCl2(p-cymene)]2 without additional acids also delivered the 
para-alkylated product 180b with similar catalytic efficacy (entry 6).  
 
Table 7: Screening of ruthenium complexes and phosphine ligands for the remote para-alkylation 
of 125a.[a] 
 
Entry cat. [Ru] Phosphine 180b (%) 
1 [Ru(O2CMes)2(p-cymene)] (33) - 37[b] 
2 33 PPh3 56[b] 
3 33 P(4-FC6H4)3 57[b] 
4 [Ru(OPiv)2(p-cymene)] PPh3 49% 
5 [Ru(O2CAd)2(p-cymene)] (163) PPh3 49% 
6 [RuCl2(p-cymene)]2 PPh3 56% 
[a] Reaction conditions: 125a (0.25 mmol), 140k (0.75 mmol), [Ru] (10 mol %), phosphine (10 mol %), K2CO3 
(0.50 mmol), m-xylene (1.0 mL), 120 °C, 20 h, under N2; yield of isolated products. [b] Reactions were performed by 
N. Kaplaneris. 
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3.4 Late-Stage Diversification by Selectivity Switch in meta-C–H Activation 
In 2009, Ackermann first reported on ruthenium-catalyzed direct C–H benzylations using primary 
benzyl chlorides.[35] On the principle of the atom- and step-economical C–H/C–H activation[14] for 
the construction of new C–C bonds, the groups of Shi/Zhao[68] and Shi[69] later reported on 
oxidative ruthenium-catalyzed remote C–H benzylations of toluene derivatives using 
di-tert-butylperoxide (DTBP) and heptafluoroisopropyl iodide (i-C3F7I) as the radical initiators, 
respectively. Even though the prefunctionalized substrates are not required for the C–H/C–H 
activation, an excess of toluene derivative is mandatory in these catalytic transformations. 
 
3.4.1 Optimization Studies 
The synergistic ruthenium catalysis with phosphine ligands was further examined for a remote 
meta-C–H benzylations of arene 139a and secondary benzyl chloride 142a (Table 8). First, the 
addition of triphenylphosphine significantly enhanced the catalytic efficacy (entries 1–2). Second, 
the reaction at lower reaction temperature of 40 °C dramatically increased the yield of the 
meta-benzylated product 143a (entry 3), while the reaction at an ambient temperature of 23 °C 
furnished 47% of the corresponding product 143a (entry 4). Third, among inorganic bases, K2CO3 
and K3PO4 were found to be optimal bases in the catalytic transformation (entries 5–10). 
 
Table 8: Bases and reaction temperatures for the remote meta-C–H benzylation.[a] 
 
Entry Base T (°C) 143a (%) 
1 K2CO3 120 16[b] 
2 K2CO3 120 39 
3 K2CO3 40 62 (73) 
4 K2CO3 23 47 (52) 
5 KOAc 23 41 (46) 
6 K3PO4 23 51 (58) 
7 K3PO4 40 64 (76) 
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Entry Base T (°C) 143a (%) 
8 K3PO4 60 (64) 
9 Li3PO4 40 (5) 
10 Na3PO4 40 59 (73) 
[a] Reaction conditions: 139a (0.50 mmol), 142a (1.50 mmol), [Ru(O2CMes)2(p-cymene)] (33, 10 mol %), PPh3 
(10 mol %), base (1.00 mmol), 1,4-dioxane (2.0 mL), T, 20 h, under N2; yield of isolated products. The yield in 
parentheses was determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard.           
[b] Without PPh3. 
 
Among a variety triarylphosphines, PPh3, tris(4-fluorophenyl)phosphine, and tris(4-
trifluoromethylphenyl)phosphine provided similar results (Table 9, entries 1─10). Due to the 
reasonable price and commercial availability, PPh3 was selected as the optimal ligand for the 
remote meta-C–H benzylation. While trialkylphosphines and phosphine oxides failed to give any 
conversion (entries 11─15), triphenyl or triethyl phosphites provided the low formation of the 
corresponding product 143a (entries 16─17). Moreover, 2-(diphenylphosphino)benzoic acid gave 
unsatisfactory results with two different ruthenium sources (entries 18─19). In addition, no 
conversion was observed when bidentate phosphine ligands were employed (entries 20─21). 
Although N-Heterocyclic carbene (NHC) (entry 22) and chiral phosphine oxide (entry 24) were 
absolutely ineffective in the catalytic transformation, the chiral phosphoramidite ligand delivered 
30% of the desired product 143a (entry 23). 
 
Table 9: Screening of phosphine ligands for the remote meta-C–H benzylation.[a] 
 
Entry Ligand 143a (%) Entry Ligand 143a (%) 




2 P(4-FC6H4)3 65 (75) 




4 P(4-MeOC6H4)3 (69) 
5 P(4-MeC6H4)3 (46) 20 rac-BINAP ---[b] 
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Entry Ligand 143a (%) Entry Ligand 143a (%) 





7 P(2,4,6-Me3C6H2)3 --- 
8 P(2,4,6-(MeO)3C6H2)3 --- 
9 P(C6F5)3 --- 
10 P(2-furyl)3 (64) 





12 P(n-Bu)3 (2) 
13 O=PPh3 --- 




15 n-Bu2P(O)H ---[b] 




17 P(OEt)3 (15)[b] 
[a] Reaction conditions: 139a (0.50 mmol), 142a (1.50 mmol), [Ru(O2CMes)2(p-cymene)] (33, 10 mol %), phosphine 
(10 mol %), K3PO4 (1.00 mmol), 1,4-dioxane (2.0 mL), 40 °C, 20 h, under N2; yield of isolated products. The yield in 
parentheses was determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard.          
[b] [Ru(OAc)2(p-cymene)] (181, 10 mol %). [c] [RuCl2(p-cymene)]2 (5.0 mol %). 
 
Afterwards, various ruthenium source and additives were tested in the remote benzylation     
(Table 10). No conversion was observed when the reaction was performed without a ruthenium 
catalyst (entry 1). Several ruthenium sources, such as RuCl3·nH2O (entries 2─3), RuCl2(PPh3)3 
(entry 4), Ru(OAc)2(PPh3)2 (entries 5─7), Ru(OAc)2(PPh3)3 (entry 8), and [Ru(NCMe)6]X2 
(entries 9─10) provided unsatisfactory results. However, Ru(OAc)2(PPh3)2[103] was highly 
catalytically effective when the reaction was performed at high reaction temperature of 100 °C 
(entry 6). Notably, carboxylate was found to be essential in this C–H functionalization 
(entries 11─16). Moreover, a variety of ruthenium(II) biscarboxylate precatalysts comparably 
provided the high catalytic efficacy. The 1:1 ratio of ruthenium catalysts to phosphine ligands 
furnished the best results for the meta-C–H benzylation (entries 17─21). In addition, the addition 
of phosphine ligand was required in the ruthenium-catalyzed remote C─H benzylations (entry 22). 
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Table 10: Ruthenium sources and additives for the remote meta-C–H benzylation.[a] 
 
Entry cat. [Ru] Additive 143a (%) 
1 --- --- --- 
2 RuCl3·nH2O (30) MesCO2H (31) --- 
3 30 KOAc (6)[b, c, d] 
4 RuCl2(PPh3)3 31 ---[e] 
5 Ru(OAc)2(PPh3)2 --- --- 
6 Ru(OAc)2(PPh3)2 --- ---[e], (3)[c, d, e], (68)[c, e, j] 
7 Ru(OAc)2(PPh3)2 --- (3)[c, d] 
8 Ru(OAc)2(PPh3)3 --- ---[e] 
9 [Ru(NCMe)6][BF4]2 KOAc ---[c, d] 
10 [Ru(NCMe)6][SbF6]2 KOAc ---[c, d] 
11 [RuCl2(p-cymene)]2 --- ---[f] 
12 [Ru(O2CMes)2(p-cymene)] (33) --- 64 (76) 
13 [Ru(OAc)2(p-cymene)] (181) --- 69 (76) 
14 [Ru(O2CAd)2(p-cymene)] (163) --- 68 (76) 
15 [Ru(OPiv)2(p-cymene)] --- 68 (75) 
16 181 --- 68 (75)[c] 
17 181 --- (5)[g] 
18 181 --- (42)[h] 
19 181 --- (3)[i] 
20 181 --- (56)[g, h] 
21 181 --- 68 (76)[c, d] 
22 181 --- (1)[c, d, e] 
[a] Reaction conditions: 139a (0.50 mmol), 142a (1.50 mmol), [Ru] (10 mol %), PPh3 (10 mol %), K3PO4 (1.00 mmol), 
1,4-dioxane (2.0 mL), 40 °C, 20 h, under N2; yield of isolated products. The yield in parentheses was determined by 
1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard. [b] NMP (1.0 mL). [c] K2CO3. [d] 60 °C.  
[e] Without PPh3. [f] [RuCl2(p-cymene)]2 (5.0 mol %). [g] [Ru] (5.0 mol %). [h] PPh3 (5.0 mol %). [i] PPh3 (20 mol %).                 
[j] 100 °C. 
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The synergistic ruthenium-catalyzed C─H transformations similarly showed high efficiency in 
various organic solvents (Table 11, entries 1─4), while the catalytic reaction failed to give any 
conversion in MeCN (entry 5). 
 
Table 11: Screening of solvents for the remote meta-C–H benzylation.[a] 
 
Entry Solvent 143a (%) 
1 1,4-dioxane 69 (76) 
2 2-MeTHF 65 (71) 
3 PhMe 67 (76) 
4 1,2-DCE 64 (70) 
5 MeCN --- 
[a] Reaction conditions: 139a (0.50 mmol), 142a (1.50 mmol), [Ru(OAc)2(p-cymene)] (181, 10 mol %), PPh3 (10 mol %), 
K3PO4 (1.0 mmol), solvent (2.0 mL), 40 °C, 20 h, under N2; yield of isolated products. The yield in parentheses was 
determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard. 
 
In contrast to the report on a ruthenium-catalyzed direct C─H benzylation with primary benzyl 
chloride in 2009,[35] the reaction of pyrimidine 139a and 4-methoxybenzyl chloride (142b) under 
the synergistic ruthenium catalysis conditions selectively afforded the meta-benzylated product 
143b (Table 12, entries 1─2), with the best results being accomplished using K2CO3 as base. In 
addition, no conversion was observed in the absence of phosphine ligands (entry 3). Although the 
remote C─H benzylations under photoredox catalysis furnished the corresponding product 143b 
(entries 4─5), visible light was verified to be inessential in the remote C─H transformations by the 
control experiment under dark condition (entry 6). 
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Table 12: Reaction studies for remote meta-benzylation of primary benzyl chloride 142b.[a] 
 
Entry Base T (°C) 143b (%) 
1 K3PO4 60 (37), [7] 
2 K2CO3 60 59 (64), [5] 
3 K2CO3 60 (3)[b] 
4 K2CO3 30 67[c] 
5 K2CO3 30 (36)[c, d], [3] 
6 K2CO3 30 (52), [2] 
[a] Reaction conditions: 139a (0.50 mmol), 142b (1.50 mmol), [Ru(OAc)2(p-cymene)] (181, 10 mol %), PPh3 (10 mol %), 
base (1.00 mmol), 1,4-dioxane (2.0 mL), T, 20 h, under N2; yield of isolated products. The yield in parentheses was 
determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard. The yield of the 
ortho-benzylated products is given in square brackets. [b] Without PPh3. [c] Under Blue LED (5 W). [d] 2 MeTHF. 
 
Notably, the reaction of benzylphosphonium salt 182 under ruthenium catalyst did not deliver any 
formation of the corresponding product 143c (Scheme 62). This finding was supportive of the 
benzylphosphonium not being an intermediate in the catalytic transformation.  
 
 
Scheme 62: Ruthenium-catalyzed benzylation of benzylphosphonium salt 182. 
 
In the remote C─H functionalization with primary benzyl chloride 142b, cationic ruthenium(II) 
complexes and [Ru(OAc)2(PPh3)2] were not effective (Table 13, entries 1─3), even though the 
reaction was conducted at high reaction temperature at 100 °C (entry 4). 
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Table 13: Various ruthenium sources for remote meta-benzylation of primary benzyl chloride 
142b.[a] 
 
Entry cat. [Ru] 143d (%) 68b (%) 
1 [Ru(NCMe)6][BF4]2 --- 96 
2 [Ru(NCMe)6][SbF4]2 --- 88 
3[b] [Ru(OAc)2(PPh3)2] 13 71 
4[b, c] [Ru(OAc)2(PPh3)2] 32 --- 
[a] Reaction conditions: 68b (0.50 mmol), 142b (1.50 mmol), [Ru] (10 mol %), PPh3 (10 mol %), KOAc (20 mol %), K2CO3 
(1.00 mmol), 1,4-dioxane (2.0 mL), 60 °C, 20 h, under N2. Yields were determined by 1H-NMR spectroscopy using 
1,3,5-trimethoxybenzene as the internal standard [b] Without PPh3 and KOAc. [c] 100 °C.
 
 
3.4.2 Effect of Phosphine Ligand to Site-Selectivity 
The site-selectivity of the ruthenium-catalyzed C─H benzylation was controlled by the addition of 
a phosphine ligand, as shown in Scheme 63. The reaction without phosphine ligand afforded the 
ortho-benzylated products 183 with excellent levels of positional selectivity. It was found that the 
site-selectivity switched from ortho to meta position in the presence of phosphine ligands. 
 
 
Scheme 63: Influence of phosphine ligands to site-selectivity of ruthenium-catalyzed benzylation. 
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To elucidate the role of the carboxylate and phosphine ligands, the reactions were performed 
using the catalytic amount of monocyclometalated (98) or biscyclometalated (184) ruthenium 
complexes in the absence and presence of ligands (Table 14). It was verified in the reaction of 
ruthenacycle 98 that carboxylate ligand was essential in the C–H bond cleavage, while the addition 
of phosphine ligand controlled the site-selectivity of the C–H benzylations. On the other hand, 
biscyclometalated ruthenium complexes 184 was ineffective in any reaction conditions. 
 
Table 14: Roles of carboxylate and phosphine ligands in ruthenium-catalyzed benzylation.[a] 
 
Entry KOAc PPh3 [Ru] 143d (%) 183 (%) 68b (%) 
1 
  
98 9 14[b] 62 
2 184 --- --- 85 
3 
  
98 5 2[b] 83 







6 184 --- --- 87 
7 
  
98 80, 72[c] 15 (1.0:2.8) --- 
8 184 --- --- 90 
[a] Reaction conditions: 68b (0.50 mmol), 142b (1.50 mmol), [Ru] (10 mol %), PPh3 (10 mol %), KOAc (20 mol %), K2CO3 
(1.00 mmol), 1,4-dioxane (2.0 mL), 60 °C, 20 h, under N2. Yields were determined by 1H-NMR spectroscopy using 
1,3,5-trimethoxybenzene as the internal standard and ratios of mono- to dibenzylated products were given in the 
parentheses. [b] Only monobenzylated product was observed. [c] Isolated yields. 
  
Afterwards, the stoichiometry of ruthenium to phosphine was studied (Table 15 and Figure 9). 
Increasing amounts of PPh3 up to 20 mol % had an impact on acceleration and inhibition of the 
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formation of 143d and 183, respectively. Higher loadings of PPh3 poisoned the active catalyst and 
led to inhibition of any C–H benzylation. 
 
Table 15: Stoichiometry of ruthenium to phosphine in the benzylation reaction.[a] 
 
Entry PPh3 (x mol %) 143d (%) 183 (%)[b] 
1 0 22 18 (1.0:2.6) 
2 5 30 56 (1.0:1.3) 
3 10 52 25 (1.0:7.3) 
4 15 76 6 (1.0:1.0) 
5 20 65 --- 
6 25 27 --- 
7 30 27 --- 
8 35 16 --- 
9 40 15 --- 
[a] Reaction conditions: 68b (0.50 mmol), 142b (1.50 mmol), [Ru(OAc)2(p-cymene)] (181, 10 mol %), PPh3 (x mol %), 
K2CO3 (1.00 mmol), 1,4-dioxane (2.0 mL), 60 °C, 20 h, under N2. Yields were determined by 1H-NMR spectroscopy 
using 1,3,5-trimethoxybenzene as the internal standard. [b] Combined yield of mono- and dibenzylated products was 
given and the ratio of mono- to dibenzylated products was shown in the parentheses. 
 
 
Figure 9: Site-selectivity of ruthenium-catalyzed benzylation with different amount of phosphine 
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3.4.3 Scope of the meta-Selective C─H Benzylation 
With the optimized conditions for the ruthenium-catalyzed meta-C–H benzylation in hand, the 
versatility of this remote C–H functionalization was explored with different heteroarenes 68, 139 
and benzyl chlorides 142 (Scheme 64). The protocol was highly effective for primary and secondary 
benzylation. Furthermore, the synergistic ruthenium catalysis was applicable to pyrimidines, 
pyridines, and synthetically transformative oxazolines. It was found that sterically hindered 1-
chloro-2-(1-chloroethyl)benzene (142e) smoothly delivered the desired meta-benzylated 
products 143l. The connectivity of meta-benzylated products 143 was established by 
two-dimensional nuclear magnetic resonance (2D-NMR) and X-ray crystal structure analyses.  
The potential of the synergistic ruthenium-catalyzed meta-C–H transformation was also reflected 
by late-stage transformations of biorelevant purines 123 (Scheme 65). Notably, the robustness of 
ruthenium(II) catalysis proved to tolerate a wide range of functional groups, including ester 
(185ah), halides (185ai–185ak), ketone (185hb), and amide (185kb). Likewise, the twofold C–H 
functionalizations with dichloro-p-xylene (142n) effortlessly delivered bis-purine xylene 185an. 
The positional selectivity of meta-benzylated products 185 was confirmed by 2D-NMR and X-ray 
crystal structure analysis. 
 




Scheme 64: Remote meta-C–H benzylation under ruthenium catalysis. 
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Scheme 65: Ruthenium-catalyzed meta-C–H benzylation of purines 123. 
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3.4.4 Scope for Late-Stage Diversification through the remote meta-C─H Activation 
In addition to simple and commercially available benzyl chlorides, the synergistic protocol for the 
remote C–H functionalizations was applicable to structurally complex electrophiles (Scheme 66). 
Late-stage diversification of purine bases with BODIPY fluorescence labels was accomplished by 
carboxylate-phosphine ruthenium catalysis (187a and 187b). Notably, electrophiles bearing amino 
acids were smoothly transformed to the corresponding products 187c–187i with high levels of 
chemo-selectivity without any evidence for racemization. It was highlighted that reactive 
unprotected hydroxyl groups in serine (187f) and tyrosine (187i) as well as free NH-indole in 
tryptophan (187h) were fully tolerated. In addition, more structurally complex peptides 
underwent the desired chemical ligation to form products 187j and 187k, featuring among others 
sensitive methionine. The synergistic ruthenium(II) catalyst verified also fully compatible with 
triglycerides derived from saturated and unsaturated fatty acids (187l–187o) and vitamin 
D-α-tocopherol (187p). Particularly, the chemo-selectivity of the meta-C–H transformation in the 
presence of unsaturated fatty acids (187n and 187o) is noteworthy, since they are simply disposed 
to olefinic and allylic functionalizations. Remarkably, the late-stage modification of marketed 
drugs was accomplished, including transformations of neuroprotective agent gastrodin (187q–
187s) and anti-inflammatory salicin (187t). The ruthenium catalysis was not restricted to benzylic 
electrophiles, but also synthetically useful monosaccharide bromoesters afforded the desired 
meta-alkylated products 187u–187w with high catalytic efficacy. It is noteworthy that fully 
unprotected OH-free monosaccharides (187t) proved to be compatible for the first time in 
ruthenium catalysis. Notably, purine-uridine hybrids 187x and 187y were obtained by the 
synergistic catalysis via catalytic nucleoside ligation.  
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Scheme 66: Late-stage diversification of structurally complex drugs and natural product 
molecules by remote meta-C–H functionalization. 




Scheme 66 (cont.): Late-stage diversification of structurally complex drugs and natural product 
molecules by remote meta-C–H functionalization. 
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Scheme 66 (cont.): Late-stage diversification of structurally complex drugs and natural product 
molecules by remote meta-C–H functionalization. 
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Although the synergistic ruthenium catalysis proved to be robust and versatile, low conversion of 
pyrazoles (143o) and azobenzenes (143t) was noted (Scheme 67). The reactions of 
oxazolinylbenzenes with different primary benzyl chlorides delivered the corresponding product 
143p–143s in low yields. Moreover, fully unreactive arenes, such as O-methyloximes, 
dimethylpyrazoles, N-pyrimidylanilines, benzodiazepines, 2-pyridylpyridone, and others, as well 
as ineffective alkyl chlorides or bromides are listed in Scheme 67. 
 
 
Scheme 67: Unsuccessful results and ineffective substrates in the synergistic 
ruthenium-phosphine catalysis. 
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3.4.5 Mechanistic Studies 
Since the carboxylate-phosphine ruthenium catalysis effectively transformed several 
electrophiles, competition experiments were conducted to examine their reactivities (Scheme 68). 
The results showed that primary benzyl chloride 142b is less active than bromoesters 84a, 140a, 
and 140k, whereas no reactivity was observed in case of bromocycloheptane (136h). 
 
 
Scheme 68: Intermolecular competition experiments of electrophiles under the 
carboxylate-phosphine ruthenium catalysis. 
 
Moreover, an intermolecular competition experiment of arenes 68a and 68b highlighted 
electron-rich arenes to be more efficiently converted (Scheme 69) 




Scheme 69: Intermolecular competition experiment of pyridines 68a and 68b. 
 
To understand the cleavage of C–X bond, experiments with radical scavengers were investigated 
(Scheme 70). The typically used radical scavenger TEMPO fully inhibited the synergistic C–H 
transformations. The isolated TEMPO adduct 191 strongly indicated the homolytic C–X bond 
cleavage. While the addition of BHT did not have any influence on the catatytic potential, the 
reaction with 1,1-diphenylethylene significantly reduced the formation of the meta-benzylated 
product 143b. Moreover, the adduct derived from 1,1-diphenylethylene and benzyl chloride was 
detected by GC-MS spectrometry. These findings suggested a radical mechanism through 
homolytic C–X bond cleavage. 
 
 
Scheme 70: meta-Benzylation in the presence of radical scavengers. 
 
Afterwards, isotopically labelled substrates [D]2-68b and [D]3-68b were employed in the 
synergistic catalysis (Scheme 71). The substrates were efficiently converted into the 
corresponding product [D]n-143d. The deuteration degree of product [D]n-143d was measured by 
1H-NMR spectroscopy, where H/D scrambling at ortho position was observed. Owing to a trace 
amount of H2O from K2CO3, it could not indicate proton source in protodemetalation process. 
However, it was suggestive of a reversible C–H metalation process. 
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Scheme 71: Ruthenium-catalyzed meta-benzylation of isotopically labeled substrates [D]2- and 
[D]3-68b. 
 
To delineate the mechanism of the synergistic C–H functionalization, the series of well-defined 
ruthenium intermediates were prepared (Scheme 72). First, 1H-NMR spectroscopic studies 
revealed the p-cymene dissociation from the ruthenium precatalyst, which suggested 
p-cymene-coordinated ruthenacycle was not involved in the catalytic cycle. Second, the obtained 
single crystals from mixture of pyridine 68b, [Ru(OAc)2(p-cymene)] (181), and PPh3 were analyzed 
by X-ray crystallography, providing the structure of ruthenacycle trans-192a with two phosphines 
(Scheme 72a). Due to two phosphine equivalents on complex trans-192a, an additional equivalent 
of phosphine was added into the complex mixture, affording 59% of complex trans-192a (Scheme 
72b). Moreover, pyridine 68d gave under the same conditions a 1:17 mixture of cis- and trans-
ruthenacycle 192b. The alternative protocol with two equivalents of phosphine ligands delivered 
a 1:1 mixture of cis- and trans-ruthenacycle 192a (Scheme 72c). In the case of the bidentate 
phosphine ligand DPEPhos, monocyclometalated complex 193 was obtained and confirmed by 
X-ray crystal structure analysis (Scheme 72d).  




Scheme 72: Preparation of well-defined ruthenacycles 192 and 193. 
 
In addition, the carboxylate-phosphine ruthenium complex trans-192a could be derived from 
cationic monocyclometalated complex 98 with two equivalents of phosphine (Scheme 73a). In 
contrast, the reaction with one equivalent of phosphine smoothly delivered ruthenacycle 194 
(Scheme 73b). The structure of complex 194 was established by X-ray crystallography. 
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Scheme 73: Ligand modification of cyclometalated ruthenium complex 98. 
 
Having a series of well-defined ruthenacycles in hand, the isomerization of complex 192a was 
examined by 31P{1H}-NMR spectroscopy (Scheme 74). The solution of complex trans-192a in 
THF-d8 was heated at 60 °C, affording a 0.3:1.0 mixture of cis- and trans-192a. This finding 
indicated that one of the phosphine ligands is simply labile in the ruthenium complex. These 
results are in good agreement with the Ru–P bond lengths of well-defined ruthenium complexes. 
According to X-ray crystallographic data, ruthenacycle trans-192a has Ru–P bond lengths of 2.3421 
and 2.3355 Å, which are longer than complex 194 with a bond length of 2.2451 Å. In addition, 
bidentate phosphine ruthenium complex 193 has an axial Ru–P bond length of 2.2377 Å and an 
equatorial Ru–P bond length of 2.3263 Å. These data supported the weak coordination of 
phosphine ligand on ruthenium complex trans-192a. 
 
 
Scheme 74: Isomerization of trans-192a by temperature. 
 
Afterwards, the second C–H metalation of monocyclometalated complex cis-/trans-192a and 
pyridine 68d was investigated (Table 16). 31P{1H}-NMR spectroscopic studies did not detect any 
construction of the biscyclometalated ruthenium complex. However, ligand exchange of 
ruthenacycles cis-/trans-192 with pyridine 68d was observed in the presence and absence of 
K2CO3, leading to the formation of ruthenium complexes cis-/trans-192b. 
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Table 16: Studies on ligand exchange of ruthenacycle cis-/trans-192a and pyridine 68d. 
 
 cis-192a trans-192a cis-192b trans-192b 
without K2CO3 19% 6% 16% 59% 
with K2CO3 33% 3% 13% 51% 
 
In addition, redox properties of the novel ruthenacycles 192–194 were studied by cyclic 
voltammetry (Figure 10). The results of ruthenacycle 98 and 192–194 showed reversible one-
electron redox processes at E1/2 = 0.75 V (98), E1/2 = 0.32 V (trans-192a), E1/2 = 0.44 V (193), and 
E1/2 = 0.47 V (194) versus Ag/AgCl. The change of the half wave potential (E1/2) suggested that 
phosphine ligands significantly reduced oxidation potential of ruthenium(II/III) complexes. In 
contrast, the p-cymene-coordinated ruthenium complex 195 exhibited an irreversible oxidation 
event at E = 0.81 V.  
 

























Figure 10: Cyclic voltammetry studies in 1,2-DCE containing 0.1 mol∙L–1 n-Bu4NPF6, scan rate 
100 mV∙s–1. 
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Figure 10 (cont.): Cyclic voltammetry studies in 1,2-DCE containing 0.1 mol∙L–1 n-Bu4NPF6, scan 
rate 100 mV∙s–1. 
 
Then, the catalytic efficacy of well-defined ruthenacycle 192a–194 was evaluated in the remote 
meta-C–H benzylations (Table 17). Complex trans-192a and 194 efficiently delivered the desired 
product 143d, while bidentate phosphine ruthenium complex 193 failed to give any conversion of 
substrate 68b.  
 
Table 17: Remote meta-C–H benzylation catalyzed by cyclometalated ruthenium complexes.[a] 
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Entry [Ru] 143d (%) 
1 trans-192a 54 (39) 
2 193 --- (---) 
3 194 59 (50) 
[a] Reaction conditions: 68b (0.50 mmol), 142b (1.50 mmol), [Ru] (10 mol %), KOAc (10 mol %), K2CO3 (1.0 mmol), 
1,4-dioxane (2.0 mL), 60 °C, 20 h, under N2; yield of isolated products. The yield in parentheses was obtained in the 
absence of KOAc. 
 
Furthermore, the stoichiometric experiments of ruthenacycle 192a with benzyl chloride 142b 
selectively afforded the corresponding product 143d (Scheme 75a). It is noteworthy that 
demetalation by the addition of 2,2’-bipyridine and acetic acid was obligatory after the 
transformation. On the other hand, carboxylate-phosphine ruthenium complex 194 failed to 
provide the desired product 143d (Scheme 75b). 
 
 
Scheme 75: Stoichiometric benzylation of ruthenacycle 192a and 194. 
 
3.4.6 Proposed Catalytic Cycle 
On the basis of experimental and computational findings,[104] a plausible catalytic cycle 
commences by carboxylate-assisted ortho-C–H ruthenation to generate complex trans-192a 
(Scheme 76). Then, single-electron transfer (SET) from the ruthenium(II) complex trans-192a to 
the benzyl halide 142, generates the ruthenium-(III) intermediate 196. The benzyl radical 197 
attacks on the arene moiety at the position para to ruthenium, providing triplet species 198. Next, 
ligand-to-metal charge-transfer leads to the significantly stabilized singlet ruthenacycle 199. 
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Finally, rearomatization and ligand exchange delivers the desired meta-benzylated product 143 
and regenerates ruthenium(II) complex trans-192a. 
 
 
Scheme 76: Proposed catalytic cycle for ruthenium-catalyzed remote C–H benzylation. 
 
3.5 Ruthenium(II)-Catalyzed Decarboxylative Alkylation 
During the last decades, methods of site-selective C–H functionalizations have gained enormous 
attention.[13, 90] In particular, ruthenium catalysis allowed for ortho-,[33-34] meta-,[61-62, 96, 101] and 
para-selective[87-89] C–H alkylations. In contrast, ruthenium-catalyzed C–C bond activations remain 
seldom.[105] 
Recently, the group of Ackermann reported the first ruthenium(II)-catalyzed decarbamoylative 
and decarboxylative C–C arylation of aromatic amides and acids.[91] Due to the versatility and 
robustness of the ruthenium catalyst, Dr. M. Moselage in the Ackermann group further developed 
the method for decarboxylative alkylations of acid 144a, as shown in Scheme 77.[106] The C–C 
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alkylation with primary alkyl bromide 136t efficiently delivered the ortho-alkylated product 145at 
with excellent levels of positional selectivity. 
 
 
Scheme 77: Ruthenium-catalyzed decarboxylative alkylation of primary alkyl bromide 136t. 
 
3.5.1 Optimization Studies for Decarboxylative meta-C–H Alkylation 
In addition, the ruthenium catalysis enabled decarboxylative meta-C–H alkylations of secondary 
alkyl bromide 136h (Table 18, entry 1). Different carboxylic acid additives were tested, however, 
MesCO2H (31) provided the best result (entries 1–3). The reaction without the addition of any acid 
additives still enabled product formation (entry 4), presumably because the acid starting material 
144a can act itself as carboxylate ligand. Moreover, the cationic ruthenium complexes were 
effective in the decarboxylative alkylations (entries 5–6). This indicated that a p-cymene 
cyclometalated ruthenium complex was likely not involved in the catalytic alkylation. Other 
ruthenium sources, such as RuCl3·nH2O (30) or Ru3(CO)12, failed to provide the formation of the 
corresponding product 146ah (entries 7–8). Furthermore, no conversion was observed when the 
reaction was performed without the catalyst (entry 9). It is noteworthy that the reaction in 
-valerolactone, a polar green solvent, did not allow any formation of product 146ah, while the 
formation of ester via nucleophilic substitution of acid 144a with alkyl bromide 136h was observed 
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Table 18: Optimization studies for ruthenium-catalyzed decarboxylative meta-C–H alkylation.[a] 
 
Entry cat. [Ru] Additive 146ah (%) 
1 [RuCl2(p-cymene)]2 MesCO2H (31) 73[b] 
2 [RuCl2(p-cymene)]2 1-AdCO2H (12) 49[b] 
3 [RuCl2(p-cymene)]2 PivOH 56 
4 [RuCl2(p-cymene)]2 --- 39[b] 
5 [Ru(NCt-Bu)6][BF4]2 31 60 
6 [Ru(NCt-Bu)6][SbF6]2 31 49 
7 RuCl3·nH2O (30) 31 --- 
8 Ru3(CO)12 31 --- 
9 --- 31 --- 
10 [RuCl2(p-cymene)]2 31 trace[c] 
[a] Reaction conditions: 144a (0.50 mmol), 136h (1.50 mmol), [Ru] (5.0 mol %), additive (30 mol %), K2CO3 (1.0 mmol), 
o-xylene (1.0 mL), 120 °C, 16 h, under N2; yield of isolated products. [b] Reactions were performed by Dr. M. Moselage. 
[c] -Valerolactone (GVL). 
 
3.5.2 Scope of the Ruthenium-Catalyzed Decarboxylative Alkylation 
With the optimized conditions for the ruthenium-catalyzed decarboxylative alkylation in hand, the 
versatility of this remote transformation was explored with different acids 144 and alkyl bromides 
136 (Scheme 78). Primary alkyl bromide 136t was efficiently converted to the ortho-alkylated 
product 145et. The decarboxylative alkylation of acid 144f and alkyl bromide 136t afforded the 
corresponding product 145ft as well as ortho-benzylated adduct 201 as a side-product, which 
resulted from benzylic hydrogen abstraction of o-xylene solvent. Unprecedentedly, secondary 
alkyl bromides, such as bromocyclohexane (136j) and exo-2-bromonorbornane (136u), were 
mainly converted into the ortho-alkylated products 145aj, 145fj, and 145fu. In contrast, 
cycloheptyl and cyclooctyl bromides 136h and 136k, respectively, were generally transformed into 
the meta-alkylated products 146. Moreover, the catalytic functionalizations of tertiary alkyl 
bromides 136b and 136v furnished the corresponding meta-alkylated products 146eb–146gb and 
146av with excellent levels of site-selectivity. The connectivity of the thus-obtained products 
146eh and 201 was unambiguously confirmed by X-ray crystal structure analyses. 




Scheme 78: Decarboxylative alkylations of acids 144 with primary, secondary, tertiary alkyl 
bromides 136. 
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In addition, the catalyst was modified by the addition of a phosphine ligand and the replacement 
of PhCMe3 as solvent, enabling decarboxylative alkylation with α-bromoesters and amides 140 
(Scheme 79). Reactions of methyl 2-bromohexanoate (140a) provided the meta-alkylated product 
141g and 202a–202c with good catalytic efficacy. High chemo- and positional-selectivities were 
observed in these decarboxylative transformations, although the corresponding products 202d–
202g were obtained in lower yields. Likewise, secondary benzyl chlorides 142 were converted to 
the desired products 202h–202i, albeit in lower yields. 
 
 
Scheme 79: Site-selective meta-C–H alkylation through decarboxylation. 
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Under the developed decarboxylative alkylation conditions, some pyrazole acids and some alkyl 
bromides gave rather unsatisfactory results, which are listed in Figure 11. It is noteworthy that 
nucleophilic substitutions of acids and alkyl bromides were mostly observed as a side reaction. 
 
 
Figure 11: Inefficient acid arenes and alkyl bromides in decarboxylative alkylation. 
 
3.5.3 Mechanistic Studies 
To unravel the working mode of this ruthenium-catalyzed decarboxylative alkylation, a reaction 
was conducted in the presence of deuterated co-solvent (Scheme 80). In the presence of alkyl 
bromide 136h, the alkylated product [D]n-146ah showed deuterium incorporation of 46% and 47% 
at the ortho positions. Moreover, the proto-decarboxylative compound [D]n-147a was obtained 
with deuterium incorporation of 42% at the ortho position.  
 
 
Scheme 80: Experiment with isotopically labeled co-solvent CD3OD. 
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Then, reactions with radical scavengers were performed to explain the C–X bond cleavage process 
(Scheme 81). In the reaction of primary alkyl bromide 136t, the addition of the radical trap TEMPO 
led to complete inhibition of the transformation (Scheme 81a). Unfortunately, the alkyl-TEMPO 
product could not be detected. The decarboxylative alkylation of acid 144a with secondary alkyl 
bromide 136h gave no formation of the corresponding product 146ah when the reaction was 
conducted under air atmosphere (Scheme 81b). Moreover, the addition of radical scavenger BHT 
reduced the catalytic efficacy. Likewise, primary alkyl bromides, the reaction with 
bromocycloheptane (136h) was fully inhibited by the addition of TEMPO and the isolated 
alkyl-TEMPO adduct 156 can be explained by the homolytic C–X bond cleavage. 
 
 
Scheme 81: Decarboxylative alkylation with radical scavengers. 
 
Furthermore, a substantial amount of free p-cymene was detected in the first period of the 
decarboxylative alkylation, which was conducted by J. Struwe.[106] It again suggested that 
p-cymene-coordinated ruthenacycle was not involved as an intermediate in the catalysis.  
 
3.6 Ruthenium-Catalyzed C–H Alkylation of Pyrazoles: ortho versus meta 
Over the last decades, ruthenium-catalyzed site-selective alkylations on the arene moiety have 
gained significant momentum.[29e, 56b] These studies showed that secondary and tertiary alkyl 
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bromides were selectively converted to the corresponding meta-[61-62, 96] or para-alkylated 
products under ruthenium catalysis,[87-89] whereas the reactions of primary alkyl bromides 
afforded the ortho-alkylated products.[33-34] As shown in Scheme 78 in section 3.5, ruthenium-
catalyzed decarboxylative alkylation of bromocyclohexane (136j) and exo-2-bromonorbornane 
(136u) extraordinarily delivered the ortho-alkylated products. After these findings, it became of 
interest to investigate the mechanism for ruthenium-catalyzed ortho-alkylations. 
The site-selectivity of alkylation reactions was first examined through a ruthenium-catalyzed C–H 
functionalization of pyridine 68b and pyrazole 147a (Scheme 82). The catalytic transformation of 
pyridine 68b with bromocyclohexane (136j) or bromocyclopentane (136i) afforded the 
corresponding meta-alkylated arenes 203a and 203b, respectively, with excellent levels of 
positional selectivity (Scheme 82a and b). Conversely, the C–H alkylation of pyrazole 147a 
occurred at the ortho position (Scheme 82c). Moreover, trace amounts of benzylated adducts 
were observed by GC-MS spectrometry, when o-xylene was used as the solvent.  
 
 
Scheme 82: Ruthenium-catalyzed C–H alkylation of pyridine 68b and pyrazole 147a with 
bromocyclohexane (136j) and bromocyclopentane (136i). 
 
To prevent the side reaction, PhCMe3 was employed as the solvent in the catalytic transformation 
(Scheme 83). The alkylation reaction of bromide 136j gave a 5:1 mixture of the corresponding 
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ortho- and meta-alkylated products 145aj and 146aj, respectively. Likewise, cyclohexyl chloride 
and iodide were transformed into the ortho-alkylated product 145aj as a major product. 
 
 
Scheme 83: C–H Alkylation of pyrazole 147a with cyclohexyl halides 136j. 
 
3.6.1 Site-Selectivity in Ruthenium-Catalyzed C–H Alkylation of Pyrazoles 
Then, the effect of the ring size of the bromocycloalkanes 136 on the positional selectivity was 
investigated (Scheme 84a). The catalytic alkylations of unsubstituted phenylpyrazole 147a with 
bromocyclobutane (136w) and bromocyclohexane (136j) favorably gave the ortho-alkylated 
products 145aw and 145aj, respectively, while bromocycloheptane (136h) and bromocyclooctane 
(136k) preferentially delivered the meta-alkylated products 146ah and 146ak. Low site-selectivity 
was observed in the reaction of bromocyclopentane (136i). In addition, no formation of products 
was observed in the reactions of pyrazole 147a with bromocyclopropane. Then, the scope of 
primary alkyl bromide as well as secondary alkyl bromides 136 was explored in the C–H alkylations 
(Scheme 84b). The reactions with neopentyl bromide (136t) or exo-2-bromonorbornane (136u) 
provided the ortho-alkylated products 145at and 145au, respectively. Acyclic secondary alkyl 
bromides 136m and 136n were efficiently converted into the meta-alkylated products 146am and 
146an, respectively, with excellent levels of site-selectivity. 
Afterwards, the electronic influence on the site-selectivity was probed by the reactions of the 
differently substituted pyrazolylarenes 147 with bromocyclohexane (136j) (Scheme 85). Electron-
donating groups at the para position afforded a mixture of ortho- and meta-alkylated products 
145 and 146, while electron-withdrawing groups exclusively furnished the ortho-alkylated 
products 145gj–145jj. The molecular structure of 145jj was established by X-ray crystal structure 
analysis. 




Scheme 84: (a) Positional selectivity of ruthenium-catalyzed C–H alkylation of pyrazole 147a with 
various bromocycloalkanes 136 and (b) scope of C–H alkylations of phenylpyrazole 147a. 
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Scheme 85: Electronic effect on the site-selectivity of ruthenium-catalyzed C–H alkylation of 
pyrazoles 147 with bromocyclohexane 136j. 
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In contrast to arylpyrazoles 147a and 147d–147j, the alkylation reactions of 3,5-dimethyl-1-
phenyl-1H-pyrazole (147c) with cyclic or acyclic secondary alkyl bromides 136 solely furnished the 
meta-alkylated products 146 (Scheme 86). Moreover, the reaction of neopentyl bromide (136t) 
selectively provided the meta-alkylated arene 146ct, albeit in lower yield.  
 
 
Scheme 86: meta-C–H Alkylations of pyrazole 147c with alkyl bromides 136. 
 
3.6.2 Mechanistic Studies 
To delineate C─X bond cleavage event of the ruthenium-catalyzed C─H alkylations, the reactions 
of 1-phenylpyrazole (147a) with 2-bromocyclohexane (136j) in the presence of radical scarvengers 
were conducted by J. Struwe.[106] The catalytic alkylations were fully inhibited by the addition of 
TEMPO. Moreover, the lower catalytic efficacy was observed in the reactions with 
1,1-diphenylethylene and the isolation of 2-cyclohexyl-1,1-diphenylethylene can be explained by 
homolytic C─X bond cleavage. The reaction mechanism was further studied by the alkylation 
reactions with diastereomerically pure electrophilles 136s and 136x (Scheme 87). The reaction 
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with endo-2-bromobornane (endo-136x) gave the ortho-alkylated product endo-145jx as well as a 
diastereomeric mixture of the meta-alkylated products 146jx (Scheme 87a). Likewise, the 
stereochemistry of tert-butylcyclohexyl bromide cis-136s and trans-136s translated directly into 
the corresponding ortho-alkylated product cis-145js and trans-145js, respectively (Scheme 87b 
and c). Therefore, these results are strongly supportive of a concerted oxidative 
addition/reductive elimination mechanism to be operative for the ortho-alkylation. In contrast, 
the meta-functionlized product 146js was obtained as cis- and trans-isomers from the alkylation 
reaction with the single diastereomer cis-136s, which is indicative of the formation of an alkyl 
radical via a single-electron transfer (SET) process. The site-selectivity and stereochemistry of the 
obtained products 145 and 146 were confirmed by 2D-NMR and X-ray analysis. 
To elucidate the working mode of the ruthenium catalysis, the well-defined cationic 
cyclometalated ruthenium complex 204 was employed as the catalyst in the alkylation reaction 
(Scheme 88). In the presence of MesCO2H (31), the reaction afforded the meta-alkylated product 
146cj with excellent level of positional selectivity. While, the reaction in the absence of acid 31 
resulted in a mixture of ortho- and meta-functionalized products 145cj and 146cj, which is in 
contrast to the standard reaction condition. Moreover, 62% of free p-cymene was observed in the 
first period of the catalytic alkylations by gas chromatography analysis, which was conducted by 
J. Struwe.[106]  




Scheme 87: C–H Alkylation of pyrazole 147j with diastereomerically pure alkyl bromides 136x 
and 136s. 
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Scheme 88: C–H Alkylation catalyzed by the cationic cyclometalated ruthenium complex 204. 
 
3.6.3 Proposed Catalytic Cycle 
On the basis of these findings in experiments and computations,[106] a plausible catalytic cycle for 
the ortho-C─H alkylation commences by a carboxylate-assisted C─H ruthenation and dissociation 
of p-cymene, therefore leading to the cyclometalated ruthenium complex 206 (Scheme 89, left). 
A second molecule of phenylpyrazole 147 coordinates to ruthenacycle 206 and undergoes C–H 
activation to form biscyclometalated complex 207. The oxidative addition of alkyl bromide 136 to 
complex 207 generates the stable ruthenium(IV) intermediate 208. Finally, reductive elimination 
followed by ligand exchange delivers the ortho-alkylated product 145 and ruthenacycle 206. In 
contrast, meta-C─H alkylation occurs through a single-electron transfer (SET) process from 
ruthenium(II) complex 206 to alkyl bromides 136, generating the ruthenacycle(III) intermediate 
210 and a stabilized alkyl radical 211 (Scheme 89, right). Subsequently, the radical 211 
preferentially attacks on the arene moiety at the position para to ruthenium, leading to triplet 
ruthenium intermediate 212. Ligand-to-metal electron transfer and rearomatization furnish 
ruthenacycle 213, which undergoes protodemetalation and C─H activation to afford the 
meta-alkylated product 146 and regenerate the active ruthenium species 206. 
 




Scheme 89: Proposed catalytic cycle for ortho- and meta-C–H alkylation. 
 
3.7 Photo-Induced Ruthenium-Catalyzed C–H Arylations at Room Temperature 
In addition to C─H alkylations, ruthenium-catalyzed direct arylations have become an important 
role in crop protection, material sciences, and drug discovery.[29b] The synthesis of biological active 
compounds, such as Anacetrapib, Valsartan, and Candesartan, through direct C─H arylations was 
contributed by Ouellet at Merck,[39] Ackermann,[44] and Seki,[107] respectively (Figure 12). In 
addition, the versatility of ruthenium-catalyzed C─H arylations was reflected by late-stage 
peptide[108] and nucleoside[109] transformations. In spite of major advances, those reports generally 
require high reaction temperatures of 100─140 °C. 
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Figure 12: Selected examples of biologically active biaryl compounds. 
 
Photoredox catalysis[110] allows for direct C─H functionalizations at room temperature, 
nonetheless, additional iridium[111] or ruthenium[112] photocatalysts are typically required in these 
catalytic transformations. To avoid this issue, the group of Ackermann[92] and then Greaney[113] 
disclosed visible-light-induced ruthenium-catalyzed remote C─H alkylations. According to those 
protocols, an in situ generated cyclometalated ruthenium complex performed as a catalyst for 
photocatalysis and cross couplings. The versatility of photo-induced ruthenium-catalyzed C─H 
transformations was further examined for direct arylations (Scheme 90). Among different 
arylating agents, 4-iodoanisole (46a) provided the best results for the photoredox arylations. 
 
  
Scheme 90: Ruthenium-catalyzed direct C–H arylation under photoredox condition. 
 
3.7.1 Optimization Studies 
The reaction conditions for room temperature direct arylations were probed by using various 
organic solvents and micellar media (Table 19). DMA solvent provided the best catalytic efficacy 
for direct arylations (entries 1─9). Although the reaction in 1,4-dioxane gave slightly lower 
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efficiency, 1,4-dioxane was also chosen as the optimal solvents since it is easy to operate. It is 
noteworthy that the reaction in the dark furnished only a trace amount of product 151a, which 
proved blue light to be essential in the catalytic transformations (entry 3). Moreover, 
environmentally benign water and micellar medium afforded the low to moderate yields of the 
corresponding product 151a (entries 10─18).  
 
Table 19: Reaction media for photo-induced direct arylation.[a] 
 
Entry x equiv Solvent/Medium 151a (%) 
1 1.5 1,4-dioxane 66 (68) 
2 2.0 1,4-dioxane 70 (72) 
3 2.0 1,4-dioxane (3)[b] 
4 2.0 1,2-DCE (22)[c] 
5 2.0 PhMe (12) 
6 1.5 2-MeTHF (17) 
7 1.5 MeCN (3)[c] 
8 1.5 DMA 84 (86)[c] 
9 1.5 NMP (49)[c] 
10 1.5 TPGS-750-M/H2O (2 wt%) (16) 
11 1.5 SPGS-550-M/H2O (2 wt%) (38) 
12 1.5 PTS/H2O (5 wt%) (30) 
13 1.5 Triton X-100/H2O (10 wt%) (54) 
14 1.5 Tween 20/H2O (10 wt%) (51) 
15 1.5 Brij 93/H2O (10 wt%) (15) 
16 1.5 Brij 35/H2O (10 wt%) (26) 
17 1.5 SDS/H2O (10 wt%) (47) 
18 1.5 H2O (19) 
[a] Reaction conditions: 68e (0.5 mmol), 46a (x equiv), [RuCl2(p-cymene)]2 (5.0 mol %), NaOAc (1.0 mmol), solvent 
(2.0 mL), 30─35 °C, 24 h, under N2, irradiate Blue LEDs; yield of isolated products. The conversion in the parentheses 
were determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard. [b] without light 
at 30─35 °C. [c] Reactions were performed by M. Waeterschoot. 
 
3 Results and Discussion 
106 
Among acetate bases, KOAc in 1,4-dioxane or DMA similarly provided the high catalytic efficacy 
(Table 20, entries 1─5). While phosphate base failed to give any conversion (entry 6), the 
combination of carboxylic acid additives and K2CO3 smoothly delivered the corresponding product 
151a (entries 7─10). 
 
Table 20: Screening of bases for photo-induced direct arylation.[a] 
 
Entry Additive Base Solvent 151a (%) 
1 --- LiOAc 1,4-dioxane (9)[b] 
2 --- NaOAc 1,4-dioxane 66 (68) 
3 --- KOAc 1,4-dioxane 90 (92)[b] 
4 --- CsOAc 1,4-dioxane (27)[b] 
5 --- KOAc DMA 87 (88) 
6 MesCO2H (31) K3PO4 1,4-dioxane --- 
7 31 K2CO3 1,4-dioxane 91 (93) 
8 31 K2CO3 DMA 89 (88) 
9 1-AdCO2H (12) K2CO3 1,4-dioxane 86 (86) 
10 PivOH K2CO3 1,4-dioxane 93 (93) 
[a] Reaction conditions: 68e (0.50 mmol), 46a (0.75 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), additive (30 mol %), base 
(1.0 mmol), solvent (2.0 mL), 30─35 °C, 24 h, under N2, irradiate Blue LEDs; yield of isolated products. The conversion 
in the parentheses were determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal 
standard. [b] Reactions were performed by M. Waeterschoot. 
 
Afterwards, various ruthenium sources were examined (Table 21). Well-defined 
carboxylate-coordinated ruthenium complexes were highly effective under photoredox 
conditions (entries 1─2). Due to their low solubility in 1,4-dioxane, cationic ruthenium complexes 
provided the unsatisfactory results (entries 3─4), while the reaction in DMA efficiently delivered 
the desired product 151a in moderate yield (entry 5). Other ruthenium sources, such as Ru3(CO)12 
and RuCl3·nH2O (30), failed to furnish product 151a (entries 6─8). 
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Table 21: Ruthenium sources for photo-induced direct arylation.[a] 
 
Entry cat. [Ru] 151a (%) 
1 [Ru(OAc)2(p-cymene)] (181) 94 (95)[b] 
2 [Ru(O2CMes)2(p-cymene)] (33) 88 (91)[b] 
3 [Ru(NCt-Bu)6][BF4]2 (6) 
4 [Ru(NCt-Bu)6][PF6]2 (4) 
5 [Ru(NCt-Bu)6][PF6]2 (52)[c] 
6 Ru3(CO)12 ---[d] 
7 RuCl3·nH2O (30) ---[d] 
8 30 ---[d, e] 
[a] Reaction conditions: 68e (0.50 mmol), 46a (0.75 mmol), [Ru] (10 mol %), MesCO2H (30 mol %), K2CO3 (1.0 mmol), 
1,4-dioxane (2.0 mL), 30─35 °C, 24 h, under N2, irradiate Blue LEDs; yield of isolated products. The conversion in the 
parentheses were determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal standard.        
[b] Without MesCO2H. [c] DMA (2.0 mL). [d] Reactions were performed by M. Waeterschoot. [e] NMP (2.0 mL). 
 
Notably, aryl iodide proved to be the most effective substrate in the photo-induced arylations 
(Table 22). The reactions of aryl bromide also furnished the desired arylated product 151a with 
high catalytic efficacy (entries 2─3), while chloride and triflate delivered the moderate yields of 
the product 151a (entries 4─6). In addition, control experiments verified the essential role of the 
ruthenium catalyst, carboxylate, base, and blue light, as conducted by M. Waeterschoot.[114] 
 
Table 22: Screening of aryl (pseudo)halides for photo-induced direct arylation.[a] 
 
Entry X Solvent 151a (%) 
1 I 1,4-dioxane 94 (95) 
2 Br 1,4-dioxane 68 (69) 
3 Br DMA 75 (75) 
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Entry X Solvent 151a (%) 
4 Cl 1,4-dioxane (43) 
5 Cl DMA (6) 
6 OTf 1,4-dioxane 39[b] 
[a] Reaction conditions: 68e (0.50 mmol), ArX 46a (0.75 mmol), [Ru(OAc)2(p-cymene)] (10 mol %), K2CO3 (1.0 mmol), 
1,4-dioxane or DMA (2.0 mL), 30─35 °C, 24 h, under N2, irradiate Blue LEDs; yield of isolated products. The conversion 
in the parentheses were determined by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as the internal 
standard. [b] Reactions were performed by A. Casnati. 
 
3.7.2 Scope of Photo-Induced Ruthenium-Catalyzed Direct C–H Arylation 
Having the optimized reaction conditions in hand, the robustness of photo-induced 
ruthenium-catalyzed direct C–H arylation was explored by a variety of aryl iodides 46 (Scheme 91). 
Electron-donating and electron-withdrawing groups of para- and meta-substituted aryl halides 46 
were well tolerated, providing the corresponding arylated products 151 with moderate to high 
efficacy. It is noteworthy that the ruthenium-catalyzed C–H arylation proved broadly applicable, 
tolerating sensitive functional groups, including halides (151c─151e, 151i), ketone (151k), ester 
(151f and 151s) and nitrile (151l). Sterically hindered 2-iodoanisole (46m) was also converted to 
the desired product 151m. Furthermore, the ruthenium(II) catalysis was effective for (NH)-free 
indole (151o) and carbazole (151t). The connectivity of the thus-obtained products 151o and 151t 
was unambiguously confirmed by X-ray crystal structure analyses.  
Besides monohaloarenes, the versatility of the room temperature ruthenium catalysis was 
mirrored by twofold (216a and 216b) and threefold C–H functionalization (216c) (Scheme 92). The 
molecular structure of product 216b was established by X-ray crystal structure analysis. 




Scheme 91: Visible-light-induced ruthenium-catalyzed direct arylation of pyridine 68e. 
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Scheme 92: Twofold and threefold C–H arylations of pyridine 68e. 
 
The photo-induced direct arylation was not limited to the assistance of pyridines. Indeed, arenes 
bearing pyrimidines (151x), transformable imidates (151y), removable pyrazoles (151z and 
151aa), and substituted click-triazoles (151ab) were effective in the photoredox direct arylations 
(Scheme 93). The potential of the visible-light-induced ruthenium-catalyzed direct arylation was 
highlighted by the late-stage diversification of biorelevant purines 151ac–151ad, sensitive 
nucleoside 151ae, and nucleotide 151af. 
 




Scheme 93: Light-induced direct arylation of various heterorenes. 
 
In addition, ketimine 135z underwent the direct arylation followed by acidic hydrolysis to deliver 
the ortho-arylated acetophenone 217, which was unambiguously confirmed by X-ray crystal 
structure analysis (Scheme 94). 
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Scheme 94: Photoredox arylation of ketimine 135z at room temperature. 
 
Despite of broad applicability of the reaction procedure, some unsuccessful starting materials, 
such as 2-pyridylindole, 1-naphthol, and 2-pyridylpyrrole, among others, as well as some 
ineffective aryl halides are listed in Figure 13. 
 
 
Figure 13: Unsuccessful substrates and aryl halides in the direct arylation. 
 
3.7.3 Mechanistic Studies 
Given the versatility of the room temperature photo-indued direct C–H arylations, mechanistic 
experiments were conducted to explain its working mode. A cationic monocyclometalated 
complex 218 proved to be highly effective in the presence of KOAc (Scheme 95). Moreover, the 
significant amount of free p-cymene was detected in the first period of the photo-induced 
transformation, which was found by J. Struwe.[114] These findings are suggestive of a  
p-cymene-free carboxylate-modified ruthenacycle as a catalytically active intermediate in the 
photoredox catalysis. Under the visible-light-driven direct arylations conditions, the quantum 
3.7 Photo-Induced Ruthenium-Catalyzed C–H Arylations at Room Temperature 
 
113 
yield of Ф = 0.087 was observed.[114] Furthermore, an on/off light experiment performed by J. 
Struwe was indicative of the photoredox arylation not involving a radical chain process.[114] 
 
 
Scheme 95: Light-driven direct arylation catalyzed by cyclometalated ruthenium 218. 
 
3.7.4 Plausible Catalytic Cycle 
On the basis of the mechanistic findings in experiments and computations,[114] a plausible catalytic 
cycle was proposed, which commences by twofold carboxylate-assisted C–H ruthenation and 
dissociation of p-cymene, affording the corresponding biscyclometalated complex 219 (Scheme 
96). The coordination of iodoarene to complex 219 leads to ruthenacycle 220, which is excited by 
blue-light-absorption to form singlet excited species 220*. Relaxation through intersystem 
crossing (ISC) furnishes a long-lived triplet ruthenacycle 220**. Afterwards, an inner-sphere 
electron transfer (ISET) to iodoarene generates ruthenium(III) intermediate 221 and a phenyl 
radical (222), which readily recombine to form stable ruthenium(IV) intermediate 223. Reductive 
elimination and ligand exchange deliver the arylated product 151 and ruthenium(II) complex 224, 
which finally undergoes C–H bond activation to regenerate the photocatalytically active 
ruthenium(II) complex 219. 
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4 Summary and Outlook 
C–H and C–C activations have proven to bear great potential for the construction of C–C and           
C–Het bonds, with widespread applications to pharmaceutical, agrochemical chemistry, and 
material sciences. Ruthenium catalysis offers a powerful tool for site-selective C–H 
functionalizations. To further promote the catalytic C–H and C–C activation, a mechanistic 
understanding of the transformations is essential. Within this thesis, several new synthetic 
strategies were investigated for ruthenium-catalyzed site-selective C–H and C–C functionalization. 
First, methods for remote meta-C–H bromination were developed (Scheme 97).[95] Both of 
homogeneous RuCl3·nH2O (30) and heterogeneous ruthenium catalyst 152 showed comparable 
catalytic efficacy, furnishing the meta-brominated products 133 with excellent levels of positional 
selectivity. In addition to pyridine and pyrimidine, biorelevant purines 123 was for the first time 
employed as a directing group in remote C–H functionalization.  
 
 
Scheme 97: Remote meta-C–H bromination of purine 123 by homogeneous or heterogenous 
ruthenium catalyst. 
 
The second project focused on remote meta-C–H alkylations of arenes bearing with removable 
and transformable ketimines 135 (Scheme 98).[96] The alkylation reaction required PhCMe3 as the 
solvent to prevent a side reaction at the benzylic position. Sequential one-pot remote alkylation 
followed by acid hydrolysis highlighted a broad substrate scope of different arylketimines 135 and 
a variety of secondary and tertiary alkyl bromides 136. Moreover, the method was tolerant of 
various functional groups, valuable heterocycles, and structurally complex cholesterol. TMP-NH2 
could be recovered by an acid-base extraction. Mechanistic experiments gave strong support for 
a radical-type mechanism of meta-C–H alkylations. The power of this remote transformation set 
the stage for operationally simple one-pot protocols for the synthesis of meta-alkylated benzyl 
amines and the sequential twofold meta-/ortho-C–H activation. Furthermore, the transformation 
of the obtained alkylated phenones 154 provided a general platform to synthetically useful meta-
substituted arenes, including anilines, phenols, acids, and indoles.  
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Scheme 98: Sequential one-pot ruthenium-catalyzed remote meta-alkylation. 
 
In continuation of ruthenium-catalyzed remote transformations, the cooperation of carboxylate 
and phosphine ligands in ruthenium catalysis offered a general method for highly selective 
meta-C–H alkylations of α-bromo carbonyl compounds 140, such as ketones, esters, and amides 
(Scheme 99a).[101] In contrast to the previous projects, the synergistic ruthenium catalysis was 
performed at lower reaction temperature. Moreover, the remote protocol was applicable to 
broad heterocyclic directing groups, such as pyridines, pyrimidines, removable pyrazoles, 
transformable oxazolines, and biologically relevant purines. In particular, remote alkylation of 
ketimine led to concise synthesis of an anti-inflammatory drug, Ketoprofen derivatives. 
Furthermore, the synergistic transformation was highlighted by sequential meta-alkylation/ortho-
arylation in a user-friendly one-pot fashion, allowing for late-stage fluorescence labelling on 
purine bases. In addition to site-selectivity, the excellent chemo-selectivity of ruthenium-
catalyzed twofold C–H activations was obtained by controlling reaction temperature. Detailed 
experimental mechanistic studies, including unprecedented EPR studies, were strongly supportive 
of a reversible C–H ruthenation and a single-electron transfer process, suggesting the formation 
of an arene-ligand-free cyclometalated ruthenium(III) complex. In contrast, the catalytic alkylation 
of N-pyrimidyl aniline 125a took place on the arene at the position para to directing group, 
delivering the para-alkylated product 180a (Scheme 99b). Detailed mechanistic investigations for 
para-selective transformation should be provided in the future. 




Scheme 99: Carboxylate-phosphine ruthenium catalysis for remote meta- or para-C–H alkylation. 
 
In addition to meta-alkylation, the synergistic ruthenium catalysis proved to be a general tool for 
remote meta-benzylation (Scheme 100a).[104] The addition of phosphine ligand exerted an 
influence on positional selectivity of a ruthenium-catalyzed C–H benzylation. In addition to a broad 
substrate scope, the cooperative ruthenium catalysis set a stage for broadly effective late-stage 
C–H diversification of biologically relevant molecules and structurally complex drugs, including 
monosaccharides, nucleotides, triglycerides, amino acids, and peptides, as well as fluorescence 
label BODIPY (Scheme 100b). Particularly, fully unprotected OH-free monosaccharides proved to 
be tolerant. Mechanistic insights were suggestive of a reversible, carboxylate-assisted C–H 
ruthenation and a radical-involving mechanism. Moreover, the well-defined ruthenacycle trans-
192a showed a reversible redox event and proved to be a key intermediate of the remote 
functionalization.   
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Scheme 100: Remote meta-benzylation and late-stage diversification. 
 
The next project focused on a ruthenium-catalyzed decarboxylative C–C activation enabled 
site-selective new C–C bond formation (Scheme 101).[106] Catalytic reaction of primary alkyl 
bromides provided the ortho-alkylated products 145, whereas secondary and tertiary alkyl 
bromides mostly led to meta-selective alkylation. Surprisingly, the decarboxylative 
transformations of bromocyclohexane (136j) and exo-2-bromonorbornane (136u) afforded the 
alkylation at the ortho position, which were unusual for secondary alkyl halides. In case of 
α-bromo carbonyl compounds and secondary benzyl chlorides, the addition of phosphine ligand 
was essential for the decarboxylative alkylation. Mechanistic insights including experiments with 
radical scavengers and the observed benzylation as a side-reaction were supportive of the 
homolytic C–X bond cleavage of alkyl halide. Additionally, p-cymene-free cyclometalated 
ruthenium complex was proposed as a catalytically active species. To understand the working 
mode of C–C activation, more detailed mechanistic insights by experiment and computation 
should be investigated in the future. 




Scheme 101: Ruthenium-catalyzed decarboxylative alkylation of acid 144. 
 
In spite of major breakthrough in C–C activation chemistry, the nucleophilic substitution of 
carboxylate to alkyl halide forming alkyl ester became the limitation of the decarboxylative 
transformation.   
Owing to decarboxylative ortho-selective alkylation of bromocyclohexane and 
exo-2-bromonorbornane, positional selectivity in ruthenium-catalyzed C–H alkylation of pyrazoles 
was examined (Scheme 102).[106] Steric hindrance of alkyl halides and directing group of arenes 
had significant impacts on positional selectivity of the catalytic alkylation. Detailed mechanistic 
experiments were suggestive of two distinct mechanisms, a concerted oxidative 
addition/reductive elimination event for the ortho-C–H alkylation, while a SET pathway is 
proposed for the meta-functionalization. In addition, an arene-ligand-free ruthenacycle was 
identified as the catalytically active species in the catalysis. 
 
 
Scheme 102: Site-selective ortho- or meta-alkylation of pyrazoles 147 under ruthenium catalysis. 
 
The last project focused on integrating the chemistry of C–H activation and photoredox for direct 
arylation under exceedingly mild conditions (Scheme 103). Visible-light-induced ruthenium-
catalyzed direct C–H arylation at room temperature was evolved without exogenous 
photocatalysts.[114] The catalytic method was tolerant of various functional groups and valuable 
heteroaromatic compounds, especially NH-free indole. In addition, twofold and threefold C–H 
activations of di- and triiodoarenes were highly effective. Notably, the power of this photoredox 
transformation set a stage for late-stage C–H arylation of sensitive nucleosides and nucleotides. 
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Detailed mechanistic investigations by experiments and computations were indicative of the 
in situ generated cyclometalated ruthenium complex 219 being a photocatalytically active species, 
which underwent light-induced metal-to-ligand charge-transfer and intersystem crossing to form 
long-lived triplet species. In addition, calculations were suggestive of an inner-sphere electron 
transfer process to be a preferable pathway. 
 
 
Scheme 103: Visible-light-induced ruthenium-catalyzed direct arylation at room temperature. 
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5 Experimental Part 
5.1 General Remarks 
All reactions involving moisture- or air-sensitive reagents or products were performed under an 
atmosphere of nitrogen using pre-dried glassware and standard Schlenk techniques. If not 
otherwise mentioned yields refer to isolated compounds, estimated to be >95% pure as 
determined by 1H-NMR. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on Merck, silica gel 60 F254 aluminum 
sheets. Detection was performed under UV light at 254 or 365 nm or developed by treatment with 
a potassium permanganate solution followed by careful warming or iodine spray technique. 
Chromatographic purification of products was accomplished by flash column chromatography on 
Merck Geduran® silica gel, grade 60 (0.040–0.063 mm, 230–400 mesh ASTM). 
 
High-performance Liquid Chromatography 
Analytical high-performance liquid chromatography (HPLC) for determination of the enantiomeric 
excess was performed on an Agilent 1260/1290 Infinity equipped with Daicel CHIRALPAK IA-3 or 
IC-3 (4.6 mm × 250 mm, 3 μm particle size, 1 mL/min flow rate). Preparative HPLC from Agilent 
1260 Infinity equipped with VP 250/16 Nucleodur 100-10 C18 ec column. 
 
Recycling Preparative HPLC 
Recycling preparative HPLC or gel permeation chromatography (GPC) was performed on a Japan 
Analytical Industries (JAI) LC-92XX II NEXT system equipped with a JAIGEL 2.5HR or JAIGEL 2HH 
column. Chloroform was used as the solvent. 
 
Cyclic Voltammetry  
Cyclic Voltammetry (CV) spectra were measured using a Metrohm Autolab PGSTAT204 
workstation using a glassy-carbon disc electrode (3.0 mm diameter, CH Instruments) as a working 
electrode, a platinum wire (1.0 mm diameter, 99.99%, chempur) as a counter electrode and a 
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Ag/AgCl electrode as a reference electrode. The CV spectra were measured with n-Bu4NPF6 (0.1 M 
in 1,2-DCE, Sigma-Aldrich) as electrolyte and a sample concentration of 4 mM, at a 100 mV∙s–1 
scanning rate. The data were analysed with NOVA 2.1.3 software (Metrohm) 
 
Electron Paramagnetic Resonance 
Continuous-wave (CW) electron paramagnetic resonance (EPR) spectra were recorded at X-band 
microwave frequencies (9 GHz) using a Bruker ElexSys E500 spectrometer with a Bruker SuperX 
CW bridge. The spectrometer was equipped with the Bruker SHQ rectangular microwave cavity 




Fluorescence excitation and emission data in solution were recorded on a Jasco® FP-8500 
spectrofluorometer. The scan speed was adjusted to 500 or 1000 nm/min. All compounds were 
measured at a concentration of 1 mg∙L–1 in CHCl3.  
 
UV-VIS Spectroscopy  
UV-Visible Spectroscopy was performed on a Jasco® V-770 spectrophotometer. A baseline in the 
appropriate solvent was obtained prior to recording spectra. 
 
Gas Chromatography 
Gas chromatographic analysis (GC) was performed on an Agilent 7890A GC system or Agilent 
7890B GC System equipped with an Agilent HP-5 column (30 m, 0.320 mm diameter, 0.25 μm film 
thickness) and a flame-ionization detector (FID) using hydrogen as the carrier gas. Gas 
chromatography coupled with mass spectrometry (GC-MS) was performed on the same 
instrument equipped with an Agilent HP-5MS column (30 m, 0.250 mm diameter, 0.25 μm film 
thickness) and an Agilent 5875C Triple-Axis-Detector or an Agilent 5977B MSD. Mass spectra were 








Infrared (IR) spectra were recorded on a Bruker Alpha-P FT-IR spectrometer with a diamond ATR 
probe in the range of 4000–400 cm–1. Liquid samples were measured as film and solid samples 




Electron-ionization (EI) and EI high resolution mass spectra (HR-MS) were recorded on a Jeol 
AccuTOF instrument at 70 eV. Electrospray-ionization (ESI) mass spectra were obtained on Bruker 
micrOTOF and maXis instruments. All systems are equipped with time-of-flight (TOF) analyzers. 
Liquid injection field desorption/ionization (LIFDI) mass spectra were measured on a Jeol AccuTOF 
instrument with a Linden CMS. The ratios of mass to charge (m/z) are indicated and the intensity 
relative to the base peak (I = 100) is given in parenthesis. 
 
Melting Points 
Melting points (m.p.) were measured on a Stuart® Melting Point Apparatus SMP3 from 
Barloworld Scientific. All values are uncorrected. 
 
Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectra were recorded on Varian Mercury Plus 300, Inova 500, 
Inova 600 or Bruker Avance III 300, Avance III HD 300, Avance III 400, Avance III HD 400, Avance 
Neo 400, Avance III HD 500 spectrometer. All measurements were performed at 298 K. Chemical 
shifts (δ) are reported in ppm. 1H- and 13C-NMR spectra were calibrated using the residual proton 
peak or carbon peak of the deuterated solvent, respectively (see table). For 19F- and 31P-NMR 
spectra were referenced using CFCl3 and 85% phosphoric acid as external standard, respectively. 
 
Solvent 1H-NMR 13C-NMR 
CDCl3 7.26 ppm 77.16 ppm 
CD2Cl2 5.32 ppm 53.84 ppm 
DMSO-d6 2.50 ppm 39.52 ppm 
Acetone-d6 2.05 ppm 29.84, 206.26 ppm 
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Solvent 1H-NMR 13C-NMR 
PhMe-d8 2.08, 6.97, 7.01, 7.09 ppm 
20.43, 125.13, 127.96, 
128.87, 137.48 ppm 
THF-d8 1.72, 3.58 ppm 25.31, 67.21 ppm 
MeCN-d3 1.94 ppm 1.32, 118.26 ppm 
 
The observed multiplicities are reported as follows: s (singlet), d (doublet), t (triplet), q (quartet), 
p (pentet), hept (heptet), m (multiplet) or combinations thereof. The coupling constants J are 
given in Hertz (Hz). All spectra were analyzed using Mestrelab Research MestReNova v. 10.0.2 
software. 
 
Crystal Structure Analysis 
X-ray structures were measured on a Bruker D8 Venture four-circle-diffractometer from Bruker 
AXS GmbH equipped with a Photon II detector purchased from Bruker AXS GmbH and using 
microfocus IμS Cu/Mo radiation from Incoatec GmbH with HELIOS mirror optics and single-hole 
collimator from Bruker AXS GmbH. 
 
Vacuum 




All solvents used for work-up and purification were distilled prior to use. Solvents used in reactions 
involving air- or moisture-sensitive compounds were dried, distilled, and stored under an inert 
atmosphere of nitrogen or argon according to the following standard procedures. 
Solvents purified by solvent purification system (SPS-800) from M. Braun: Dichloromethane, 
diethyl ether, N,N-dimethylformamide, tetrahydrofuran, toluene.  
Solvents dried and distilled over Na using benzophenone as indicator: 1,4-Dioxane, n-hexane, 
toluene, o-xylene. 
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Solvents dried and distilled over CaH2: 1,2-Dichloroethane, N,N-dimethylacetamide, 
N,N-dimethylformamide, dimethylsulfoxide, N-methyl-2-pyrrolidone, pyridine, triethylamine.  
Solvents dried over molecular sieve and degassed by freeze-pump-thaw cycles: Acetonitrile (3 Å), 
acetonitrile-d3 (3 Å), tert-butylbenzene (4 Å), chloroform-d (4 Å), dichloromethane-d2 (4 Å), 
2-methyltetrahydrofuran (4 Å), tetrahydrofuran-d8 (4 Å), toluene-d8 (4 Å).  
Methanol was dried and distilled over Mg(OMe)2. 
Water was degassed before its use by repeated freeze-pump-thaw cycles. 
 
Reagents 
Chemicals obtained from commercial sources were used without further purification unless stated 
otherwise. K2CO3 was dried at 140 °C and 4∙10–1 mbar for 16 h and stored under an atmosphere 
of N2.  
The following compounds were synthesized according to previously described literature 
protocols: 
2-Arylpyridines 68a, 68d, 68e, 68h,[115] ruthenacycle 98, 218,[46] purines 123a, 123d,[116]               
123l–123n,[117] ketimines 135,[118] 1-bromo-1-methylcyclohexane (136a),[119] 2-arylpyrimidines 
139a–139c, 139e–139g,[120]  2-(o-tolyl)pyrimidine (139d),[121] 4-butyl-1-(2-methoxyphenyl)-1H-
1,2,3-triazole (139m),[41] arylpyrazoles 147a, 147d–147j,[122] 4-bromo-1-phenyl-1H-pyrazole 
(147b),[123] 3,5-dimethyl-1-phenyl-1H-pyrazole (147c),[124] [Ru(O2CAd)2(p-cymene)] (163),[33] 
[Ru(OPiv)2(p-cymene)],[33] benzyl chlorides 142d–142e, 186n,[125] BODIPY 186a,[126] 2,7-diiodo-9H-
fluorene (215a),[127] 3,6-diiodo-9H-carbazole (215b),[128] and tris(4-iodophenyl)amine (215c).[129] 
The following chemicals were kindly provided by the persons named below:  
Karsten Rauch: [RuCl2(p-cymene)]2, [Ru(O2CMes)2(p-cymene)] (33), [Ru(OAc)2(p-cymene)] (181).  
Dr. David J. Burns: purines 123e–123g. 
Dr. Svenja Warratz: Ru@SiO2 (152), [RuCl2(PhCMe3)]2, Ru(OAc)2(PPh3)2, Ru(OAc)2(PPh3)3. 
Prof. Dr. Hongjun Ren: 1-(4-bromophenyl)pyrene (165d).  
Nikolaos Kaplaneris: 5-chloro-N-phenylpyrimidin-2-amine (125a), 2-(4-methoxyphenyl)-4,5-
dihydrooxazole (139i), 2-(4-bromophenyl)-4,5-dihydrooxazole (139j), 2-(2-ethoxyphenyl)-4,5-
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dihydrooxazole (139k), 2-bromo-1-morpholinopropan-1-one (140e), methyl 2,5-
dibromopentanoate (140f), 2-bromo-N,N-diethylpropanamide (140h), (tetrahydrofuran-2-
yl)methyl 2-bromopropanoate (140l), benzoic acid 178.  
Dr. Torben Rogge: 2-(2-methoxyphenyl)pyridine (68f), 2-[2-(trifluoromethyl)phenyl]pyridine 
(68g). 
Dr. Joachim Loup: chiral phosphoramidite ligands. 
 
5.2 General Procedures 
5.2.1 General Procedure A: Ruthenium-Catalyzed meta-Selective Bromination 
A microwave vial was charged with purine 123 or heteroarene 68, 139, 147 (0.30 mmol), NBS (62, 
107 mg, 0.60 mmol) and 152 (0.14 mmol[Ru]/g, 214 mg, 10 mol %) in DMA (0.6 mL) and the 
mixture was stirred open to air at 80–100 °C. After 20 h, the resulting mixture was filtered and 
washed with CH2Cl2 (20 mL). The filtrate was concentrated in vacuo. Purification of the residue by 
column chromatography (SiO2, n-hexane/EtOAc) yielded meta-brominated products 133 or 153. 
 
5.2.2 General Procedure B: Ruthenium(II)-Catalyzed Remote meta-C–H Alkylations of 
Ketimines using 1-AdCO2H as the Ligand 
Ketimine 135 (0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 25.0 μmol, 5.0 mol %), 1-AdCO2H (12, 
27.3 mg, 0.15 mmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 25 mL 
pressure tube. The tube was evacuated and purged with N2 for three times. Alkyl bromide 136 
(1.50 mmol) and PhCMe3 (2.0 mL) were then added and the mixture was stirred at 120 °C for 20 h. 
At ambient temperature, HCl (2 N, 3.0 mL) was added, and the resulting mixture was stirred for an 
additional 3 h, and then extracted with EtOAc or Et2O (3 × 20 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc or n-pentane/Et2O) yielded phenone 154. 
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5.2.3 General Procedure C: Ruthenium(II)-Catalyzed Remote meta-C–H Alkylations of 
Ketimines using Piv-Ile-OH as the Ligand 
Ketimine 135 (0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 25.0 μmol, 5.0 mol %), Piv-Ile-OH (155, 
32.3 mg, 0.15 mmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 25 mL 
pressure tube. The tube was evacuated and purged with N2 for three times. Alkyl bromide 136 
(1.50 mmol) and PhCMe3 (2.0 mL) were then added and the mixture was stirred at 120 °C for 20 h. 
At ambient temperature, HCl (2 N, 3.0 mL) was added, and the resulting mixture was stirred for an 
additional 3 h, and then extracted with EtOAc or Et2O (3 × 20 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc or n-pentane/Et2O) yielded phenone 154. 
 
5.2.4 General Procedure D: Ruthenium(II)-Catalyzed Remote meta-C–H Alkylations of 
Ketimines Followed by Reduction in One-Pot Fashion 
Ketimine 135 (0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 25.0 μmol, 5.0 mol %), 1-AdCO2H (12, 
27.3 mg, 0.15 mmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 25 mL 
pressure tube. The tube was evacuated and purged with N2 for three times. Alkyl bromide 136 
(1.50 mmol) and PhCMe3 (2.0 mL) were then added and the mixture was stirred at 120 °C for 20 h. 
Then, a solution of ZnCl2 in THF (1.0 M, 0.50 mmol), NaBH3CN (63.5 mg, 2.00 mmol) and MeOH 
(1.5 mL) were successively added to the reaction mixture at ambient temperature. The reaction 
mixture was stirred at ambient temperature for 16 h and then distributed between Et2O (8 mL) 
and sat. aq. K2CO3 (8 mL). The aqueous phase was extracted with Et2O (2 × 10 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography (SiO2, n-hexane/EtOAc) yielded 157. 
 
5.2.5 General Procedure E: Ruthenium(II)-Catalyzed Remote meta-C–H Alkylations using 
PPh3 as the Ligand 
Heteroarene 68b, 123a, 139, or 147 (0.50 mmol), [Ru(O2CAd)2(p-cymene)] (163, 29.7 mg, 
50.0 μmol, 10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were 
placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 for three 
times. Alkyl bromide 140 (1.50 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture 
was stirred at 40 °C. After 20 h, the resulting mixture was filtered through a pad of silica gel and 
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washed with EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc) yielded meta-alkylated product 141. 
 
5.2.6 General Procedure F: Ruthenium(II)-Catalyzed Sequential meta-Alkylation/ortho-
Arylation  
Heteroarene 123a or 147 (0.50 mmol), [Ru(O2CAd)2(p-cymene)] (163, 29.7 mg, 50.0 μmol, 
10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) were placed in a 
pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 for three times. Alkyl 
bromide 140 (1.50 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred 
at 60 °C. After 20 h, bromoarene 165 (1.00 or 1.50 mmol) was added to the reaction mixture at 
ambient temperature and the mixture was stirred at 120 °C for an additional 20 h. The resulting 
mixture was filtered through a pad of silica gel and washed with EtOAc. The filtrate was 
concentrated in vacuo. Purification of the residue by column chromatography (SiO2, 
n-hexane/EtOAc) yielded product 166. 
 
5.2.7 General Procedure G: Ruthenium(II)-Catalyzed Sequential meta-Alkylation/ortho-
Arylation in One-Pot Fashion by Temperature Control 
Heteroarene 139 or 147 (0.50 mmol), [Ru(O2CAd)2(p-cymene)] (163, 29.7 mg, 50.0 μmol, 
10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (276 mg, 2.00 mmol) were placed in a 
pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 for three times. Alkyl 
bromide 140a (1.50 mmol), bromoarene 165 (1.50 mmol), and 1,4-dioxane (2.0 mL) were then 
added and the mixture was stirred at 40 °C. After 18 h, the reaction mixture was stirred at 120 °C 
for an additional 18 h. Afterwards, the resulting mixture was filtered through a pad of silica gel 
and washed with EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by 
column chromatography (SiO2, n-hexane/EtOAc) yielded product 166. 
 
5.2.8 General Procedure H: Photocatalytic Decarboxylation 
Carboxylic acid 175 or 178 (0.20 mmol), bis(4-chlorophenyl)disulfide (5.8 mg, 20.0 μmol, 
10 mol %), and photocatalyst [Mes-Acr-Me][ClO4] (176, 1.0–4.8 mol %) were placed in 10 mL vial. 
The vial was evacuated and purged with N2 for three times. To the reaction mixture was added 
2,6-lutidine (5 μL, 40.0 μmol, 20 mol %) and 1,2-DCE (8.0 mL). The mixture was degassed for 
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5 min. The reaction mixture was stirred under blue LED irradiation (8 W). After 16 h, the solvent 
was removed in vacuo. Purification of the residue by column chromatography (SiO2, n-
hexane/EtOAc or CH2Cl2/HOAc) yielded product 177 or 179. 
 
5.2.9 General Procedure I: Ruthenium(II)-Catalyzed meta-C–H Benzylation of 
Heteroarenes 
Heteroarene 68, 139 or purine 123 (0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 
10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a 
pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. Benzyl 
chloride 142 (1.50 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred 
at 60 °C. After 20 h, the resulting mixture was filtered through a pad of silica gel and washed with 
EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc) yielded meta-benzylated product 143 or 185. 
 
5.2.10 General Procedure J: Late-Satge Diversification through Ruthenium(II)-Catalyzed 
meta-C–H Activation  
Purine 123 (0.25 mmol), [Ru(OAc)2(p-cymene)] (181, 8.9 mg, 25.0 μmol, 10 mol %), PPh3 (6.6 mg, 
25.0 μmol, 10 mol %) and K2CO3 (69 mg, 1.00 mmol) were placed in a pre-dried 25 mL Schlenk 
tube. The tube was evacuated and purged with N2 three times. Alkyl halide 186 (0.50 mmol) and 
1,4-dioxane (1.0 mL) were then added and the mixture was stirred at 60 °C. After 20 h, the 
resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The filtrate was 
concentrated in vacuo. Purification of the residue by column chromatography (SiO2, 
n-hexane/EtOAc) yielded meta-alkylated product 187. 
 
5.2.11 General Procedure K: Ruthenium(II)-Catalyzed C–C Alkylation of Acids 144 
Carboxylic acid 144 (0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 12.5 µmol, 2.5 mol %), MesCO2H 
(31, 24.6 mg, 0.15 mmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 
25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. Alkyl bromide 136 
(1.50 mmol) and o-xylene (1.0 mL) were then added. The Schlenk tube was degassed and filled 
with N2 three times and the mixture was stirred at 120 °C. After 16 h, the resulting mixture was 
filtered through a pad of silica gel and washed with EtOAc. The filtrate was concentrated in vacuo. 
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Purification of the residue by column chromatography (SiO2, n-hexane/EtOAc) yielded alkylated 
product 145 or 146. 
 
5.2.12 General Procedure L: Ruthenium(II)-Catalyzed C–C Alkylation of Acids 144 using 
PPh3 as the Ligand 
Carboxylic acid 144 (0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 12.5 µmol, 2.5 mol %), MesCO2H 
(31, 24.6 mg, 0.15 mmol, 30 mol %), PPh3 (6.6 mg, 25.0 μmol, 5 mol %) and K2CO3 (138 mg, 
1.00 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged 
with N2 three times. Alkyl bromide 140 or benzyl chloride 142 (1.50 mmol) and PhCMe3 (1.0 mL) 
were then added. The Schlenk tube was degassed and filled with N2 three times and the mixture 
was stirred at 120 °C. After 16 h, the resulting mixture was filtered through a pad of silica gel and 
washed with EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc) yielded meta-alkylated product 141g or 202. 
 
5.2.13 General Procedure M: Ruthenium-Catalyzed C–H Alkylations of Pyrazoles 
Pyrazole 147 (0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 12.5 µmol, 2.5 mol %), MesCO2H (31, 
24.6 mg, 0.15 mmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 25 mL 
Schlenk tube. The tube was evacuated and purged with N2 three times. Alkyl bromide 136 (0.75–
1.50 mmol) and PhCMe3 (1.0 mL) were then added and the mixture was stirred at 120 °C. After 
16 h, the resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The 
filtrate was concentrated in vacuo. Purification of the residue by column chromatography (SiO2, 
n-hexane/EtOAc) yielded alkylated product 145 or 146. 
 
5.2.14 General Procedure N: Photo-Induced Ruthenium-Catalyzed C–H Arylations at 
Room Temperature 
Heteroarene 68, 123, 139, or 147 (0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 
10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a 10 mL vial. The vial was capped with a 
septum and wrapped with parafilm. The vial was evacuated and purged with N2 three times. Aryl 
iodide 46 (0.75 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred 
under visible light irradiation (2 × Kessil A360N, temperature was maintained between 30 °C and 
35 °C). After 24 h, the resulting mixture was filtered through a pad of silica gel and washed with 
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EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc) yielded ortho-arylated product 151. 
 
5.3 Experimental Procedures and Analytical Data 
5.3.1 Ruthenium-Catalyzed meta-Selective Bromination 
6-(3-Bromophenyl)-9-iso-propyl-9H-purine (133a) 
The general procedure A was followed using purine 123a (59.6 mg, 0.25 mmol) at 
80 °C. After 20 h, purification by column chromatography (n-hexane/EtOAc 3:1) 
yielded 133a (49.6 mg, 63%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 8.99 (s, 1H), 8.94 (ddd, J = 2.1, 1.6, 0.4 Hz, 1H), 8.78 
(ddd, J = 7.9, 1.6, 1.1 Hz, 1H), 8.18 (s, 1H), 7.62 (ddd, J = 7.9, 2.1, 1.1 Hz, 1H), 7.41 (ddd, J = 7.9, 7.9, 
0.4 Hz, 1H), 4.97 (hept, J = 6.8 Hz, 1H), 1.66 (d, J = 6.8 Hz, 6H). 
 13C-NMR (75 MHz, CDCl3): δ = 152.8 (Cq), 152.2 (Cq), 151.9 (CH), 142.3 (CH), 137.7 (Cq), 133.7 (CH), 
132.3 (CH), 131.5 (Cq), 130.1 (CH), 128.4 (CH), 122.8 (Cq), 47.3 (CH), 22.5 (CH3). 
IR (ATR): ṽ = 2977, 1576, 1553, 1447, 1324, 1217, 786, 736, 698, 646 cm–1. 
m.p.: 120–121 °C. 
MS (EI) m/z (relative intensity): 318 (68) [M(81Br)]+, 316 (69) [M(79Br)]+, 276 (92) [M(81Br)–i-Pr]+, 
274 (94) [M(79Br)–i-Pr]+, 195 (100) [M–i-Pr–Br]+, 141 (27), 44 (48). 
HR-MS (ESI): m/z calcd for C14H1479BrN4+ [M+H]+ 317.0396, found 317.0399. 
 
6-(3-Bromophenyl)-9-n-butyl-9H-purine (133b) 
The general procedure A was followed using purine 123b (75.7 mg, 0.30 mmol) at 
80 °C. After 20 h, purification by column chromatography (n-hexane/EtOAc 3:1) 
yielded 133b (67.7 mg, 68%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 9.02 (s, 1H), 8.97 (dd, J = 2.0, 1.6 Hz, 1H), 8.80 (ddd, 
J = 7.9, 1.6, 1.3 Hz, 1H), 8.13 (s, 1H), 7.65 (ddd, J = 8.0, 2.0, 1.3 Hz, 1H), 7.43 (dd, J = 8.0, 7.9 Hz, 
1H), 4.32 (t, J = 7.3 Hz, 2H), 2.00–1.87 (m, 2H), 1.47–1.33 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). 
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13C-NMR (100 MHz, CDCl3): δ = 152.9 (Cq), 152.7 (Cq), 152.2 (CH), 144.6 (CH), 137.7 (Cq), 133.8 (CH), 
132.4 (CH), 131.1 (Cq), 130.1 (CH), 128.5 (CH), 122.9 (Cq), 43.8 (CH2), 31.9 (CH2), 19.9 (CH2), 13.5 
(CH3). 
IR (ATR): ṽ = 2957, 1579, 1450, 1216, 869, 580, 693, 580, 498, 420 cm–1. 
m.p.: 70−71 °C. 
MS (EI) m/z (relative intensity): 332 (13) [M(81Br)]+, 330 (75) [M(79Br)]+, 289 (100), 274 (42), 208 
(26), 195 (77), 168 (28), 141 (33). 
HR-MS (EI): m/z calcd for C15H1579BrN4+ [M]+ 330.0475, found 330.0476. 
 
6-(3-Bromophenyl)-9-phenyl-9H-purine (133c) 
The general procedure A was followed using purine 123c (81.7 mg, 0.30 mmol) at 
100 °C. After 20 h, purification by column chromatography (n-hexane/EtOAc 4:1) 
yielded 133c (52.4 mg, 50%) as a white soild. 
1H-NMR (400 MHz, CDCl3): δ = 9.08 (s, 1H), 9.01 (ddd, J = 2.1, 1.6, 0.4 Hz, 1H), 8.84 (ddd, J = 7.9, 
1.6, 1.1 Hz, 1H), 8.41 (s, 1H), 7.77–7.73 (m, 2H), 7.67 (ddd, J = 8.0, 2.1, 1.1 Hz, 1H), 7.65–7.59 (m, 
2H), 7.53–7.48 (m, 1H), 7.46 (ddd, J = 8.0, 7.9, 0.4 Hz, 1H). 
13C-NMR (100 MHz, CDCl3): δ = 153.6 (Cq), 153.0 (CH), 152.4 (Cq), 143.6 (CH), 137.5 (Cq), 134.3 (Cq), 
134.0 (CH), 132.5 (CH), 131.5 (Cq), 130.2 (CH), 130.0 (CH), 128.6 (CH), 128.5 (CH), 123.7 (CH), 122.9 
(Cq). 
IR (ATR): ṽ = 3050, 1571, 1507, 1328, 1225, 1192, 928, 755, 686, 645 cm–1. 
m.p.: 180−181 °C. 
MS (EI) m/z (relative intensity): 352 (97) [M(81Br)]+, 350 (100) [M(79Br)]+, 323 (17), 271 (42) [M–
Br]+, 244 (16), 141 (19), 77 (59), 51 (28). 
HR-MS (EI): m/z calcd for C17H1179BrN4+ [M]+ 350.0162, found 350.0161. 
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6-(3-Bromophenyl)-9-(4-fluorobenzyl)-9H-purine (133e)  
The general procedure A was followed using purine 123e (91.3 mg, 
0.30 mmol) at 80 °C. After 20 h, purification by column chromatography 
(n-hexane/EtOAc 3:1) yielded 133e (74.1 mg, 64%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 9.03 (s, 1H), 8.96 (dd, J = 1.9, 1.7 Hz, 1H), 8.79 
(ddd, J = 7.9, 1.7, 1.1 Hz, 1H), 8.09 (s, 1H), 7.63 (ddd, J = 8.0, 1.9, 1.1 Hz, 1H), 7.41 (dd, J = 8.0, 
7.9 Hz, 1H), 7.32 (dd, J = 8.8, 5.2 Hz, 2H), 7.04 (dd, J = 8.8, 8.9 Hz, 2H), 5.43 (s, 2H). 
13C-NMR (75 MHz, CDCl3): δ = 162.7 (d, 1JC–F = 248 Hz, Cq), 153.0 (Cq), 152.5 (Cq), 152.5 (CH), 144.2 
(CH), 137.5 (Cq), 133.8 (CH), 132.4 (CH), 130.9 (Cq), 130.9 (Cq), 130.1 (CH), 129.7 (d, 3JC–F = 8 Hz, 
CH), 128.4 (CH), 122.8 (Cq), 116.1 (d, 2JC–F = 22 Hz, CH), 46.6 (CH2). 
19F-NMR (282 MHz, CDCl3): δ = −112.8 (tt, J = 8.9, 5.2 Hz). 
IR (ATR): ṽ = 3064, 1577, 1552, 1506, 1224, 1202, 765, 733, 697, 641 cm−1. 
m.p.: 155−156 °C. 
MS (EI) m/z (relative intensity): 384 (36) [M(81Br)]+, 383 (38) [M(81Br)−H]+, 382 (36) [M(79Br)]+, 381 
(32) [M(79Br)−H]+, 207 (91), 109 (100), 44 (59). 
HR-MS (ESI): m/z calcd for C18H1379BrFN4+ [M+H]+ 383.0302, found 383.0300. 
 
6-(3-Bromophenyl)-9-(4-chlorobenzyl)-9H-purine (133f)  
The general procedure A was followed using purine 123f (96.3 mg, 
0.30 mmol) at 80 °C. After 20 h, purification by column chromatography 
(n-hexane/EtOAc 3:1) yielded 133f (76.2 mg, 64%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 9.03 (s, 1H), 8.96 (dd, J = 1.9, 1.7 Hz, 1H), 
8.79 (ddd, J = 7.9, 1.7, 1.1 Hz, 1H), 8.10 (s, 1H), 7.64 (ddd, J = 8.0, 1.9, 1.1 Hz, 
1H), 7.42 (dd, J = 8.0, 7.9 Hz, 1H), 7.33 (dAB, J = 8.8 Hz, 2H), 7.26 (dAB, J = 8.8 Hz, 2H), 5.43 (s, 2H). 
13C-NMR (75 MHz, CDCl3): δ = 153.1 (Cq), 152.5 (Cq), 152.5 (CH), 144.2 (CH), 137.5 (Cq), 134.6 (Cq), 
133.9 (CH), 133.5 (Cq), 132.4 (CH), 130.9 (Cq), 130.1 (CH), 129.3 (CH), 129.1 (CH), 128.4 (CH), 122.8 
(Cq), 46.6 (CH2). 
IR (ATR): ṽ = 3058, 2926, 1578, 1495, 1324, 1213, 1091, 764, 695, 638 cm−1. 
m.p.: 166−167 °C. 
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HR-MS (ESI): m/z calcd for C18H1379Br35ClN4+ [M+H]+ 399.0007, found 398.9993. 
 
6-(3-Bromophenyl)-9-[2-(trifluoromethyl)benzyl]-9H-purine (133g) 
The general procedure A was followed using purine 123g (106 mg, 0.30 mmol) 
at 80 °C. After 20 h, purification by column chromatography (n-hexane/EtOAc 
4:1) yielded 133g (86.4 mg, 66%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 9.05 (s, 1H), 8.98 (dd, J = 1.9, 1.8 Hz, 1H), 8.80 
(ddd, J = 7.9, 1.8, 1.1 Hz, 1H), 8.09 (s, 1H), 7.75 (dd, J = 7.4, 1.8 Hz, 1H), 7.64 
(ddd, J = 8.0, 1.9, 1.1 Hz, 1H), 7.50−7.43 (m, 2H), 7.42 (dd, J = 8.0, 7.9 Hz, 1H), 7.22 (dd, J = 7.5, 
1.6 Hz, 1H), 5.70 (s, 2H). 
13C-NMR (100 MHz, CDCl3): δ = 153.3 (Cq), 152.9 (Cq), 152.7 (CH), 144.5 (CH), 137.5 (Cq), 133.9 (CH), 
133.5 (q, 3JC–F = 2 Hz, Cq), 132.7 (q, 4JC–F = 1 Hz, CH), 132.5 (CH), 130.8 (Cq), 130.1 (CH), 129.7 (CH), 
128.7 (CH), 128.5 (CH), 128.1 (q, 2JC–F = 31 Hz, Cq), 126.5 (q, 3JC–F = 6 Hz, CH), 124.2 (q, 1JC–F = 274 Hz, 
Cq), 122.9 (Cq), 43.5 (q, 4JC–F = 3 Hz, CH2). 
19F-NMR (282 MHz, CDCl3): δ = −59.2 (s). 
IR (ATR): ṽ = 3086, 1578, 1555, 1309, 1164, 1100, 1033, 774, 730, 633 cm−1. 
m.p.: 145−146 °C. 
MS (EI) m/z (relative intensity): 434 (17) [M(81Br)]+, 433 (15) [M(81Br)−H]+, 432 (18) [M(79Br)]+, 431 
(13) [M(79Br)−H]+, 365 (57) [M(81Br)−CF3]+, 363 (51) [M(79Br)−CF3]+, 207 (100), 159 (31), 44 (63). 
HR-MS (ESI): m/z calcd for C19H1379BrF3N4 [M+H]+ 433.0270, found 433.0266. 
 
2-(3-Bromo-4-methylphenyl)pyrimidine (153a) 
The general procedure A was followed using 2-(p-tolyl)pyrimidine (139b, 51.1 mg, 
0.30 mmol) at 80 °C. After 20 h, purification by column chromatography 
(n-hexane/CH2Cl2 1:1) yielded 153a (60.1 mg, 80%) as a white soild. 
1H-NMR (600 MHz, CDCl3): δ = 8.78 (d, J = 4.8 Hz, 2H), 8.63 (d, J = 1.8 Hz, 1H), 8.27 (dd, 
J = 7.9, 1.8 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.17 (t, J = 4.8 Hz, 1H), 2.46 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 163.3 (Cq), 157.1 (CH), 140.5 (Cq), 136.9 (Cq), 131.9 (CH), 130.8 (CH), 
126.8 (CH), 125.2 (Cq), 119.2 (CH), 23.0 (CH3). 
5.3 Experimental Procedures and Analytical Data 
 
135 
IR (ATR): ṽ = 3069, 2971, 1566, 1541, 1409, 1374, 1032, 795, 676 cm–1. 
m.p.: 69−70 °C. 
MS (ESI) m/z (relative intensity): 251 (98) [M(81Br)+H]+, 249 (100) [M(79Br)+H]+. 
HR-MS (ESI): m/z calcd for C11H1079BrN2+ [M+H]+ 249.0022, found 249.0025. 
The spectral data are in accordance with those reported in the literature.[78] 
 
2-(3-Bromo-4-fluorophenyl)pyrimidine (153b) 
The general procedure A was followed using 2-(4-fluorophenyl)pyrimidine (139c, 
52.3 mg, 0.30 mmol) at 100 °C. After 20 h, purification by column chromatography 
(n-hexane/CH2Cl2/EtOAc 7:2:1) yielded 153b (21.3 mg, 28%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 8.79 (d, J = 4.9 Hz, 2H), 8.70 (dd, J = 6.9, 2.2 Hz, 1H), 8.39 (ddd, J = 
8.7, 4.9, 2.2 Hz, 1H), 7.22 (dd, J = 8.7, 8.3 Hz, 1H), 7.21 (t, J = 4.9 Hz, 1H). 
13C-NMR (125 MHz, CDCl3): δ = 162.5 (d, 5JC–F = 1 Hz, Cq), 160.7 (d, 1JC–F = 251 Hz, Cq), 157.2 (CH), 
135.0 (d, 4JC–F = 4 Hz, Cq), 133.5 (CH), 128.9 (d, 3JC–F = 8 Hz, CH), 119.3 (CH), 116.4 (d, 2JC–F = 23 Hz, 
CH), 109.4 (d, 2JC–F = 21 Hz, Cq). 
19F-NMR (282 MHz, CDCl3): δ = −104.7 (ddd, J = 8.3, 6.9, 4.9 Hz). 
IR (ATR): ṽ = 2927, 1557, 1489, 1408, 1315, 1242, 810, 796, 675, 601 cm–1. 
m.p.: 112−114 °C. 
MS (EI) m/z (relative intensity): 255 (9) [M(81Br)+H]+, 254 (96) [M(81Br)]+, 253 (16) [M(79Br)+H]+, 
252 (100) [M(79Br)]+, 201 (56), 199 (57), 173 (47) [M−Br]+, 120 (40), 100 (22), 91 (13), 69 (11). 
HR-MS (EI): m/z calcd for C10H679BrFN2+ [M]+ 251.9693, found 251.9693. 
 
2-(3-Bromo-2-methylphenyl)pyrimidine (153c) 
The general procedure A was followed using 2-(o-tolyl)pyrimidine (139d, 51.1 mg, 
0.30 mmol) at 80 °C. After 20 h, purification by column chromatography 
(n-hexane/CH2Cl2/EtOAc 7:2:1) yielded 153c (46.4 mg, 62%) as a colorless oil and 
dibrominated product 153c’ (12.9 mg, 13%) as a white soild. 
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1H-NMR (500 MHz, CDCl3): δ = 8.85 (d, J = 4.9 Hz, 2H), 7.65 (dd, J = 7.9, 1.3 Hz, 1H), 7.60 (dd, J = 
7.8, 1.3 Hz, 1H), 7.25 (t, J = 4.9 Hz, 1H), 7.15 (dd, J = 7.9, 7.8 Hz, 1H), 2.51 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 167.4 (Cq), 157.0 (CH), 140.5 (Cq), 136.5 (Cq), 133.5 (CH), 129.5 (CH), 
126.9 (CH), 126.8 (Cq), 118.9 (CH), 20.6 (CH3). 
IR (ATR): ṽ = 3038, 1567, 1551, 1408, 1001, 777, 672 cm–1. 
MS (EI) m/z (relative intensity): 250 (71) [M(81Br)]+, 249 (100) [M(81Br)−H]+, 248 (74) [M(79Br)]+, 247 
(95) [M(79Br)−H]+, 168 (93) [M−HBr]+, 141 (10), 115 (26), 89 (30), 63 (17). 
HR-MS (ESI): m/z calcd for C11H1079BrN2+ [M+H]+ 249.0022, found 249.0026. 
The spectral data are in accordance with those reported in the literature.[78] 
 
2-(3,6-Dibromo-2-methylphenyl)pyrimidine (153c’) 
1H-NMR (400 MHz, CDCl3): δ = 8.91 (d, J = 5.0 Hz, 2H), 7.49 (d, J = 8.5 Hz, 1H), 7.37 
(dq, J = 8.5, 0.6 Hz, 1H), 7.35 (t, J = 5.0 Hz, 1H), 2.15 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 166.9 (Cq), 157.4 (CH), 141.3 (Cq), 137.7 (Cq), 133.6 
(CH), 131.1 (CH), 124.6 (Cq), 120.9 (Cq), 119.7 (CH), 21.1 (CH3). 
IR (ATR): ṽ = 2924, 1559, 1423, 1386, 1005, 813, 579 cm–1. 
m.p.: 71−72 °C. 
MS (ESI) m/z (relative intensity): 331 (48) [M(81Br81Br)+H]+, 329 (100) [M(81Br79Br)+H]+, 327 (49) 
[M(79Br79Br)+H]+. 
HR-MS (ESI): m/z calcd for C11H979Br81BrN2+ [M+H]+ 328.9107, found 328.9111. 
 
4-Bromo-1-(3-bromophenyl)-1H-pyrazole (153d) 
The general procedure A was followed using 4-bromo-1-phenyl-1H-pyrazole (147b, 
67.0 mg, 0.30 mmol) at 100 °C. After 20 h, purification by column chromatography 
(n-hexane/CH2Cl2 1:1) yielded 153d (21.1 mg, 23%) as a white soild. 
1H-NMR (600 MHz, CDCl3): δ = 7.92 (d, J = 0.7 Hz, 1H), 7.86 (dd, J = 2.1, 2.0 Hz, 1H), 7.67 
(d, J = 0.7 Hz, 1H), 7.57 (ddd, J = 8.2, 2.1, 1.0 Hz, 1H), 7.44 (ddd, J = 8.1, 2.0, 1.0 Hz, 1H), 7.32 (dd, 
J = 8.2, 8.1 Hz, 1H). 
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13C-NMR (125 MHz, CDCl3): δ = 141.9 (CH), 140.5 (Cq), 130.7 (CH), 129.9 (CH), 126.9 (CH), 123.2 
(Cq), 122.1 (CH), 117.2 (CH), 96.2 (Cq). 
IR (ATR): ṽ = 3122, 1579, 1484, 1430, 1378, 1034, 954, 841, 774, 671 cm–1. 
m.p.: 63−64 °C. 
MS (EI) m/z (relative intensity): 305 (5), 304 (50) [M(81Br81Br)]+, 303 (10), 302 (100) [M(81Br79Br)]+, 
301 (5), 300 (51) [M(79Br79Br)]+, 223 (7) [M(81Br)−Br]+, 221 (8) [M(79Br)−Br]+, 196 (16), 194 (14), 157 
(18), 155 (18), 142 (45) [M−Br−Br]+, 115 (17), 75 (20), 63 (12). 
HR-MS (EI): m/z calcd for C9H679Br2N2+ [M]+ 299.8892, found 299.8897. 
The spectral data are in accordance with those reported in the literature.[78] 
 
5.3.2 Ruthenium(II)-Catalyzed Remote meta-C–H Alkylation of Ketimines  
5.3.2.1 Characterization Data for 154 
1-[4-Fluoro-3-(1-methylcyclohexyl)phenyl]ethan-1-one (154aa) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and 1-bromo-1-methylcyclohexane (136a, 266 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-pentane/Et2O 50:1) yielded 154aa 
(85.1 mg, 73%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.99 (dd, J = 8.1, 2.3 Hz, 1H), 7.78 (ddd, J = 8.4, 4.5, 2.3 Hz, 1H), 7.04 
(dd, J = 12.4, 8.4 Hz, 1H), 2.57 (s, 3H), 2.13–2.01 (m, 2H), 1.73–1.53 (m, 4H), 1.53–1.33 (m, 4H), 
1.29 (d, J = 1.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 196.9 (Cq), 165.2 (d, 1JC–F = 257 Hz, Cq), 136.8 (d, 2JC–F = 12 Hz, Cq), 
133.2 (d, 4JC–F = 3 Hz, Cq), 129.1 (d, 3JC–F = 8 Hz, CH), 128.3 (d, 3JC–F = 11 Hz, CH), 116.7 (d, 2JC–F = 26 Hz, 
CH), 37.9 (d, 3JC–F = 4 Hz, Cq), 37.0 (d, 4JC–F = 4 Hz, CH2), 26.5 (CH3), 26.4 (CH3), 26.2 (CH2), 22.5 (CH2).  
19F-NMR (376 MHz, CDCl3): δ = –101.0 (ddd, J = 12.7, 7.9, 4.6 Hz).  
IR (ATR): ṽ = 2953, 2870, 1687, 1590, 1340, 1280, 1067, 830 cm−1.  
MS (EI) m/z (relative intensity): 234 (24) [M]+, 219 (60) [M–Me]+, 178 (35), 163 (62).  
HR-MS (EI): m/z calcd for C15H19FO+ [M]+ 234.1414, found 234.1420. 




The general procedure B was followed using ketimine 135b (143 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 154bb (62.6 mg, 71%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135b (143 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 50:1) yielded 154bb (48.0 mg, 54%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.01 (ddd, J = 2.1, 1.8, 0.5 Hz, 1H), 7.76 (ddd, J = 7.8, 1.8, 1.1 Hz, 
1H), 7.61 (ddd, J = 7.8, 2.1, 1.1 Hz, 1H), 7.40 (ddd, J = 7.8, 7.8, 0.5 Hz, 1H), 2.61 (s, 3H), 1.36 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 198.3 (Cq), 151.6 (Cq), 136.9 (Cq), 130.2 (CH), 128.2 (CH), 125.7 (CH), 
124.8 (CH), 34.9 (Cq), 31.3 (CH3), 26.8 (CH3).  
IR (ATR): ṽ = 2962, 2869, 1682, 1581, 1460, 1353, 1283, 967, 795 cm−1.  
MS (EI) m/z (relative intensity): 176 (21) [M]+, 161 (100) [M–Me]+, 133 (23) [M–Ac]+, 115 (8).  
HR-MS (EI): m/z calcd for C12H16O+ [M]+ 176.1196, found 176.1203. 
The spectral data are in accordance with those reported in the literature.[130] 
 
1-[3-(tert-Butyl)-4-fluorophenyl]ethan-1-one (154ab) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 154ab (72.0 mg, 74%) as a colorless 
oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.97 (dd, J = 8.1, 2.3 Hz, 1H), 7.80 (ddd, J = 8.4, 4.5, 2.3 Hz, 1H), 7.06 
(dd, J = 12.0, 8.4 Hz, 1H), 2.59 (s, 3H), 1.41 (d, J = 1.1 Hz, 9H). 
13C-NMR (125 MHz, CDCl3): δ = 196.8 (Cq), 165.0 (d, 1JC–F = 257 Hz, Cq), 137.5 (d, 2JC–F = 12 Hz, Cq), 
133.1 (d, 4JC–F = 3 Hz, Cq), 128.5 (d, 3JC–F = 10 Hz, CH), 127.9 (d, 3JC–F = 8 Hz, CH), 116.4 (d, 2JC–F = 25 Hz, 
CH), 34.5 (d, 3JC–F = 3 Hz, Cq), 29.8 (d, 4JC–F = 3 Hz, CH3), 26.6 (CH3).  
19F-NMR (376 MHz, CDCl3): δ = (–101.5)–(–101.8) (m). 
IR (ATR): ṽ = 2961, 2873, 1683, 1606, 1490, 1355, 1235, 1094, 817 cm−1.  
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MS (EI) m/z (relative intensity): 194 (18) [M]+, 179 (100) [M–Me]+, 151 (58) [M–Ac]+, 136 (10).  
HR-MS (EI): m/z calcd for C12H15FO+ [M]+ 194.1101, found 194.1106. 
 
1-[3-(tert-Butyl)-4-chlorophenyl]ethan-1-one (154cb) 
The general procedure B was followed using ketimine 135c (160 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 154cb (64.8 mg, 62%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135c (160 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 50:1) yielded 154cb (68.9 mg, 65%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.05 (d, J = 2.2 Hz, 1H), 7.69 (dd, J = 8.2, 2.2 Hz, 1H), 7.43 (d, J = 
8.2 Hz, 1H), 2.59 (s, 3H), 1.51 (s, 9H). 
13C-NMR (125 MHz, CDCl3): δ = 197.2 (Cq), 146.9 (Cq), 139.0 (Cq), 135.3 (Cq), 132.1 (CH), 127.6 (CH), 
127.0 (CH), 36.3 (Cq), 29.5 (CH3), 26.6 (CH3). 
IR (ATR): ṽ = 2964, 1684, 1588, 1353, 1233, 1038, 818, 529 cm−1.  
MS (EI) m/z (relative intensity): 212 (9) [M(37Cl)]+, 210 (25) [M(35Cl)]+, 197 (28) [M(37Cl)–Me]+, 195 
(82) [M(35Cl)–Me]+, 169 (34) [M(37Cl)–Ac]+, 167 (100) [M(35Cl)–Ac]+, 115 (26), 91 (13), 75 (9), 57 
(10), 43 (81).  
HR-MS (ESI): m/z calcd for C12H16ClO+ [M+H]+ 211.0884, found 211.0885. 
 
1-[3-(tert-Butyl)-4-methoxyphenyl]ethan-1-one (154db) 
The general procedure B was followed using ketimine 135d (158 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 10:1) yielded 154db (83.8 mg, 81%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135d (158 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 10:1) yielded 154db (67.6 mg, 66%) as a colorless oil. 
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1H-NMR (300 MHz, CDCl3): δ = 7.94 (d, J = 2.3 Hz, 1H), 7.83 (dd, J = 8.5, 2.3 Hz, 1H), 6.89 (d, J = 
8.5 Hz, 1H), 3.91 (s, 3H), 2.56 (s, 3H), 1.39 (s, 9H). 
13C-NMR (125 MHz, CDCl3): δ = 197.1 (Cq), 162.4 (Cq), 138.2 (Cq), 129.7 (Cq), 128.5 (CH), 127.0 (CH), 
110.6 (CH), 55.2 (CH3), 35.0 (Cq), 29.6 (CH3), 26.4 (CH3). 
IR (ATR): ṽ = 2958, 1674, 1595, 1495, 1457, 1357, 1237, 1182, 1026, 970 cm−1.  
MS (EI) m/z (relative intensity): 206 (36) [M]+, 191 (100) [M–Me]+, 163 (42) [M–Ac]+, 133 (18).  
HR-MS (EI): m/z calcd for C13H18O2+ [M]+ 206.1301, found 206.1297. 
The spectral data are in accordance with those reported in the literature.[131] 
 
1-(3-(tert-Butyl)-4-methylphenyl)ethan-1-one (154eb) 
The general procedure B was followed using ketimine 135e (150 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 70:1) yielded 154eb (43.6 mg, 46%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135e (150 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 70:1) yielded 154eb (38.1 mg, 40%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.01 (d, J = 1.9 Hz, 1H), 7.67 (ddd, J = 7.9, 1.9 Hz, 1H), 7.20 (d, J = 
7.9 Hz, 1H), 2.60 (s, 3H), 2.58 (s, 3H), 1.44 (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 198.2 (Cq), 148.4 (Cq), 142.4 (Cq), 134.9 (Cq), 132.9 (CH), 126.0 (CH), 
125.9 (CH), 35.9 (Cq), 30.7 (CH3), 26.5 (CH3), 23.4 (CH3). 
IR (ATR): ṽ = 2963, 1681, 1601, 1355, 1267, 1237, 815 cm−1.  
MS (ESI) m/z (relative intensity): 213 (100) [M+Na]+, 191 (20) [M+H]+.  
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4-Acetyl-2-(tert-butyl)phenyl benzoate (154fb) 
The general procedure B was followed using ketimine 135f (203 mg, 0.50 mmol) 
and tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 9:1) yielded 154fb (89.7 mg, 61%) as a 
viscous colorless oil. 
The general procedure C was followed using ketimine 135f (203 mg, 0.50 mmol) 
and tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 9:1) yielded 154fb (65.1 mg, 44%) as a viscous colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.27–8.21 (m, 2H), 8.11 (d, J = 2.2 Hz, 1H), 7.87 (dd, J = 8.4, 2.2 Hz, 
1H), 7.68 (tt, J = 6.7, 1.3 Hz, 1H), 7.59–7.52 (m, 2H), 7.20 (d, J = 8.4 Hz, 1H), 2.62 (s, 3H), 1.42 (s, 
9H). 
13C-NMR (125 MHz, CDCl3): δ = 197.1 (Cq), 164.8 (Cq), 153.2 (Cq), 141.9 (Cq), 134.5 (Cq), 133.8 (CH), 
130.2 (CH), 129.3 (Cq), 128.7 (CH), 127.6 (CH), 127.4 (CH), 124.4 (CH), 34.9 (Cq), 30.2 (CH3), 26.7 
(CH3). 
IR (ATR): ṽ = 2964, 1736, 1682, 1599, 1356, 1237, 1190, 1083, 1053, 703 cm−1.  
MS (ESI) m/z (relative intensity): 615 (11) [2M+Na]+, 319 (100) [M+Na]+, 297 (11) [M+H]+.  
HR-MS (ESI): m/z calcd for C19H20O3Na+ [M+Na]+ 319.1305, found 319.1306. 
 
1-[3-(1-Methylcyclohexyl)phenyl]ethan-1-one (154ba) 
The general procedure B was followed using ketimine 135b (143 mg, 0.50 mmol) 
and 1-bromo-1-methylcyclohexane (136a, 266 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-pentane/Et2O 50:1) yielded 154ba 
(64.8 mg, 60%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.00 (dd, J = 1.9, 1.9 Hz, 1H), 7.76 (ddd, J = 7.7, 1.7, 1.1 Hz, 1H), 7.59 
(ddd, J = 7.7, 2.1, 1.1 Hz, 1H), 7.40 (ddd, J = 7.7, 7.7, 0.5 Hz, 1H), 2.60 (s, 3H), 2.08–1.96 (m, 2H), 
1.68–1.51 (m, 4H), 1.51–1.34 (m, 4H), 1.20 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 198.5 (Cq), 150.6 (Cq), 137.1 (Cq), 130.9 (CH), 128.4 (CH), 125.6 (CH), 
125.6 (CH), 38.1 (Cq), 37.8 (CH2), 30.3 (CH3), 26.7 (CH3), 26.2 (CH2), 22.5 (CH2). 
IR (ATR): ṽ = 2925, 2856, 1682, 1597, 1425, 1356, 1256, 1196, 1080, 965 cm−1.  
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MS (EI) m/z (relative intensity): 216 (40) [M]+, 201 (75) [M–Me]+, 173 (26) [M–Ac]+, 160 (32), 145 
(48). 
HR-MS (EI): m/z calcd for C15H20O+ [M]+ 216.1509, found 216.1512. 
 
1-[4-Fluoro-3-(tert-pentyl)phenyl]ethan-1-one (154ac) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and 2-bromo-2-methylbutane (136c, 227 mg, 1.50 mmol). After 20 h, purification 
by column chromatography (n-pentane/Et2O 50:1) yielded 154ac (78.7 mg, 76%) as 
a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.91 (dd, J = 8.1, 2.3 Hz, 1H), 7.79 (ddd, J = 8.4, 4.5, 2.3 Hz, 1H), 7.03 
(dd, J = 12.1, 8.4 Hz, 1H), 2.57 (s, 3H), 1.78 (qd, J = 7.5, 1.6 Hz, 2H), 1.36 (d, J = 1.2 Hz, 6H), 0.66 (td, 
J = 7.5, 0.6 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 196.9 (Cq), 164.9 (d, 1JC–F = 257 Hz, Cq), 136.0 (d, 2JC–F = 12 Hz, Cq), 
133.1 (d, 4JC–F = 3 Hz, Cq), 129.1 (d, 3JC–F = 8 Hz, CH), 128.6 (d, 3JC–F = 10 Hz, CH), 116.3 (d, 2JC–F = 26 Hz, 
CH), 38.1 (d, 3JC–F = 3 Hz, Cq), 34.0 (d, 4JC–F = 4 Hz, CH2), 27.6 (d, 4JC–F = 3 Hz, CH3), 26.5 (CH3), 9.3 (CH3).  
19F-NMR (376 MHz, CDCl3): δ = (–101.5)–(–101.7) (m).  
IR (ATR): ṽ = 2965, 2877, 1683, 1604, 1491, 1355, 1252, 1094, 822 cm−1.  
MS (EI) m/z (relative intensity): 208 (7) [M]+, 179 (100) [M–Et]+, 151 (65), 136 (10).  
HR-MS (EI): m/z calcd for C13H17FO+ [M]+ 208.1258, found 208.1266. 
 
1-[4-Fluoro-3-(2-methylpentan-2-yl)phenyl]ethan-1-one (154ad) 
The general procedure B was followed using ketimine 135a (152 mg, 
0.50 mmol) and 2-bromo-2-methylpentane (136d, 249 mg, 1.50 mmol). After 
20 h, purification by column chromatography (n-pentane/Et2O 50:1) yielded 
154ad (53.3 mg, 48%) as a colorless oil. 
The general procedure C was followed using ketimine 135a (152 mg, 0.50 mmol), 2-bromo-2-
methylpentane (136d, 249 mg, 1.50 mmol), and [RuCl2(C6H6)]2 (12.6 mg, 5 mol %). After 20 h, 
purification by column chromatography (n-pentane/Et2O 50:1) yielded 154ad (61.4 mg, 55%) as a 
colorless oil. 
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1H-NMR (400 MHz, CDCl3): δ = 7.90 (dd, J = 8.0, 2.3 Hz, 1H), 7.79 (ddd, J = 8.4, 4.5, 2.3 Hz, 1H), 7.04 
(dd, J = 12.1, 8.4 Hz, 1H), 2.57 (s, 3H), 1.74–1.68 (m, 2H), 1.37 (d, J = 1.1 Hz, 6H), 1.09–0.97 (m, 
2H), 0.83 (t, J = 7.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 196.9 (Cq), 164.9 (d, 1JC–F = 257 Hz, Cq), 136.3 (d, 2JC–F = 12 Hz, Cq), 
133.1 (d, 4JC–F = 3 Hz, Cq), 129.0 (d, 3JC–F = 8 Hz, CH), 128.5 (d, 3JC–F = 10 Hz, CH), 116.4 (d, 2JC–F = 26 Hz, 
CH), 44.0 (d, 4JC–F = 4 Hz, CH2), 37.9 (d, 3JC–F = 3 Hz, Cq), 28.1 (d, 4JC–F = 3 Hz, CH3), 26.5 (CH3), 18.3 
(CH2), 14.6 (CH3).  
19F-NMR (376 MHz, CDCl3): δ = (–101.4)–(–101.7) (m).  
IR (ATR): ṽ = 2958, 2931, 1683, 1583, 1490, 1355, 1247, 1097, 958 cm−1.  
MS (EI) m/z (relative intensity): 222 (5) [M]+, 179 (100) [M–Pr]+, 151 (56), 115 (6). 
HR-MS (ESI): m/z calcd for C14H20FO+ [M+H]+ 223.1493, found 223.1493. 
 
1-[3-(2-Methyl-4-phenylbutan-2-yl)phenyl]ethan-1-one (154ae) 
The general procedure B was followed using ketimine 135a (152 mg, 
0.50 mmol) and (3-bromo-3-methylbutyl)benzene (136e, 341 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-pentane/Et2O 50:1) 
yielded 154ae (84.1 mg, 59%) as a colorless oil. 
1H-NMR (500 MHz, CDCl3): δ = 7.98  (dd, J = 8.0, 2.3 Hz, 1H), 7.83 (ddd, J = 8.4, 4.5, 2.3 Hz, 1H), 
7.26–7.21 (m, 2H), 7.17–7.12 (m, 1H), 7.12–7.06 (m, 3H), 2.60 (s, 3H), 2.36–2.30 (m, 2H), 2.12–
2.06 (m, 2H), 1.47 (d, J = 1.0 Hz, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 197.0 (Cq), 164.9 (d, 1JC–F = 257 Hz, Cq), 142.5 (Cq), 135.7 (d, 2JC–F = 
12 Hz, Cq), 133.2 (d, 4JC–F = 3 Hz, Cq), 129.0 (d, 3JC–F = 8 Hz, CH), 128.9 (d, 3JC–F = 10 Hz, CH), 128.3 (CH), 
128.2 (CH), 125.6 (CH), 116.5 (d, 2JC–F = 26 Hz, CH), 43.6 (d, 4JC–F = 5 Hz, CH2), 38.0 (d, 3JC–F = 3 Hz, Cq), 
31.7 (CH2), 28.2 (d, 4JC–F = 3 Hz, CH3), 26.6 (CH3).  
19F-NMR (470 MHz, CDCl3): δ = (–101.5)–(–101.7) (m).  
IR (ATR): ṽ = 3026, 2965, 1683, 1491, 1355, 1257, 1220, 823, 698 cm−1.  
MS (EI) m/z (relative intensity): 284 (14) [M]+, 179 (100), 151 (53), 105 (36), 91 (43), 77 (9), 65 (11), 
43 (42).  
HR-MS (EI): m/z calcd for C19H21FO+ [M]+ 284.1571, found 284.1577. 




The general procedure B was followed using ketimine 135a (152 mg, 
0.50 mmol) and 4-bromo-1-chloro-4-methylpentane (136f, 299 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 50:1) yielded 154af (70.6 mg, 55%) as a colorless oil. 
The general procedure C was followed using ketimine 135a (152 mg, 0.50 mmol) and 4-bromo-1-
chloro-4-methylpentane (136f, 299 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 154af (28.0 mg, 22%) as a colorless oil. 
1H-NMR (500 MHz, CDCl3): δ = 7.91 (dd, J = 8.0, 2.3 Hz, 1H), 7.81 (ddd, J = 8.4, 4.5, 2.3 Hz, 1H), 7.07 
(dd, J = 12.1, 8.4 Hz, 1H), 3.44 (t, J = 6.7 Hz, 2H), 2.58 (s, 3H), 1.92–1.86 (m, 2H), 1.54–1.46 (m, 2H), 
1.41 (d, J = 1.0 Hz, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 196.9 (Cq), 164.8 (d, 1JC–F = 257 Hz, Cq), 135.4 (d, 2JC–F = 12 Hz, Cq), 
133.2 (d, 4JC–F = 3 Hz, Cq), 128.9 (d, 3JC–F = 10 Hz, CH), 128.8 (d, 3JC–F = 8 Hz, CH), 116.5 (d, 2JC–F = 26 Hz, 
CH), 45.4 (CH2), 38.8 (d, 4JC–F = 4 Hz, CH2), 37.5 (d, 3JC–F = 3 Hz, Cq), 28.6 (CH2), 28.1 (d, 4JC–F = 3 Hz, 
CH3), 26.5 (CH3).  
19F-NMR (470 MHz, CDCl3): δ = (–101.6)–(–101.7) (m).  
IR (ATR): ṽ = 2961, 2874, 1682, 1581, 1477, 1258, 1090, 822 cm−1.  
MS (EI) m/z (relative intensity): 258 (1) [M(37Cl)]+, 256 (3) [M(35Cl)]+, 179 (100), 151 (48), 115 (5).  
HR-MS (ESI): m/z calcd for C14H19F35ClO+ [M+H]+ 257.1103, found 257.1103. 
 
1-[3-(tert-Butyl)phenyl]propan-1-one (154gb) 
The general procedure B was followed using ketimine 135g (150 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 80:1) yielded 154gb (76.2 mg, 80%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135g (150 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 80:1) yielded 154gb (55.8 mg, 59%) as a colorless oil. 
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1H-NMR (400 MHz, CDCl3): δ = 8.02 (ddd, J = 2.0, 1.9, 0.5 Hz, 1H), 7.77 (ddd, J = 7.8, 1.9, 1.1 Hz, 
1H), 7.59 (ddd, J = 7.8, 2.0, 1.1 Hz, 1H), 7.39 (ddd, J = 7.8, 7.8, 0.5 Hz, 1H), 3.01 (q, J = 7.3 Hz, 2H), 
1.35 (s, 9H), 1.23 (t, J = 7.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 201.2 (Cq), 151.6 (Cq), 136.8 (Cq), 130.0 (CH), 128.2 (CH), 125.3 (CH), 
124.7 (CH), 34.8 (Cq), 31.9 (CH2), 31.2 (CH3), 8.3 (CH3).  
IR (ATR): ṽ = 2963, 2872, 1685, 1581, 1459, 1364, 1209, 850 cm−1.  
MS (EI) m/z (relative intensity): 190 (6) [M]+, 161 (100) [M–Et]+, 133 (13), 115 (10).  
HR-MS (ESI): m/z calcd for C13H19O+ [M+H]+ 191.1430, found 191.1436. 
 
1-[3-(tert-Butyl)-4-fluorophenyl]propan-1-one (154hb) 
The general procedure B was followed using ketimine 135h (159 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 80:1) yielded 154hb (85.5 mg, 83%) as a white 
solid. 
1H-NMR (500 MHz, CDCl3): δ = 7.98 (dd, J = 8.1, 2.3 Hz, 1H), 7.80 (ddd, J = 8.5, 4.5, 2.3 Hz, 1H), 7.05 
(dd, J = 12.0, 8.5 Hz, 1H), 2.97 (q, J = 7.3 Hz, 2H), 1.40 (d, J = 1.2 Hz, 9H), 1.22 (t, J = 7.3 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 199.7 (Cq), 164.9 (d, 1JC–F = 257 Hz, Cq), 137.5 (d, 2JC–F = 12 Hz, Cq), 
132.9 (d, 4JC–F = 3 Hz, Cq), 128.1 (d, 3JC–F = 10 Hz, CH), 127.7 (d, 3JC–F = 7 Hz, CH), 116.4 (d, 2JC–F = 25 Hz, 
CH), 34.4 (d, 3JC–F = 3 Hz, Cq), 31.7 (CH2), 29.7 (d, 4JC–F = 4 Hz, CH3), 8.3 (CH3).  
19F-NMR (470 MHz, CDCl3) δ = (–102.0)–(–102.1) (m). 
IR (ATR): ṽ = 2945, 2022, 1686, 1605, 1458, 1366, 1210, 1089, 800 cm−1.  
m.p.: 44–45 °C. 
MS (EI) m/z (relative intensity): 208 (7) [M]+, 193 (14) [M–Me]+, 179 (100) [M–Et]+, 165 (22). 








The general procedure B was followed using ketimine 135i (164 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 100:1) yielded 154ib (81.0 mg, 74%) as a colorless 
oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.02–7.99 (m, 1H), 7.76 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 7.59 (ddd, J = 
7.8, 2.1, 1.1 Hz, 1H), 7.39 (ddd, J = 7.8, 7.8, 0.5 Hz, 1H), 2.97 (dd, J = 7.7, 7.1 Hz, 2H), 1.77–1.68 (m, 
2H), 1.47–1.37 (m, 2H), 1.35 (s, 9H), 0.96 (t, J = 7.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 200.9 (Cq), 151.6 (Cq), 136.9 (Cq), 130.0 (CH), 128.2 (CH), 125.4 (CH), 
124.7 (CH), 38.4 (CH2), 34.8 (Cq), 31.3 (CH3), 26.6 (CH2), 22.5 (CH2), 13.9 (CH3). 
IR (ATR): ṽ = 2959, 2871, 1684, 1598, 1462, 1365, 1285, 1243, 1020, 793 cm−1.  
MS (EI) m/z (relative intensity): 218 (5) [M]+, 203 (8) [M–Me]+, 176 (32) [M–Pr]+, 161 (100) [M–
Bu]+.  
HR-MS (EI): m/z calcd for C15H22O+ [M]+ 218.1665, found 218.1682. 
 
1-[4-Fluoro-3-(1-methylcyclohexyl)phenyl]propan-1-one (154ha) 
The general procedure B was followed using ketimine 135h (159 mg, 0.50 mmol) 
and 1-bromo-1-methylcyclohexane (136a, 266 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-pentane/Et2O 70:1) yielded 154ha 
(87.3 mg, 70%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.00 (dd, J = 8.1, 2.3 Hz, 1H), 7.80 (ddd, J = 8.4, 4.5, 2.3 Hz, 1H), 7.04 
(dd, J = 12.4, 8.4 Hz, 1H), 2.98 (q, J = 7.2 Hz, 2H), 2.16–2.01 (m, 2H), 1.75–1.53 (m, 4H), 1.53–1.34 
(m, 4H), 1.30 (d, J = 1.0 Hz, 3H), 1.22 (t, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 199.5 (Cq), 165.0 (d, 1JC–F = 256 Hz, Cq), 136.7 (d, 2JC–F = 11 Hz, Cq), 
132.8 (d, 4JC–F = 3 Hz, Cq), 128.8 (d, 3JC–F = 8 Hz, CH), 127.7 (d, 3JC–F = 10 Hz, CH), 116.7 (d, 2JC–F = 26 Hz, 
CH), 38.0 (d, 3JC–F = 4 Hz, Cq), 37.1 (d, 4JC–F = 4 Hz, CH2), 31.7 (CH2), 26.6 (CH3), 26.4 (CH2), 22.7 (CH2), 
8.4 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –101.4 (ddd, J = 12.7, 8.2, 4.8 Hz). 
IR (ATR): ṽ = 2927, 2858, 1685, 1581, 1488, 1451, 1228, 1182, 799 cm−1. 
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MS (EI) m/z (relative intensity): 248 (8) [M]+, 219 (100) [M–Et]+, 163 (22), 133 (12). 
HR-MS (EI): m/z calcd for C16H21FO+ [M]+ 248.1571, found 248.1579. 
 
1-[4-Fluoro-3-(4-methyltetrahydro-2H-pyran-4-yl)phenyl]ethan-1-one (154ag) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and 4-bromo-4-methyltetrahydro-2H-pyran (136g, 269 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-pentane/Et2O 3:1) yielded 154ag 
(66.9 mg, 57%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.93 (dd, J = 7.9, 2.3 Hz, 1H), 7.82 (ddd, J = 8.4, 4.6, 2.3 Hz, 1H), 7.09 
(dd, J = 12.4, 8.4 Hz, 1H), 3.80 (dABdd, J = 11.0, 9.1, 3.1 Hz, 2H), 3.70 (dABdd, J = 11.0, 6.2, 3.8 Hz, 
2H), 2.58 (s, 3H), 2.20 (ddd, J = 12.7, 9.1, 3.8 Hz, 2H), 1.91–1.82 (m, 2H), 1.40 (d, J = 1.0 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 196.7 (Cq), 165.0 (d, 1JC–F = 257 Hz, Cq), 135.9 (d, 2JC–F = 11 Hz, Cq), 
133.3 (d, 4JC–F = 3 Hz, Cq), 128.8 (d, 3JC–F = 11 Hz, CH), 128.2 (d, 3JC–F = 8 Hz, CH), 116.9 (d, 2JC–F = 26 Hz, 
CH), 64.2 (CH2), 36.7 (d, 4JC–F = 4 Hz, CH2), 35.5 (d, 3JC–F = 3 Hz, Cq), 26.5 (CH3), 25.3 (d, 4JC–F = 3 Hz, 
CH3). 
19F-NMR (376 MHz, CDCl3): δ = –101.8 (ddd, J = 12.4, 7.9, 4.6 Hz). 
IR (ATR): ṽ = 2932, 2853, 1683, 1605, 1490, 1356, 1244, 1106, 826 cm−1.  
MS (EI) m/z (relative intensity): 236 (10) [M]+, 221 (14) [M–Me]+, 192 (53), 177 (65), 163 (90), 149 
(49), 133 (20), 83 (22), 49 (22), 43 (100).  
HR-MS (EI): m/z calcd for C14H17FO2+ [M]+ 236.1207, found 236.1226. 
 
1-[2-(tert-Butyl)-[1,1'-biphenyl]-4-yl]ethan-1-one (154jb) 
The general procedure B was followed using ketimine 135j (181 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 154jb (34.1 mg, 27%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135j (181 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 50:1) yielded 154jb (48.0 mg, 38%) as a colorless oil. 
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1H-NMR (400 MHz, CDCl3): δ = 8.18 (dd, J = 1.9,  0.4 Hz, 1H), 7.74 (dd, J = 7.9, 1.9 Hz, 1H), 7.39–
7.34 (m, 3H), 7.27–7.23 (m, 2H), 7.12 (dd, J = 7.9, 0.4 Hz, 1H), 2.64 (s, 3H), 1.22 (s, 9H).  
13C-NMR (100 MHz, CDCl3): δ = 198.2 (Cq), 148.3 (Cq), 147.1 (Cq), 144.2 (Cq), 135.9 (Cq), 132.9 (CH), 
129.5 (CH), 127.3 (CH), 127.0 (CH), 126.7 (CH), 124.9 (CH), 36.7 (Cq), 32.5 (CH3), 26.7 (CH3).  
IR (ATR): ṽ = 2964, 1686, 1596, 1398, 1354, 1236, 770, 707 cm−1.  
MS (ESI) m/z (relative intensity): 527 (74) [2M+Na]+, 275 (100) [M+Na]+, 253 (13) [M+H]+.  
HR-MS (ESI): m/z calcd for C18H20ONa+ [M+Na]+ 275.1406, found 275.1407. 
 
Methyl 4-acetyl-2-(tert-butyl)benzoate (154kb) 
The general procedure B was followed using ketimine 135k (172 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 10:1) yielded 154kb (15.6 mg, 13%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135k (172 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 10:1) yielded 154kb (32.3 mg, 28%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.10 (dd, J = 1.7, 0.5 Hz, 1H), 7.77 (dd, J = 7.9, 1.7 Hz, 1H), 7.36 (dd, 
J = 7.9, 0.5 Hz, 1H), 3.92 (s, 3H), 2.61 (s, 3H), 1.42 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 197.5 (Cq), 171.5 (Cq), 148.1 (Cq), 137.7 (Cq), 136.9 (Cq), 128.8 (CH), 
126.8 (CH), 125.4 (CH), 52.6 (CH3), 36.1 (Cq), 31.3 (CH3), 26.8 (CH3). 
IR (ATR): ṽ = 2954, 1729, 1687, 1434, 1291, 1255, 1121, 1069 cm−1.  
MS (EI) m/z (relative intensity): 234 (2) [M]+, 219 (43) [M–Me]+, 203 (58) [M–OMe]+, 187 (100), 
177 (23) [M–t-Bu]+, 115 (29), 91 (17), 43 (79).  









The general procedure B was followed using ketimine 135l (155 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 10:1) yielded 154lb (19.8 mg, 20%) as a colorless 
oil. 
The general procedure C was followed using ketimine 135l (155 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 10:1) yielded 154lb (26.7 mg, 27%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.06 (dd, J = 1.6, 0.6 Hz, 1H), 7.82 (dABd, J = 7.9, 1.6 Hz, 1H), 7.78 
(dABd, J = 7.9, 0.6 Hz, 1H), 2.63 (s, 3H), 1.55 (s, 9H). 
13C-NMR (125 MHz, CDCl3): δ = 196.9 (Cq), 154.3 (Cq), 139.6 (Cq), 135.8 (CH), 125.7 (CH), 125.7 (CH), 
119.3 (Cq), 114.7 (Cq), 35.9 (Cq), 30.1 (CH3), 26.9 (CH3). 
IR (ATR): ṽ = 2967, 2223, 1692, 1483, 1404, 1288, 1237, 835 cm−1.  
MS (EI) m/z (relative intensity): 201 (10) [M]+, 186 (100) [M–Me]+, 158 (31) [M–Ac]+, 143 (14) [M–
t-Bu]+, 115 (14), 43 (29).  
HR-MS (EI): m/z calcd for C13H15NO+ [M]+ 201.1148, found 201.1150. 
 
1-[3-(tert-Butyl)-4-(piperidin-1-yl)phenyl]ethan-1-one (154nb) 
The general procedure B was followed using ketimine 135n (184 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, to the reaction mixture 
was added HCl (2 N, 3.0 mL) and the resulting mixture was stirred for additional 3 h, 
and then neutralized with sat. aq. NaHCO3 solution until pH 8. The reaction mixture 
was extracted with Et2O (3 × 20 mL). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. Purification by column chromatography (n-hexane/EtOAc 19:1 
to 9:1) yielded 154nb (18.7 mg, 14%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.01 (d, J = 2.2 Hz, 1H), 7.80 (dd, J = 8.2, 2.2 Hz, 1H), 7.39 (d, J = 
8.2 Hz, 1H), 2.90–2.63 (m, 4H), 2.58 (s, 3H), 1.89–1.65 (m, 4H), 1.46 (s, 9H), 1.45–1.23 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 197.8 (Cq), 159.7 (Cq), 147.7 (Cq), 134.3 (Cq), 127.1 (CH), 127.1 (CH), 
125.7 (CH), 55.3 (CH2), 35.8 (Cq), 30.7 (CH3), 26.6 (CH3), 26.2 (CH2), 24.3 (CH2). 
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IR (ATR): ṽ = 2932, 1682, 1594, 1352, 1237, 1216, 918, 833 cm−1.  
MS (EI) m/z (relative intensity): 259 (65) [M]+, 258 (38) [M–H]+, 244 (100) [M–Me]+, 230 (8), 216 
(64), 202 (17), 188 (14), 43 (44).  
HR-MS (EI): m/z calcd for C17H25NO+ [M]+ 259.1931, found 259.1934. 
 
1-[7-(tert-Butyl)benzo[d][1,3]dioxol-5-yl]ethan-1-one (154pb) 
The general procedure B was followed using ketimine 135p (165 mg, 0.50 mmol) 
and tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 10:1) yielded 154pb (38.8 mg, 35%) as a 
white solid. 
1H-NMR (300 MHz, CDCl3): δ = 7.52 (d, J = 1.7 Hz, 1H), 7.31 (d, J = 1.7 Hz, 1H), 6.04 (s, 2H), 2.54 (s, 
3H), 1.38 (s, 9H). 
13C-NMR (125 MHz, CDCl3): δ = 196.4 (Cq), 149.2 (Cq), 147.9 (Cq), 132.3 (Cq), 131.4 (Cq), 121.6 (CH), 
106.3 (CH), 101.1 (CH2), 34.1 (Cq), 29.3 (CH3), 26.6 (CH3).  
IR (ATR): ṽ = 2961, 2908, 1669, 1588, 1419, 1290, 1252, 1044, 966, 867 cm−1.  
m.p.: 114–115 °C. 
MS (ESI) m/z (relative intensity): 463 (67) [2M+Na]+, 243 (100) [M+Na]+, 221 (94) [M+H]+.  
HR-MS (ESI): m/z calcd for C13H16O3Na+ [M+Na]+ 243.0992, found 243.0988. 
 
1-[4-(tert-Butyl)naphthalen-2-yl]ethan-1-one (154qb) 
The general procedure B was followed using ketimine 135q (168 mg, 0.50 mmol) 
and tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154qb (42.9 mg, 38%) as a 
white solid. 
The general procedure C was followed using ketimine 135q (168 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 50:1) yielded 154qb (21.0 mg, 19%) as a white solid. 
5.3 Experimental Procedures and Analytical Data 
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1H-NMR (300 MHz, CDCl3): δ = 8.49 (dddd, J = 8.8, 1.1, 0.9, 0.8 Hz, 1H), 8.32 (ddd J = 1.7, 0.9, 0.7 Hz, 
1H), 8.10 (d, J = 1.7 Hz, 1H), 7.99 (dddd, J = 8.0, 1.7, 0.8, 0.7 Hz, 1H), 7.61 (ddd, J = 8.8, 6.9, 1.7 Hz, 
1H), 7.52 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H), 2.73 (s, 3H), 1.66 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 198.2 (Cq), 146.8 (Cq), 134.2 (Cq), 133.9 (Cq), 133.5 (Cq), 131.2 (CH), 
129.8 (CH), 127.1 (CH), 126.9 (CH), 125.4 (CH), 120.9 (CH), 36.3 (Cq), 31.8 (CH3), 26.6 (CH3).  
IR (ATR): ṽ = 2965, 1679, 1388, 1288, 1240, 1213, 894, 791, 758 cm−1.  
m.p.: 71–72 °C. 
MS (EI) m/z (relative intensity): 226 (46) [M]+, 211 (100) [M–Me]+, 165 (14), 152 (19), 141 (10), 43 
(92).  
HR-MS (EI): m/z calcd for C16H18O+ [M]+ 226.1352, found 226.1361. 
 
1-[5-(tert-Butyl)thiophen-3-yl]ethan-1-one (154rb) 
The general procedure B was followed using ketimine 135r (146 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 154rb (25.4 mg, 14%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 1.4 Hz, 1H), 7.26 (d, J = 1.4 Hz, 1H), 2.49 (s, 3H), 1.38 (s, 
9H).  
13C-NMR (75 MHz, CDCl3): δ = 192.7 (Cq), 158.7 (Cq), 142.1 (Cq), 130.2 (CH), 120.7 (CH), 34.6 (Cq), 
32.3 (CH3), 27.1 (CH3).  
IR (ATR): ṽ = 3098, 2963, 1668, 1395, 1232, 853, 792, 647, 598 cm−1.  
MS (ESI) m/z (relative intensity): 205 (100) [M+Na]+, 183 (48) [M+H]+.  
HR-MS (ESI): m/z calcd for C10H14OSNa+ [M+Na]+ 205.0658, found 205.0660. 
 
1-[3-(tert-Butyl)phenyl]-2-methylpropan-1-one (154sb) 
The general procedure B was followed using ketimine 135s (157 mg, 0.50 mmol) and 
tert-butyl bromide (136b, 206 mg, 1.50 mmol) in PhMe (2.0 mL). After 20 h, 
purification by column chromatography (n-pentane/Et2O 50:1) yielded 154sb 
(13.6 mg, 13%) as a colorless oil. 
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The general procedure C was followed using ketimine 135s (157 mg, 0.50 mmol) and tert-butyl 
bromide (136b, 206 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-pentane/Et2O 50:1) yielded 154sb (30.6 mg, 30%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.01 (ddd, J = 2.0, 1.7, 0.5 Hz, 1H), 7.76 (ddd, J = 7.7, 1.7, 1.1 Hz, 
1H), 7.59 (ddd, J = 7.8, 2.0, 1.1 Hz, 1H), 7.39 (ddd, J = 7.8, 7.7, 0.5 Hz, 1H), 3.57 (hept, J = 6.8 Hz, 
1H), 1.36 (s, 9H), 1.23 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 204.6 (Cq), 151.6 (Cq), 136.0 (Cq), 129.8 (CH), 128.2 (CH), 125.5 (CH), 
125.1 (CH), 35.5 (CH), 34.9 (Cq), 31.3 (CH3), 19.3 (CH3).  
IR (ATR): ṽ = 2965, 1682, 1467, 1365, 1213, 1162, 991, 743, 696 cm−1.  
MS (EI) m/z (relative intensity): 204 (4) [M]+, 189 (4) [M–Me]+, 161 (100) [M–i-Pr]+, 133 (16) [M–
C(O)i-Pr]+, 105 (19), 91 (16), 77 (9), 43 (19).  
HR-MS (EI): m/z calcd for C14H20O+ [M]+ 204.1509, found 204.1519. 
 
1-(3-Cycloheptylphenyl)ethan-1-one (154bh) 
The general procedure B was followed using ketimine 135b (143 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154bh (74.6 mg, 69%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.81–7.77 (m, 1H), 7.74 (ddd, J = 7.0, 1.8, 1.8 Hz, 1H), 7.42–7.32 (m, 
2H), 2.79–2.67 (m, 1H), 2.59 (s, 3H), 1.97–1.47 (m, 12H).  
13C-NMR (125 MHz, CDCl3): δ = 198.2 (Cq), 150.3 (Cq), 137.1 (Cq), 131.5 (CH), 128.4 (CH), 126.3 (CH), 
125.7 (CH), 47.0 (CH), 36.7 (CH2), 27.9 (CH2), 27.2 (CH2), 26.7 (CH3).  
IR (ATR): ṽ = 3352, 2921, 2853, 1681, 1582, 1434, 1356, 1270, 793 cm−1.  
MS (EI) m/z (relative intensity): 216 (60) [M]+, 201 (100) [M–Me]+, 146 (36), 131 (64).  








The general procedure B was followed using ketimine 135e (150 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154eh (82.3 mg, 71%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 1.8 Hz, 1H), 7.65 (dd, J = 7.9, 1.8 Hz, 1H), 7.20 (d, J = 
7.9 Hz, 1H), 2.95–2.83 (m, 1H), 2.57 (s, 3H), 2.38 (s, 3H), 1.90–1.78 (m, 4H), 1.78–1.46 (m, 8H).  
13C-NMR (75 MHz, CDCl3): δ = 198.1 (Cq), 148.4 (Cq), 140.4 (Cq), 135.4 (Cq), 130.2 (CH), 125.5 (CH), 
125.4 (CH), 41.8 (CH), 35.9 (CH2), 27.6 (CH2), 27.5 (CH2), 26.5 (CH3), 19.7 (CH3).  
IR (ATR): ṽ = 2920, 2853, 1678, 1602, 1444, 1353, 1242, 813 cm−1.  
MS (EI) m/z (relative intensity): 230 (42) [M]+, 215 (100) [M–Me]+, 145 (40), 115 (18).  
HR-MS (EI): m/z calcd for C16H22O+ [M]+ 230.1665, found 230.1673. 
 
1-(3-Cycloheptyl-4-methoxyphenyl)ethan-1-one (154dh) 
The general procedure B was followed using ketimine 135d (158 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 10:1) yielded 154dh (99.7 mg, 81%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 2.3 Hz, 1H), 7.78 (dd, J = 8.5, 2.3 Hz, 1H), 6.84 (d, J = 
8.5 Hz, 1H), 3.88 (s, 3H), 3.17–3.02 (m, 1H), 2.54 (s, 3H), 1.93–1.45 (m, 12H).  
13C-NMR (75 MHz, CDCl3): δ = 197.1 (Cq), 160.2 (Cq), 138.2 (Cq), 130.0 (Cq), 127.9 (CH), 127.1 (CH), 
109.5 (CH), 55.5 (CH3), 38.9 (CH), 35.2 (CH2), 27.8 (CH2), 27.4 (CH2), 26.3 (CH3). 
IR (ATR): ṽ = 2919, 2852, 1672, 1596, 1495, 1354, 1241, 1025, 810 cm−1. 
MS (EI) m/z (relative intensity): 246 (95) [M]+, 231 (100) [M–Me]+, 161 (57), 147 (26). 








The general procedure B was followed using ketimine 135j (181 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154jh (92.4 mg, 63%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.95 (d, J = 1.8 Hz, 1H), 7.75 (dd, J = 8.0, 1.8 Hz, 1H), 7.46–7.32 (m, 
3H), 7.28–7.22 (m, 3H), 2.89–2.77 (m, 1H), 2.62 (s, 3H), 1.85–1.61 (m, 6H), 1.57–1.46 (m, 4H), 
1.39–1.23 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 197.9 (Cq), 147.9 (Cq), 145.2 (Cq), 140.9 (Cq), 136.4 (Cq), 130.0 (CH), 
128.8 (CH), 128.0 (CH), 127.1 (CH), 126.3 (CH), 125.1 (CH), 41.6 (CH), 36.8 (CH2), 27.7 (CH2), 27.3 
(CH2), 26.7 (CH3).  
IR (ATR): ṽ = 2919, 2852, 1681, 1597, 1458, 1353, 1277, 1008, 827 cm−1.  
MS (EI) m/z (relative intensity): 292 (85) [M]+, 221 (46), 165 (41), 115 (6).  
HR-MS (ESI): m/z calcd for C21H25O+ [M+H]+ 293.1900, found 293.1905. 
 
4-Acetyl-2-cycloheptylphenyl benzoate (154fh) 
The general procedure B was followed using ketimine 135f (203 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 95:5) yielded 154fh (88.1 mg, 52%) 
as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.25–8.20 (m, 2H), 7.98 (d, J = 2.2 Hz, 1H), 7.83 
(dd, J = 8.4, 2.2 Hz, 1H), 7.71–7.65 (m, 1H), 7.58–7.52 (m, 2H), 7.23 (d, J = 8.4 Hz, 1H), 2.92 (tt, J = 
10.5, 3.4 Hz, 1H), 2.62 (s, 3H), 1.95–1.87 (m, 2H), 1.83–1.39 (m, 10H).  
13C-NMR (100 MHz, CDCl3): δ = 197.3 (Cq), 164.8 (Cq), 151.7 (Cq), 141.9 (Cq), 135.2 (Cq), 133.9 (CH), 
130.2 (CH), 129.1 (Cq), 128.7 (CH), 127.9 (CH), 127.0 (CH), 122.7 (CH), 40.2 (CH), 35.4 (CH2), 27.6 
(CH2), 27.4 (CH2), 26.6 (CH3). 
IR (ATR): ṽ = 2922, 1737, 1683, 1600, 1451, 1238, 1081, 1056, 1023, 707 cm−1. 
MS (EI) m/z (relative intensity): 336 (2) [M]+, 231 (10) [M–Bz]+, 135 (15), 105 (100), 77 (35), 51 (5), 
43 (13). 
5.3 Experimental Procedures and Analytical Data 
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HR-MS (ESI): m/z calcd for C22H24O3Na+ [M+Na]+ 359.1618, found 359.1622. 
 
1-[3-Cycloheptyl-4-(trifluoromethyl)phenyl]ethan-1-one (154uh) 
The general procedure B was followed using ketimine 135u (177 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154uh (84.0 mg, 59%) as 
a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.99 (s, 1H), 7.78 (dq, J = 8.2, 0.8 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H), 
3.15–3.06 (m, 1H), 2.63 (s, 3H), 1.91–1.78 (m, 4H), 1.78–1.51 (m, 8H).  
13C-NMR (100 MHz, CDCl3): δ = 197.4 (Cq), 149.9 (q, 3JC–F = 2 Hz, Cq), 139.8 (Cq), 130.7 (q, 2JC–F = 
30 Hz, Cq), 127.8 (CH), 125.9 (q, 3JC–F = 6 Hz, CH), 125.2 (CH), 124.1 (q, 1JC–F = 273 Hz, Cq), 41.6 (q, 
4JC–F = 2 Hz, CH), 36.9 (CH2), 27.5 (CH2), 27.4 (CH2), 26.8 (CH3).  
19F-NMR (376 MHz, CDCl3): δ = –59.5 (s).  
IR (ATR): ṽ = 2925, 2856, 1692, 1574, 1415, 1310, 1238, 1154, 1035, 829 cm−1.  
MS (EI) m/z (relative intensity): 284 (35) [M]+, 214 (55), 199 (100), 151 (23).  
HR-MS (ESI): m/z calcd for C16H19F3NaO+ [M+Na]+ 307.1280, found 307.1286. 
 
1-(4-Chloro-3-cycloheptylphenyl)ethan-1-one (154ch) 
The general procedure B was followed using ketimine 135c (160 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154ch (68.1 mg, 54%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.87 (dd, J = 2.2, 0.4 Hz, 1H), 7.66 (dd, J = 8.3, 2.2 Hz, 1H), 7.41 (dd, 
J = 8.3, 0.4 Hz, 1H), 3.27–3.14 (m, 1H), 2.58 (s, 3H), 1.98–1.52 (m, 12H).  
13C-NMR (125 MHz, CDCl3): δ = 197.1 (Cq), 147.2 (Cq), 138.2 (Cq), 135.8 (Cq), 129.5 (CH), 127.2 (CH), 
126.5 (CH), 42.3 (CH), 35.4 (CH2), 27.8 (CH2), 27.4 (CH2), 26.6 (CH3). 
IR (ATR): ṽ = 2922, 2854, 1684, 1591, 1406, 1355, 1235, 1038, 815, 523 cm−1. 
5 Experimental Part 
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MS (EI) m/z (relative intensity): 252 (17) [M(37Cl)]+, 250 (48) [M(35Cl)]+, 237 (27) [M(37Cl)–Me]+, 235 
(81) [M(35Cl)–Me]+, 215 (44) [M–Cl]+, 180 (41), 165 (73), 115 (27), 55 (23), 43 (100). 
HR-MS (EI): m/z calcd for C15H19ClO+ [M]+ 250.1119, found 250.1118. 
 
Methyl 4-acetyl-2-cycloheptylbenzoate (154kh) 
The general procedure B was followed using ketimine 135k (172 mg, 
0.50 mmol) and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-pentane/Et2O 10:1) yielded 154kh 
(97.9 mg, 71%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.94 (dd, J = 1.2, 1.2 Hz, 1H), 7.76–7.72 (m, 2H), 3.93 (s, 3H), 3.40 
(tt, J = 10.3, 3.2 Hz, 1H), 2.62 (s, 3H), 1.99–1.49 (m, 12H).  
13C-NMR (125 MHz, CDCl3): δ = 197.6 (Cq), 168.1 (Cq), 150.8 (Cq), 139.1 (Cq), 133.4 (Cq), 129.6 (CH), 
126.8 (CH), 125.0 (CH), 52.3 (CH3), 42.1 (CH), 36.8 (CH2), 27.8 (CH2), 27.6 (CH2), 26.9 (CH3). 
IR (ATR): ṽ = 2921, 2854, 1723, 1686, 1433, 1270, 1233, 1096, 1065, 785 cm−1. 
MS (EI) m/z (relative intensity): 274 (28) [M]+, 259 (17) [M–Me]+, 243 (73), 199 (34), 181 (28), 115 
(23), 59 (18), 43 (100). 
HR-MS (ESI): m/z calcd for C17H23O3+ [M+H]+ 275.1642, found 275.1646. 
 
4-Acetyl-2-cycloheptylbenzonitrile (154lh) 
The general procedure B was followed using ketimine 135l (155 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 10:1) yielded 154lh (56.3 mg, 47%) as a 
yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.92 (dd, J = 1.7, 0.5 Hz, 1H), 7.79 (dd, J = 8.1, 1.7 Hz, 1H), 7.68 (dd, 
J = 8.1, 0.5 Hz, 1H), 3.17 (tt, J = 10.3, 3.4 Hz, 1H), 2.62 (s, 3H), 2.00–1.55 (m, 12H). 
13C-NMR (125 MHz, CDCl3): δ = 196.8 (Cq), 153.9 (Cq), 140.1 (Cq), 133.0 (CH), 126.1 (CH), 125.6 (CH), 
117.4 (Cq), 115.3 (Cq), 44.9 (CH), 36.0 (CH2), 27.7 (CH2), 27.4 (CH2), 26.9 (CH3). 
IR (ATR): ṽ = 2923, 2855, 2224, 1688, 1410, 1357, 1241, 831, 541 cm−1. 
5.3 Experimental Procedures and Analytical Data 
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MS (EI) m/z (relative intensity): 241 (25) [M]+, 240 (12) [M–H]+, 226 (79) [M–Me]+, 212 (27), 198 
(34) [M–Ac]+, 186 (24), 172 (29), 156 (100), 128 (20), 115 (19), 55 (32), 43 (76). 
HR-MS (ESI): m/z calcd for C16H19NONa+ [M+Na]+ 264.1359, found 264.1364. 
 
1-(3-Cycloheptylphenyl)propan-1-one (154gh) 
The general procedure B was followed using ketimine 135g (150 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 80:1) yielded 154gh (67.7 mg, 59%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.81–7.77 (m, 1H), 7.77–7.72 (m, 1H), 7.41–7.30 (m, 2H), 2.99 (q, J 
= 7.3 Hz, 2H), 2.78–2.66 (m, 1H), 1.97–1.45 (m, 12H), 1.22 (t, J = 7.3 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 201.0 (Cq), 150.3 (Cq), 137.0 (Cq), 131.3 (CH), 128.4 (CH), 126.1 (CH), 
125.3 (CH), 47.0 (CH), 36.7 (CH2), 31.9 (CH2), 27.9 (CH2), 27.2 (CH2), 8.4 (CH3).  
IR (ATR): ṽ = 3391, 2921, 2853, 1683, 1582, 1482, 1348, 1233, 1161, 781 cm−1.  
MS (EI) m/z (relative intensity): 230 (5) [M]+, 201 (100) [M–Et]+, 179 (13), 131 (8).  
HR-MS (ESI): m/z calcd for C16H23O + [M+H]+ 231.1743, found 231.1749. 
 
1-(3-Cycloheptyl-4-fluorophenyl)propan-1-one (154hh) 
The general procedure B was followed using ketimine 135h (159 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 80:1) yielded 154hh (96.9 mg, 78%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 7.3, 2.3 Hz, 1H), 7.76 (ddd, J = 8.5, 4.9, 2.3 Hz, 1H), 7.03 
(dd, J = 9.9, 8.5 Hz, 1H), 3.07–2.91 (m, 3H), 1.94–1.47 (m, 12H), 1.21 (t, J = 7.2 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 199.4 (Cq), 162.8 (d, 1JC–F = 252 Hz, Cq), 136.6 (d, 2JC–F = 16 Hz, Cq), 
133.2 (d, 4JC–F = 3 Hz, Cq), 128.3 (d, 3JC–F = 7 Hz, CH), 127.3 (d, 3JC–F = 10 Hz, CH), 115.3 (d, 2JC–F = 24 Hz, 
CH), 39.6 (CH), 35.3 (CH2), 31.7 (CH2), 27.8 (CH2), 27.3 (CH2), 8.4 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = (–111.4)–(–111.6) (m). 
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IR (ATR): ṽ = 2923, 2855, 1685, 1586, 1492, 1350, 1237, 1150, 797 cm−1. 
MS (EI) m/z (relative intensity): 248 (6) [M]+, 219 (100) [M–Et]+, 149 (10), 109 (13).  
HR-MS (ESI): m/z calcd for C16H22FO+ [M+H]+ 249.1649, found 249.1654. 
 
1-(3-Cyclopentyl-4-fluorophenyl)ethan-1-one (154ai) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and bromocyclopentane (136i, 224 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154ai (73.0 mg, 71%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.90 (dd, J = 7.3, 2.3 Hz, 1H), 7.76 (ddd, J = 8.5, 4.9, 2.3 Hz, 1H), 7.04 
(dd, J = 9.9, 8.5 Hz, 1H), 3.32–3.16 (m, 1H), 2.57 (d, J = 0.5 Hz, 3H), 2.14–1.97 (m, 2H), 1.91–1.52 
(m, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 196.6 (Cq), 164.0 (d, 1JC–F = 253 Hz, Cq), 133.4 (d, 2JC–F = 16 Hz, Cq), 
133.3 (d, 4JC–F = 3 Hz, Cq), 128.5 (d, 3JC–F = 7 Hz, CH), 128.0 (d, 3JC–F = 10 Hz, CH), 115.3 (d, 2JC–F = 24 Hz, 
CH), 38.8 (d, 3JC–F = 1 Hz, CH), 33.1 (d, 4JC–F = 1 Hz, CH2), 26.5 (CH3), 25.4 (CH2).  
19F-NMR (282 MHz, CDCl3): δ = –109.7 (ddd, J = 9.9, 7.3, 5.0 Hz).  
IR (ATR): ṽ = 3348, 2954, 2871, 1682, 1585, 1492, 1356, 1250, 1112, 822 cm−1.  
MS (EI) m/z (relative intensity): 206 (23) [M]+, 191 (100) [M–Me]+, 163 (16), 149 (20).  
HR-MS (EI): m/z calcd for C13H15FO+ [M]+ 206.1101, found 206.1112. 
 
1-(3-Cyclohexyl-4-fluorophenyl)ethan-1-one (154aj) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and bromocyclohexane (136j, 245 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154aj (76.3 mg, 69%) as a 
colorless oil 
1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 7.2, 2.3 Hz, 1H), 7.77 (ddd, J = 8.5, 4.9, 2.3 Hz, 1H), 7.05 
(dd, J = 9.9, 8.5 Hz, 1H), 2.94–2.81 (m, 1H), 2.57 (s, 3H), 1.90–1.71 (m, 5H), 1.57–1.18 (m, 5H).  
5.3 Experimental Procedures and Analytical Data 
 
159 
13C-NMR (125 MHz, CDCl3): δ = 196.7 (Cq), 163.5 (d, 1JC–F = 253 Hz, Cq), 134.9 (d, 2JC–F = 16 Hz, Cq), 
133.4 (d, 4JC–F = 3 Hz, Cq), 128.3 (d, 3JC–F = 7 Hz, CH), 128.0 (d, 3JC–F = 10 Hz, CH), 115.3 (d, 2JC–F = 24 Hz, 
CH), 37.2 (d, 3JC–F = 2 Hz, CH), 32.9 (CH2), 26.8 (CH2), 26.6 (CH3), 26.1 (CH2).  
19F-NMR (282 MHz, CDCl3): δ = –111.6 (ddd, J = 9.9, 7.2, 4.9 Hz).  
IR (ATR): ṽ = 2926, 2852, 1682, 1586, 1492, 1355, 1254, 1107, 820 cm−1.  
MS (EI) m/z (relative intensity): 220 (23) [M]+, 205 (100) [M–Me]+, 149 (23), 109 (12). 
HR-MS (EI): m/z calcd for C14H17FO+ [M]+ 220.1258, found 220.1262. 
 
1-(3-Cycloheptyl-4-fluorophenyl)ethan-1-one (154ah) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154ah (94.7 mg, 81%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 7.3, 2.3 Hz, 1H), 7.75 (ddd, J = 8.5, 4.9, 2.3 Hz, 1H), 7.04 
(dd, J = 9.8, 8.5 Hz, 1H), 3.08–2.94 (m, 1H), 2.55 (s, 3H), 1.95–1.46 (m, 12H). 
13C-NMR (75 MHz, CDCl3): δ = 196.9 (Cq), 163.1 (d, 1JC–F = 253 Hz, Cq), 136.8 (d, 2JC–F = 16 Hz, Cq), 
133.5 (d, 4JC–F = 3 Hz, Cq), 128.6 (d, 3JC–F = 7 Hz, CH), 127.9 (d, 3JC–F = 10 Hz, CH), 115.4 (d, 2JC–F = 24 Hz, 
CH), 39.5 (d, 3JC–F = 1 Hz, CH), 35.2 (d, 4JC–F = 1 Hz, CH2), 27.7 (CH2), 27.2 (CH2), 26.5 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = (–111.0)–(–111.1) (m).  
IR (ATR): ṽ = 2921, 1682, 1585, 1492, 1416, 1355, 1243, 1170, 1104, 819 cm−1.  
MS (EI) m/z (relative intensity): 234 (41) [M]+, 219 (100) [M–Me]+, 164 (40), 149 (70).  
HR-MS (EI): m/z calcd for C15H19FO+ [M]+ 234.1414, found 234.1416. 
 
1-(3-Cyclooctyl-4-fluorophenyl)ethan-1-one (154ak) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and bromocyclooctane (136k, 287 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154ak (82.7 mg, 67%) as 
a colorless oil. 
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1H-NMR (300 MHz, CDCl3): δ = 7.87 (dd, J = 7.3, 2.3 Hz, 1H), 7.75 (ddd, J = 8.5, 4.9, 2.3 Hz, 1H), 7.04 
(dd, J = 9.9, 8.5 Hz, 1H), 3.20–3.05 (m, 1H), 2.57 (s, 3H), 1.90–1.73 (m, 6H), 1.73–1.50 (m, 8H).  
13C-NMR (125 MHz, CDCl3): δ = 196.7 (Cq), 163.1 (d, 1JC–F = 253 Hz, Cq), 137.2 (d, 2JC–F = 16 Hz, Cq), 
133.4 (d, 4JC–F = 3 Hz, Cq), 128.8 (d, 3JC–F = 7 Hz, CH), 127.8 (d, 3JC–F = 10 Hz, CH), 115.4 (d, 2JC–F = 24 Hz, 
CH), 37.3 (CH), 33.4 (CH2), 26.7 (CH2), 26.6 (CH3), 26.4 (CH2), 26.0 (CH2).  
19F-NMR (282 MHz, CDCl3): δ = (–110.5)–(–110.7) (m). 
IR (ATR): ṽ = 2919, 2852, 1682, 1585, 1492, 1355, 1283, 1108, 822 cm−1.  
MS (EI) m/z (relative intensity): 248 (47) [M]+, 233 (38) [M–Me]+, 164 (69), 149 (100).  
HR-MS (ESI): m/z calcd for C16H22FO+ [M+H]+ 249.1649, found 249.1654. 
 
1-[3-Cycloheptyl-4-(piperidin-1-yl)phenyl]ethan-1-one (154nh) 
The general procedure B was followed using ketimine 135n (184 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, to the reaction 
mixture was added HCl (2 N, 3.0 mL) and the resulting mixture was stirred for 
additional 3 h, and then neutralized with sat. aq. NaHCO3 solution until pH 8. The 
reaction mixture was extracted with Et2O (3 × 20 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification of the residue by column 
chromatography (n-hexane/EtOAc 95:5) yielded 154nh (105 mg, 70%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 2.2 Hz, 1H), 7.70 (dd, J = 8.3, 2.2 Hz, 1H), 7.01 (d, J = 
8.3 Hz, 1H), 3.15 (tt, J = 10.1, 3.2 Hz, 1H), 2.86 (dd, J = 5.3, 5.1 Hz, 4H), 2.55 (s, 3H), 1.89–1.45 (m, 
18H).  
13C-NMR (75 MHz, CDCl3): δ = 197.6 (Cq), 156.0 (Cq), 145.1 (Cq), 132.2 (Cq), 127.4 (CH), 126.9 (CH), 
119.0 (CH), 54.2 (CH2), 38.9 (CH), 36.8 (CH2), 28.0 (CH2), 27.7 (CH2), 26.5 (CH2), 26.4 (CH3), 24.3 
(CH2).  
IR (ATR): ṽ = 2917, 2852, 1676, 1595, 1354, 1266, 920, 827, 599 cm−1.  
MS (EI) m/z (relative intensity): 299 (100) [M]+, 284 (19) [M–Me]+, 242 (30), 228 (35), 217 (35), 200 
(19), 186 (38), 172 (27), 144 (14), 130 (14), 43 (42).  
HR-MS (EI): m/z calcd for C20H29NO+ [M]+ 299.2244, found 299.2260. 
 




The general procedure B was followed using ketimine 135o (186 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, to the reaction 
mixture was added HCl (2 N, 3.0 mL) and the resulting mixture was stirred for 
additional 3 h, and then neutralized with sat. aq. NaHCO3 solution until pH 8. The 
reaction mixture was extracted with Et2O (3 × 20 mL). The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Purification of the residue by column 
chromatography (n-hexane/EtOAc 4:1) yielded 154oh (88.0 mg, 58%) as a yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 2.2 Hz, 1H), 7.73 (dd, J = 8.3, 2.2 Hz, 1H), 7.06 (d, J = 
8.3 Hz, 1H), 3.93–3.83 (m, 4H), 3.18 (tt, J = 9.9, 3.6 Hz, 1H), 2.98–2.88 (m, 4H), 2.56 (s, 3H), 1.90–
1.43 (m, 12H).  
13C-NMR (125 MHz, CDCl3): δ = 197.3 (Cq), 154.0 (Cq), 145.1 (Cq), 133.0 (Cq), 127.6 (CH), 126.9 (CH), 
119.2 (CH), 67.3 (CH2), 53.2 (CH2), 39.1 (CH), 36.8 (CH2), 28.0 (CH2), 27.7 (CH2), 26.5 (CH3).  
IR (ATR): ṽ = 2915, 2850, 1677, 1595, 1450, 1355, 1235, 1114, 919, 828 cm−1.  
MS (EI) m/z (relative intensity): 301 (100) [M]+, 286 (11) [M–Me]+, 244 (18), 228 (29), 219 (28), 200 
(24), 186 (25), 172 (40), 144 (16), 130 (15), 43 (37).  
HR-MS (EI): m/z calcd for C19H27NO2+ [M]+ 301.2036, found 301.2047. 
 
1-(4-iso-Propylnaphthalen-2-yl)ethan-1-one (154ql) 
The general procedure B was followed using ketimine 135q (168 mg, 0.50 mmol) 
and 2-bromopropane (136l, 185 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154ql (89.3 mg, 84%) as a 
white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.32 (br s, 1H), 8.15 (d, J = 8.5 Hz, 1H), 8.01 (d, J = 1.7 Hz, 1H), 7.99 
(dd, J = 8.1, 1.2 Hz, 1H), 7.64 (ddd, J = 8.5, 6.8, 1.2 Hz, 1H), 7.54 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 3.75 
(hept, J = 6.9 Hz, 1H), 2.73 (s, 3H), 1.44 (d, J = 6.9 Hz, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 198.2 (Cq), 145.3 (Cq), 134.0 (Cq), 133.6 (Cq), 133.0 (Cq), 130.4 (CH), 
128.7 (CH), 128.2 (CH), 126.0 (CH), 123.3 (CH), 119.4 (CH), 28.8 (CH), 26.6 (CH3), 23.4 (CH3).  
IR (ATR): ṽ = 3063, 2960, 1671, 1397, 1271, 1229, 1194, 1142, 882 cm−1.  
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m.p.: 60–62 °C. 
MS (EI) m/z (relative intensity): 212 (58) [M]+, 197 (100) [M–Me]+, 152 (25), 115 (8).  
HR-MS (EI): m/z calcd for C15H16O+ [M]+ 212.1196, found 212.1209. 
 
1-[4-(sec-Butyl)naphthalen-2-yl]ethan-1-one (154qm) 
The general procedure B was followed using ketimine 135q (168 mg, 0.50 mmol) 
and 2-bromobutane (136m, 206 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154qm (87.7 mg, 78%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.32 (d, J = 1.5 Hz, 1H), 8.15 (d, J = 8.5 Hz, 1H), 8.01–7.94 (m, 2H), 
7.63 (ddd, J = 8.5, 6.8, 1.5 Hz, 1H), 7.54 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 3.52 (dt, J = 6.9, 6.9 Hz, 1H), 
2.73 (s, 3H), 1.98–1.83 (m, 1H), 1.83–1.67 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 198.2 (Cq), 144.5 (Cq), 134.1 (Cq), 134.0 (Cq), 133.0 (Cq), 130.4 (CH), 
128.6 (CH), 128.1 (CH), 126.0 (CH), 123.3 (CH), 120.1 (CH), 35.5 (CH), 30.5 (CH2), 26.6 (CH3), 21.1 
(CH3), 12.3 (CH3).  
IR (ATR): ṽ = 3056, 2961, 1674, 1622, 1425, 1396, 1278, 1174, 885 cm−1.  
MS (EI) m/z (relative intensity): 226 (52) [M]+, 197 (100) [M–Et]+, 153 (25), 127 (10).  
HR-MS (EI): m/z calcd for C16H18O+ [M]+ 226.1352, found 226.1365. 
 
1-[4-(Pentan-2-yl)naphthalen-2-yl]ethan-1-one (154qn) 
The general procedure B was followed using ketimine 135q (168 mg, 0.50 mmol) 
and 2-bromopentane (136n, 227 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154qn (91.8 mg, 77%) as 
a light yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.31 (d, J = 1.5 Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 8.00–7.95 (m, 2H), 
7.63 (ddd, J = 8.6, 6.8, 1.5 Hz, 1H), 7.55 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 3.61 (dt, J = 6.9, 6.9 Hz, 1H), 
2.74 (s, 3H), 1.91–1.61 (m, 2H), 1.48–1.25 (m, 5H), 0.92 (t, J = 7.3 Hz, 3H).  
5.3 Experimental Procedures and Analytical Data 
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13C-NMR (125 MHz, CDCl3): δ = 198.2 (Cq), 144.8 (Cq), 134.0 (Cq), 134.0 (Cq), 133.0 (Cq), 130.5 (CH), 
128.6 (CH), 128.1 (CH), 126.0 (CH), 123.2 (CH), 120.2 (CH), 40.0 (CH2), 33.6 (CH), 26.6 (CH3), 21.6 
(CH3), 20.9 (CH2), 14.3 (CH3). j 
IR (ATR): ṽ = 2957, 2928, 1675, 1623, 1453, 1375, 1277, 1194, 885 cm−1.  
MS (EI) m/z (relative intensity): 240 (53) [M]+, 197 (100) [M–Pr]+, 153 (26), 127 (11).  
HR-MS (EI): m/z calcd for C17H20O+ [M]+ 240.1509, found 240.1523. 
 
1-[4-(Octan-2-yl)naphthalen-2-yl]ethan-1-one (154qo) 
The general procedure B was followed using ketimine 135q (168 mg, 0.50 mmol) 
and 2-bromooctane (136o, 290 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154qo (111.9 mg, 79%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.32 (s, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.01–7.94 (m, 2H), 7.63 (ddd, J 
= 8.5, 6.8, 1.5 Hz, 1H), 7.54 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 3.59 (dt, J = 6.9, 6.9 Hz, 1H), 2.74 (s, 3H), 
1.93–1.79 (m, 1H), 1.79–1.64 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H), 1.37–1.16 (m, 8H), 0.92–0.75 (m, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 198.2 (Cq), 144.8 (Cq), 134.0 (Cq), 134.0 (Cq), 133.0 (Cq), 130.5 (CH), 
128.6 (CH), 128.1 (CH), 126.0 (CH), 123.2 (CH), 120.1 (CH), 37.8 (CH2), 33.9 (CH), 31.8 (CH2), 29.5 
(CH2), 27.8 (CH2), 26.6 (CH3), 22.7 (CH2), 21.6 (CH3), 14.1 (CH3). 
IR (ATR): ṽ = 2956, 2954, 1677, 1454, 1352, 1276, 1195, 885 cm−1.  
MS (EI) m/z (relative intensity): 282 (50) [M]+, 191 (100), 153 (22), 127 (5). 
HR-MS (EI): m/z calcd for C20H26O+ [M]+ 282.1978, found 282.1994. 
 
1-(4-Cycloheptylnaphthalen-2-yl)ethan-1-one (154qh) 
The general procedure B was followed using ketimine 135q (168 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154qh (117.9 mg, 89%) 
as a light yellow oil. 
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1H-NMR (300 MHz, CDCl3): δ = 8.29 (br s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.99–7.93 (m, 2H), 7.67–7.59 
(m, 1H), 7.57–7.49 (m, 1H), 3.55–3.41 (m, 1H), 2.72 (d, J = 1.5 Hz, 3H), 2.14–1.99 (m, 2H), 1.99–
1.56 (m, 10H).  
13C-NMR (125 MHz, CDCl3): δ = 198.2 (Cq), 146.5 (Cq), 134.0 (Cq), 133.4 (Cq), 133.0 (Cq), 130.5 (CH), 
128.5 (CH), 128.2 (CH), 126.0 (CH), 123.4 (CH), 120.3 (CH), 41.2 (CH), 36.3 (CH2), 27.9 (CH2), 27.7 
(CH2), 26.6 (CH3).  
IR (ATR): ṽ = 2919, 2852, 1674, 1457, 1397, 1260, 1194, 885 cm−1.  
MS (EI) m/z (relative intensity): 266 (100) [M]+, 209 (16), 183 (28), 153 (40).  
HR-MS (EI): m/z calcd for C19H22O+ [M]+ 266.1665, found 266.1661. 
 
tert-Butyl 4-(3-acetylnaphthalen-1-yl)piperidine-1-carboxylate (154qp) 
The general procedure B was followed using ketimine 135q (168 mg, 
0.50 mmol) and tert-butyl 4-bromopiperidine-1-carboxylate (136p, 396 mg, 
1.50 mmol) was added by syringe pump over 5.5 h at 140 °C. After 20 h, to 
the reaction mixture was added HCl (2 N, 3.0 mL) and the resulting mixture 
was stirred for additional 3 h, and then neutralized with sat. aq. NaHCO3 solution until pH 8. The 
reaction mixture was extracted with Et2O (3 × 20 mL). The combined organic layers were dried 
over Na2SO4 and concentrated in vacuo. Purification of the residue by column chromatography 
(n-pentane/Et2O 3:1) yielded 154qp (96.3 mg, 54%) as a white solid 
1H-NMR (300 MHz, CDCl3): δ = 8.32 (d, J = 1.6 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 8.01–7.96 (m, 1H), 
7.93 (d, J = 1.6 Hz, 1H), 7.64 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.55 (ddd, J = 8.0, 6.9, 1.2 Hz, 1H), 4.34 
(br d, J = 13.1 Hz, 2H), 3.46 (tt, J = 11.8, 3.3 Hz, 1H), 2.96 (t, J = 12.8 Hz, 2H), 2.71 (s, 3H), 2.03–1.92 
(m, 2H), 1.92–1.72 (m, 2H), 1.50 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 197.9 (Cq), 154.6 (Cq), 142.2 (Cq), 134.0 (Cq), 133.4 (Cq), 133.1 (Cq), 
130.6 (CH), 129.2 (CH), 128.4 (CH), 126.2 (CH), 122.8 (CH), 120.2 (CH), 79.5 (Cq), 44.6 (CH2), 37.8 
(CH), 32.8 (CH2), 28.5 (CH3), 26.5 (CH3).  
IR (ATR): ṽ = 2973, 2855, 1673, 1426, 1363, 1228, 1163, 1122, 891, 753 cm−1.  
m.p.: 139–140 °C. 
MS (EI) m/z (relative intensity): 353 (10) [M]+, 280 (10) [M–Ot-Bu]+, 253 (46) [M–Boc]+, 198 (21), 
165 (9), 152 (14), 83 (17), 69 (9), 57 (100), 43 (61).  
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HR-MS (EI): m/z calcd for C22H27NO3+ [M]+ 353.1985, found 353.1980. 
 
1-[4-Fluoro-3-(tetrahydro-2H-pyran-4-yl)phenyl]ethan-1-one (154aq) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and 4-bromotetrahydro-2H-pyran (136q, 248 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-pentane/Et2O 10:1 to 3:1) yielded 
154aq (46.7 mg, 42%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.88 (dd, J = 7.3, 2.4 Hz, 1H), 7.81 (ddd, J = 8.5, 5.1, 2.4 Hz, 1H), 7.08 
(dd, J = 9.9, 8.5 Hz, 1H), 4.08 (ddt, J = 11.7, 4.3, 1.1 Hz, 2H), 3.55 (ddd, J = 11.8, 11.7, 2.1 Hz, 2H), 
3.13 (ddt, J = 12.1, 7.6, 3.8 Hz, 1H), 2.57 (s, 3H), 1.94–1.82 (m, 2H), 1.78–1.71 (m, 2H). 
13C-NMR (100 MHz, CDCl3): δ = 196.6 (Cq), 163.7 (d, 1JC–F = 254 Hz, Cq), 133.7 (d, 4JC–F = 3 Hz, Cq), 
132.9 (d, 2JC–F = 15 Hz, Cq), 128.6 (d, 3JC–F = 10 Hz, CH), 128.3 (d, 3JC–F = 7 Hz, CH), 115.6 (d, 2JC–F = 
24 Hz, CH), 68.2 (CH2), 34.6 (d, 3JC–F = 2 Hz, CH), 32.3 (d, 4JC–F = 1 Hz, CH2), 26.5 (CH3). 
19F-NMR (376 MHz, CDCl3): δ = –111.5 (ddd, J = 9.9, 7.3, 5.1 Hz). 
IR (ATR): ṽ = 2952, 2843, 1682, 1586, 1494, 1356, 1234, 1087, 821 cm−1.  
MS (EI) m/z (relative intensity): 222 (44) [M]+, 207 (33) [M–Me]+, 178 (31), 163 (71), 149 (60), 133 
(14), 101 (19), 58 (17), 43 (100).  
HR-MS (EI): m/z calcd for C13H15FO2+ [M]+ 222.1051, found 222.1050. 
 
tert-Butyl 4-(5-acetyl-2-fluorophenyl)piperidine-1-carboxylate (154ap) 
The general procedure B was followed using ketimine 135a (152 mg, 
0.50 mmol) and tert-butyl 4-bromopiperidine-1-carboxylate (136p, 396 mg, 
1.50 mmol) was added in 3 portions after 3 h and 6 h at 140 °C. After 20 h, to 
the reaction mixture was added HCl (2 N, 3.0 mL) and the resulting mixture 
was stirred for additional 3 h, and then neutralized with sat. aq. NaHCO3 solution until pH 8. The 
reaction mixture was extracted with Et2O (3 × 20 mL). The combined organic layers were dried 
over Na2SO4 and concentrated in vacuo. Purification of the residue by column chromatography 
(n-pentane/Et2O 3:1) yielded 154ap (83.1 mg, 52%) as a colorless oil. 
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1H-NMR (300 MHz, CDCl3): δ = 7.86 (dd, J = 7.2, 2.3 Hz, 1H), 7.81 (ddd, J = 8.5, 5.0, 2.3 Hz, 1H), 7.09 
(dd, J = 9.9, 8.5 Hz, 1H), 4.27 (d, J = 13.0 Hz, 2H), 3.03 (tt, J = 12.3, 3.7 Hz, 1H), 2.83 (dd, J = 13.0, 
12.6 Hz, 2H), 2.58 (s, 3H), 1.81 (dAB, J = 12.6 Hz, 2H), 1.69 (dABddd, J = 12.6, 12.6, 12.3, 4.1 Hz, 2H), 
1.49 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 196.4 (Cq), 163.5 (d, 1JC–F = 253 Hz, Cq), 154.6 (Cq), 133.7 (d, 4JC–F = 
3 Hz, Cq), 132.8 (d, 2JC–F = 15 Hz, Cq), 128.6 (d, 3JC–F = 10 Hz, CH), 128.2 (d, 3JC–F = 7 Hz, CH), 115.6 (d, 
2JC–F = 24 Hz, CH), 79.6 (Cq), 44.3 (CH2), 35.7 (d, 3JC–F = 2 Hz, CH), 31.7 (CH2), 28.6 (CH3), 26.6 (CH3). 
19F-NMR (282 MHz, CDCl3): δ = –111.5 (ddd, J = 9.9, 7.2, 5.0 Hz). 
IR (ATR): ṽ = 2975, 2930, 1685, 1587, 1420, 1365, 1233, 1166, 1021, 819 cm−1.  
MS (EI) m/z (relative intensity): 321 (2) [M]+, 266 (7) [M–t-Bu]+, 248 (21) [M–t-Bu–Me]+, 221 (51), 
83 (9), 57 (100), 43 (40).  
HR-MS (EI): m/z calcd for C18H24FNO3+ [M]+ 321.1735, found 321.1742. 
 
1-[4-Fluoro-3-(tetrahydrofuran-3-yl)phenyl]ethan-1-one (154ar) 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) 
and 3-bromotetrahydrofuran (136r, 226 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 10:1 to 4:1) yielded 154ar (26.1 mg, 25%) 
as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.93 (dd, J = 7.3, 2.3 Hz, 1H), 7.83 (ddd, J = 8.5, 5.0, 2.3 Hz, 1H), 7.10 
(dd, J = 9.7, 8.5 Hz, 1H), 4.19–4.12 (m, 1H), 4.08 (ddd, J = 8.3, 8.1, 5.0 Hz, 1H), 3.94 (ddd, J = 8.3, 
7.4, 7.4 Hz, 1H), 3.81–3.74 (m, 1H), 3.69 (p, J = 7.4 Hz, 1H), 2.58 (s, 3H), 2.45–2.32 (m, 1H), 2.13–
2.01 (m, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 196.4 (Cq), 163.7 (d, 1JC–F = 254 Hz, Cq), 133.7 (d, 4JC–F = 3 Hz, Cq), 
130.0 (d, 2JC–F = 15 Hz, Cq), 128.8 (d, 3JC–F = 10 Hz, CH), 128.7 (d, 3JC–F = 6 Hz, CH), 115.6 (d, 2JC–F = 
24 Hz, CH), 73.0 (d, 4JC–F = 2.0 Hz, CH2), 68.2 (CH2), 37.9 (d, 3JC–F = 1.6 Hz, CH), 33.0 (CH2), 26.6 (CH3). 
19F-NMR (282 MHz, CDCl3): δ = –109.6 (ddd, J = 9.7, 7.3, 5.0 Hz). 
IR (ATR): ṽ = 2876, 1684, 1588, 1496, 1359, 1254, 1063, 830, 572 cm−1. 
MS (ESI) m/z (relative intensity): 231 (100) [M+Na]+, 209 (41) [M+H]+. 
HR-MS (ESI): m/z calcd for C12H13FO2Na+ [M+Na]+ 231.0792, found 231.0794. 
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4-Acetyl-2-cycloheptylphenyl 4-cyanobenzoate (154vh) 
The general procedure B was followed using ketimine 135v (108 mg, 
0.25 mmol) and bromocycloheptane (136h, 133 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 9:1) yielded 154vh 
(10.2 mg, 11%) as a yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.32 (d, J = 8.7 Hz, 2H), 7.98 (d, J = 2.2 Hz, 1H), 
7.87 (d, J = 8.7 Hz, 2H), 7.84 (dd, J = 8.4, 2.2 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 2.85 
(tt, J = 10.4, 3.3 Hz, 1H), 2.62 (s, 3H), 1.95–1.37 (m, 12H).  
13C-NMR (125 MHz, CDCl3): δ = 197.0 (Cq), 163.1 (Cq), 151.0 (Cq), 141.6 (Cq), 135.5 (Cq), 132.8 (Cq), 
132.5 (CH), 130.5 (CH), 128.0 (CH), 127.1 (CH), 122.4 (CH), 117.6 (Cq), 117.3 (Cq), 40.4 (CH), 35.5 
(CH2), 27.7 (CH2), 27.5 (CH2), 26.7 (CH3). 
IR (ATR): ṽ = 2924, 2856, 2232, 1743, 1684, 1239, 1081, 1018, 761 cm−1. 
MS (ESI) m/z (relative intensity): 384 (100) [M+Na]+, 362 (47) [M+H]+. 
HR-MS (ESI): m/z calcd for C23H23NO3Na+ [M+Na]+ 384.1570, found 384.1575. 
 
5.3.2.2 Mechanistic Studies 
5.3.2.2.1 Intermolecular Competition Experiments 
 
Ketimine 135b (143 mg, 0.50 mmol), 135a (152 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 
25.0 μmol, 5.0 mol %), 1-AdCO2H (12, 27.3 mg, 0.15 mmol, 30 mol %) and K2CO3 (138 mg, 
1.00 mmol) were placed in a pre-dried 25 mL pressure tube. The tube was evacuated and purged 
with N2 for three times. Bromocycloheptane (136h, 70.8 mg, 0.40 mmol) and PhCMe3 (2.0 mL) 
were then added and the mixture was stirred at 120 °C for 6 h. At ambient temperature, the 
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resulting mixture was filtered and washed with EtOAc. The filtrate was concentrated in vacuo. The 
crude mixture was analyzed by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene (84.1 mg, 
0.50 mmol) as the internal standard (Figure 14). The mixture was dissolved with Et2O (10 mL) and 
then treated with HCl (2 N, 3.0 mL). The resulting mixture was stirred at ambient temperature for 
3 h, and then extracted with Et2O (3 × 20 mL). The combined organic layers were dried over Na2SO4 




Figure 14: 1H-NMR spectrum for a crude mixture before hydrolysis (H = ●, F = ●). 
 




Figure 15: 1H-NMR spectrum for a crude mixture after hydrolysis (154bh (H)=●, 154ah (F)=●). 
 
 
Ketimine 135e (150 mg, 0.50 mmol), 135u (177 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 
25.0 μmol, 5.0 mol %), 1-AdCO2H (12, 27.3 mg, 0.15 mmol, 30 mol %) and K2CO3 (138 mg, 
1.00 mmol) were placed in a pre-dried 25 mL pressure tube. The tube was evacuated and purged 
with N2 for three times. Bromocycloheptane (136h, 70.8 mg, 0.40 mmol) and PhCMe3 (2.0 mL) 
were then added and the mixture was stirred at 120 °C for 6 h. At ambient temperature, the 
resulting mixture was filtered and washed with EtOAc. The filtrate was concentrated in vacuo. The 
crude mixture was analyzed by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene (84.1 mg, 
0.50 mmol) as the internal standard (Figure 16). The mixture was dissolved with Et2O (10 mL) and 
then treated with HCl (2 N, 3.0 mL). The resulting mixture was stirred at ambient temperature for 
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3 h, and then extracted with Et2O (3 × 20 mL). The combined organic layers were dried over Na2SO4 




Figure 16: 1H-NMR spectrum for a crude mixture before hydrolysis (CH3 = ●, CF3 = ●). 
 




Figure 17: 1H-NMR spectrum for a crude mixture after hydrolysis (154eh (CH3)=●, 154uh (CF3)=●). 
 
5.3.2.2.2 Intramolecular Competition Experiment 
 
Alkyl bromide 136h (1.2 equiv) 
The general procedure B was followed using ketimine 135w (183 mg, 0.50 mmol) and 
bromocycloheptane (136h, 107 mg, 0.60 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) followed by recycling preparative HPLC yielded 
monoalkylated 154wh (43.0 mg, 29%) as a colorless oil as well as dialkylated 154wh’ (9.1 mg, 5%) 
as a colorless oil and recovered unreacted ketone (43.2 mg, 43%) as a colorless oil. 
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Alkyl bromide 136h (1.5 equiv) 
The general procedure B was followed using ketimine 135w (183 mg, 0.50 mmol) and 
bromocycloheptane (136h, 133 mg, 0.75 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 100:1) followed by recycling preparative HPLC yielded 
monoalkylated 154wh (68.1 mg, 46%) as a colorless oil as well as dialkylated 154wh’ (62.2 mg, 
31%) as a colorless oil and recovered unreacted ketone (8.1 mg, 8%) as a colorless oil. 
 
(3-Cycloheptyl-4-fluorophenyl)(phenyl)methanone (154wh) 
1H-NMR (600 MHz, CDCl3): δ = 7.78–7.75 (m, 3H), 7.61–7.57 (m, 2H), 7.51–7.47 
(m, 2H), 7.07 (dd, J = 9.9, 8.4 Hz, 1H), 3.05 (tt, J = 10.7, 3.5 Hz, 1H), 1.94–1.88 (m, 
2H), 1.84–1.77 (m, 2H), 1.75–1.65 (m, 4H), 1.63–1.53 (m, 4H). 
13C-NMR (125 MHz, CDCl3): δ = 195.7 (Cq), 162.8 (d, 1JC–F = 253 Hz, Cq), 137.7 (Cq), 
136.7 (d, 2JC–F = 16 Hz, Cq), 133.6 (d, 4JC–F = 3 Hz, Cq), 132.3 (CH), 130.5 (d, 3JC–F = 7 Hz, CH), 129.9 
(CH), 129.7 (d, 3JC–F = 10 Hz, CH), 128.3 (CH), 115.2 (d, 2JC–F = 24 Hz, CH), 39.5 (CH), 35.2 (CH2), 27.7 
(CH2), 27.3 (CH2). 
19F-NMR (470 MHz, CDCl3): δ = (–111.7)–(–111.8) (m).  
IR (ATR): ṽ = 2924, 2855, 1657, 1599, 1490, 1446, 1281, 1092, 713 cm−1.  
MS (EI) m/z (relative intensity): 296 (92) [M]+, 226 (68), 149 (53), 105 (100).  
HR-MS (ESI): m/z calcd for C20H22FO+ [M+H]+ 297.1649, found 297.1654. 
 
(3-Cycloheptyl-4-fluorophenyl)(3-cycloheptylphenyl)methanone (154wh’) 
1H-NMR (600 MHz, CDCl3): δ = 7.74 (dd, J = 7.3, 2.3 Hz, 1H), 7.62 (ddd, J = 8.5, 
5.0, 2.3 Hz, 1H), 7.60–7.59 (m, 1H), 7.56 (ddd, J = 7.4, 1.6, 1.6 Hz, 1H), 7.42 
(ddd, J = 7.6, 1.6, 1.6 Hz, 1H), 7.38 (dd, J = 7.6, 7.4 Hz, 1H), 7.08 (dd, J = 9.9, 
8.5 Hz, 1H), 3.06 (tt, J = 10.7, 3.5 Hz, 1H), 2.74 (tt, J = 10.7, 3.6 Hz, 1H), 1.97–
1.89 (m, 4H), 1.85–1.77 (m, 4H), 1.74–1.65 (m, 8H), 1.63–1.51 (m, 8H). 
13C-NMR (100 MHz, CDCl3): δ = 195.9 (Cq), 162.7 (d, 1JC–F = 252 Hz, Cq), 150.1 (Cq), 137.7 (Cq), 136.5 
(d, 2JC–F = 16 Hz, Cq), 133.8 (d, 4JC–F = 3 Hz, Cq), 130.9 (CH), 130.6 (d, 3JC–F = 7 Hz, CH), 129.6 (d, 3JC–F = 
10 Hz, CH), 128.3 (CH), 128.2 (CH), 127.3 (CH), 115.2 (d, 2JC–F = 24 Hz, CH), 46.9 (CH), 39.3 (CH), 36.8 
(CH2), 35.3 (CH2), 27.8 (CH2), 27.8 (CH2), 27.3 (CH2), 27.2 (CH2). 
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19F-NMR (282 MHz, CDCl3): δ = (–112.1)–(–112.2) (m).  
IR (ATR): ṽ = 2919, 1657, 1583, 1284, 1246, 1170, 1091, 833, 806, 755 cm−1.  
MS (EI) m/z (relative intensity): 392 (100) [M]+, 310 (22), 219 (57), 201 (22), 149 (24), 55 (19).  
HR-MS (EI): m/z calcd for C27H33FO+ [M]+ 392.2510, found 392.2523. 
 
5.3.2.2.3 Reactions with Radical Scavengers 
 
Ketimine 135a (152 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 25.0 μmol, 5.0 mol %), 
1-AdCO2H (12, 27.3 mg, 0.15 mmol, 30 mol %), K2CO3 (138 mg, 1.00 mmol) and BHT (110 mg, 
0.50 mmol) were placed in a pre-dried 25 mL pressure tube. The tube was evacuated and purged 
with N2 for three times. Bromocycloheptane (136h, 266 mg, 1.50 mmol) and PhCMe3 (2.0 mL) 
were then added and the mixture was stirred at 120 °C for 20 h. At ambient temperature, HCl (2 N, 
3.0 mL) was added, and the resulting mixture was stirred for additional 3 h, and then extracted 
with Et2O (3 × 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by column chromatography (n-pentane/Et2O 50:1) yielded 
product 154ah (91.0 mg, 78%) as a colorless oil. 
 
 
Ketimine 135a (152 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 25.0 μmol, 5.0 mol %), 
1-AdCO2H (12, 27.3 mg, 0.15 mmol, 30 mol %), K2CO3 (138 mg, 1.00 mmol) and TEMPO (78.5 mg, 
0.50 mmol) were placed in a pre-dried 25 mL pressure tube. The tube was evacuated and purged 
with N2 for three times. Bromocycloheptane (136h, 266 mg, 1.50 mmol) and PhCMe3 (2.0 mL) 
were then added and the mixture was stirred at 120 °C for 20 h. At ambient temperature, HCl (2 N, 
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3.0 mL) was added, and the resulting mixture was stirred for additional 3 h, and then extracted 
with Et2O (3 × 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by column chromatography (n-pentane/Et2O 50:1) yielded 
TEMPO-adduct 156 (20.0 mg, 16%) as a colorless oil. 
 
1-(Cycloheptyloxy)-2,2,6,6-tetramethylpiperidine (156) 
1H-NMR (300 MHz, CDCl3): δ = 3.82 (tt, J = 8.5, 4.4 Hz, 1H), 2.07–1.95 (m, 2H), 
1.71–1.41 (m, 13H), 1.40–1.22 (m, 3H), 1.11 (s, 12H).  
13C-NMR (75 MHz, CDCl3): δ = 83.8 (CH), 59.7 (Cq), 40.3 (CH2), 34.4 (CH3), 33.5 
(CH2), 28.6 (CH2), 23.4 (CH2), 20.4 (CH3), 17.3 (CH2).  
IR (ATR): ṽ = 2924, 2856, 1458, 1359, 1132, 1006, 973 cm−1.  
MS (ESI) m/z (relative intensity): 254 (100) [M+H]+, 126 (33).  
HR-MS (ESI): m/z calcd for C16H32NO+ [M+H]+ 254.2478, found 254.2479. 
The spectral data are in accordance with those reported in the literature.[132] 
 
5.3.2.2.4 Reactions with Diastereomerically Pure Alkyl Bromide 136s 
 
The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) and cis-1-bromo-
4-(tert-butyl)cyclohexane (cis-136s, 329 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-pentane/Et2O 50:1) yielded 154as as a mixture of cis- and trans-isomers 
(cis-154as/trans-154as 43:57, 104 mg, 75%). 
 




The general procedure B was followed using ketimine 135a (152 mg, 0.50 mmol) and trans-1-
bromo-4-(tert-butyl)cyclohexane (trans-136s, 329 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-pentane/Et2O 50:1) yielded 154as as a mixture of cis- and 




1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 7.1, 2.3 Hz, 1H), 7.77 (ddd, J = 
8.5, 4.9, 2.3 Hz, 1H), 7.05 (dd, J = 9.9, 8.5 Hz, 1H), 2.83 (tt, J = 12.2, 3.4 Hz, 
1H), 2.58 (s, 3H), 2.00–1.86 (m, 4H), 1.60–1.42 (m, 2H), 1.28–1.05 (m, 3H), 0.89 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 196.7 (Cq), 163.7 (d, 1JC–F = 253 Hz, Cq), 134.7 (d, 2JC–F = 16 Hz, Cq), 
133.5 (d, 4JC–F = 3 Hz, Cq), 128.3 (d, 3JC–F = 7 Hz, CH), 128.0 (d, 3JC–F = 10 Hz, CH), 115.4 (d, 2JC–F = 24 Hz, 
CH), 47.7 (CH), 37.2 (d, 3JC–F = 2 Hz, CH), 33.3 (CH2), 32.5 (Cq), 27.6 (CH3), 27.6 (CH2), 26.6 (CH3). 
19F-NMR (282 MHz, CDCl3): δ = –111.5 (ddd, J = 9.9, 7.1, 4.9 Hz). 
IR (ATR): ṽ = 2940, 2859, 1681, 1606, 1491, 1354, 1281, 1116, 825, 570 cm−1.  
m.p.: 54–55 °C. 
MS (EI) m/z (relative intensity): 276 (32) [M]+, 261 (11) [M–Me]+, 220 (71) [M–Bu]+, 205 (100), 177 
(25), 151 (34), 57 (94), 43 (96).  












1H-NMR (300 MHz, CDCl3): δ = 8.11 (ddd, J = 7.6, 2.3, 0.8 Hz, 1H), 7.79 (dddd, J 
= 8.5, 4.8, 2.3, 0.5 Hz, 1H), 7.05 (dd, J = 11.0, 8.5 Hz, 1H), 3.35–3.26 (m, 1H), 
2.59 (s, 3H), 2.17–2.07 (m, 2H), 1.88–1.73 (m, 2H), 1.72–1.60 (m, 2H), 1.26 (qd, J = 12.1, 3.5 Hz, 
2H), 1.14 (tt, J = 11.2, 3.0 Hz, 1H), 0.85 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 196.7 (Cq), 164.2 (d, 1JC–F = 254 Hz, Cq), 133.8 (d, 2JC–F = 14 Hz, Cq), 
132.9 (d, 4JC–F = 3 Hz, Cq), 129.7 (d, 3JC–F = 6 Hz, CH), 128.0 (d, 3JC–F = 10 Hz, CH), 115.4 (d, 2JC–F = 24 Hz, 
CH), 47.4 (CH), 32.7 (Cq), 31.1 (CH), 29.9 (CH2), 29.9 (CH2), 27.6 (CH3), 26.6 (CH3), 23.3 (CH2).  
19F-NMR (282 MHz, CDCl3): δ = –107.9 (ddd, J = 11.0, 7.6, 4.8 Hz). 
IR (ATR): ṽ = 2941, 2866, 1687, 1584, 1491, 1357, 1254, 1112, 828, 575 cm−1.  
MS (EI) m/z (relative intensity): 276 (2) [M]+, 261 (3) [M–Me]+, 220 (29) [M–Bu]+, 205 (23), 177 
(14), 149 (10), 57 (26), 43 (100).  
HR-MS (EI): m/z calcd for C18H25FO+ [M]+ 276.1884, found 276.1884. 
 
5.3.2.3 Late-Stage Diversifications 
Remote meta-C–H Alkylations Followed by Reduction in One-Pot Fashion 
N-[1-(4-Cycloheptylnaphthalen-2-yl)ethyl]-3,4,5-trimethoxyaniline (157a) 
The general procedure D was followed using ketimine 135q (168 mg, 0.50 mmol) 
and bromocycloheptane (136h, 266 mg, 1.50 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 157a (167 mg, 77%) as a white 
solid as well as alkylated phenone 154qh (4.1 mg, 3%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.10 (d, J = 7.9 Hz, 1H), 7.84–7.80 (m, 1H), 7.69 (br s, 1H), 7.52–7.40 
(m, 3H), 5.85 (s, 2H), 4.59 (q, J = 6.7 Hz, 1H), 4.07 (br s, 1H), 3.74 (s, 3H), 3.70 (s, 6H), 3.56–3.47 
(m, 1H), 2.14–2.03 (m, 2H), 1.96–1.75 (m, 6H), 1.75–1.63 (m, 4H), 1.61 (d, J = 6.7 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 153.6 (Cq), 146.4 (Cq), 144.2 (Cq), 142.3 (Cq), 134.1 (Cq), 130.3 (Cq), 
129.8 (Cq), 128.8 (CH), 125.4 (CH), 125.2 (CH), 123.1 (CH), 122.1 (CH), 121.3 (CH), 91.1 (CH), 60.9 
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(CH3), 55.7 (CH3), 54.5 (CH), 40.9 (CH), 36.5 (CH2), 36.2 (CH2), 27.8 (CH2), 27.8 (CH2), 27.6 (CH2), 
27.6 (CH2), 24.6 (CH3).  
IR (ATR): ṽ = 3362, 2919, 1604, 1507, 1446, 1235, 1123, 1009, 810, 749 cm−1. 
m.p.: 158–159 °C. 
MS (EI) m/z (relative intensity): 433 (80) [M]+, 418 (18) [M–Me]+, 251 (100), 183 (24), 168 (35), 155 
(16), 55 (24).  
HR-MS (EI): m/z calcd for C28H35NO3+ [M]+ 433.2611, found 433.2628. 
 
3,4,5-Trimethoxy-N-{1-[4-(pentan-2-yl)naphthalen-2-yl]ethyl}aniline (157b) 
The general procedure D was followed using ketimine 135q (168 mg, 0.50 mmol) 
and 2-bromopentane (136n, 227 mg, 1.50 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1 to 4:1) yielded 157b (164 mg, 80%, 
dr 1.0:1.3) as a viscous yellow oil. 
1H-NMR (300 MHz, CDCl3, determined as a diastereomeric mixture (1.0:1.3)): δ = 8.12–8.06 (m, 
2H), 7.84–7.78 (m, 2H), 7.69–7.66 (m, 2H), 7.50–7.40 (m, 4H), 7.38 (d, J = 1.7 Hz, 2H), 5.81 (s, 2H), 
5.80 (s, 2H), 4.58 (qd, J = 6.7, 3.4 Hz, 2H), 4.03 (br s, 2H), 3.71 (s, 3H), 3.70 (s, 3H), 3.67 (s, 6H), 3.67 
(s, 6H), 3.65–3.55 (m, 2H), 1.86–1.62 (m, 4H), 1.59 (d, J = 6.7 Hz, 3H), 1.59 (d, J = 6.7 Hz, 3H), 1.36 
(d, J = 6.9 Hz, 6H), 1.40–1.20 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H), 0.85 (t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3, determined as a diastereomeric mixture (1.0:1.3)): δ = 153.7 (4 × Cq), 
144.7 (Cq), 144.6 (Cq), 144.2 (Cq), 144.2 (Cq), 142.3 (Cq), 142.3 (Cq), 134.2 (2 × Cq), 131.0 (2 × Cq), 
129.9 (2 × Cq), 128.9 (CH), 128.8 (CH), 125.4 (2 × CH), 125.3 (2 × CH), 123.1 (2 × CH), 122.4 (CH), 
122.3 (CH), 121.3 (CH), 121.2 (CH), 91.2 (2 × CH), 91.1 (2 × CH), 61.0 (2 × CH3), 55.7 (2 × CH3), 55.7 
(2 × CH3), 54.6 (CH), 54.5 (CH), 40.3 (CH2), 40.0 (CH2), 33.5 (CH), 33.4 (CH), 24.8 (2 × CH3), 22.0 
(CH3), 21.7 (CH3), 20.9 (CH2), 20.8 (CH2), 14.2 (CH3), 14.2 (CH3).  
IR (ATR): ṽ = 3390, 2958, 1610, 1509, 1452, 1234, 1128, 1012, 784, 748 cm−1. 
MS (EI) m/z (relative intensity): 407 (49) [M]+, 392 (15) [M–Me]+, 295 (14), 225 (100) [M–NHTMP]+, 
183 (30) [NH2TMP]+, 168 (42) [TMP]+, 155 (35), 91 (11), 43 (23).  
HR-MS (EI): m/z calcd for C26H33NO3+ [M]+ 407.2455, found 407.2446. 
 




The general procedure D was followed using ketimine 135q (168 mg, 0.50 mmol) 
and 2-bromooctane (136o, 290 mg, 1.50 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1 to 4:1) yielded 157c (169 mg, 75%, 
dr 1.0:1.2) as a viscous yellow oil. 
1H-NMR (300 MHz, CDCl3, determined as a diastereomeric mixture (1.0:1.2)): δ = 8.11–8.06 (m, 
2H), 7.83–7.78 (m, 2H), 7.68 (br s, 2H), 7.49–7.41 (m, 4H), 7.40–7.36 (m, 2H), 5.82 (s, 2H), 5.81 (s, 
2H), 4.58 (q, J = 6.7 Hz, 2H), 4.02 (br s, 2H), 3.71 (s, 3H), 3.70 (s, 3H), 3.68 (s, 6H), 3.67 (s, 6H), 3.62–
3.52 (m, 2H), 1.89–1.73 (m, 2H), 1.73–1.63 (m, 2H), 1.59 (d, J = 6.7 Hz, 3H), 1.58 (d, J = 6.7 Hz, 3H), 
1.36 (d, J = 6.9 Hz, 3H), 1.35 (d, J = 6.9 Hz, 3H), 1.33–1.17 (m, 16H), 0.91–0.80 (m, 6H).  
13C-NMR (75 MHz, CDCl3, determined as a diastereomeric mixture (1.0:1.2)): δ = 153.7 (4 × Cq), 
144.8 (Cq), 144.7 (Cq), 144.2 (Cq), 144.2 (Cq), 142.3 (Cq), 142.3 (Cq), 134.2 (Cq), 134.2 (Cq), 131.0 (Cq), 
131.0 (Cq), 129.9 (2 × Cq), 128.8 (CH), 128.8 (CH), 125.4 (2 × CH), 125.3 (2 × CH), 123.1 (2 × CH), 
122.3 (CH), 122.3 (CH), 121.2 (2 × CH), 91.1 (4 × CH), 61.0 (CH3), 61.0 (CH3), 55.7 (4 × CH3), 54.5 (2 
× CH), 38.1 (CH2), 37.7 (CH2), 33.8 (CH), 33.7 (CH), 31.8 (CH2), 31.7 (CH2), 29.5 (CH2), 29.4 (CH2), 
27.8 (CH2), 27.7 (CH2), 24.8 (2 × CH3), 22.7 (CH2), 22.6 (CH2), 22.0 (CH3), 21.7 (CH3), 14.1 (CH3), 14.0 
(CH3).  
IR (ATR): ṽ = 3383, 2926, 1608, 1507, 1451, 1232, 1125, 1011, 782, 746 cm−1. 
MS (EI) m/z (relative intensity): 449 (65) [M]+, 434 (19) [M–Me]+, 267 (100), 183 (35), 168 (39), 155 
(16), 43 (13).  
HR-MS (EI): m/z calcd for C29H39NO3+ [M]+ 449.2924, found 449.2921. 
 
N-[1-(3-Cycloheptylphenyl)ethyl]-3,4,5-trimethoxyaniline (157d) 
The general procedure D was followed using ketimine 135b (285 mg, 1.00 mmol) 
and bromocycloheptane (136h, 531 mg, 3.0 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 157d (200 mg, 52%) as a light 
yellow oil as well as alkylated phenone 154bh (51.3 mg, 24%) as a colorless oil. 
1H-NMR (500 MHz, CDCl3): δ = 7.23 (dd, J = 7.5, 7.5 Hz, 1H), 7.19–7.15 (m, 2H), 7.08–7.04 (m, 1H), 
5.76 (s, 2H), 4.39 (q, J = 6.7 Hz, 1H), 3.92 (br s, 1H), 3.72 (s, 3H), 3.69 (s, 6H), 2.65 (tt, J = 10.6, 
3.6 Hz, 1H), 1.92–1.84 (m, 2H), 1.82–1.74 (m, 2H), 1.74–1.53 (m, 8H), 1.51 (d, J = 6.7 Hz, 3H).  
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13C-NMR (125 MHz, CDCl3): δ = 153.6 (Cq), 150.4 (Cq), 145.3 (Cq), 144.2 (Cq), 129.7 (Cq), 128.6 (CH), 
125.2 (CH), 124.4 (CH), 122.8 (CH), 90.9 (CH), 61.0 (CH3), 55.7 (CH3), 54.4 (CH), 47.0 (CH), 37.0 
(CH2), 36.7 (CH2), 27.9 (CH2), 27.9 (CH2), 27.2 (CH2), 27.2 (CH2), 24.8 (CH3).  
IR (ATR): ṽ = 3356, 2996, 2850, 1599, 1507, 1447, 1205, 1126, 1008, 812 cm−1.  
MS (EI) m/z (relative intensity): 383 (92) [M]+, 201 (100), 168 (78), 119 (15).  
HR-MS (EI): m/z calcd for C24H33NO3+ [M]+ 383.2455, found 383.2469. 
 
Oxidation of Phenone 
3-(tert-Butyl)-4-fluorobenzoic acid (159) 
A mixture of phenone 154ab (97.5 mg, 0.50 mmol) and anhydrous Mn(OAc)2 
(1.0 mg, 5.8 μmol) in acetic acid (1.0 mL) was stirred at 100 °C under an oxygen 
atmosphere for 15 h.[97] The reaction mixture was concentrated in vacuo to give a 
crude mixture. The crude mixture was dissolved with EtOAc and washed with HCl 
(1 N, 10 mL). The organic phase was dried over anhydrous Na2SO4. Filtration followed by 
evaporation gave a crude product. Purification of the residue by column chromatography 
(n-hexane/EtOAc 9:1 to 1:1) yielded the corresponding product 159 (87.4 mg, 89%) as a white 
solid. 
1H-NMR (500 MHz, CDCl3): δ = 8.11 (dd, J = 8.0, 2.2 Hz, 1H), 7.98 (ddd, J = 8.5, 4.6, 2.2 Hz, 1H), 7.08 
(dd, J = 12.0, 8.5 Hz, 1H), 1.42 (d, J = 1.0 Hz, 9H). 
13C-NMR (125 MHz, CDCl3): δ = 171.4 (Cq), 165.6 (d, 1JC–F = 258 Hz, Cq), 137.6 (d, 2JC–F = 13 Hz, Cq), 
130.4 (d, 3JC–F = 11 Hz, CH), 130.1 (d, 3JC–F = 8 Hz, CH), 124.9 (d, 4JC–F = 3 Hz, Cq), 116.7 (d, 2JC–F = 26 Hz, 
CH), 34.4 (d, 3JC–F = 3 Hz, Cq), 29.7 (d, 4JC–F = 3 Hz, CH3). 
19F-NMR (470 MHz, CDCl3): δ = (–100.4)–(–100.5) (m).  
mp.: 154–155 °C. 
IR (ATR): ṽ = 2964, 1683, 1428, 1294, 1258, 1217, 1089, 839, 772 cm−1.  
MS (EI) m/z (relative intensity): 196 (14) [M]+, 181 (100) [M–Me]+, 153 (79), 109 (15).  
HR-MS (EI): m/z calcd for C11H13FO2+ [M]+ 196.0894, found 196.0902. 
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Baeyer-Villiger Oxidation of Phenone 
4-Fluoro-3-(tert-pentyl)phenol (160b) 
Phenone 154ac (83.5 mg, 0.40 mmol) and m-CPBA (207 mg, 1.20 mmol) were placed 
in a pre-dried 10 mL pressure tube and CH2Cl2 (3.0 mL) was added. The mixture was 
stirred at 60 °C. After 6 h, the mixture was concentrated in vacuo. The residue was 
dissolved in EtOH (1.5 mL) and aq. NaOH solution (50%, 1.5 mL) and stirred at 
ambient temperature for 16 h. Then, the resulting mixture was neutralized with HCl (1 N) until 
pH 7 and extracted with CH2Cl2 (3 × 20 mL). The combined organic phase was dried over Na2SO4 
and concentrated in vacuo. Purification of the residue by column chromatography 
(n-pentane/Et2O 10:1 to 1:1) yielded phenol 160b (53.5 mg, 73%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 6.84 (dd, J = 12.0, 8.6 Hz, 1H), 6.73 (dd, J = 6.6, 3.2 Hz, 1H), 6.62 
(ddd, J = 8.6, 3.3, 3.2 Hz, 1H), 1.75 (qd, J = 7.5, 1.4 Hz, 2H), 1.30 (d, J = 1.0 Hz, 6H), 0.69 (td, J = 7.5, 
0.6 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 156.2 (d, 1JC–F = 240 Hz, Cq), 150.8 (d, 4JC–F = 2 Hz, Cq), 136.7 (d, 2JC–F 
= 13 Hz, Cq), 116.6 (d, 2JC–F = 27 Hz, CH), 115.3 (d, 3JC–F = 6 Hz, CH), 113.3 (d, 3JC–F = 9 Hz, CH), 38.0 
(d, 3JC–F = 3 Hz, Cq), 34.1 (d, 4JC–F = 4 Hz, CH2), 27.6 (d, 4JC–F = 3 Hz, CH3), 9.4 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = (–120.2)–(–120.4) (m). 
IR (ATR): ṽ = 3315, 2965, 1482, 1440, 1194, 811, 761, 738 cm−1.  
MS (EI) m/z (relative intensity): 182 (36) [M]+, 153 (100) [M–Et]+, 125 (81).  
HR-MS (EI): m/z calcd for C11H15FO+ [M]+ 182.1101, found 182.1103. 
 
Fischer Indole Synthesis 
2-[4-Fluoro-3-(tert-pentyl)phenyl]-1H-indole (162)  
The indole was prepared by a modified literature procedure.[133] Phenone 154ac 
(104 mg, 0.50 mmol), phenylhydrazine hydrochloride salt (145 mg, 1.00 mmol), 
and polyphosphoric acid (0.5 mL) in a microwave tube were stirred at 120 °C under 
microwave irradiation for 1 h. Then, sat. aq. NaHCO3 solution (20 mL) and EtOAc 
(20 mL) were added. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over Na2SO4 and 
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concentrated in vacuo. Purification by column chromatography (n-hexane/EtOAc 20:1 and Et3N 
1%) yielded indole 162 (81.2 mg, 58%) as a pale yellow solid.   
1H-NMR (500 MHz, CDCl3): δ = 8.27 (br s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.54 (dd, J = 7.7, 2.4 Hz, 1H), 
7.46 (ddd, J = 8.3, 4.4, 2.4 Hz, 1H), 7.41 (dd, J = 8.1, 1.1 Hz, 1H), 7.20 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 
7.13 (ddd, J = 7.9, 7.1, 1.1 Hz, 1H), 7.07 (dd, J = 12.3, 8.3 Hz, 1H), 6.76 (dd, J = 2.2, 0.9 Hz, 1H), 1.84 
(qd, J = 7.5, 1.5 Hz, 2H), 1.42 (d, J = 1.1 Hz, 6H), 0.74 (t, J = 7.5 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 161.6 (d, 1JC–F = 250 Hz, Cq), 137.7 (Cq), 136.7 (Cq), 136.2 (d, 2JC–F = 
12 Hz, Cq), 129.3 (Cq), 128.2 (d, 4JC–F = 3 Hz, Cq), 125.6 (d, 3JC–F = 6 Hz, CH), 124.4 (d, 3JC–F = 9 Hz, CH), 
122.2 (CH), 120.5 (CH), 120.3 (CH), 116.9 (d, 2JC–F = 26 Hz, CH), 110.8 (CH), 99.7 (d, 6JC–F = 1 Hz, CH), 
38.1 (d, 3JC–F = 3 Hz, Cq), 34.1 (d, 4JC–F = 4 Hz, CH2), 27.7 (d, 4JC–F = 3 Hz, CH3), 9.5 (CH3).  
19F-NMR (470 MHz, CDCl3): δ = (–109.9)–(–110.1) (m). 
IR (ATR): ṽ = 3423, 2967, 1480, 1454, 1230, 797, 747 cm−1.  
m.p.: 142–144 °C. 
MS (ESI) m/z (relative intensity): 561 (25), 490 (45), 381 (77), 312 (41), 282 (74) [M+H]+, 118 (100).  
HR-MS (ESI): m/z calcd for C19H21FN+ [M+H]+ 282.1653, found 282.1642. 
 
5.3.3 Sequential meta-/ortho-C–H Functionalizations by One-Pot Ruthenium(II/III) 
Catalysis 
5.3.3.1 Characterization Data for 141 
Methyl 2-[3-(pyrimidin-2-yl)phenyl]hexanoate (141a) 
The general procedure E was followed using 2-phenylpyrimidine (139a, 78.1 mg, 
0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 1.50 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 10:1) yielded 
141a (121 mg, 85%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.81 (d, J = 4.8 Hz, 2H), 8.40–8.37 (m, 1H), 8.37–8.30 (m, 1H), 7.49–
7.42 (m, 2H), 7.19 (t, J = 4.8 Hz, 1H), 3.70–3.63 (m, 4H), 2.15 (dddd, J = 13.4, 9.4, 8.0, 5.7 Hz, 1H), 
1.85 (dddd, J = 13.4, 9.4, 7.4, 5.7 Hz, 1H), 1.41–1.17 (m, 4H), 0.87 (t, J = 7.0 Hz, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 174.4 (Cq), 164.5 (Cq), 157.1 (CH), 139.7 (Cq), 137.8 (Cq), 130.0 (CH), 
128.8 (CH), 127.9 (CH), 127.0 (CH), 119.0 (CH), 52.0 (CH3), 51.7 (CH), 33.4 (CH2), 29.9 (CH2), 22.5 
(CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 2860, 1732, 1567, 1555, 1409, 1158, 775, 697 cm−1.  
MS (EI) m/z (relative intensity): 284 (24) [M]+, 228 (59) [M–Bu]+, 225 (83) [M–CO2Me]+, 183 (14), 
169 (100) [M–Bu–CO2Me]+. 
HR-MS (EI): m/z calcd for C17H20N2O2+ [M]+ 284.1519, found 284.1524. 
 
Methyl 2-[2-methyl-5-(pyrimidin-2-yl)phenyl]hexanoate (141b) 
The general procedure E was followed using 2-(p-tolyl)pyrimidine (139b, 
85.3 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 9:1) yielded 141b (123 mg, 82%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 8.78 (d, J = 4.8 Hz, 2H), 8.43 (d, J = 1.8 Hz, 1H), 8.21 (dd, J = 8.0, 
1.8 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.14 (t, J = 4.8 Hz, 1H), 3.88 (dd, J = 8.1, 7.0 Hz, 1H), 3.65 (s, 
3H), 2.44 (s, 3H), 2.31–2.17 (m, 1H), 1.91–1.77 (m, 1H), 1.41–1.22 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.4 (Cq), 164.5 (Cq), 157.0 (CH), 139.1 (Cq), 138.2 (Cq), 135.8 (Cq), 
130.7 (CH), 126.8 (CH), 126.5 (CH), 118.7 (CH), 51.9 (CH3), 47.2 (CH), 32.8 (CH2), 30.0 (CH2), 22.7 
(CH2), 20.0 (CH3), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 2859, 1726, 1549, 1417, 1158, 796, 782 cm−1.  
m.p.: 58–59 °C. 
MS (EI) m/z (relative intensity): 298 (34) [M]+, 283 (13) [M–Me]+, 255 (18) [M–Pr]+, 239 (49) [M–
CO2Me]+, 183 (100), 168 (22).  
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Methyl 2-[2-methoxy-5-(pyrimidin-2-yl)phenyl]hexanoate (141c) 
The general procedure E was followed using 2-(4-methoxyphenyl)pyrimidine 
(139e, 93.3 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 5:1) yielded 141c (115 mg, 73%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.75 (d, J = 4.8 Hz, 2H), 8.38 (d, J = 2.2 Hz, 1H), 8.34 (dd, J = 8.6, 
2.2 Hz, 1H), 7.10 (t, J = 4.8 Hz, 1H), 6.97 (d, J = 8.6 Hz, 1H), 4.02 (dd, J = 7.6, 7.6 Hz, 1H), 3.89 (s, 
3H), 3.66 (s, 3H), 2.15 (dddd, J = 13.0, 9.7, 7.6, 5.6 Hz, 1H), 1.83 (dddd, J = 13.3, 9.7, 7.6, 5.4 Hz, 
1H), 1.39–1.20 (m, 4H), 0.87 (t, J = 7.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.6 (Cq), 164.3 (Cq), 159.1 (Cq), 157.0 (CH), 130.1 (Cq), 128.7 (CH), 
128.3 (CH), 128.3 (Cq), 118.2 (CH), 110.5 (CH), 55.8 (CH3), 51.8 (CH3), 44.5 (CH), 32.0 (CH2), 29.9 
(CH2), 22.6 (CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 2859, 1732, 1567, 1402, 1246, 1026, 798 cm−1.  
MS (EI) m/z (relative intensity): 314 (41) [M]+, 255 (47) [M–CO2Me]+, 199 (100), 169 (27).  
HR-MS (EI): m/z calcd for C18H22N2O3+ [M]+ 314.1625, found 314.1629. 
 
Methyl 2-[2-chloro-5-(pyrimidin-2-yl)phenyl]hexanoate (141d) 
The general procedure E was followed using 2-(4-chlorophenyl)pyrimidine 
(139f, 95.5 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 9:1) yielded 141d (107 mg, 67%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 8.80 (d, J = 4.8 Hz, 2H), 8.51 (d, J = 2.1 Hz, 1H), 8.28 (dd, J = 8.4, 
2.1 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.19 (t, J = 4.8 Hz, 1H), 4.20 (dd, J = 7.6, 7.6 Hz, 1H), 3.69 (s, 
3H), 2.19 (dddd, J = 13.5, 9.9, 7.6, 4.9 Hz, 1H), 1.88 (dddd, J = 16.0, 9.9, 7.6, 5.2 Hz, 1H), 1.40–1.31 
(m, 3H), 1.30–1.23 (m, 1H), 0.88 (t, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 173.7 (Cq), 163.5 (Cq), 157.1 (CH), 137.4 (Cq), 136.7 (Cq), 136.6 (Cq), 
129.8 (CH), 128.6 (CH), 127.8 (CH), 119.2 (CH), 52.1 (CH3), 47.5 (CH), 32.6 (CH2), 29.7 (CH2), 22.6 
(CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2955, 2861, 1733, 1568, 1551, 1416, 1165, 1036, 797 cm−1.  
5 Experimental Part 
 
184 
MS (EI) m/z (relative intensity): 320 (3) [M(37Cl)]+, 318 (9) [M(35Cl)]+, 283 (100) [M–Cl]+, 264 (8) 
[M(37Cl)–Bu]+, 262 (26) [M(35Cl)–Bu]+, 261 (12) [M(35Cl)–CO2Me]+, 259 (35) [M(35Cl)–CO2Me]+, 203 
(65), 168 (19).  
HR-MS (EI): m/z calcd for C17H1935ClN2O2+ [M]+ 318.1130, found 318.1136. 
 
Methyl 2-(1-methoxy-1-oxohexan-2-yl)-4-(pyrimidin-2-yl)benzoate (141e) 
The general procedure E was followed using methyl 4-(pyrimidin-2-
yl)benzoate (139g, 107 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 
314 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 5:1) yielded 141e (126 mg, 74%) as a white solid. 
1H-NMR (600 MHz, CDCl3): δ = 8.83 (d, J = 4.8 Hz, 2H), 8.56 (d, J = 1.7 Hz, 1H), 8.38 (dd, J = 8.2, 
1.7 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.22 (t, J = 4.8 Hz, 1H), 4.64 (dd, J = 7.4, 7.4 Hz, 1H), 3.93 (s, 
3H), 3.65 (s, 3H), 2.26–2.20 (m, 1H), 1.91–1.83 (m, 1H), 1.39–1.29 (m, 3H), 1.29–1.20 (m, 1H), 0.86 
(t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 167.7 (Cq), 163.5 (Cq), 157.2 (CH), 140.9 (Cq), 140.7 (Cq), 
131.5 (Cq), 130.8 (CH), 128.6 (CH), 126.3 (CH), 119.5 (CH), 52.2 (CH3), 52.0 (CH3), 47.3 (CH), 33.2 
(CH2), 30.0 (CH2), 22.6 (CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 2859, 1726, 1549, 1417, 1158, 796, 782 cm−1.  
m.p.: 77–78 °C. 
MS (EI) m/z (relative intensity): 342 (7) [M]+, 310 (74) [M–Et]+, 282 (100) [M–CO2Me]+, 267 (97) 
[M–Me–CO2Me]+, 239 (74) [M–Pr–CO2Me]+, 211 (28), 169 (19), 59 (12).  
HR-MS (EI): m/z calcd for C19H22N2O4+ [M]+ 342.1574, found 342.1582. 
 
Methyl 2-[3-(4,5-dihydrooxazol-2-yl)phenyl]hexanoate (141f) 
The general procedure E was followed using 2-phenyl-4,5-dihydrooxazole (139h, 
73.6 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 4:1) yielded 141f (99.2 mg, 72%) as a colorless oil. 
5.3 Experimental Procedures and Analytical Data 
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1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 1.7, 1.7 Hz, 1H), 7.83 (ddd, J = 7.6, 1.7, 1.6 Hz, 1H), 7.43 
(ddd, J = 7.7, 1.7, 1.6 Hz, 1H), 7.36 (ddd, J = 7.7, 7.6, 0.6 Hz, 1H), 4.43 (td, J = 9.6, 0.8 Hz, 2H), 4.05 
(td, J = 9.6, 0.8 Hz, 2H), 3.64 (s, 3H), 3.57 (dd, J = 7.8, 7.7 Hz, 1H), 2.09 (dddd, J = 13.3, 9.4, 7.8, 
5.6 Hz, 1H), 1.78 (dddd, J = 13.5, 9.4, 7.7, 5.9 Hz, 1H), 1.39–1.11 (m, 4H), 0.86 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.1 (Cq), 164.4 (Cq), 139.5 (Cq), 130.6 (CH), 128.5 (CH), 128.0 (Cq), 
127.8 (CH), 126.9 (CH), 67.6 (CH2), 55.0 (CH2), 52.0 (CH3), 51.5 (CH), 33.2 (CH2), 29.8 (CH2), 22.5 
(CH2), 13.9 (CH3).  
IR (ATR): ṽ = 2952, 2872, 1733, 1649, 1357, 1160, 950, 709 cm–1. 
MS (ESI) m/z (relative intensity): 298 (14) [M+Na] +, 276 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C16H22NO3+ [M+H]+ 276.1594, found 276.1597. 
 
Methyl 2-[3-(1H-pyrazol-1-yl)phenyl]hexanoate (141g) 
The general procedure E was followed using 1-phenyl-1H-pyrazole (147a, 
72.1 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded 141g (97.0 mg, 71%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.93 (dd, J = 2.5, 0.6 Hz, 1H), 7.72 (dd, J = 1.8, 0.6 Hz, 1H), 7.67 (dd, 
J = 2.3, 1.7 Hz, 1H), 7.58 (ddd, J = 8.0, 2.3, 1.1 Hz, 1H), 7.40 (dd, J = 8.0, 7.8 Hz, 1H), 7.24 (ddd, J = 
7.8, 1.7, 1.1 Hz, 1H), 6.46 (dd, J = 2.5, 1.8 Hz, 1H), 3.67 (s, 3H), 3.61 (dd, J = 7.9, 7.6 Hz, 1H), 2.11 
(dddd, J = 13.5, 9.3, 7.9, 5.8 Hz, 1H), 1.82 (dddd, J = 13.5, 9.3, 7.6, 6.0 Hz, 1H), 1.41–1.16 (m, 4H), 
0.87 (t, J = 7.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.1 (Cq), 141.0 (CH), 140.8 (Cq), 140.3 (Cq), 129.5 (CH), 126.7 (CH), 
125.9 (CH), 118.9 (CH), 117.9 (CH), 107.5 (CH), 52.0 (CH3), 51.6 (CH), 33.3 (CH2), 29.8 (CH2), 22.5 
(CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 2860, 1732, 1593, 1520, 1392, 1160, 1044, 747, 695 cm−1.  
MS (EI) m/z (relative intensity): 272 (79) [M]+, 216 (67) [M–Bu]+, 213 (72) [M–CO2Me]+, 185 (47) 
[M–Et–CO2Me]+, 171 (37) [M–Pr–CO2Me]+, 157 (100) [M–Bu–CO2Me]+, 130 (19), 115 (18), 77 (16). 
HR-MS (EI): m/z calcd for C16H20N2O2+ [M]+ 272.1519, found 272.1526. 
 
5 Experimental Part 
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Methyl 2-[3-(4-bromo-1H-pyrazol-1-yl)phenyl]hexanoate (141h) 
The general procedure E was followed using 4-bromo-1-phenyl-1H-pyrazole 
(147b, 112 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol) at 60 °C. After 20 h, purification by column chromatography 
(n-hexane/EtOAc 20:1) yielded 141h (147 mg, 84%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.95 (d, J = 0.7 Hz, 1H), 7.67 (d, J = 0.7 Hz, 1H), 7.61 (dd, J = 2.2, 
2.0 Hz, 1H), 7.53 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 7.40 (dd, J = 8.0, 7.9 Hz, 1H), 7.29–7.24 (m, 1H), 
3.67 (s, 3H), 3.60 (dd, J = 7.9, 7.6 Hz, 1H), 2.11 (dddd, J = 13.6, 9.5, 7.9, 5.8 Hz, 1H), 1.80 (dddd, J = 
13.5, 9.5, 7.6, 6.0 Hz, 1H), 1.38–1.17 (m, 4H), 0.87 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 173.9 (Cq), 141.4 (CH), 141.0 (Cq), 139.8 (Cq), 129.6 (CH), 127.0 (CH), 
126.5 (CH), 118.6 (CH), 117.8 (CH), 95.6 (Cq), 52.1 (CH3), 51.6 (CH), 33.4 (CH2), 29.8 (CH2), 22.5 
(CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 2860, 1731, 1593, 1336, 1160, 953, 791, 694 cm−1.  
MS (EI) m/z (relative intensity): 352 (86) [M(81Br)]+, 350 (88) [M(79Br)]+, 296 (88) [M(81Br)–Bu]+, 294 
(100) [M(79Br)–Bu]+, 293 (63) [M(81Br)–CO2Me]+, 291 (63) [M(79Br)–CO2Me]+, 264 (54) [M(81Br)–Et–
CO2Me]+, 262 (39) [M(79Br)–Et–CO2Me]+, 251 (45) [M(81Br)–Pr–CO2Me]+, 249 (41) [M(79Br)–Pr–
CO2Me]+, 237 (94) [M(81Br)–Bu–CO2Me]+, 235 (94) [M(79Br)–Bu–CO2Me]+, 212 (24) [M–Br–Bu]+, 
183 (31), 155 (31), 115 (41), 91 (61), 77 (36). 
HR-MS (EI): m/z calcd for C16H1979BrN2O2+ [M]+ 350.0624, found 350.0630. 
 
Methyl 2-[3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]hexanoate (141i) 
The general procedure E was followed using 3,5-dimethyl-1-phenyl-1H-
pyrazole (147c, 86.2 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 
314 mg, 1.50 mmol) at 60 °C. After 20 h, purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 141i (78.3 mg, 52%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.42–7.36 (m, 2H), 7.35–7.26 (m, 2H), 6.00–5.98 (m, 1H), 3.66 (s, 
3H), 3.58 (dd, J = 7.9, 7.5 Hz, 1H), 2.30 (s, 3H), 2.29 (s, 3H), 2.08 (dddd, J = 13.5, 9.2, 7.9, 5.9 Hz, 
1H), 1.79 (dddd, J = 13.5, 9.2, 7.5, 6.0 Hz, 1H), 1.38–1.15 (m, 4H), 0.87 (t, J = 7.1 Hz, 3H). 
5.3 Experimental Procedures and Analytical Data 
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13C-NMR (125 MHz, CDCl3): δ = 174.1 (Cq), 148.9 (Cq), 140.2 (Cq), 140.0 (Cq), 139.3 (Cq), 129.1 (CH), 
126.7 (CH), 124.3 (CH), 123.4 (CH), 106.9 (CH), 52.0 (CH3), 51.5 (CH), 33.4 (CH2), 29.8 (CH2), 22.5 
(CH2), 14.0 (CH3), 13.6 (CH3), 12.5 (CH3).  
IR (ATR): ṽ = 2953, 2860, 1734, 1607, 1591, 1494, 1160, 779, 700 cm−1.  
MS (EI) m/z (relative intensity): 300 (100) [M]+, 257 (51) [M–Pr]+, 244 (38) [M–Bu]+, 241 (59) [M–
CO2Me]+, 213 (44) [M–Et–CO2Me]+, 199 (44) [M–Pr–CO2Me]+, 186 (82) [M–Bu–CO2Me]+, 144 (12), 
115 (13), 77 (10). 
HR-MS (EI): m/z calcd for C18H24N2O2+ [M]+ 300.1832, found 300.1837. 
 
Methyl 2-[3-(9-iso-propyl-9H-purin-6-yl)phenyl]hexanoate (141j) 
The general procedure E was followed using purine 123a (119 mg, 0.50 mmol) 
and methyl 2-bromohexanoate (140a, 314 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 3:1) yielded 141j 
(159 mg, 87%) as a light yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.01 (s, 1H), 8.74 (ddd, J = 6.6, 2.5, 1.7 Hz, 1H), 8.69–8.66 (m, 1H), 
8.19 (s, 1H), 7.55–7.47 (m, 2H), 4.99 (hept, J = 6.8 Hz, 1H), 3.71 (t, J = 7.7 Hz, 1H), 3.67 (s, 3H), 
2.23–2.09 (m, 1H), 1.95–1.80 (m, 1H), 1.67 (d, J = 6.8 Hz, 6H), 1.41–1.19 (m, 4H), 0.87 (t, J = 7.0 Hz, 
3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.4 (Cq), 154.4 (Cq), 152.0 (Cq), 151.9 (CH), 141.9 (CH), 139.7 (Cq), 
136.0 (Cq), 131.5 (Cq), 130.1 (CH), 129.3 (CH), 128.9 (CH), 128.8 (CH), 52.0 (CH3), 51.8 (CH), 47.3 
(CH), 33.4 (CH2), 29.9 (CH2), 22.7 (CH3), 22.5 (CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 2872, 1732, 1568, 1324, 1218, 1160, 799, 702, 646 cm−1.  
MS (EI) m/z (relative intensity): 366 (63) [M]+, 323 (30) [M–Pr]+, 310 (100) [M–Bu]+, 307 (49) [M–
CO2Me]+, 278 (58) [M–Et–CO2Me]+, 265 (95) [M–Pr–CO2Me]+, 251 (49) [M–Bu–CO2Me]+, 236 (25), 
209 (41), 59 (12).  




5 Experimental Part 
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Methyl 2-[3-(pyrimidin-2-yl)phenyl]acetate (141k) 
The general procedure E was followed using 2-phenylpyrimidine (139a, 78.1 mg, 
0.50 mmol) and methyl 2-bromoacetate (140b, 230 mg, 1.50 mmol) at 60 °C. 
After 20 h, purification by column chromatography (n-hexane/EtOAc 5:1) 
yielded 141k (57.0 mg, 50%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.78 (d, J = 4.8 Hz, 2H), 8.36 (d, J = 1.7 Hz, 1H), 8.34 (ddd, J = 6.7, 
1.8, 1.7 Hz, 1H), 7.52–7.36 (m, 2H), 7.16 (t, J = 4.8 Hz, 1H), 3.73 (s, 2H), 3.69 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 171.6 (Cq), 164.3 (Cq), 157.0 (CH), 137.8 (Cq), 134.3 (Cq), 131.5 (CH), 
129.0 (CH), 128.7 (CH), 126.8 (CH), 119.0 (CH), 52.0 (CH3), 41.1 (CH2). 
IR (ATR): ṽ = 2952, 1735, 1568, 1556, 1411, 1159, 1013, 789, 769 cm−1.  
MS (EI) m/z (relative intensity): 228 (35) [M]+, 213 (34) [M–Me]+, 185 (15), 169 (100) [M–CO2Me]+, 
116 (11), 89 (13).  
HR-MS (EI): m/z calcd for C13H12N2O2+ [M]+ 228.0893, found 228.0898. 
 
1-(Piperidin-1-yl)-2-[3-(pyrimidin-2-yl)phenyl]hexan-1-one (141l) 
The general procedure E was followed using 2-phenylpyrimidine (139a, 
78.1 mg, 0.50 mmol) and 2-bromo-1-(piperidin-1-yl)hexan-1-one (140c, 
394 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 4:1) yielded 141l (110 mg, 65%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 8.80 (d, J = 4.8 Hz, 2H), 8.33–8.28 (m, 2H), 7.47–7.39 (m, 2H), 7.18 
(t, J = 4.8 Hz, 1H), 3.83 (dd, J = 7.6, 6.8 Hz, 1H), 3.71–3.61 (m, 1H), 3.53–3.35 (m, 3H), 2.16 (dddd, 
J = 13.4, 10.1, 7.6, 4.6 Hz, 1H), 1.75 (dddd, J = 13.2, 10.1, 6.8, 5.0 Hz, 1H), 1.57–1.24 (m, 8H), 1.24–
0.99 (m, 2H), 0.86 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 171.0 (Cq), 164.5 (Cq), 157.1 (CH), 141.4 (Cq), 137.7 (Cq), 129.8 (CH), 
129.0 (CH), 127.8 (CH), 126.4 (CH), 119.0 (CH), 48.8 (CH), 46.7 (CH2), 43.2 (CH2), 34.9 (CH2), 30.2 
(CH2), 26.2 (CH2), 25.7 (CH2), 24.6 (CH2), 22.8 (CH2), 14.1 (CH3).  
IR (ATR): ṽ = 2932, 2855, 1633, 1567, 1554, 1408, 1249, 1011, 776, 701 cm−1.  
m.p.: 72–73 °C. 
5.3 Experimental Procedures and Analytical Data 
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MS (EI) m/z (relative intensity): 337 (21) [M]+, 281 (35) [M–Bu]+, 238 (14), 225 (17), 169 (34), 112 
(100), 84 (13), 69 (42), 41 (15).  
HR-MS (EI): m/z calcd for C21H27N3O+ [M]+ 337.2149, found 337.2145. 
 
1-Phenyl-2-[3-(pyrimidin-2-yl)phenyl]pentan-1-one (141m) 
The general procedure E was followed using 2-phenylpyrimidine (139a, 
78.1 mg, 0.50 mmol) and 2-bromo-1-phenylpentan-1-one (140d, 362 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 4:1) yielded 141m (113 mg, 71%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.80 (d, J = 4.9 Hz, 2H), 8.43 (dd, J = 1.8, 1.8 Hz, 1H), 8.30 (ddd, J = 
7.0, 1.9, 1.8 Hz, 1H), 8.03–7.98 (m, 2H), 7.49–7.35 (m, 5H), 7.17 (t, J = 4.9 Hz, 1H), 4.70 (dd, J = 7.3, 
7.3 Hz, 1H), 2.23 (dddd, J = 13.6, 10.0, 7.3, 5.7 Hz, 1H), 1.88 (dddd, J = 13.6, 10.0, 7.3, 5.6 Hz, 1H), 
1.45–1.22 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 199.8 (Cq), 164.3 (Cq), 157.1 (CH), 140.2 (Cq), 138.0 (Cq), 136.9 (Cq), 
132.7 (CH), 130.3 (CH), 129.1 (CH), 128.6 (CH), 128.4 (CH), 128.2 (CH), 126.8 (CH), 119.1 (CH), 53.5 
(CH), 36.4 (CH2), 21.0 (CH2), 14.2 (CH3).  
IR (ATR): ṽ = 2957, 1679, 1567, 1554, 1409, 1204, 783, 696 cm−1.  
MS (EI) m/z (relative intensity): 316 (11) [M]+, 274 (6) [M–Pr]+, 211 (31) [M–Bz]+, 169 (60) [M–Pr–
Bz]+, 105 (100) [Bz]+, 77 (13).  
HR-MS (EI): m/z calcd for C21H20N2O+ [M]+ 316.1570, found 316.1584. 
 
1-Morpholino-2-[3-(pyrimidin-2-yl)phenyl]propan-1-one (141n) 
The general procedure E was followed using 2-phenylpyrimidine (139a, 
78.1 mg, 0.50 mmol) and 2-bromo-1-morpholinopropan-1-one (140e, 
334 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 2:3) yielded 141n (105 mg, 71%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.81 (d, J = 4.8 Hz, 2H), 8.38–8.28 (m, 2H), 7.47 (dd, J = 7.9, 7.8 Hz, 
1H), 7.38 (ddd, J = 7.8, 1.5, 1.5 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 3.97 (q, J = 6.8 Hz, 1H), 3.88–3.76 
(m, 1H), 3.75–3.61 (m, 1H), 3.60–3.29 (m, 5H), 3.21–3.10 (m, 1H), 1.52 (d, J = 6.8 Hz, 3H). 
5 Experimental Part 
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13C-NMR (125 MHz, CDCl3): δ = 171.9 (Cq), 164.2 (Cq), 157.1 (CH), 142.2 (Cq), 138.1 (Cq), 129.3 (CH), 
129.2 (CH), 127.2 (CH), 126.7 (CH), 119.2 (CH), 66.8 (CH2), 66.3 (CH2), 46.1 (CH2), 43.4 (CH), 42.5 
(CH2), 20.7 (CH3).  
IR (ATR): ṽ = 2971, 2855, 1641, 1558, 1415, 1232, 1121, 834, 789, 699 cm−1.  
m.p.: 123–125 °C. 
MS (EI) m/z (relative intensity): 297 (8) [M]+, 267 (42), 210 (31), 183 (98), 168 (54), 114 (100), 70 
(58).  
HR-MS (EI): m/z calcd for C17H19N3O2+ [M]+ 297.1472, found 297.1479. 
 
2-[3-(Pyrimidin-2-yl)phenyl]cyclohexan-1-one (141p) 
The general procedure E was followed using 2-phenylpyrimidine (139a, 78.1 mg, 
0.50 mmol) and 2-bromocyclohexan-1-one (140g, 266 mg, 1.50 mmol) at 60 °C. 
After 20 h, purification by column chromatography (n-hexane/EtOAc 4:1) yielded 
141p (68.7 mg, 54%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.79 (d, J = 4.8 Hz, 2H), 8.35 (ddd, J = 7.8, 1.7, 1.2 Hz, 1H), 8.24 (dd, 
J = 1.7, 1.7 Hz, 1H), 7.47 (dd, J = 7.8, 7.7 Hz, 1H), 7.29 (ddd, J = 7.7, 1.7, 1.2 Hz, 1H), 7.17 (t, J = 
4.8 Hz, 1H), 3.74 (dd, J = 12.4, 5.4 Hz, 1H), 2.60–2.53 (m, 1H), 2.53–2.43 (m, 1H), 2.39–2.30 (m, 
1H), 2.23–2.07 (m, 2H), 2.07–1.98 (m, 1H), 1.92–1.80 (m, 2H). 
13C-NMR (125 MHz, CDCl3): δ = 209.7 (Cq), 164.6 (Cq), 157.0 (CH), 139.1 (Cq), 137.5 (Cq), 131.1 (CH), 
128.5 (CH), 128.3 (CH), 126.7 (CH), 119.0 (CH), 57.5 (CH), 42.3 (CH2), 35.3 (CH2), 27.9 (CH2), 25.5 
(CH2).  
IR (ATR): ṽ = 2935, 2862, 1706, 1567, 1554, 1408, 1125, 784, 699 cm−1.  
MS (EI) m/z (relative intensity): 252 (67) [M]+, 224 (73), 209 (47), 207 (53), 195 (100), 183 (64), 168 
(35), 156 (20), 129 (29), 115 (26), 103 (15).  
HR-MS (EI): m/z calcd for C16H16N2O+ [M]+ 252.1257, found 252.1259. 
 




The general procedure E was followed using 2-phenylpyrimidine (139a, 78.1 mg, 
0.50 mmol) and 2-bromo-N,N-diethylpropanamide (140h, 313 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 3:2) 
yielded 141q (89.0 mg, 63%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 8.81 (d, J = 4.9 Hz, 2H), 8.35 (br s, 1H), 8.31 (ddd, J = 5.1, 3.7, 1.7 Hz, 
1H), 7.47–7.41 (m, 2H), 7.19 (t, J = 4.9 Hz, 1H), 3.96 (q, J = 6.9 Hz, 1H), 3.53 (dq, J = 14.1, 7.1 Hz, 
1H), 3.37 (dq, J = 14.5, 7.1 Hz, 1H), 3.24 (dq, J = 14.1, 7.1 Hz, 1H), 3.11 (dq, J = 14.5, 7.1 Hz, 1H), 
1.50 (d, J = 6.9 Hz, 3H), 1.10 (t, J = 7.1 Hz, 3H), 1.01 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 172.5 (Cq), 164.5 (Cq), 157.1 (CH), 142.8 (Cq), 137.9 (Cq), 129.3 (CH), 
129.1 (CH), 127.3 (CH), 126.5 (CH), 119.0 (CH), 43.2 (CH), 41.7 (CH2), 40.3 (CH2), 21.1 (CH3), 14.4 
(CH3), 12.9 (CH3).  
IR (ATR): ṽ = 2973, 1623, 1551, 1411, 1269, 1082, 789, 700, 636 cm−1.  
m.p.: 133–134 °C. 
MS (EI) m/z (relative intensity): 283 (19) [M]+, 226 (4) [M–2Et]+, 210 (4) [M–NEt2]+, 183 (17) [M–
C(O)NEt2]+, 168 (19) [M–Me–C(O)NEt2]+, 100 (100) [C(O)NEt2]+, 72 (44).  
HR-MS (EI): m/z calcd for C17H21N3O+ [M]+ 283.1679, found 283.1672. 
 
5.3.3.2 Characterization Data for 164 
Methyl 2-(5-acetyl-2-fluorophenyl)hexanoate (164a) 
The general procedure E was followed using ketimine 135a (152 mg, 0.50 mmol) 
and methyl 2-bromohexanoate (140a, 314 mg, 1.50 mmol). After 20 h, HCl (2 N, 
3.0 mL) was added at ambient temperature, and the resulting mixture was 
stirred for an additional 3 h, extracted with Et2O (3 × 20 mL). The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Purification of the residue by column 
chromatography (n-pentane/Et2O 20:1) yielded phenone 164a (85.1 mg, 64%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.99 (dd, J = 7.1, 2.3 Hz, 1H), 7.87 (ddd, J = 8.6, 5.0, 2.3 Hz, 1H), 7.12 
(dd, J = 9.5, 8.6 Hz, 1H), 3.93 (dd, J = 7.7, 7.5 Hz, 1H), 3.68 (s, 3H), 2.59 (s, 3H), 2.13 (dddd, J = 12.8, 
9.8, 7.5, 5.5 Hz, 1H), 1.88–1.73 (m, 1H), 1.42–1.15 (m, 4H), 0.87 (t, J = 7.1 Hz, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 196.3 (Cq), 173.3 (Cq), 163.4 (d, 1JC–F = 254 Hz, Cq), 133.7 (d, 4JC–F = 
3 Hz, Cq), 129.9 (d, 3JC–F  = 6 Hz, CH), 129.3 (d, 3JC–F = 10 Hz, CH), 126.9 (d, 2JC–F = 16 Hz, Cq), 115.7 
(d, 2JC–F = 24 Hz, CH), 52.2 (CH3), 43.7 (d, 3JC–F = 2 Hz, CH), 32.2 (CH2), 29.6 (CH2), 26.6 (CH3), 22.4 
(CH2), 13.9 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –110.4 (ddd, J = 9.5, 7.1, 5.0 Hz). 
IR (ATR): ṽ = 2956, 1736, 1686, 1590, 1358, 1253, 1171, 827, 567 cm−1.  
MS (EI) m/z (relative intensity): 266 (2) [M]+, 251 (58) [M–Me]+, 223 (5) [M–Ac]+, 210 (100) [M–
Bu]+, 178 (27) [M–Bu–OMe]+, 163 (15), 151 (68) [M–Bu–CO2Me]+, 136 (12).  
HR-MS (EI): m/z calcd for C15H19FO3+ [M]+ 266.1313, found 266.1318. 
 
Methyl 2-(3-benzoylphenyl)propanoate (164b) 
The general procedure E was followed using ketimine 135x (174 mg, 0.50 mmol) 
and methyl 2-bromopropanoate (140i, 251 mg, 1.50 mmol). After 20 h, HCl (2 N, 
3.0 mL) was added at ambient temperature, and the resulting mixture was 
stirred for an additional 3 h, extracted with Et2O (3 × 20 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification of the residue by 
column chromatography (n-hexane/EtOAc 10:1 to 4:1) yielded phenone 164b (53.3 mg, 40%) as a 
colorless oil and 164b’ (72.3 mg, 41%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.83–7.78 (m, 2H), 7.75 (dd, J = 1.8, 1.8 Hz, 1H), 7.68 (ddd, J = 7.6, 
1.8, 1.3 Hz, 1H), 7.63–7.56 (m, 1H), 7.54 (dddd, J = 7.7, 1.8, 1.3, 0.5 Hz, 1H), 7.52–7.40 (m, 3H), 
3.81 (q, J = 7.2 Hz, 1H), 3.68 (s, 3H), 1.54 (d, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 196.3 (Cq), 174.4 (Cq), 140.7 (Cq), 137.8 (Cq), 137.4 (Cq), 132.4 (CH), 
131.4 (CH), 130.0 (CH), 129.1 (CH), 128.9 (CH), 128.5 (CH), 128.2 (CH), 52.2 (CH3), 45.3 (CH), 18.6 
(CH3).  
IR (ATR): ṽ = 2981, 2951, 1733, 1657, 1447, 1281, 1206, 1164, 703, 642 cm−1.  
MS (EI) m/z (relative intensity): 268 (31) [M]+, 209 (100) [M–CO2Me]+, 191 (24), 105 (71) [Bz]+, 77 
(51).  
HR-MS (EI): m/z calcd for C17H16O3+ [M]+ 268.1094, found 268.1097. 
The spectral data are in accordance with those reported in the literature.[134] 
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Dimethyl 2,2'-[carbonylbis(3,1-phenylene)]dipropionate (164b’) 
1H-NMR (600 MHz, CDCl3, 2 diastereomers): δ = 7.75–7.74 (m, 4H), 7.67 
(ddd, J = 7.7, 1.6, 1.6 Hz, 2H), 7.67 (ddd, J = 7.7, 1.6, 1.6 Hz, 2H), 7.56–7.53 
(m, 4H), 7.44 (dd, J = 7.7, 7.7 Hz, 4H), 3.80 (q, J = 7.2 Hz, 4H), 3.68 (s, 6H), 
3.68 (s, 6H), 1.54 (d, J = 7.2 Hz, 6H), 1.54 (d, J = 7.2 Hz, 6H). 
13C-NMR (125 MHz, CDCl3, 2 diastereomers): δ = 196.0 (Cq), 174.3 (Cq), 140.8 (Cq), 140.7 (Cq), 137.7 
(Cq), 137.7 (Cq), 131.5 (CH), 131.5 (CH), 129.2 (CH), 129.1 (CH), 128.9 (CH), 128.5 (CH), 128.5 (CH), 
52.2 (CH3), 45.3 (CH), 18.6 (CH3), 18.6 (CH3).  
IR (ATR): ṽ = 2981, 2952, 1731, 1659, 1434, 1287, 1162, 1067, 742, 696 cm−1.  
MS (EI) m/z (relative intensity): 354 (4) [M]+, 322 (60) [M–OMe]+, 295 (54) [M–CO2Me]+, 235 (100) 
[M–2CO2Me]+, 191 (59), 131 (56), 103 (53), 77 (19), 59 (12), 43 (17).  
HR-MS (EI): m/z calcd for C21H22O5+ [M]+ 354.1462, found 354.1458. 
 
Methyl 2-[3-(3-chlorobenzoyl)phenyl]propanoate (164c) 
The general procedure E was followed using ketimine 135y (191 mg, 0.50 mmol) 
and methyl 2-bromopropanoate (140i, 251 mg, 1.50 mmol). After 20 h, HCl (2 N, 
3.0 mL) was added at ambient temperature, and the resulting mixture was 
stirred for an additional 3 h, extracted with Et2O (3 × 20 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification 
of the residue by column chromatography (n-hexane/EtOAc 10:1) yielded phenone 164c (78.6 mg, 
52%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.77 (ddd, J = 2.1, 1.6, 0.5 Hz, 1H), 7.74 (td, J = 1.8, 0.9 Hz, 1H), 
7.69–7.63 (m, 2H), 7.59–7.53 (m, 2H), 7.49–7.40 (m, 2H), 3.81 (q, J = 7.2 Hz, 1H), 3.69 (s, 3H), 1.54 
(d, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 194.7 (Cq), 174.2 (Cq), 140.9 (Cq), 139.1 (Cq), 137.2 (Cq), 134.5 (Cq), 
132.3 (CH), 131.8 (CH), 129.9 (CH), 129.6 (CH), 129.1 (CH), 128.8 (CH), 128.6 (CH), 128.0 (CH), 52.2 
(CH3), 45.3 (CH), 18.6 (CH3).  
IR (ATR): ṽ = 2981, 2952, 1733, 1661, 1434, 1281, 1203, 1163, 737, 679 cm−1.  
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MS (EI) m/z (relative intensity): 304 (10) [M(37Cl)]+, 302 (32) [M(35Cl)]+, 245 (34) [M(37Cl)–CO2Me]+, 
243 (100) [M(35Cl)–CO2Me]+, 191 (24), 141 (19), 139 (57), 113 (10), 111 (30), 103 (19), 77 (12), 43 
(24).  
HR-MS (EI): m/z calcd for C17H1535ClO3+ [M]+ 302.0704, found 302.0712. 
 
5.3.3.3 Characterization Data for 166 
Methyl 2-[2-(1H-pyrazol-1-yl)-[1,1'-biphenyl]-4-yl]propanoate (166a) 
The general procedure F was followed using 1-phenyl-1H-pyrazole (147a, 
72.1 mg, 0.50 mmol), methyl 2-bromopropanoate (140i, 251 mg, 
1.50 mmol), and bromobenzene (165a, 236 mg, 1.50 mmol). Purification 
by column chromatography (n-hexane/EtOAc 10:1) yielded 166a 
(88.3 mg, 58%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.63 (dd, J = 1.9, 0.6 Hz, 1H), 7.57–7.55 (m, 1H), 7.43 (dABd, J = 8.1, 
0.8 Hz, 1H), 7.41 (dABd, J = 8.1, 1.7 Hz, 1H), 7.30–7.24 (m, 3H), 7.11–7.06 (m, 2H), 7.05 (dd, J = 2.4, 
0.6 Hz, 1H), 6.18 (dd, J = 2.4, 1.9 Hz, 1H), 3.83 (q, J = 7.2 Hz, 1H), 3.70 (s, 3H), 1.58 (d, J = 7.2 Hz, 
3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 140.8 (Cq), 140.2 (CH), 138.5 (Cq), 138.1 (Cq), 135.3 (Cq), 
131.3 (CH), 131.2 (CH), 128.4 (CH), 128.3 (CH), 127.3 (CH), 127.2 (CH), 125.7 (CH), 106.3 (CH), 52.2 
(CH3), 45.0 (CH), 18.5 (CH3).  
IR (ATR): ṽ = 2980, 2950, 1732, 1519, 1442, 1200, 1164, 1042, 739, 699 cm−1.  
MS (EI) m/z (relative intensity): 306 (38) [M]+, 305 (100) [M–H]+, 247 (23) [M–CO2Me]+, 245 (29).  
HR-MS (ESI): m/z calcd for C19H19N2O2+ [M+H]+ 307.1441, found 307.1443. 
 
Methyl 2-[5-methoxy-2-(1H-pyrazol-1-yl)-[1,1'-biphenyl]-4-yl]propanoate (166b) 
The general procedure F was followed using 1-(4-methoxyphenyl)-1H-
pyrazole (147d, 87.1 mg, 0.50 mmol), methyl 2-bromopropanoate (140i, 
251 mg, 1.50 mmol), and bromobenzene (165a, 236 mg, 1.50 mmol). 
Purification by column chromatography (n-hexane/EtOAc 7:1) yielded 
166b (94.5 mg, 56%) as a viscous colorless oil. 
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1H-NMR (600 MHz, CDCl3): δ = 7.59 (dd, J = 2.0, 0.6 Hz, 1H), 7.44 (s, 1H), 7.28–7.24 (m, 3H), 7.12–
7.09 (m, 2H), 7.04 (dd, J = 2.3, 0.6 Hz, 1H), 6.91 (s, 1H), 6.15 (dd, J = 2.3, 2.0 Hz, 1H), 4.07 (q, J = 
7.2 Hz, 1H), 3.88 (s, 3H), 3.68 (s, 3H), 1.52 (d, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.7 (Cq), 156.2 (Cq), 139.8 (CH), 138.3 (Cq), 136.7 (Cq), 131.7 (Cq), 
131.3 (CH), 129.4 (Cq), 128.3 (CH), 128.2 (CH), 127.4 (CH), 126.6 (CH), 112.4 (CH), 106.0 (CH), 55.9 
(CH3), 52.0 (CH3), 39.2 (CH), 17.1 (CH3).  
IR (ATR): ṽ = 2981, 2947, 1733, 1518, 1488, 1222, 1036, 750, 700 cm−1.  
MS (EI) m/z (relative intensity): 336 (96) [M]+, 335 (100) [M–H]+, 277 (81) [M–CO2Me]+, 261 (29), 
165 (11), 59 (13).  
HR-MS (ESI): m/z calcd for C20H21N2O3+ [M+H]+ 337.1547, found 337.1547. 
 
Methyl 2-[4'-fluoro-2-(1H-pyrazol-1-yl)-[1,1'-biphenyl]-4-yl]hexanoate (166c) 
The general procedure F was followed using 1-phenyl-1H-pyrazole 
(147a, 72.1 mg, 0.50 mmol), methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol), and 1-bromo-4-fluorobenzene (165b, 263 mg, 
1.50 mmol). Purification by column chromatography (n-hexane/EtOAc 
20:1) yielded 166c (130 mg, 71%) as a viscous light yellow oil. 
The general procedure G was followed using 1-phenyl-1H-pyrazole (147a, 72.1 mg, 0.50 mmol), 
methyl 2-bromohexanoate (140a, 314 mg, 1.50 mmol), and 1-bromo-4-fluorobenzene (165b, 
263 mg, 1.50 mmol). Purification by column chromatography (n-hexane/EtOAc 15:1) yielded 166c 
(133 mg, 72%) as a viscous light yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.63 (dd, J = 1.9, 0.6 Hz, 1H), 7.53 (d, J = 1.9 Hz, 1H), 7.42 (dABd, J = 
8.1, 1.9 Hz, 1H), 7.39 (dABd, J = 8.1, 0.5 Hz, 1H), 7.09 (dd, J = 2.4, 0.6 Hz, 1H), 7.04 (dd, J = 8.9, 5.4 Hz, 
2H), 6.96 (dd, J = 8.9, 8.6 Hz, 2H), 6.21 (dd, J = 2.4, 1.9 Hz, 1H), 3.69 (s, 3H), 3.63 (dd, J = 7.7, 7.7 Hz, 
1H), 2.19–2.07 (m, 1H), 1.89–1.78 (m, 1H), 1.41–1.23 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 174.1 (Cq), 162.2 (d, 1JC–F = 247 Hz, Cq), 140.4 (CH), 140.0 (Cq), 138.6 
(Cq), 134.6 (Cq), 134.2 (d, 4JC–F = 3 Hz, Cq), 131.2 (CH), 131.1 (CH), 130.1 (d, 3JC–F = 8 Hz, CH), 127.8 
(CH), 126.4 (CH), 115.4 (d, 2JC–F = 21 Hz, CH), 106.5 (CH), 52.1 (CH3), 51.2 (CH), 33.3 (CH2), 29.8 
(CH2), 22.4 (CH2), 13.9 (CH3). 
19F-NMR (376 MHz, CDCl3): δ = –114.7 (tt, J = 8.6, 5.4 Hz). 
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IR (ATR): ṽ = 2954, 2860, 1733, 1489, 1222, 1158, 1040, 828, 749 cm−1.  
MS (EI) m/z (relative intensity): 366 (52) [M]+, 365 (100) [M–H]+, 307 (15) [M–CO2Me]+, 263 (10), 
251 (24).  
HR-MS (ESI): m/z calcd for C22H23FN2O2Na+ [M+Na]+ 389.1636, found 389.1627. 
 
Methyl 2-[4'-methoxy-2-(1H-pyrazol-1-yl)-[1,1'-biphenyl]-4-yl]hexanoate (166d) 
The general procedure F was followed using 1-phenyl-1H-pyrazole 
(147a, 72.1 mg, 0.50 mmol), methyl 2-bromohexanoate (140a, 
314 mg, 1.50 mmol), and 1-bromo-4-methoxybenzene (165c, 
281 mg, 1.50 mmol). Purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded 166d (122 mg, 65%) as a viscous light yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.64 (dd, J = 1.8, 0.7 Hz, 1H), 7.52 (dd, J = 1.2, 1.2 Hz, 1H), 7.41–7.38 
(m, 2H), 7.09 (dd, J = 2.4, 0.7 Hz, 1H), 7.00 (d, J = 8.8 Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 6.20 (dd, J = 
2.4, 1.8 Hz, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 3.62 (dd, J = 8.2, 7.3 Hz, 1H), 2.22–2.04 (m, 1H), 1.91–
1.76 (m, 1H), 1.43–1.21 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.0 (Cq), 158.9 (Cq), 140.1 (CH), 139.2 (Cq), 138.4 (Cq), 135.1 (Cq), 
131.3 (CH), 131.0 (CH), 130.4 (Cq), 129.5 (CH), 127.5 (CH), 126.2 (CH), 113.9 (CH), 106.3 (CH), 55.2 
(CH3), 52.1 (CH3), 51.2 (CH), 33.3 (CH2), 29.9 (CH2), 22.5 (CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2954, 1733, 1609, 1489, 1245, 1161, 1039, 826, 750 cm−1.  
MS (EI) m/z (relative intensity): 378 (62) [M]+, 377 (100) [M–H]+, 319 (10) [M–CO2Me]+, 263 (19), 
261 (15).  
HR-MS (ESI): m/z calcd for C23H26N2O3Na+ [M+Na]+ 401.1836, found 401.1825. 
 
Methyl 2-[2-(9-iso-propyl-9H-purin-6-yl)-4'-(pyren-1-yl)-[1,1'-biphenyl]-4-yl]hexanoate (166e) 
The general procedure F was followed using purine 123a 
(119 mg, 0.50 mmol), methyl 2-bromohexanoate (140a, 
314 mg, 1.50 mmol), and 1-(4-bromophenyl)pyrene (165d, 
357 mg, 1.00 mmol). Purification by column 
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chromatography (n-hexane/EtOAc 3:1) yielded 166e (190 mg, 59%) as a light yellow solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.98 (s, 1H), 8.20–8.13 (m, 3H), 8.07 (s, 2H), 8.04 (d, J = 7.6 Hz, 1H), 
8.02 (s, 1H), 8.01–7.95 (m, 2H), 7.89 (d, J = 7.9 Hz, 1H), 7.80 (d, J = 1.9 Hz, 1H), 7.67 (dAB, J = 8.0 Hz, 
1H), 7.61 (dABd, J = 8.0, 1.9 Hz, 1H), 7.39 (dAB, J = 8.5 Hz, 2H), 7.34 (dAB, J = 8.5 Hz, 2H), 4.94 (hept, 
J = 6.8 Hz, 1H), 3.77–3.67 (m, 4H), 2.29–2.11 (m, 1H), 1.99–1.83 (m, 1H), 1.64 (d, J = 6.8 Hz, 6H), 
1.48–1.26 (m, 4H), 0.92 (t, J = 6.9 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 158.7 (Cq), 151.9 (CH), 151.1 (Cq), 141.8 (CH), 140.5 (Cq), 
139.9 (Cq), 139.1 (Cq), 138.5 (Cq), 137.3 (Cq), 134.8 (Cq), 132.6 (Cq), 131.4 (Cq), 130.8 (Cq), 130.8 (CH), 
130.4 (Cq), 129.9 (CH), 129.2 (CH), 129.1 (CH), 128.3 (Cq), 127.4 (CH), 127.3 (CH), 127.3 (CH), 127.2 
(CH), 125.9 (CH), 125.0 (CH), 125.0 (CH), 124.9 (Cq), 124.8 (Cq), 124.7 (CH), 124.5 (CH), 52.0 (CH3), 
51.4 (CH), 47.3 (CH), 33.5 (CH2), 30.0 (CH2), 22.6 (CH3), 22.6 (CH2), 14.0 (CH3). 
IR (ATR): ṽ = 3038, 2951, 1732, 1580, 1328, 1214, 1162, 846, 722, 647 cm−1.  
m.p.: 109–110 °C. 
MS (EI) m/z (relative intensity): 642 (100) [M]+, 641 (76) [M–H]+, 599 (17) [M–Pr]+.  
HR-MS (ESI): m/z calcd for C43H38N4O2Na+ [M+Na]+ 665.2887, found 665.2887. 
Em: λmax (1.0 mg/L in CHCl3, Ex 280 nm) = 434 nm. 
 
Methyl 2-[4-(7-bromo-9H-fluoren-2-yl)-3-(9-iso-propyl-9H-purin-6-yl)phenyl]hexanoate (166f) 
The general procedure F was followed using purine 123a (119 mg, 
0.50 mmol), methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol), and 2,7-dibromofluorene (165e, 486 mg, 
1.50 mmol). Purification by column chromatography 
(n-hexane/EtOAc 3:1) yielded 166f (158 mg, 52%) as a light yellow 
solid. 
1H-NMR (600 MHz, CDCl3): δ = 8.86 (s, 1H), 7.91 (s, 1H), 7.71 (d, J = 1.8 Hz, 1H), 7.61 (d, J = 1.6 Hz, 
1H), 7.55 (dAB, J = 8.0 Hz, 1H), 7.54 (dABd, J = 8.0, 1.7 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.46–7.43 (m, 
2H), 7.42–7.41 (m, 1H), 7.08 (dd, J = 7.9, 1.6 Hz, 1H), 4.86 (hept, J = 6.8 Hz, 1H), 3.74 (br s, 2H), 
3.69–3.65 (m, 4H), 2.19–2.11 (m, 1H), 1.90–1.82 (m, 1H), 1.58 (d, J = 6.8 Hz, 6H), 1.38–1.27 (m, 
4H), 0.89 (t, J = 7.1 Hz, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 158.7 (Cq), 151.8 (CH), 151.1 (Cq), 145.3 (Cq), 142.5 (Cq), 
141.9 (CH), 140.7 (Cq), 140.4 (Cq), 140.1 (Cq), 138.9 (Cq), 138.3 (Cq), 134.7 (Cq), 132.6 (Cq), 130.9 
(CH), 130.8 (CH), 129.8 (CH), 129.1 (CH), 128.3 (CH), 128.1 (CH), 125.7 (CH), 120.9 (CH), 120.2 (Cq), 
119.1 (CH), 52.0 (CH3), 51.4 (CH), 47.3 (CH), 36.7 (CH2), 33.5 (CH2), 30.0 (CH2), 22.6 (CH2), 22.5 
(CH3), 14.0 (CH3). 
IR (ATR): ṽ = 2952, 2870, 1732, 1577, 1455, 1327, 1214, 1162, 812, 647 cm−1.  
m.p.: 92–94 °C. 
MS (EI) m/z (relative intensity): 610 (71) [M(81Br)]+, 609 (100) [M(81Br)–H]+, 608 (69) [M(79Br)]+, 607 
(81) [M(79Br)–H]+, 43 (17).  
HR-MS (ESI): m/z calcd for C34H3479BrN4O2+ [M+H]+ 609.1860, found 609.1857. 
Em: λmax (1.0 mg/L in CHCl3, Ex 280 nm) = 441 nm. 
 
Methyl 2-[2-(pyrimidin-2-yl)-[1,1'-biphenyl]-4-yl]hexanoate (166g) 
The general procedure G was followed using 2-phenylpyrimidine (139a, 
78.1 mg, 0.50 mmol), methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol), and bromobenzene (165a, 236 mg, 1.50 mmol). Purification 
by column chromatography (n-hexane/EtOAc 7:1) yielded 166g (113 mg, 
63%) as a light yellow oil. 
In case of using chlorobenzene (165a’) (169 mg, 1.50 mmol), the reaction provided product 166g 
(126 mg, 70%). 
1H-NMR (600 MHz, CDCl3): δ = 8.63 (d, J = 4.9 Hz, 2H), 7.72 (d, J = 1.9 Hz, 1H), 7.48 (dABd, J = 7.9, 
1.9 Hz, 1H), 7.43 (dAB, J = 7.9 Hz, 1H), 7.24–7.18 (m, 3H), 7.13–7.11 (m, 2H), 7.09 (t, J = 4.9 Hz, 1H), 
3.67 (s, 3H), 3.65 (dd, J = 8.0, 7.4 Hz, 1H), 2.15 (dddd, J = 13.3, 9.6, 8.0, 5.3 Hz, 1H), 1.85 (dddd, J = 
13.3, 9.3, 7.4, 5.8 Hz, 1H), 1.39–1.23 (m, 4H), 0.88 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 167.8 (Cq), 156.6 (CH), 141.2 (Cq), 140.3 (Cq), 138.4 (Cq), 
138.3 (Cq), 130.9 (CH), 130.2 (CH), 129.0 (CH), 128.7 (CH), 127.9 (CH), 126.4 (CH), 118.4 (CH), 52.0 
(CH3), 51.4 (CH), 33.4 (CH2), 29.9 (CH2), 22.6 (CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2953, 1732, 1566, 1553, 1437, 1400, 1161, 818, 747, 700 cm−1.  
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MS (EI) m/z (relative intensity): 360 (39) [M]+, 359 (100) [M–H]+, 301 (6) [M–CO2Me]+, 257 (13) 
[M–CO2Me–Pr]+, 245 (20) [M–CO2Me–Bu]+.  
HR-MS (ESI): m/z calcd for C23H24N2O2Na+ [M+Na]+ 383.1730, found 383.1730. 
 
Methyl 2-[4'-fluoro-5-methyl-2-(pyrimidin-2-yl)-[1,1'-biphenyl]-4-yl]hexanoate (166h) 
The general procedure G was followed using 2-(p-tolyl)pyrimidine 
(139b, 85.3 mg, 0.50 mmol), methyl 2-bromohexanoate (140a, 
314 mg, 1.50 mmol), and 1-bromo-4-fluorobenzene (165b, 263 mg, 
1.50 mmol). Purification by column chromatography (n-hexane/EtOAc 
7:1) yielded 166h (124 mg, 63%) as a yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.61 (d, J = 4.8 Hz, 2H), 7.76 (s, 1H), 7.22 (s, 1H), 7.11–7.03 (m, 3H), 
6.90 (dd, J = 8.8, 8.8 Hz, 2H), 3.88 (dd, J = 8.4, 6.7 Hz, 1H), 3.65 (s, 3H), 2.46 (s, 3H), 2.27–2.13 (m, 
1H), 1.88–1.73 (m, 1H), 1.42–1.22 (m, 4H), 0.89 (t, J = 6.8 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 167.5 (Cq), 161.6 (d, 1JC–F = 245 Hz, Cq), 156.5 (CH), 138.7 
(Cq), 137.4 (Cq), 137.3 (d, 4JC–F = 3 Hz, Cq), 137.2 (Cq), 136.2 (Cq), 132.6 (CH), 130.4 (d, 3JC–F = 8 Hz, 
CH), 129.3 (CH), 118.2 (CH), 114.7 (d, 2JC–F = 21 Hz, CH), 51.9 (CH3), 46.8 (CH), 32.9 (CH2), 30.0 (CH2), 
22.6 (CH2), 19.8 (CH3), 14.0 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = –116.6 (tt, J = 8.8, 5.4 Hz). 
IR (ATR): ṽ = 2954, 1733, 1565, 1495, 1421, 1219, 1160, 837, 812 cm−1.  
MS (ESI) m/z (relative intensity): 807 (18) [2M+Na]+, 415 (48) [M+Na]+, 393 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C24H26FN2O2+ [M+H]+ 393.1973, found 393.1973. 
 
Methyl 2-[2-(4,5-dihydrooxazol-2-yl)-5-methoxy-[1,1'-biphenyl]-4-yl]hexanoate (166i) 
The general procedure G was followed using 2-(4-methoxyphenyl)-4,5-
dihydrooxazole (139i, 88.6 mg, 0.50 mmol), methyl 2-bromohexanoate 
(140a, 314 mg, 1.50 mmol), and bromobenzene (165a, 236 mg, 
1.50 mmol). Purification by column chromatography (n-hexane/EtOAc 
3:2) yielded 166i (87.2 mg, 46%) as a colorless oil. 
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In case of using chlorobenzene (165a’) (169 mg, 1.50 mmol), the reaction provided product 166i 
(52.2 mg, 27%). 
1H-NMR (400 MHz, CDCl3): δ = 7.71 (s, 1H), 7.41–7.31 (m, 5H), 6.82 (s, 1H), 4.14–4.03 (m, 2H), 4.00 
(dd, J = 7.7, 7.6 Hz, 1H), 3.88 (dd, J = 10.0, 8.9 Hz, 2H), 3.86 (s, 3H), 3.67 (s, 3H), 2.10 (dddd, J = 
13.1, 9.6, 7.7, 5.5 Hz, 1H), 1.78 (dddd, J = 13.4, 9.6, 7.6, 5.7 Hz, 1H), 1.40–1.20 (m, 4H), 0.88 (t, J = 
7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 174.5 (Cq), 165.7 (Cq), 158.2 (Cq), 142.3 (Cq), 141.5 (Cq), 130.6 (CH), 
128.3 (CH), 127.9 (CH), 127.2 (CH), 127.1 (Cq), 119.8 (Cq), 112.6 (CH), 67.5 (CH2), 55.8 (CH3), 55.0 
(CH2), 51.9 (CH3), 43.8 (CH), 32.0 (CH2), 29.8 (CH2), 22.5 (CH2), 13.9 (CH3).  
IR (ATR): ṽ = 2953, 1733, 1647, 1609, 1487, 1346, 1224, 1166, 752, 700 cm−1.  
MS (ESI) m/z (relative intensity): 785 (80) [2M+Na]+, 763 (37) [2M+H]+, 404 (27) [M+Na]+, 382 (100) 
[M+H]+.  
HR-MS (ESI): m/z calcd for C23H28NO4+ [M+H]+ 382.2013, found 382.2011. 
 
5.3.3.4 Mechanistic Studies 
5.3.3.4.1 Reaction with TEMPO 
 
2-Phenylpyrimidine (139a, 78.1 mg, 0.50 mmol), [Ru(O2CMes)2(p-cymene)] (33, 28.1 mg, 
50.0 μmol, 10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %), K2CO3 (138 mg, 1.00 mmol), and 
TEMPO (78.2 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was 
evacuated and purged with N2 for three times. Methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 40 °C. After 
20 h, the resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The 
filtrate was concentrated in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc 30:1) followed by recycling preparative HPLC yielded TEMPO-adduct 167 
(18.1 mg, 13%) as a colorless oil. 
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Methyl 2-[(2,2,6,6-tetramethylpiperidin-1-yl)oxy]hexanoate (167) 
1H-NMR (400 MHz, CDCl3): δ = 4.25–4.20 (m, 1H), 3.70 (s, 3H), 1.88–1.74 (m, 
2H), 1.50–1.14 (m, 13H), 1.12 (s, 3H), 1.10 (s, 3H), 1.01 (s, 3H), 0.89 (t, J = 
7.2 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 174.1 (Cq), 85.7 (CH), 60.3 (Cq), 59.4 (Cq), 51.3 (CH3), 40.3 (CH2), 
40.2 (CH2), 33.5 (CH3), 32.9 (CH3), 31.8 (CH2), 26.8 (CH2), 22.6 (CH2), 20.2 (CH3), 20.1 (CH3), 17.1 
(CH2), 13.9 (CH3).  
IR (ATR): ṽ = 2931, 2872, 1742, 1458, 1375, 1261, 1170, 1132, 1034, 791 cm−1.  
MS (EI) m/z (relative intensity): 285 (1) [M]+, 270 (4) [M–Me]+, 156 (100) [TEMPO]+, 123 (29), 83 
(15), 69 (22), 55 (26), 41 (18).  
HR-MS (EI): m/z calcd for C16H31NO3+ [M]+ 285.2298, found 285.2309. 
 
5.3.3.4.2 Reactions with Diastereomerically Pure Alkyl Bromide 
 
The general procedure E was followed using 2-phenylpyrimidine (139a, 102 mg, 0.65 mmol) and 
(S)-4-benzyl-3-((S)-2-bromopropanoyl)oxazolidin-2-one (140j, 156 mg, 0.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 3:1) yielded 141r (141 mg, 73%, 
dr 1.0:1.4). Two diastereomers was separated by recycling preparative HPLC to provide isomer A 
(57.3 mg, 30%) as a white solid and isomer B (41.8 mg, 36%) as a colorless oil. 
 
(S)-4-Benzyl-3-{(S)-2-[3-(pyrimidin-2-yl)phenyl]propanoyl}oxazolidin-2-one (141rA) 
1H-NMR (600 MHz, CDCl3): δ = 8.80 (d, J = 4.8 Hz, 2H), 8.46 (dd, J = 1.8, 1.7 Hz, 1H), 8.33 (ddd, J = 
7.7, 1.8, 1.4 Hz, 1H), 7.52 (ddd, J = 7.7, 1.7, 1.4 Hz, 1H), 7.45 (dd, J = 7.7, 7.7 Hz, 1H), 7.36–7.31 (m, 
2H), 7.30–7.27 (m, 1H), 7.24–7.21 (m, 2H), 7.18 (t, J = 4.8 Hz, 1H), 5.23 (q, J = 7.0 Hz, 1H), 4.62 
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(dddd, J = 9.8, 7.6, 3.3, 2.4 Hz, 1H), 4.11 (dABd, J = 9.1, 
2.4 Hz, 1H), 4.07 (dABdd, J = 9.1, 7.6, 0.6 Hz, 1H), 3.37 (dd, 
J = 13.3, 3.3 Hz, 1H), 2.81 (dd, J = 13.3, 9.8 Hz, 1H), 1.63 
(d, J = 7.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.4 (Cq), 164.5 (Cq), 
157.1 (CH), 152.8 (Cq), 140.6 (Cq), 137.9 (Cq), 135.3 (Cq), 
130.6 (CH), 129.4 (CH), 128.9 (CH), 128.8 (CH), 127.9 (CH), 127.3 (CH), 127.1 (CH), 119.0 (CH), 65.9 
(CH2), 55.8 (CH), 43.4 (CH), 38.0 (CH2), 19.5 (CH3). 
IR (ATR): ṽ = 2977, 1771, 1694, 1554, 1410, 1357, 1209, 760, 745, 699 cm−1.  
m.p.: 140–141 °C. 
MS (EI) m/z (relative intensity): 387 (33) [M]+, 210 (100), 183 (51), 168 (34), 91 (14) [Bn].  
HR-MS (EI): m/z calcd for C23H21N3O3+ [M]+ 387.1577, found 387.1583. 
 
(S)-4-Benzyl-3-{(R)-2-[3-(pyrimidin-2-yl)phenyl]propanoyl}oxazolidin-2-one (141rB) 
1H-NMR (600 MHz, CDCl3): δ = 8.80 (d, J = 4.8 Hz, 1H), 8.53 (dd, J = 1.8, 1.7 Hz, 
1H), 8.37 (ddd, J = 7.8, 1.8, 1.4 Hz, 1H), 7.56 (ddd, J = 7.7, 1.7, 1.4 Hz, 1H), 7.49 
(dd, J = 7.8, 7.7 Hz, 1H), 7.20–7.18 (m, 3H), 7.17 (t, J = 4.8 Hz, 1H), 7.03–6.99 
(m, 2H), 5.22 (q, J = 7.1 Hz, 1H), 4.76 (dddd, J = 9.2, 8.1, 3.4, 3.3 Hz, 1H), 4.19 
(dd, J = 9.0, 8.1 Hz, 1H), 4.08 (dd, J = 9.0, 3.3 Hz, 1H), 3.17 (dd, J = 13.5, 3.4 Hz, 1H), 2.60 (dd, J = 
13.5, 9.2 Hz, 1H), 1.60 (d, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 164.4 (Cq), 157.1 (CH), 152.8 (Cq), 140.6 (Cq), 138.0 (Cq), 
135.0 (Cq), 130.6 (CH), 129.3 (CH), 128.9 (CH), 128.7 (CH), 128.1 (CH), 127.1 (CH), 127.0 (CH), 119.0 
(CH), 65.9 (CH2), 55.1 (CH), 43.5 (CH), 37.5 (CH2), 19.3 (CH3). 
IR (ATR): ṽ = 2977, 1772, 1693, 1555, 1410, 1356, 1210, 734, 699 cm−1.  
MS (EI) m/z (relative intensity): 387 (29) [M]+, 210 (100), 183 (47), 168 (34), 91 (18) [Bn].  
HR-MS (EI): m/z calcd for C23H21N3O3+ [M]+ 387.1577, found 387.1586. 
 




The general procedure E was followed using [Ru(O2CMes)2(p-cymene)] (33, 28.1 mg, 50.0 μmol, 
10 mol %), 2-phenyl-4,5-dihydrooxazole (139h, 57.6 mg, 0.39 mmol) and (S)-4-benzyl-3-((S)-2-
bromopropanoyl)oxazolidin-2-one (140j, 93.8 mg, 0.30 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 3:2) yielded 141s (65.1 mg, 57%, dr 1.0:1.7). Two 
diastereomers was separated by recycling preparative HPLC to provide isomer A (23.8 mg, 21%) 




1H-NMR (600 MHz, CDCl3): δ = 8.00 (dd, J = 1.7, 1.6 Hz, 1H), 7.88 (ddd, J = 7.8, 
1.6, 1.5 Hz, 1H), 7.54 (ddd, J = 7.7, 1.7, 1.5 Hz, 1H), 7.40 (dd, J = 7.8, 7.7 Hz, 1H), 
7.23–7.19 (m, 3H), 7.02–6.98 (m, 2H), 5.14 (q, J = 7.0 Hz, 1H), 4.74 (dddd, J = 
9.2, 8.2, 3.4, 3.3 Hz, 1H), 4.42 (t, J = 9.6 Hz, 2H), 4.19 (dd, J = 9.0, 8.2 Hz, 1H), 4.09 (dd, J = 9.0, 
3.3 Hz, 1H), 4.05 (t, J = 9.6 Hz, 2H), 3.13 (dd, J = 13.5, 3.4 Hz, 1H), 2.59 (dd, J = 13.5, 9.2 Hz, 1H), 
1.54 (d, J = 7.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 174.0 (Cq), 164.3 (Cq), 152.8 (Cq), 140.4 (Cq), 134.9 (Cq), 131.2 (CH), 
129.3 (CH), 128.8 (CH), 128.6 (CH), 128.2 (Cq), 127.9 (CH), 127.1 (CH), 127.1 (CH), 67.6 (CH2), 65.9 
(CH2), 55.0 (CH), 55.0 (CH2), 43.2 (CH), 37.5 (CH2), 19.2 (CH3).  
IR (ATR): ṽ = 2978, 2933, 1779, 1697, 1650, 1360, 1214, 1068, 948, 706 cm−1.  
MS (EI) m/z (relative intensity): 378 (100) [M]+, 201 (96), 174 (76), 143 (29), 131 (42), 103 (35), 91 
(20) [Bn], 77 (13).  
HR-MS (EI): m/z calcd for C22H22N2O4+ [M]+ 378.1574, found 378.1590. 
 
 




1H-NMR (400 MHz, CDCl3): δ = 7.94 (dd, J = 1.7, 1.6 Hz, 1H), 7.84 (ddd, J = 7.7, 1.6, 1.5 Hz, 1H), 7.49 
(ddd, J = 7.8, 1.7, 1.5 Hz, 1H), 7.39–7.31 (m, 3H), 7.30–7.24 (m, 1H), 7.24–7.18 (m, 2H), 5.15 (q, J = 
7.0 Hz, 1H), 4.61 (dddd, J = 9.8, 7.4, 3.3, 2.6 Hz, 1H), 4.42 (t, J = 9.5 Hz, 2H), 4.12 (dd, J = 9.1, 2.6 Hz, 
1H), 4.10–4.02 (m, 3H), 3.35 (dd, J = 13.3, 3.3 Hz, 1H), 2.80 (dd, J = 13.3, 9.8 Hz, 1H), 1.57 (d, J = 
7.0 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 174.2 (Cq), 164.4 (Cq), 152.8 (Cq), 140.5 (Cq), 135.3 (Cq), 131.3 (CH), 
129.4 (CH), 128.9 (CH), 128.6 (CH), 128.1 (Cq), 127.8 (CH), 127.3 (CH), 127.1 (CH), 67.6 (CH2), 65.9 
(CH2), 55.7 (CH), 54.9 (CH2), 43.1 (CH), 37.9 (CH2), 19.4 (CH3). 
IR (ATR): ṽ = 2976, 2932, 1777, 1696, 1650, 1359, 1212, 1069, 948, 706 cm−1.  
MS (EI) m/z (relative intensity): 378 (87) [M]+, 201 (100), 174 (83), 143 (40), 131 (47), 115 (15), 103 
(42), 91 (58) [Bn], 77 (18), 65 (13).  
HR-MS (EI): m/z calcd for C22H22N2O4+ [M]+ 378.1574, found 378.1583. 
 
5.3.3.4.3 Spin Trapping with DMPO 
 
A mixture of 2-phenyl-4,5-dihydrooxazole (139h, 17.7 mg, 0.12 mmol), methyl 2-bromohexanoate 
(140a, 75.3 mg, 0.36 mmol), [Ru(O2CMes)2(p-cymene)] (33, 33.7 mg, 60 μmol), PPh3 (15.7 mg, 
60 μmol), K2CO3 (33.2 mg, 0.24 mmol) and DMPO (6.8 mg, 60 μmol) in 1,4-dioxane (3.0 mL) was 
heated to 60 °C for 30 min in a glovebox with N2-atmosphere. A filtered sample was transferred 
to an EPR-tube and measured directly (Figure 18).  
DMPO itself gave small background signals which are different to the strong ones observed after 
the reaction. The observed spectrum is in accordance to reported DMPO-adducts with alkyl 
radicals.[135] 
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Figure 18: EPR spectroscopic studies for the synergistic ruthenium catalytic system. 
 
5.3.3.5 Late-Stage Diversifications 
Saponification of Esters 
2-[3-(Pyrimidin-2-yl)phenyl]hexanoic acid (175a) 
To a solution of 141a (569 mg, 2.00 mmol) in CH2Cl2/MeOH (9:1, 20 mL) was 
added NaOH in MeOH (2 M, 2.0 mL). The reaction mixture was stirred at ambient 
temperature. After 24 h, the reaction mixture was concentrated in vacuo and 
acidified with 2 N HCl until pH 1–2. The resulting mixture was extracted with 
EtOAc (3 × 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by column chromatography (CH2Cl2/MeOH 50:1) yielded product 
175a (508 mg, 94%) as a viscous colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 10.54 (br s, 1H), 8.85 (d, J = 4.9 Hz, 2H), 8.38 (dd, J = 1.8, 1.7 Hz, 
1H), 8.30 (ddd, J = 7.3, 1.7, 1.7 Hz, 1H), 7.51 (ddd, J = 7.7, 1.8, 1.7 Hz, 1H), 7.44 (dd, J = 7.7, 7.3 Hz, 
1H), 7.19 (t, J = 4.9 Hz, 1H), 3.69 (dd, J = 7.8, 7.7 Hz, 1H), 2.19 (dddd, J = 13.2, 9.5, 7.8, 5.6 Hz, 1H), 
1.89 (dddd, J = 13.2, 9.5, 7.7, 5.3 Hz, 1H), 1.43–1.19 (m, 4H), 0.87 (t, J = 6.9 Hz, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 178.5 (Cq), 164.3 (Cq), 157.1 (CH), 139.4 (Cq), 137.4 (Cq), 130.4 (CH), 
128.8 (CH), 128.0 (CH), 127.3 (CH), 119.1 (CH), 51.8 (CH), 32.8 (CH2), 29.8 (CH2), 22.5 (CH2), 13.9 
(CH3).  
IR (ATR): ṽ = 2956, 2930, 1704, 1556, 1411, 1168, 907, 727, 646 cm−1.  
MS (EI) m/z (relative intensity): 270 (28) [M]+, 225 (50) [M–CO2H]+, 214 (51) [M–Bu]+, 196 (23) [M–
CO2H–Et]+, 183 (27) [M–CO2H–Pr]+, 169 (79) [M–CO2H–Bu]+, 84 (10), 58 (41) [Bu], 43 (100) [Pr]. 
HR-MS (EI): m/z calcd for C16H18N2O2+ [M]+ 270.1363, found 270.1377. 
 
2-[2-(Pyrimidin-2-yl)-[1,1'-biphenyl]-4-yl]hexanoic acid (175b) 
To a solution of 166g (113 mg, 0.31 mmol) in CH2Cl2/MeOH (9:1, 3.0 mL) 
was added NaOH in MeOH (2 M, 0.3 mL). The reaction mixture was stirred 
at ambient temperature. After 24 h, the reaction mixture was concentrated 
in vacuo and acidified with 2 N HCl until pH 1–2. The resulting mixture was 
extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. Purification of the residue by column chromatography (CH2Cl2/MeOH 50:1) 
yielded product 175b (96.4 mg, 89%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.72 (d, J = 5.0 Hz, 2H), 7.68 (d, J = 1.8 Hz, 1H), 7.50 (dABd, J = 8.0, 
1.8 Hz, 1H), 7.43 (dAB, J = 8.0 Hz, 1H), 7.23–7.17 (m, 3H), 7.15 (t, J = 5.0 Hz, 1H), 7.12–7.06 (m, 2H), 
3.64 (dd, J = 7.7, 7.7 Hz, 1H), 2.23–2.08 (m, 1H), 1.86 (dddd, J = 13.4, 9.4, 7.7, 5.5 Hz, 1H), 1.41–
1.21 (m, 4H), 0.88 (t, J = 6.9 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 177.3 (Cq), 167.5 (Cq), 156.6 (CH), 140.9 (Cq), 140.4 (Cq), 138.5 (Cq), 
137.4 (Cq), 130.9 (CH), 130.5 (CH), 129.1 (CH), 128.9 (CH), 127.9 (CH), 126.5 (CH), 118.6 (CH), 51.3 
(CH), 32.7 (CH2), 29.8 (CH2), 22.6 (CH2), 14.0 (CH3).  
IR (ATR): ṽ = 2955, 2929, 1710, 1567, 1439, 1401, 1176, 910, 732, 701 cm−1.  
m.p.: 79–80 °C. 
MS (EI) m/z (relative intensity): 346 (40) [M]+, 345 (100) [M–H]+, 288 (6) [M–Bu]+, 271 (8) [M–
CO2H–Et]+, 257 (12) [M–CO2H–Pr]+, 244 (12) [M–CO2H–Bu]+.  
HR-MS (ESI): m/z calcd for C22H22N2O2Na+ [M+Na]+ 369.1573, found 369.1569. 
 





The general procedure H was followed using substrate 175a (54.1 mg, 0.20 mmol) 
and photocatalyst [Mes-Acr-Me][ClO4] (176, 1.0 mg, 2.4 μmol, 1.2 mol %). After 
16 h, purification by column chromatography (n-hexane/EtOAc 10:1) yielded 177a 
(39.9 mg, 88%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.81 (d, J = 4.8 Hz, 2H), 8.27–8.23 (m, 2H), 7.41 (dd, J = 8.3, 7.6 Hz, 
1H), 7.31 (ddd, J = 7.6, 1.9, 1.3 Hz, 1H), 7.18 (t, J = 4.8 Hz, 1H), 2.71 (dd, J = 8.0, 7.6 Hz, 2H), 1.76–
1.59 (m, 2H), 1.41–1.30 (m, 4H), 0.93–0.86 (m, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 164.9 (Cq), 157.1 (CH), 143.3 (Cq), 137.4 (Cq), 130.9 (CH), 128.4 (CH), 
128.0 (CH), 125.5 (CH), 118.9 (CH), 36.1 (CH2), 31.7 (CH2), 31.3 (CH2), 22.6 (CH2), 14.1 (CH3).  
IR (ATR): ṽ = 2927, 2856, 1568, 1553, 1423, 1408, 782, 697, 636 cm−1.  
MS (EI) m/z (relative intensity): 226 (47) [M]+, 197 (7) [M–Et]+, 183 (45) [M–Pr]+, 170 (93), 169 
(100) [M–Bu]+, 116 (8), 89 (7). 
HR-MS (ESI): m/z calcd for C15H19N2+ [M+H]+ 227.1543, found 227.1538. 
 
2-(4-Pentyl-[1,1'-biphenyl]-2-yl)pyrimidine (177b) 
The general procedure H was followed using substrate 175b (34.7 mg, 
0.10 mmol) and photocatalyst [Mes-Acr-Me][ClO4] (176, 2.0 mg, 4.8 μmol, 
4.8 mol %). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded 177b (16.3 mg, 54%) as a light yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.63 (d, J = 4.9 Hz, 2H), 7.61 (dd, J = 1.9, 0.6 Hz, 1H), 7.39 (dABd, J = 
7.8, 0.6 Hz, 1H), 7.34 (dABd, J = 7.8, 1.9 Hz, 1H), 7.25–7.18 (m, 3H), 7.15–7.10 (m, 2H), 7.08 (t, J = 
4.9 Hz, 1H), 2.71 (dd, J = 7.9, 7.7 Hz, 2H), 1.76–1.65 (m, 2H), 1.41–1.31 (m, 4H), 0.94–0.87 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 168.3 (Cq), 156.7 (CH), 142.2 (Cq), 141.6 (Cq), 138.8 (Cq), 138.0 (Cq), 
130.6 (CH), 130.4 (CH), 129.5 (CH), 129.1 (CH), 127.9 (CH), 126.2 (CH), 118.3 (CH), 35.5 (CH2), 31.6 
(CH2), 31.1 (CH2), 22.5 (CH2), 14.0 (CH3). 
IR (ATR): ṽ = 2927, 2856, 1566, 1552, 1423, 1397, 817, 770, 699 cm−1.  
MS (EI) m/z (relative intensity): 302 (37) [M]+, 301 (100) [M–H]+, 244 (27) [M–Bu]+. 
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HR-MS (ESI): m/z calcd for C21H23N2+ [M+H]+ 303.1856, found 303.1860. 
 
3-Pentylbenzoic acid (179) 
The general procedure H was followed using substrate 178 (47.3 mg, 0.20 mmol) and 
photocatalyst [Mes-Acr-Me][ClO4] (176, 2.0 mg, 4.8 μmol, 2.4 mol %). After 16 h, 
purification by column chromatography (CH2Cl2/HOAc 100:1) yielded 179 (34.5 mg, 
90%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 11.48 (br s, 1H), 7.98–7.91 (m, 2H), 7.43 (ddd, J = 7.7, 1.6, 1.6 Hz, 
1H), 7.38 (dd, J = 7.8, 7.7 Hz, 1H), 2.67 (dd, J = 7.9, 7.6 Hz, 2H), 1.73–1.58 (m, 2H), 1.44–1.25 (m, 
4H), 0.91 (t, J = 6.8 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 172.6 (Cq), 143.3 (Cq), 133.9 (CH), 130.1 (CH), 129.5 (Cq), 128.4 (CH), 
127.6 (CH), 35.7 (CH2), 31.4 (CH2), 31.0 (CH2), 22.5 (CH2), 14.0 (CH3). 
IR (ATR): ṽ = 2925, 2854, 1678, 1451, 1275, 946, 739, 666 cm−1.  
m.p.: 58–59 °C. 
MS (EI) m/z (relative intensity): 192 (41) [M]+, 149 (10) [M–Pr]+, 136 (100) [M–Bu]+, 135 (85), 105 
(10), 92 (37), 91 (47), 77 (19), 58 (22) [Bu], 43 (66) [Pr]. 
HR-MS (EI): m/z calcd for C12H16O2+ [M]+ 192.1145, found 192.1149. 
The spectral data are in accordance with those reported in the literature.[136] 
 
5.3.3.6 Characterization Data for 180 
Ethyl 2-methyl-2-[4-(pyrimidin-2-ylamino)phenyl]propanoate (180a) 
Pyrimidyl aniline 125b (42.8 mg, 0.25 mmol), [Ru(O2CMes)2(p-cymene)] (33, 
14.1 mg, 25.0 μmol, 10 mol %), PPh3 (6.6 mg, 25.0 μmol, 10 mol %) and K2CO3 
(69.1 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube 
was evacuated and purged with N2 for three times. Ethyl 2-bromo-2-
methylpropanoate (140k, 146 mg, 0.75 mmol) and PhCMe3 (1.0 mL) were then 
added and the mixture was stirred at 120 °C. After 20 h, the resulting mixture was filtered through 
a pad of siliga gel and washed with EtOAc. The filtrate was concentrated in vacuo. Purification of 
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the residue by column chromatography (n-hexane/EtOAc 6:1) yielded monoalkylated product 
180a (18.9 mg, 26%) as a colorless oil and dialkylated product 180a’ (22.8 mg, 23%) as a white 
solid. 
1H-NMR (300 MHz, CDCl3): δ =  8.42 (d, J = 4.8 Hz, 2H), 7.56 (d, J = 8.7 Hz, 2H), 7.35 (br s, 1H), 7.32 
(d, J = 8.7 Hz, 2H), 6.71 (t, J = 4.8 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 1.57 (s, 6H), 1.19 (t, J = 7.1 Hz, 
3H). 
13C-NMR (75 MHz, CDCl3): δ = 176.8 (Cq), 160.2 (Cq), 158.1 (CH), 139.1 (Cq), 137.8 (Cq), 126.3 (CH), 
119.4 (CH), 112.6 (CH), 60.8 (CH2), 45.9 (Cq), 26.5 (CH3), 14.1 (CH3). 
IR (ATR): ṽ = 2975, 1720, 1579, 1522, 1446, 1415, 1243, 1143, 796 cm−1.  
MS (ESI) m/z (relative intensity): 308 (22) [M+Na]+, 286 (100) [M+H]+, 212 (9). 




1H-NMR (300 MHz, CDCl3): δ =  8.44 (s, 2H), 7.55 (d, J = 8.9 Hz, 2H), 7.44 
(br s, 1H), 7.31 (d, J = 8.9 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 4.11 (q, J = 
7.1 Hz, 2H), 1.59 (s, 6H), 1.56 (s, 6H), 1.21 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 
7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 176.6 (Cq), 175.4 (Cq), 158.8 (Cq), 155.8 
(CH), 138.9 (Cq), 137.8 (Cq), 128.2 (Cq), 126.2 (CH), 119.2 (CH), 61.3 (CH2), 60.7 (CH2), 46.0 (Cq), 43.1 
(Cq), 26.6 (CH3), 26.0 (CH3), 14.1 (CH3). 
IR (ATR): ṽ = 3390, 2978, 1709, 1595, 1519, 1436, 1249, 1144, 800 cm−1.  
m.p.: 105–106 °C. 
MS (EI) m/z (relative intensity): 399 (15) [M]+, 326 (100) [M–CO2Et]+, 298 (14), 252 (14). 
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Ethyl 2-{4-[(5-chloropyrimidin-2-yl)amino]phenyl}-2-methylpropanoate (180b) 
Pyrimidyl aniline 125a (51.5 mg, 0.25 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 
12.5 μmol, 5.0 mol %), PPh3 (6.6 mg, 25.0 μmol, 10 mol %) and K2CO3 
(69.1 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube 
was evacuated and purged with N2 for three times. Ethyl 2-bromo-2-
methylpropanoate (140k, 146 mg, 0.75 mmol) and m-xylene (1.0 mL) were 
then added and the mixture was stirred at 120 °C. After 20 h, the resulting mixture was filtered 
through a pad of siliga gel and washed with EtOAc. The filtrate was concentrated in vacuo. 
Purification of the residue by column chromatography (n-hexane/EtOAc 10:1) yielded 180b 
(44.4 mg, 56%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.34 (s, 2H), 7.52 (d, J = 8.8 Hz, 2H), 7.40–7.29 (m, 3H), 4.12 (q, J = 
7.1 Hz, 2H), 1.57 (s, 6H), 1.19 (t, J = 7.1 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 176.7 (Cq), 158.2 (Cq), 156.2 (CH), 139.5 (Cq), 137.3 (Cq), 126.3 (CH), 
120.8 (Cq), 119.3 (CH), 60.8 (CH2), 45.9 (Cq), 26.5 (CH3), 14.1 (CH3). 
IR (ATR): ṽ = 2981, 1718, 1612, 1522, 1429, 1241, 1149, 1026, 839, 779 cm−1.  
m.p.: 92–94 °C. 
MS (ESI) m/z (relative intensity): 344 (13) [M(37Cl)+Na]+, 342 (40) [M(35Cl)+Na]+, 322 (33) 
[M(37Cl)+H]+, 320 (100) [M(35Cl)+H]+,  246 (9). 
HR-MS (ESI): m/z calcd for C16H1935ClN3O2+ [M+H]+ 320.1160, found 320.1164. 








5.3 Experimental Procedures and Analytical Data 
 
211 
5.3.3.7 Fluorescence Spectra 
Concentration of sample: 1 mg/L in CHCl3  
 
Figure 19: Excitation/emission fluorescence spectrum of 166e. 
 
 
Figure 20: Excitation/emission fluorescence spectrum of 166f. 
 




Figure 21: Emission fluorescence spectra of 141j, 166e, and 166f (excitation at 280 nm). 
 
5.3.3.8 X-Ray Crystallographic Analysis 
A suitable crystal was selected and the crystal was mounted on a MITIGEN holder in NVH oil on a 
Bruker D8 Venture diffractometer. The crystal was kept at 100 K during data collection. Using 
Olex2,[137] the structure was solved with the XT[138] structure solution program using Intrinsic 
Phasing and refined with the XL[139] refinement package using Least Squares minimisation. 
 
 
Figure 22: Molecular structure of 141l with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
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Crystal Data for C21H27N3O (M = 337.45 g/mol): triclinic, space group P-1 (no. 2), a = 10.1934(6) Å, 
b = 10.7135(6) Å, c = 17.2661(11) Å, α = 89.316(2)°, β = 85.141(2)°, γ = 82.592(2)°, V = 
1863.12(19) Å3, Z = 4, T = 99.99 K, μ(MoKα) = 0.075 mm-1, Dcalc = 1.203 g/cm3, 105267 reflections 
measured (4.504° ≤ 2Θ ≤ 63.066°), 12396 unique (Rint = 0.0272, Rsigma = 0.0158) which were used 
in all calculations. The final R1 was 0.0394 (I > 2σ(I)) and wR2 was 0.1119 (all data).  
 
Table 23: Crystal data and structure refinement for 141l. 
Compound 141l 
CCDC 1865623 
Identification code mo_0069_CG_0m 
Empirical formula C21H27N3O 
Formula weight 337.45 
Temperature/K 99.99 
Crystal system triclinic 












Crystal size/mm3 0.417 × 0.182 × 0.144 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.504 to 63.066 
Index ranges -14 ≤ h ≤ 14, -15 ≤ k ≤ 15, -25 ≤ l ≤ 25 
Reflections collected 105267 
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Independent reflections 12396 [Rint = 0.0272, Rsigma = 0.0158] 
Data/restraints/parameters 12396/0/453 
Goodness-of-fit on F2 1.043 
Final R indexes [I>=2σ (I)] R1 = 0.0394, wR2 = 0.1086 
Final R indexes [all data] R1 = 0.0432, wR2 = 0.1119 
Largest diff. peak/hole / e Å-3 0.46/-0.19 
 
Table 24: Selected bond lengths [Å] for 141l. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C1 1.2355(9) C7 C8 1.3975(10) 
N1 C1 1.3513(10) C7 C12 1.3944(10) 
N1 C17 1.4651(10) C8 C9 1.3913(11) 
N1 C21 1.4627(10) C9 C10 1.3896(11) 
N2 C13 1.3399(10) C10 C11 1.3963(10) 
N2 C16 1.3364(11) C11 C12 1.3993(10) 
N3 C13 1.3420(10) C11 C13 1.4850(10) 
N3 C14 1.3402(11) C14 C15 1.3800(13) 
C1 C2 1.5304(10) C15 C16 1.3876(12) 
C2 C3 1.5348(10) C17 C18 1.5238(13) 
C2 C7 1.5221(10) C18 C19 1.5261(14) 
C3 C4 1.5233(11) C19 C20 1.5285(14) 
C4 C5 1.5284(11) C20 C21 1.5262(12) 
C5 C6 1.5198(12)    
 
Table 25: Selected bond angles [°] for 141l. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 N1 C17 119.50(7) C10 C9 C8 120.53(7) 
C1 N1 C21 126.89(7) C9 C10 C11 119.87(7) 
C21 N1 C17 113.30(7) C10 C11 C12 119.40(7) 
C16 N2 C13 116.50(7) C10 C11 C13 120.52(6) 
C14 N3 C13 116.07(7) C12 C11 C13 120.00(6) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
O1 C1 N1 121.74(7) C7 C12 C11 120.87(7) 
O1 C1 C2 119.41(7) N2 C13 N3 125.84(7) 
N1 C1 C2 118.77(6) N2 C13 C11 117.18(6) 
C1 C2 C3 110.00(6) N3 C13 C11 116.95(7) 
C7 C2 C1 107.55(6) N3 C14 C15 122.84(8) 
C7 C2 C3 112.95(6) C14 C15 C16 116.30(8) 
C4 C3 C2 111.68(6) N2 C16 C15 122.44(8) 
C3 C4 C5 113.94(7) N1 C17 C18 110.21(7) 
C6 C5 C4 112.75(7) C17 C18 C19 110.35(8) 
C8 C7 C2 120.00(6) C18 C19 C20 110.57(8) 
C12 C7 C2 120.91(6) C21 C20 C19 111.20(8) 
C12 C7 C8 119.08(7) N1 C21 C20 110.04(7) 
C9 C8 C7 120.22(7)     
 
 
Figure 23: Molecular structure of 141n with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C17H19N3O2 (M = 297.35 g/mol): monoclinic, space group P21/n (no. 14), a = 
10.0431(10) Å, b = 9.7828(11) Å, c = 15.4733(11) Å, β = 99.887(4)°, V = 1497.7(2) Å3, Z = 4, T = 
100.01 K, μ(MoKα) = 0.088 mm-1, Dcalc = 1.319 g/cm3, 20654 reflections measured (4.506° ≤ 2Θ ≤ 
65.196°), 5448 unique (Rint = 0.0229, Rsigma = 0.0212) which were used in all calculations. The final 
R1 was 0.0406 (I > 2σ(I)) and wR2 was 0.1176 (all data). 
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Table 26: Crystal data and structure refinement for 141n. 
Compound 141n 
CCDC 1865620 
Identification code mo_0090_CG_0m 
Empirical formula C17H19N3O2 
Formula weight 297.35 
Temperature/K 100.01 
Crystal system monoclinic 












Crystal size/mm3 0.283 × 0.2 × 0.138 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.506 to 65.196 
Index ranges -15 ≤ h ≤ 15, -14 ≤ k ≤ 14, -23 ≤ l ≤ 23 
Reflections collected 20654 
Independent reflections 5448 [Rint = 0.0229, Rsigma = 0.0212] 
Data/restraints/parameters 5448/0/255 
Goodness-of-fit on F2 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0406, wR2 = 0.1135 
Final R indexes [all data] R1 = 0.0452, wR2 = 0.1176 
Largest diff. peak/hole / e Å-3 0.46/-0.22 
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Table 27: Bond lengths [Å] for 141n. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C13 1.2275(10) C2 C3 1.3850(10) 
O2A C15A 1.416(5) C3 C4 1.3853(11) 
O2A C16A 1.423(5) C5 C6 1.3979(10) 
O2B C15B 1.445(12) C5 C10 1.3956(10) 
O2B C16B 1.416(14) C6 C7 1.3931(10) 
N1 C1 1.3396(9) C7 C8 1.3968(10) 
N1 C2 1.3404(9) C7 C11 1.5198(10) 
N2 C1 1.3408(9) C8 C9 1.3907(11) 
N2 C4 1.3355(10) C9 C10 1.3914(11) 
N3A C13 1.375(2) C11 C12 1.5282(11) 
N3A C14A 1.469(2) C11 C13 1.5296(10) 
N3A C17A 1.463(2) C14A C15A 1.5151(17) 
N3B C13 1.348(7) C14B C15B 1.502(6) 
N3B C14B 1.465(7) C16A C17A 1.5144(18) 
N3B C17B 1.477(7) C16B C17B 1.504(6) 
C1 C5 1.4831(10)    
 
Table 28: Bond angles [°] for 141n. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C15A O2A C16A 109.0(3) C6 C7 C11 121.72(6) 
C16B O2B C15B 109.9(6) C8 C7 C11 119.39(6) 
C1 N1 C2 116.51(6) C9 C8 C7 120.35(7) 
C4 N2 C1 116.43(7) C8 C9 C10 120.49(7) 
C13 N3A C14A 124.20(17) C9 C10 C5 119.79(7) 
C13 N3A C17A 117.43(16) C7 C11 C12 110.30(6) 
C17A N3A C14A 114.48(15) C7 C11 C13 110.77(6) 
C13 N3B C14B 127.1(5) C12 C11 C13 110.99(6) 
C13 N3B C17B 120.7(5) O1 C13 N3A 121.07(11) 
C14B N3B C17B 110.7(5) O1 C13 N3B 121.3(3) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N1 C1 N2 125.59(7) O1 C13 C11 120.96(7) 
N1 C1 C5 117.24(6) N3A C13 C11 117.73(11) 
N2 C1 C5 117.17(6) N3B C13 C11 115.9(3) 
N1 C2 C3 122.54(7) N3A C14A C15A 109.85(13) 
C2 C3 C4 116.08(7) N3B C14B C15B 110.2(3) 
N2 C4 C3 122.82(7) O2A C15A C14A 111.18(16) 
C6 C5 C1 120.28(6) O2B C15B C14B 111.1(6) 
C10 C5 C1 120.35(7) O2A C16A C17A 111.01(15) 
C10 C5 C6 119.36(7) O2B C16B C17B 111.8(6) 
C7 C6 C5 121.13(6) N3A C17A C16A 110.80(13) 
C6 C7 C8 118.87(7) N3B C17B C16B 109.6(4) 
 
 
Figure 24: Molecular structure of 141q with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C17H21N3O (M = 283.37 g/mol): monoclinic, space group P21/n (no. 14), a = 
10.0808(7) Å, b = 9.7488(6) Å, c = 15.9224(12) Å, β = 108.079(3)°, V = 1487.53(18) Å3, Z = 4, T = 
100.01 K, μ(MoKα) = 0.081 mm-1, Dcalc = 1.265 g/cm3, 18332 reflections measured (4.97° ≤ 2Θ ≤ 
61.044°), 4530 unique (Rint = 0.0270, Rsigma = 0.0240) which were used in all calculations. The final 
R1 was 0.0395 (I > 2σ(I)) and wR2 was 0.1064 (all data). 
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Table 29: Crystal data and structure refinement for 141q. 
Compound 141q 
CCDC 1865624 
Identification code mo_0087_CG_0m 
Empirical formula C17H21N3O 
Formula weight 283.37 
Temperature/K 100.01 
Crystal system monoclinic 












Crystal size/mm3 0.54 × 0.516 × 0.182 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.97 to 61.044 
Index ranges -14 ≤ h ≤ 12, -13 ≤ k ≤ 13, -22 ≤ l ≤ 22 
Reflections collected 18332 
Independent reflections 4530 [Rint = 0.0270, Rsigma = 0.0240] 
Data/restraints/parameters 4530/0/193 
Goodness-of-fit on F2 1.053 
Final R indexes [I>=2σ (I)] R1 = 0.0395, wR2 = 0.1026 
Final R indexes [all data] R1 = 0.0432, wR2 = 0.1064 
Largest diff. peak/hole / e Å-3 0.44/-0.29 
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Table 30: Bond lengths [Å] for 141q. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C13 1.2356(10) C5 C6 1.3983(11) 
N1 C1 1.3419(10) C5 C10 1.3982(11) 
N1 C2 1.3397(11) C6 C7 1.3955(11) 
N2 C1 1.3431(10) C7 C8 1.3948(11) 
N2 C4 1.3389(11) C7 C11 1.5238(11) 
N3 C13 1.3527(11) C8 C9 1.3923(11) 
N3 C14 1.4674(11) C9 C10 1.3901(12) 
N3 C16 1.4708(11) C11 C12 1.5323(12) 
C1 C5 1.4836(11) C11 C13 1.5302(11) 
C2 C3 1.3851(12) C14 C15 1.5207(12) 
C3 C4 1.3869(12) C16 C17 1.5198(13) 
 
Table 31: Bond angles [°] for 141q. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 N1 C1 116.25(7) C6 C7 C11 121.59(7) 
C4 N2 C1 116.39(7) C8 C7 C6 118.79(7) 
C13 N3 C14 125.90(7) C8 C7 C11 119.62(7) 
C13 N3 C16 118.00(7) C9 C8 C7 120.46(7) 
C14 N3 C16 116.03(7) C10 C9 C8 120.60(7) 
N1 C1 N2 125.83(7) C9 C10 C5 119.56(7) 
N1 C1 C5 116.91(7) C7 C11 C12 110.89(7) 
N2 C1 C5 117.26(7) C7 C11 C13 109.21(6) 
N1 C2 C3 122.64(8) C13 C11 C12 111.01(7) 
C2 C3 C4 116.37(8) O1 C13 N3 121.27(8) 
N2 C4 C3 122.47(8) O1 C13 C11 119.69(7) 
C6 C5 C1 119.88(7) N3 C13 C11 118.87(7) 
C10 C5 C1 120.60(7) N3 C14 C15 113.59(7) 
C10 C5 C6 119.52(7) N3 C16 C17 112.62(7) 
C7 C6 C5 121.05(7)     
 




Figure 25: Molecular structure of 166f with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C34H33BrN4O2 (M = 609.55 g/mol): triclinic, space group P-1 (no. 2), a = 
8.4938(10) Å, b = 10.8107(10) Å, c = 16.6719(19) Å, α = 104.927(3)°, β = 95.326(4)°, γ = 99.344(4)°, 
V = 1445.0(3) Å3, Z = 2, T = 99.98 K, μ(MoKα) = 1.461 mm-1, Dcalc = 1.401 g/cm3, 47834 reflections 
measured (4.91° ≤ 2Θ ≤ 61.12°), 8840 unique (Rint = 0.0269, Rsigma = 0.0227) which were used in all 
calculations. The final R1 was 0.0380 (I > 2σ(I)) and wR2 was 0.0989 (all data). 
 
Table 32: Crystal data and structure refinement for 166f. 
Compound 166f 
CCDC 1865621 
Identification code mo_0133_CG_0m 
Empirical formula C34H33BrN4O2 
Formula weight 609.55 
Temperature/K 99.98 
Crystal system triclinic 















Crystal size/mm3 0.518 × 0.179 × 0.08 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.91 to 61.12 
Index ranges -12 ≤ h ≤ 12, -15 ≤ k ≤ 15, -23 ≤ l ≤ 23 
Reflections collected 47834 
Independent reflections 8840 [Rint = 0.0269, Rsigma = 0.0227] 
Data/restraints/parameters 8840/12/439 
Goodness-of-fit on F2 1.028 
Final R indexes [I>=2σ (I)] R1 = 0.0380, wR2 = 0.0968 
Final R indexes [all data] R1 = 0.0417, wR2 = 0.0989 
Largest diff. peak/hole / e Å-3 1.48/-0.69 
 
Table 33: Bond lengths [Å] for 166f. 
Atom Atom Length/Å Atom Atom Length/Å 
Br1 C1 1.8987(17) C9 C10 1.389(2) 
O1A C29A 1.205(5) C10 C11 1.399(2) 
O1B C29B 1.158(10) C11 C12 1.406(2) 
O2A C29A 1.323(5) C11 C14 1.481(2) 
O2A C30A 1.430(9) C12 C13 1.386(2) 
O2B C29B 1.340(12) C14 C15 1.402(2) 
O2B C30B 1.482(16) C14 C19 1.404(2) 
N1 C20 1.3455(18) C15 C16 1.398(2) 
N1 C21 1.345(2) C15 C20 1.486(2) 
N2 C21 1.336(2) C16 C17 1.399(3) 
5.3 Experimental Procedures and Analytical Data 
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Atom Atom Length/Å Atom Atom Length/Å 
N2 C22 1.3367(17) C17 C18 1.381(3) 
N3 C22 1.3702(17) C17 C28A 1.484(3) 
N3 C24 1.3710(17) C17 C28B 1.672(5) 
N3 C25 1.4744(18) C18 C19 1.383(3) 
N4 C23 1.3870(17) C20 C23 1.3936(19) 
N4 C24 1.3135(18) C22 C23 1.4075(19) 
C1 C2 1.390(2) C25 C26 1.519(2) 
C1 C6 1.393(3) C25 C27 1.519(2) 
C2 C3 1.393(2) C28A C29A 1.511(6) 
C3 C4 1.403(2) C28A C31A 1.518(4) 
C3 C7 1.508(2) C28B C29B 1.562(12) 
C4 C5 1.389(2) C28B C31B 1.541(7) 
C4 C8 1.470(2) C31A C32A 1.608(9) 
C5 C6 1.389(2) C31B C32B 1.471(12) 
C7 C9 1.513(2) C32A C33 1.455(10) 
C8 C9 1.404(2) C32B C33 1.503(8) 
C8 C13 1.388(2) C33 C34 1.519(4) 
 
Table 34: Bond angles [°] for 166f. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C29A O2A C30A 116.2(4) C16 C17 C28A 127.1(2) 
C29B O2B C30B 111.8(10) C16 C17 C28B 106.4(3) 
C21 N1 C20 118.61(13) C18 C17 C16 118.68(16) 
C21 N2 C22 111.67(13) C18 C17 C28A 114.3(2) 
C22 N3 C24 105.33(11) C18 C17 C28B 134.6(3) 
C22 N3 C25 128.54(11) C17 C18 C19 120.60(16) 
C24 N3 C25 125.95(12) C18 C19 C14 121.59(17) 
C24 N4 C23 103.60(11) N1 C20 C15 117.32(13) 
C2 C1 Br1 119.06(13) N1 C20 C23 118.64(13) 
C2 C1 C6 122.32(16) C23 C20 C15 123.59(12) 
5 Experimental Part 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C6 C1 Br1 118.62(13) N2 C21 N1 128.40(14) 
C1 C2 C3 117.71(15) N2 C22 N3 127.91(13) 
C2 C3 C4 120.18(15) N2 C22 C23 125.94(13) 
C2 C3 C7 129.15(14) N3 C22 C23 106.08(11) 
C4 C3 C7 110.67(14) N4 C23 C20 132.92(13) 
C3 C4 C8 108.08(13) N4 C23 C22 110.08(12) 
C5 C4 C3 121.42(15) C20 C23 C22 116.64(12) 
C5 C4 C8 130.49(15) N4 C24 N3 114.91(12) 
C4 C5 C6 118.55(16) N3 C25 C26 110.44(12) 
C5 C6 C1 119.82(16) N3 C25 C27 111.12(12) 
C3 C7 C9 102.45(13) C26 C25 C27 112.39(13) 
C9 C8 C4 108.69(13) C17 C28A C29A 107.6(3) 
C13 C8 C4 129.92(14) C17 C28A C31A 110.0(2) 
C13 C8 C9 121.39(14) C29A C28A C31A 111.4(3) 
C8 C9 C7 110.09(14) C29B C28B C17 105.5(5) 
C10 C9 C7 129.85(14) C31B C28B C17 106.7(4) 
C10 C9 C8 120.05(14) C31B C28B C29B 105.6(6) 
C9 C10 C11 119.26(14) O1A C29A O2A 123.0(4) 
C10 C11 C12 119.62(14) O1A C29A C28A 125.3(4) 
C10 C11 C14 122.39(14) O2A C29A C28A 111.6(4) 
C12 C11 C14 117.96(13) O1B C29B O2B 124.3(10) 
C13 C12 C11 121.52(14) O1B C29B C28B 129.0(10) 
C12 C13 C8 118.14(14) O2B C29B C28B 106.7(7) 
C15 C14 C11 123.91(13) C28A C31A C32A 113.2(4) 
C15 C14 C19 118.03(15) C32B C31B C28B 102.1(6) 
C19 C14 C11 118.06(14) C33 C32A C31A 104.5(6) 
C14 C15 C20 124.28(13) C31B C32B C33 136.5(8) 
C16 C15 C14 119.77(14) C32A C33 C34 113.8(5) 
C16 C15 C20 115.83(14) C32B C33 C34 114.2(5) 
C15 C16 C17 121.27(17)     
 




Figure 26: Molecular structure of 141rA with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C23H21N3O3 (M = 387.43 g/mol): orthorhombic, space group P212121 (no. 19), a = 
6.2748(5) Å, b = 13.1370(11) Å, c = 24.081(2) Å, V = 1985.1(3) Å3, Z = 4, T = 101.23 K, μ(CuKα) = 
0.708 mm-1, Dcalc = 1.296 g/cm3, 16924 reflections measured (7.342° ≤ 2Θ ≤ 149.108°), 4024 
unique (Rint = 0.0197, Rsigma = 0.0181) which were used in all calculations. The final R1 was 0.0259 
(I > 2σ(I)) and wR2 was 0.0659 (all data). 
 
Table 35: Crystal data and structure refinement for 141rA. 
Compound 141rA 
CCDC 1865622 
Identification code cu_0123_CG_0m 
Empirical formula C23H21N3O3 
Formula weight 387.43 
Temperature/K 101.23 
Crystal system orthorhombic 















Crystal size/mm3 0.49 × 0.21 × 0.092 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 7.342 to 149.108 
Index ranges -7 ≤ h ≤ 7, -13 ≤ k ≤ 16, -30 ≤ l ≤ 29 
Reflections collected 16924 
Independent reflections 4024 [Rint = 0.0197, Rsigma = 0.0181] 
Data/restraints/parameters 4024/0/263 
Goodness-of-fit on F2 1.077 
Final R indexes [I>=2σ (I)] R1 = 0.0259, wR2 = 0.0658 
Final R indexes [all data] R1 = 0.0260, wR2 = 0.0659 
Largest diff. peak/hole / e Å-3 0.14/-0.18 
Flack parameter 0.03(3) 
 
Table 36: Bond lengths [Å] for 141rA. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C11 1.2140(18) C6 C7 1.389(2) 
O2 C1 1.1994(17) C7 C8 1.385(3) 
O3 C1 1.3474(16) C8 C9 1.387(2) 
O3 C2 1.4597(18) C9 C10 1.394(2) 
N1 C1 1.3927(17) C11 C12 1.516(2) 
N1 C3 1.4654(18) C12 C13 1.530(2) 
N1 C11 1.3999(18) C12 C14 1.5263(18) 
N2 C20 1.3424(19) C14 C15 1.390(2) 
N2 C21 1.339(2) C14 C19 1.393(2) 
5.3 Experimental Procedures and Analytical Data 
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Atom Atom Length/Å Atom Atom Length/Å 
N3 C20 1.3420(18) C15 C16 1.3984(19) 
N3 C23 1.335(2) C16 C17 1.397(2) 
C2 C3 1.517(2) C16 C20 1.484(2) 
C3 C4 1.5420(18) C17 C18 1.388(2) 
C4 C5 1.509(2) C18 C19 1.390(2) 
C5 C6 1.397(2) C21 C22 1.381(2) 
C5 C10 1.398(2) C22 C23 1.384(2) 
 
Table 37: Bond angles [°] for 141rA. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 O3 C2 109.68(11) O1 C11 N1 118.31(13) 
C1 N1 C3 110.80(11) O1 C11 C12 123.74(13) 
C1 N1 C11 128.92(12) N1 C11 C12 117.87(12) 
C11 N1 C3 120.23(11) C11 C12 C13 110.38(12) 
C21 N2 C20 116.29(13) C11 C12 C14 109.18(11) 
C23 N3 C20 116.49(13) C14 C12 C13 111.37(11) 
O2 C1 O3 122.29(13) C15 C14 C12 120.41(12) 
O2 C1 N1 129.25(13) C15 C14 C19 119.20(12) 
O3 C1 N1 108.45(11) C19 C14 C12 120.34(13) 
O3 C2 C3 104.65(11) C14 C15 C16 120.93(13) 
N1 C3 C2 99.96(11) C15 C16 C20 119.57(13) 
N1 C3 C4 112.47(11) C17 C16 C15 119.20(13) 
C2 C3 C4 114.86(12) C17 C16 C20 121.23(13) 
C5 C4 C3 114.11(11) C18 C17 C16 120.01(13) 
C6 C5 C4 121.66(14) C17 C18 C19 120.30(13) 
C6 C5 C10 117.99(14) C18 C19 C14 120.36(13) 
C10 C5 C4 120.35(13) N2 C20 C16 117.40(12) 
C7 C6 C5 120.85(15) N3 C20 N2 125.43(13) 
C8 C7 C6 120.45(14) N3 C20 C16 117.16(13) 
C7 C8 C9 119.67(15) N2 C21 C22 122.92(15) 
5 Experimental Part 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C8 C9 C10 119.81(16) C21 C22 C23 115.97(15) 
C9 C10 C5 121.22(14) N3 C23 C22 122.89(14) 
 
5.3.4 Late-Stage Diversification by Selectivity Switch in meta-C–H Activation 
5.3.4.1 Characterization Data for 143 and 183 
2-[3-(1-Phenylethyl)phenyl]pyrimidine (143a) 
The general procedure I was followed using 2-phenylpyrimidine (139a, 78.1 mg, 
0.50 mmol) and (1-chloroethyl)benzene (142a, 211 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 10:1) followed by 
recycling preparative HPLC yielded 143a (88.6 mg, 68%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.76 (d, J = 4.9 Hz, 2H), 8.38 (dd, J = 1.8, 1.8 Hz, 1H), 8.28 (ddd, J = 
7.6, 1.8, 1.3 Hz, 1H), 7.40 (dd, J = 7.6, 7.6 Hz, 1H), 7.33–7.29 (m, 1H), 7.29–7.24 (m, 4H), 7.20–7.14 
(m, 1H), 7.11 (t, J = 4.9 Hz, 1H), 4.27 (q, J = 7.2 Hz, 1H), 1.71 (d, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 164.7 (Cq), 157.0 (CH), 146.6 (Cq), 146.1 (Cq), 137.5 (Cq), 130.1 (CH), 
128.6 (CH), 128.3 (CH), 127.5 (CH), 127.3 (CH), 126.0 (CH), 125.9 (CH), 118.9 (CH), 44.9 (CH), 21.9 
(CH3).  
IR (ATR): ṽ = 3027, 2966, 1567, 1553, 1422, 1407, 794, 765, 698 cm−1.  
m.p.: 78–79 °C. 
MS (EI) m/z (relative intensity): 260 (42) [M]+, 259 (14) [M–H]+, 245 (100) [M–Me]+, 190 (6), 165 
(18), 122 (7). 
HR-MS (EI): m/z calcd for C18H16N2+ [M]+ 260.1308, found 260.1321. 
 
2-[3-(4-Methoxybenzyl)phenyl]pyrimidine (143b) 
The general procedure I was followed using 2-phenylpyrimidine (139a, 
78.1 mg, 0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded 143b (82.2 mg, 59%) as a white soild. 
5.3 Experimental Procedures and Analytical Data 
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1H-NMR (600 MHz, CDCl3): δ = 8.79 (d, J = 4.8 Hz, 2H), 8.32 (ddd, J = 1.8, 1.7, 0.6 Hz, 1H), 8.28 (ddd, 
J = 7.7, 1.7, 1.5 Hz, 1H), 7.41 (dd, J = 7.7, 7.6 Hz, 1H), 7.31–7.28 (m, 1H), 7.17 (t, J = 4.8 Hz, 1H), 
7.16 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 4.03 (s, 2H), 3.78 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 164.7 (Cq), 157.9 (Cq), 157.0 (CH), 141.9 (Cq), 137.6 (Cq), 133.1 (Cq), 
131.3 (CH), 129.8 (CH), 128.7 (CH), 128.5 (CH), 125.9 (CH), 118.9 (CH), 113.9 (CH), 55.3 (CH3), 41.1 
(CH2). 
IR (ATR): ṽ = 3033, 2908, 1567, 1555, 1509, 1407, 1242, 1033, 786, 696 cm−1.  
m.p.: 90–92 °C. 
MS (EI) m/z (relative intensity): 276 (100) [M]+, 275 (53) [M–H]+, 261 (39) [M–Me]+, 245 (12) [M–
OMe]+, 231 (8), 121 (12). 
HR-MS (EI): m/z calcd for C18H16N2O+ [M]+ 276.1257, found 276.1264. 
 
2-(3-Benzylphenyl)pyrimidine (143c) 
The general procedure I was followed using 2-phenylpyrimidine (139a, 78.1 mg, 
0.50 mmol) and benzyl chloride (142c, 190 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 10:1) yielded 143c 
(63.7 mg, 52%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.79 (d, J = 4.9 Hz, 2H), 8.36–8.34 (m, 1H), 8.31 (ddd, J = 7.8, 1.8, 
1.3 Hz, 1H), 7.43 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.34–7.20 (m, 6H), 7.16 (t, J = 4.9 Hz, 1H), 4.10 (s, 
2H). 
13C-NMR (125 MHz, CDCl3): δ = 164.6 (Cq), 157.0 (CH), 141.4 (Cq), 140.9 (Cq), 137.7 (Cq), 131.4 (CH), 
128.8 (CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 126.0 (CH), 118.9 (CH), 42.0 (CH2).  
IR (ATR): ṽ = 3024, 2918, 1566, 1553, 1425, 1408, 778, 759, 701, 635 cm−1. 
m.p.: 76–78 °C.  
MS (EI) m/z (relative intensity): 246 (98) [M]+, 245 (100) [M–H]+, 190 (8), 165 (24), 152 (5), 122 (7), 
91 (8) [Bn]+, 43 (19). 
HR-MS (EI): m/z calcd for C17H14N2+ [M]+ 246.1151, found 246.1149. 
The spectral data are in accordance with those reported in the literature.[69] 




The general procedure I was followed using 2-phenylpyridine (68b, 
77.6 mg, 0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded 143d (75.4 mg, 55%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 7.86 (ddd, J = 1.7, 1.5, 0.6 Hz, 
1H), 7.81 (ddd, J = 7.8, 1.7, 1.2 Hz, 1H), 7.76–7.67 (m, 2H), 7.39 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.25–
7.19 (m, 2H), 7.15 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 4.03 (s, 2H), 3.78 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 157.9 (Cq), 157.4 (Cq), 149.5 (CH), 142.0 (Cq), 139.5 (Cq), 136.5 (CH), 
133.0 (Cq), 129.8 (CH), 129.4 (CH), 128.8 (CH), 127.4 (CH), 124.6 (CH), 121.9 (CH), 120.6 (CH), 113.8 
(CH), 55.3 (CH3), 41.1 (CH2).  
IR (ATR): ṽ = 2906, 2834, 1583, 1509, 1461, 1242, 1033, 811, 774, 696 cm−1.  
MS (EI) m/z (relative intensity): 275 (100) [M]+, 274 (94) [M–H]+, 260 (45) [M–Me]+, 230 (12), 121 
(12), 78 (11), 51 (6). 
HR-MS (EI): m/z calcd for C19H17NO+ [M]+ 275.1305, found 275.1312. 
 
2-[2-(4-Methoxybenzyl)phenyl]pyridine (183) 
2-Phenylpyridine (68b, 233 mg, 1.50 mmol), [Ru(OAc)2(p-cymene)] (181, 
17.7 mg, 50.0 μmol, 10.0 mol %) and K2CO3 (138 mg, 1.00 mmol) were 
placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and 
purged with N2 three times. 4-Methoxybenzyl chloride (142b, 78.3 mg, 
0.50 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 100 °C. After 
20 h, the resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The 
filtrate was concentrated in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc 8:1) yielded monobenzylated product 183 (26.4 mg, 19%) as a colorless oil and 
dibenzylated product 183’ (71.2 mg, 72%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.64 (ddd, J = 7.5, 1.8 Hz, 1H), 
7.39–7.18 (m, 6H), 6.88 (d, J = 8.8 Hz, 2H), 6.71 (d, J = 8.8 Hz, 2H), 4.05 (s, 2H), 3.73 (s, 3H). 
5.3 Experimental Procedures and Analytical Data 
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13C-NMR (125 MHz, CDCl3): δ = 159.8 (Cq), 157.5 (Cq), 149.0 (CH), 140.5 (Cq), 139.1 (Cq), 136.0 (CH), 
133.3 (Cq), 130.4 (CH), 129.7 (CH), 129.7 (CH), 128.3 (CH), 126.1 (CH), 124.1 (CH), 121.6 (CH), 113.5 
(CH), 55.2 (CH3), 37.9 (CH2).  
IR (ATR): ṽ = 3003, 2907, 2834, 1585, 1510, 1468, 1245, 1176, 1036, 753 cm−1.  
MS (EI) m/z (relative intensity): 275 (75) [M]+, 274 (100) [M–H]+, 260 (30) [M–Me]+, 230 (18), 167 
(45). 
HR-MS (ESI): m/z calcd for C19H18NO+ [M+H]+ 276.1383, found 276.1384. 
The spectral data are in accordance with those reported in the literature.[35] 
 
2-[2,6-Bis(4-methoxybenzyl)phenyl]pyridine (183’) 
1H-NMR (600 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 1.8, 1.1 Hz, 
1H), 7.54 (ddd, J = 7.8, 7.7, 1.8 Hz, 1H), 7.25 (t, J = 7.7 Hz, 1H), 
7.20 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 7.09 (d, J = 7.7 Hz, 2H), 6.92 
(ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 6.84 (d, J = 8.7 Hz, 4H), 6.73 (d, 
J = 8.7 Hz, 4H), 3.75 (s, 6H), 3.72 (dAB, J = 15.6 Hz, 2H), 3.65 (dAB, J = 15.6 Hz, 2H). 
13C-NMR (125 MHz, CDCl3): δ = 158.8 (Cq), 157.5 (Cq), 149.2 (CH), 140.2 (Cq), 139.4 (Cq), 135.5 (CH), 
132.9 (Cq), 129.6 (CH), 128.0 (CH), 127.8 (CH), 125.2 (CH), 121.6 (CH), 113.4 (CH), 55.2 (CH3), 38.5 
(CH2).  
IR (ATR): ṽ = 3002, 2906, 2834, 1610, 1508, 1241, 1175, 1033, 789, 750 cm−1.  
MS (EI) m/z (relative intensity): 395 (94) [M]+, 394 (100) [M–H]+, 380 (12) [M–Me]+, 286 (29), 272 
(25), 242 (9), 121 (9). 
HR-MS (ESI): m/z calcd for C27H26NO2+ [M+H]+ 396.1958, found 396.1962. 
 
2-[4-Methoxy-3-(4-methoxybenzyl)phenyl]pyridine (143e) 
The general procedure I was followed using 2-(4-methoxyphenyl)pyridine 
(68a, 92.6 mg, 0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 6:1) yielded 143e (94.9 mg, 62%) as a colorless oil. 
5 Experimental Part 
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1H-NMR (400 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.86 (dd, J = 8.6, 2.3 Hz, 1H), 7.78 
(d, J = 2.3 Hz, 1H), 7.67 (ddd, J = 8.0, 7.3, 1.9 Hz, 1H), 7.61 (ddd, J = 8.0, 1.2, 1.1 Hz, 1H), 7.18 (d, J 
= 8.5 Hz, 2H), 7.14 (ddd, J = 7.3, 4.9, 1.2 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 8.5 Hz, 2H), 
4.00 (s, 2H), 3.87 (s, 3H), 3.77 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 158.3 (Cq), 157.7 (Cq), 157.3 (Cq), 149.5 (CH), 136.5 (CH), 133.0 (Cq), 
131.7 (Cq), 130.3 (Cq), 129.7 (CH), 128.9 (CH), 126.1 (CH), 121.3 (CH), 119.8 (CH), 113.6 (CH), 110.6 
(CH), 55.5 (CH3), 55.2 (CH3), 35.2 (CH2).  
IR (ATR): ṽ = 3003, 2931, 2834, 1607, 1584, 1507, 1463, 1240, 1026, 779 cm−1.  
MS (ESI) m/z (relative intensity): 306 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C20H20NO2+ [M+H]+ 306.1489, found 306.1494. 
 
4-Methoxy-2-[3-(4-methoxybenzyl)phenyl]pyridine (143f) 
The general procedure I was followed using 4-methoxy-2-phenylpyridine 
(68c, 92.6 mg, 0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 7:3) yielded 143f (99.5 mg, 65%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.51 (dd, J = 5.8, 0.5 Hz, 1H), 7.84–7.82 (m, 1H), 7.77 (ddt, J = 7.8, 
1.8, 0.9 Hz, 1H), 7.38 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.23–7.19 (m, 1H), 7.20 (dd, J = 2.5, 0.5 Hz, 1H), 
7.14 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 6.77 (dd, J = 5.8, 2.5 Hz, 1H), 4.01 (s, 2H), 3.90 (s, 
3H), 3.78 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 166.3 (Cq), 159.1 (Cq), 157.9 (Cq), 150.7 (CH), 141.9 (Cq), 139.4 (Cq), 
133.0 (Cq), 129.8 (CH), 129.5 (CH), 128.7 (CH), 127.5 (CH), 124.6 (CH), 113.8 (CH), 108.0 (CH), 107.0 
(CH), 55.3 (CH3), 55.2 (CH3), 41.1 (CH2). 
IR (ATR): ṽ = 2936, 2835, 1590, 1563, 1509, 1243, 1175, 1032, 794, 699 cm−1.  
MS (EI) m/z (relative intensity): 305 (64) [M]+, 304 (100) [M–H]+, 290 (25) [M–Me]+, 260 (6) [M–
Me–OMe]+, 121 (8), 43 (9). 
HR-MS (EI): m/z calcd for C20H19NO2+ [M]+ 305.1410, found 305.1408. 
 
 




The general procedure I was followed using 2-(4-fluorophenyl)pyrimidine 
(139c, 87.1 mg, 0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 6:1) yielded 143g (74.6 mg, 51%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.75 (d, J = 4.8 Hz, 2H), 8.36–8.27 (m, 2H), 7.20 (d, J = 8.7 Hz, 2H), 
7.14 (dd, J = 9.6, 8.5 Hz, 1H), 7.14 (t, J = 4.8 Hz, 1H), 6.83 (d, J = 8.7 Hz, 2H), 4.03 (s, 2H), 3.77 (s, 
3H). 
13C-NMR (125 MHz, CDCl3): δ = 163.8 (Cq), 162.8 (d, 1JC–F = 248 Hz, Cq), 157.9 (Cq), 157.0 (CH), 133.6 
(d, 4JC–F = 3 Hz, Cq), 131.8 (Cq), 131.1 (d, 3JC–F = 6 Hz, CH), 129.5 (CH), 128.6 (d, 2JC–F = 16 Hz, Cq), 
128.1 (d, 3JC–F = 9 Hz, CH), 118.8 (CH), 115.6 (d, 2JC–F = 23 Hz, CH), 113.9 (CH), 55.2 (CH3), 34.3 (d, 
3JC–F = 3 Hz, CH2). 
19F-NMR (282 MHz, CDCl3): δ = (–114.8)–(–115.0) (m). 
IR (ATR): ṽ = 3010, 2936, 1556, 1514, 1494, 1415, 1240, 1028, 796, 568 cm−1.  
m.p.: 89–90 °C. 
MS (EI) m/z (relative intensity): 294 (100) [M]+, 293 (55) [M–H]+, 279 (24) [M–Me]+, 263 (11) [M–
OMe]+, 121 (13), 91 (4) [Bn]+, 77 (4), 43 (6). 
HR-MS (EI): m/z calcd for C18H15FN2O+ [M]+ 294.1163, found 294.1167. 
 
2-[3-(4-Methoxybenzyl)phenyl]-4,5-dihydrooxazole (143h) 
The general procedure I was followed using 2-phenyl-4,5-dihydrooxazole 
(139h, 73.6 mg, 0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 7:3) yielded 143h (80.7 mg, 60%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.83–7.80 (m, 1H), 7.77 (ddd, J = 7.2, 1.7, 1.7 Hz, 1H), 7.35–7.27 (m, 
2H), 7.10 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 4.41 (td, J = 9.4, 0.8 Hz, 2H), 4.04 (td, J = 9.4, 
0.8 Hz, 2H), 3.94 (s, 2H), 3.77 (s, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 164.6 (Cq), 157.9 (Cq), 141.7 (Cq), 132.7 (Cq), 131.7 (CH), 129.7 (CH), 
128.5 (CH), 128.4 (CH), 127.8 (Cq), 125.8 (CH), 113.9 (CH), 67.5 (CH2), 55.3 (CH3), 54.9 (CH2), 40.9 
(CH2).  
IR (ATR): ṽ = 2904, 2835, 1647, 1509, 1242, 1176, 1033, 952, 801, 707 cm−1.  
MS (EI) m/z (relative intensity): 267 (100) [M]+, 266 (34) [M–H]+, 252 (16) [M–Me]+, 236 (16) [M–
OMe]+, 223 (10), 208 (10), 165 (15), 152 (14), 121 (25), 105 (17), 89 (6), 77 (7). 
HR-MS (EI): m/z calcd for C17H17NO2+ [M]+ 267.1254, found 267.1262. 
 
2-[4-Bromo-3-(4-methoxybenzyl)phenyl]-4,5-dihydrooxazole (143i) 
The general procedure I was followed using 2-(4-bromophenyl)-4,5-
dihydrooxazole (139j, 113 mg, 0.50 mmol) and 4-methoxybenzyl chloride 
(142b, 235 mg, 1.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 7:3) yielded 143i (87.2 mg, 50%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.78 (dd, J = 2.0, 0.5 Hz, 1H), 7.64 (dABd, J = 8.3, 2.0 Hz, 1H), 7.60 
(dABd, J = 8.3, 0.5 Hz, 1H), 7.12 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 4.40 (td, J = 9.5, 0.8 Hz, 
2H), 4.08 (s, 2H), 4.02 (td, J = 9.5, 0.8 Hz, 2H), 3.78 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 163.8 (Cq), 158.0 (Cq), 140.9 (Cq), 132.9 (CH), 131.0 (Cq), 130.5 (CH), 
129.7 (CH), 128.1 (Cq), 127.3 (CH), 127.1 (Cq), 113.9 (CH), 67.7 (CH2), 55.2 (CH3), 55.0 (CH2), 40.9 
(CH2). 
IR (ATR): ṽ = 2903, 1648, 1509, 1243, 1176, 1074, 1023, 811, 722 cm−1.  
MS (EI) m/z (relative intensity): 347 (98) [M(81Br)]+, 345 (100) [M(79Br)]+, 316 (16), 266 (40) [M–
Br]+, 223 (22), 195 (18), 152 (26), 121 (39). 
HR-MS (EI): m/z calcd for C17H1679BrNO2+ [M]+ 345.0359, found 345.0354. 
 




The general procedure I was followed using 2-phenylpyrimidine (139a, 
78.1 mg, 0.50 mmol) and 1-(1-chloroethyl)-4-fluorobenzene (142d, 238 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded 143j (113 mg, 81%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.80 (d, J = 4.9 Hz, 2H), 8.34 (ddt, J = 1.9, 1.5, 0.6 Hz, 1H), 8.28 
(dddd, J = 7.7, 1.5, 1.2, 0.3 Hz, 1H), 7.42 (dd, J = 7.7, 7.7 Hz, 1H), 7.30 (dddd, J = 7.7, 1.9, 1.2, 0.6 Hz, 
1H), 7.25–7.20 (m, 2H), 7.18 (t, J = 4.9 Hz, 1H), 6.97 (dd, J = 8.7, 8.7 Hz, 2H), 4.26 (q, J = 7.3 Hz, 1H), 
1.70 (d, J = 7.3 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 164.7 (Cq), 161.2 (d, 1JC–F = 244 Hz, Cq), 157.1 (CH), 146.5 (Cq), 141.8 
(d, 4JC–F = 3 Hz, Cq), 137.7 (Cq), 130.0 (CH), 128.9 (d, 3JC–F = 8 Hz, CH), 128.7 (CH), 127.2 (CH), 126.1 
(CH), 119.0 (CH), 115.0 (d, 2JC–F = 21 Hz, CH), 44.2 (CH), 22.1 (CH3). 
19F-NMR (282 MHz, CDCl3): δ = –117.5 (tt, J = 8.7, 5.4 Hz). 
IR (ATR): ṽ = 2961, 1567, 1554, 1505, 1406, 1219, 1158, 835, 782, 690 cm−1.  
m.p.: 88–90 °C. 
MS (EI) m/z (relative intensity): 278 (38) [M]+, 263 (100) [M–Me]+, 243 (11), 208 (7), 183 (17). 
HR-MS (EI): m/z calcd for C18H15FN2+ [M]+ 278.1214, found 278.1211. 
 
2-[3-(1-Phenylethyl)phenyl]pyridine (143k) 
The general procedure I was followed using 2-phenylpyridine (68b, 77.6 mg, 
0.50 mmol) and (1-chloroethyl)benzene (142a, 211 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 10:1) followed by 
recycling preparative HPLC yielded 143k (96.2 mg, 74%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.89 (dd, J = 1.9, 1.9 Hz, 1H), 7.78 
(ddd, J = 7.7, 1.9, 1.2 Hz, 1H), 7.75–7.65 (m, 2H), 7.38 (dd, J = 7.7, 7.7 Hz, 1H), 7.32–7.13 (m, 7H), 
4.25 (q, J = 7.2 Hz, 1H), 1.70 (d, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 157.5 (Cq), 149.5 (CH), 146.8 (Cq), 146.1 (Cq), 139.4 (Cq), 136.5 (CH), 
128.7 (CH), 128.3 (CH), 128.2 (CH), 127.6 (CH), 126.3 (CH), 126.0 (CH), 124.7 (CH), 121.9 (CH), 120.6 
(CH), 44.9 (CH), 22.0 (CH3).  
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IR (ATR): ṽ = 2966, 1583, 1565, 1433, 1414, 761, 696, 614 cm−1.  
MS (EI) m/z (relative intensity): 259 (63) [M]+, 258 (100) [M–H]+, 244 (90) [M–Me]+, 165 (20), 78 
(12), 51 (9). 
HR-MS (ESI): m/z calcd for C19H18N+ [M+H]+ 260.1434, found 260.1435. 
The spectral data are in accordance with those reported in the literature.[68-69] 
 
2-{3-[1-(2-Chlorophenyl)ethyl]phenyl}pyrimidine (143l) 
The general procedure I was followed using 2-phenylpyrimidine (139a, 78.1 mg, 
0.50 mmol) and 1-chloro-2-(1-chloroethyl)benzene (142e, 263 mg, 1.50 mmol) 
at 80 °C. After 20 h, purification by column chromatography (n-hexane/EtOAc 
10:1) yielded 143l (76.3 mg, 52%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.80 (d, J = 4.8 Hz, 2H), 8.39 (ddd, J = 1.9, 1.7, 0.8 Hz, 1H), 8.30 (ddd, 
J = 7.7, 1.7, 1.4 Hz, 1H), 7.42 (ddd, J = 7.7, 7.7, 0.8 Hz, 1H), 7.36 (dd, J = 7.6, 1.5 Hz, 1H), 7.33 (dddd, 
J = 7.7, 1.9, 1.4, 0.6 Hz, 1H), 7.27 (dd, J = 7.6, 2.0 Hz, 1H), 7.21 (ddd, J = 7.6, 7.5, 1.5 Hz, 1H), 7.17 
(t, J = 4.8 Hz, 1H), 7.13 (ddd, J = 7.6, 7.5, 2.0 Hz, 1H), 4.77 (q, J = 7.2 Hz, 1H), 1.70 (d, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 164.7 (Cq), 157.1 (CH), 145.2 (Cq), 143.5 (Cq), 137.6 (Cq), 133.8 (Cq), 
130.3 (CH), 129.5 (CH), 128.6 (CH), 128.6 (CH), 127.4 (CH), 127.3 (CH), 126.9 (CH), 126.1 (CH), 118.9 
(CH), 41.2 (CH), 21.2 (CH3).  
IR (ATR): ṽ = 2968, 1567, 1553, 1422, 1407, 1034, 793, 757, 699, 635 cm−1.  
MS (EI) m/z (relative intensity): 296 (31) [M(37Cl)]+, 294 (89) [M(35Cl)]+, 281 (35) [M(37Cl)–Me]+, 279 
(100) [M(35Cl)–Me]+, 259 (24) [M–Cl]+, 243 (60) [M–Me–Cl]+, 190 (26), 165 (12), 129 (10), 122 (10), 
103 (14), 77 (13). 
HR-MS (ESI): m/z calcd for C18H1635ClN2+ [M+H]+ 295.0997, found 295.0999. 
 
2-[3-(1-Phenylethyl)phenyl]-4,5-dihydrooxazole (143m) 
The general procedure I was followed using 2-phenyl-4,5-dihydrooxazole (139h, 
73.6 mg, 0.50 mmol) and (1-chloroethyl)benzene (142a, 211 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 3:1) 
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followed by recycling preparative HPLC yielded 143m (65.6 mg, 52%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.89–7.87 (m, 1H), 7.79–7.74 (m, 1H), 7.35–7.26 (m, 4H), 7.24–7.15 
(m, 3H), 4.42 (td, J = 9.5, 0.6 Hz, 2H), 4.19 (q, J = 7.3 Hz, 1H), 4.05 (t, J = 9.5 Hz, 2H), 1.66 (d, J = 
7.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 164.8 (Cq), 146.6 (Cq), 145.9 (Cq), 130.7 (CH), 128.4 (CH), 127.8 (Cq), 
127.6 (CH), 127.2 (CH), 126.1 (CH), 126.0 (CH), 67.5 (CH2), 54.9 (CH2), 44.7 (CH), 21.7 (CH3).  
IR (ATR): ṽ = 2967, 2875, 1647, 1450, 1356, 1264, 1178, 1066, 947, 700 cm−1.  
MS (EI) m/z (relative intensity): 251 (69) [M]+, 236 (100) [M–Me]+, 221 (12), 193 (40), 192 (40), 178 
(15), 165 (68), 103 (19), 89 (9), 77 (16). 
HR-MS (EI): m/z calcd for C17H17NO+ [M]+ 251.1305, found 251.1316. 
 
2-[3-(Naphthalen-1-ylmethyl)phenyl]pyridine (143n) 
The general procedure I was followed using 2-phenylpyridine (68b, 77.6 mg, 
0.50 mmol) and 1-(chloromethyl)naphthalene (142m, 265 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 20:1) 
yielded 143n (28.8 mg, 20%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.70 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.09–8.02 (m, 1H), 7.96 (dddd, J 
= 1.8, 1.2, 0.6, 0.6 Hz, 1H), 7.91–7.85 (m, 1H), 7.82 (dddd, J = 7.7, 1.2, 1.2, 0.6 Hz, 1H), 7.79 (dtt, J 
= 8.1, 0.9, 0.5 Hz, 1H), 7.71 (dABdd, J = 8.0, 7.0, 1.8 Hz, 1H), 7.67 (dABdd, J = 8.0, 1.6, 1.0 Hz, 1H), 
7.50–7.41 (m, 3H), 7.37 (ddd, J = 7.7, 7.7, 0.6 Hz, 1H), 7.37–7.33 (m, 1H), 7.24–7.18 (m, 2H), 4.56 
(s, 2H). 
13C-NMR (125 MHz, CDCl3): δ = 157.4 (Cq), 149.5 (CH), 141.1 (Cq), 139.5 (Cq), 136.5 (CH), 136.4 (Cq), 
133.8 (Cq), 132.0 (Cq), 129.3 (CH), 128.8 (CH), 128.6 (CH), 127.3 (CH), 127.1 (CH), 125.9 (CH), 125.5 
(CH), 124.7 (CH), 124.2 (CH), 121.9 (CH), 120.6 (CH), 39.2 (CH2). 
IR (ATR): ṽ = 3045, 1584, 1565, 1461, 1435, 769, 744 cm−1.  
MS (EI) m/z (relative intensity): 295 (75) [M]+, 294 (100) [M–H]+, 215 (27), 147 (14), 115 (7), 43 
(10). 
HR-MS (EI): m/z calcd for C22H17N+ [M]+ 295.1356, found 295.1350. 
The spectral data are in accordance with those reported in the literature.[68] 




The general procedure I was followed using 1-phenyl-1H-pyrazole (147a, 
72.1 mg, 0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 30:1) yielded 143o (48.9 mg, 37%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.88 (dd, J = 2.5, 0.6 Hz, 1H), 7.71 (dd, J = 1.8, 0.6 Hz, 1H), 7.57–7.55 
(m, 1H), 7.52–7.48 (m, 1H), 7.36 (ddd, J = 7.8, 7.7, 0.5 Hz, 1H), 7.13 (d, J = 8.8 Hz, 2H), 7.10 (dddd, 
J = 7.7, 2.2, 0.9, 0.5 Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 6.44 (dd, J = 2.5, 1.8 Hz, 1H), 3.99 (s, 2H), 3.78 
(s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 158.1 (Cq), 143.3 (Cq), 141.0 (CH), 140.3 (Cq), 132.6 (Cq), 129.9 (CH), 
129.4 (CH), 126.9 (CH), 126.8 (CH), 119.8 (CH), 116.9 (CH), 114.0 (CH), 107.4 (CH), 55.2 (CH3), 41.0 
(CH2). 
IR (ATR): ṽ = 2835, 1608, 1592, 1509, 1391, 1242, 1176, 1033, 786, 747 cm−1.  
MS (EI) m/z (relative intensity): 264 (100) [M]+, 249 (22) [M–Me]+, 152 (13), 121 (21), 77 (9). 
HR-MS (EI): m/z calcd for C17H16N2O+ [M]+ 264.1257, found 264.1270. 
 
2-(3-Benzylphenyl)-4,5-dihydrooxazole (143p) 
The general procedure I was followed using 2-phenyl-4,5-dihydrooxazole (139h, 
73.6 mg, 0.50 mmol) and benzyl chloride (142c, 190 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 7:3) followed by 
recycling preparative HPLC yielded 143p (33.9 mg, 29%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.84 (s, 1H), 7.79 (d, J = 7.4 Hz, 1H), 7.37–7.16 (m, 7H), 4.42 (t, J = 
9.8 Hz, 2H), 4.05 (t, J = 9.8 Hz, 2H), 4.02 (s, 2H). 
13C-NMR (125 MHz, CDCl3): δ = 164.5 (Cq), 141.3 (Cq), 140.5 (Cq), 131.8 (CH), 128.8 (CH), 128.6 (CH), 
128.4 (CH), 127.8 (Cq), 126.1 (CH), 125.9 (CH), 67.6 (CH2), 54.9 (CH2), 41.8 (CH2). 
IR (ATR): ṽ = 2903, 1647, 1600, 1493, 1357, 1263, 1179, 1065, 952, 700 cm−1.  
MS (EI) m/z (relative intensity): 237 (100) [M]+, 236 (34) [M–H]+, 207 (84), 193 (13), 165 (55), 152 
(15), 91 (31) [Bn]+, 65 (9). 
HR-MS (EI): m/z calcd for C16H15NO+ [M]+ 237.1148, found 237.1149. 




The general procedure I was followed using 2-phenyl-4,5-dihydrooxazole 
(139h, 73.6 mg, 0.50 mmol) and 4-methylbenzyl chloride (142f, 211 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 7:3) followed by recycling preparative HPLC yielded 143q 
(37.4 mg, 30%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.83 (ddd, J = 1.7, 1.7, 0.7 Hz, 1H), 7.77 (ddd, J = 7.4, 1.7, 1.7 Hz, 
1H), 7.32 (ddd, J = 7.6, 7.4, 0.7 Hz, 1H), 7.28 (ddd, J = 7.6, 1.7, 1.7 Hz, 1H), 7.11–7.06 (m, 4H), 4.41 
(t, J = 9.5 Hz, 2H), 4.05 (t, J = 9.5 Hz, 2H), 3.97 (s, 2H), 2.31 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 164.7 (Cq), 141.7 (Cq), 137.6 (Cq), 135.7 (Cq), 131.8 (CH), 129.2 (CH), 
128.7 (CH), 128.6 (CH), 128.5 (CH), 127.8 (Cq), 125.9 (CH), 67.5 (CH2), 54.9 (CH2), 41.4 (CH2), 21.0 
(CH3). 
IR (ATR): ṽ = 2903, 1648, 1513, 1356, 1262, 1180, 1064, 951, 797, 707 cm−1.  
MS (EI) m/z (relative intensity): 251 (100) [M]+, 236 (5) [M–Me]+, 221 (16), 206 (14), 193 (10), 179 
(12), 165 (24), 105 (15) [MeBn]+. 
HR-MS (EI): m/z calcd for C17H17NO+ [M]+ 251.1305, found 251.1308. 
 
2-[3-(4-Fluorobenzyl)phenyl]-4,5-dihydrooxazole (143r) 
The general procedure I was followed using 2-phenyl-4,5-dihydrooxazole 
(139h, 73.6 mg, 0.50 mmol) and 4-fluorobenzyl chloride (142i, 217 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 7:3) followed by recycling preparative HPLC yielded 143r 
(42.7 mg, 33%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.84–7.74 (m, 2H), 7.34 (dd, J = 7.5, 7.5 Hz, 1H), 7.30–7.24 (m, 1H), 
7.13 (dd, J = 8.8, 5.4 Hz, 2H), 6.96 (dd, J = 8.8, 8.7 Hz, 2H), 4.42 (t, J = 9.5 Hz, 2H), 4.05 (t, J = 9.5 Hz, 
2H), 3.97 (s, 2H). 
13C-NMR (125 MHz, CDCl3): δ = 164.5 (Cq), 161.3 (d, 1JC–F = 244 Hz, Cq), 141.1 (Cq), 136.2 (d, 4JC–F = 
3 Hz, Cq), 131.7 (CH), 130.2 (d, 3JC–F = 8 Hz, CH), 128.5 (CH), 127.9 (Cq), 126.0 (CH), 115.2 (d, 2JC–F = 
21 Hz, CH), 67.6 (CH2), 54.9 (CH2), 41.0 (CH2). 
19F-NMR (282 MHz, CDCl3): δ = (–117.1)–(–117.3) (m). 
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IR (ATR): ṽ = 2877, 1648, 1602, 1507, 1357, 1219, 1157, 1065, 952, 707 cm−1.  
MS (EI) m/z (relative intensity): 255 (100) [M]+, 254 (32) [M–H]+, 225 (88), 211 (13), 183 (38), 165 
(16), 109 (34) [FBn]+, 89 (9), 43 (22). 
HR-MS (EI): m/z calcd for C16H14FNO+ [M]+ 255.1054, found 255.1063. 
 
2-[3-(4-Chlorobenzyl)phenyl]-4,5-dihydrooxazole (143s) 
The general procedure I was followed using 2-phenyl-4,5-dihydrooxazole 
(139h, 73.6 mg, 0.50 mmol) and 4-chlorobenzyl chloride (142j, 242 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 7:3) followed by recycling preparative HPLC yielded 143s 
(39.0 mg, 29%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 7.90–7.70 (m, 2H), 7.33 (dd, J = 7.6, 7.5 Hz, 1H), 7.26 (d, J = 7.6 Hz, 
1H), 7.24 (d, J = 8.3 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 4.42 (t, J = 9.4 Hz, 2H), 4.05 (br s, 2H), 3.97 (s, 
2H). 
13C-NMR (125 MHz, CDCl3): δ = 164.4 (Cq), 140.7 (Cq), 139.0 (Cq), 131.9 (Cq), 131.7 (CH), 130.1 (CH), 
128.5 (CH), 128.0 (Cq), 126.2 (CH), 67.6 (CH2), 54.9 (CH2), 41.1 (CH2). 
IR (ATR): ṽ = 2903, 1649, 1490, 1357, 1264, 1181, 1084, 980, 791, 709 cm−1.  
MS (EI) m/z (relative intensity): 273 (34) [M(37Cl)]+, 272 (29) [M(37Cl)–H]+, 271 (100) [M(35Cl)]+, 270 
(37) [M(35Cl)–H]+, 243 (30), 241 (89), 193 (14), 178 (11), 165 (56), 127 (9) [37ClBn]+, 125 (23) 
[35ClBn]+, 103 (17), 89 (17). 
HR-MS (EI): m/z calcd for C16H1435ClNO+ [M]+ 271.0758, found 271.0758. 
 
(E)-1-Phenyl-2-[3-(1-phenylethyl)phenyl]diazene (143t) 
The general procedure I was followed using azobenzene (139l, 91.2 mg, 
0.50 mmol) and (1-chloroethyl)benzene (142a, 211 mg, 1.50 mmol). After 
20 h, purification by column chromatography (n-hexane to n-hexane/EtOAc 
100:1) followed by recycling preparative HPLC yielded 143t (39.1 mg, 27%) as 
an orange oil. 
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1H-NMR (300 MHz, CDCl3): δ = 7.96–7.91 (m, 2H), 7.88 (dd, J = 1.9, 1.8 Hz, 1H), 7.77 (ddd, J = 7.8, 
1.9, 1.3 Hz, 1H), 7.57–7.48 (m, 3H), 7.45 (dd, J = 7.8, 7.7 Hz, 1H), 7.38–7.27 (m, 5H), 7.27–7.19 (m, 
1H), 4.30 (q, J = 7.2 Hz, 1H), 1.75 (d, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 152.7 (Cq), 152.6 (Cq), 147.4 (Cq), 145.8 (Cq), 130.8 (CH), 130.4 (CH), 
129.0 (CH), 128.4 (CH), 127.6 (CH), 126.1 (CH), 122.7 (CH), 122.5 (CH), 120.1 (CH), 44.8 (CH), 21.9 
(CH3). 
IR (ATR): ṽ = 2967, 1598, 1492, 1449, 1150, 1027, 763, 690, 529 cm−1.  
MS (EI) m/z (relative intensity): 286 (68) [M]+, 209 (9) [M–Ph]+, 181 (88) [M–Ph–N2]+, 166 (60), 165 
(68), 105 (48) [EtPh]+, 77 (100) [Ph]+. 
HR-MS (EI): m/z calcd for C20H18N2+ [M]+ 286.1465, found 286.1461. 
 
5.3.4.2 Characterization Data for 185 
6-(3-Benzylphenyl)-9-iso-propyl-9H-purine (185ac) 
The general procedure I was followed using purine 123a (119 mg, 0.50 mmol) 
and benzyl chloride (142c, 190 mg, 1.50 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 3:1) yielded 185ac (116 mg, 71%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.01 (s, 1H), 8.68 (ddd, J = 7.7, 1.8, 1.3 Hz, 1H), 8.62 (ddd, J = 1.8, 
1.3, 0.6 Hz, 1H), 8.18 (s, 1H), 7.48 (ddd, J = 7.7, 7.7, 0.6 Hz, 1H), 7.32 (dddd, J = 7.7, 1.3, 1.3, 0.6 Hz, 
1H), 7.30–7.15 (m, 5H), 4.98 (hept, J = 6.8 Hz, 1H), 4.14 (s, 2H), 1.67 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 154.7 (Cq), 152.0 (Cq), 151.9 (CH), 141.8 (CH), 141.4 (Cq), 140.9 (Cq), 
135.9 (Cq), 131.5 (Cq and CH), 129.9 (CH), 128.9 (CH), 128.7 (CH), 128.4 (CH), 127.9 (CH), 126.0 
(CH), 47.3 (CH), 42.1 (CH2), 22.6 (CH3).  
IR (ATR): ṽ = 2977, 1567, 1494, 1324, 1217, 783, 700, 646 cm−1.  
MS (EI) m/z (relative intensity): 328 (42) [M]+, 327 (41) [M–H]+, 285 (100) [M–i-Pr]+, 165 (8), 91 (6). 
HR-MS (EI): m/z calcd for C21H20N4+ [M]+ 328.1682, found 328.1685. 
 
 




The general procedure I was followed using purine 123a (119 mg, 
0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 3:1) 
yielded 185ab (133 mg, 74%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.01 (s, 1H), 8.66 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.59 (ddd, J = 1.8, 
1.5, 0.6 Hz, 1H), 8.18 (s, 1H), 7.47 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.30 (dddd, J = 7.7, 1.5, 1.2, 0.6 Hz, 
1H), 7.16 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 4.98 (hept, J = 6.8 Hz, 1H), 4.07 (s, 2H), 3.77 (s, 
3H), 1.67 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 157.9 (Cq), 154.8 (Cq), 152.0 (Cq), 151.9 (CH), 141.9 (Cq), 141.8 (CH), 
135.8 (Cq), 133.1 (Cq), 131.5 (Cq), 131.4 (CH), 129.8 (CH), 129.8 (CH), 128.7 (CH), 127.8 (CH), 113.8 
(CH), 55.3 (CH3), 47.3 (CH), 41.2 (CH2), 22.6 (CH3).  
IR (ATR): ṽ = 2977, 1567, 1509, 1324, 1243, 1217, 1033, 791, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 358 (84) [M]+, 357 (30) [M–H]+, 343 (14) [M–Me]+, 315 (100) [M–
i-Pr]+, 301 (43), 121 (13), 43 (8). 
HR-MS (EI): m/z calcd for C22H22N4O+ [M]+ 358.1788, found 358.1796. 
 
9-iso-Propyl-6-[3-(4-methylbenzyl)phenyl]-9H-purine (185af) 
The general procedure I was followed using purine 123a (119 mg, 
0.50 mmol) and 4-methylbenzyl chloride (142f, 211 mg, 1.50 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 3:1) yielded 
185af (106 mg, 62%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 9.01 (s, 1H), 8.67 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.61 (ddd, J = 1.8, 
1.2, 0.6 Hz, 1H), 8.18 (s, 1H), 7.47 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.31 (dddd, J = 7.7, 1.2, 1.2, 0.6 Hz, 
1H), 7.14 (dAB, J = 8.0 Hz, 2H), 7.09 (dAB, J = 8.0 Hz, 2H), 4.98 (hept, J = 6.8 Hz, 1H), 4.09 (s, 2H), 2.30 
(s, 3H), 1.67 (d, J = 6.8 Hz, 6H). 
13C-NMR (100 MHz, CDCl3): δ = 154.9 (Cq), 152.1 (Cq), 152.0 (CH), 141.9 (CH), 141.8 (Cq), 138.0 (Cq), 
135.9 (Cq), 135.5 (Cq), 131.5 (Cq), 131.5 (CH), 129.9 (CH), 129.1 (CH), 128.8 (CH), 128.8 (CH), 127.9 
(CH), 47.2 (CH), 41.6 (CH2), 22.6 (CH3), 21.0 (CH3). 
IR (ATR): ṽ = 2977, 2919, 1567, 1495, 1445, 1324, 1217, 790, 702, 646 cm−1.  
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MS (EI) m/z (relative intensity): 342 (75) [M]+, 341 (27) [M–H]+, 327 (2) [M–Me]+, 299 (100) [M–
i-Pr]+, 285 (11), 165 (6), 142 (7). 
HR-MS (EI): m/z calcd for C22H22N4+ [M]+ 342.1839, found 342.1845. 
 
9-iso-Propyl-6-{3-[4-(trifluoromethyl)benzyl]phenyl}-9H-purine (185ag) 
The general procedure I was followed using purine 123a (119 mg, 
0.50 mmol) and 4-(trifluoromethyl)benzyl chloride (142g, 292 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 3:1) yielded 185ag (146 mg, 73%) as a colorless oil. 
1H-NMR (500 MHz, CDCl3): δ = 9.01 (s, 1H), 8.70 (ddd, J = 7.8, 1.5, 1.3 Hz, 1H), 8.61 (dd, J = 1.7, 
1.5 Hz, 1H), 8.18 (s, 1H), 7.53 (d, J = 8.0 Hz, 2H), 7.50 (dd, J = 7.8, 7.7 Hz, 1H), 7.36 (d, J = 8.0 Hz, 
2H), 7.31 (ddd, J = 7.7, 1.7, 1.3 Hz, 1H), 4.99 (hept, J = 6.9 Hz, 1H), 4.18 (s, 2H), 1.68 (d, J = 6.9 Hz, 
6H). 
13C-NMR (125 MHz, CDCl3): δ = 154.6 (Cq), 152.1 (Cq), 152.0 (CH), 145.1 (Cq), 142.0 (CH), 140.4 (Cq), 
136.2 (Cq), 131.5 (Cq), 131.5 (CH), 130.0 (CH), 129.2 (CH), 129.0 (CH), 128.4 (q, 2JC–F = 32 Hz, Cq), 
128.3 (CH), 125.4 (q, 3JC–F = 4 Hz, CH), 124.3 (q, 1JC–F = 270 Hz, Cq), 47.3 (CH), 41.8 (CH2), 22.6 (CH3).  
19F-NMR (470 MHz, CDCl3): δ = –62.3 (s). 
IR (ATR): ṽ = 2980, 1568, 1321, 1219, 1107, 1065, 1018, 788, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 396 (46) [M]+, 395 (58) [M–H]+, 353 (100) [M–i-Pr]+, 333 (17). 
HR-MS (EI): m/z calcd for C22H19F3N4+ [M]+ 396.1556, found 396.1557. 
 
Ethyl 4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoate (185ah) 
The general procedure I was followed using purine 123a (119 mg, 
0.50 mmol) and ethyl 4-(chloromethyl)benzoate (142h, 298 mg, 
1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 2:1) yielded 185ah (144 mg, 72%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.00 (s, 1H), 8.69 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.60 (ddd, J = 1.8, 
1.8, 0.6 Hz, 1H), 8.18 (s, 1H), 7.96 (d, J = 8.6 Hz, 2H), 7.49 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.34–7.27 
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(m, 3H), 4.98 (hept, J = 6.8 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 4.18 (s, 2H), 1.67 (d, J = 6.8 Hz, 6H), 
1.37 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 166.4 (Cq), 154.5 (Cq), 152.0 (Cq), 151.9 (CH), 146.2 (Cq), 141.9 (CH), 
140.5 (Cq), 136.0 (Cq), 131.5 (Cq), 131.4 (CH), 130.0 (CH), 129.7 (CH), 128.9 (CH), 128.8 (CH), 128.4 
(Cq), 128.1 (CH), 60.8 (CH2), 47.3 (CH), 42.0 (CH2), 22.6 (CH3), 14.4 (CH3).  
IR (ATR): ṽ = 2978, 1711, 1567, 1325, 1272, 1219, 1101, 1021, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 400 (60) [M]+, 399 (100) [M–H]+, 371 (10) [M–Et]+, 357 (47) [M–
i-Pr]+, 329 (21) [M–i-Pr–Et]+, 311 (48), 285 (19), 283 (26) [M–i-Pr–CO2Et]+, 165 (9), 156 (11), 142 
(9). 
HR-MS (EI): m/z calcd for C24H24N4O2+ [M]+ 400.1894, found 400.1883. 
 
6-[3-(4-Fluorobenzyl)phenyl]-9-iso-propyl-9H-purine (185ai) 
The general procedure I was followed using purine 123a (119 mg, 0.50 mmol) 
and 4-fluorobenzyl chloride (142i, 217 mg, 1.50 mmol). After 20 h, purification 
by column chromatography (n-hexane/EtOAc 3:1) yielded 185ai (123 mg, 
71%) as a white solid. 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.68 (ddd, J = 7.8, 1.8, 1.3 Hz, 1H), 8.59 (dd, J = 2.0, 
1.8 Hz, 1H), 8.18 (s, 1H), 7.48 (dd, J = 7.8, 7.7 Hz, 1H), 7.29 (ddd, J = 7.7, 2.0, 1.3 Hz, 1H), 7.19 (dd, 
J = 8.8, 5.4 Hz, 2H), 6.96 (dd, J = 8.8, 8.7 Hz, 2H), 4.98 (hept, J = 6.8 Hz, 1H), 4.09 (s, 2H), 1.67 (d, J 
= 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 161.3 (d, 1JC–F = 244 Hz, Cq), 154.6 (Cq), 152.0 (Cq), 151.9 (CH), 141.8 
(CH), 141.2 (Cq), 136.6 (d, 4JC–F = 3 Hz, Cq), 136.0 (Cq), 131.5 (Cq), 131.3 (CH), 130.2 (d, 3JC–F = 8 Hz, 
CH), 129.8 (CH), 128.8 (CH), 128.0 (CH), 115.1 (d, 2JC–F = 21 Hz, CH), 47.3 (CH), 41.2 (CH2), 22.6 
(CH3). 
19F-NMR (282 MHz, CDCl3): δ = –117.4 (tt, J = 8.7, 5.4 Hz). 
IR (ATR): ṽ = 2980, 1567, 1506, 1444, 1326, 1221, 834, 794, 704, 651 cm−1.  
m.p.: 95–96 °C.  
MS (EI) m/z (relative intensity): 346 (41) [M]+, 345 (38) [M–H]+, 303 (100) [M–i-Pr]+, 183 (5), 109 
(9), 43 (6). 
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HR-MS (EI): m/z calcd for C21H19FN4+ [M]+ 346.1588, found 346.1591. 
 
6-[3-(4-Chlorobenzyl)phenyl]-9-iso-propyl-9H-purine (185aj) 
The general procedure I was followed using purine 123a (119 mg, 0.50 mmol) 
and 4-chlorobenzyl chloride (142j, 242 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 3:1) yielded 185aj 
(132 mg, 73%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 9.01 (s, 1H), 8.68 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.58 (ddd, J = 1.8, 
1.2, 0.6 Hz, 1H), 8.18 (s, 1H), 7.48 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.29 (dddd, J = 7.7, 1.2, 1.2, 0.6 Hz, 
1H), 7.25 (d, J = 8.9 Hz, 2H), 7.17 (d, J = 8.9 Hz, 2H), 4.98 (hept, J = 6.8 Hz, 1H), 4.09 (s, 2H), 1.67 (d, 
J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 154.6 (Cq), 152.0 (Cq), 151.9 (CH), 141.8 (CH), 140.8 (Cq), 139.4 (Cq), 
136.0 (Cq), 131.8 (Cq), 131.5 (Cq), 131.3 (CH), 130.2 (CH), 129.9 (CH), 128.8 (CH), 128.5 (CH), 128.1 
(CH), 47.3 (CH), 41.4 (CH2), 22.6 (CH3).  
IR (ATR): ṽ = 2977, 1567, 1490, 1448, 1324, 1217, 1089, 781, 700, 647 cm−1.  
m.p.: 104–105 °C.  
MS (EI) m/z (relative intensity): 364 (16) [M(37Cl)]+, 363 (25) [M(37Cl)–H]+, 362 (46) [M(35Cl)]+, 361 
(51) [M(35Cl)–H]+, 321 (35) [M(37Cl)–i-Pr]+, 319 (100) [M(35Cl)–i-Pr]+, 283 (16) [M–i-Pr–Cl]+, 165 (7), 
142 (10), 125 (9), 43 (7). 
HR-MS (EI): m/z calcd for C21H1935ClN4+ [M]+ 362.1293, found 362.1287. 
 
6-[3-(4-Bromobenzyl)phenyl]-9-iso-propyl-9H-purine (185ak) 
The general procedure I was followed using purine 123a (119 mg, 0.50 mmol) 
and 4-bromobenzyl chloride (142k, 308 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 3:1) yielded 185ak 
(142 mg, 70%) as a pale yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.00 (s, 1H), 8.68 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.59 (ddd, J = 1.8, 
1.2, 0.6 Hz, 1H), 8.16 (s, 1H), 7.47 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.38 (d, J = 8.6 Hz, 2H), 7.28 (dddd, 
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J = 7.7, 1.2, 1.2, 0.6 Hz, 1H), 7.10 (d, J = 8.6 Hz, 2H), 4.96 (hept, J = 6.8 Hz, 1H), 4.06 (s, 2H), 1.65 (d, 
J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 154.5 (Cq), 152.0 (Cq), 151.8 (CH), 141.8 (CH), 140.7 (Cq), 139.9 (Cq), 
136.0 (Cq), 131.4 (Cq), 131.4 (CH), 131.3 (CH), 130.6 (CH), 129.8 (CH), 128.8 (CH), 128.1 (CH), 119.8 
(Cq), 47.2 (CH), 41.4 (CH2), 22.6 (CH3). 
IR (ATR): ṽ = 2977, 1567, 1486, 1325, 1218, 1070, 1011, 781, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 408 (48) [M(81Br)]+, 407 (64) [M(81Br)–H]+, 406 (48) [M(79Br)]+, 405 
(55) [M(79Br)–H]+, 365 (100) [M(81Br)–i-Pr]+, 363 (100) [M(79Br)–i-Pr]+, 283 (39) [M–i-Pr–Br]+, 165 
(14), 142 (11). 
HR-MS (EI): m/z calcd for C21H1979BrN4+ [M]+ 406.0788, found 406.0778. 
 
1-{4-{6-[3-(4-Methoxybenzyl)phenyl]-9H-purin-9-yl}phenyl}ethan-1-one (185hb) 
The general procedure I was followed using purine 123h (157 mg, 
0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 7:3) 
yielded 185hb (147 mg, 68%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 9.09 (s, 1H), 8.70 (ddd, J = 7.8, 1.8, 1.2 Hz, 
1H), 8.64 (ddd, J = 1.9, 1.8, 0.9 Hz, 1H), 8.46 (s, 1H), 8.21 (d, J = 8.9 Hz, 2H), 
7.97 (d, J = 8.9 Hz, 2H), 7.50 (dd, J = 7.8, 7.7 Hz, 1H), 7.35 (ddd, J = 7.7, 1.9, 1.2 Hz, 1H), 7.18 (d, J = 
8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 4.09 (s, 2H), 3.78 (s, 3H), 2.69 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 196.4 (Cq), 157.9 (Cq), 155.8 (Cq), 153.1 (CH), 152.0 (Cq), 142.3 (CH), 
142.1 (Cq), 138.2 (Cq), 136.4 (Cq), 135.4 (Cq), 133.0 (Cq), 131.8 (CH), 131.6 (Cq), 130.1 (CH), 129.9 
(CH), 129.8 (CH), 128.8 (CH), 128.0 (CH), 122.9 (CH), 113.9 (CH), 55.3 (CH3), 41.2 (CH2), 26.8 (CH3). 
IR (ATR): ṽ = 3112, 1679, 1557, 1509, 1233, 1173, 1026, 928, 835, 786 cm−1. 
m.p.: 159–160 °C.  
MS (EI) m/z (relative intensity): 434 (100) [M]+, 433 (63) [M–H]+, 419 (53) [M–Me]+, 210 (9), 121 
(9), 43 (16). 
HR-MS (EI): m/z calcd for C27H22N4O2+ [M]+ 434.1737, found 434.1743. 
 




The general procedure I was followed using purine 123i (128 mg, 0.50 mmol) 
and 4-methylbenzyl chloride (142f, 211 mg, 1.50 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 3:1) followed by 
recycling preparative HPLC yielded 185if (90.5 mg, 50%) as a white soild. 
1H-NMR (300 MHz, CDCl3): δ = 8.98 (s, 1H), 8.76 (ddd, J = 8.6, 5.2, 2.3 Hz, 1H), 8.71 (dd, J = 7.5, 
2.3 Hz, 1H), 8.16 (s, 1H), 7.21 (dd, J = 9.5, 8.6 Hz, 1H), 7.18 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 7.9 Hz, 
2H), 4.96 (hept, J = 6.8 Hz, 1H), 4.10 (s, 2H), 2.29 (s, 3H), 1.66 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 162.7 (d, 1JC–F = 251 Hz, Cq), 153.6 (Cq), 151.9 (Cq), 151.8 (CH), 141.7 
(CH), 136.7 (Cq), 135.5 (Cq), 132.6 (d, 3JC–F = 6 Hz, CH), 131.9 (d, 4JC–F = 3 Hz, Cq), 131.1 (Cq), 130.2 
(d, 3JC–F = 9 Hz, CH), 129.0 (CH), 128.6 (d, 2JC–F = 16 Hz, Cq), 128.4 (CH), 115.6 (d, 2JC–F = 23 Hz, CH), 
47.3 (CH), 34.9 (d, 3JC–F = 3 Hz, CH2), 22.6 (CH3), 21.0 (CH3). 
19F-NMR (282 MHz, CDCl3): δ = (–113.6)–(–113.8) (m). 
IR (ATR): ṽ = 2978, 1574, 1502, 1446, 1326, 1219, 834, 806, 646 cm−1. 
m.p.: 72–74 °C.  
MS (EI) m/z (relative intensity): 360 (90) [M]+, 359 (26) [M–H]+, 345 (2) [M–Me]+, 317 (100) [M–
i-Pr]+, 303 (9). 
HR-MS (EI): m/z calcd for C22H21FN4+ [M]+ 360.1745, found 360.1748. 
 
6-[3-(4-Methoxybenzyl)phenyl]-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (185jb) 
The general procedure I was followed using purine 123j (140 mg, 
0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 3:1) 
yielded 185jb (150 mg, 75%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.01 (s, 1H), 8.68 (ddd, J = 7.8, 1.8, 1.2 Hz, 
1H), 8.61 (ddd, J = 1.8, 1.8, 0.6 Hz, 1H), 8.32 (s, 1H), 7.46 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.30 (ddd, 
J = 7.7, 1.8, 1.2 Hz, 1H), 7.15 (d, J = 8.8 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 5.82 (dd, J = 9.9, 3.0 Hz, 
1H), 4.20–4.13 (m, 1H), 4.06 (s, 2H), 3.82–3.73 (m, 1H), 3.74 (s, 3H), 2.19–1.98 (m, 3H), 1.86–1.58 
(m, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 157.8 (Cq), 154.8 (Cq), 152.1 (CH), 151.5 (Cq), 141.8 (Cq and CH), 
135.6 (Cq), 132.9 (Cq), 131.4 (CH), 131.0 (Cq), 129.7 (CH), 128.6 (CH), 127.8 (CH), 113.7 (CH), 81.9 
(CH), 68.7 (CH2), 55.1 (CH3), 41.1 (CH2), 31.7 (CH2), 24.8 (CH2), 22.8 (CH2). 
IR (ATR): ṽ = 2946, 1567, 1509, 1323, 1243, 1083, 1042, 734, 701, 643 cm−1.  
MS (EI) m/z (relative intensity): 400 (41) [M]+, 372 (11) [M–Et]+, 316 (100) [M–THP]+, 315 (76), 301 
(52), 121 (22), 85 (33), 67 (11), 41 (12). 
HR-MS (EI): m/z calcd for C24H24N4O2+ [M]+ 400.1894, found 400.1903. 
 
N,N-Di-iso-propyl-4-{{6-[3-(4-methoxybenzyl)phenyl]-9H-purin-9-yl}methyl}benzamide (185kb) 
The general procedure I was followed using purine 123k (207 mg, 
0.50 mmol) and 4-methoxybenzyl chloride (142b, 235 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 2:3) 
yielded 185kb (167 mg, 63%) as a white soild. 
1H-NMR (400 MHz, CDCl3): δ = 9.04 (s, 1H), 8.68 (ddd, J = 7.8, 1.8, 1.2 Hz, 
1H), 8.62 (ddd, J = 1.8, 1.8, 0.6 Hz, 1H), 8.10 (s, 1H), 7.47 (dd, J = 7.8, 7.7 Hz, 
1H), 7.33–7.28 (m, 5H), 7.15 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.47 (s, 2H), 4.06 (s, 2H), 
3.75 (s, 3H), 3.87–3.39 (br, 2H), 1.78–0.88 (br, 12H). 
13C-NMR (100 MHz, CDCl3): δ = 170.1 (Cq), 157.9 (Cq), 155.0 (Cq), 152.6 (CH), 152.4 (Cq), 144.0 (CH), 
142.0 (Cq), 139.2 (Cq), 135.7 (Cq), 133.1 (Cq), 131.6 (CH), 130.9 (Cq), 129.9 (CH), 129.8 (CH), 128.8 
(CH), 127.9 (CH), 127.8 (CH), 126.4 (CH), 113.8 (CH), 55.2 (CH3), 51.6–50.0 (br, CH), 46.8 (CH2), 
46.6–45.2 (br, CH), 41.1 (CH2), 20.6 (CH3). 
IR (ATR): ṽ = 2967, 1623, 1568, 1509, 1439, 1323, 1244, 1035, 794, 703 cm−1. 
m.p.: 68–70 °C.  
MS (EI) m/z (relative intensity): 533 (56) [M]+, 532 (10) [M–H]+, 518 (5) [M–Me]+, 490 (21) [M–
i-Pr]+, 433 (100) [M–N(i-Pr)2]+, 405 (18) [M–C(O)N(i-Pr)2]+, 315 (25), 217 (14), 118 (19), 91 (23) 
[Bn]+, 58 (14), 43 (52). 
HR-MS (EI): m/z calcd for C33H35N5O2+ [M]+ 533.2785, found 533.2807. 
 
 




The general procedure I was followed using purine 123a (119 mg, 
0.50 mmol) and 3,5-dimethoxybenzyl chloride (142l, 280 mg, 1.50 mmol). 
After 20 h, purification by column chromatography (n-hexane/EtOAc 2:1) 
yielded 185al (130 mg, 67%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.99 (s, 1H), 8.67 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.62 (ddd, J = 1.8, 
1.5, 0.6 Hz, 1H), 8.14 (s, 1H), 7.46 (ddd, J = 7.8, 7.7, 0.6 Hz, 1H), 7.32 (dddd, J = 7.7, 1.5, 1.2, 0.6 Hz, 
1H), 6.40 (d, J = 2.3 Hz, 2H), 6.29 (t, J = 2.3 Hz, 1H), 4.94 (hept, J = 6.8 Hz, 1H), 4.05 (s, 2H), 3.72 (s, 
6H), 1.63 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 160.6 (Cq), 154.5 (Cq), 151.9 (Cq), 151.8 (CH), 143.1 (Cq), 141.7 (CH), 
140.9 (Cq), 135.8 (Cq), 131.3 (Cq), 131.3 (CH), 129.8 (CH), 128.6 (CH), 127.9 (CH), 107.0 (CH), 98.0 
(CH), 55.1 (CH3), 47.2 (CH), 42.2 (CH2), 22.5 (CH3). 
IR (ATR): ṽ = 2936, 1567, 1457, 1324, 1204, 1145, 1063, 791, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 388 (97) [M]+, 387 (58) [M–H]+, 373 (4) [M–Me]+, 345 (100) [M–
i-Pr]+, 331 (10) [M–i-Pr–Me]+, 313 (20), 299 (8), 173 (8), 151 (6), 43 (14). 
HR-MS (EI): m/z calcd for C23H24N4O2+ [M]+ 388.1894, found 388.1894. 
 
9-iso-Propyl-6-[3-(naphthalen-1-ylmethyl)phenyl]-9H-purine (185am) 
The general procedure I was followed using purine 123a (119 mg, 0.50 mmol) 
and 1-(chloromethyl)naphthalene (142m, 265 mg, 1.50 mmol) at 80 °C. After 
20 h, purification by column chromatography (n-hexane/EtOAc 3:1) yielded 
185am (127 mg, 67%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 9.02 (s, 1H), 8.73 (ddd, J = 1.8, 1.5, 0.6 Hz, 1H), 8.67 (ddd, J = 7.8, 
1.8, 1.2 Hz, 1H), 8.17 (s, 1H), 8.09–8.03 (m, 1H), 7.89–7.83 (m, 1H), 7.76 (br d, J = 8.1 Hz, 1H), 7.48–
7.40 (m, 4H), 7.35 (ddt, J = 7.0, 1.4, 0.8 Hz, 1H), 7.26 (dddd, J = 7.6, 1.5, 1.2, 0.6 Hz, 1H), 4.98 (hept, 
J = 6.8 Hz, 1H), 4.61 (s, 2H), 1.67 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 154.8 (Cq), 152.0 (Cq), 151.9 (CH), 141.8 (CH), 141.0 (Cq), 136.5 (Cq), 
135.9 (Cq), 133.8 (Cq), 132.0 (Cq), 131.5 (Cq), 131.2 (CH), 129.9 (CH), 128.7 (CH), 128.5 (CH), 127.9 
(CH), 127.3 (CH), 127.1 (CH), 125.9 (CH), 125.5 (CH), 125.4 (CH), 124.2 (CH), 47.3 (CH), 39.2 (CH2), 
22.6 (CH3). 
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IR (ATR): ṽ = 2978, 1569, 1444, 1324, 1225, 791, 705, 647, 571 cm−1.  
m.p.: 114–116 °C.  
MS (ESI) m/z (relative intensity): 757 (6) [2M+H]+, 401 (2) [M+Na]+, 379 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C25H23N4+ [M+H]+ 379.1917, found 379.1920. 
 
1,4-Bis[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzene (185an) 
Purine 123a (297 mg, 1.25 mmol), α,α’-dichloro-p-xylene 
(142n, 87.6 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 
17.7 mg, 50.0 μmol, 10 mol %), PPh3 (13.1 mg, 50.0 μmol, 
10 mol %) and K2CO3 (276 mg, 2.00 mmol) were placed in a 
pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. 
1,4-Dioxane (2.0 mL) was then added and the mixture was stirred at 60 °C. After 20 h, the resulting 
mixture was filtered through a pad of silica gel and washed with EtOAc. The filtrate was 
concentrated in vacuo. Purification of the residue by column chromatography (n-hexane/EtOAc 
1:2) yielded 185an (139 mg, 48%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 8.99 (s, 2H), 8.65 (ddd, J = 7.8, 1.8, 1.2 Hz, 2H), 8.61 (ddd, J = 1.8, 
1.8, 0.6 Hz, 2H), 8.15 (s, 2H), 7.45 (ddd, J = 7.8, 7.7, 0.6 Hz, 2H), 7.30 (ddd, J = 7.7, 1.8, 1.2 Hz, 2H), 
7.16 (s, 4H), 4.96 (hept, J = 6.8 Hz, 2H), 4.08 (s, 4H), 1.65 (d, J = 6.8 Hz, 12H). 
13C-NMR (125 MHz, CDCl3): δ = 154.7 (Cq), 151.9 (Cq), 151.8 (CH), 141.7 (CH), 141.5 (Cq), 138.6 (Cq), 
135.8 (Cq), 131.4 (Cq and CH), 129.9 (CH), 128.9 (CH), 128.6 (CH), 127.8 (CH), 47.2 (CH), 41.6 (CH2), 
22.6 (CH3). 
IR (ATR): ṽ = 2975, 1570, 1441, 1326, 1218, 790, 699, 646, 582 cm−1.  
m.p.: 156–158 °C. 
MS (EI) m/z (relative intensity): 578 (100) [M]+, 536 (17) [M–i-Pr]+, 493 (12) [M–i-Pr–i-Pr]+, 285 
(21), 246 (12), 209 (17), 43 (6). 








The general procedure I was followed using purine 123a (119 mg, 0.50 mmol) 
and (1-chloroethyl)benzene (142a, 211 mg, 1.50 mmol). After 20 h, purification 
by column chromatography (n-hexane/EtOAc 3:1) yielded 185aa (149 mg, 87%) 
as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.68 (dd, J = 1.8, 1.6 Hz, 1H), 8.66 
(ddd, J = 7.7, 1.6, 1.4 Hz, 1H), 8.18 (s, 1H), 7.47 (dd, J = 7.7, 7.7 Hz, 1H), 7.35–7.33 (m, 1H), 7.31–
7.27 (m, 4H), 7.19–7.16 (m, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.32 (q, J = 7.2 Hz, 1H), 1.74 (d, J = 
7.2 Hz, 3H), 1.67 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 154.9 (Cq), 152.0 (Cq), 151.9 (CH), 146.7 (Cq), 146.1 (Cq), 141.8 (CH), 
135.8 (Cq), 131.5 (Cq), 130.2 (CH), 128.6 (CH), 128.6 (CH), 128.3 (CH), 127.9 (CH), 127.6 (CH), 125.9 
(CH), 47.3 (CH), 45.0 (CH), 22.7 (CH3), 22.0 (CH3).  
IR (ATR): ṽ = 2973, 1566, 1494, 1446, 1324, 1218, 799, 700, 646, 573 cm−1.  
MS (EI) m/z (relative intensity): 342 (81) [M]+, 341 (63) [M–H]+, 327 (34) [M–Me]+, 299 (95) [M–
i-Pr]+, 285 (100) [M–i-Pr–Me]+, 165 (14), 142 (8). 
HR-MS (EI): m/z calcd for C22H22N4+ [M]+ 342.1839, found 342.1832. 
 
5.3.4.3 Characterization Data for 187 
5,5-Difluoro-10-{4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]phenyl}-1,3,7,9-tetramethyl-5H-
4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine (187a) 
The general procedure J was followed using purine 123a (23.9 mg, 
0.10 mmol) and benzyl chloride 186a (75 mg, 0.20 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 7:3) 
yielded 187a (26.1 mg, 45%) as an orange solid.  
1H-NMR (600 MHz, CDCl3): δ = 9.00 (s, 1H), 8.71 (ddd, J = 7.8, 1.7, 1.3 Hz, 1H), 8.57 (dd, J = 2.0, 
1.7 Hz, 1H), 8.18 (s, 1H), 7.50 (dd, J = 7.8, 7.7 Hz, 1H), 7.37 (d, J = 8.1 Hz, 2H), 7.31 (ddd, J = 7.7, 
2.0, 1.3 Hz, 1H), 7.20 (d, J = 8.1 Hz, 2H), 5.96 (s, 2H), 4.99 (hept, J = 6.8 Hz, 1H), 4.22 (s, 2H), 2.54 
(s, 6H), 1.68 (d, J = 6.8 Hz, 6H), 1.39 (s, 6H). 
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13C-NMR (125 MHz, CDCl3): δ = 155.1 (Cq), 154.6 (Cq), 152.0 (Cq), 151.9 (CH), 143.1 (Cq), 141.8 (Cq 
and CH), 141.8 (Cq), 141.0 (Cq), 136.0 (Cq), 132.7 (Cq), 131.4 (Cq), 131.2 (CH), 129.8 (CH), 129.7 (CH), 
128.8 (CH), 128.1 (CH), 128.0 (CH), 121.0 (CH), 47.3 (CH), 41.7 (CH2), 22.7 (CH3), 14.6 (CH3), 14.5 
(CH3). 
11B-NMR (128 MHz, CDCl3): δ = 0.8 (t, 1JB–F = 33.1 Hz). 
19F-NMR (376 MHz, CDCl3): δ = –146.3 (q, 1JF–B = 33.1 Hz). 
IR (ATR): ṽ = 2925, 1542, 1508, 1306, 1191, 1155, 976, 731, 703, 647 cm−1.  
m.p.: 170–172 °C (decomp.). 
MS (ESI) m/z (relative intensity): 1150 (5) [2M+H]+, 597 (4) [M+Na]+, 575 (100) [M+H]+, 177 (6), 
117 (19). 
HR-MS (ESI): m/z calcd for C34H34BF2N6+ [M+H]+ 575.2906, found 575.2903. 
UV-Vis: λmax (1.0 mg/L in CHCl3) = 502 nm. 




d][1,3]dioxol-4-yl}methyl diethyl phosphate (187b) 
The general procedure J was followed using purine 
123l (50.5 mg, 0.10 mmol) and benzyl chloride 186a 
(75 mg, 0.20 mmol). After 20 h, purification by 
column chromatography (n-hexane/EtOAc 3:7) 
yielded 187b (12.9 mg, 15%) as an orange solid.  
1H-NMR (300 MHz, CDCl3): δ = 9.01 (s, 1H), 8.71 (d, J = 7.8 Hz, 1H), 8.57 (s, 1H), 8.29 (s, 1H), 7.50 
(dd, J = 7.8, 7.8 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 8.0 Hz, 2H), 6.27 
(d, J = 2.6 Hz, 1H), 5.97 (s, 2H), 5.45 (dd, J = 6.3, 2.6 Hz, 1H), 5.13 (dd, J = 6.3, 3.0 Hz, 1H), 4.58–
4.51 (m, 1H), 4.30 (ddd, J = 10.8, 6.3, 4.4 Hz, 1H), 4.26–4.17 (m, 1H), 4.22 (s, 2H), 4.13–3.98 (m, 
4H), 2.54 (s, 6H), 1.66 (s, 3H), 1.42 (s, 3H), 1.40 (s, 6H), 1.31–1.22 (m, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 155.3 (Cq), 155.1 (Cq), 152.5 (CH), 151.7 (Cq), 143.2 (CH), 143.1 (Cq), 
141.8 (Cq), 141.8 (Cq), 141.2 (Cq), 135.7 (Cq), 132.8 (Cq), 131.7 (Cq), 131.6 (CH), 131.5 (Cq), 129.9 
5.3 Experimental Procedures and Analytical Data 
 
253 
(CH), 129.8 (CH), 128.9 (CH), 128.3 (CH), 128.1 (CH), 121.1 (CH), 114.8 (Cq), 91.1 (CH), 85.2 (d,        
3JC–P = 8 Hz, CH), 84.2 (CH), 81.3 (CH), 66.6 (d, 2JC–P = 6 Hz, CH2), 64.1 (d, 2JC–P = 6 Hz, CH2), 64.1 (d, 
2JC–P = 6 Hz, CH2), 41.6 (CH2), 27.2 (CH3), 25.3 (CH3), 16.1 (d, 3JC–P = 7 Hz, CH3), 16.1 (d, 3JC–P = 7 Hz, 
CH3), 14.6 (t, 4JC–F = 2 Hz, CH3), 14.4 (CH3). 
11B-NMR (128 MHz, CDCl3): δ = 0.8 (t, 1JB–F = 33.0 Hz). 
19F-NMR (376 MHz, CDCl3): δ = –146.3 (q, 1JF–B = 33.0 Hz). 
31P-NMR (162 MHz, CDCl3): δ = (–0.8)–(–1.2) (m). 
IR (ATR): ṽ = 2927, 1543, 1509, 1306, 1192, 1155, 1020, 972, 752, 643 cm−1.  
MS (ESI) m/z (relative intensity): 863 (100) [M+Na]+, 841 (13) [M+H]+, 821 (16) [M–F]+. 
HR-MS (ESI): m/z calcd for C43H48BF2N6O7PNa+ [M+Na]+ 863.3283, found 863.3273. 
UV-Vis: λmax (1.0 mg/L in CHCl3) = 502 nm. 
Em: λmax (1.0 mg/L in CHCl3) = 514 nm. 
 
Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-L-isoleucinate (187c) 
The general procedure J was followed using purine 123a (59.6 mg, 
0.25 mmol) and benzyl chloride 186b (149 mg, 0.50 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 
1:1) yielded 187c (92.4 mg, 74%) as a viscous colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.00 (s, 1H), 8.68 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.60 (dd, J = 1.8, 
1.6 Hz, 1H), 8.18 (s, 1H), 7.72 (d, J = 8.2 Hz, 2H), 7.48 (dd, J = 7.8, 7.7 Hz, 1H), 7.32 (d, J = 8.2 Hz, 
2H), 7.31–7.27 (m, 1H), 6.61 (d, J = 8.5 Hz, 1H), 4.97 (hept, J = 6.8 Hz, 1H), 4.79 (dd, J = 8.5, 4.9 Hz, 
1H), 4.16 (s, 2H), 3.74 (s, 3H), 2.06–1.85 (m, 1H), 1.66 (d, J = 6.8 Hz, 6H), 1.58–1.42 (m, 1H), 1.31–
1.13 (m, 1H), 0.94 (d, J = 6.5 Hz, 3H), 0.94 (t, J = 7.3 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 172.4 (Cq), 166.8 (Cq), 154.5 (Cq), 152.0 (Cq), 151.9 (CH), 145.0 (Cq), 
141.9 (CH), 140.5 (Cq), 136.0 (Cq), 131.9 (Cq), 131.4 (Cq), 131.4 (CH), 129.9 (CH), 129.1 (CH), 128.8 
(CH), 128.1 (CH), 127.2 (CH), 56.7 (CH), 52.1 (CH3), 47.3 (CH), 41.9 (CH2), 38.3 (CH), 25.4 (CH2), 22.6 
(CH3), 15.5 (CH3), 11.7 (CH3). 
IR (ATR): ṽ = 3311, 2966, 1737, 1646, 1569, 1496, 1326, 1218, 733, 647 cm−1.  
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MS (EI) m/z (relative intensity): 499 (9) [M]+, 440 (53) [M–CO2Me]+, 355 (100) [M–(H-Leu-OMe)]+, 
328 (19), 285 (32), 156 (12). 




The general procedure J was followed using purine 123l (126 mg, 
0.25 mmol) and benzyl chloride S-186c (142 mg, 0.50 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 
1:3) yielded 187d (110 mg, 59%) as a viscous colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.02 (s, 1H), 8.68 (ddd, J = 7.8, 1.6, 
1.4 Hz, 1H), 8.60 (dd, J = 1.8, 1.6 Hz, 1H), 8.29 (s, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 7.8, 
7.7 Hz, 1H), 7.33 (d, J = 8.3 Hz, 2H), 7.31 (ddd, J = 7.7, 1.8, 1.4 Hz, 1H), 6.58 (d, J = 8.7 Hz, 1H), 6.26 
(d, J = 2.5 Hz, 1H), 5.45 (dd, J = 6.3, 2.5 Hz, 1H), 5.13 (dd, J = 6.3, 3.1 Hz, 1H), 4.76 (dd, J = 8.7, 
4.9 Hz, 1H), 4.53 (dddd, J = 4.9, 4.5, 3.1, 1.2 Hz, 1H), 4.29 (ddd, J = 11.0, 6.2, 4.5 Hz, 1H), 4.21 (ddd, 
J = 11.0, 6.9, 4.9 Hz, 1H), 4.17 (s, 2H), 4.10–4.00 (m, 4H), 3.76 (s, 3H), 2.25 (pd, J = 6.9, 4.9 Hz, 1H), 
1.65 (s, 3H), 1.41 (s, 3H), 1.27 (td, J = 7.1, 1.0 Hz, 3H), 1.24 (td, J = 7.1, 1.0 Hz, 3H), 0.99 (d, J = 
6.9 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 172.5 (Cq), 166.9 (Cq), 155.0 (Cq), 152.4 (CH), 151.6 (Cq), 144.9 (Cq), 
143.1 (CH), 140.7 (Cq), 135.7 (Cq), 132.0 (Cq), 131.6 (Cq and CH), 130.0 (CH), 129.1 (CH), 128.9 (CH), 
128.2 (CH), 127.3 (CH), 114.7 (Cq), 91.1 (CH), 85.3 (d, 3JC–P = 8 Hz, CH), 84.2 (CH), 81.4 (CH), 66.6 (d, 
2JC–P = 6 Hz, CH2), 64.0 (d, 2JC–P = 6 Hz, CH2), 63.9 (d, 2JC–P = 6 Hz, CH2), 57.4 (CH), 52.2 (CH3), 41.9 
(CH2), 31.7 (CH), 27.3 (CH3), 25.4 (CH3), 19.1 (CH3), 18.0 (CH3), 16.1 (d, 3JC–P = 7 Hz, CH3). 
31P{1H }-NMR (121 MHz, CDCl3): δ = –1.1 (s). 
IR (ATR): ṽ = 3327, 2981, 1739, 1648, 1569, 1498, 1260, 1209, 1020, 733 cm−1.  
MS (ESI) m/z (relative intensity): 774 (33) [M+Na]+, 752 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C37H47N5O10P+ [M+H]+ 752.3055, found 752.3055. 
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Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-L-valinate (S-187e) 
The general procedure J was followed using purine 123a (59.6 mg, 
0.25 mmol) and benzyl chloride S-186c (142 mg, 0.50 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 
1:1) yielded S-187e (85.3 mg, 70%) as a white solid. 
1H-NMR (600 MHz, CDCl3): δ = 9.00 (s, 1H), 8.68 (ddd, J = 7.8, 1.6, 1.2 Hz, 1H), 8.60 (dd, J = 1.8, 
1.6 Hz, 1H), 8.18 (s, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.49 (dd, J = 7.8, 7.7 Hz, 1H), 7.33 (d, J = 8.4 Hz, 
2H), 7.30 (ddd, J = 7.7, 1.8, 1.2 Hz, 1H), 6.57 (d, J = 8.7 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.76 (dd, 
J = 8.7, 4.9 Hz, 1H), 4.17 (s, 2H), 3.75 (s, 3H), 2.25 (heptd, J = 6.9, 4.9 Hz, 1H), 1.67 (d, J = 6.8 Hz, 
6H), 0.99 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 172.5 (Cq), 167.0 (Cq), 154.5 (Cq), 152.0 (Cq), 151.9 (CH), 145.0 (Cq), 
141.9 (CH), 140.6 (Cq), 136.1 (Cq), 132.0 (Cq), 131.4 (Cq), 131.4 (CH), 129.9 (CH), 129.1 (CH), 128.9 
(CH), 128.1 (CH), 127.2 (CH), 57.4 (CH), 52.2 (CH3), 47.3 (CH), 41.9 (CH2), 31.7 (CH), 22.6 (CH3), 19.1 
(CH3), 18.0 (CH3). 
IR (ATR): ṽ = 3321, 2965, 1737, 1644, 1568, 1495, 1325, 1214, 783, 646 cm−1. 
m.p.: 62–64 °C.  
MS (EI) m/z (relative intensity): 485 (14) [M]+, 453 (8) [M–OMe]+, 426 (49) [M–CO2Me]+, 355 (100) 
[M–(H-Val-OMe)]+, 328 (23), 285 (34), 165 (7), 156 (13), 142 (8), 43 (16). 
HR-MS (EI): m/z calcd for C28H31N5O3+ [M]+ 485.2421, found 485.2409. 
 
Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-D-valinate (R-187e) 
The general procedure J was followed using purine 123a (59.6 mg, 
0.25 mmol) and benzyl chloride R-186c (142 mg, 0.50 mmol). 
After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:1) yielded R-187e (92.9 mg, 77%) as a viscous 
colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.68 (ddd, J = 7.8, 1.5, 1.3 Hz, 1H), 8.61 (dd, J = 1.7, 
1.5 Hz, 1H), 8.18 (s, 1H), 7.73 (d, J = 8.5 Hz, 2H), 7.49 (dd, J = 7.8, 7.7 Hz, 1H), 7.33 (d, J = 8.5 Hz, 
2H), 7.30 (ddd, J = 7.7, 1.7, 1.3 Hz, 1H), 6.57 (d, J = 8.7 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.76 (dd, 
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J = 8.7, 4.9 Hz, 1H), 4.18 (s, 2H), 3.76 (s, 3H), 2.25 (pd, J = 6.9, 4.9 Hz, 1H), 1.67 (d, J = 6.8 Hz, 6H), 
0.99 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 172.5 (Cq), 167.0 (Cq), 154.5 (Cq), 152.0 (Cq), 151.9 (CH), 145.0 (Cq), 
141.9 (CH), 140.6 (Cq), 136.1 (Cq), 132.0 (Cq), 131.5 (Cq), 131.4 (CH), 129.9 (CH), 129.2 (CH), 128.9 
(CH), 128.1 (CH), 127.2 (CH), 57.4 (CH), 52.2 (CH3), 47.3 (CH), 41.9 (CH2), 31.7 (CH), 22.7 (CH3), 19.1 
(CH3), 18.0 (CH3). 
IR (ATR): ṽ = 3319, 2966, 1736, 1644, 1568, 1495, 1325, 1213, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 485 (10) [M]+, 426 (46) [M–CO2Me]+, 355 (100) [M–(H-Val-OMe)]+, 
328 (15), 285 (31), 156 (14). 
HR-MS (ESI): m/z calcd for C28H32N5O3+ [M+H]+ 486.2500, found 486.2497. 
 
Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-L-serinate (S-187f) 
The general procedure J was followed using purine 123a (59.6 mg, 
0.25 mmol) and benzyl chloride S-186d (136 mg, 0.50 mmol). 
After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:9) yielded S-187f (59.1 mg, 50%) as a colorless 
oil. 
1H-NMR (500 MHz, CDCl3): δ = 8.99 (s, 1H), 8.64 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.55 (dd, J = 1.7, 
1.6 Hz, 1H), 8.19 (s, 1H), 7.71 (d, J = 8.3 Hz, 2H), 7.48 (dd, J = 7.8, 7.7 Hz, 1H), 7.30–7.26 (m, 1H), 
7.28 (d, J = 8.3 Hz, 2H), 7.12 (d, J = 7.3 Hz, 1H), 4.97 (hept, J = 6.8 Hz, 1H), 4.81 (ddd, J = 7.3, 3.7, 
3.5 Hz, 1H), 4.14 (s, 2H), 4.02 (dd, J = 11.2, 3.7 Hz, 1H), 3.97 (dd, J = 11.2, 3.5 Hz, 1H), 3.77 (s, 3H), 
3.18 (br s, 1H), 1.66 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 171.0 (Cq), 167.5 (Cq), 154.6 (Cq), 152.1 (Cq), 152.0 (CH), 145.3 (Cq), 
142.1 (CH), 140.6 (Cq), 136.0 (Cq), 131.5 (CH), 131.4 (Cq), 131.3 (Cq), 130.0 (CH), 129.2 (CH), 129.0 
(CH), 128.2 (CH), 127.4 (CH), 63.4 (CH2), 55.1 (CH), 52.8 (CH3), 47.3 (CH), 41.8 (CH2), 22.5 (CH3). 
IR (ATR): ṽ = 3355, 2980, 1741, 1644, 1569, 1497, 1326, 1219, 703, 647 cm−1.  
MS (EI) m/z (relative intensity): 473 (7) [M]+, 472 (5) [M–H]+, 455 (5) [M–H2O]+, 443 (32) [M–
CHOH]+, 414 (8) [M–CO2Me]+, 400 (13), 372 (12), 355 (100) [M–(H-Ser-OMe)]+, 328 (23), 285 (41), 
165 (10), 156 (20), 142 (13). 
HR-MS (EI): m/z calcd for C26H27N5O4+ [M]+ 473.2058, found 473.2079. 
5.3 Experimental Procedures and Analytical Data 
 
257 
Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-D/L-serinate (rac-187f) 
The general procedure J was followed using purine 123a (59.6 mg, 
0.25 mmol) and benzyl chloride rac-186d (136 mg, 0.50 mmol). 
After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:9) yielded rac-187f (65.5 mg, 55%) as a white 
solid. 
1H-NMR (600 MHz, CDCl3): δ = 8.99 (s, 1H), 8.65 (ddd, J = 7.8, 1.6, 1.5 Hz, 1H), 8.57 (dd, J = 1.6, 
1.6 Hz, 1H), 8.18 (s, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.48 (dd, J = 7.8, 7.7 Hz, 1H), 7.31–7.28 (m, 1H), 
7.29 (d, J = 8.3 Hz, 2H), 7.09 (d, J = 7.2 Hz, 1H), 4.97 (hept, J = 6.8 Hz, 1H), 4.83 (ddd, J = 7.2, 3.7, 
3.5 Hz, 1H), 4.15 (s, 2H), 4.03 (dd, J = 11.3, 3.7 Hz, 1H), 3.99 (dd, J = 11.3, 3.5 Hz, 1H), 3.78 (s, 3H), 
3.01 (br s, 1H), 1.66 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 170.9 (Cq), 167.3 (Cq), 154.5 (Cq), 152.0 (Cq), 151.9 (CH), 145.3 (Cq), 
142.0 (CH), 140.5 (Cq), 136.0 (Cq), 131.4 (Cq and CH), 131.3 (Cq), 129.9 (CH), 129.1 (CH), 128.9 (CH), 
128.1 (CH), 127.3 (CH), 63.5 (CH2), 55.2 (CH), 52.8 (CH3), 47.3 (CH), 41.9 (CH2), 22.6 (CH3). 
IR (ATR): ṽ = 3333, 2976, 1739, 1643, 1569, 1496, 1326, 1218, 703, 646 cm−1.  
m.p.: 73–75 °C. 
MS (EI) m/z (relative intensity): 473 (4) [M]+, 472 (3) [M–H]+, 455 (11) [M–H2O]+, 443 (29) [M–
CHOH]+, 414 (5) [M–CO2Me]+, 400 (9), 372 (7), 355 (100) [M–(H-Ser-OMe)]+, 328 (16), 311 (14), 
285 (38), 165 (9), 156 (20), 142 (13). 




The general procedure J was followed using purine 123a 
(59.6 mg, 0.25 mmol) and benzyl chloride 186e (196 mg, 
0.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 1:1) yielded 187g 
(117 mg, 79%) as a viscous colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.69 (ddd, J = 7.8, 1.6, 1.3 Hz, 1H), 8.62 (dd, J = 1.9, 
1.6 Hz, 1H), 8.18 (s, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 7.8, 7.7 Hz, 1H), 7.33 (d, J = 8.3 Hz, 
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2H), 7.30 (ddd, J = 7.7, 1.9, 1.3 Hz, 1H), 7.14 (d, J = 7.8 Hz, 2H), 7.06 (d, J = 7.8 Hz, 2H), 6.86 (d, J = 
7.5 Hz, 1H), 4.98 (hept, J = 6.9 Hz, 1H), 4.98 (ddd, J = 7.5, 5.3, 5.1 Hz, 1H), 4.17 (s, 2H), 3.76 (s, 3H), 
3.67 (dAB, J = 13.5 Hz, 1H), 3.66 (dAB, J = 13.5 Hz, 1H), 3.01 (dABd, J = 13.9, 5.1 Hz, 1H), 2.96 (dABd, J 
= 13.9, 5.3 Hz, 1H), 2.27 (s, 3H), 1.67 (d, J = 6.9 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 171.2 (Cq), 166.7 (Cq), 154.5 (Cq), 152.0 (Cq), 151.9 (CH), 145.2 (Cq), 
141.9 (CH), 140.5 (Cq), 136.8 (Cq), 136.1 (Cq), 134.4 (Cq), 131.4 (Cq), 131.4 (CH), 129.9 (CH), 129.2 
(CH), 129.1 (CH), 128.8 (CH), 128.6 (CH), 128.1 (CH), 127.3 (CH), 52.7 (CH3), 52.0 (CH), 47.3 (CH), 
41.9 (CH2), 36.5 (CH2), 33.5 (CH2), 22.6 (CH3), 21.1 (CH3). 
IR (ATR): ṽ = 3329, 2979, 1741, 1650, 1569, 1494, 1325, 1216, 731, 647 cm−1.  
MS (ESI) m/z (relative intensity): 1209 (16) [2M+Na]+, 1187 (9) [2M+H]+, 616 (100) [M+Na]+, 594 
(47) [M+H]+. 
HR-MS (ESI): m/z calcd for C34H35N5O3SNa+ [M+Na]+ 616.2353, found 616.2372. 
 
Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-L-tryptophanate (187h) 
The general procedure J was followed using purine 123a 
(59.6 mg, 0.25 mmol) and benzyl chloride 186f (186 mg, 
0.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:2) yielded 187h (96.5 mg, 67%) as a viscous 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.01 (s, 1H), 8.67 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.58 (dd, J = 1.8, 
1.6 Hz, 1H), 8.23 (br s, 1H), 8.18 (s, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.53 (dd, J = 7.9, 1.1 Hz, 1H), 7.48 
(dd, J = 7.8, 7.7 Hz, 1H), 7.32 (d, J = 8.2, 1.0 Hz, 1H), 7.30–7.26 (m, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.16 
(ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.06 (ddd, J = 7.9, 7.0, 1.0 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.63 (d, J 
= 7.7 Hz, 1H), 5.12 (dt, J = 7.7, 5.3 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.13 (s, 2H), 3.69 (s, 3H), 3.42 
(d, J = 5.3 Hz, 2H), 1.67 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 172.2 (Cq), 166.6 (Cq), 154.5 (Cq), 152.0 (Cq), 151.8 (CH), 144.9 (Cq), 
142.0 (CH), 140.6 (Cq), 136.0 (Cq), 135.9 (Cq), 131.7 (Cq), 131.4 (CH), 131.4 (Cq), 129.9 (CH), 129.1 
(CH), 128.9 (CH), 128.1 (CH), 127.5 (Cq), 127.2 (CH), 122.7 (CH), 122.2 (CH), 119.6 (CH), 118.6 (CH), 
111.2 (CH), 110.0 (Cq), 53.4 (CH), 52.4 (CH3), 47.3 (CH), 41.8 (CH2), 27.7 (CH2), 22.6 (CH3). 
IR (ATR): ṽ = 3300, 2980, 1737, 1644, 1570, 1495, 1327, 1218, 736, 647 cm−1.  
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MS (ESI) m/z (relative intensity): 1168 (5) [2M+Na]+, 1145 (19) [2M+H]+, 595 (10) [M+Na]+, 573 
(100) [M+H]+. 
HR-MS (ESI): m/z calcd for C34H33N6O3+ [M+H]+ 573.2609, found 573.2608. 
 
Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-L-tyrosinate (187i) 
The general procedure J was followed using purine 123a 
(59.6 mg, 0.25 mmol) and benzyl chloride 186g (174 mg, 
0.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 1:2) yielded 187i (72.2 mg, 
53%) as a viscous colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.62 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.53 (dd, J = 1.8, 
1.6 Hz, 1H), 8.20 (s, 1H), 7.61 (d, J = 8.3 Hz, 2H), 7.45 (dd, J = 7.8, 7.7 Hz, 1H), 7.28–7.25 (m, 1H), 
7.23 (d, J = 8.3 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 6.86 (br s, 1H), 6.69 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 
7.7 Hz, 1H), 5.00 (dt, J = 7.7, 5.6 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.10 (s, 2H), 3.72 (s, 3H), 3.16 
(dd, J = 14.0, 5.6 Hz, 1H), 3.09 (dd, J = 14.0, 5.6 Hz, 1H), 1.66 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 172.0 (Cq), 166.8 (Cq), 155.3 (Cq), 154.7 (Cq), 152.0 (Cq), 151.9 (CH), 
145.1 (Cq), 142.1 (CH), 140.6 (Cq), 135.8 (Cq), 131.6 (Cq), 131.5 (CH), 131.3 (Cq), 130.3 (CH), 130.0 
(CH), 129.1 (CH), 128.9 (CH), 128.1 (CH), 127.2 (CH), 127.1 (Cq), 115.6 (CH), 53.7 (CH), 52.4 (CH3), 
47.4 (CH), 41.8 (CH2), 37.1 (CH2), 22.6 (CH3). 
IR (ATR): ṽ = 3269, 2978, 1736, 1639, 1569, 1326, 1217, 784, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 549 (3) [M]+, 490 (5) [M–CO2Me]+, 443 (100) [M–(4-OHBn)]+, 400 
(40) [M–(4-OHBn)–iPr]+, 372 (24), 355 (58) [M–(H-Tyr-OMe)]+, 328 (37), 313 (18), 285 (45), 178 (8), 
147 (7), 107 (19), 43 (8). 
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Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-L-prolyl-L-leucinate (187j) 
The general procedure J was followed using purine 123a 
(59.6 mg, 0.25 mmol) and benzyl chloride 186h (198 mg, 
0.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:4) yielded 187j (107 mg, 72%) as a viscous 
colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 8.99 (s, 1H), 8.68 (d, J = 7.8 Hz, 1H), 8.58 (s, 1H), 8.18 (s, 1H), 7.48 
(dd, J = 7.8, 7.8 Hz, 1H), 7.41 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.28 
(d, J = 8.0 Hz, 2H), 4.98 (hept, J = 6.8 Hz, 1H), 4.78 (dd, J = 7.9, 4.7 Hz, 1H), 4.54 (ddd, J = 8.0, 7.8, 
4.5 Hz, 1H), 4.14 (s, 2H), 3.71 (s, 3H), 3.54–3.48 (m, 1H), 3.48–3.42 (m, 1H), 2.48–2.38 (m, 1H), 
2.06–1.97 (m, 2H), 1.83–1.75 (m, 1H), 1.66 (d, J = 6.8 Hz, 6H), 1.67–1.53 (m, 3H), 0.88 (d, J = 6.1 Hz, 
3H), 0.87 (d, J = 6.4 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 173.0 (Cq), 170.9 (Cq), 170.7 (Cq), 154.5 (Cq), 152.0 (Cq), 151.9 (CH), 
143.4 (Cq), 141.9 (CH), 140.6 (Cq), 136.0 (Cq), 133.9 (Cq), 131.4 (Cq and CH), 129.9 (CH), 128.8 (CH), 
128.8 (CH), 128.1 (CH), 127.2 (CH), 59.6 (CH), 52.2 (CH3), 51.1 (CH), 50.4 (CH2), 47.3 (CH), 41.9 
(CH2), 41.2 (CH2), 27.0 (CH2), 25.5 (CH2), 25.0 (CH), 22.8 (CH3), 22.6 (CH3), 21.9 (CH3). 
IR (ATR): ṽ = 3282, 2957, 1743, 1681, 1614, 1570, 1428, 1327, 1221, 648 cm−1.  
MS (EI) m/z (relative intensity): 596 (5) [M]+, 424 (30) [M–(C(O)-Leu-OMe)]+, 355 (100) [M–(H-Pro-
Leu-OMe)]+, 328 (11), 285 (18), 156 (9), 43 (6). 
HR-MS (EI): m/z calcd for C34H40N6O4+ [M]+ 596.3106, found 596.3124. 
 
Methyl {4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoyl}-L-leucyl-L-methioninate (187k) 
The general procedure J was followed using purine 123a 
(59.6 mg, 0.25 mmol) and benzyl chloride 186i (215 mg, 
0.50 mmol). After 20 h, purification by column 
chromatography (n-hexane/EtOAc 1:2) yielded 187k 
(117 mg, 74%) as a viscous colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.00 (s, 1H), 8.68 (ddd, J = 7.8, 1.6, 1.3 Hz, 1H), 8.59 (dd, J = 1.9, 
1.6 Hz, 1H), 8.19 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.48 (dd, J = 7.8, 7.7 Hz, 1H), 7.30 (d, J = 8.3 Hz, 
2H), 7.28 (ddd, J = 7.7, 1.9, 1.3 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.2 Hz, 1H), 4.98 (hept, 
J = 6.8 Hz, 1H), 4.72–4.66 (m, 2H), 4.15 (s, 2H), 3.74 (s, 3H), 2.45 (t, J = 7.4 Hz, 2H), 2.17–2.09 (m, 
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1H), 2.02–1.93 (m, 1H), 1.99 (s, 3H), 1.79–1.61 (m, 3H), 1.67 (d, J = 6.8 Hz, 6H), 0.95 (d, J = 6.4 Hz, 
3H), 0.95 (d, J = 6.3 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 171.9 (Cq), 171.7 (Cq), 167.1 (Cq), 154.4 (Cq), 152.0 (Cq), 151.8 (CH), 
145.2 (Cq), 142.0 (CH), 140.5 (Cq), 135.9 (Cq), 131.5 (Cq), 131.4 (Cq and CH), 129.9 (CH), 129.2 (CH), 
128.9 (CH), 128.1 (CH), 127.2 (CH), 52.5 (CH3), 52.0 (CH), 51.6 (CH), 47.3 (CH), 41.9 (CH2), 41.1 
(CH2), 31.5 (CH2), 30.0 (CH2), 24.9 (CH), 22.9 (CH3), 22.6 (CH3), 22.3 (CH3), 15.5 (CH3). 
IR (ATR): ṽ = 3272, 2954, 1742, 1632, 1568, 1325, 1218, 784, 703, 646 cm−1.  
MS (EI) m/z (relative intensity): 630 (1) [M]+, 615 (1) [M–Me]+, 569 (6) [M–SMe2]+, 556 (33) [M–
EtSMe]+, 500 (32) [M–EtSMe–Bu]+, 468 (11) [M–EtSMe–Bu–OMe]+, 440 (20) [M–EtSMe–Bu–
CO2Me]+, 355 (100) [M–(H-Leu-Met-OMe)]+, 328 (17), 313 (7), 285 (30), 156 (10), 43 (8). 




The general procedure J was 
followed using purine 123a (59.6 mg, 
0.25 mmol) and benzyl chloride 
R-186j (305 mg, 0.50 mmol). After 
20 h, purification by column 
chromatography (n-hexane/EtOAc 4:1) yielded R-187l (153 mg, 75%) as a yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 9.01 (s, 1H), 8.70 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.62 (dd, J = 1.8, 
1.6 Hz, 1H), 8.18 (s, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 7.8, 7.7 Hz, 1H), 7.32 (d, J = 8.3 Hz, 
2H), 7.31–7.27 (m, 1H), 5.40 (dddd, J = 6.0, 5.9, 4.4, 4.3 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.49 
(dABd, J = 11.9, 4.3 Hz, 1H), 4.39 (dABd, J = 11.9, 6.0 Hz, 1H), 4.37 (dd, J = 11.9, 4.4 Hz, 1H), 4.22 (dd, 
J = 11.9, 5.9 Hz, 1H), 4.18 (s, 2H), 2.31 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.68 (d, J = 6.8 Hz, 
6H), 1.64–1.55 (m, 4H), 1.33–1.17 (m, 32H), 0.87 (t, J = 7.0 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 173.3 (Cq), 172.9 (Cq), 165.9 (Cq), 154.6 (Cq), 152.1 (Cq), 152.0 (CH), 
146.9 (Cq), 142.0 (CH), 140.4 (Cq), 136.2 (Cq), 131.5 (Cq), 131.5 (CH), 130.0 (CH), 130.0 (CH), 129.1 
(CH), 129.0 (CH), 128.3 (CH), 127.5 (Cq), 68.9 (CH), 62.7 (CH2), 62.2 (CH2), 47.2 (CH), 42.0 (CH2), 
34.2 (CH2), 34.0 (CH2), 31.9 (CH2), 29.6 (CH2), 29.4 (CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 
(CH2), 29.0 (CH2), 24.9 (CH2), 24.8 (CH2), 22.7 (CH2), 22.6 (CH3), 14.1 (CH3). 
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IR (ATR): ṽ = 2923, 2853, 1726, 1569, 1326, 1269, 1102, 783, 703, 647 cm−1.  
MS (ESI) m/z (relative intensity): 1622 (33) [2M+H]+, 834 (32) [M+Na]+, 812 (100) [M+H]+. 




The general procedure J was 
followed using purine 123a (59.6 mg, 
0.25 mmol) and benzyl chloride 
rac-186j (305 mg, 0.50 mmol). After 
20 h, purification by column 
chromatography (n-hexane/EtOAc 4:1) yielded rac-187l (153 mg, 75%) as a yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.00 (s, 1H), 8.70 (ddd, J = 7.8, 1.7, 1.5 Hz, 1H), 8.62 (dd, J = 1.8, 
1.7 Hz, 1H), 8.18 (s, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 7.8, 7.7 Hz, 1H), 7.32 (d, J = 8.3 Hz, 
2H), 7.31–7.27 (m, 1H), 5.40 (dddd, J = 5.9, 5.8, 4.3, 4.2 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.48 
(dABd, J = 11.9, 4.3 Hz, 1H), 4.39 (dABd, J = 11.9, 5.8 Hz, 1H), 4.37 (dd, J = 11.9, 4.2 Hz, 1H), 4.22 (dd, 
J = 11.9, 5.9 Hz, 1H), 4.17 (s, 2H), 2.31 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.67 (d, J = 6.8 Hz, 
6H), 1.65–1.53 (m, 4H), 1.34–1.15 (m, 32H), 0.86 (t, J = 6.6 Hz, 3H), 0.86 (t, J = 6.6 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 173.1 (Cq), 172.7 (Cq), 165.8 (Cq), 154.4 (Cq), 152.0 (Cq), 151.9 (CH), 
146.7 (Cq), 141.9 (CH), 140.3 (Cq), 136.1 (Cq), 131.4 (Cq), 131.3 (CH), 129.9 (CH), 129.9 (CH), 129.0 
(CH), 128.9 (CH), 128.2 (CH), 127.4 (Cq), 68.9 (CH), 62.7 (CH2), 62.2 (CH2), 47.3 (CH), 42.0 (CH2), 
34.3 (CH2), 34.1 (CH2), 31.9 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 29.1 
(CH2), 29.1 (CH2), 25.0 (CH2), 24.9 (CH2), 22.7 (CH2), 22.6 (CH3), 14.2 (CH3). 
IR (ATR): ṽ = 2922, 2853, 1725, 1569, 1326, 1269, 1102, 783, 704, 647 cm−1.  
MS (ESI) m/z (relative intensity): 834 (1) [M+Na]+, 812 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C49H71N4O6+ [M+H]+ 811.5368, found 811.5352. 
 
 






The general procedure J was followed 
using purine 123m (135 mg, 
0.25 mmol) and benzyl chloride R-186j 
(305 mg, 0.50 mmol). After 20 h, 
purification by column 
chromatography (n-hexane/EtOAc 
6:1) yielded 187m (195 mg, 70%) as a yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.99 (s, 1H), 8.70 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.61 (dd, J = 1.8, 
1.6 Hz, 1H), 8.42 (s, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 7.8, 7.7 Hz, 1H), 7.32 (d, J = 8.3 Hz, 
2H), 7.31–7.27 (m, 1H), 6.57 (dd, J = 6.7, 6.3 Hz, 1H), 5.40 (dddd, J = 6.0, 5.9, 4.4, 4.3 Hz, 1H), 4.65 
(ddd, J = 5.9, 3.6, 3.3 Hz, 1H), 4.49 (dABd, J = 11.9, 4.3 Hz, 1H), 4.40 (dABd, J = 11.9, 6.0 Hz, 1H), 4.37 
(dd, J = 11.9, 4.4 Hz, 1H), 4.22 (dd, J = 11.9, 5.9 Hz, 1H), 4.17 (s, 2H), 4.06 (ddd, J = 4.3, 3.3, 3.3 Hz, 
1H), 3.88 (dABd, J = 11.2, 4.3 Hz, 1H), 3.80 (dABd, J = 11.2, 3.3 Hz, 1H), 2.71 (ddd, J = 13.0, 6.7, 5.9 Hz, 
1H), 2.49 (ddd, J = 13.0, 6.3, 3.6 Hz, 1H), 2.31 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.67–1.54 
(m, 4H), 1.33–1.17 (m, 32H), 0.93 (s, 9H), 0.91 (s, 9H), 0.87 (t, J = 6.9 Hz, 3H), 0.87 (t, J = 6.9 Hz, 
3H), 0.12 (s, 6H), 0.09 (s, 3H), 0.09 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 173.3 (Cq), 172.9 (Cq), 165.9 (Cq), 154.7 (Cq), 152.2 (CH), 152.0 (Cq), 
146.9 (Cq), 142.8 (CH), 140.4 (Cq), 136.0 (Cq), 131.7 (Cq), 131.5 (CH), 130.0 (CH), 129.1 (CH), 129.0 
(CH), 128.4 (CH), 127.5 (Cq), 88.0 (CH), 84.5 (CH), 72.0 (CH), 68.9 (CH), 62.8 (CH2), 62.7 (CH2), 62.2 
(CH2), 42.0 (CH2), 41.1 (CH2), 34.2 (CH2), 34.0 (CH2), 31.9 (CH2), 29.6 (CH2), 29.4 (CH2), 29.4 (CH2), 
29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 29.0 (CH2), 25.9 (CH3), 25.8 (CH3), 24.9 (CH2), 24.8 (CH2), 22.7 
(CH2), 18.4 (Cq), 18.0 (Cq), 14.1 (CH3), –4.7 (CH3), –4.8 (CH3), –5.4 (CH3), –5.5 (CH3). 
IR (ATR): ṽ = 2925, 2854, 1727, 1570, 1256, 1107, 835, 778, 703, 646 cm−1.  
MS (ESI) m/z (relative intensity): 2227 (38) [2M+H]+, 1136 (39) [M+Na]+, 1114 (100) [M+H]+. 
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3-{{4-[3-(9-iso-Propyl-9H-purin-6-yl)benzyl]benzoyl}oxy}propane-1,2-diyl dioleate (187n) 
The general procedure 
J was followed using 
purine 123a (59.6 mg, 
0.25 mmol) and benzyl 
chloride 186k 
(387 mg, 0.50 mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 4:1) 
yielded 187n (174 mg, 71%) as a pale yellow oil. 
1H-NMR (300 MHz, CDCl3): δ = 9.00 (s, 1H), 8.70 (ddd, J = 7.8, 1.7, 1.5 Hz, 1H), 8.62 (dd, J = 1.8, 
1.7 Hz, 1H), 8.18 (s, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 7.8, 7.7 Hz, 1H), 7.32 (d, J = 8.3 Hz, 
2H), 7.31–7.27 (m, 1H), 5.44–5.25 (m, 5H), 4.98 (hept, J = 6.8 Hz, 1H), 4.48 (dABd, J = 11.9, 4.3 Hz, 
1H), 4.39 (dABd, J = 11.9, 5.6 Hz, 1H), 4.37 (dd, J = 11.9, 4.1 Hz, 1H), 4.22 (dd, J = 11.9, 5.9 Hz, 1H), 
4.18 (s, 2H), 2.31 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 2.08–1.91 (m, 8H), 1.67 (d, J = 6.8 Hz, 
6H), 1.64–1.52 (m, 4H), 1.37–1.18 (m, 40H), 0.87 (t, J = 6.6 Hz, 3H), 0.87 (t, J = 6.6 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 173.1 (Cq), 172.7 (Cq), 165.8 (Cq), 154.4 (Cq), 152.0 (Cq), 151.9 (CH), 
146.7 (Cq), 141.8 (CH), 140.3 (Cq), 136.1 (Cq), 131.4 (Cq), 131.3 (CH), 129.9 (CH), 129.9 (CH), 129.6 
(CH), 129.6 (CH), 129.0 (CH), 128.8 (CH), 128.2 (CH), 127.4 (Cq), 68.9 (CH), 62.7 (CH2), 62.2 (CH2), 
47.3 (CH), 42.0 (CH2), 34.2 (CH2), 34.1 (CH2), 31.9 (CH2), 29.8 (CH2), 29.7 (CH2), 29.6 (CH2), 29.3 
(CH2), 29.2 (CH2), 29.1 (CH2), 29.1 (CH2), 29.1 (CH2), 27.3 (CH2), 27.2 (CH2), 24.9 (CH2), 24.9 (CH2), 
22.7 (CH2), 22.6 (CH3), 14.2 (CH3). 
IR (ATR): ṽ = 2923, 2853, 1726, 1570, 1458, 1269, 1175, 1096, 703, 647 cm−1.  
MS (ESI) m/z (relative intensity): 1951 (14) [2M+H]+, 976 (100) [M+H]+. 











[3,4-d][1,3]dioxol-4-yl}-9H-purin-6-yl}benzyl}benzoyl}oxy}propane-1,2-diyl dioleate (187o) 
The general procedure J 
was followed using 
purine 123l (126 mg, 
0.25 mmol) and benzyl 
chloride 186k (387 mg, 
0.50 mmol). After 20 h, 
purification by column 
chromatography (n-hexane/EtOAc 3:2) yielded 187o (172 mg, 55%) as a greenish yellow oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.69 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.61 (dd, J = 1.9, 
1.6 Hz, 1H), 8.28 (s, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.48 (dd, J = 7.8, 7.7 Hz, 1H), 7.31 (d, J = 8.4 Hz, 
2H), 7.31–7.28 (m, 1H), 6.26 (d, J = 2.6 Hz, 1H), 5.45 (dd, J = 6.3, 2.6 Hz, 1H), 5.39 (dddd, J = 6.0, 
5.9, 4.3, 4.3 Hz, 1H), 5.36–5.27 (m, 4H), 5.13 (dd, J = 6.3, 3.1 Hz, 1H), 4.53 (dddd, J = 4.5, 4.5, 3.1, 
1.1 Hz, 1H), 4.48 (dABd, J = 11.9, 4.3 Hz, 1H), 4.38 (dABd, J = 11.9, 6.0 Hz, 1H), 4.36 (dd, J = 11.9, 
4.3 Hz, 1H), 4.29 (ddd, J = 10.9, 6.3, 4.5 Hz, 1H), 4.21 (dd, J = 11.9, 5.9 Hz, 1H), 4.20 (ddd, J = 10.9, 
6.8, 4.5 Hz, 1H), 4.17 (s, 2H), 4.09–4.00 (m, 4H), 2.30 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 7.6 Hz, 2H), 
2.06–1.95 (m, 8H), 1.64 (s, 3H), 1.63–1.55 (m, 4H), 1.41 (s, 3H), 1.36–1.19 (m, 46H), 0.86 (t, J = 
7.2 Hz, 3H), 0.86 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 173.1 (Cq), 172.7 (Cq), 165.7 (Cq), 154.9 (Cq), 152.3 (CH), 151.6 (Cq), 
146.6 (Cq), 143.1 (CH), 140.4 (Cq), 135.7 (Cq), 131.6 (Cq and CH), 129.9 (CH), 129.9 (CH), 129.8 (CH), 
129.6 (CH), 129.6 (CH), 129.0 (CH), 128.9 (CH), 128.3 (CH), 127.4 (Cq), 114.6 (Cq), 91.0 (CH), 85.3 
(d, 3JC–P = 8 Hz, CH), 84.2 (CH), 81.3 (CH), 68.9 (CH), 66.6 (d, 2JC–P = 6 Hz, CH2), 64.1 (d, 2JC–P = 5 Hz, 
CH2), 64.1 (d, 2JC–P = 5 Hz, CH2), 62.7 (CH2), 62.2 (CH2), 42.0 (CH2), 34.2 (CH2), 34.1 (CH2), 31.9 (CH2), 
29.8 (CH2), 29.7 (CH2), 29.6 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 29.1 (CH2), 29.0 (CH2), 27.3 
(CH2), 27.2 (CH3), 27.2 (CH2), 25.4 (CH3), 24.9 (CH2), 24.9 (CH2), 22.7 (CH2), 16.11 (d, 3JC–P = 7 Hz, 
CH3), 14.2 (CH3). 
31P-NMR (162 MHz, CDCl3): δ = (–0.8)–(–1.2) (m). 
IR (ATR): ṽ = 2923, 2853, 1741, 1569, 1268, 1097, 1021, 703, 645 cm−1.  
MS (ESI) m/z (relative intensity): 2484 (15) [2M+H]+, 1264 (32) [M+Na]+, 1242 (100) [M+H]+, 632 
(4) [M+H+Na]2+. 
HR-MS (ESI): m/z calcd for C70H106N4O13P+ [M+H]+ 1241.7489, found 1241.7480. 





The general procedure J was 
followed using purine 123a 
(59.6 mg, 0.25 mmol) and benzyl 
chloride 186l (292 mg, 
0.50 mmol). After 20 h, purification by column chromatography (n-hexane/EtOAc 3:1) yielded 
187p (127 mg, 65%) as a viscous pale yellow oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.03 (s, 1H), 8.73 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.68 (dd, J = 1.7, 
1.6 Hz, 1H), 8.19 (s, 1H), 8.18 (d, J = 8.3 Hz, 2H), 7.52 (dd, J = 7.8, 7.7 Hz, 1H), 7.41 (d, J = 8.3 Hz, 
2H), 7.36 (ddd, J = 7.7, 1.7, 1.4 Hz, 1H), 4.99 (hept, J = 6.8 Hz, 1H), 4.23 (s, 2H), 2.61 (dd, J = 7.0, 
6.8 Hz, 2H), 2.12 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.83 (dt, J = 13.9, 7.0 Hz, 1H), 1.80–1.73 (m, 1H), 
1.68 (d, J = 6.8 Hz, 6H), 1.62–1.02 (m, 24H), 0.90–0.83 (m, 12H). 
13C-NMR (125 MHz, CDCl3, 1:1 Conformer A and B): δ = 164.9 (Cq), 154.4 (Cq), 152.0 (Cq), 151.9 
(CH), 149.3 (Cq), 146.9 (Cq), 141.9 (CH), 140.5 (Cq), 140.3 (Cq), 136.1 (Cq), 131.5 (Cq), 131.4 (CH), 
130.3 (CH), 130.0 (CH), 129.0 (CH), 128.9 (CH), 128.2 (CH), 127.5 (Cq), 126.8 (Cq), 125.0 (Cq), 122.9 
(Cq), 117.3 (Cq), 75.0 (Cq), 47.3 (CH), 42.1 (CH2), 40.4 and 39.7 (CH2), 39.4 (CH2), 37.5 (CH2), 37.5 
(CH2), 37.3 (CH2), 32.8 (CH), 32.8 and 32.7 (CH), 31.3 and 31.1 (CH2), 28.0 (CH), 24.8 (CH2), 24.5 
(CH2), 24.2 and 23.8 (CH3), 22.8 (CH3), 22.7 (CH3), 22.6 (CH3), 21.1 (CH2), 20.7 (CH2), 19.8 (CH3), 19.7 
(CH3), 13.1 (CH3), 12.3 (CH3), 11.9 (CH3). Conformer A and B originate from the hindered rotation 
around the C–C bond to the ester group. 
IR (ATR): ṽ = 2925, 1732, 1571, 1459, 1327, 1273, 1237, 1092, 704, 648 cm−1.  
MS (ESI) m/z (relative intensity): 808 (14) [M+Na]+, 786 (100) [M+H]+. 










tetrahydro-2H-pyran-3,4,5-triyl triacetate (187q) 
The general procedure J was followed using purine 123a (119 mg, 
0.50 mmol) and benzyl chloride 186m (473 mg, 1.00 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 
1:1) yielded 187q (240 mg, 71%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ = 9.00 (s, 1H), 8.67 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.58 (ddd, J = 1.8, 
1.8, 0.6 Hz, 1H), 8.18 (s, 1H), 7.47 (ddd, J = 7.8, 7.7, 0.5 Hz, 1H), 7.29 (ddd, J = 7.7, 1.8, 1.2 Hz, 1H), 
7.16 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H), 5.29–5.22 (m, 2H), 5.14 (dd, J = 9.9, 9.7 Hz, 1H), 
5.03 (d, J = 7.8 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.27 (dd, J = 12.3, 5.3 Hz, 1H), 4.14 (dd, J = 12.3, 
2.5 Hz, 1H), 4.08 (s, 2H), 3.82 (ddd, J = 9.9, 5.3, 2.5 Hz, 1H), 2.04 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 
2.02 (s, 3H), 1.68 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 170.4 (Cq), 170.0 (Cq), 169.2 (Cq), 169.1 (Cq), 155.2 (Cq), 154.6 (Cq), 
152.0 (Cq), 151.9 (CH), 141.8 (CH), 141.4 (Cq), 136.1 (Cq), 135.9 (Cq), 131.5 (Cq), 131.3 (CH), 129.9 
(CH), 129.8 (CH), 128.7 (CH), 128.0 (CH), 117.1 (CH), 99.3 (CH), 72.8 (CH), 72.0 (CH), 71.2 (CH), 68.4 
(CH), 62.0 (CH2), 47.3 (CH), 41.6 (CH2), 22.6 (CH3), 20.7 (CH3), 20.7 (CH3), 20.7 (CH3), 20.6 (CH3). 
IR (ATR): ṽ = 2977, 1746, 1570, 1508, 1367, 1213, 1035, 704, 647, 598 cm−1.  
m.p.: 182–184 °C. 
MS (ESI) m/z (relative intensity): 697 (8) [M+Na]+, 675 (100) [M+H]+. 





The general procedure J was followed using purine 123n (182 mg, 
0.40 mmol) and benzyl chloride 186m (379 mg, 0.80 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 
2:3) yielded 187r (231 mg, 67%) as a viscous pale yellow oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.64 (ddd, J = 7.8, 1.8, 
1.2 Hz, 1H), 8.56 (dd, J = 1.8, 1.7 Hz, 1H), 8.27 (s, 1H), 7.47 (dd, J = 7.8, 7.6 Hz, 1H), 7.30 (ddd, J = 
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7.6, 1.7, 1.2 Hz, 1H), 7.16 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H), 6.29 (d, J = 5.4 Hz, 1H), 6.00 
(dd, J = 5.5, 5.4 Hz, 1H), 5.70 (dd, J = 5.5, 4.5 Hz, 1H), 5.28–5.22 (m, 2H), 5.14 (dd, J = 10.0, 9.1 Hz, 
1H), 5.02 (d, J = 7.6 Hz, 1H), 4.49–4.45 (m, 2H), 4.42–4.37 (m, 1H), 4.27 (dd, J = 12.3, 5.3 Hz, 1H), 
4.13 (dd, J = 12.3, 2.4 Hz, 1H), 4.07 (s, 2H), 3.82 (ddd, J = 10.1, 5.3, 2.4 Hz, 1H), 2.16 (s, 3H), 2.13 
(s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 170.4 (Cq), 170.1 (Cq), 170.0 (Cq), 169.4 (Cq), 169.2 (Cq), 169.1 (Cq), 
155.3 (Cq), 155.2 (Cq), 152.5 (CH), 151.9 (Cq), 142.4 (CH), 141.5 (Cq), 135.9 (Cq), 135.5 (Cq), 131.6 
(CH), 131.6 (Cq), 129.9 (CH), 129.8 (CH), 128.8 (CH), 128.0 (CH), 117.1 (CH), 99.3 (CH), 86.4 (CH), 
80.4 (CH), 73.1 (CH), 72.8 (CH), 72.0 (CH), 71.2 (CH), 70.7 (CH), 68.3 (CH), 63.1 (CH2), 62.0 (CH2), 
41.2 (CH2), 20.8 (CH3), 20.7 (CH3), 20.7 (CH3), 20.6 (CH3), 20.6 (CH3), 20.6 (CH3), 20.4 (CH3). 
IR (ATR): ṽ = 1745, 1569, 1508, 1368, 1216, 1038, 907, 703, 642, 600 cm−1.  
MS (ESI) m/z (relative intensity): 913 (37) [M+Na]+, 891 (100) [M+H]+, 465 (38). 




tetrahydro-2H-pyran-3,4,5-triyl triacetate (187s) 
The general procedure J was followed using purine 123l (99.0 mg, 
0.20 mmol) and benzyl chloride 186m (189 mg, 0.40 mmol). After 
20 h, purification by column chromatography (n-hexane/EtOAc 
1:4) yielded 187s (130 mg, 69%) as a viscous pale yellow oil. 
1H-NMR (600 MHz, CDCl3): δ = 8.99 (s, 1H), 8.64 (ddd, J = 7.8, 1.6, 
1.4 Hz, 1H), 8.55 (dd, J = 1.6, 1.6 Hz, 1H), 8.26 (s, 1H), 7.45 (dd, J = 
7.8, 7.8 Hz, 1H), 7.28 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 7.14 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 
6.24 (d, J = 2.5 Hz, 1H), 5.43 (dd, J = 6.3, 2.5 Hz, 1H), 5.27–5.20 (m, 2H), 5.12 (dd, J = 10.1, 9.1 Hz, 
1H), 5.10 (dd, J = 6.3, 3.0 Hz, 1H), 5.01 (d, J = 7.7 Hz, 1H), 4.51 (dddd, J = 5.1, 4.5, 3.0, 1.2 Hz, 1H), 
4.27 (ddd, J = 11.0, 6.4, 4.5 Hz, 1H), 4.25 (dd, J = 12.2, 5.3 Hz, 1H), 4.19 (ddd, J = 11.0, 6.9, 5.1 Hz, 
1H), 4.11 (dd, J = 12.2, 2.4 Hz, 1H), 4.07–3.99 (m, 6H), 3.80 (ddd, J = 10.1, 5.3, 2.4 Hz, 1H), 2.02 (s, 
3H), 2.01 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.62 (s, 3H), 1.39 (s, 3H), 1.25 (td, J = 7.2, 1.1 Hz, 3H), 
1.22 (td, J = 7.1, 1.1 Hz, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 170.4 (Cq), 170.0 (Cq), 169.2 (Cq), 169.1 (Cq), 155.2 (Cq), 155.1 (Cq), 
152.4 (CH), 151.6 (Cq), 143.1 (CH), 141.5 (Cq), 135.9 (Cq), 135.6 (Cq), 131.6 (Cq), 131.6 (CH), 129.9 
(CH), 129.8 (CH), 128.8 (CH), 128.1 (CH), 117.1 (CH), 114.7 (Cq), 99.3 (CH), 91.0 (CH), 85.3 (d, 3JC–P 
= 8 Hz, CH), 84.2 (CH), 81.4 (CH), 72.8 (CH), 72.0 (CH), 71.2 (CH), 68.3 (CH), 66.6 (d, 2JC–P = 5 Hz, 
CH2), 64.1 (d, 2JC–P = 6 Hz, CH2), 64.1 (d, 2JC–P = 6 Hz, CH2), 62.0 (CH2), 41.2 (CH2), 27.2 (CH3), 25.4 
(CH3), 20.7 (CH3), 20.7 (CH3), 20.7 (CH3), 20.6 (CH3), 16.1 (d, 3JC–P = 7 Hz, CH3). 
31P{1H}-NMR (121 MHz, CDCl3): δ = –1.1 (s). 
IR (ATR): ṽ = 2985, 1754, 1569, 1508, 1373, 1213, 1029, 733, 702, 645 cm−1.  
MS (ESI) m/z (relative intensity): 1904 (8) [2M+Na]+, 1882 (13) [2M+H]+, 963 (66) [M+Na]+, 941 
(100) [M+H]+, 655 (3), 482 (12). 




The general procedure J was followed using purine 123a (119 mg, 
0.50 mmol) and benzyl chloride 186n (305 mg, 1.00 mmol) at 80 °C. After 
20 h, purification by column chromatography (CH2Cl2/acetone 1:1) followed 
by reverse phase HPLC (H2O/MeCN 60:40) yielded 187t (139 mg, 55%) as a 
viscous colorless oil. 
1H-NMR (600 MHz, acetone-d6): δ = 8.96 (s, 1H), 8.90 (dd, J = 1.7, 1.7 Hz, 
1H), 8.70 (ddd, J = 7.6, 1.7, 1.6 Hz, 1H), 8.63 (s, 1H), 7.49 (ddd, J = 7.6, 1.7, 
1.6 Hz, 1H), 7.46 (dd, J = 7.6, 7.6 Hz, 1H), 7.31 (dd, J = 7.4, 1.7 Hz, 1H), 7.19 (dd, J = 8.3, 1.5 Hz, 1H), 
7.16 (ddd, J = 8.3, 7.2, 1.7 Hz, 1H), 6.97 (ddd, J = 7.4, 7.2, 1.5 Hz, 1H), 5.26 (br s, 1H), 5.02 (hept, J 
= 6.8 Hz, 1H), 5.02 (d, J = 7.6 Hz, 1H), 4.48 (br s, 1H), 4.30 (br s, 1H), 4.19 (dAB, J = 14.2 Hz, 1H), 4.13 
(dAB, J = 14.2 Hz, 1H), 3.90–3.84 (m, 1H), 3.75–3.66 (m, 3H), 3.55 (t, J = 8.9 Hz, 1H), 3.53–3.49 (m, 
1H), 3.46 (t, J = 9.2 Hz, 1H), 1.69 (d, J = 6.8 Hz, 6H). 
13C-NMR (125 MHz, acetone-d6): δ = 156.4 (Cq), 154.4 (Cq), 153.1 (Cq), 152.4 (CH), 144.6 (CH), 142.3 
(Cq), 136.5 (Cq), 132.2 (CH), 131.9 (Cq), 131.6 (CH), 131.4 (Cq), 131.0 (CH), 129.0 (CH), 128.3 (CH), 
128.1 (CH), 122.7 (CH), 116.1 (CH), 102.1 (CH), 78.2 (CH), 77.7 (CH), 74.5 (CH), 71.3 (CH), 62.7 (CH2), 
48.4 (CH), 37.2 (CH2), 22.4 (CH3), 22.4 (CH3). 
IR (ATR): ṽ = 3340, 2919, 1572, 1491, 1454, 1328, 1223, 1072, 1043, 648 cm−1.  
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MS (ESI) m/z (relative intensity): 529 (42) [M+Na]+, 507 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C27H31N4O6+ [M+H]+ 507.2238, found 507.2249. 
 
(3aR,5R,6S,6aR)-5-[(R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyltetrahydrofuro[2,3-d][1,3] 
dioxol-6-yl 2-[3-(9-iso-propyl-9H-purin-6-yl)phenyl]acetate (187u) 
The general procedure J was followed using purine 123a (119 mg, 
0.50 mmol) and alkyl bromide 186o (381 mg, 1.00 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 3:2) yielded 
187u (145 mg, 54%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.00 (s, 1H), 8.76 (ddd, J = 7.8, 1.7, 1.5 Hz, 
1H), 8.68 (dd, J = 1.7, 1.6 Hz, 1H), 8.18 (s, 1H), 7.52 (dd, J = 7.8, 7.7 Hz, 1H), 
7.45 (ddd, J = 7.7, 1.6, 1.5 Hz, 1H), 5.85 (d, J = 3.6 Hz, 1H), 5.30 (d, J = 2.9 Hz, 
1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.47 (d, J = 3.6 Hz, 1H), 4.18 (dABd, J = 8.0, 2.9 Hz, 1H), 4.16 (dABdd, 
J = 8.0, 5.7, 4.8 Hz, 1H), 3.98 (dABd, J = 8.6, 5.7 Hz, 1H), 3.96 (dABd, J = 8.6, 4.8 Hz, 1H), 3.82 (dAB, J = 
15.3 Hz, 1H), 3.80 (dAB, J = 15.3 Hz, 1H), 1.67 (d, J = 6.8 Hz, 6H), 1.49 (s, 3H), 1.36 (s, 3H), 1.26 (s, 
3H), 1.20 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 169.8 (Cq), 154.0 (Cq), 152.1 (Cq), 151.9 (CH), 141.9 (CH), 136.1 (Cq), 
133.7 (Cq), 131.6 (CH), 131.4 (Cq), 130.2 (CH), 128.9 (CH), 128.8 (CH), 112.2 (Cq), 109.2 (Cq), 105.0 
(CH), 83.2 (CH), 79.9 (CH), 76.4 (CH), 72.3 (CH), 67.2 (CH2), 47.3 (CH), 41.4 (CH2), 26.9 (CH3), 26.8 
(CH3), 26.3 (CH3), 25.1 (CH3), 22.6 (CH3). 
IR (ATR): ṽ = 2984, 1742, 1570, 1372, 1215, 1072, 1018, 843, 703, 647 cm−1.  
MS (ESI) m/z (relative intensity): 1100 (12) [2M+Na]+, 561 (43) [M+Na]+, 539 (100) [M+H]+. 










dioxol-6-yl 2-[3-(9-iso-propyl-9H-purin-6-yl)phenyl]-2-methylpropanoate (187v) 
The general procedure J was followed using purine 123a (119 mg, 
0.50 mmol) and alkyl bromide 186p (409 mg, 1.00 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 2:1) yielded 187v 
(241 mg, 76%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 9.00 (s, 1H), 8.79 (dd, J = 1.8, 1.7 Hz, 1H), 
8.74 (ddd, J = 7.5, 1.7, 1.7 Hz, 1H), 8.18 (s, 1H), 7.52 (dd, J = 7.7, 7.5 Hz, 1H), 
7.49 (ddd, J = 7.7, 1.8, 1.7 Hz, 1H), 5.66 (d, J = 3.6 Hz, 1H), 5.31 (d, J = 3.1 Hz, 
1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.48 (d, J = 3.6 Hz, 1H), 4.16 (dd, J = 8.0, 3.1 Hz, 1H), 4.01 (ddd, J = 
8.0, 6.1, 5.3 Hz, 1H), 3.88 (dABd, J = 8.6, 6.1 Hz, 1H), 3.85 (dABd, J = 8.6, 5.3 Hz, 1H), 1.71 (s, 3H), 
1.68–1.66 (m, 9H), 1.48 (s, 3H), 1.36 (s, 3H), 1.23 (s, 3H), 1.19 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 175.1 (Cq), 154.3 (Cq), 152.0 (Cq), 151.9 (CH), 144.5 (Cq), 141.9 (CH), 
135.9 (Cq), 131.4 (Cq), 128.6 (CH), 128.5 (CH), 128.0 (CH), 126.9 (CH), 112.1 (Cq), 109.1 (Cq), 105.1 
(CH), 83.0 (CH), 80.2 (CH), 76.3 (CH), 72.3 (CH), 67.3 (CH2), 47.3 (CH), 47.1 (Cq), 26.9 (CH3), 26.8 
(CH3), 26.8 (CH3), 26.3 (CH3), 26.1 (CH3), 25.1 (CH3), 22.7 (CH3). 
IR (ATR): ṽ = 2983, 1737, 1569, 1372, 1217, 1140, 1073, 1020, 845, 647 cm−1.  
MS (ESI) m/z (relative intensity): 1156 (6) [2M+Na]+, 589 (14) [M+Na]+, 567 (100) [M+H]+. 




The general procedure J was followed using purine 123a (119 mg, 
0.50 mmol) and alkyl bromide 186q (339 mg, 1.00 mmol). After 20 h, 
purification by column chromatography (n-hexane/EtOAc 1:1) followed 
by recycling preparative HPLC yielded 187w (169 mg, 68%) as a viscous 
colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 8.97 (s, 1H), 8.58 (ddd, J = 6.7, 2.3, 2.1 Hz, 
1H), 8.28 (dd, J = 2.3, 1.4 Hz, 1H), 8.22 (s, 1H), 7.58–7.53 (m, 2H), 5.92 
(d, J = 3.5 Hz, 1H), 5.78 (d, J = 4.5 Hz, 1H), 4.99 (hept, J = 6.8 Hz, 1H), 4.74 (dd, J = 10.3, 10.3 Hz, 
1H), 4.40 (d, J = 3.5 Hz, 1H), 4.28 (ddd, J = 10.3, 4.6, 3.2 Hz, 1H), 4.13 (dd, J = 10.3, 4.6 Hz, 1H), 3.85 
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(dd, J = 4.5, 3.2 Hz, 1H), 1.70 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H), 1.68 (d, J = 6.8 Hz, 3H), 1.57 (s, 3H), 
1.40 (s, 3H), 1.24 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 176.1 (Cq), 155.0 (Cq), 152.1 (Cq), 151.7 (CH), 145.4 (Cq), 142.6 (CH), 
135.1 (Cq), 131.4 (Cq), 128.9 (CH), 128.8 (CH), 127.2 (CH), 111.6 (Cq), 105.0 (CH), 85.6 (CH), 77.6 
(CH), 72.7 (CH), 60.7 (CH2), 47.6 (CH), 47.1 (Cq), 28.0 (CH3), 26.9 (CH3), 26.2 (CH3), 25.8 (CH3), 22.7 
(CH3), 22.6 (CH3). 
IR (ATR): ṽ = 2978, 1729, 1569, 1326, 1217, 1147, 1070, 1012, 702, 647 cm−1.  
MS (ESI) m/z (relative intensity): 1016 (65) [2M+Na]+, 994 (6) [2M+H]+, 519 (66) [M+Na]+, 497 (100) 
[M+H]+. 
HR-MS (ESI): m/z calcd for C26H33N4O6+ [M+H]+ 497.2395, found 497.2384. 
 
{(3aR,4R,6R,6aR)-6-[2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl]-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl}methyl 4-[3-(9-iso-propyl-9H-purin-6-yl)benzyl]benzoate (187x) 
The general procedure J was followed using purine 123a 
(59.6 mg, 0.25 mmol) and benzyl chloride 186r (219 mg, 
0.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 1:3) yielded 187x (87.3 mg, 55%) as a white 
solid. 
1H-NMR (600 MHz, CDCl3): δ = 9.62 (d, J = 2.1 Hz, 1H), 8.99 (s, 1H), 8.66 (ddd, J = 7.8, 1.6, 1.4 Hz, 
1H), 8.54 (dd, J = 1.8, 1.6 Hz, 1H), 8.20 (s, 1H), 7.88 (d, J = 8.3 Hz, 2H), 7.50 (dd, J = 7.8, 7.7 Hz, 1H), 
7.33–7.30 (m, 1H), 7.30 (d, J = 8.3 Hz, 2H), 7.24 (d, J = 8.1 Hz, 1H), 5.64 (d, J = 2.1 Hz, 1H), 5.52 (dd, 
J = 8.1, 2.1 Hz, 1H), 5.03 (dd, J = 6.3, 2.1 Hz, 1H), 4.97 (hept, J = 6.8 Hz, 1H), 4.90 (dd, J = 6.3, 3.4 Hz, 
1H), 4.61 (dd, J = 12.1, 3.4 Hz, 1H), 4.55 (ddd, J = 4.9, 3.4, 3.4 Hz, 1H), 4.44 (dd, J = 12.1, 4.9 Hz, 
1H), 4.17 (dAB, J = 15.5 Hz, 1H), 4.15 (dAB, J = 15.5 Hz, 1H), 1.66 (d, J = 6.8 Hz, 6H), 1.56 (s, 3H), 1.35 
(s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 165.8 (Cq), 162.8 (Cq), 154.6 (Cq), 152.0 (Cq), 151.9 (CH), 149.9 (Cq), 
147.1 (Cq), 142.1 (CH), 140.8 (CH), 140.1 (Cq), 136.1 (Cq), 131.5 (CH), 131.3 (Cq), 130.0 (CH), 129.6 
(CH), 129.0 (CH), 128.9 (CH), 128.3 (CH), 127.3 (Cq), 114.3 (Cq), 102.3 (CH), 95.0 (CH), 85.4 (CH), 
85.1 (CH), 81.2 (CH), 64.4 (CH2), 47.3 (CH), 42.0 (CH2), 27.2 (CH3), 25.3 (CH3), 22.6 (CH3). 
IR (ATR): ṽ = 2983, 1688, 1570, 1456, 1378, 1270, 1216, 1087, 750, 647 cm−1.  
m.p.: 87–90 °C. 
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MS (ESI) m/z (relative intensity): 661 (3) [M+Na]+, 639 (100) [M+H]+. 





The general procedure J was followed using purine 123l 
(126 mg, 0.25 mmol) and benzyl chloride 186r (219 mg, 
0.50 mmol). After 20 h, purification by column chromatography 
(CH2Cl2/acetone 3:1) yielded 187y (83.5 mg, 37%) as a viscous 
colorless oil.  
1H-NMR (600 MHz, CDCl3): δ = 9.24 (d, J = 2.2 Hz, 1H), 9.01 (s, 
1H), 8.66 (ddd, J = 7.8, 1.6, 1.4 Hz, 1H), 8.55 (dd, J = 1.6, 1.6 Hz, 1H), 8.31 (s, 1H), 7.88 (d, J = 8.3 Hz, 
2H), 7.50 (dd, J = 7.8, 7.7 Hz, 1H), 7.34 (ddd, J = 7.7, 1.6, 1.4 Hz, 1H), 7.32 (d, J = 8.3 Hz, 2H), 7.24 
(d, J = 8.1 Hz, 1H), 6.26 (d, J = 2.5 Hz, 1H), 5.66 (d, J = 2.1 Hz, 1H), 5.51 (dd, J = 8.1, 2.2 Hz, 1H), 5.45 
(dd, J = 6.3, 2.5 Hz, 1H), 5.13 (dd, J = 6.3, 3.1 Hz, 1H), 5.02 (dd, J = 6.3, 2.1 Hz, 1H), 4.90 (dd, J = 6.3, 
3.3 Hz, 1H), 4.62 (dd, J = 12.1, 3.3 Hz, 1H), 4.56–4.51 (m, 2H), 4.45 (dd, J = 12.1, 4.8 Hz, 1H), 4.29 
(ddd, J = 11.1, 6.3, 4.6 Hz, 1H), 4.20 (ddd, J = 11.1, 6.9, 5.3 Hz, 1H), 4.18 (dAB, J = 15.5 Hz, 1H), 4.15 
(dAB, J = 15.5 Hz, 1H), 4.11–4.01 (m, 4H), 1.64 (s, 3H), 1.57 (s, 3H), 1.41 (s, 3H), 1.35 (s, 3H), 1.27 
(td, J = 7.1, 0.9 Hz, 3H), 1.24 (td, J = 7.1, 1.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 165.8 (Cq), 162.5 (Cq), 155.0 (Cq), 152.3 (CH), 151.6 (Cq), 149.9 (Cq), 
147.0 (Cq), 143.4 (CH), 140.7 (CH), 140.3 (Cq), 135.7 (Cq), 131.8 (CH), 131.6 (Cq), 130.0 (CH), 129.6 
(CH), 129.1 (CH), 129.0 (CH), 128.4 (CH), 127.4 (Cq), 114.7 (Cq), 114.3 (Cq), 102.4 (CH), 94.9 (CH), 
91.0 (CH), 85.4 (CH), 85.3 (d, 3JC–P = 8 Hz, CH), 85.1 (CH), 84.2 (CH), 81.4 (CH), 81.2 (CH), 66.6 (d, 
2JC–P = 5 Hz, CH2), 64.4 (CH2), 64.1 (d, 2JC–P = 5 Hz, CH2), 64.1 (d, 2JC–P = 6 Hz, CH2), 42.0 (CH2), 27.2 
(CH3), 27.2 (CH3), 25.4 (CH3), 25.3 (CH3), 16.1 (d, 3JC–P = 7 Hz, CH3). 
31P{1H }-NMR (121 MHz, CDCl3): δ = –1.1 (s). 
IR (ATR): ṽ = 3493, 2988, 1694, 1571, 1382, 1270, 1213, 1088, 1029, 866 cm−1.  
MS (ESI) m/z (relative intensity): 1832 (2) [2M+Na]+, 1811 (4) [2M+H]+, 928 (12) [M+Na]+, 906 (100) 
[M+H]+. 
HR-MS (ESI): m/z calcd for C43H50N6O14P+ [M+H]+ 905.3117, found 905.3120. 
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5.3.4.4 Mechanistic Studies 
5.3.4.4.1 Competition Experiments of Alkyl Halides 
 
Purine 123a (119 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 10 mol %), 
PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 
25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. Ethyl 2-bromo-2-
methylpropanoate (140k, 195 mg, 1.00 mmol), 4-methoxybenzyl chloride (142b, 157 mg, 
1.00 mmol), and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 60 °C. After 
20 h, the resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The 
filtrate was concentrated in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc 3:1) yielded 188 (137 mg, 78%) as a colorless oil. 
 
Ethyl 2-[3-(9-iso-propyl-9H-purin-6-yl)phenyl]-2-methylpropanoate (188) 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.81 (dd, J = 1.8, 1.7 Hz, 1H), 8.71 
(ddd, J = 7.5, 1.7, 1.6 Hz, 1H), 8.18 (s, 1H), 7.51 (dd, J = 7.8, 7.5 Hz, 1H), 7.48 (ddd, 
J = 7.8, 1.8, 1.6 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 1.68 
(s, 6H), 1.67 (d, J = 6.8 Hz, 6H), 1.18 (t, J = 7.1 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 176.5 (Cq), 154.6 (Cq), 152.0 (Cq), 151.9 (CH), 
145.2 (Cq), 141.8 (CH), 135.8 (Cq), 131.5 (Cq), 128.4 (CH), 128.4 (CH), 128.3 (CH), 126.8 (CH), 60.8 
(CH2), 47.2 (CH), 46.8 (Cq), 26.7 (CH3), 22.7 (CH3), 14.1 (CH3). 
IR (ATR): ṽ = 2977, 1722, 1567, 1324, 1218, 1142, 1025, 798, 702, 646 cm−1.  
MS (EI) m/z (relative intensity): 352 (18) [M]+, 323 (4) [M–Et]+, 279 (89) [M–CO2Et]+, 237 (100) [M–
C(Me)2CO2Et]+, 221 (12). 
HR-MS (EI): m/z calcd for C20H24N4O2+ [M]+ 352.1894, found 352.1897. 
 




Purine 123a (119 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 10 mol %), 
PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 
25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. Methyl 2-
bromohexanoate (140a, 209 mg, 1.00 mmol), 4-methoxybenzyl chloride (142b, 157 mg, 
1.00 mmol), and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 60 °C. After 
20 h, the resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The 
filtrate was concentrated in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc 3:1) yielded 141j[101] (114 mg, 62%) as a colorless oil and 185ab (11.3 mg, 6%) as 
a colorless oil. 
 
 
Purine 123a (119 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 10 mol %), 
PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 
25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. Ethyl 2-bromo-2,2-
difluoroacetate (84a, 203 mg, 1.00 mmol), 4-methoxybenzyl chloride (142b, 157 mg, 1.00 mmol), 
and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 60 °C. After 20 h, the 
resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The filtrate was 
concentrated in vacuo. Purification of the residue by column chromatography (n-hexane/EtOAc 
3:1) yielded 189[103] (79.3 mg, 44%) as a colorless oil and 185ab (27.7 mg, 15%) as a colorless oil. 




Purine 123a (119 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 10 mol %), 
PPh3 (13.1 mg, 50.0 μmol, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 
25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. Bromocycloheptane 
(136h, 177 mg, 1.00 mmol), 4-Methoxybenzyl chloride (142b, 157 mg, 1.00 mmol), and 
1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 60 °C. After 20 h, the 
resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The filtrate was 
concentrated in vacuo. Purification of the residue by column chromatography (n-hexane/EtOAc 
3:1) yielded 185ab (122 mg, 68%) as a colorless oil. 
 
5.3.4.4.2 Intermolecular Competition Experiment 
 
2-Phenylpyridine (68b, 77.6 mg, 0.50 mmol), 2-(4-methoxyphenyl)pyridine (68a, 92.6 mg, 
0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 10 mol %), PPh3 (13.1 mg, 50.0 μmol, 
10 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a pre-dried 25 mL Schlenk tube. The 
tube was evacuated and purged with N2 three times. 4-Methoxybenzyl chloride (142b, 117 mg, 
0.75 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 60 °C. After 
20 h, the resulting mixture was filtered through a pad of silica gel and washed with EtOAc. The 
filtrate was concentrated in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc 6:1) yielded 143d (32.1 mg, 23%) as a colorless oil, 143e (122 mg, 80%) as a 
colorless oil, and recovered 68b (43.1 mg, 56%) as a colorless oil. 
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5.3.4.4.3 Reactions with Radical Scavengers 
 
2-Phenylpyrimidine (139a, 78.1 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 
10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %), K2CO3 (138 mg, 1.00 mmol) and TEMPO (78.2 mg, 
0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged 
with N2 three times. 4-Methoxybenzyl chloride (142b, 235 mg, 1.50 mmol) and 1,4-dioxane 
(2.0 mL) were then added and the mixture was stirred at 60 °C. After 20 h, the resulting mixture 
was filtered through a pad of silica gel and washed with EtOAc. The filtrate was concentrated in 
vacuo. Purification of the residue by column chromatography (n-hexane/EtOAc 20:1) followed by 
recycling preparative HPLC yielded TEMPO-adduct 191 (23.0 mg, 17%) as a colorless oil and 
recovered 139a (61.0 mg, 78%) as a colorless oil. 
 
1-[(4-Methoxybenzyl)oxy]-2,2,6,6-tetramethylpiperidine (191) 
1H-NMR (300 MHz, CDCl3): δ = 7.29 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 
4.74 (s, 2H), 3.81 (s, 3H), 1.62–1.31 (m, 6H), 1.26 (s, 6H), 1.13 (s, 6H). 
13C-NMR (75 MHz, CDCl3): δ = 159.0 (Cq), 130.4 (Cq), 129.2 (CH), 113.6 (CH), 78.4 
(CH2), 60.0 (Cq), 55.3 (CH3), 39.7 (CH2), 33.2 (CH3), 20.3 (CH3), 17.1 (CH2). 
IR (ATR): ṽ = 2930, 1613, 1513, 1359, 1247, 1173, 1036, 821, 695, 603 cm−1.  
MS (ESI) m/z (relative intensity): 278 (100) [M+H]+, 243 (3), 137 (16). 
HR-MS (ESI): m/z calcd for C17H28NO2+ [M+H]+ 278.2115, found 278.2120. 
The spectral data are in accordance with those reported in the literature.[140] 
 
 




2-Phenylpyrimidine (139a, 78.1 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 
10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %), K2CO3 (138 mg, 1.00 mmol) and BHT (110 mg, 
0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged 
with N2 three times. 4-Methoxybenzyl chloride (142b, 235 mg, 1.50 mmol) and 1,4-dioxane 
(2.0 mL) were then added and the mixture was stirred at 60 °C. After 20 h, the resulting mixture 
was filtered through a pad of silica gel and washed with EtOAc. The filtrate was concentrated in 
vacuo. Purification of the residue by column chromatography (n-hexane/EtOAc 10:1) yielded 143b 
(91.4 mg, 66%) as a colorless oil. 
 
 
2-Phenylpyrimidine (139a, 78.1 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 17.7 mg, 50.0 μmol, 
10 mol %), PPh3 (13.1 mg, 50.0 μmol, 10 mol %), K2CO3 (138 mg, 1.00 mmol) and 
1,1-diphenylethylene (90.1 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The 
tube was evacuated and purged with N2 three times. 4-Methoxybenzyl chloride (142b, 235 mg, 
1.50 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 60 °C. After 
20 h, the resulting mixture was filtered throough a pad of silica gel and washed with EtOAc. The 
filtrate was concentrated in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc 10:1) yielded 143b (42.3 mg, 31%) as a colorless oil and recovered 139a 
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5.3.4.4.4 Isotopic Studies 
Preparation of [D]2-68b 
 
2-Phenylpyridine (68b, 776 mg, 5.00 mmol), [RuCl2(p-cymene)]2 (76.5 mg, 0.13 mmol, 2.5 mol %), 
MesCO2H (31, 246 mg, 1.50 mmol, 30 mol %) and K2CO3 (1.38 g, 10.0 mmol) were placed in a 
pre-dried 50 mL Schlenk tube. The tube was evacuated and purged with N2 three times. D2O 
(17 mL) was then added and the mixture was stirred at 100 °C. After 24 h, the resulting mixture 
was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. Purification of the residue by column chromatography (n-hexane/EtOAc 
10:1) yielded [D]2-68b (630 mg, 80%) as a colorless oil. The degree of deuteration was determined 
by 1H-NMR spectroscopy (Figure 27).  
 
 
Figure 27: 1H-NMR spectrum of [D]2-68b. 
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Preparation of [D]3-68b 
 
[D]5-2-Phenylpyridine ([D]5-68b, 481 mg, 3.00 mmol), [RuCl2(p-cymene)]2 (45.9 mg, 75.0 μmol, 
2.5 mol %), MesCO2H (31, 148 mg, 0.90 mmol, 30 mol %) and K2CO3 (829 mg, 6.00 mmol) were 
placed in a pre-dried 50 mL Schlenk tube. The tube was evacuated and purged with N2 three times. 
H2O (10 mL) was then added and the mixture was stirred at 100 °C. After 24 h, the resulting 
mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. Purification of the residue by column chromatography 
(n-hexane/EtOAc 10:1) yielded [D]3-68b (317 mg, 67%) as a colorless oil. The degree of deuteration 
was determined by 1H-NMR spectroscopy (Figure 28).  
 
 
Figure 28: 1H-NMR spectrum of [D]3-68b. 
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Ruthenium-Catalyzed meta-Benzylation of [D]2-68b 
 
The general procedure I was followed using [D]2-68b (78.6 mg, 0.50 mmol) and 4-methoxybenzyl 
chloride (142b, 235 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded [D]n-143d (83.6 mg, 60%) as a colorless oil. The degree of 
deuteration was determined by 1H-NMR spectroscopy (Figure 29).  
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Ruthenium-Catalyzed meta-Benzylation of [D]3-68b 
 
The general procedure I was followed using [D]3-68b (79.1 mg, 0.50 mmol) and 4-methoxybenzyl 
chloride (142b, 235 mg, 1.50 mmol). After 20 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded [D]n-143d (92.4 mg, 66%) as a colorless oil. The degree of 
deuteration was determined by 1H-NMR spectroscopy (Figure 30).  
 
 
Figure 30: 1H-NMR spectrum of [D]n-143d. 
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5.3.4.4.5 Cyclometallic Complex Studies 
Preparation of Ruthenacycle 192a 
 
2-Phenylpyridine (68b, 77.6 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 177 mg, 0.50 mmol), 
and PPh3 (131 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was 
evacuated and purged with N2 three times. THF (2.0 mL) was added and the mixture was stirred 
at 60 °C. After 2 h, an additional PPh3 (131 mg, 0.50 mmol) was added into the reaction mixture 
at ambient temperature and the mixture was again stirred at 60 °C for an additional 2 h. An orange 
solid formed during this time and the reaction was cooled to ambient temperature. The orange 
solid was collected and washed with THF (5.0 mL) and dry n-hexane (2 × 10 mL). The orange solid 
was dried under vacuum, providing complex trans-192a (249 mg, 59%). Suitable crystals of 
trans-192a for X-ray crystallography were grown by slow crystallization from THF/n-hexane (see 
X-Ray Crystallographic Analysis section). 
 
 
2-Phenylpyridine (68b, 155 mg, 1.00 mmol), [Ru(OAc)2(p-cymene)] (181, 353 mg, 1.00 mmol), and 
PPh3 (525 mg, 2.00 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated 
and purged with N2 three times. THF (2.0 mL) was added and the mixture was stirred at 60 °C for 
4 h. An orange solid formed during this time and the reaction was cooled to ambient temperature. 
The orange solid was collected and washed with THF (5.0 mL) and dry n-hexane (2 × 10 mL). The 
orange solid was dried under vacuum, providing complex 192a (690 mg, 82%).  
 




Ruthenacycle 98 (282 mg, 0.50 mmol), TBAOAc (151 mg, 0.50 mmol), and PPh3 (262 mg, 
1.00 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged 
with N2 three times. 1,4-Dioxane (1.6 mL) was added and the mixture was stirred at 60 °C for 1 h. 
Then, the reaction was cooled to ambient temperature. The orange solid was collected and 
washed with THF (5.0 mL) and dry n-hexane (2 × 10 mL). The orange solid was dried under vacuum, 
providing complex trans-192a (203 mg, 48%).  
 
Characteristic Data for trans-192a 
1H-NMR (300 MHz, CD2Cl2): δ = 8.79 (d, J = 5.7 Hz, 1H), 7.90 (d, J = 7.4 Hz, 
1H), 7.30–7.06 (m, 30H), 6.93–6.84 (m, 1H), 6.74 (dd, J = 7.4, 1.7 Hz, 1H), 
6.64 (d, J = 8.2 Hz, 1H), 6.53 (ddd, J = 7.4, 7.1, 1.7 Hz, 1H), 6.46 (dd, J = 7.4, 
7.1 Hz, 1H), 6.34 (ddd, J = 7.2, 5.7, 1.5 Hz, 1H), 0.77 (s, 3H).  
13C-NMR (75 MHz, CD2Cl2): δ = 184.5 (dd, J = 23, 11 Hz, Cq), 180.9 (Cq), 169.8 (Cq), 153.2 (CH), 148.8 
(Cq), 140.7 (CH), 134.7 (t, 2JC–P + 4JC–P = 11 Hz, CH), 133.0 (t, 1JC–P + 3JC–P = 35 Hz, Cq), 131.9 (CH), 
129.1 (CH), 127.7 (t, 3JC–P + 5JC–P = 9 Hz, CH), 125.3 (CH), 123.5 (CH), 118.8 (CH), 118.0 (CH), 117.9 
(CH), 22.8 (CH3). 
31P{1H}-NMR (121 MHz, CD2Cl2): δ = 41.2 (s). 
IR (ATR): ṽ = 3047, 1536, 1431, 1090, 1067, 745, 693, 672, 510, 493 cm−1.  
m.p.: 100–103 °C (decomp.). 
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Preparation of Ruthenacycle 192b 
 
2-(4-Fluorophenyl)pyridine (68d, 86.6 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 177 mg, 
0.50 mmol), and PPh3 (131 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The 
tube was evacuated and purged with N2 three times. THF (2.0 mL) was added and the mixture was 
stirred at 60 °C. After 2 h, an additional PPh3 (131 mg, 0.50 mmol) was added into the reaction 
mixture at ambient temperature and the mixture was again stirred at 60 °C for an additional 2 h. 
An orange solid formed during this time and the reaction was cooled to ambient temperature. The 
orange solid was collected and washed with THF (5.0 mL) and dry n-hexane (2 × 10 mL). The 
orange solid was dried under vacuum, providing complex 192b (145 mg, 34%, cis:trans = 1:17). 
Suitable crystals of trans-192b for X-ray crystallography were grown by slow crystallization from 
CH2Cl2/n-hexane (see X-Ray Crystallographic Analysis section). 
 
Characteristic Data for 192b 
1H-NMR (300 MHz, CD2Cl2, determined as a mixture of cis- and trans-
isomer 1:16): δ = 8.78 (d, J = 5.7 Hz, 1H, trans-isomer), 8.22 (d, J = 5.7 Hz, 
1H, cis-isomer), 7.54 (dd, J = 10.7, 2.6 Hz, 1H, trans-isomer), 7.33–7.06 (m, 
30H, trans-isomer), 6.91 (ddd, J = 7.9, 7.5, 1.5 Hz, 1H, trans-isomer), 6.69 (dd, J = 8.7, 5.9 Hz, 1H, 
trans-isomer), 6.60 (d, J = 7.9 Hz, 1H, trans-isomer), 6.51 (ddd, J = 8.5, 8.5, 2.5 Hz, 1H, cis-isomer), 
6.35 (ddd, J = 7.5, 5.7, 1.4 Hz, 1H, trans-isomer), 6.14 (ddd, J = 8.9, 8.7, 2.6 Hz, 1H, trans-isomer), 
1.07 (s, 3H, cis-isomer), 0.77 (s, 3H, trans-isomer). Due to overlapping, some proton peaks of cis-
192b could determined by 1H-NMR. 
19F{1H}-NMR (282 MHz, CD2Cl2, determined as a mixture of cis- and trans-isomer 1:16): δ = –116.7 
(s, cis-isomer), –116.9 (s, trans-isomer). 
31P{1H}-NMR (121 MHz, CD2Cl2, determined as a mixture of cis- and trans-isomer 1:16): δ = 56.5 
(d, J = 31.8 Hz, 1P, cis-isomer), 51.7 (d, J = 31.8 Hz, 1P, cis-isomer), 41.1 (s, trans-isomer). 
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IR (ATR): ṽ = 3053, 1585, 1541, 1430, 1090, 855, 740, 693, 510, 405 cm−1.  
m.p.: 130–133 °C (decomp.). 
MS (LIFDI) m/z (relative intensity): 857.2 (100) [M]+. 
 
Preparation of Ruthenacycle 193 
 
2-Phenylpyridine (68b, 77.6 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 177 mg, 0.50 mmol), 
and bis[2-(diphenylphosphino)phenyl]ether (DPEPhos, 269 mg, 0.50 mmol) were placed in a 
pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. THF 
(2.0 mL) was added and the mixture was stirred at 60 °C for 4 h. A yellow solid formed during this 
time and the reaction was cooled to ambient temperature. The yellow solid was collected and 
washed with dry n-hexane (2 × 10 mL). The yellow solid was dried under vacuum, providing 
complex 193 (276 mg, 65%). Suitable crystals of 193 for X-ray crystallography were grown by slow 
crystallization from THF/n-hexane (see X-Ray Crystallographic Analysis section). 
1H-NMR (400 MHz, CD2Cl2): δ = 7.94–7.89 (m, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 
7.54–7.06 (m, 20H), 6.91 (dd, J = 7.4, 7.4 Hz, 1H), 6.87–6.79 (m, 2H), 6.74–6.62 (m, 5H), 6.57 (dd, 
J = 8.3, 8.3 Hz, 1H), 6.43 (dd, J = 6.5, 6.5 Hz, 1H), 6.23 (dd, J = 7.5, 7.5 Hz, 1H), 6.08 (dd, J = 8.7, 
8.7 Hz, 2H), 0.87 (d, J = 1.7 Hz, 3H). 
13C-NMR (100 MHz, CD2Cl2): δ = 184.5 (d, 3JC–P = 2 Hz, Cq), 182.0 (dd, 3JC–P = 17, 8 Hz, Cq), 164.5 (Cq), 
160.7 (d, 2JC–P = 8 Hz, Cq), 158.9 (d, 2JC–P = 8 Hz, Cq), 151.1 (CH), 146.6 (d, 2JC–P = 1 Hz, Cq), 145.3 (d, 
4JC–P = 4 Hz, CH), 136.8 (d, 1JC–P = 42 Hz, Cq), 136.3 (d, 1JC–P = 43 Hz, Cq), 136.1–135.5 (m, CH), 135.4 
(CH), 135.2 (d, 1JC–P = 39 Hz, Cq), 135.2–134.6 (br, CH), 134.0 (d, 1JC–P = 37 Hz, Cq), 134.1–133.6 (m, 
CH), 131.6 (d, 2JC–P = 9 Hz, CH), 131.3 (CH), 131.1 (CH), 129.3 (CH), 128.6 (d, 4JC–P = 2 Hz, CH), 127.9 
(d, 4JC–P = 2 Hz, CH), 127.8 (d, 3JC–P = 7 Hz, CH), 127.7 (d, 3JC–P = 7 Hz, CH), 127.4 (d, 1JC–P = 39 Hz, Cq), 
127.2 (d, 3JC–P = 9 Hz, CH), 126.9 (d, 3JC–P = 8 Hz, CH), 125.7 (CH), 125.4 (d, 1JC–P = 38 Hz, Cq), 124.7 
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(d, 3JC–P = 6 Hz, CH), 124.4 (d, 3JC–P = 5 Hz, CH), 123.3 (d, 3JC–P = 6 Hz, CH), 122.9 (CH), 120.1 (d, 4JC–P 
= 3 Hz, CH), 119.7 (CH), 118.6 (br, CH), 117.6 (d, 4JC–P = 2 Hz, CH), 23.6 (d, 4JC–P = 2 Hz, CH3). 
31P{1H}-NMR (162 MHz, CD2Cl2): δ = 59.5 (d, J = 37.7 Hz), 46.7 (d, J = 37.7 Hz). 
IR (ATR): ṽ = 3050, 1578, 1454, 1433, 1232, 1091, 744, 695, 673, 518 cm−1.  
m.p.: 215–217 °C (decomp.). 
MS (LIFDI) m/z (relative intensity): 853.1 (100) [M]+. 
 
Preparation of Ruthenacycle 194 
 
Ruthenacycle 98 (282 mg, 0.50 mmol), TBAOAc (151 mg, 0.50 mmol), and PPh3 (131 mg, 
0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged 
with N2 three times. 1,4-Dioxane (1.6 mL) was added and the mixture was stirred at 60 °C for 1 h. 
Then, the reaction was cooled to ambient temperature. The orange solid was collected and 
washed with THF (5.0 mL) and dry n-hexane (2 × 10 mL). The orange solid was dried under vacuum, 
providing complex 194 (234 mg, 75%). Suitable crystals of 194 for X-ray crystallography were 
grown by slow crystallization from CH2Cl2/n-hexane (see X-Ray Crystallographic Analysis section). 
1H-NMR (300 MHz, CD2Cl2): δ = 8.44 (d, J = 5.9 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.47–7.34 (m, 3H), 
7.30–7.19 (m, 3H), 7.19–7.08 (m, 12H), 6.83 (ddd, J = 7.5, 7.3, 1.5 Hz, 1H), 6.78–6.67 (m, 2H), 2.12 
(s, 3H), 1.89 (s, 3H). 
13C-NMR (100 MHz, CD2Cl2): δ = 187.3 (d, 2JC–P = 16 Hz, Cq), 185.3 (Cq), 167.4 (Cq), 151.8 (CH), 146.6 
(Cq), 140.0 (CH), 135.7 (d, 1JC–P = 43 Hz, Cq), 134.7 (CH), 133.6 (d, 2JC–P = 10 Hz, CH), 129.1 (d, 4JC–P = 
2 Hz, CH), 127.9 (d, 3JC–P = 9 Hz, CH), 126.8 (CH), 123.9 (CH), 122.1 (Cq), 120.6 (CH), 119.1 (CH), 
118.0 (CH), 24.7 (CH3), 4.9 (CH3). 
31P{1H}-NMR (162 MHz, CD2Cl2): δ = 65.7 (s). 
IR (ATR): ṽ = 3052, 2241, 1538, 1474, 1434, 1092, 751, 696, 664, 518 cm−1.  
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m.p.: 147–149 °C (decomp.). 
MS (LIFDI) m/z (relative intensity): 618.2 (100) [M]+. 
 
Isomerization of Ruthenacycle trans-192a 
 
The NMR tube equipped with J. Young valve was charged with the solution of trans-192a (42.0 mg, 
50 μmol) in THF-d8 (0.5 mL). Then, the tube was heated at 60 °C. After 4 h, the tube was cooled to 
ambient temperature and measured 31P{1H}-NMR spectroscopy (Figure 31). 
 
 
Figure 31: Isomerization of ruthenacycle trans-192a determined by 31P{1H}-NMR spectroscopy 
(cis-isomer = ●, trans-isomer = ●). 
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Ligand Exchange of Ruthenacycle cis-/trans-192a with pyridine 68d 
 
The NMR tube equipped with J. Young valve was charged with the solution of cis-/trans-192a 
(42.0 mg, 50 μmol, cis:trans = 1:10) and pyridine 68d (8.7 mg, 50 μmol) in PhMe-d8 (0.5 mL). K2CO3 
(7.0 mg, 50 μmol) was then added and the tube was heated at 60 °C. After 4 h, the tube was cooled 
to ambient temperature and measured 31P{1H}-NMR spectroscopy. 
 
 
Figure 32: Ligand exchange of ruthenacycle 192a with 68d determined by 31P{1H}-NMR 








Cyclic voltammetric analysis was carried out with a Metrohm Autolab PGSTAT204 workstation and 
analysis was performed with Nova 2.1.4 software. A glassy-carbon electrode (3 mm-diameter, 
disc-electrode) was used as the working electrode, a Pt wire was used as the auxiliary electrode 
and a Ag/AgCl electrode was used as the reference. 1,2-DCE with 0.1 mol∙L–1 n-Bu4NPF6 as 
conducting salt served as electrolytes for the measurements. 1,2-DCE was dried and degassed 




Figure 33: Cyclic voltammogram at 100 mV∙s–1 in 1,2-DCE. n-Bu4NPF6 (0.1 M in 1,2-DCE), 
concentration of substrates 4 mM. E1/2 of 98 = 0.75 V, E1/2 of cis-/trans-192a = 0.33 and 0.56 V, E1/2 
of trans-192a = 0.32 V, E1/2 of 194 = 0.47 V. 
 





Figure 34: Cyclic voltammogram at 100 mV∙s–1 in 1,2-DCE. n-Bu4NPF6 (0.1 M in 1,2-DCE), 
concentration of substrates 4 mM. E1/2 of 193 = 0.44 V, Eox of 195 = 0.81 V. 
 
Catalytic Reactions with Ruthenacycle trans-192a, 193, and 194 
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Reactions with Ruthenacycle trans-192a 
2-Phenylpyridine (68b, 38.8 mg, 0.25 mmol), trans-192a (21.0 mg, 25.0 μmol, 10 mol %), KOAc 
(2.5 mg, 25.0 μmol, 10 mol %) and K2CO3 (69 mg, 0.50 mmol) were placed in a pre-dried 25 mL 
Schlenk tube. The tube was evacuated and purged with N2 three times. 4-Methoxybenzyl chloride 
(142b, 118 mg, 0.75 mmol) and 1,4-dioxane (1.0 mL) were then added and the mixture was stirred 
at 60 °C. After 20 h, the resulting mixture was filtered through a pad of silica gel and washed with 
EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (n-hexane/EtOAc 10:1) yielded meta-benzylated product 143d (37.2 mg, 54%). 
In case of the condition without KOAc, the reaction gave the product 143d (26.8 mg, 39%). 
 
Reactions with Ruthenacycle 193 
2-Phenylpyridine (68b, 38.8 mg, 0.25 mmol), 193 (21.3 mg, 25.0 μmol, 10 mol %), KOAc (2.5 mg, 
25.0 μmol, 10 mol %) and K2CO3 (69 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk 
tube. The tube was evacuated and purged with N2 three times. 4-Methoxybenzyl chloride (142b, 
118 mg, 0.75 mmol) and 1,4-dioxane (1.0 mL) were then added and the mixture was stirred at 
60 °C. After 20 h, the resulting mixture was determined by gas chromatography. Both reactions 
with and without KOAc did not afford any conversion of the product 143d. 
 
Reactions with Ruthenacycle 194 
2-Phenylpyridine (68b, 77.6 mg, 0.5 mmol), 194 (30.9 mg, 50.0 μmol, 10 mol %), KOAc (5.0 mg, 
50.0 μmol, 10 mol %) and K2CO3 (139 mg, 1.00 mmol) were placed in a pre-dried 25 mL Schlenk 
tube. The tube was evacuated and purged with N2 three times. 4-Methoxybenzyl chloride (142b, 
235 mg, 1.5 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred at 
60 °C. After 20 h, the resulting mixture was filtered through a pad of silica gel and washed with 
EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (n-hexane/EtOAc 10:1) yielded meta-benzylated product 194 (81.0 mg, 59%). In 
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Stoichiometric Reactions of Ruthenacycle 192a 
 
Ruthenacycle 192a (84.0 mg, 0.10 mmol) and K2CO3 (28.0 mg, 0.20 mmol) were placed in a 
pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. 
4-Methoxybenzyl chloride (142b, 23.5 mg, 0.15 mmol) and 1,4-dioxane (1.0 mL) were then added 
and the mixture was stirred at 80 °C for 20 h. At ambient temperature, 2,2’-bipyridine (46.9 mg, 
0.30 mmol), AcOH (30.0 mg, 0.50 mmol) and 1,2-DCE (1.0 mL) were added, and the resulting 
mixture was stirred at ambient temperature for 16 h. Then, the reaction mixture was quenched 
with sat. aq. NaHCO3 solution (10 mL) and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). 
The combined organic layers were dried over Na2SO4 and concentrated in vacuo. Purification of 
the residue by column chromatography (n-hexane/EtOAc 10:1) yielded meta-benzylated product 
143d (in case of cis-/trans-192a: 11.0 mg, 40%, in case of trans-192a: 13.2 mg, 48%) as a colorless 
oil. 
 
5.3.4.5 Racemization Examination 
Benzyl chlorides S-186c and R-186c were examined by HPLC with a Daicel CHIRALPAK IA-3 (4.6 mm 
x 250 mm, 3 µm particle size) n-hexane/i-PrOH 80:20, 1 mL/min flow rate, detection at 250 nm. 
S-186c: tr = 13.6 min. R-186c: tr = 9.9 min. 
  









Mixture of S-186c and R-186c 
 





Benzyl chlorides rac-186d and S-186d were examined by HPLC with a Daicel CHIRALPAK IA-3 
(4.6 mm x 250 mm, 3 µm particle size) n-hexane/i-PrOH 70:30, 1 mL/min flow rate, detection at 











Benzyl chlorides rac-186j and R-186j were examined by HPLC with a Daicel CHIRALPAK IC-3 
(4.6 mm x 250 mm, 3 µm particle size) n-hexane/EtOAc 95:5, 1 mL/min flow rate, detection at 











Compound S-187e and R-187e were examined by HPLC with a Daicel CHIRALPAK IA-3 (4.6 mm x 
250 mm, 3 µm particle size) n-hexane/i-PrOH 50:50, 1 mL/min flow rate, detection at 250 nm. 















Compound rac-187f and S-187f were examined by HPLC with a Daicel CHIRALPAK IA-3 (4.6 mm x 
250 mm, 3 µm particle size) n-hexane/i-PrOH 50:50, 1 mL/min flow rate, detection at 250 nm. 
S-187f: tr = 10.1 min. R-187f: tr = 8.0 min. 
 









Compound rac-187l and R-187l were examined by HPLC with a Daicel CHIRALPAK IC-3 (4.6 mm x 
250 mm, 3 µm particle size) n-hexane/EtOAc 85:15, 1 mL/min flow rate, detection at 274 nm. 
R-187l: tr = 13.6 min. S-187l: tr = 14.8 min. 
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5.3.4.6 Fluorescence Spectra 
Concentration of sample: 1 mg/L in CHCl3 
 
Figure 35: Excitation/emission fluorescence spectrum of 187a. 
 
 
Figure 36: Excitation/emission fluorescence spectrum of 187b. 
 




Figure 37: Emission fluorescence spectra of 187a and 187b (excitation at 502 nm). 
 
5.3.4.7 X-Ray Crystallographic Analysis 
A suitable crystal was selected and the crystal was mounted on a MITIGEN holder in NVH oil on a 
Bruker D8 Venture diffractometer. The crystal was kept at 100 or 150 K during data collection. 
Using Olex2,[137] the structure was solved with the XT[138] structure solution program using Intrinsic 
Phasing and refined with the XL[139] refinement package using Least Squares minimisation. 
 
 
Figure 38: Molecular structure of 143a with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
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Crystal Data for C18H16N2 (M = 260.33 g/mol): orthorhombic, space group Pca21 (no. 29), a = 
12.2928(3) Å, b = 6.01020(10) Å, c = 36.9034(9) Å, V = 2726.50(10) Å3, Z = 8, T = 99.97 K, 
μ(MoKα) = 0.075 mm-1, Dcalc = 1.268 g/cm3, 28332 reflections measured (6.624° ≤ 2Θ ≤ 59.142°), 
7604 unique (Rint = 0.0264, Rsigma = 0.0245) which were used in all calculations. The final R1 was 
0.0431 (I > 2σ(I)) and wR2 was 0.1162 (all data). 
 
Table 38: Crystal data and structure refinement for 143a. 
Compound 143a 
CCDC number 1915687 
Identification code Pca21 
Empirical formula C18H16N2 
Formula weight 260.33 
Temperature/K 99.97 
Crystal system orthorhombic 












Crystal size/mm3 0.309 × 0.268 × 0.244 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.624 to 59.142 
Index ranges -17 ≤ h ≤ 17, -8 ≤ k ≤ 8, -51 ≤ l ≤ 51 
Reflections collected 28332 
5 Experimental Part 
 
304 
Independent reflections 7604 [Rint = 0.0264, Rsigma = 0.0245] 
Data/restraints/parameters 7604/151/452 
Goodness-of-fit on F2 1.050 
Final R indexes [I>=2σ (I)] R1 = 0.0431, wR2 = 0.1153 
Final R indexes [all data] R1 = 0.0443, wR2 = 0.1162 
Largest diff. peak/hole / e Å-3 0.52/-0.25 
Flack parameter -0.2(5) 
 
Table 39: Bond lengths [Å] for 143a. 
Atom Atom Length/Å Atom Atom Length/Å 
N1 C1 1.342(3) C7 C11 1.541(3) 
N1 C4 1.337(2) C8 C9 1.403(3) 
N2 C3 1.334(3) C9 C10 1.388(3) 
N2 C4 1.342(3) C11 C12 1.524(3) 
C1 C2 1.378(3) C11 C18 1.522(3) 
C2 C3 1.391(3) C12 C13 1.393(3) 
C4 C5 1.486(3) C12 C17 1.384(4) 
C5 C6 1.394(3) C13 C14 1.397(3) 
C5 C10 1.396(3) C14 C15 1.388(4) 
C6 C7 1.399(3) C15 C16 1.379(4) 
C7 C8 1.391(3) C16 C17 1.385(4) 
 
Table 40: Bond angles [°] for 143a. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C4 N1 C1 116.03(18) C7 C8 C9 120.75(19) 
C3 N2 C4 116.4(2) C10 C9 C8 120.37(19) 
N1 C1 C2 122.9(2) C9 C10 C5 119.62(19) 
C1 C2 C3 116.23(19) C12 C11 C7 109.22(17) 
N2 C3 C2 122.4(2) C18 C11 C7 113.9(2) 
N1 C4 N2 126.02(18) C18 C11 C12 111.3(2) 
N1 C4 C5 117.10(17) C13 C12 C11 122.1(2) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 C4 C5 116.87(17) C17 C12 C11 119.1(2) 
C6 C5 C4 119.36(17) C17 C12 C13 118.8(2) 
C6 C5 C10 119.46(18) C12 C13 C14 120.3(2) 
C10 C5 C4 121.18(17) C15 C14 C13 119.8(2) 
C5 C6 C7 121.70(19) C16 C15 C14 119.9(2) 
C6 C7 C11 117.46(19) C15 C16 C17 120.1(2) 
C8 C7 C6 118.1(2) C12 C17 C16 121.1(2) 
C8 C7 C11 124.44(19)     
 
 
Figure 39: Molecular structure of 143b with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C18H16N2O (M = 276.33 g/mol): orthorhombic, space group Pbca (no. 61), a = 
18.7085(6) Å, b = 6.2302(2) Å, c = 24.4878(10) Å, V = 2854.24(17) Å3, Z = 8, T = 100.0 K, μ(MoKα) = 
0.081 mm-1, Dcalc = 1.286 g/cm3, 37416 reflections measured (4.354° ≤ 2Θ ≤ 59.152°), 3996 
unique (Rint = 0.0318, Rsigma = 0.0169) which were used in all calculations. The final R1 was 0.0436 
(I > 2σ(I)) and wR2 was 0.1102 (all data). 
 
Table 41: Crystal data and structure refinement for 143b. 
Compound 143b 
CCDC number 1915683 
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Identification code Pbca 
Empirical formula C18H16N2O 
Formula weight 276.33 
Temperature/K 100.0 
Crystal system orthorhombic 












Crystal size/mm3 0.251 × 0.204 × 0.076 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.354 to 59.152 
Index ranges -21 ≤ h ≤ 25, -8 ≤ k ≤ 8, -33 ≤ l ≤ 33 
Reflections collected 37416 
Independent reflections 3996 [Rint = 0.0318, Rsigma = 0.0169] 
Data/restraints/parameters 3996/0/191 
Goodness-of-fit on F2 1.068 
Final R indexes [I>=2σ (I)] R1 = 0.0436, wR2 = 0.1080 
Final R indexes [all data] R1 = 0.0469, wR2 = 0.1102 
Largest diff. peak/hole / e Å-3 0.37/-0.23 
 
5.3 Experimental Procedures and Analytical Data 
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Table 42: Bond lengths [Å] for 143b. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C1 1.4292(13) C6 C7 1.3970(14) 
O1 C2 1.3748(12) C8 C9 1.5199(13) 
N1 C15 1.3420(13) C9 C10 1.3965(14) 
N1 C16 1.3384(14) C9 C14 1.3961(13) 
N2 C15 1.3436(13) C10 C11 1.3915(14) 
N2 C18 1.3394(15) C11 C12 1.3880(14) 
C2 C3 1.3954(13) C12 C13 1.3999(14) 
C2 C7 1.3883(14) C13 C14 1.3976(13) 
C3 C4 1.3854(14) C13 C15 1.4850(14) 
C4 C5 1.4001(13) C16 C17 1.3807(17) 
C5 C6 1.3907(13) C17 C18 1.3810(18) 
C5 C8 1.5123(13)    
 
Table 43: Bond angles [°] for 143b. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 O1 C1 117.38(8) C14 C9 C8 119.58(9) 
C16 N1 C15 116.26(10) C14 C9 C10 118.70(9) 
C18 N2 C15 116.37(10) C11 C10 C9 120.51(9) 
O1 C2 C3 115.48(9) C12 C11 C10 120.57(9) 
O1 C2 C7 124.56(9) C11 C12 C13 119.69(9) 
C7 C2 C3 119.95(9) C12 C13 C15 119.76(9) 
C4 C3 C2 119.97(9) C14 C13 C12 119.40(9) 
C3 C4 C5 121.13(9) C14 C13 C15 120.79(9) 
C4 C5 C8 120.37(9) C9 C14 C13 121.12(9) 
C6 C5 C4 117.99(9) N1 C15 N2 125.58(10) 
C6 C5 C8 121.62(9) N1 C15 C13 117.25(9) 
C5 C6 C7 121.62(9) N2 C15 C13 117.17(9) 
C2 C7 C6 119.33(9) N1 C16 C17 122.81(11) 
C5 C8 C9 115.13(8) C16 C17 C18 116.37(10) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C10 C9 C8 121.71(9) N2 C18 C17 122.60(11) 
 
 
Figure 40: Molecular structure of 143g with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C18H15FN2O (M = 294.32 g/mol): monoclinic, space group P21/c (no. 14), a = 
8.1191(4) Å, b = 5.6386(3) Å, c = 31.0628(17) Å, β = 93.276(2)°, V = 1419.74(13) Å3, Z = 4, T = 
99.98 K, μ(MoKα) = 0.096 mm-1, Dcalc = 1.377 g/cm3, 20105 reflections measured (5.026° ≤ 2Θ ≤ 
59.122°), 3964 unique (Rint = 0.0168, Rsigma = 0.0125) which were used in all calculations. The final 
R1 was 0.0370 (I > 2σ(I)) and wR2 was 0.1001 (all data).  
 
Table 44: Crystal data and structure refinement for 143g. 
Compound 143g 
CCDC number 1915686 
Identification code mo_0182_CG_0m 
Empirical formula C18H15FN2O 
Formula weight 294.32 
Temperature/K 99.98 
Crystal system monoclinic 
Space group P21/c 
a/Å 8.1191(4) 
b/Å 5.6386(3) 












Crystal size/mm3 0.426 × 0.412 × 0.326 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.026 to 59.122 
Index ranges -11 ≤ h ≤ 11, -7 ≤ k ≤ 7, -43 ≤ l ≤ 39 
Reflections collected 20105 
Independent reflections 3964 [Rint = 0.0168, Rsigma = 0.0125] 
Data/restraints/parameters 3964/0/200 
Goodness-of-fit on F2 1.039 
Final R indexes [I>=2σ (I)] R1 = 0.0370, wR2 = 0.0984 
Final R indexes [all data] R1 = 0.0389, wR2 = 0.1001 
Largest diff. peak/hole / e Å-3 0.43/-0.19 
 
Table 45: Bond lengths [Å] for 143g. 
Atom Atom Length/Å Atom Atom Length/Å 
F1 C1 1.3658(10) C4 C7 1.4836(12) 
O1 C15 1.3692(11) C5 C6 1.3964(12) 
O1 C18 1.4255(12) C6 C11 1.5157(12) 
N1 C7 1.3444(12) C8 C9 1.3867(14) 
N1 C8 1.3381(12) C9 C10 1.3840(15) 
N2 C7 1.3431(11) C11 C12 1.5145(12) 
N2 C10 1.3342(12) C12 C13 1.3920(12) 
C1 C2 1.3830(13) C12 C17 1.3964(13) 
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Atom Atom Length/Å Atom Atom Length/Å 
C1 C6 1.3860(13) C13 C14 1.3952(13) 
C2 C3 1.3880(12) C14 C15 1.3929(12) 
C3 C4 1.3963(12) C15 C16 1.3945(13) 
C4 C5 1.3949(12) C16 C17 1.3873(13) 
 
Table 46: Bond angles [°] for 143g. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C15 O1 C18 116.57(8) N2 C7 N1 125.87(8) 
C8 N1 C7 116.46(8) N2 C7 C4 116.77(8) 
C10 N2 C7 116.10(8) N1 C8 C9 122.20(9) 
F1 C1 C2 117.78(8) C10 C9 C8 116.53(9) 
F1 C1 C6 118.51(8) N2 C10 C9 122.85(9) 
C2 C1 C6 123.71(8) C12 C11 C6 111.51(7) 
C1 C2 C3 118.22(8) C13 C12 C11 120.96(8) 
C2 C3 C4 120.48(8) C13 C12 C17 117.98(8) 
C3 C4 C7 119.94(8) C17 C12 C11 121.03(8) 
C5 C4 C3 119.27(8) C12 C13 C14 121.67(8) 
C5 C4 C7 120.79(8) C15 C14 C13 119.26(8) 
C4 C5 C6 121.60(8) O1 C15 C14 124.28(8) 
C1 C6 C5 116.69(8) O1 C15 C16 115.79(8) 
C1 C6 C11 122.40(8) C14 C15 C16 119.92(8) 
C5 C6 C11 120.90(8) C17 C16 C15 119.86(8) 
N1 C7 C4 117.36(8) C16 C17 C12 121.29(8) 
 




Figure 41: Molecular structure of 143j with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C18H15FN2 (M = 278.32 g/mol): monoclinic, space group P21/c (no. 14), a = 
19.3115(8) Å, b = 5.8472(3) Å, c = 12.7090(5) Å, β = 106.294(2)°, V = 1377.44(11) Å3, Z = 4, T = 
100.01 K, μ(MoKα) = 0.089 mm-1, Dcalc = 1.342 g/cm3, 39008 reflections measured (4.394° ≤ 2Θ ≤ 
59.996°), 4019 unique (Rint = 0.0356, Rsigma = 0.0218) which were used in all calculations. The final 
R1 was 0.0533 (I > 2σ(I)) and wR2 was 0.1230 (all data).  
 
Table 47: Crystal data and structure refinement for 143j. 
Compound 143j 
CCDC number 1915684 
Identification code mo_0065_CG_0m 
Empirical formula C18H15FN2 
Formula weight 278.32 
Temperature/K 100.01 
Crystal system monoclinic 















Crystal size/mm3 0.29 × 0.17 × 0.065 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.394 to 59.996 
Index ranges -26 ≤ h ≤ 27, -8 ≤ k ≤ 8, -17 ≤ l ≤ 17 
Reflections collected 39008 
Independent reflections 4019 [Rint = 0.0356, Rsigma = 0.0218] 
Data/restraints/parameters 4019/36/295 
Goodness-of-fit on F2 1.183 
Final R indexes [I>=2σ (I)] R1 = 0.0533, wR2 = 0.1197 
Final R indexes [all data] R1 = 0.0588, wR2 = 0.1230 
Largest diff. peak/hole / e Å-3 0.40/-0.33 
 
Table 48: Selected bond lengths [Å] for 143j. 
Atom Atom Length/Å Atom Atom Length/Å 
F1 C1A 1.374(3) C7A C8A 1.528(3) 
N1 C15 1.3446(17) C7A C9A 1.528(3) 
N1 C16 1.3374(19) C9A C10A 1.391(3) 
N2 C15 1.3429(17) C9A C14A 1.395(3) 
N2 C18 1.3355(18) C10A C11A 1.388(4) 
C1A C2A 1.373(4) C11A C12A 1.375(4) 
C1A C6A 1.382(4) C12A C13A 1.399(4) 
C2A C3A 1.382(4) C13A C14A 1.395(3) 
C3A C4A 1.396(3) C13A C15 1.478(3) 
C4A C5A 1.392(3) C16 C17 1.379(2) 
C4A C7A 1.526(3) C17 C18 1.380(2) 
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Atom Atom Length/Å Atom Atom Length/Å 
C5A C6A 1.395(4)    
 
Table 49: Selected bond angles [°] for 143j. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C16 N1 C15 116.14(12) C10A C9A C14A 117.9(2) 
C18 N2 C15 116.38(12) C14A C9A C7A 118.4(2) 
F1 C1A C6A 114.0(4) C11A C10A C9A 120.9(2) 
C2A C1A F1 122.3(4) C12A C11A C10A 120.2(3) 
C2A C1A C6A 123.7(3) C11A C12A C13A 120.8(3) 
C1A C2A C3A 117.9(3) C12A C13A C15 122.2(3) 
C2A C3A C4A 121.3(2) C14A C13A C12A 118.0(2) 
C3A C4A C7A 120.0(2) C14A C13A C15 119.7(3) 
C5A C4A C3A 118.6(2) C13A C14A C9A 122.2(2) 
C5A C4A C7A 121.4(3) N1 C15 C13A 118.11(19) 
C4A C5A C6A 121.4(2) N2 C15 N1 125.54(13) 
C1A C6A C5A 117.1(3) N2 C15 C13A 116.36(19) 
C4A C7A C8A 111.63(18) N1 C16 C17 122.83(13) 
C4A C7A C9A 109.42(19) C16 C17 C18 116.39(13) 
C8A C7A C9A 114.46(18) N2 C18 C17 122.71(14) 
C10A C9A C7A 123.7(2)     
 




Figure 42: Molecular structure of 185ai with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C21H19FN4 (M = 346.40 g/mol): monoclinic, space group P21/c (no. 14), a = 
11.2425(7) Å, b = 9.3295(6) Å, c = 16.3348(11) Å, β = 94.764(2)°, V = 1707.39(19) Å3, Z = 4, T = 
99.98 K, μ(MoKα) = 0.090 mm-1, Dcalc = 1.348 g/cm3, 5632 reflections measured (5.004° ≤ 2Θ ≤ 
63.084°), 5632 unique (Rint = 0.0, Rsigma = 0.0206) which were used in all calculations. The final R1 
was 0.0392 (I > 2σ(I)) and wR2 was 0.1096 (all data).  
 
Table 50: Crystal data and structure refinement for 185ai. 
Compound 185ai 
CCDC number 1915675 
Identification code mo_0272_CG_0m_4 
Empirical formula C21H19FN4 
Formula weight 346.40 
Temperature/K 99.98 
Crystal system monoclinic 















Crystal size/mm3 0.424 × 0.247 × 0.21 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.004 to 63.084 
Index ranges -16 ≤ h ≤ 16, 13 ≤ k ≤ 0, 24 ≤ l ≤ 0 
Reflections collected 5632 
Independent reflections 5632 [Rint = 0.0, Rsigma = 0.0206] 
Data/restraints/parameters 5632/0/237 
Goodness-of-fit on F2 1.041 
Final R indexes [I>=2σ (I)] R1 = 0.0392, wR2 = 0.1076 
Final R indexes [all data] R1 = 0.0428, wR2 = 0.1096 
Largest diff. peak/hole / e Å-3 0.44/-0.27 
 
Table 51: Bond lengths [Å] for 185ai. 
Atom Atom Length/Å Atom Atom Length/Å 
F1 C1 1.3554(11) C4 C7 1.5150(12) 
N1 C14 1.3502(10) C5 C6 1.3911(13) 
N1 C15 1.3397(11) C7 C8 1.5132(12) 
N2 C15 1.3367(11) C8 C9 1.3925(11) 
N2 C16 1.3337(10) C8 C13 1.3960(12) 
N3 C16 1.3730(10) C9 C10 1.4001(11) 
N3 C17 1.3691(10) C10 C11 1.4004(11) 
N3 C19 1.4762(10) C10 C14 1.4770(11) 
N4 C17 1.3179(11) C11 C12 1.3882(12) 
N4 C18 1.3913(10) C12 C13 1.3908(12) 
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Atom Atom Length/Å Atom Atom Length/Å 
C1 C2 1.3774(13) C14 C18 1.4032(11) 
C1 C6 1.3841(12) C16 C18 1.4076(11) 
C2 C3 1.3891(14) C19 C20 1.5227(13) 
C3 C4 1.3948(12) C19 C21 1.5200(12) 
C4 C5 1.3969(11)    
 
Table 52: Bond angles [°] for 185ai. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C15 N1 C14 119.49(7) C9 C10 C11 119.40(7) 
C16 N2 C15 111.22(7) C9 C10 C14 119.41(7) 
C16 N3 C19 125.59(7) C11 C10 C14 121.19(7) 
C17 N3 C16 105.56(7) C12 C11 C10 119.80(8) 
C17 N3 C19 128.70(7) C11 C12 C13 120.20(8) 
C17 N4 C18 104.01(7) C12 C13 C8 120.91(8) 
F1 C1 C2 118.70(8) N1 C14 C10 117.00(7) 
F1 C1 C6 118.57(8) N1 C14 C18 117.75(7) 
C2 C1 C6 122.73(9) C18 C14 C10 125.25(7) 
C1 C2 C3 117.97(8) N2 C15 N1 128.32(8) 
C2 C3 C4 121.76(8) N2 C16 N3 126.86(7) 
C3 C4 C5 118.12(8) N2 C16 C18 126.84(7) 
C3 C4 C7 120.23(8) N3 C16 C18 106.29(7) 
C5 C4 C7 121.63(8) N4 C17 N3 114.51(7) 
C6 C5 C4 121.33(8) N4 C18 C14 134.05(7) 
C1 C6 C5 118.10(8) N4 C18 C16 109.63(7) 
C8 C7 C4 114.04(7) C14 C18 C16 116.32(7) 
C9 C8 C7 120.19(8) N3 C19 C20 109.47(7) 
C9 C8 C13 118.62(8) N3 C19 C21 110.16(7) 
C13 C8 C7 121.19(8) C21 C19 C20 112.01(7) 
C8 C9 C10 121.07(7)     
 




Figure 43: Molecular structure of 185aj with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C21H19ClN4 (M = 362.85 g/mol): triclinic, space group P-1 (no. 2), a = 8.9649(8) Å, 
b = 9.9520(7) Å, c = 11.7814(11) Å, α = 100.554(3)°, β = 105.986(3)°, γ = 111.878(2)°, V = 
888.28(13) Å3, Z = 2, T = 100.0 K, μ(MoKα) = 0.227 mm-1, Dcalc = 1.357 g/cm3, 12425 reflections 
measured (4.656° ≤ 2Θ ≤ 63.036°), 5883 unique (Rint = 0.0176, Rsigma = 0.0255) which were used in 
all calculations. The final R1 was 0.0376 (I > 2σ(I)) and wR2 was 0.1059 (all data). 
 
Table 53: Crystal data and structure refinement for 185aj. 
Compound 185aj 
CCDC number 1915610 
Identification code mo_0273_CG_0m 
Empirical formula C21H19ClN4 
Formula weight 362.85 
Temperature/K 100.0 
Crystal system triclinic 















Crystal size/mm3 0.287 × 0.198 × 0.162 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.656 to 63.036 
Index ranges -13 ≤ h ≤ 9, -14 ≤ k ≤ 14, -17 ≤ l ≤ 17 
Reflections collected 12425 
Independent reflections 5883 [Rint = 0.0176, Rsigma = 0.0255] 
Data/restraints/parameters 5883/0/237 
Goodness-of-fit on F2 1.078 
Final R indexes [I>=2σ (I)] R1 = 0.0376, wR2 = 0.1031 
Final R indexes [all data] R1 = 0.0407, wR2 = 0.1059 
Largest diff. peak/hole / e Å-3 0.49/-0.52 
 
Table 54: Bond lengths [Å] for 185aj. 
Atom Atom Length/Å Atom Atom Length/Å 
Cl1 C1 1.7425(10) C4 C7 1.5099(15) 
N1 C14 1.3485(12) C5 C6 1.3913(15) 
N1 C15 1.3365(12) C7 C8 1.5123(14) 
N2 C15 1.3376(12) C8 C9 1.3949(13) 
N2 C16 1.3310(12) C8 C13 1.3933(15) 
N3 C16 1.3715(11) C9 C10 1.4013(13) 
N3 C18 1.3729(12) C10 C11 1.3992(13) 
N3 C19 1.4755(12) C10 C14 1.4782(13) 
N4 C17 1.3905(12) C11 C12 1.3905(13) 
N4 C18 1.3172(12) C12 C13 1.3885(15) 
C1 C2 1.3885(13) C14 C17 1.4048(12) 
C1 C6 1.3821(14) C16 C17 1.4063(12) 
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Atom Atom Length/Å Atom Atom Length/Å 
C2 C3 1.3915(14) C19 C20 1.5140(16) 
C3 C4 1.3956(14) C19 C21 1.5035(16) 
C4 C5 1.3920(15)    
 
Table 55: Bond angles [°] for 185aj. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C15 N1 C14 119.56(8) C9 C10 C14 119.50(8) 
C16 N2 C15 111.07(8) C11 C10 C9 119.16(9) 
C16 N3 C18 105.30(8) C11 C10 C14 121.32(8) 
C16 N3 C19 124.64(8) C12 C11 C10 119.88(9) 
C18 N3 C19 130.03(8) C13 C12 C11 120.36(10) 
C18 N4 C17 104.07(8) C12 C13 C8 120.72(9) 
C2 C1 Cl1 119.39(8) N1 C14 C10 117.03(8) 
C6 C1 Cl1 118.85(8) N1 C14 C17 117.62(8) 
C6 C1 C2 121.76(9) C17 C14 C10 125.36(8) 
C1 C2 C3 118.39(9) N1 C15 N2 128.45(9) 
C2 C3 C4 121.37(9) N2 C16 N3 126.45(8) 
C3 C4 C7 121.12(9) N2 C16 C17 126.96(8) 
C5 C4 C3 118.47(9) N3 C16 C17 106.58(8) 
C5 C4 C7 120.31(9) N4 C17 C14 134.12(8) 
C6 C5 C4 121.19(9) N4 C17 C16 109.54(8) 
C1 C6 C5 118.82(9) C14 C17 C16 116.33(8) 
C4 C7 C8 115.92(8) N4 C18 N3 114.51(8) 
C9 C8 C7 120.82(10) N3 C19 C20 110.46(8) 
C13 C8 C7 120.33(9) N3 C19 C21 110.84(9) 
C13 C8 C9 118.79(9) C21 C19 C20 112.70(12) 
C8 C9 C10 121.08(9)     
 




Figure 44: Molecular structure of 185hb with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C27H22N4O2 (M = 434.48 g/mol): triclinic, space group P-1 (no. 2), a = 6.3344(7) Å, 
b = 12.4251(18) Å, c = 13.9524(19) Å, α = 106.848(5)°, β = 91.291(5)°, γ = 93.640(5)°, V = 
1047.9(2) Å3, Z = 2, T = 100.01 K, μ(MoKα) = 0.089 mm-1, Dcalc = 1.377 g/cm3, 38890 reflections 
measured (5.22° ≤ 2Θ ≤ 63.094°), 7003 unique (Rint = 0.0243, Rsigma = 0.0175) which were used in 
all calculations. The final R1 was 0.0393 (I > 2σ(I)) and wR2 was 0.1124 (all data). 
 
Table 56: Crystal data and structure refinement for 185hb. 
Compound 185hb 
CCDC number 1915681 
Identification code mo_0250_CG_0m 
Empirical formula C27H22N4O2 
Formula weight 434.48 
Temperature/K 100.01 
Crystal system triclinic 
Space group P-1 














Crystal size/mm3 0.567 × 0.17 × 0.062 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.22 to 63.094 
Index ranges -9 ≤ h ≤ 9, -18 ≤ k ≤ 18, -20 ≤ l ≤ 20 
Reflections collected 38890 
Independent reflections 7003 [Rint = 0.0243, Rsigma = 0.0175] 
Data/restraints/parameters 7003/0/300 
Goodness-of-fit on F2 1.045 
Final R indexes [I>=2σ (I)] R1 = 0.0393, wR2 = 0.1089 
Final R indexes [all data] R1 = 0.0433, wR2 = 0.1124 
Largest diff. peak/hole / e Å-3 0.47/-0.23 
 
Table 57: Bond lengths [Å] for 185hb. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C1 1.4302(11) C8 C9 1.5137(12) 
O1 C2 1.3665(10) C9 C10 1.3900(12) 
O2 C26 1.2206(11) C9 C14 1.3993(13) 
N1 C15 1.3497(11) C10 C11 1.4028(11) 
N1 C16 1.3356(11) C11 C12 1.4009(12) 
N2 C16 1.3425(11) C11 C15 1.4799(12) 
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Atom Atom Length/Å Atom Atom Length/Å 
N2 C17 1.3333(10) C12 C13 1.3930(13) 
N3 C18 1.3907(11) C13 C14 1.3911(13) 
N3 C19 1.3055(11) C15 C18 1.4012(11) 
N4 C17 1.3881(10) C17 C18 1.4052(11) 
N4 C19 1.3875(11) C20 C21 1.3907(12) 
N4 C20 1.4193(11) C20 C25 1.3985(11) 
C2 C3 1.3901(12) C21 C22 1.3892(12) 
C2 C7 1.3984(12) C22 C23 1.3957(12) 
C3 C4 1.3973(12) C23 C24 1.3966(12) 
C4 C5 1.3902(12) C23 C26 1.4906(12) 
C5 C6 1.3994(12) C24 C25 1.3853(12) 
C5 C8 1.5085(12) C26 C27 1.5076(13) 
C6 C7 1.3844(12)    
 
Table 58: Bond angles [°] for 185hb. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 O1 C1 116.58(7) C14 C13 C12 120.74(9) 
C16 N1 C15 119.31(7) C13 C14 C9 120.36(8) 
C17 N2 C16 111.49(7) N1 C15 C11 116.88(7) 
C19 N3 C18 104.44(7) N1 C15 C18 117.56(8) 
C17 N4 C20 129.35(7) C18 C15 C11 125.50(8) 
C19 N4 C17 105.13(7) N1 C16 N2 128.45(8) 
C19 N4 C20 125.52(7) N2 C17 N4 128.29(8) 
O1 C2 C3 124.61(8) N2 C17 C18 125.97(8) 
O1 C2 C7 115.72(8) N4 C17 C18 105.73(7) 
C3 C2 C7 119.66(8) N3 C18 C15 132.49(8) 
C2 C3 C4 119.19(8) N3 C18 C17 110.28(7) 
C5 C4 C3 121.92(8) C15 C18 C17 117.21(7) 
C4 C5 C6 117.86(8) N3 C19 N4 114.39(7) 
C4 C5 C8 121.14(8) C21 C20 N4 120.61(7) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C6 C5 C8 120.92(8) C21 C20 C25 120.25(8) 
C7 C6 C5 121.06(8) C25 C20 N4 119.14(7) 
C6 C7 C2 120.24(8) C22 C21 C20 119.57(8) 
C5 C8 C9 116.24(7) C21 C22 C23 120.87(8) 
C10 C9 C8 119.52(8) C22 C23 C24 118.79(8) 
C10 C9 C14 118.68(8) C22 C23 C26 122.55(8) 
C14 C9 C8 121.75(8) C24 C23 C26 118.65(7) 
C9 C10 C11 121.58(8) C25 C24 C23 120.92(8) 
C10 C11 C15 118.78(7) C24 C25 C20 119.50(8) 
C12 C11 C10 119.01(8) O2 C26 C23 120.55(8) 
C12 C11 C15 122.14(8) O2 C26 C27 121.26(8) 
C13 C12 C11 119.62(8) C23 C26 C27 118.16(7) 
 
 
Figure 45: Molecular structure of 185kb with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
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Crystal Data for C33H35N5O2 (M = 533.66 g/mol): monoclinic, space group P21/n (no. 14), a = 
10.1416(6) Å, b = 27.4937(13) Å, c = 10.2461(6) Å, β = 101.977(2)°, V = 2794.7(3) Å3, Z = 4, T = 
100.0 K, μ(MoKα) = 0.081 mm-1, Dcalc = 1.268 g/cm3, 44140 reflections measured (5.03° ≤ 2Θ ≤ 
62.986°), 9275 unique (Rint = 0.0219, Rsigma = 0.0176) which were used in all calculations. The final 
R1 was 0.0409 (I > 2σ(I)) and wR2 was 0.1117 (all data). 
 
Table 59: Crystal data and structure refinement for 185kb. 
Compound 185kb 
CCDC number 1915682 
Identification code mo_0241_CG_0m 
Empirical formula C33H35N5O2 
Formula weight 533.66 
Temperature/K 100.0 
Crystal system monoclinic 












Crystal size/mm3 0.438 × 0.434 × 0.37 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.03 to 62.986 
Index ranges -14 ≤ h ≤ 14, -40 ≤ k ≤ 40, -15 ≤ l ≤ 14 
Reflections collected 44140 
5.3 Experimental Procedures and Analytical Data 
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Independent reflections 9275 [Rint = 0.0219, Rsigma = 0.0176] 
Data/restraints/parameters 9275/0/366 
Goodness-of-fit on F2 1.039 
Final R indexes [I>=2σ (I)] R1 = 0.0409, wR2 = 0.1081 
Final R indexes [all data] R1 = 0.0455, wR2 = 0.1117 
Largest diff. peak/hole / e Å-3 0.46/-0.24 
 
Table 60: Bond lengths [Å] for 185kb. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C1 1.4265(12) C8 C9 1.5110(12) 
O1 C2 1.3681(10) C9 C10 1.3938(12) 
O2 C27 1.2366(11) C9 C14 1.3978(12) 
N1 C15 1.3529(10) C10 C11 1.3999(11) 
N1 C16 1.3418(11) C11 C12 1.4006(11) 
N2 C16 1.3392(12) C11 C15 1.4787(11) 
N2 C17 1.3324(11) C12 C13 1.3941(12) 
N3 C17 1.3718(11) C13 C14 1.3936(12) 
N3 C19 1.3727(12) C15 C18 1.3996(11) 
N3 C20 1.4611(11) C17 C18 1.4062(11) 
N4 C18 1.3921(10) C20 C21 1.5135(12) 
N4 C19 1.3156(11) C21 C22 1.3898(12) 
N5 C27 1.3496(11) C21 C26 1.3963(12) 
N5 C28 1.4869(10) C22 C23 1.3948(12) 
N5 C31 1.4843(11) C23 C24 1.3904(12) 
C2 C3 1.3954(12) C24 C25 1.3940(12) 
C2 C7 1.3937(12) C24 C27 1.5105(11) 
C3 C4 1.3942(12) C25 C26 1.3939(12) 
C4 C5 1.3964(11) C28 C29 1.5193(13) 
C5 C6 1.3940(11) C28 C30 1.5176(14) 
C5 C8 1.5155(12) C31 C32 1.5266(14) 
C6 C7 1.3892(12) C31 C33 1.5277(13) 
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Table 61: Bond angles [°] for 185kb. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 O1 C1 116.90(7) N1 C15 C11 117.52(7) 
C16 N1 C15 119.01(7) N1 C15 C18 118.02(7) 
C17 N2 C16 111.16(7) C18 C15 C11 124.46(7) 
C17 N3 C19 106.04(7) N2 C16 N1 128.49(8) 
C17 N3 C20 125.94(8) N2 C17 N3 127.32(8) 
C19 N3 C20 127.37(8) N2 C17 C18 126.84(8) 
C19 N4 C18 104.00(7) N3 C17 C18 105.80(7) 
C27 N5 C28 120.29(7) N4 C18 C15 133.51(7) 
C27 N5 C31 122.97(7) N4 C18 C17 110.02(7) 
C31 N5 C28 116.05(7) C15 C18 C17 116.45(7) 
O1 C2 C3 124.48(8) N4 C19 N3 114.12(8) 
O1 C2 C7 115.57(8) N3 C20 C21 115.36(7) 
C7 C2 C3 119.95(8) C22 C21 C20 119.83(8) 
C4 C3 C2 119.17(8) C22 C21 C26 118.82(8) 
C3 C4 C5 121.69(8) C26 C21 C20 121.09(8) 
C4 C5 C8 119.26(7) C21 C22 C23 120.83(8) 
C6 C5 C4 117.99(8) C24 C23 C22 120.03(8) 
C6 C5 C8 122.74(7) C23 C24 C25 119.44(7) 
C7 C6 C5 121.27(8) C23 C24 C27 118.20(8) 
C6 C7 C2 119.92(8) C25 C24 C27 122.36(8) 
C9 C8 C5 115.97(7) C26 C25 C24 120.14(8) 
C10 C9 C8 120.18(8) C25 C26 C21 120.51(8) 
C10 C9 C14 118.59(8) O2 C27 N5 123.26(8) 
C14 C9 C8 121.21(8) O2 C27 C24 119.35(8) 
C9 C10 C11 121.30(7) N5 C27 C24 117.35(7) 
C10 C11 C12 119.37(7) N5 C28 C29 112.50(7) 
C10 C11 C15 119.10(7) N5 C28 C30 112.69(7) 
C12 C11 C15 121.53(7) C30 C28 C29 112.42(9) 
C13 C12 C11 119.70(8) N5 C31 C32 111.04(7) 
C14 C13 C12 120.27(8) N5 C31 C33 111.36(8) 
5.3 Experimental Procedures and Analytical Data 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C13 C14 C9 120.76(8) C32 C31 C33 112.64(8) 
 
 
Figure 46: Molecular structure of 187a with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C34H33BF2N6 (M = 574.47 g/mol): triclinic, space group P-1 (no. 2), a = 
10.4593(10) Å, b = 16.8136(17) Å, c = 16.9094(11) Å, α = 94.418(2)°, β = 94.020(3)°, γ = 90.953(3)°, 
V = 2956.8(5) Å3, Z = 4, T = 100.0 K, μ(MoKα) = 0.086 mm-1, Dcalc = 1.290 g/cm3, 108206 
reflections measured (4.646° ≤ 2Θ ≤ 61.34°), 18151 unique (Rint = 0.0389, Rsigma = 0.0271) which 
were used in all calculations. The final R1 was 0.0464 (I > 2σ(I)) and wR2 was 0.1302 (all data).  
 
Table 62: Crystal data and structure refinement for 187a. 
Compound 187a 
CCDC number 1915685 
Identification code 0408_CG_0m 
Empirical formula C34H33BF2N6 
Formula weight 574.47 
Temperature/K 100.0 
Crystal system triclinic 















Crystal size/mm3 0.607 × 0.465 × 0.242 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.646 to 61.34 
Index ranges -14 ≤ h ≤ 15, -24 ≤ k ≤ 24, -24 ≤ l ≤ 24 
Reflections collected 108206 
Independent reflections 18151 [Rint = 0.0389, Rsigma = 0.0271] 
Data/restraints/parameters 18151/0/787 
Goodness-of-fit on F2 1.031 
Final R indexes [I>=2σ (I)] R1 = 0.0464, wR2 = 0.1217 
Final R indexes [all data] R1 = 0.0569, wR2 = 0.1302 
Largest diff. peak/hole / e Å-3 0.41/-0.39 
 
Table 63: Selected bond lengths [Å] for 187a. 
Atom Atom Length/Å Atom Atom Length/Å 
F1 B1 1.3996(14) C6 C7 1.4289(15) 
F2 B1 1.3927(14) C7 C8 1.3877(17) 
N1 C1 1.3475(14) C7 C11 1.4966(16) 
N1 C4 1.4020(14) C8 C9 1.4069(16) 
N1 B1 1.5470(15) C9 C10 1.4859(16) 
N2 C6 1.4010(14) C12 C13 1.3906(16) 
N2 C9 1.3491(14) C12 C17 1.3926(16) 
N2 B1 1.5453(15) C13 C14 1.3928(16) 
N3 C22 1.3502(14) C14 C15 1.3921(17) 
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Atom Atom Length/Å Atom Atom Length/Å 
N3 C30 1.3373(15) C15 C16 1.3950(17) 
N4 C24 1.3329(14) C15 C18 1.5119(16) 
N4 C30 1.3398(15) C16 C17 1.3896(16) 
N5 C24 1.3710(14) C18 C19 1.5179(16) 
N5 C31 1.3715(15) C19 C20 1.3929(16) 
N5 C32 1.4766(15) C19 C27 1.3986(15) 
N6 C23 1.3863(14) C20 C21 1.3993(16) 
N6 C31 1.3127(16) C21 C22 1.4786(15) 
C1 C2 1.4041(16) C21 C25 1.4015(15) 
C1 C29 1.4879(16) C22 C23 1.3978(16) 
C2 C3 1.3863(16) C23 C24 1.4073(16) 
C3 C4 1.4261(16) C25 C26 1.3905(16) 
C3 C28 1.4987(16) C26 C27 1.3877(17) 
C4 C5 1.3954(15) C32 C33 1.500(2) 
C5 C6 1.3939(16) C32 C34 1.5037(19) 
C5 C12 1.4910(15)    
 
Table 64: Selected bond angles [°] for 187a. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 N1 C4 108.40(9) C12 C13 C14 120.02(11) 
C1 N1 B1 125.97(9) C15 C14 C13 121.08(11) 
C4 N1 B1 125.63(9) C14 C15 C16 118.40(10) 
C6 N2 B1 125.75(9) C14 C15 C18 121.26(11) 
C9 N2 C6 108.57(9) C16 C15 C18 120.29(11) 
C9 N2 B1 125.66(9) C17 C16 C15 120.88(11) 
C30 N3 C22 118.63(10) C16 C17 C12 120.25(11) 
C24 N4 C30 111.08(10) C15 C18 C19 113.56(10) 
C24 N5 C31 105.50(10) C20 C19 C18 121.67(10) 
C24 N5 C32 125.65(10) C20 C19 C27 118.66(11) 
C31 N5 C32 128.73(10) C27 C19 C18 119.64(10) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C31 N6 C23 103.92(10) C19 C20 C21 121.09(10) 
N1 C1 C2 109.01(10) C20 C21 C22 119.32(10) 
N1 C1 C29 123.13(11) C20 C21 C25 119.37(10) 
C2 C1 C29 127.85(11) C25 C21 C22 121.30(10) 
C3 C2 C1 108.62(10) N3 C22 C21 117.52(10) 
C2 C3 C4 106.09(10) N3 C22 C23 118.04(10) 
C2 C3 C28 124.72(11) C23 C22 C21 124.44(10) 
C4 C3 C28 129.18(11) N6 C23 C22 133.07(11) 
N1 C4 C3 107.86(9) N6 C23 C24 109.96(10) 
C5 C4 N1 120.38(10) C22 C23 C24 116.93(10) 
C5 C4 C3 131.61(10) N4 C24 N5 127.74(11) 
C4 C5 C12 118.72(10) N4 C24 C23 126.21(10) 
C6 C5 C4 121.09(10) N5 C24 C23 106.02(10) 
C6 C5 C12 120.19(10) C26 C25 C21 119.71(11) 
N2 C6 C7 107.79(10) C27 C26 C25 120.35(10) 
C5 C6 N2 120.33(10) C26 C27 C19 120.78(11) 
C5 C6 C7 131.71(10) N3 C30 N4 129.10(11) 
C6 C7 C11 128.87(11) N6 C31 N5 114.60(10) 
C8 C7 C6 106.15(10) N5 C32 C33 111.27(10) 
C8 C7 C11 124.97(11) N5 C32 C34 110.42(11) 
C7 C8 C9 108.55(10) C33 C32 C34 113.29(14) 
N2 C9 C8 108.93(10) F1 B1 N1 110.21(9) 
N2 C9 C10 122.61(10) F1 B1 N2 110.45(9) 
C8 C9 C10 128.47(11) F2 B1 F1 108.57(9) 
C13 C12 C5 120.36(10) F2 B1 N1 110.56(9) 
C13 C12 C17 119.37(10) F2 B1 N2 110.59(9) 
C17 C12 C5 120.24(10) N2 B1 N1 106.46(9) 
 




Figure 47: Molecular structure of trans-192a with thermal ellipoids at 50% probability level. The 
hydrogen atoms and THF are omitted for clarity. 
 
Crystal Data for C55H53NO3.5P2Ru (M = 946.99 g/mol): monoclinic, space group P21/n (no. 14), a = 
11.9019(7) Å, b = 15.2039(9) Å, c = 24.7562(15) Å, β = 93.907(3)°, V = 4469.4(5) Å3, Z = 4, T = 
99.99 K, μ(MoKα) = 0.471 mm-1, Dcalc = 1.407 g/cm3, 13699 reflections measured (4.57° ≤ 2Θ ≤ 
61.146°), 13699 unique (Rint = 0, Rsigma = 0.0303) which were used in all calculations. The final R1 
was 0.0435 (I > 2σ(I)) and wR2 was 0.1183 (all data). 
 
Table 65: Crystal data and structure refinement for trans-192a. 
Compound trans-192a 
CCDC number 1915676 
Identification code 0473_CG_0m_4 
Empirical formula C55H53NO3.5P2Ru 
Formula weight 946.99 
Temperature/K 99.99 
Crystal system monoclinic 















Crystal size/mm3 0.317 × 0.086 × 0.063 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.57 to 61.146 
Index ranges -16 ≤ h ≤ 16, 0 ≤ k ≤ 21, 0 ≤ l ≤ 35 
Reflections collected 13699 
Independent reflections 13699 [Rint = 0, Rsigma = 0.0303] 
Data/restraints/parameters 13699/30/587 
Goodness-of-fit on F2 1.048 
Final R indexes [I>=2σ (I)] R1 = 0.0435, wR2 = 0.1132 
Final R indexes [all data] R1 = 0.0516, wR2 = 0.1183 
Largest diff. peak/hole / e Å-3 1.34/-0.94 
 
Table 66: Selected bond lengths [Å] for trans-192a. 
Atom Atom Length/Å Atom Atom Length/Å 
Ru1 P1 2.3421(5) C16 C17 1.392(3) 
Ru1 P2 2.3355(5) C18 C19 1.395(3) 
Ru1 O1 2.1592(16) C18 C23 1.395(3) 
Ru1 O2 2.3317(17) C19 C20 1.387(3) 
Ru1 N1 2.0554(18) C20 C21 1.380(4) 
Ru1 C1 2.0031(17) C21 C22 1.380(4) 
P1 C12 1.8378(19) C22 C23 1.386(3) 
P1 C18 1.828(2) C24 C25 1.397(3) 
P1 C24 1.8314(19) C24 C29 1.392(3) 
P2 C30 1.832(2) C25 C26 1.389(3) 
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Atom Atom Length/Å Atom Atom Length/Å 
P2 C36 1.8312(19) C26 C27 1.392(3) 
P2 C42 1.837(2) C27 C28 1.383(3) 
O1 C48 1.264(2) C28 C29 1.393(3) 
O2 C48 1.261(2) C30 C31 1.390(3) 
N1 C2 1.387(3) C30 C35 1.398(3) 
N1 C11 1.379(3) C31 C32 1.398(3) 
C1 C3 1.382(3) C32 C33 1.382(3) 
C1 C7 1.386(2) C33 C34 1.390(3) 
C2 C3 1.451(3) C34 C35 1.386(3) 
C2 C8 1.397(3) C36 C37 1.393(3) 
C3 C4 1.397(3) C36 C41 1.398(3) 
C4 C5 1.385(3) C37 C38 1.392(3) 
C5 C6 1.387(3) C38 C39 1.384(3) 
C6 C7 1.383(3) C39 C40 1.381(3) 
C8 C9 1.381(3) C40 C41 1.386(3) 
C9 C10 1.390(4) C42 C43 1.392(3) 
C10 C11 1.385(3) C42 C47 1.397(3) 
C12 C13 1.394(3) C43 C44 1.386(3) 
C12 C17 1.388(3) C44 C45 1.387(3) 
C13 C14 1.394(3) C45 C46 1.384(3) 
C14 C15 1.383(3) C46 C47 1.395(3) 
C15 C16 1.386(3) C48 C49 1.489(3) 
 
Table 67: Selected bond angles [°] for trans-192a. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
P2 Ru1 P1 172.681(17) C17 C12 P1 119.96(15) 
O1 Ru1 P1 91.03(4) C17 C12 C13 118.84(18) 
O1 Ru1 P2 92.19(4) C14 C13 C12 120.6(2) 
O1 Ru1 O2 57.94(6) C15 C14 C13 120.0(2) 
O2 Ru1 P1 85.36(4) C14 C15 C16 119.67(19) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
O2 Ru1 P2 90.78(4) C15 C16 C17 120.4(2) 
N1 Ru1 P1 88.04(5) C12 C17 C16 120.5(2) 
N1 Ru1 P2 88.70(5) C19 C18 P1 122.35(16) 
N1 Ru1 O1 179.02(6) C19 C18 C23 118.57(19) 
N1 Ru1 O2 121.66(6) C23 C18 P1 119.01(16) 
C1 Ru1 P1 93.47(5) C20 C19 C18 120.7(2) 
C1 Ru1 P2 92.29(5) C21 C20 C19 119.8(2) 
C1 Ru1 O1 101.95(6) C22 C21 C20 120.3(2) 
C1 Ru1 O2 159.78(6) C21 C22 C23 120.1(2) 
C1 Ru1 N1 78.41(7) C22 C23 C18 120.5(2) 
C12 P1 Ru1 115.92(7) C25 C24 P1 117.64(15) 
C18 P1 Ru1 115.73(6) C29 C24 P1 123.60(15) 
C18 P1 C12 101.27(9) C29 C24 C25 118.73(18) 
C18 P1 C24 103.56(9) C26 C25 C24 120.78(19) 
C24 P1 Ru1 115.02(6) C25 C26 C27 119.8(2) 
C24 P1 C12 103.44(9) C28 C27 C26 119.8(2) 
C30 P2 Ru1 115.18(6) C27 C28 C29 120.3(2) 
C30 P2 C42 104.39(9) C24 C29 C28 120.51(19) 
C36 P2 Ru1 115.02(6) C31 C30 P2 122.18(15) 
C36 P2 C30 102.04(9) C31 C30 C35 118.87(18) 
C36 P2 C42 102.48(9) C35 C30 P2 118.83(15) 
C42 P2 Ru1 115.91(6) C30 C31 C32 120.29(19) 
C48 O1 Ru1 95.11(13) C33 C32 C31 120.39(19) 
C48 O2 Ru1 87.27(13) C32 C33 C34 119.54(19) 
C2 N1 Ru1 115.92(13) C35 C34 C33 120.31(19) 
C11 N1 Ru1 126.77(16) C34 C35 C30 120.59(18) 
C11 N1 C2 117.31(18) C37 C36 P2 122.21(14) 
C3 C1 Ru1 118.20(13) C37 C36 C41 118.53(17) 
C3 C1 C7 118.03(17) C41 C36 P2 119.20(15) 
C7 C1 Ru1 123.77(14) C38 C37 C36 120.64(19) 
N1 C2 C3 113.97(17) C39 C38 C37 120.21(19) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N1 C2 C8 121.79(19) C40 C39 C38 119.51(18) 
C8 C2 C3 124.23(19) C39 C40 C41 120.67(19) 
C1 C3 C2 113.47(17) C40 C41 C36 120.42(19) 
C1 C3 C4 120.81(18) C43 C42 P2 118.07(15) 
C4 C3 C2 125.70(19) C43 C42 C47 118.63(18) 
C5 C4 C3 120.1(2) C47 C42 P2 123.20(15) 
C4 C5 C6 119.6(2) C44 C43 C42 120.85(19) 
C7 C6 C5 119.4(2) C43 C44 C45 120.17(19) 
C6 C7 C1 122.04(19) C46 C45 C44 119.8(2) 
C9 C8 C2 119.7(2) C45 C46 C47 120.1(2) 
C8 C9 C10 119.2(2) C46 C47 C42 120.46(18) 
C11 C10 C9 120.0(2) O1 C48 C49 119.0(2) 
N1 C11 C10 122.0(2) O2 C48 O1 119.45(19) 
C13 C12 P1 121.20(15) O2 C48 C49 121.5(2) 
 
 
Figure 48: Molecular structure of trans-192b with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C50H42Cl2FNO2P2Ru (M = 941.75 g/mol): monoclinic, space group Pc (no. 7), a = 
12.5538(4) Å, b = 20.7915(6) Å, c = 17.2221(5) Å, β = 109.9250(10)°, V = 4226.1(2) Å3, Z = 4, T = 
100.0 K, μ(MoKα) = 0.620 mm-1, Dcalc = 1.480 g/cm3, 196620 reflections measured (4.656° ≤ 2Θ ≤ 
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63.094°), 28065 unique (Rint = 0.0236, Rsigma = 0.0164) which were used in all calculations. The final 
R1 was 0.0240 (I > 2σ(I)) and wR2 was 0.0645 (all data). 
 
Table 68: Crystal data and structure refinement for trans-192b. 
Compound trans-192b 
CCDC number 1979318 
Identification code 0497_CG_0m 
Empirical formula C50H42Cl2FNO2P2Ru 
Formula weight 941.75 
Temperature/K 100.0 
Crystal system monoclinic 












Crystal size/mm3 0.344 × 0.309 × 0.17 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.656 to 63.094 
Index ranges -18 ≤ h ≤ 18, -30 ≤ k ≤ 30, -25 ≤ l ≤ 25 
Reflections collected 196620 
Independent reflections 28065 [Rint = 0.0236, Rsigma = 0.0164] 
Data/restraints/parameters 28065/2/1085 
Goodness-of-fit on F2 1.069 
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Final R indexes [I>=2σ (I)] R1 = 0.0240, wR2 = 0.0639 
Final R indexes [all data] R1 = 0.0250, wR2 = 0.0645 
Largest diff. peak/hole / e Å-3 0.62/-0.98 
Flack parameter -0.004(4) 
 
Table 69: Selected bond angles [°] for trans-192b. 
Atom Atom Length/Å Atom Atom Length/Å 
Ru1 P1 2.3514(9) C15 C16 1.385(4) 
Ru1 P2 2.3266(10) C16 C17 1.393(3) 
Ru1 O1 2.3822(19) C18 C19 1.399(3) 
Ru1 O2 2.1251(19) C18 C23 1.397(3) 
Ru1 N1 2.056(2) C19 C20 1.397(4) 
Ru1 C1 1.981(2) C20 C21 1.382(4) 
Ru1 C48 2.598(2) C21 C22 1.384(4) 
P1 C12 1.830(2) C22 C23 1.402(4) 
P1 C18 1.833(3) C24 C25 1.399(3) 
P1 C24 1.821(2) C24 C29 1.399(4) 
P2 C30 1.840(2) C25 C26 1.394(3) 
P2 C36 1.836(3) C26 C27 1.393(4) 
P2 C42 1.826(2) C27 C28 1.388(4) 
F1 C5 1.366(3) C28 C29 1.382(4) 
O1 C48 1.267(3) C30 C31 1.401(3) 
O2 C48 1.260(3) C30 C35 1.396(3) 
N1 C7 1.369(3) C31 C32 1.385(3) 
N1 C11 1.354(3) C32 C33 1.394(4) 
C1 C2 1.410(3) C33 C34 1.382(4) 
C1 C6 1.404(3) C34 C35 1.393(4) 
C2 C3 1.399(3) C36 C37 1.395(3) 
C2 C7 1.460(4) C36 C41 1.402(3) 
C3 C4 1.399(4) C37 C38 1.395(3) 
C4 C5 1.383(3) C38 C39 1.389(4) 
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Atom Atom Length/Å Atom Atom Length/Å 
C5 C6 1.375(3) C39 C40 1.386(4) 
C7 C8 1.396(3) C40 C41 1.389(3) 
C8 C9 1.376(4) C42 C43 1.396(3) 
C9 C10 1.397(3) C42 C47 1.408(3) 
C10 C11 1.385(3) C43 C44 1.396(4) 
C12 C13 1.397(3) C44 C45 1.385(4) 
C12 C17 1.396(3) C45 C46 1.385(4) 
C13 C14 1.386(3) C46 C47 1.385(3) 
C14 C15 1.392(4) C48 C49 1.516(4) 
 
Table 70: Selected bond angles [°] for trans-192b. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
P1 Ru1 O1 87.75(5) N1 C11 C10 123.1(2) 
P1 Ru1 C48 88.14(6) C13 C12 P1 119.17(19) 
P2 Ru1 P1 178.80(3) C17 C12 P1 121.85(18) 
P2 Ru1 O1 92.96(5) C17 C12 C13 118.5(2) 
P2 Ru1 C48 92.95(6) C14 C13 C12 120.9(3) 
O1 Ru1 C48 29.06(7) C13 C14 C15 120.0(3) 
O2 Ru1 P1 90.88(6) C16 C15 C14 119.8(2) 
O2 Ru1 P2 90.31(6) C15 C16 C17 120.1(3) 
O2 Ru1 O1 57.81(7) C16 C17 C12 120.7(2) 
O2 Ru1 C48 28.79(8) C19 C18 P1 117.76(18) 
N1 Ru1 P1 88.41(6) C23 C18 P1 123.57(19) 
N1 Ru1 P2 90.40(6) C23 C18 C19 118.6(2) 
N1 Ru1 O1 120.61(7) C20 C19 C18 120.8(2) 
N1 Ru1 O2 178.31(8) C21 C20 C19 120.1(3) 
N1 Ru1 C48 149.61(8) C20 C21 C22 119.8(2) 
C1 Ru1 P1 90.08(7) C21 C22 C23 120.6(3) 
C1 Ru1 P2 89.58(7) C18 C23 C22 120.1(3) 
C1 Ru1 O1 160.14(9) C25 C24 P1 119.70(17) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 Ru1 O2 102.52(9) C25 C24 C29 119.0(2) 
C1 Ru1 N1 79.02(9) C29 C24 P1 121.23(19) 
C1 Ru1 C48 131.16(10) C26 C25 C24 120.0(2) 
C12 P1 Ru1 112.99(8) C27 C26 C25 120.4(2) 
C12 P1 C18 105.23(12) C28 C27 C26 119.5(2) 
C18 P1 Ru1 115.22(8) C29 C28 C27 120.3(2) 
C24 P1 Ru1 118.05(9) C28 C29 C24 120.7(3) 
C24 P1 C12 101.52(11) C31 C30 P2 117.07(17) 
C24 P1 C18 102.05(11) C35 C30 P2 125.08(19) 
C30 P2 Ru1 116.23(8) C35 C30 C31 117.8(2) 
C36 P2 Ru1 117.38(8) C32 C31 C30 121.3(2) 
C36 P2 C30 99.83(12) C31 C32 C33 120.3(2) 
C42 P2 Ru1 113.34(9) C34 C33 C32 119.0(2) 
C42 P2 C30 105.57(11) C33 C34 C35 120.9(3) 
C42 P2 C36 102.59(11) C34 C35 C30 120.7(3) 
C48 O1 Ru1 84.96(15) C37 C36 P2 119.89(18) 
C48 O2 Ru1 96.92(16) C37 C36 C41 119.4(2) 
C7 N1 Ru1 116.60(16) C41 C36 P2 120.64(17) 
C11 N1 Ru1 124.81(15) C36 C37 C38 119.9(2) 
C11 N1 C7 118.6(2) C39 C38 C37 120.3(2) 
C2 C1 Ru1 117.31(18) C40 C39 C38 119.9(2) 
C6 C1 Ru1 125.20(17) C39 C40 C41 120.3(2) 
C6 C1 C2 117.5(2) C40 C41 C36 120.1(2) 
C1 C2 C7 113.7(2) C43 C42 P2 121.87(19) 
C3 C2 C1 122.2(2) C43 C42 C47 118.5(2) 
C3 C2 C7 124.1(2) C47 C42 P2 119.48(17) 
C2 C3 C4 119.4(2) C44 C43 C42 120.4(2) 
C5 C4 C3 117.6(2) C45 C44 C43 120.4(2) 
F1 C5 C4 118.0(2) C44 C45 C46 119.7(2) 
F1 C5 C6 117.9(2) C45 C46 C47 120.5(2) 
C6 C5 C4 124.0(2) C46 C47 C42 120.4(2) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C5 C6 C1 119.3(2) O1 C48 Ru1 65.98(13) 
N1 C7 C2 113.4(2) O1 C48 C49 120.2(2) 
N1 C7 C8 120.4(2) O2 C48 Ru1 54.29(12) 
C8 C7 C2 126.2(2) O2 C48 O1 120.2(2) 
C9 C8 C7 120.4(2) O2 C48 C49 119.5(3) 
C8 C9 C10 119.3(2) C49 C48 Ru1 170.5(2) 
C11 C10 C9 118.2(2)     
 
 
Figure 49: Molecular structure of 193 with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
  
Crystal Data for C49H39NO3P2Ru (M = 852.82 g/mol): monoclinic, space group C2/c (no. 15), a = 
19.1587(12) Å, b = 20.6734(11) Å, c = 20.6880(9) Å, β = 107.466(2)°, V = 7816.2(7) Å3, Z = 8, T = 
149.96 K, μ(MoKα) = 0.529 mm-1, Dcalc = 1.449 g/cm3, 182744 reflections measured (5.086° ≤ 2Θ 
≤ 63.122°), 13014 unique (Rint = 0.0258, Rsigma = 0.0112) which were used in all calculations. The 
final R1 was 0.0217 (I > 2σ(I)) and wR2 was 0.0600 (all data). 
 
Table 71: Crystal data and structure refinement for 193. 
Compound 193 
CCDC number 1915688 
Identification code 0527_CG_0m 
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Empirical formula C49H39NO3P2Ru 
Formula weight 852.82 
Temperature/K 149.96 
Crystal system monoclinic 












Crystal size/mm3 0.529 × 0.31 × 0.154 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.086 to 63.122 
Index ranges -28 ≤ h ≤ 28, -29 ≤ k ≤ 29, -28 ≤ l ≤ 30 
Reflections collected 182744 
Independent reflections 13014 [Rint = 0.0258, Rsigma = 0.0112] 
Data/restraints/parameters 13014/0/506 
Goodness-of-fit on F2 1.052 
Final R indexes [I>=2σ (I)] R1 = 0.0217, wR2 = 0.0583 
Final R indexes [all data] R1 = 0.0240, wR2 = 0.0600 
Largest diff. peak/hole / e Å-3 0.44/-0.54 
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Table 72: Selected bond lengths [Å] for 193. 
Atom Atom Length/Å Atom Atom Length/Å 
Ru1 P1 2.2377(3) C15 C16 1.3885(17) 
Ru1 P2 2.3263(3) C16 C17 1.3830(18) 
Ru1 O1 2.2928(8) C17 C18 1.3903(16) 
Ru1 O2 2.1987(8) C19 C20 1.3870(14) 
Ru1 N1 2.0836(9) C19 C24 1.3922(15) 
Ru1 C37 2.5928(11) C20 C21 1.3865(17) 
Ru1 C45 2.0302(10) C21 C22 1.3808(19) 
P1 C1 1.8379(11) C22 C23 1.3910(16) 
P1 C7 1.8263(10) C23 C24 1.3990(15) 
P1 C13 1.8506(10) C25 C26 1.3963(15) 
P2 C24 1.8388(10) C25 C30 1.3989(16) 
P2 C25 1.8503(11) C26 C27 1.3934(17) 
P2 C31 1.8325(11) C27 C28 1.381(2) 
O1 C37 1.2627(13) C28 C29 1.389(2) 
O2 C37 1.2700(13) C29 C30 1.3893(17) 
O3 C14 1.3899(13) C31 C32 1.3923(15) 
O3 C19 1.3839(13) C31 C36 1.3966(15) 
N1 C39 1.3452(14) C32 C33 1.3908(15) 
N1 C43 1.3561(13) C33 C34 1.3822(18) 
C1 C2 1.3936(15) C34 C35 1.3881(17) 
C1 C6 1.3966(15) C35 C36 1.3897(16) 
C2 C3 1.3926(16) C37 C38 1.5027(16) 
C3 C4 1.377(2) C39 C40 1.3827(16) 
C4 C5 1.380(2) C40 C41 1.3874(18) 
C5 C6 1.3904(18) C41 C42 1.3819(16) 
C7 C8 1.3952(15) C42 C43 1.3977(14) 
C7 C12 1.3906(14) C43 C44 1.4616(14) 
C8 C9 1.3844(16) C44 C45 1.4264(14) 
C9 C10 1.385(2) C44 C49 1.4016(14) 
C10 C11 1.379(2) C45 C46 1.4080(14) 
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Atom Atom Length/Å Atom Atom Length/Å 
C11 C12 1.3948(16) C46 C47 1.3919(15) 
C13 C14 1.3961(15) C47 C48 1.3908(16) 
C13 C18 1.4026(15) C48 C49 1.3826(16) 
C14 C15 1.3863(15)    
 
Table 73: Selected bond angles [°] for 193. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
P1 Ru1 P2 96.827(9) C18 C13 P1 122.74(8) 
P1 Ru1 O1 111.67(2) O3 C14 C13 119.50(9) 
P1 Ru1 C37 140.68(3) C15 C14 O3 117.78(10) 
P2 Ru1 C37 88.90(3) C15 C14 C13 122.62(10) 
O1 Ru1 P2 90.52(2) C14 C15 C16 119.60(11) 
O1 Ru1 C37 29.14(3) C17 C16 C15 119.49(11) 
O2 Ru1 P1 169.67(2) C16 C17 C18 120.21(11) 
O2 Ru1 P2 86.58(2) C17 C18 C13 121.78(11) 
O2 Ru1 O1 58.41(3) O3 C19 C20 122.38(10) 
O2 Ru1 C37 29.29(3) O3 C19 C24 115.08(9) 
N1 Ru1 P1 93.69(3) C20 C19 C24 122.43(10) 
N1 Ru1 P2 169.30(3) C21 C20 C19 118.66(11) 
N1 Ru1 O1 83.73(3) C22 C21 C20 120.59(11) 
N1 Ru1 O2 82.72(3) C21 C22 C23 119.98(11) 
N1 Ru1 C37 81.68(3) C22 C23 C24 120.86(11) 
C45 Ru1 P1 91.38(3) C19 C24 P2 116.57(8) 
C45 Ru1 P2 101.60(3) C19 C24 C23 117.42(10) 
C45 Ru1 O1 152.61(3) C23 C24 P2 126.01(9) 
C45 Ru1 O2 97.50(3) C26 C25 P2 123.27(9) 
C45 Ru1 N1 80.07(4) C26 C25 C30 118.14(10) 
C45 Ru1 C37 125.59(4) C30 C25 P2 118.58(8) 
C1 P1 Ru1 112.82(3) C27 C26 C25 120.49(12) 
C1 P1 C13 99.47(5) C28 C27 C26 120.65(12) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C7 P1 Ru1 113.34(3) C27 C28 C29 119.63(12) 
C7 P1 C1 100.59(5) C28 C29 C30 119.83(13) 
C7 P1 C13 102.72(5) C29 C30 C25 121.24(12) 
C13 P1 Ru1 124.57(3) C32 C31 P2 122.92(8) 
C24 P2 Ru1 123.17(3) C32 C31 C36 118.78(10) 
C24 P2 C25 99.76(5) C36 C31 P2 118.23(8) 
C25 P2 Ru1 111.22(3) C33 C32 C31 120.69(10) 
C31 P2 Ru1 117.34(3) C34 C33 C32 120.16(11) 
C31 P2 C24 101.20(5) C33 C34 C35 119.70(11) 
C31 P2 C25 100.65(5) C34 C35 C36 120.33(11) 
C37 O1 Ru1 88.72(6) C35 C36 C31 120.32(11) 
C37 O2 Ru1 92.83(6) O1 C37 Ru1 62.14(5) 
C19 O3 C14 118.07(8) O1 C37 O2 119.99(10) 
C39 N1 Ru1 125.21(7) O1 C37 C38 120.32(10) 
C39 N1 C43 119.79(9) O2 C37 Ru1 57.88(5) 
C43 N1 Ru1 114.43(7) O2 C37 C38 119.68(10) 
C2 C1 P1 122.72(8) C38 C37 Ru1 177.39(9) 
C2 C1 C6 118.59(10) N1 C39 C40 122.52(11) 
C6 C1 P1 118.67(8) C39 C40 C41 118.15(11) 
C3 C2 C1 120.69(12) C42 C41 C40 119.64(10) 
C4 C3 C2 120.18(13) C41 C42 C43 119.79(10) 
C3 C4 C5 119.69(12) N1 C43 C42 119.94(10) 
C4 C5 C6 120.74(12) N1 C43 C44 113.83(9) 
C5 C6 C1 120.10(12) C42 C43 C44 126.20(9) 
C8 C7 P1 115.36(8) C45 C44 C43 116.48(9) 
C12 C7 P1 125.30(8) C49 C44 C43 121.34(9) 
C12 C7 C8 119.31(10) C49 C44 C45 122.16(9) 
C9 C8 C7 120.16(11) C44 C45 Ru1 112.30(7) 
C10 C9 C8 120.18(12) C46 C45 Ru1 132.00(8) 
C11 C10 C9 120.14(11) C46 C45 C44 115.37(9) 
C10 C11 C12 120.01(12) C47 C46 C45 122.18(10) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C7 C12 C11 120.09(11) C48 C47 C46 120.97(10) 
C14 C13 P1 120.96(8) C49 C48 C47 119.01(10) 
C14 C13 C18 116.28(9) C48 C49 C44 120.24(10) 
 
 
Figure 50: Molecular structure of 194 with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C33H29N2O2PRu (M = 617.62 g/mol): orthorhombic, space group Pna21 (no. 33), 
a = 16.2264(8) Å, b = 9.3716(4) Å, c = 17.7053(10) Å, V = 2692.4(2) Å3, Z = 4, T = 100.1 K, μ(MoKα) = 
0.676 mm-1, Dcalc = 1.524 g/cm3, 57514 reflections measured (4.602° ≤ 2Θ ≤ 63.044°), 8977 
unique (Rint = 0.0242, Rsigma = 0.0160) which were used in all calculations. The final R1 was 0.0155 
(I > 2σ(I)) and wR2 was 0.0412 (all data). 
 
Table 74: Crystal data and structure refinement for 194. 
Compound 194 
CCDC number 1915689 
Identification code Pna21 
Empirical formula C33H29N2O2PRu 
Formula weight 617.62 
Temperature/K 100.1 
Crystal system orthorhombic 
Space group Pna21 
a/Å 16.2264(8) 













Crystal size/mm3 0.305 × 0.139 × 0.09 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.602 to 63.044 
Index ranges -23 ≤ h ≤ 23, -13 ≤ k ≤ 13, -26 ≤ l ≤ 26 
Reflections collected 57514 
Independent reflections 8977 [Rint = 0.0242, Rsigma = 0.0160] 
Data/restraints/parameters 8977/1/354 
Goodness-of-fit on F2 1.034 
Final R indexes [I>=2σ (I)] R1 = 0.0155, wR2 = 0.0408 
Final R indexes [all data] R1 = 0.0160, wR2 = 0.0412 
Largest diff. peak/hole / e Å-3 0.37/-0.43 
Flack parameter -0.032(5) 
 
Table 75: Bond lengths [Å] for 194. 
Atom Atom Length/Å Atom Atom Length/Å 
Ru1 P1 2.2451(5) C9 C10 1.393(3) 
Ru1 O1 2.2216(12) C10 C11 1.389(2) 
Ru1 O2 2.2956(11) C12 C13 1.397(2) 
Ru1 N1 2.0531(13) C12 C17 1.394(2) 
Ru1 N2 2.0148(14) C13 C14 1.395(2) 
Ru1 C1 2.0085(15) C14 C15 1.394(3) 
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Atom Atom Length/Å Atom Atom Length/Å 
P1 C12 1.8372(16) C15 C16 1.388(3) 
P1 C18 1.8283(16) C16 C17 1.391(2) 
P1 C24 1.8394(16) C18 C19 1.396(2) 
O1 C30 1.267(2) C18 C23 1.400(2) 
O2 C30 1.2635(19) C19 C20 1.395(2) 
N1 C3 1.3643(19) C20 C21 1.381(2) 
N1 C7 1.345(2) C21 C22 1.393(3) 
N2 C32 1.147(2) C22 C23 1.390(2) 
C1 C2 1.424(2) C24 C25 1.396(2) 
C1 C11 1.412(2) C24 C29 1.398(2) 
C2 C3 1.456(2) C25 C26 1.395(2) 
C2 C8 1.403(2) C26 C27 1.383(3) 
C3 C4 1.396(2) C27 C28 1.390(3) 
C4 C5 1.380(3) C28 C29 1.390(2) 
C5 C6 1.394(3) C30 C31 1.507(2) 
C6 C7 1.383(2) C32 C33 1.460(2) 
C8 C9 1.382(3)    
 
Table 76: Bond angles [°] for 194. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
P1 Ru1 O2 105.56(3) C5 C4 C3 120.03(16) 
O1 Ru1 P1 163.66(3) C4 C5 C6 118.98(16) 
O1 Ru1 O2 58.10(4) C7 C6 C5 118.58(16) 
N1 Ru1 P1 92.21(4) N1 C7 C6 122.93(16) 
N1 Ru1 O1 88.19(5) C9 C8 C2 120.10(15) 
N1 Ru1 O2 91.65(5) C8 C9 C10 119.48(16) 
N2 Ru1 P1 93.88(4) C11 C10 C9 120.47(16) 
N2 Ru1 O1 87.33(5) C10 C11 C1 122.38(16) 
N2 Ru1 O2 91.42(5) C13 C12 P1 123.40(12) 
N2 Ru1 N1 172.18(6) C17 C12 P1 118.07(12) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 Ru1 P1 95.99(4) C17 C12 C13 118.48(14) 
C1 Ru1 O1 100.17(5) C14 C13 C12 120.72(16) 
C1 Ru1 O2 157.26(5) C15 C14 C13 119.83(16) 
C1 Ru1 N1 80.16(6) C16 C15 C14 119.97(16) 
C1 Ru1 N2 94.33(6) C15 C16 C17 119.78(16) 
C12 P1 Ru1 121.81(5) C16 C17 C12 121.19(15) 
C12 P1 C24 101.16(7) C19 C18 P1 121.80(12) 
C18 P1 Ru1 113.59(5) C19 C18 C23 118.57(14) 
C18 P1 C12 102.78(7) C23 C18 P1 119.34(12) 
C18 P1 C24 101.24(7) C20 C19 C18 120.50(15) 
C24 P1 Ru1 113.57(5) C21 C20 C19 120.46(16) 
C30 O1 Ru1 92.44(9) C20 C21 C22 119.60(18) 
C30 O2 Ru1 89.14(10) C23 C22 C21 120.18(17) 
C3 N1 Ru1 115.95(10) C22 C23 C18 120.66(15) 
C7 N1 Ru1 125.24(11) C25 C24 P1 119.44(12) 
C7 N1 C3 118.82(13) C25 C24 C29 119.11(14) 
C32 N2 Ru1 174.61(14) C29 C24 P1 121.43(12) 
C2 C1 Ru1 113.99(11) C26 C25 C24 120.21(15) 
C11 C1 Ru1 129.80(12) C27 C26 C25 120.23(16) 
C11 C1 C2 115.52(14) C26 C27 C28 119.99(16) 
C1 C2 C3 115.34(13) C27 C28 C29 120.04(16) 
C8 C2 C1 122.04(14) C28 C29 C24 120.42(15) 
C8 C2 C3 122.62(15) O1 C30 C31 120.13(15) 
N1 C3 C2 113.71(13) O2 C30 O1 120.31(15) 
N1 C3 C4 120.63(15) O2 C30 C31 119.57(15) 
C4 C3 C2 125.62(15) N2 C32 C33 177.99(19) 
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5.3.5 Ruthenium(II)-Catalyzed Decarboxylative Alkylation 
5.3.5.1 Characterization Data for 145, 146, and 201 
1-(3-Cycloheptylphenyl)-1H-pyrazole (146ah) 
The general procedure K was followed using 2-(1H-pyrazol-1-yl)benzoic acid 
(144a, 94.1 mg, 0.50 mmol) and bromocycloheptane (136h, 266 mg, 1.50 mmol) 
and [Ru(NCt-Bu)6][BF4]2 (19.3 mg, 25.0 µmol, 5.0 mol %). After 16 h, purification 
by column chromatography (n-hexane/EtOAc 30:1) yielded meta-alkylated 
product 146ah (71.8 mg, 60%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.92 (dd, J = 2.5, 0.7 Hz, 1H), 7.72 (dd, J = 1.8, 0.7 Hz, 1H), 7.57 (dd, 
J = 2.2, 1.8 Hz, 1H), 7.43 (ddd, J = 7.9, 2.2, 1.3 Hz, 1H), 7.34 (dd, J = 7.9, 7.7 Hz, 1H), 7.12 (ddd, J = 
7.7, 1.8, 1.3 Hz, 1H), 6.45 (dd, J = 2.5, 1.8 Hz, 1H), 2.74 (tt, J = 10.6, 3.6 Hz, 1H), 1.99–1.91 (m, 2H), 
1.85–1.77 (m, 2H), 1.76–1.50 (m, 8H). 
13C-NMR (100 MHz, CDCl3): δ = 151.7 (Cq), 140.8 (CH), 140.2 (Cq), 129.2 (CH), 126.8 (CH), 124.9 
(CH), 117.9 (CH), 116.3 (CH), 107.3 (CH), 47.1 (CH), 36.7 (CH2), 27.8 (CH2), 27.2 (CH2). 
IR (ATR): ṽ = 2919, 2852, 1607, 1590, 1518, 1392, 1043, 784, 744, 697 cm−1. 
MS (EI) m/z (relative intensity): 240 (100) [M]+, 239 (36) [M–H]+, 225 (10), 211 (17), 197 (26), 183 
(29), 171 (53), 158 (61), 144 (14), 130 (15), 115 (23), 77 (12). 
HR-MS (EI): m/z calcd for C16H20N2+ [M]+ 240.1621, found 240.1633. 
 
1-(4-Methyl-2-neopentylphenyl)-1H-pyrazole (145et) 
The general procedure K was followed using 5-methyl-2-(1H-pyrazol-1-yl)benzoic 
acid (144e, 101 mg, 0.50 mmol) and neopentyl bromide (136t, 227 mg, 1.50 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 20:1) yielded 
ortho-alkylated product 145et (57.0 mg, 50%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.68 (dd, J = 2.0, 0.7 Hz, 1H), 7.54 (dd, J = 2.1, 0.7 Hz, 1H), 7.15 (d, J 
= 8.5 Hz, 1H), 7.11–7.06 (m, 2H), 6.39 (dd, J = 2.1, 2.0 Hz, 1H), 2.69 (s, 2H), 2.39 (s, 3H), 0.68 (s, 
9H).  
13C-NMR (125 MHz, CDCl3): δ = 139.7 (CH), 138.0 (Cq), 137.2 (Cq), 135.1 (Cq), 133.5 (CH), 130.9 (CH), 
127.4 (CH), 126.4 (CH), 105.9 (CH), 44.0 (CH2), 32.1 (Cq), 29.4 (CH3), 21.2 (CH3). 
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IR (ATR): ṽ = 2950, 2865, 1518, 1476, 1395, 1234, 1044, 818, 746 cm−1.  
MS (EI) m/z (relative intensity): 228 (29) [M]+, 213 (30) [M–Me]+, 172 (100) [M–t-Bu]+, 171 (67), 
144 (52), 130 (9), 115 (9), 57 (13), 43 (14).  
HR-MS (EI): m/z calcd for C15H20N2+ [M]+ 228.1621, found 228.1632. 
 
1-(4-Methoxy-2-neopentylphenyl)-5-methyl-1H-pyrazole (145ft) 
The general procedure K was followed using 5-methoxy-2-(5-methyl-1H-
pyrazol-1-yl)benzoic acid (144f, 116 mg, 0.50 mmol) and neopentyl bromide 
(136t, 227 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded ortho-alkylated product 145ft (51.2 mg, 40%) as 
a colorless oil and ortho-benzylated product 201 (54.3 mg, 37%) as a white solid. 
1H-NMR (500 MHz, CDCl3): δ = 7.54 (d, J = 1.8 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 6.84 (d, J = 2.9 Hz, 
1H), 6.81 (dd, J = 8.6, 2.9 Hz, 1H), 6.13 (dq, J = 1.8, 0.8 Hz, 1H), 3.84 (s, 3H), 2.47 (br s, 2H), 2.13 (d, 
J = 0.8 Hz, 3H), 0.75 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 158.7 (Cq), 139.5 (Cq), 138.9 (CH), 138.8 (Cq), 132.2 (Cq), 128.8 (CH), 
117.7 (CH), 111.6 (CH), 105.2 (CH), 55.4 (CH3), 44.1 (CH2), 32.2 (Cq), 29.7 (CH3), 11.8 (CH3). 
IR (ATR): ṽ = 2952, 1608, 1505, 1464, 1279, 1238, 1052, 922, 813, 770 cm−1.  
MS (EI) m/z (relative intensity): 258 (42) [M]+, 243 (100) [M–Me]+, 202 (65) [M–t-Bu]+, 187 (74) 
[M–CH2t-Bu]+, 174 (18), 160 (13), 57 (12), 41 (13).  
HR-MS (EI): m/z calcd for C16H22N2O+ [M]+ 258.1727, found 258.1738. 
 
1-[4-Methoxy-2-(2-methylbenzyl)phenyl]-5-methyl-1H-pyrazole (201) 
1H-NMR (500 MHz, CDCl3): δ = 7.57 (d, J = 1.8 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 
7.12–7.05 (m, 3H), 6.94 (dd, J = 7.0, 1.2 Hz, 1H), 6.81 (dd, J = 8.6, 2.9 Hz, 1H), 
6.56 (d, J = 2.9 Hz, 1H), 6.11 (dd, J = 1.8, 0.8 Hz, 1H), 3.75 (s, 3H), 3.66 (s, 2H), 
2.09 (s, 3H), 1.98 (d, J = 0.8 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 159.9 (Cq), 140.4 (Cq), 139.9 (Cq), 139.5 (CH), 137.3 (Cq), 136.6 (Cq), 
131.6 (Cq), 130.2 (CH), 130.0 (CH), 129.0 (CH), 126.5 (CH), 125.9 (CH), 115.8 (CH), 111.2 (CH), 105.1 
(CH), 55.4 (CH3), 34.5 (CH2), 19.6 (CH3), 11.2 (CH3). 
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IR (ATR): ṽ = 2961, 1610, 1499, 1438, 1280, 1217, 1110, 1045, 799, 742 cm−1.  
m.p.: 65–66 °C 
MS (EI) m/z (relative intensity): 292 (100) [M]+, 291 (22) [M–H]+, 277 (38) [M–Me]+, 264 (35), 250 
(9), 210 (16), 179 (12), 174 (17), 165 (15), 152 (12), 43 (13).  
HR-MS (EI): m/z calcd for C19H20N2O+ [M]+ 292.1570, found 292.1571. 
 
1-(2-Cyclohexylphenyl)-1H-pyrazole (145aj) 
The general procedure K was followed using 2-(1H-pyrazol-1-yl)benzoic acid (144a, 
94.1 mg, 0.50 mmol) and bromocyclohexane (136j, 245 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 20:1) followed by 
recycling preparative HPLC yielded ortho-alkylated product 145aj (45.4 mg, 40%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.72 (dd, J = 1.9, 0.7 Hz, 1H), 7.55 (dd, J = 2.3, 0.7 Hz, 1H), 7.42–7.38 
(m, 2H), 7.29–7.24 (m, 2H), 6.44 (dd, J = 2.3, 1.9 Hz, 1H), 2.44 (tt, J = 12.0, 3.1 Hz, 1H), 1.82–1.66 
(m, 5H), 1.48–1.33 (m, 2H), 1.30–1.16 (m, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 144.0 (Cq), 140.0 (CH), 138.9 (Cq), 130.9 (CH), 128.8 (CH), 127.1 
(CH), 126.9 (CH), 126.0 (CH), 105.9 (CH), 38.3 (CH), 34.3 (CH2), 26.8 (CH2), 26.1 (CH2).  
IR (ATR): ṽ = 2924, 2851, 1515, 1448, 1394, 1043, 938, 745, 620 cm−1.  
MS (EI) m/z (relative intensity): 226 (74) [M]+, 225 (100) [M–H]+, 208 (14), 197 (21), 183 (39), 169 
(46), 157 (17), 143 (13), 130 (25), 115 (17).  
HR-MS (ESI): m/z calcd for C15H19N2+ [M+H]+ 227.1543, found 227.1552. 
 
1-(2-Cyclohexyl-4-methoxyphenyl)-5-methyl-1H-pyrazole (145fj) 
The general procedure K was followed using 5-methoxy-2-(5-methyl-1H-
pyrazol-1-yl)benzoic acid (144f, 116 mg, 0.50 mmol) and bromocyclohexane 
(136j, 245 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded ortho-alkylated product 145fj (44.3 mg, 33%, as 
a 10:1 mixture of ortho and meta product) as a colorless oil. 
1H-NMR (300 MHz, CDCl3, determined as a 10:1 mixture of ortho- and meta-isomer): δ = 7.54 (d, J 
= 1.7 Hz, 1H), 7.24 (d, J = 2.6 Hz, 1H, meta-isomer), 7.18 (dd, J = 8.6, 2.6 Hz, 1H, meta-isomer), 7.10 
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(d, J = 8.6 Hz, 1H), 6.90 (d, J = 2.9 Hz, 1H), 6.77 (dd, J = 8.6, 2.9 Hz, 1H), 6.16–6.13 (m, 1H), 3.86 (s, 
3H, meta-isomer), 3.85 (s, 3H), 2.98 (tt, J = 11.7, 3.2 Hz, 1H, meta-isomer), 2.29 (s, 3H, meta-
isomer), 2.07 (s, 3H), 2.03 (tt, J = 11.9, 3.2 Hz, 1H), 1.88–1.60 (m, 5H), 1.45–1.04 (m, 5H). Some 
proton peaks of meta isomer could observed by 1H-NMR spectroscopy. 
13C-NMR (125 MHz, CDCl3, determined as a 10:1 mixture of ortho and meta isomer): δ = 160.0 (Cq), 
147.4 (Cq), 139.8 (Cq), 139.2 (CH, meta-isomer), 139.0 (CH), 136.9 (Cq, meta-isomer), 132.8 (Cq, 
meta-isomer), 130.6 (Cq), 128.9 (CH), 123.8 (CH, meta-isomer), 123.0 (CH, meta-isomer), 112.8 
(CH), 110.8 (CH), 110.2 (CH, meta-isomer), 106.1 (CH, meta-isomer), 104.7 (CH), 55.7 (CH3, meta-
isomer), 55.4 (CH3), 38.7 (CH), 36.9 (CH, meta-isomer), 33.1 (CH2, meta-isomer), 27.1 (CH2, meta-
isomer), 26.8 (CH2), 26.4 (CH2, meta-isomer), 26.1 (CH2), 12.3 (CH3, meta-isomer), 11.6 (CH3). Due 
to overlapping, some carbon peaks of meta-isomer could not be detected by 13C-NMR 
spectroscopy. 
IR (ATR): ṽ = 2924, 2850, 1608, 1506, 1445, 1294, 1242, 1051, 922, 770 cm−1.  
MS (EI) m/z (relative intensity): 270 (38) [M]+, 269 (12) [M–H]+, 255 (100) [M–Me]+, 241 (6), 227 
(17), 213 (12), 187 (10).  
HR-MS (EI): m/z calcd for C17H22N2O+ [M]+ 270.1727, found 270.1727. 
 
1-[exo-2-(Bicyclo[2.2.1]heptan-2-yl)-4-methoxyphenyl]-5-methyl-1H-pyrazole (145fu) 
The general procedure K was followed using 5-methoxy-2-(5-methyl-1H-
pyrazol-1-yl)benzoic acid (144f, 116 mg, 0.50 mmol) and exo-2-
bromonorbornane (136u, 263 mg, 1.50 mmol). After 16 h, purification by 
column chromatography (n-hexane/EtOAc 10:1) yielded ortho-alkylated 
product 145fu (76.5 mg, 54%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.55 (d, J = 1.9 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 2.8 Hz, 
1H), 6.75 (dd, J = 8.5, 2.8 Hz, 1H), 6.14 (dq, J = 1.9, 0.8 Hz, 1H), 3.85 (s, 3H), 2.50–2.17 (m, 3H), 2.08 
(s, 3H), 1.56 (dt, J = 9.8, 2.0 Hz, 1H), 1.52–1.24 (m, 4H), 1.19 (ddt, J = 9.7, 2.2, 1.4 Hz, 1H), 1.13–
0.96 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 159.8 (Cq), 147.0 (Cq), 139.6 (Cq), 139.1 (CH), 131.3 (Cq), 129.0 (CH), 
112.9 (CH), 109.9 (CH), 104.7 (CH), 55.4 (CH3), 42.2 (CH), 41.5 (CH), 39.4 (CH2), 36.7 (CH), 36.5 
(CH2), 30.7 (CH2), 28.4 (CH2), 11.7 (CH3). 
IR (ATR): ṽ = 2950, 2869, 1607, 1503, 1299, 1225, 1111, 1041, 922, 769 cm−1.  
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MS (EI) m/z (relative intensity): 282 (88) [M]+, 267 (68) [M–Me]+, 253 (100), 241 (26), 226 (50), 200 
(16), 115 (12), 77 (11), 67 (14), 43 (24).  
HR-MS (EI): m/z calcd for C18H22N2O+ [M]+ 282.1727, found 282.1736. 
 
1-(3-Cycloheptyl-4-fluorophenyl)-1H-pyrazole (146gh) 
The general procedure K was followed using 5-fluoro-2-(1H-pyrazol-1-yl)benzoic 
acid (144g, 103 mg, 0.50 mmol) and bromocycloheptane (136h, 266 mg, 
1.50 mmol). After 16 h, purification by column chromatography (n-hexane/EtOAc 
15:1) yielded meta-alkylated product 146gh (82.6 mg, 64%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 2.5, 0.6 Hz, 1H), 7.71 (dd, J = 1.8, 0.6 Hz, 1H), 7.58 (dd, 
J = 6.4, 2.8 Hz, 1H), 7.38 (ddd, J = 8.8, 4.3, 2.8 Hz, 1H), 7.06 (dd, J = 9.9, 8.8 Hz, 1H), 6.45 (dd, J = 
2.5, 1.8 Hz, 1H), 3.04 (tt, J = 10.4, 3.5 Hz, 1H), 2.01–1.49 (m, 12H). 
13C-NMR (125 MHz, CDCl3): δ = 158.3 (d, 1JC–F = 244 Hz, Cq), 140.8 (CH), 137.5 (d, 2JC–F = 17 Hz, Cq), 
136.4 (d, 4JC–F = 3 Hz, Cq), 126.8 (CH), 119.4 (d, 3JC–F = 6 Hz, CH), 117.7 (d, 3JC–F = 9 Hz, CH), 115.9 (d, 
2JC–F = 25 Hz, CH), 107.4 (CH), 39.8 (CH), 35.3 (CH2), 27.8 (CH2), 27.4 (CH2). 
19F-NMR (282 MHz, CDCl3): δ = –121.6 (ddd, J = 9.9, 6.4, 4.3 Hz). 
IR (ATR): ṽ = 2922, 2855, 1519, 1494, 1393, 1220, 1039, 811, 744, 635 cm−1. 
MS (EI) m/z (relative intensity): 258 (100) [M]+, 229 (9), 215 (9), 201 (17), 188 (43), 176 (35), 133 
(16), 41 (12). 
HR-MS (EI): m/z calcd for C16H19FN2+ [M]+ 258.1527, found 258.1531. 
 
1-(3-Cycloheptyl-4-methylphenyl)-1H-pyrazole (146eh) 
The general procedure K was followed using 5-methyl-2-(1H-pyrazol-1-yl)benzoic 
acid (144e, 101 mg, 0.50 mmol) and bromocycloheptane (136h, 266 mg, 
1.50 mmol). After 16 h, purification by column chromatography (n-hexane/EtOAc 
30:1) yielded meta-alkylated product 146eh (74.5 mg, 59%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 2.5, 0.7 Hz, 1H), 7.71 (dd, J = 1.8, 0.7 Hz, 1H), 7.56 (d, J 
= 2.4 Hz, 1H), 7.32 (dd, J = 8.2, 2.4 Hz, 1H), 7.17 (d, J = 8.2 Hz, 1H), 6.44 (dd, J = 2.5, 1.8 Hz, 1H), 
2.91 (tt, J = 10.4, 3.1 Hz, 1H), 2.35 (s, 3H), 1.96–1.49 (m, 12H).  
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13C-NMR (125 MHz, CDCl3): δ = 149.3 (Cq), 140.5 (CH), 138.6 (Cq), 132.8 (Cq), 130.7 (CH), 126.6 (CH), 
117.0 (CH), 116.0 (CH), 107.0 (CH), 42.2 (CH), 36.0 (CH2), 27.8 (CH2), 27.7 (CH2), 19.1 (CH3).  
IR (ATR): ṽ = 2920, 2853, 1611, 1518, 1391, 1334, 1043, 808, 743 cm−1.  
MS (EI) m/z (relative intensity): 254 (100) [M]+, 239 (11) [M–Me]+, 225 (9), 211 (19), 197 (24), 185 
(35), 172 (38), 128 (16), 115 (21), 41 (14).  
HR-MS (EI): m/z calcd for C17H22N2+ [M]+ 254.1778, found 254.1783. 
 
1-(3-Cyclooctyl-4-methylphenyl)-1H-pyrazole (146ek) 
The general procedure K was followed using 5-methyl-2-(1H-pyrazol-1-yl)benzoic 
acid (144e, 101 mg, 0.50 mmol) and bromocyclooctane (136k, 287 mg, 
1.50 mmol). After 16 h, purification by column chromatography (n-hexane/EtOAc 
30:1) yielded meta-alkylated product 146ek (46.4 mg, 35%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.88 (dd, J = 2.4, 0.7 Hz, 1H), 7.71 (dd, J = 1.8, 0.7 Hz, 1H), 7.54 (d, J 
= 2.4 Hz, 1H), 7.32 (dd, J = 8.2, 2.4 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 6.44 (dd, J = 2.4, 1.8 Hz, 1H), 
3.08–2.99 (m, 1H), 2.36 (s, 3H), 1.88–1.54 (m, 14H).  
13C-NMR (100 MHz, CDCl3): δ = 150.2 (Cq), 140.6 (CH), 138.6 (Cq), 132.8 (Cq), 130.8 (CH), 126.7 (CH), 
117.5 (CH), 116.0 (CH), 107.1 (CH), 39.6 (CH), 34.3 (CH2), 26.7 (CH2), 26.4 (CH2), 19.2 (CH3).  
IR (ATR): ṽ = 2917, 2850, 1611, 1585, 1518, 1392, 1334, 1043, 809, 743 cm−1.  
MS (EI) m/z (relative intensity): 268 (100) [M]+, 253 (8) [M–Me]+, 225 (11), 211 (17), 197 (24), 185 
(46), 172 (41), 128 (14), 115 (19), 41 (21).  
HR-MS (EI): m/z calcd for C18H24N2+ [M]+ 268.1934, found 268.1941. 
 
1-(3-Cycloheptyl-4-methoxyphenyl)-5-methyl-1H-pyrazole (146fh) 
The general procedure K was followed using 5-methoxy-2-(5-methyl-1H-pyrazol-
1-yl)benzoic acid (144f, 116 mg, 0.50 mmol) and bromocycloheptane (136h, 
266 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded meta-alkylated product 146fh (39.3 mg, 28%) as a 
colorless oil. 
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1H-NMR (500 MHz, CDCl3): δ = 7.54 (d, J = 1.8 Hz, 1H), 7.23 (d, J = 2.7 Hz, 1H), 7.16 (dd, J = 8.6, 
2.7 Hz, 1H), 6.88 (d, J = 8.6 Hz, 1H), 6.16 (dq, J = 1.8, 0.9 Hz, 1H), 3.87 (s, 3H), 3.13 (tt, J = 10.2, 
3.3 Hz, 1H), 2.29 (s, 3H), 1.92–1.84 (m, 2H), 1.82–1.74 (m, 2H), 1.73–1.65 (m, 2H), 1.64–1.50 (m, 
6H).  
13C-NMR (125 MHz, CDCl3): δ = 155.6 (Cq), 139.3 (CH), 138.9 (Cq), 138.6 (Cq), 132.8 (Cq), 124.1 (CH), 
122.9 (CH), 110.3 (CH), 106.1 (CH), 55.7 (CH3), 38.8 (CH), 35.4 (CH2), 27.9 (CH2), 27.4 (CH2), 12.3 
(CH3).  
IR (ATR): ṽ = 2920, 2852, 1499, 1442, 1238, 1102, 1028, 921, 811, 771 cm−1.  
MS (EI) m/z (relative intensity): 284 (100) [M]+, 269 (5) [M–Me]+, 255 (8), 241 (9), 227 (20), 215 
(15), 201 (14), 171 (11), 55 (9), 41 (13).  
HR-MS (EI): m/z calcd for C18H24N2O+ [M]+ 284.1883, found 284.1891. 
 
1-[3-(tert-Butyl)-4-methoxyphenyl]-5-methyl-1H-pyrazole (146fb) 
The general procedure K was followed using 5-methoxy-2-(5-methyl-1H-pyrazol-1-
yl)benzoic acid (144f, 116 mg, 0.50 mmol) and tert-butyl bromide (136b, 206 mg, 
1.50 mmol). After 16 h, purification by column chromatography (n-hexane/EtOAc 
10:1) yielded meta-alkylated product 146fb (65.9 mg, 54%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.54 (dq, J = 1.8, 0.5 Hz, 1H), 7.32 (d, J = 2.7 Hz, 1H), 7.21 (dd, J = 
8.6, 2.7 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 6.17 (dq, J = 1.8, 0.8 Hz, 1H), 3.88 (s, 3H), 2.30 (dd, J = 0.8, 
0.5 Hz, 3H), 1.39 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 157.8 (Cq), 139.2 (CH), 139.0 (Cq), 138.5 (Cq), 132.5 (Cq), 124.1 (CH), 
123.5 (CH), 111.4 (CH), 106.1 (CH), 55.3 (CH3), 35.1 (Cq), 29.6 (CH3), 12.3 (CH3). 
IR (ATR): ṽ = 2955, 1497, 1454, 1234, 1091, 1027, 922, 814, 772 cm−1.  
MS (EI) m/z (relative intensity): 244 (76) [M]+, 229 (100) [M–Me]+, 214 (23) [M–2Me]+, 201 (25), 
171 (9), 77 (8), 43 (9).  








The general procedure K was followed using 5-fluoro-2-(1H-pyrazol-1-yl)benzoic acid 
(144g, 103 mg, 0.50 mmol) and tert-butyl bromide (136b, 206 mg, 1.50 mmol). After 
16 h, purification by column chromatography (n-hexane/EtOAc 25:1) yielded meta-
alkylated product 146gb (59.1 mg, 54%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 2.5, 0.6 Hz, 1H), 7.71 (dd, J = 1.9, 0.6 Hz, 1H), 7.65 (dd, 
J = 7.1, 2.8 Hz, 1H), 7.42 (ddd, J = 8.7, 3.9, 2.8 Hz, 1H), 7.07 (dd, J = 11.8, 8.7 Hz, 1H), 6.45 (dd, J = 
2.5, 1.9 Hz, 1H), 1.43 (d, J = 1.1 Hz, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 160.2 (d, 1JC–F = 248 Hz, Cq), 140.8 (CH), 138.4 (d, 2JC–F = 13 Hz, Cq), 
136.1 (d, 4JC–F = 3 Hz, Cq), 126.9 (CH), 119.1 (d, 3JC–F = 6 Hz, CH), 118.4 (d, 3JC–F = 9 Hz, CH), 116.9 (d, 
2JC–F = 26 Hz, CH), 107.4 (CH), 34.6 (d, 3JC–F = 3 Hz, Cq), 29.8 (d, 4JC–F = 4 Hz, CH3). 
19F-NMR (282 MHz, CDCl3): δ = (–112.1)–(–112.2) (m). 
IR (ATR): ṽ = 2961, 1518, 1491, 1395, 1211, 1044, 949, 812, 744, 640 cm−1.  
MS (EI) m/z (relative intensity): 218 (67) [M]+, 203 (100) [M–Me]+, 175 (74).  
HR-MS (EI): m/z calcd for C13H15FN2+ [M]+ 218.1214, found 218.1221. 
The analytical data correspond with those reported in the literature.[62] 
 
1-[3-(tert-Butyl)-4-methylphenyl]-1H-pyrazole (146eb) 
The general procedure K was followed using 5-methyl-2-(1H-pyrazol-1-yl)benzoic 
acid (144e, 101 mg, 0.50 mmol) and tert-butyl bromide (136b, 206 mg, 1.50 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 25:1) yielded 
meta-alkylated product 146eb (30.4 mg, 28%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 2.4, 0.7 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.71 (dd, J = 
1.8, 0.7 Hz, 1H), 7.35 (dd, J = 8.2, 2.4 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 6.44 (dd, J = 2.4, 1.8 Hz, 1H), 
2.57 (s, 3H), 1.46 (s, 9H).  
13C-NMR (125 MHz, CDCl3): δ = 149.3 (Cq), 140.6 (CH), 138.1 (Cq), 134.6 (Cq), 133.4 (CH), 126.7 (CH), 
117.7 (CH), 116.6 (CH), 107.1 (CH), 36.1 (Cq), 30.7 (CH3), 22.9 (CH3). 
IR (ATR): ṽ = 2959, 1610, 1517, 1492, 1395, 1045, 949, 811, 745 cm−1.  
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MS (EI) m/z (relative intensity): 214 (52) [M]+, 199 (100) [M–Me]+, 184 (9) [M–2Me]+, 171 (18), 115 
(10), 91 (9), 77 (6), 41 (7).  
HR-MS (EI): m/z calcd for C14H18N2+ [M]+ 214.1465, found 214.1475. 
The spectral data are in accordance with those reported in the literature.[103] 
 
1-[3-(Adamantan-1-yl)phenyl]-1H-pyrazole (146av) 
The general procedure K was followed using 2-(1H-pyrazol-1-yl)benzoic acid (144a, 
94.1 mg, 0.50 mmol) and 1-bromoadamantane (136v, 324 mg, 1.50 mmol). After 
16 h, purification by column chromatography (n-hexane/EtOAc 30:1) yielded meta-
alkylated product 146av (42.7 mg, 31%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.93 (dd, J = 2.5, 0.6 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.73 (d, J = 
1.7 Hz, 1H), 7.45 (ddd, J = 7.8, 2.0, 1.6 Hz, 1H), 7.39 (dd, J = 7.8, 7.6 Hz, 1H), 7.30 (dt, J = 7.6, 1.6 Hz, 
1H), 6.46 (dd, J = 2.5, 1.7 Hz, 1H), 2.16–2.08 (m, 3H), 2.00–1.93 (m, 6H), 1.85–1.72 (m, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 153.0 (Cq), 140.8 (CH), 140.1 (Cq), 128.9 (CH), 126.8 (CH), 123.1 
(CH), 116.5 (CH), 116.4 (CH), 107.3 (CH), 43.2 (CH2), 36.8 (CH2), 36.5 (Cq), 29.0 (CH). 
IR (ATR): ṽ = 2899, 2846, 1606, 1518, 1391, 1032, 945, 781, 743, 696 cm−1.  
MS (EI) m/z (relative intensity): 278 (100) [M]+, 235 (8), 221 (65), 184 (9).  
HR-MS (EI): m/z calcd for C19H22N2+ [M]+ 278.1778, found 278.1784. 
 
5.3.5.2 Characterization Data for 141g and 202 
Methyl 2-[3-(1H-pyrazol-1-yl)phenyl]hexanoate (141g) 
The general procedure L was followed using 2-(1H-pyrazol-1-yl)benzoic acid 
(144a, 94.1 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded meta-alkylated product 141g (80.1 mg, 59%) as a 
colorless oil. The analytical data of 141g are in section 5.3.3.1. 
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Methyl 2-[2-methyl-5-(1H-pyrazol-1-yl)phenyl]hexanoate (202a) 
The general procedure L was followed using 5-methyl-2-(1H-pyrazol-1-
yl)benzoic acid (144e, 101 mg, 0.50 mmol) and methyl 2-bromohexanoate 
(140a, 314 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 15:1) yielded meta-alkylated product 202a (82.1 mg, 57%) as 
a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 7.89 (dd, J = 2.5, 0.7 Hz, 1H), 7.70 (dd, J = 1.8, 0.7 Hz, 1H), 7.63 (d, J 
= 2.4 Hz, 1H), 7.49 (dd, J = 8.2, 2.4 Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 6.44 (dd, J = 2.5, 1.8 Hz, 1H), 
3.85 (dd, J = 8.1, 7.0 Hz, 1H), 3.66 (s, 3H), 2.39 (s, 3H), 2.15 (dddd, J = 13.2, 10.0, 8.1, 5.0 Hz, 1H), 
1.78 (dddd, J = 13.7, 10.0, 7.0, 5.5 Hz, 1H), 1.37–1.19 (m, 4H), 0.88 (t, J = 7.2 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 174.2 (Cq), 140.7 (CH), 139.0 (Cq), 138.7 (Cq), 134.3 (Cq), 131.2 (CH), 
126.7 (CH), 117.8 (CH), 117.7 (CH), 107.3 (CH), 52.0 (CH3), 47.1 (CH), 33.0 (CH2), 29.9 (CH2), 22.6 
(CH2), 19.5 (CH3), 14.0 (CH3). 
IR (ATR): ṽ = 2954, 1732, 1613, 1520, 1392, 1161, 1043, 956, 815, 747 cm−1.  
MS (EI) m/z (relative intensity): 286 (62) [M]+, 271 (4) [M–Me]+, 257 (9) [M–Et]+, 243 (39) [M–Pr]+, 
230 (60) [M–Bu]+, 227 (83) [M–CO2Me]+, 213 (23) [M–CO2Me–Me]+, 199 (18) [M–CO2Me–Et]+, 185 
(31) [M–CO2Me–Pr]+, 171 (100) [M–CO2Me–Bu]+, 157 (17), 128 (14), 115 (24), 41 (18).  
HR-MS (EI): m/z calcd for C17H22N2O2+ [M]+ 286.1676, found 286.1681. 
 
Methyl 2-[2-fluoro-5-(1H-pyrazol-1-yl)phenyl]hexanoate (202b) 
The general procedure L was followed using 5-fluoro-2-(1H-pyrazol-1-yl)benzoic 
acid (144g, 103 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded meta-alkylated product 202b (93.9 mg, 65%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.87 (dd, J = 2.5, 0.6 Hz, 1H), 7.71 (dd, J = 1.8, 0.6 Hz, 1H), 7.68 (dd, 
J = 6.2, 2.8 Hz, 1H), 7.56 (ddd, J = 8.9, 4.4, 2.8 Hz, 1H), 7.13 (dd, J = 9.5, 8.9 Hz, 1H), 6.46 (dd, J = 
2.5, 1.8 Hz, 1H), 3.96 (t, J = 7.7 Hz, 1H), 3.69 (s, 3H), 2.20–2.05 (m, 1H), 1.89–1.74 (m, 1H), 1.45–
1.13 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H).   
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13C-NMR (125 MHz, CDCl3): δ = 173.3 (Cq), 158.7 (d, 1JC–F = 245 Hz, Cq), 141.0 (CH), 136.6 (d, 4JC–F = 
3 Hz, Cq), 127.5 (d, 2JC–F = 17 Hz, Cq), 126.9 (CH), 120.0 (d, 3JC–F = 4 Hz, CH), 119.6 (d, 3JC–F = 9 Hz, 
CH), 116.2 (d, 2JC–F = 25 Hz, CH), 107.6 (CH), 52.2 (CH3), 43.7 (d, 3JC–F = 2 Hz, CH), 32.4 (CH2), 29.7 
(CH2), 22.4 (CH2), 13.9 (CH3). 
19F-NMR (282 MHz, CDCl3): δ = –120.9 (ddd, J = 9.5, 6.2, 4.4 Hz). 
IR (ATR): ṽ = 2955, 2861, 1734, 1520, 1500, 1394, 1224, 1039, 819, 747 cm−1.  
MS (EI) m/z (relative intensity): 290 (77) [M]+, 247 (9) [M–Pr]+, 234 (60) [M–Bu]+, 231 (70) [M–
CO2Me]+, 203 (14) [M–CO2Me–Et]+, 189 (24) [M–CO2Me–Pr]+, 175 (100) [M–CO2Me–Bu]+, 148 (13), 
133 (10).  
HR-MS (EI): m/z calcd for C16H19FN2O2+ [M]+ 290.1425, found 290.1434. 
 
Methyl 2-[2-chloro-5-(1H-pyrazol-1-yl)phenyl]hexanoate (202c) 
The general procedure L was followed using 5-chloro-2-(1H-pyrazol-1-yl)benzoic 
acid (144h, 111 mg, 0.50 mmol) and methyl 2-bromohexanoate (140a, 314 mg, 
1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded meta-alkylated product 202c (91.2 mg, 59%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.90 (dd, J = 2.5, 0.6 Hz, 1H), 7.73 (d, J = 2.6 Hz, 1H), 7.72 (dd, J = 
1.8, 0.6 Hz, 1H), 7.56 (dd, J = 8.7, 2.6 Hz, 1H), 7.45 (d, J = 8.7 Hz, 1H), 6.47 (dd, J = 2.5, 1.8 Hz, 1H), 
4.18 (dd, J = 7.7, 7.6 Hz, 1H), 3.69 (s, 3H), 2.13 (dddd, J = 13.1, 9.7, 7.7, 5.5 Hz, 1H), 1.82 (dddd, J = 
13.4, 9.7, 7.6, 5.5 Hz, 1H), 1.41–1.18 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H).   
13C-NMR (125 MHz, CDCl3): δ = 173.5 (Cq), 141.3 (CH), 139.1 (Cq), 138.3 (Cq), 131.5 (Cq), 130.4 (CH), 
126.7 (CH), 119.2 (CH), 118.9 (CH), 107.9 (CH), 52.2 (CH3), 47.4 (CH), 32.9 (CH2), 29.6 (CH2), 22.5 
(CH2), 14.0 (CH3). 
IR (ATR): ṽ = 2954, 2860, 1733, 1519, 1481, 1392, 1166, 1032, 818, 746 cm−1.  
MS (EI) m/z (relative intensity): 308 (17) [M(37Cl)]+, 306 (47) [M(35Cl)]+, 271 (100) [M–Cl]+, 252 (8) 
[M(37Cl)–Bu]+, 250 (24) [M(35Cl)–Bu]+, 249 (12) [M(37Cl)–CO2Me]+, 247 (35) [M(35Cl)–CO2Me]+, 193 
(23) [M(37Cl)–CO2Me–Bu]+, 191 (58) [M(35Cl)–CO2Me–Bu]+, 155 (12), 115 (13), 59 (13), 43 (35).  
HR-MS (EI): m/z calcd for C16H1935ClN2O2+ [M]+ 306.1130, found 306.1136. 
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Methyl 2-[2-methyl-5-(1H-pyrazol-1-yl)phenyl]propanoate (202d) 
The general procedure L was followed using 5-methyl-2-(1H-pyrazol-1-
yl)benzoic acid (144e, 101 mg, 0.50 mmol) and methyl 2-bromopropanoate 
(140i, 251 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded meta-alkylated product 202d (33.3 mg, 27%) as 
a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 2.5, 0.7 Hz, 1H), 7.70 (dd, J = 1.8, 0.7 Hz, 1H), 7.59 (d, J 
= 2.4 Hz, 1H), 7.47 (dd, J = 8.2, 2.4 Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 6.44 (dd, J = 2.5, 1.8 Hz, 1H), 
3.99 (q, J = 7.2 Hz, 1H), 3.67 (s, 3H), 2.38 (s, 3H), 1.54 (d, J = 7.2 Hz, 3H).   
13C-NMR (125 MHz, CDCl3): δ = 174.6 (Cq), 140.7 (CH), 140.2 (Cq), 138.7 (Cq), 134.0 (Cq), 131.3 (CH), 
126.7 (CH), 117.8 (CH), 117.7 (CH), 107.3 (CH), 52.1 (CH3), 41.5 (CH), 19.2 (CH3), 17.9 (CH3). 
IR (ATR): ṽ = 2951, 1731, 1613, 1520, 1393, 1335, 1199, 1045, 946, 750 cm−1.  
MS (EI) m/z (relative intensity): 244 (59) [M]+, 212 (8) [M–OMe]+, 185 (100) [M–CO2Me]+, 170 (13) 
[M–CO2Me–Me]+, 157 (12), 143 (11), 115 (17), 91 (12), 77 (7), 59 (9), 43 (10).  
HR-MS (EI): m/z calcd for C14H16N2O2+ [M]+ 244.1206, found 244.1210. 
 
(Tetrahydrofuran-2-yl)methyl 2-[2-methyl-5-(1H-pyrazol-1-yl)phenyl]propanoate (202e) 
The general procedure L was followed using 5-methyl-2-(1H-pyrazol-1-
yl)benzoic acid (144e, 101 mg, 0.50 mmol) and (tetrahydrofuran-2-
yl)methyl 2-bromopropanoate (140l, 356 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 7:1) yielded 
meta-alkylated product 202e (68.6 mg, 44%, as a diastereomeric mixture (1:1)) as a colorless oil. 
1H-NMR (300 MHz, CDCl3, determined as a diastereomeric mixture (1:1)): δ = 7.91 (dd, J = 2.5, 
0.7 Hz, 1H), 7.91 (dd, J = 2.5, 0.7 Hz, 1H), 7.69 (dd, J = 1.8, 0.7 Hz, 2H), 7.61 (d, J = 2.4 Hz, 1H), 7.60 
(d, J = 2.4 Hz, 1H), 7.49 (dd, J = 8.2, 2.4 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 6.43 (dd, J = 2.5, 1.8 Hz, 
2H), 4.22–3.98 (m, 8H), 3.82–3.67 (m, 4H), 2.39 (s, 6H), 1.97–1.71 (m, 6H), 1.54 (d, J = 7.1 Hz, 3H), 
1.54 (d, J = 7.1 Hz, 3H), 1.54–1.43 (m, 2H). 
13C-NMR (125 MHz, CDCl3, determined as a diastereomeric mixture (1:1)): δ = 174.1 (Cq), 174.0 
(Cq), 140.7 (2 × CH), 140.1 (Cq), 140.1 (Cq), 138.7 (2 × Cq), 134.0 (2 × Cq), 131.2 (2 × CH), 126.7 (2 × 
CH), 117.8 (CH), 117.8 (CH), 117.6 (CH), 117.6 (CH), 107.2 (2 × CH), 76.4 (CH), 76.3 (CH), 68.4 (CH2), 
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68.3 (CH2), 66.8 (CH2), 66.6 (CH2), 41.6 (CH), 41.6 (CH), 28.0 (CH2), 27.8 (CH2), 25.7 (CH2), 25.7 (CH2), 
19.2 (2 × CH3), 17.9 (CH3), 17.9 (CH3). 
IR (ATR): ṽ = 2975, 2873, 1730, 1613, 1520, 1393, 1187, 1044, 947, 749 cm−1.  
MS (EI) m/z (relative intensity): 314 (42) [M]+, 271 (13), 244 (9) [M–THF]+, 230 (21) [M–CH2THF]+, 
212 (31) [M–OCH2THF]+, 186 (98), 185 (100) [M–CO2CH2THF]+, 171 (37) [M–CO2CH2THF–Me]+, 143 
(14), 115 (24), 91 (15), 71 (71), 43 (61), 41 (26).  
HR-MS (EI): m/z calcd for C18H22N2O3+ [M]+ 314.1625, found 314.1637. 
 
2-[2-Methyl-5-(1H-pyrazol-1-yl)phenyl]-1-morpholinopropan-1-one (202f) 
The general procedure L was followed using 5-methyl-2-(1H-pyrazol-1-
yl)benzoic acid (144e, 101 mg, 0.50 mmol) and 2-bromo-1-
morpholinopropan-1-one (140e, 333 mg, 1.50 mmol). After 16 h, purification 
by column chromatography (n-hexane/EtOAc 1:1) yielded meta-alkylated 
product 202f (54.8 mg, 37%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.87 (dd, J = 2.5, 0.6 Hz, 1H), 7.68 (dd, J = 1.8, 0.6 Hz, 1H), 7.54 (dd, 
J = 8.2, 2.4 Hz, 1H), 7.44 (d, J = 2.4 Hz, 1H), 7.25 (d, J = 8.2 Hz, 1H), 6.43 (dd, J = 2.5, 1.8 Hz, 1H), 
3.95 (q, J = 6.8 Hz, 1H), 3.88–3.77 (m, 1H), 3.73–3.61 (m, 1H), 3.60–3.41 (m, 3H), 3.34–3.22 (m, 
1H), 3.18–3.04 (m, 2H), 2.37 (s, 3H), 1.44 (d, J = 6.8 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 172.1 (Cq), 141.2 (Cq), 140.8 (CH), 139.1 (Cq), 132.2 (Cq), 131.7 (CH), 
126.6 (CH), 117.9 (CH), 117.0 (CH), 107.4 (CH), 66.8 (CH2), 66.2 (CH2), 45.7 (CH2), 42.5 (CH2), 40.0 
(CH), 18.9 (CH3), 18.7 (CH3). 
IR (ATR): ṽ = 2969, 2856, 1643, 1519, 1429, 1394, 1228, 1114, 1029, 753 cm−1.  
MS (EI) m/z (relative intensity): 299 (20) [M]+, 269 (34), 212 (29), 185 (100), 170 (14), 158 (9), 143 
(12), 114 (99), 91 (14), 70 (68), 43 (24).  
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Methyl 5-bromo-2-[2-methyl-5-(1H-pyrazol-1-yl)phenyl]pentanoate (202g) 
The general procedure L was followed using 5-methyl-2-(1H-pyrazol-1-
yl)benzoic acid (144e, 101 mg, 0.50 mmol) and methyl 2,5-dibromopentanoate 
(140f, 411 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 10:1) yielded meta-alkylated product 202g (33.5 mg, 19%) as a 
colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.89 (dd, J = 2.5, 0.6 Hz, 1H), 7.71 (dd, J = 1.8, 0.6 Hz, 1H), 7.61 (d, J 
= 2.4 Hz, 1H), 7.49 (dd, J = 8.4, 2.4 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 6.45 (dd, J = 2.5, 1.8 Hz, 1H), 
3.88 (dd, J = 8.1, 6.7 Hz, 1H), 3.67 (s, 3H), 3.43–3.37(m, 2H), 2.40 (s, 3H), 2.33–2.22 (m, 1H), 2.07–
1.73 (m, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 173.6 (Cq), 140.8 (CH), 138.8 (Cq), 138.2 (Cq), 134.3 (Cq), 131.5 (CH), 
126.7 (CH), 118.1 (CH), 117.7 (CH), 107.4 (CH), 52.2 (CH3), 46.3 (CH), 33.0 (CH2), 31.5 (CH2), 30.7 
(CH2), 19.5 (CH3). 
IR (ATR): ṽ = 2951, 1730, 1613, 1520, 1434, 1393, 1198, 1162, 1043, 748 cm−1.  
MS (EI) m/z (relative intensity): 352 (22) [M(81Br)]+, 350 (22) [M(79Br)]+, 293 (28) [M(81Br)–CO2Me]+, 
291 (28) [M(79Br)–CO2Me]+, 271 (100) [M–Br]+, 243 (47) [M–Br–Et]+, 211 (70) [M–Br–CO2Me]+, 185 
(23), 183 (28), 171 (64), 157 (15), 143 (10), 128 (14), 115 (20), 91 (9).  
HR-MS (EI): m/z calcd for C16H1979BrN2O2+ [M]+ 350.0624, found 350.0643. 
 
1-[3-(1-Phenylethyl)phenyl]-1H-pyrazole (202h) 
The general procedure L was followed using 2-(1H-pyrazol-1-yl)benzoic acid 
(144a, 94.1 mg, 0.50 mmol) and (1-chloroethyl)benzene (142a, 211 mg, 
1.50 mmol). After 16 h, purification by column chromatography (n-hexane/EtOAc 
30:1) followed by recycling preparative HPLC yielded meta-benzylated product 
202h (28.8 mg, 23%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.89 (dd, J = 2.5, 0.6 Hz, 1H), 7.72 (dd, J = 1.8, 0.6 Hz, 1H), 7.63 
(dddd, J = 2.0, 1.8, 0.5, 0.5 Hz, 1H), 7.49 (ddd, J = 7.8, 2.0, 1.1 Hz, 1H), 7.36 (dd, J = 7.8, 7.7 Hz, 1H), 
7.33–7.18 (m, 5H), 7.15 (dddd, J = 7.7, 1.8, 1.1, 0.6 Hz, 1H), 6.45 (dd, J = 2.5, 1.8 Hz, 1H), 4.23 (q, J 
= 7.2 Hz, 1H), 1.70 (d, J = 7.2 Hz, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 148.0 (Cq), 145.6 (Cq), 140.8 (CH), 140.2 (Cq), 129.3 (CH), 128.4 (CH), 
127.5 (CH), 126.7 (CH), 126.1 (CH), 125.7 (CH), 118.7 (CH), 116.9 (CH), 107.4 (CH), 44.8 (CH), 21.8 
(CH3). 
IR (ATR): ṽ = 2969, 1592, 1519, 1493, 1393, 1044, 945, 750, 702 cm−1.  
MS (EI) m/z (relative intensity): 248 (83) [M]+, 233 (100) [M–Me]+, 206 (17), 179 (12), 165 (30), 115 
(8), 77 (13).  
HR-MS (EI): m/z calcd for C17H16N2+ [M]+ 248.1308, found 248.1314. 
 
1-{3-[1-(4-Fluorophenyl)ethyl]phenyl}-1H-pyrazole (202i) 
The general procedure L was followed using 2-(1H-pyrazol-1-yl)benzoic acid 
(144a, 94.1 mg, 0.50 mmol) and 1-(1-chloroethyl)-4-fluorobenzene (142d, 
238 mg, 1.50 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 30:1) yielded meta-benzylated product 202i (38.4 mg, 29%) 
as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 7.89 (dd, J = 2.5, 0.6 Hz, 1H), 7.72 (dd, J = 1.8, 0.6 Hz, 1H), 7.61 (dd, 
J = 2.2, 2.0 Hz, 1H), 7.48 (ddd, J = 7.9, 2.2, 1.0 Hz, 1H), 7.36 (dd, J = 7.9, 7.8 Hz, 1H), 7.20 (ddd, J = 
8.9, 5.4, 0.6 Hz, 2H), 7.13–7.11 (m, 1H), 6.98 (dd, J = 8.9, 8.7 Hz, 2H), 6.45 (dd, J = 2.5, 1.8 Hz, 1H), 
4.21 (q, J = 7.3 Hz, 1H), 1.67 (d, J = 7.3 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 161.2 (d, 1JC–F = 244 Hz, Cq), 147.8 (Cq), 141.3 (d, 4JC–F = 3 Hz, Cq), 
140.9 (CH), 140.2 (Cq), 129.3 (CH), 128.9 (d, 3JC–F = 8 Hz, CH), 126.7 (CH), 125.6 (CH), 118.6 (CH), 
116.9 (CH), 115.1 (d, 2JC–F = 21 Hz, CH), 107.5 (CH), 44.1 (CH), 22.0 (CH3). 
19F-NMR (376 MHz, CDCl3): δ = –117.1 (tt, J = 8.7, 5.4 Hz) 
IR (ATR): ṽ = 2968, 1607, 1592, 1508, 1393, 1222, 1040, 945, 837, 749 cm−1.  
MS (EI) m/z (relative intensity): 266 (77) [M]+, 251 (100) [M–Me]+, 231 (8) [M–Me–F]+, 224 (14), 
183 (25).  
HR-MS (EI): m/z calcd for C17H15FN2+ [M]+ 266.1214, found 266.1216. 
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5.3.5.3 Mechanistic Studies 
5.3.5.3.1 Isotopic Studies 
 
2-(1H-Pyrazol-1-yl)benzoic acid (144a, 94.1 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 13 µmol, 
2.5 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) were 
placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. 
Bromocycloheptane (136h, 266 mg, 1.50 mmol), o-xylene (0.8 mL) and D3COD (0.1 mL) were then 
added. The Schlenk tube was degassed and filled with N2 three times and the mixture was stirred 
at 120 °C. After 16 h, the resulting mixture was filtered through a pad of silica gel and washed with 
EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc 25:1) yielded [D]n-146ah (13.4 mg, 11%) and [D]n-147a 
(14.6 mg, 20%). The degree of deuteration was determined by 1H-NMR spectroscopy (Figure 51 
and Figure 52).  




Figure 51: 1H-NMR spectrum of [D]n-146ah. 
 
 
Figure 52: 1H-NMR spectrum of [D]n-147a. 
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5.3.5.3.2 Reactions with Radical Scavengers 
Primary Alkylations 
 
2-(1H-Pyrazol-1-yl)benzoic acid (144a, 94.1 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 13 µmol, 
2.5 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %), K2CO3 (138 mg, 1.00 mmol) and TEMPO 
(78.2 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and 
purged with N2 three times. Neopentyl bromide (136t, 227 mg, 1.50 mmol) and o-xylene (1.0 mL) 
were then added. The Schlenk tube was degassed and filled with N2 three times and the mixture 
was stirred at 120 °C. After 16 h, the resulting mixture was determined by GC-MS spectrometry. 




To a pre-dried 25 mL Schlenk tube charged with 2-(1H-pyrazol-1-yl)benzoic acid (144a, 94.1 mg, 
0.50 mmol), bromocycloheptane (136h, 266 mg, 1.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 
13 µmol, 2.5 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) 
was added o-xylene (1.0 mL) under air atmosphere. The mixture was then stirred at 120 °C. After 
16 h, the resulting mixture was determined by GC-MS spectrometry. The reaction did not provide 
any formation of product 146ah. 
 




2-(1H-Pyrazol-1-yl)benzoic acid (144a, 94.1 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 13 µmol, 
2.5 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %), K2CO3 (138 mg, 1.00 mmol) and BHT 
(110 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and 
purged with N2 three times. Bromocycloheptane (136h, 266 mg, 1.50 mmol) and o-xylene (1.0 mL) 
were then added. The Schlenk tube was degassed and filled with N2 three times and the mixture 
was stirred at 120 °C. After 16 h, the resulting mixture was filtered through a pad of silica gel and 
washed with EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc 25:1) yielded 146ah (66.0 mg, 55%) as a colorless oil. 
 
 
2-(1H-Pyrazol-1-yl)benzoic acid (144a, 94.1 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 13 µmol, 
2.5 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %), K2CO3 (138 mg, 1.00 mmol) and TEMPO 
(78.2 mg, 0.50 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and 
purged with N2 three times. Bromocycloheptane (136h, 266 mg, 1.50 mmol) and o-xylene (1.0 mL) 
were then added. The Schlenk tube was degassed and filled with N2 three times and the mixture 
was stirred at 120 °C. After 16 h, the resulting mixture was filtered through a pad of silica gel and 
washed with EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-pentane/Et2O 50:1) yielded TEMPO-adduct 156 (9.2 mg, 7%) as a 
colorless oil. The analytical data of 156 are in section 5.3.2.2.3. 
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5.3.5.4 X-Ray Crystallographic Analysis 
A suitable crystal was selected and the crystal was mounted on a MITIGEN holder in NVH oil on a 
Bruker D8 Venture diffractometer. The crystal was kept at 100 K during data collection. Using 
Olex2,[137] the structure was solved with the XT[138] structure solution program using Intrinsic 
Phasing and refined with the XL[139] refinement package using Least Squares minimisation. 
 
 
Figure 53: Molecular structure of 201 with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C19H20N2O (M = 292.37 g/mol): triclinic, space group P-1 (no. 2), a = 8.7004(7) Å, 
b = 9.8431(8) Å, c = 10.0077(7) Å, α = 86.914(3)°, β = 82.448(3)°, γ = 66.641(2)°, V = 779.98(11) Å3, 
Z = 2, T = 100.0 K, μ(MoKα) = 0.078 mm-1, Dcalc = 1.245 g/cm3, 26231 reflections measured (4.508° 
≤ 2Θ ≤ 61.054°), 4757 unique (Rint = 0.0192, Rsigma = 0.0154) which were used in all calculations. 
The final R1 was 0.0417 (I > 2σ(I)) and wR2 was 0.1196 (all data). 
 
Table 77: Crystal data and structure refinement for 201. 
Compound 201 
CCDC number 1979319 
Identification code mo_0190_CG_0m 
Empirical formula C19H20N2O 
Formula weight 292.37 
Temperature/K 100.0 
Crystal system triclinic 
Space group P-1 














Crystal size/mm3 0.464 × 0.395 × 0.391 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.508 to 61.054 
Index ranges -12 ≤ h ≤ 12, -14 ≤ k ≤ 14, -14 ≤ l ≤ 14 
Reflections collected 26231 
Independent reflections 4757 [Rint = 0.0192, Rsigma = 0.0154] 
Data/restraints/parameters 4757/0/202 
Goodness-of-fit on F2 1.042 
Final R indexes [I>=2σ (I)] R1 = 0.0417, wR2 = 0.1185 
Final R indexes [all data] R1 = 0.0429, wR2 = 0.1196 
Largest diff. peak/hole / e Å-3 0.42/-0.32 
 
Table 78: Bond lengths [Å] for 201. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C1 1.4290(11) C6 C12 1.5167(11) 
O1 C2 1.3627(10) C8 C9 1.4025(13) 
N1 N2 1.3649(10) C9 C10 1.3788(12) 
N1 C5 1.4298(10) C10 C11 1.4905(13) 
N1 C10 1.3624(11) C12 C13 1.5089(11) 
N2 C8 1.3313(12) C13 C14 1.3948(11) 
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Atom Atom Length/Å Atom Atom Length/Å 
C2 C3 1.3924(12) C13 C18 1.4043(11) 
C2 C7 1.3958(11) C14 C15 1.3922(12) 
C3 C4 1.3892(12) C15 C16 1.3870(15) 
C4 C5 1.3883(11) C16 C17 1.3886(14) 
C5 C6 1.4002(11) C17 C18 1.3954(12) 
C6 C7 1.3923(11) C18 C19 1.5046(12) 
 
Table 79: Bond angles [°] for 201. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 O1 C1 116.64(7) N2 C8 C9 111.89(8) 
N2 N1 C5 118.22(7) C10 C9 C8 105.48(8) 
C10 N1 N2 112.59(7) N1 C10 C9 105.90(8) 
C10 N1 C5 129.18(7) N1 C10 C11 123.30(8) 
C8 N2 N1 104.14(7) C9 C10 C11 130.80(8) 
O1 C2 C3 124.21(8) C13 C12 C6 113.98(7) 
O1 C2 C7 115.63(7) C14 C13 C12 119.86(7) 
C3 C2 C7 120.16(8) C14 C13 C18 119.50(8) 
C4 C3 C2 118.64(8) C18 C13 C12 120.63(7) 
C5 C4 C3 121.15(8) C15 C14 C13 121.17(8) 
C4 C5 N1 118.36(7) C16 C15 C14 119.35(9) 
C4 C5 C6 120.72(8) C15 C16 C17 119.86(8) 
C6 C5 N1 120.79(7) C16 C17 C18 121.44(8) 
C5 C6 C12 121.52(7) C13 C18 C19 120.86(8) 
C7 C6 C5 117.83(7) C17 C18 C13 118.66(8) 
C7 C6 C12 120.65(7) C17 C18 C19 120.47(8) 
C6 C7 C2 121.47(7)     
 




Figure 54: Molecular structure of 146eh with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C34H51Cl3N4O2 (M = 654.13 g/mol): orthorhombic, space group Pbcn (no. 60), a = 
5.2607(4) Å, b = 16.9010(10) Å, c = 39.466(3) Å, V = 3509.0(4) Å3, Z = 4, T = 99.99 K, μ(MoKα) = 
0.296 mm–1, Dcalc = 1.238 g/cm3, 29694 reflections measured (4.128° ≤ 2Θ ≤ 59.152°), 4931 
unique (Rint = 0.0287, Rsigma = 0.0209) which were used in all calculations. The final R1 was 0.0503 
(I > 2σ(I)) and wR2 was 0.1112 (all data). 
 
Table 80: Crystal data and structure refinement for 146eh. 
Compound 146eh 
CCDC number 1979310 
Identification code mo_0079_CG_0m 
Empirical formula C34H51Cl3N4O2 
Formula weight 654.13 
Temperature/K 99.99 
Crystal system orthorhombic 















Crystal size/mm3 0.406 × 0.197 × 0.167 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.128 to 59.152 
Index ranges -7 ≤ h ≤ 7, -23 ≤ k ≤ 22, -54 ≤ l ≤ 54 
Reflections collected 29694 
Independent reflections 4931 [Rint = 0.0287, Rsigma = 0.0209] 
Data/restraints/parameters 4931/4/229 
Goodness-of-fit on F2 1.217 
Final R indexes [I>=2σ (I)] R1 = 0.0503, wR2 = 0.1090 
Final R indexes [all data] R1 = 0.0554, wR2 = 0.1112 
Largest diff. peak/hole / e Å-3 0.30/-0.34 
 
Table 81: Bond lengths [Å] for 146eh. 
Atom Atom Length/Å Atom Atom Length/Å 
N1 N2 1.3510(19) C7 C10 1.508(3) 
N1 C1 1.349(2) C8 C9 1.375(3) 
N1 C4 1.430(2) C11 C12 1.536(2) 
N2 C3 1.333(2) C11 C17 1.540(2) 
C1 C2 1.372(3) C12 C13 1.533(2) 
C2 C3 1.385(3) C13 C14 1.527(2) 
C4 C5 1.385(2) C14 C15B 1.533(7) 
C4 C9 1.388(2) C14 C15A 1.565(3) 
C5 C6 1.398(2) C15B C16B 1.512(11) 
C6 C7 1.411(2) C16B C17 1.696(7) 
C6 C11 1.514(2) C17 C16A 1.499(3) 
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Atom Atom Length/Å Atom Atom Length/Å 
C7 C8 1.390(3) C15A C16A 1.532(4) 
 
Table 82: Bond angles [°] for 146eh. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C4 122.97(13) C8 C7 C10 119.42(16) 
C1 N1 N2 108.07(15) C9 C8 C7 122.69(16) 
C1 N1 C4 128.96(15) C8 C9 C4 118.25(17) 
C3 N2 N1 108.80(14) C6 C11 C12 113.02(13) 
N1 C1 C2 108.71(16) C6 C11 C17 108.88(14) 
C1 C2 C3 105.80(17) C12 C11 C17 114.08(14) 
N2 C3 C2 108.61(17) C13 C12 C11 113.08(13) 
C5 C4 N1 120.33(14) C14 C13 C12 116.43(15) 
C5 C4 C9 121.04(17) C13 C14 C15B 109.6(3) 
C9 C4 N1 118.63(15) C13 C14 C15A 116.02(16) 
C4 C5 C6 120.40(14) C16B C15B C14 107.8(5) 
C5 C6 C7 119.05(16) C15B C16B C17 112.1(6) 
C5 C6 C11 120.19(14) C11 C17 C16B 119.5(3) 
C7 C6 C11 120.71(16) C16A C17 C11 114.48(18) 
C6 C7 C10 122.02(18) C16A C15A C14 114.1(2) 
C8 C7 C6 118.55(17) C17 C16A C15A 111.8(2) 
 
5.3.6 Ruthenium-Catalyzed C–H Alkylation of Pyrazoles: ortho versus meta 
5.3.6.1 Characterization Data for 145, 146, and 203 
2-(3-Cyclohexylphenyl)pyridine (203a) 
2-Phenylpyridine (68b, 77.6 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 13 µmol, 
2.5 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %) and K2CO3 (138 mg, 
1.00 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated 
and purged with N2 three times. Bromocyclohexane (136j, 245 mg, 1.50 mmol) and 
o-xylene (1.0 mL) were then added and the mixture was stirred at 120 °C. After 16 h, the resulting 
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mixture was filtered through a pad of silica gel and washed with EtOAc. The filtrate was 
concentrated in vacuo. Purification of the residue by column chromatography (SiO2, 
n-hexane/EtOAc 10:1) yielded meta-alkylated product 203a (60.5 mg, 51%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 8.70 (ddd, J = 4.8, 1.5, 1.5 Hz, 1H), 7.87 (dddd, J = 1.9, 1.8, 0.6, 
0.6 Hz, 1H), 7.77 (ddd, J = 7.8, 1.9, 1.3 Hz, 1H), 7.75–7.70 (m, 2H), 7.40 (ddd, J = 7.8, 7.7, 0.6 Hz, 
1H), 7.27 (dddd, J = 7.7, 1.8, 1.3, 0.6 Hz, 1H), 7.22 (ddd, J = 5.4, 4.8, 3.1 Hz, 1H), 2.61 (tt, J = 11.6, 
3.4 Hz, 1H), 1.99–1.81 (m, 4H), 1.77 (dtt, J = 10.5, 3.1, 1.5 Hz, 1H), 1.59–1.37 (m, 4H), 1.37–1.19 
(m, 1H). 
13C-NMR (125 MHz, CDCl3): δ = 157.7 (Cq), 149.5 (CH), 148.5 (Cq), 139.3 (Cq), 136.5 (CH), 128.6 (CH), 
127.4 (CH), 125.5 (CH), 124.3 (CH), 121.8 (CH), 120.6 (CH), 44.8 (CH), 34.5 (CH2), 27.0 (CH2), 26.2 
(CH2). 
IR (ATR): ṽ = 2921, 2849, 1583, 1564, 1461, 1434, 1152, 768, 741, 698 cm−1.  
MS (EI) m/z (relative intensity): 237 (91) [M]+, 236 (100) [M–H]+, 222 (9), 208 (45), 194 (51), 182 
(97), 180 (32), 169 (49), 167 (44), 155 (29) [M–Cy]+, 115 (9), 78 (13), 43 (24), 41 (19).  
HR-MS (ESI): m/z calcd for C17H20N+ [M+H]+ 238.1590, found 238.1598. 
The spectral data are in accordance with those reported in the literature.[61, 113] 
 
2-(3-Cyclopentylphenyl)pyridine (203b) 
2-Phenylpyridine (68b, 77.6 mg, 0.50 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 13 µmol, 
2.5 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %) and K2CO3 (138 mg, 
1.00 mmol) were placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated 
and purged with N2 three times. Bromocyclopentane (136i, 224 mg, 1.50 mmol) and 
PhCMe3 (1.0 mL) were then added and the mixture was stirred at 120 °C. After 16 h, the resulting 
mixture was filtered through a pad of silica gel and washed with EtOAc. The filtrate was 
concentrated in vacuo. Purification of the residue by column chromatography (SiO2, 
n-hexane/EtOAc 10:1) yielded meta-alkylated product 203b (56.9 mg, 51%) as a colorless oil and 
di-meta-alkylated product 203b’ (5.2 mg, 4%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.70 (ddd, J = 4.8, 1.7, 1.1 Hz, 1H), 7.90 (dd, J = 1.9, 1.7 Hz, 1H), 7.77 
(ddd, J = 7.7, 1.9, 1.4 Hz, 1H), 7.75–7.70 (m, 2H), 7.40 (dd, J = 7.7, 7.6 Hz, 1H), 7.31 (ddd, J = 7.6, 
1.7, 1.4 Hz, 1H), 7.22 (ddd, J = 6.0, 4.8, 2.6 Hz, 1H), 3.09 (tt, J = 9.0, 7.2 Hz, 1H), 2.19–2.07 (m, 2H), 
1.91–1.62 (m, 6H). 
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13C-NMR (100 MHz, CDCl3): δ = 157.8 (Cq), 149.6 (CH), 147.1 (Cq), 139.3 (Cq), 136.6 (CH), 128.6 (CH), 
127.7 (CH), 125.8 (CH), 124.3 (CH), 121.9 (CH), 120.7 (CH), 46.1 (CH), 34.7 (CH2), 25.6 (CH2). 
IR (ATR): ṽ = 2949, 2866, 1584, 1564, 1461, 1434, 1151, 769, 742, 698 cm−1.  
MS (ESI) m/z (relative intensity): 246 (24) [M+Na]+, 224 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C16H18N+ [M+H]+ 224.1434, found 224.1436. 
The spectral data are in accordance with those reported in the literature.[113] 
 
2-(3,5-Dicyclopentylphenyl)pyridine (203b’) 
1H-NMR (400 MHz, CDCl3): δ = 8.71–8.66 (m, 1H), 7.76–7.69 (m, 2H), 7.67 (s, 
2H), 7.23–7.19 (m, 1H), 7.18 (s, 1H), 3.06 (tt, J = 8.4, 7.9 Hz, 2H), 2.18–2.04 (m, 
4H), 1.90–1.77 (m, 4H), 1.77–1.60 (m, 8H). 
13C-NMR (100 MHz, CDCl3): δ = 158.2 (Cq), 149.6 (CH), 146.9 (Cq), 139.3 (Cq), 
136.5 (CH), 126.8 (CH), 123.3 (CH), 121.8 (CH), 120.8 (CH), 46.2 (CH), 34.7 (CH2), 25.6 (CH2). 
IR (ATR): ṽ = 2949, 2866, 1585, 1566, 1474, 1441, 991, 874, 783, 743 cm−1.  
MS (EI) m/z (relative intensity): 291 (35) [M]+, 290 (19) [M–H]+, 263 (30), 250 (100), 222 (17), 220 
(9), 194 (20), 182 (13), 167 (10), 43 (10), 41 (10).  
HR-MS (EI): m/z calcd for C21H25N+ [M]+ 291.1982, found 291.1982. 
 
1-(2-Cyclohexylphenyl)-1H-pyrazole (145aj) 
The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 72.1 mg, 
0.50 mmol) and bromocyclohexane (136j, 245 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 30:1) yielded ortho-
alkylated product 145aj (68.0 mg, 60%) as a colorless oil and meta-alkylated product 146aj 
(13.1 mg, 12%) as a colorless oil.  
In case of using o-xylene (1.0 mL) as a solvent, the reaction provided the product 145aj (57.1 mg, 
50%). The analytical data of 145aj are in section 5.3.5.1. 
 
 




1H-NMR (600 MHz, CDCl3): δ = 7.92 (d, J = 2.3 Hz, 1H), 7.72 (d, J = 1.9 Hz, 1H), 7.59 
(dd, J = 2.1, 1.7 Hz, 1H), 7.46 (ddd, J = 7.9, 2.1, 1.2 Hz, 1H), 7.36 (dd, J = 7.9, 7.8 Hz, 
1H), 7.14 (ddd, J = 7.8, 1.7, 1.2 Hz, 1H), 6.46 (dd, J = 2.3, 1.9 Hz, 1H), 2.58 (tt, J = 
12.2, 3.7 Hz, 1H), 1.92 (ddd, J = 12.5, 3.7, 2.4 Hz, 2H), 1.86 (ddd, J = 13.0, 3.5, 3.1 Hz, 
2H), 1.76 (dtt, J = 12.8, 3.0, 1.5 Hz, 1H), 1.48 (dddd, J = 12.6, 12.5, 12.2, 3.1 Hz, 2H), 1.40 (ddddd, J 
= 13.0, 12.8, 12.6, 3.0, 2.4 Hz, 2H), 1.27 (dtt, J = 12.8, 12.8, 3.5 Hz, 1H). 
13C-NMR (125 MHz, CDCl3): δ = 149.7 (Cq), 140.8 (CH), 140.1 (Cq), 129.1 (CH), 126.7 (CH), 125.0 
(CH), 118.0 (CH), 116.6 (CH), 107.3 (CH), 44.7 (CH), 34.4 (CH2), 26.9 (CH2), 26.2 (CH2). 
IR (ATR): ṽ = 2924, 2851, 1608, 1591, 1519, 1448, 1393, 1044, 950, 748 cm−1.  
MS (EI) m/z (relative intensity): 226 (100) [M]+, 225 (29) [M–H]+, 211 (14), 197 (18), 183 (20), 171 
(40), 170 (29), 158 (24), 144 (10) [M–Cy]+, 115 (14), 77 (9).  
HR-MS (EI): m/z calcd for C15H18N2+ [M]+ 226.1465, found 226.1471. 
 
1-(2-Cyclobutylphenyl)-1H-pyrazole (145aw) 
The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 72.1 mg, 
0.50 mmol) and bromocyclobutane (136w, 203 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 30:1) yielded ortho-
alkylated product 145aw (70.5 mg, 71%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.71 (dd, J = 1.9, 0.7 Hz, 1H), 7.53 (dd, J = 2.4, 0.7 Hz, 1H), 7.46–7.36 
(m, 2H), 7.30–7.24 (m, 2H), 6.42 (dd, J = 2.4, 1.9 Hz, 1H), 3.70–3.56 (m, 1H), 2.10– 1.82 (m, 5H), 
1.80–1.68 (m, 1H). 
13C-NMR (125 MHz, CDCl3): δ = 141.5 (Cq), 140.1 (CH), 138.8 (Cq), 130.5 (CH), 128.5 (CH), 127.2 
(CH), 126.3 (CH), 126.3 (CH), 106.0 (CH), 36.4 (CH), 29.3 (CH2), 18.4 (CH2). 
IR (ATR): ṽ = 2972, 2865, 1516, 1498, 1394, 1044, 938, 750, 622 cm−1.  
MS (EI) m/z (relative intensity): 198 (17) [M]+, 197 (7) [M–H]+, 169 (100), 142 (9), 130 (6), 115 (12), 
77 (7).  
HR-MS (EI): m/z calcd for C13H14N2+ [M]+ 198.1151, found 198.1152. 
 




The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 72.1 mg, 
0.50 mmol) and bromocyclopentane (136i, 224 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 30:1) followed by 
recycling preparative HPLC yielded ortho-alkylated product 145ai (23.2 mg, 22%) as a colorless oil 
and meta-alkylated product 146ai (28.9 mg, 27%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.72 (dd, J = 1.9, 0.7 Hz, 1H), 7.57 (dd, J = 2.3, 0.7 Hz, 1H), 7.46–7.36 
(m, 2H), 7.29–7.22 (m, 2H), 6.43 (dd, J = 2.3, 1.9 Hz, 1H), 2.92 (ddt, J = 10.0, 8.6, 7.5 Hz, 1H), 1.97–
1.68 (m, 4H), 1.66–1.47 (m, 4H). 
13C-NMR (125 MHz, CDCl3): δ = 142.9 (Cq), 140.0 (CH), 139.6 (Cq), 130.9 (CH), 128.9 (CH), 127.0 
(CH), 126.7 (CH), 126.0 (CH), 105.9 (CH), 39.7 (CH), 34.8 (CH2), 25.8 (CH2). 
IR (ATR): ṽ = 2951, 2867, 1516, 1453, 1394, 1043, 938, 744, 621 cm−1.  
MS (EI) m/z (relative intensity): 212 (73) [M]+, 211 (51) [M–H]+, 194 (11), 183 (34), 169 (100), 156 
(18), 143 (12), 130 (19), 128 (14), 115 (24), 91 (15), 77 (14), 58 (23), 43 (70).  
HR-MS (EI): m/z calcd for C14H16N2+ [M]+ 212.1308, found 212.1315. 
The spectral data are in accordance with those reported in the literature.[141] 
 
1-(3-Cyclopentylphenyl)-1H-pyrazole (146ai) 
1H-NMR (300 MHz, CDCl3): δ = 7.92 (dd, J = 2.5, 0.7 Hz, 1H), 7.72 (dd, J = 1.8, 0.7 Hz, 
1H), 7.61 (ddd, J = 2.3, 1.6, 0.6 Hz, 1H), 7.45 (ddd, J = 7.9, 2.3, 1.2 Hz, 1H), 7.35 (dd, 
J = 7.9, 7.7 Hz, 1H), 7.18 (dddd, J = 7.7, 1.6, 1.2, 0.6 Hz, 1H), 6.46 (dd, J = 2.5, 1.8 Hz, 
1H), 3.07 (tt, J = 9.1, 7.2 Hz, 1H), 2.19–2.04 (m, 2H), 1.91–1.56 (m, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 148.2 (Cq), 140.8 (CH), 140.1 (Cq), 129.1 (CH), 126.7 (CH), 125.2 
(CH), 118.2 (CH), 116.5 (CH), 107.3 (CH), 46.0 (CH), 34.6 (CH2), 25.6 (CH2). 
IR (ATR): ṽ = 2950, 2867, 1608, 1589, 1518, 1392, 1043, 785, 746, 698 cm−1.  
MS (EI) m/z (relative intensity): 212 (100) [M]+, 211 (36) [M–H]+, 197 (8), 184 (42), 183 (35), 171 
(59), 158 (12), 144 (14), 129 (10), 115 (27), 77 (14).  
HR-MS (EI): m/z calcd for C14H16N2+ [M]+ 212.1308, found 212.1316. 
 




The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 
72.1 mg, 0.50 mmol) and bromocycloheptane (136h, 266 mg, 1.50 mmol). After 
16 h, purification by column chromatography (n-hexane/EtOAc 30:1) yielded 
meta-alkylated product 146ah (69.9 mg, 58%) as a colorless oil. The analytical data 
of 146ah are in section 5.3.5.1. 
 
1-[exo-2-(Bicyclo[2.2.1]heptan-2-yl)phenyl]-1H-pyrazole (145au) 
The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 
72.1 mg, 0.50 mmol) and exo-2-bromonorbornane (136u, 263 mg, 1.50 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 30:1) 
yielded ortho-alkylated product 145au (64.4 mg, 54%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 7.72 (dd, J = 1.9, 0.7 Hz, 1H), 7.55 (dd, J = 2.3, 0.7 Hz, 1H), 7.43 (dd, 
J = 8.0, 1.5 Hz, 1H), 7.38 (ddd, J = 8.0, 6.6, 2.2 Hz, 1H), 7.26 (dABd, J = 7.8, 2.2 Hz, 1H), 7.25 (dABdd, 
J = 7.8, 6.6, 1.5 Hz, 1H), 6.43 (dd, J = 2.3, 1.9 Hz, 1H), 2.69 (dd, J = 9.0, 5.8 Hz, 1H), 2.32 (ddd, J = 
2.7, 1.7, 1.4 Hz, 1H), 2.27 (ddd, J = 3.9, 2.5, 2.2 Hz, 1H), 1.58 (ddd, J = 9.8, 2.2, 1.7 Hz, 1H), 1.52–
1.45 (m, 3H), 1.38 (ddd, J = 12.2, 9.0, 2.4 Hz, 1H), 1.20 (ddd, J = 9.8, 2.5, 1.4 Hz, 1H), 1.16–1.09 (m, 
2H). 
13C-NMR (125 MHz, CDCl3): δ = 143.7 (Cq), 140.0 (CH), 139.7 (Cq), 131.0 (CH), 128.7 (CH), 127.1 
(CH), 126.4 (CH), 125.9 (CH), 105.9 (CH), 42.6 (CH), 41.7 (CH), 39.5 (CH2), 36.9 (CH), 36.5 (CH2), 30.5 
(CH2), 28.6 (CH2). 
IR (ATR): ṽ = 2949, 2869, 1515, 1454, 1394, 1043, 938, 747, 624 cm−1.  
MS (EI) m/z (relative intensity): 238 (100) [M]+, 237 (50) [M–H]+, 223 (10), 209 (80), 197 (45), 182 
(83), 169 (99), 156 (27), 142 (13), 130 (22), 128 (18), 115 (27), 77 (19), 41 (13).  
HR-MS (EI): m/z calcd for C16H18N2+ [M]+ 238.1465, found 238.1467. 








The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 72.1 mg, 
0.50 mmol) and 2-bromobutane (136m, 206 mg, 1.50 mmol). After 16 h, purification 
by column chromatography (n-hexane/EtOAc 30:1) yielded meta-alkylated product 
146am (39.3 mg, 39%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.92 (dd, J = 2.5, 0.7 Hz, 1H), 7.73 (dd, J = 1.8, 0.7 Hz, 1H), 7.56 (dd, 
J = 2.2, 1.6 Hz, 1H), 7.46 (ddd, J = 7.9, 2.2, 1.2 Hz, 1H), 7.36 (dd, J = 7.9, 7.7 Hz, 1H), 7.12 (dddd, J = 
7.7, 1.6, 1.2, 0.3 Hz, 1H), 6.46 (dd, J = 2.5, 1.8 Hz, 1H), 2.68 (h, J = 7.0 Hz, 1H), 1.71–1.58 (m, 2H), 
1.28 (d, J = 7.0 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 149.4 (Cq), 140.9 (CH), 140.2 (Cq), 129.2 (CH), 126.8 (CH), 125.3 
(CH), 118.2 (CH), 116.6 (CH), 107.4 (CH), 41.8 (CH), 31.1 (CH2), 21.8 (CH3), 12.2 (CH3). 
IR (ATR): ṽ = 2960, 1609, 1591, 1519, 1392, 1042, 945, 787, 745, 698 cm−1.  
MS (EI) m/z (relative intensity): 200 (47) [M]+, 185 (7) [M–Me]+, 171 (100) [M–Et]+, 156 (9) [M–
Me–Et]+, 144 (11) [M–sec-Bu]+, 130 (8), 117 (7), 103 (8), 77 (9).  
HR-MS (EI): m/z calcd for C13H16N2+ [M]+ 200.1308, found 200.1311. 
 
1-[3-(Pentan-2-yl)phenyl]-1H-pyrazole (146an) 
The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 
72.1 mg, 0.50 mmol) and 2-bromopentane (136n, 227 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 30:1) yielded meta-
alkylated product 146an (45.0 mg, 42%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.92 (dd, J = 2.5, 0.6 Hz, 1H), 7.73 (dd, J = 1.8, 0.6 Hz, 1H), 7.56 (dd, 
J = 2.1, 1.7 Hz, 1H), 7.46 (ddd, J = 7.9, 2.1, 1.3 Hz, 1H), 7.36 (dd, J = 7.9, 7.7 Hz, 1H), 7.12 (ddd, J = 
7.7, 1.7, 1.3 Hz, 1H), 6.46 (dd, J = 2.5, 1.8 Hz, 1H), 2.78 (h, J = 7.0 Hz, 1H), 1.67–1.51 (m, 2H), 1.36–
1.15 (m, 2H), 1.28 (d, J = 7.0 Hz, 3H), 0.88 (t, J = 7.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 149.7 (Cq), 140.9 (CH), 140.2 (Cq), 129.2 (CH), 126.8 (CH), 125.2 
(CH), 118.1 (CH), 116.6 (CH), 107.4 (CH), 40.5 (CH2), 39.8 (CH), 22.2 (CH3), 20.8 (CH2), 14.1 (CH3). 
IR (ATR): ṽ = 2957, 1609, 1591, 1519, 1392, 1042, 948, 787, 743, 698 cm−1.  
5 Experimental Part 
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MS (EI) m/z (relative intensity): 214 (45) [M]+, 199 (3) [M–Me]+, 185 (7) [M–Et]+, 171 (100) [M–
n-Pr]+, 157 (13) [M–n-Pr–Me]+, 144 (13), 130 (9), 103 (9), 77 (11), 58 (26), 43 (78).  
HR-MS (EI): m/z calcd for C14H18N2+ [M]+ 214.1465, found 214.1466. 
The spectral data are in accordance with those reported in the literature.[61] 
 
1-(2-Neopentylphenyl)-1H-pyrazole (145at) 
The general procedure M was followed using 1-phenyl-1H-pyrazole (147a, 72.1 mg, 
0.50 mmol) and neopentyl bromide (136t, 227 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 30:1) yielded ortho-
alkylated product 145at (53.2 mg, 50%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 7.70 (dd, J = 2.0, 0.7 Hz, 1H), 7.58 (dd, J = 2.2, 0.7 Hz, 1H), 7.34–7.26 
(m, 4H), 6.41 (dd, J = 2.2, 2.0 Hz, 1H), 2.75 (s, 2H), 0.68 (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 140.4 (Cq), 140.0 (CH), 135.5 (Cq), 133.0 (CH), 130.9 (CH), 127.6 
(CH), 126.8 (CH), 126.7 (CH), 106.1 (CH), 43.9 (CH2), 32.1 (Cq), 29.3 (CH3). 
IR (ATR): ṽ = 2950, 1517, 1476, 1394, 1364, 1044, 939, 748, 718 cm−1.  
MS (EI) m/z (relative intensity): 214 (23) [M]+, 199 (28) [M–Me]+, 158 (100) [M–t-Bu]+, 157 (74), 
130 (55), 103 (9), 77 (11), 57 (15), 41 (13).  
HR-MS (EI): m/z calcd for C14H18N2+ [M]+ 214.1465, found 214.1470. 
The spectral data are in accordance with those reported in the literature.[33] 
 
1-(2-Cyclohexyl-4-methoxyphenyl)-1H-pyrazole (145dj) 
The general procedure M was followed using 1-(4-methoxyphenyl)-1H-pyrazole 
(147d, 87.1 mg, 0.50 mmol) and bromocyclohexane (136j, 245 mg, 1.50 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 10:1) yielded 
ortho-alkylated product 145dj (86.6 mg, 68%) as a colorless oil and meta-alkylated 
product 146dj (14.7 mg, 11%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.69 (dd, J = 2.0, 0.7 Hz, 1H), 7.49 (dd, J = 2.2, 0.7 Hz, 1H), 7.20 (d, J 
= 8.6 Hz, 1H), 6.90 (d, J = 2.9 Hz, 1H), 6.76 (dd, J = 8.6, 2.9 Hz, 1H), 6.40 (dd, J = 2.2, 2.0 Hz, 1H), 
3.85 (s, 3H), 2.32 (tt, J = 12.0, 3.1 Hz, 1H), 1.80–1.62 (m, 5H), 1.43–1.30 (m, 2H), 1.27–1.11 (m, 3H). 
5.3 Experimental Procedures and Analytical Data 
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13C-NMR (100 MHz, CDCl3): δ = 159.9 (Cq), 145.9 (Cq), 139.9 (CH), 132.4 (Cq), 131.3 (CH), 128.1 (CH), 
112.7 (CH), 110.7 (CH), 105.8 (CH), 55.4 (CH3), 38.5 (CH), 34.2 (CH2), 26.7 (CH2), 26.0 (CH2). 
IR (ATR): ṽ = 2924, 2850, 1607, 1517, 1288, 1241, 1041, 944, 810, 747 cm−1.  
MS (EI) m/z (relative intensity): 256 (100) [M]+, 255 (90) [M–H]+, 239 (14), 227 (17), 213 (31), 199 
(28), 184 (10), 160 (13), 115 (9), 77 (8), 41 (9).  
HR-MS (ESI): m/z calcd for C16H20N2ONa+ [M+Na]+ 279.1468, found 279.1470. 
 
1-(3-Cyclohexyl-4-methoxyphenyl)-1H-pyrazole (146dj) 
1H-NMR (400 MHz, CDCl3): δ = 7.83 (dd, J = 2.3, 0.8 Hz, 1H), 7.70 (dd, J = 1.8, 0.8 Hz, 
1H), 7.52 (d, J = 2.7 Hz, 1H), 7.40 (dd, J = 8.7, 2.7 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 
6.43 (dd, J = 2.3, 1.8 Hz, 1H), 3.86 (s, 3H), 3.00 (tt, J = 11.5, 3.1 Hz, 1H), 1.91–1.80 
(m, 4H), 1.80–1.72 (m, 1H), 1.51–1.36 (m, 4H), 1.35–1.18 (m, 1H). 
13C-NMR (100 MHz, CDCl3): δ = 155.5 (Cq), 140.4 (CH), 137.5 (Cq), 134.0 (Cq), 126.9 (CH), 118.7 (CH), 
117.6 (CH), 110.7 (CH), 106.9 (CH), 55.7 (CH3), 36.9 (CH), 33.1 (CH2), 27.0 (CH2), 26.3 (CH2). 
IR (ATR): ṽ = 2925, 2850, 1517, 1499, 1238, 1047, 955, 809, 747, 638 cm−1.  
MS (EI) m/z (relative intensity): 256 (100) [M]+, 255 (9) [M–H]+, 213 (21), 200 (10), 187 (13), 185 
(9), 157 (12), 145 (10), 130 (10), 115 (8), 77 (6), 41 (9).  
HR-MS (ESI): m/z calcd for C16H20N2ONa+ [M+Na]+ 279.1468, found 279.1472. 
 
1-(2-Cyclohexyl-4-fluorophenyl)-1H-pyrazole (145gj) 
The general procedure M was followed using 1-(4-fluorophenyl)-1H-pyrazole (147g, 
81.1 mg, 0.50 mmol) and bromocyclohexane (136j, 245 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 30:1) yielded ortho-
alkylated product 145gj (74.2 mg, 61%) as a colorless oil.  
1H-NMR (400 MHz, CDCl3): δ = 7.71 (d, J = 2.0 Hz, 1H), 7.51 (d, J = 2.2 Hz, 1H), 7.25 (dd, J = 8.5, 
5.5 Hz, 1H), 7.08 (dd, J = 10.1, 2.9 Hz, 1H), 6.93 (ddd, J = 8.5, 8.2, 2.9 Hz, 1H), 6.43 (dd, J = 2.2, 
2.0 Hz, 1H), 2.37 (tt, J = 12.1, 2.6 Hz, 1H), 1.81–1.63 (m, 5H), 1.42–1.12 (m, 5H).  
5 Experimental Part 
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13C-NMR (100 MHz, CDCl3): δ = 163.0 (d, 1JC–F = 248 Hz, Cq), 147.2 (d, 3JC–F = 7 Hz, Cq), 140.4 (CH), 
135.3 (d, 4JC–F = 3 Hz, Cq), 131.3 (CH), 128.9 (d, 3JC–F = 9 Hz, CH), 114.1 (d,   2JC–F = 23 Hz, CH), 113.1 
(d, 2JC–F = 23 Hz, CH), 106.3 (CH), 38.6 (d, 4JC–F = 1 Hz, CH), 34.2 (CH2), 26.7 (CH2), 26.1 (CH2).  
19F-NMR (376 MHz, CDCl3): δ = (–112.1)–(–112.3) (m). 
IR (ATR): ṽ = 2926, 2852, 1517, 1498, 1395, 1238, 953, 866, 817, 747 cm−1.  
MS (ESI) m/z (relative intensity): 245 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C15H18N2F+ [M+H]+ 245.1449, found 245.1450. 
 
1-[3-Cyclohexyl-4-(1H-pyrazol-1-yl)phenyl]ethan-1-one (145jj) 
The general procedure M was followed using 1-[4-(1H-pyrazol-1-yl)phenyl]ethan-1-
one (147j, 93.1 mg, 0.50 mmol) and bromocyclohexane (136j, 245 mg, 1.50 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 10:1) yielded 
ortho-alkylated product 145jj (86.6 mg, 65%) as a white solid, di-ortho-alkylated 
product 145jj’ (36.8 mg, 21%) as a white solid and dialkylated product 145jj’’ (14.4 mg, 8%) as a 
white solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.03 (d, J = 2.0 Hz, 1H), 7.83 (dd, J = 8.2, 2.0 Hz, 1H), 7.75 (dd, J = 
1.9, 0.7 Hz, 1H), 7.59 (dd, J = 2.4, 0.7 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 6.48 (dd, J = 2.4, 1.9 Hz, 1H), 
2.64 (s, 3H), 2.62 (tt, J = 12.0, 3.1 Hz, 1H), 1.82–1.73 (m, 4H), 1.73–1.67 (m, 1H), 1.54–1.40 (m, 2H), 
1.32–1.16 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 197.4 (Cq), 144.0 (Cq), 142.7 (Cq), 140.8 (CH), 137.0 (Cq), 130.9 (CH), 
127.6 (CH), 126.9 (CH), 126.4 (CH), 106.7 (CH), 38.3 (CH), 34.1 (CH2), 26.8 (CH3), 26.6 (CH2), 25.9 
(CH2). 
IR (ATR): ṽ = 2920, 2850, 1679, 1602, 1519, 1396, 1264, 939, 834, 752 cm−1.  
m.p.: 75–77 °C. 
MS (EI) m/z (relative intensity): 268 (96) [M]+, 267 (100) [M–H]+, 251 (10), 239 (16), 225 (41) [M–
Ac]+, 211 (29), 199 (11), 185 (10), 168 (13), 157 (11), 115 (11), 58 (27), 43 (98).  
HR-MS (ESI): m/z calcd for C17H20N2ONa+ [M+Na]+ 291.1468, found 291.1471. 
 
 




1H-NMR (400 MHz, CDCl3): δ = 7.78 (s, 2H), 7.74 (dd, J = 2.0, 0.6 Hz, 1H), 7.41 
(dd, J = 2.2, 0.6 Hz, 1H), 6.47 (dd, J = 2.2, 2.0 Hz, 1H), 2.64 (s, 3H), 1.90 (tt, J = 
11.9, 3.3 Hz, 2H), 1.85–1.77 (m, 2H), 1.77–1.58 (m, 8H), 1.48–1.33 (m, 4H), 
1.27–1.04 (m, 6H). 
13C-NMR (100 MHz, CDCl3): δ = 197.9 (Cq), 146.6 (Cq), 141.1 (Cq), 140.1 
(CH), 137.8 (Cq), 131.6 (CH), 124.2 (CH), 106.0 (CH), 39.0 (CH), 34.7 (CH2), 
34.1 (CH2), 26.8 (CH3), 26.7 (CH2), 26.6 (CH2), 25.9 (CH2). 
IR (ATR): ṽ = 2922, 2850, 1692, 1444, 1393, 1271, 1193, 939, 875, 
766 cm−1.  
m.p.: 138–140 °C. 
MS (EI) m/z (relative intensity): 350 (100) [M]+, 349 (77) [M–H]+, 321 (12), 307 (25) [M–Ac]+, 295 
(25), 267 (23) [M–Cy]+, 252 (32), 184 (11) [M–Cy–Cy]+, 115 (8), 55 (13), 43 (62), 41 (18).  
HR-MS (ESI): m/z calcd for C23H30N2ONa+ [M+Na]+ 373.2250, found 373.2251. 
 
1-[2,5-Dicyclohexyl-4-(1H-pyrazol-1-yl)phenyl]ethan-1-one (145jj’’) 
1H-NMR (400 MHz, CDCl3): δ = 7.74 (dd, J = 1.9, 0.7 Hz, 1H), 7.56 (dd, J = 2.3, 
0.7 Hz, 1H), 7.45 (s, 1H), 7.26 (s, 1H), 6.46 (dd, J = 2.3, 1.9 Hz, 1H), 3.00 (tt, J 
= 11.6, 3.3 Hz, 1H), 2.60 (s, 3H), 2.51 (tt, J = 12.0, 3.0 Hz, 1H), 1.88–1.66 (m, 
10H), 1.45–1.31 (m, 6H), 1.29–1.14 (m, 4H). 
13C-NMR (100 MHz, CDCl3): δ = 203.4 (Cq), 144.8 (Cq), 140.8 (Cq), 140.7 (Cq), 140.5 (CH), 139.6 (Cq), 
130.9 (CH), 126.5 (CH), 125.5 (CH), 106.4 (CH), 39.7 (CH), 37.9 (CH), 34.5 (CH2), 34.2 (CH2), 30.9 
(CH3), 26.8 (CH2), 26.7 (CH2), 26.1 (CH2), 26.0 (CH2). 
IR (ATR): ṽ = 2922, 2852, 1691, 1517, 1449, 1402, 1218, 953, 883, 760 cm−1.  
m.p.: 165–167 °C. 
MS (EI) m/z (relative intensity): 350 (100) [M]+, 349 (85) [M–H]+, 335 (13) [M–Me]+, 318 (12), 307 
(21) [M–Ac]+, 293 (18), 267 (11) [M–Cy]+, 58 (24), 43 (73).  
HR-MS (ESI): m/z calcd for C23H31N2O+ [M+H]+ 351.2431, found 351.2437. 
 




The general procedure M was followed using 3,5-dimethyl-1-phenyl-1H-pyrazole 
(147c, 86.2 mg, 0.50 mmol) and bromocyclopentane (136i, 112 mg, 0.75 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 30:1) 
yielded meta-alkylated product 146ci (69.3 mg, 58%) as a colorless oil. 
1H-NMR (600 MHz, CDCl3): δ = 7.34 (dd, J = 7.8, 7.8 Hz, 1H), 7.30 (dd, J = 2.1, 2.0 Hz, 1H), 7.22 (ddd, 
J = 7.8, 2.0, 1.0 Hz, 1H), 7.20 (ddd, J = 7.8, 2.1, 1.0 Hz, 1H), 5.98 (s, 1H), 3.04 (tt, J = 9.6, 7.5 Hz, 1H), 
2.30 (s, 3H), 2.29 (d, J = 0.7 Hz, 3H), 2.12–2.06 (m, 2H), 1.84–1.77 (m, 2H), 1.73–1.65 (m, 2H), 1.65–
1.57 (m, 2H). 
13C-NMR (125 MHz, CDCl3): δ = 148.6 (Cq), 147.7 (Cq), 139.7 (Cq), 139.2 (Cq), 128.6 (CH), 126.0 (CH), 
123.7 (CH), 122.0 (CH), 106.6 (CH), 45.8 (CH), 34.6 (CH2), 25.6 (CH2), 13.6 (CH3), 12.4 (CH3). 
IR (ATR): ṽ = 2951, 2867, 1606, 1589, 1557, 1492, 1380, 792, 702 cm−1.  
MS (EI) m/z (relative intensity): 240 (100) [M]+, 239 (33) [M–H]+, 212 (32), 211 (27), 199 (96), 169 
(10), 130 (9), 115 (18), 91 (16), 77 (10), 43 (27), 41 (15).  
HR-MS (EI): m/z calcd for C16H20N2+ [M]+ 240.1621, found 240.1623. 
 
1-(3-Cyclohexylphenyl)-3,5-dimethyl-1H-pyrazole (146cj) 
The general procedure M was followed using 3,5-dimethyl-1-phenyl-1H-pyrazole 
(147c, 86.2 mg, 0.50 mmol) and bromocyclohexane (136j, 122 mg, 0.75 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 30:1) 
yielded meta-alkylated product 146cj (79.3 mg, 62%) as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.34 (dd, J = 7.9, 7.7 Hz, 1H), 7.27 (ddd, J = 2.3, 1.6, 0.6 Hz, 1H), 7.21 
(ddd, J = 7.9, 2.3, 1.2 Hz, 1H), 7.19 (dddd, J = 7.7, 1.6, 1.2, 0.6 Hz, 1H), 6.00–5.97 (m, 1H), 2.55 (tt, 
J = 11.6, 3.3 Hz, 1H), 2.30 (d, J = 0.4 Hz, 3H), 2.29 (d, J = 0.7 Hz, 3H), 1.96–1.71 (m, 5H), 1.52–1.18 
(m, 5H). 
13C-NMR (125 MHz, CDCl3): δ = 149.1 (Cq), 148.6 (Cq), 139.8 (Cq), 139.2 (Cq), 128.6 (CH), 125.7 (CH), 
123.4 (CH), 122.1 (CH), 106.6 (CH), 44.5 (CH), 34.4 (CH2), 26.9 (CH2), 26.2 (CH2), 13.6 (CH3), 12.4 
(CH3). 
IR (ATR): ṽ = 2922, 2850, 1605, 1590, 1492, 1446, 1380, 792, 701 cm−1.  
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MS (EI) m/z (relative intensity): 254 (100) [M]+, 253 (34) [M–H]+, 239 (8) [M–Me]+, 225 (26), 213 
(12), 211 (11), 199 (74), 186 (15), 115 (11), 91 (9), 77 (8), 41 (10).  
HR-MS (EI): m/z calcd for C17H22N2+ [M]+ 254.1778, found 254.1773. 
 
1-(3-Cycloheptylphenyl)-3,5-dimethyl-1H-pyrazole (146ch) 
The general procedure M was followed using 3,5-dimethyl-1-phenyl-1H-
pyrazole (147c, 86.2 mg, 0.50 mmol) and bromocycloheptane (136h, 133 mg, 
0.75 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 20:1) yielded meta-alkylated product 146ch (75.5 mg, 56%) as 
a colorless oil and di-meta-alkylated product 146ch’ (72.8 mg, 40%) as a 
colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.32 (dd, J = 7.9, 7.8 Hz, 1H), 7.25 (dd, J = 2.1, 2.0 Hz, 1H), 7.19 (ddd, 
J = 7.9, 2.1, 1.1 Hz, 1H), 7.18–7.15 (m, 1H), 5.98 (s, 1H), 2.71 (tt, J = 10.5, 3.5 Hz, 1H), 2.30 (s, 3H), 
2.29 (d, J = 0.8 Hz, 3H), 1.98–1.90 (m, 2H), 1.79 (dtd, J = 13.2, 6.6, 3.5 Hz, 2H), 1.74–1.47 (m, 8H). 
13C-NMR (100 MHz, CDCl3): δ = 151.1 (Cq), 148.7 (Cq), 139.8 (Cq), 139.3 (Cq), 128.7 (CH), 125.6 (CH), 
123.3 (CH), 121.9 (CH), 106.6 (CH), 46.9 (CH), 36.7 (CH2), 27.9 (CH2), 27.2 (CH2), 13.5 (CH3), 12.4 
(CH3). 
IR (ATR): ṽ = 2919, 2853, 1605, 1589, 1492, 1444, 1380, 975, 789, 702 cm−1.  
MS (EI) m/z (relative intensity): 268 (100) [M]+, 267 (23) [M–H]+, 253 (8) [M–Me]+, 239 (21), 225 
(35), 211 (20), 199 (69), 186 (64), 115 (15), 77 (10).  
HR-MS (EI): m/z calcd for C18H24N2+ [M]+ 268.1934, found 268.1944. 
 
1-(3,5-Dicycloheptylphenyl)-3,5-dimethyl-1H-pyrazole (146ch’) 
1H-NMR (400 MHz, CDCl3): δ = 7.01 (d, J = 1.7 Hz, 2H), 6.98 (t, J = 1.7 Hz, 
1H), 5.96 (q, J = 0.7 Hz, 1H), 2.67 (tt, J = 10.6, 3.6 Hz, 2H), 2.30 (s, 3H), 2.27 
(d, J = 0.7 Hz, 3H), 1.93 (dddd, J = 13.5, 6.6, 3.5, 1.6 Hz, 4H), 1.78 (dtt, J = 
13.1, 6.6, 3.1 Hz, 4H), 1.74–1.47 (m, 16H). 
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13C-NMR (100 MHz, CDCl3): δ = 150.8 (Cq), 148.5 (Cq), 139.6 (Cq), 139.3 (Cq), 124.3 (CH), 120.5 (CH), 
106.4 (CH), 47.0 (CH), 36.8 (CH2), 27.9 (CH2), 27.2 (CH2), 13.6 (CH3), 12.4 (CH3). 
IR (ATR): ṽ = 2917, 2852, 1597, 1557, 1455, 1383, 975, 776, 709 cm−1.  
MS (EI) m/z (relative intensity): 364 (100) [M]+, 363 (23) [M–H]+, 349 (8) [M–Me]+, 335 (13), 321 
(26), 309 (12), 295 (68), 282 (63), 267 (13), 225 (12), 199 (10), 55 (19), 44 (38).  
HR-MS (EI): m/z calcd for C25H36N2+ [M]+ 364.2873, found 364.2869. 
 
1-[exo-3-(Bicyclo[2.2.1]heptan-2-yl)phenyl]-3,5-dimethyl-1H-pyrazole (146cu) 
The general procedure M was followed using 3,5-dimethyl-1-phenyl-1H-
pyrazole (147c, 86.2 mg, 0.50 mmol) and exo-2-bromonorbornane (136u, 
131 mg, 0.75 mmol). After 16 h, purification by column chromatography 
(n-hexane/EtOAc 30:1) yielded meta-alkylated product 146cu (49.6 mg, 37%) 
as a colorless oil. 
1H-NMR (300 MHz, CDCl3): δ = 7.33 (dd, J = 7.8, 7.8 Hz, 1H), 7.28–7.25 (m, 1H), 7.22–7.16 (m, 2H), 
6.00–5.97 (m, 1H), 2.78 (dd, J = 8.9, 5.8 Hz, 1H), 2.43–2.38 (m, 1H), 2.38–2.33 (m, 1H), 2.30 (d, J = 
0.4 Hz, 3H), 2.29 (d, J = 0.8 Hz, 3H), 1.80 (dddd, J = 12.2, 8.9, 2.3, 0.8 Hz, 1H), 1.72–1.63 (m, 1H), 
1.63–1.50 (m, 3H), 1.40–1.23 (m, 2H), 1.23–1.16 (m, 1H). 
13C-NMR (125 MHz, CDCl3): δ = 148.7 (Cq), 148.6 (Cq), 139.7 (Cq), 139.2 (Cq), 128.6 (CH), 125.9 (CH), 
123.6 (CH), 121.8 (CH), 106.6 (CH), 47.2 (CH), 42.9 (CH), 39.3 (CH2), 36.9 (CH), 36.2 (CH2), 30.6 
(CH2), 28.9 (CH2), 13.6 (CH3), 12.5 (CH3). 
IR (ATR): ṽ = 2949, 2868, 1605, 1588, 1556, 1493, 1380, 789, 701 cm−1.  
MS (EI) m/z (relative intensity): 266 (100) [M]+, 265 (19) [M–H]+, 251 (5) [M–Me]+, 237 (12), 199 
(68), 186 (41), 128 (9), 115 (14), 84 (14), 77 (10), 67 (12), 49 (19).  









The general procedure M was followed using 3,5-dimethyl-1-phenyl-1H-pyrazole 
(147c, 86.1 mg, 0.50 mmol) and 2-bromobutane (136m, 103 mg, 0.75 mmol). After 
16 h, purification by column chromatography (n-hexane/EtOAc 20:1) yielded 
meta-alkylated product 146cm (57.5 mg, 50%) as a colorless oil and di-meta-
alkylated product 146cm’ (60.2 mg, 42%, as a diastereomeric mixture (1:1)) as a 
colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.35 (ddd, J = 7.6, 7.5, 0.9 Hz, 1H), 7.24–7.22 (m, 1H), 7.22 (ddd, J = 
7.5, 2.2, 1.2 Hz, 1H), 7.17 (dddd, J = 7.6, 1.7, 1.2, 0.5 Hz, 1H), 5.99–5.97 (m, 1H), 2.65 (h, J = 7.0 Hz, 
1H), 2.30 (s, 3H), 2.28 (d, J = 0.7 Hz, 3H), 1.67–1.56 (m, 2H), 1.26 (d, J = 7.0 Hz, 3H), 0.83 (t, J = 
7.4 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 148.8 (Cq), 148.7 (Cq), 139.8 (Cq), 139.3 (Cq), 128.7 (CH), 126.0 (CH), 
123.6 (CH), 122.3 (CH), 106.7 (CH), 41.6 (CH), 31.1 (CH2), 21.7 (CH3), 13.5 (CH3), 12.4 (CH3), 12.2 
(CH3). 
IR (ATR): ṽ = 2960, 1607, 1590, 1557, 1492, 1379, 974, 791, 702 cm−1.  
MS (EI) m/z (relative intensity): 228 (53) [M]+, 213 (18) [M–Me]+, 199 (100) [M–Et]+, 184 (7) [M–
Me–Et]+, 143 (10), 115 (7), 77 (7).  
HR-MS (EI): m/z calcd for C15H20N2+ [M]+ 228.1621, found 228.1627. 
 
1-(3,5-Di-sec-butylphenyl)-3,5-dimethyl-1H-pyrazole (146cm’) 
1H-NMR (400 MHz, CDCl3): δ = 7.03 (d, J = 1.6 Hz, 2H), 6.96 (t, J = 1.6 Hz, 1H), 
5.98 (s, 1H), 2.62 (h, J = 7.0 Hz, 2H), 2.30 (s, 3H), 2.26 (d, J = 0.8 Hz, 3H), 1.66–
1.53 (m, 4H), 1.25 (d, J = 7.0 Hz, 6H), 0.83 (t, J = 7.4 Hz, 6H). Proton signals of 
two diastereomers are identical. 
13C-NMR (100 MHz, CDCl3, determined as a diastereomeric mixture (1:1)): δ = 148.5 (2 × Cq), 148.4 
(4 × Cq), 139.7 (2 × Cq), 139.3 (2 × Cq), 125.2 (CH), 125.2 (CH), 121.1 (2 × CH), 121.1 (2 × CH), 106.4 
(2 × CH), 41.6 (4 × CH), 31.2 (2 × CH2), 31.1 (2 × CH2), 21.7 (4 × CH3), 13.6 (2 × CH3), 12.3 (2 × CH3), 
12.2 (2 × CH3), 12.2 (2 × CH3). 
IR (ATR): ṽ = 2959, 2925, 1598, 1557, 1460, 1381, 875, 778, 710 cm−1.  
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MS (EI) m/z (relative intensity): 284 (51) [M]+, 269 (20) [M–Me]+, 255 (100) [M–Et]+, 225 (15), 199 
(14), 115 (7).  
HR-MS (EI): m/z calcd for C19H28N2+ [M]+ 284.2247, found 284.2246. 
 
3,5-Dimethyl-1-[3-(pentan-2-yl)phenyl]-1H-pyrazole (146cn) 
The general procedure M was followed using 3,5-dimethyl-1-phenyl-1H-pyrazole 
(147c, 86.1 mg, 0.50 mmol) and 2-bromopentane (136n, 113 mg, 0.75 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 20:1) 
yielded meta-alkylated product 146cn (61.0 mg, 50%) as a colorless oil and di-
meta-alkylated product 146cn’ (64.1 mg, 41%, as a diastereomeric mixture (1:1)) 
as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.34 (ddd, J = 7.7, 7.5, 0.7 Hz, 1H), 7.24–7.23 (m, 1H), 7.22 (ddd, J = 
7.7, 2.2, 1.3 Hz, 1H), 7.16 (dddd, J = 7.5, 1.4, 1.3, 0.5 Hz, 1H), 5.99 (q, J = 0.8 Hz, 1H), 2.75 (h, J = 
7.0 Hz, 1H), 2.30 (s, 3H), 2.28 (d, J = 0.8 Hz, 3H), 1.65–1.48 (m, 2H), 1.34–1.14 (m, 2H), 1.25 (d, J = 
7.0 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 149.1 (Cq), 148.7 (Cq), 139.8 (Cq), 139.3 (Cq), 128.7 (CH), 126.0 (CH), 
123.6 (CH), 122.3 (CH), 106.7 (CH), 40.5 (CH2), 39.6 (CH), 22.1 (CH3), 20.8 (CH2), 14.1 (CH3), 13.5 
(CH3), 12.3 (CH3). 
IR (ATR): ṽ = 2956, 1607, 1557, 1492, 1380, 974, 890, 792, 702 cm−1.  
MS (EI) m/z (relative intensity): 242 (50) [M]+, 227 (5) [M–Me]+, 213 (13) [M–Et]+, 199 (100) [M–n-
Pr]+, 143 (9), 115 (7), 77 (7), 58 (8), 43 (30).  
HR-MS (EI): m/z calcd for C16H22N2+ [M]+ 242.1778, found 242.1778. 
 
1-[3,5-Di(pentan-2-yl)phenyl]-3,5-dimethyl-1H-pyrazole (146cn’) 
1H-NMR (400 MHz, CDCl3): δ = 7.02 (d, J = 1.6 Hz, 2H), 6.96 (t, J = 1.6 Hz, 1H), 
5.98 (s, 1H), 2.71 (h, J = 7.0 Hz, 2H), 2.31 (s, 3H), 2.26 (d, J = 0.7 Hz, 3H), 
1.63–1.46 (m, 4H), 1.34–1.14 (m, 4H), 1.24 (d, J = 7.0 Hz, 6H), 0.86 (t, J = 
7.3 Hz, 6H). Proton signals of two diastereomers are identical. 
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13C-NMR (100 MHz, CDCl3, determined as a diastereomeric mixture (1:1)): δ = 148.8 (4 × Cq), 148.5 
(2 × Cq), 139.7 (2 × Cq), 139.3 (2 × Cq), 125.1 (CH), 125.1 (CH), 121.0 (4 × CH), 106.5 (2 × CH), 40.6 
(2 × CH2), 40.6 (2 × CH2), 39.6 (4 × CH), 22.1 (4 × CH3), 20.8 (4 × CH2), 14.1 (4 × CH3), 13.6 (2 × CH3), 
12.3 (2 × CH3). 
IR (ATR): ṽ = 2956, 2926, 1599, 1557, 1459, 1383, 876, 777, 710 cm−1.  
MS (EI) m/z (relative intensity): 312 (66) [M]+, 297 (4) [M–Me]+, 283 (14) [M–Et]+, 270 (100) [M–
n-Pr]+, 269 (85) [M–Et–Me]+, 227 (13) [M–n-Pr–n-Pr]+, 225 (17), 199 (14), 115 (6), 43 (19), 41 (11).  
HR-MS (EI): m/z calcd for C21H32N2+ [M]+ 312.2560, found 312.2568. 
 
3,5-Dimethyl-1-(3-neopentylphenyl)-1H-pyrazole (146ct) 
The general procedure M was followed using 3,5-dimethyl-1-phenyl-1H-pyrazole 
(147c, 86.1 mg, 0.50 mmol) and neopentyl bromide (136t, 113 mg, 0.75 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 20:1) 
yielded meta-alkylated product 146ct (39.2 mg, 32%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.33 (ddd, J = 8.0, 7.5, 0.6 Hz, 1H), 7.27 (ddd, J = 8.0, 2.2, 1.3 Hz, 
1H), 7.16 (ddd, J = 2.2, 1.7, 0.6 Hz, 1H), 7.11 (ddd, J = 7.5, 1.7, 1.3 Hz, 1H), 5.99–5.97 (m, 1H), 2.54 
(s, 2H), 2.30 (d, J = 0.4 Hz, 3H), 2.29 (d, J = 0.8 Hz, 3H), 0.93 (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 148.7 (Cq), 140.7 (Cq), 139.4 (Cq), 139.3 (Cq), 129.4 (CH), 128.2 (CH), 
126.7 (CH), 122.5 (CH), 106.6 (CH), 50.0 (CH2), 31.8 (Cq), 29.4 (CH3), 13.5 (CH3), 12.4 (CH3). 
IR (ATR): ṽ = 2951, 1607, 1557, 1494, 1380, 1363, 975, 797, 742, 702 cm−1.  
MS (EI) m/z (relative intensity): 242 (27) [M]+, 227 (13) [M–Me]+, 186 (100) [M–t-Bu]+, 171 (6) [M–
CH2t-Bu]+, 144 (10), 130 (6), 115 (5), 57 (15), 41 (10).  
HR-MS (EI): m/z calcd for C16H22N2+ [M]+ 242.1778, found 242.1782. 
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5.3.6.2 Mechanistic Studies 
5.3.6.2.1 Reactions with Diastereomerically Pure Alkyl Bromides 
 
The general procedure M was followed using 1-[4-(1H-pyrazol-1-yl)phenyl]ethan-1-one (147j, 
93.1 mg, 0.50 mmol) and endo-2-bromobornane (endo-136x, 327 mg, 1.50 mmol). After 16 h, 
purification by column chromatography (n-hexane/EtOAc 10:1) yielded ortho-alkylated product 
endo-145jx (27.4 mg, 17%) as a white solid, meta-alkylated product exo-146jx (22.0 mg, 14%) as a 




1H-NMR (300 MHz, CDCl3): δ = 8.13 (d, J = 2.0 Hz, 1H), 7.86 (dd, J = 8.2, 2.0 Hz, 
1H), 7.72 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 6.44 
(dd, J = 2.3, 2.0 Hz, 1H), 3.86 (ddd, J = 11.7, 5.7, 2.3 Hz, 1H), 2.67 (s, 3H), 2.34–
2.18 (m, 1H), 1.93–1.80 (m, 1H), 1.77 (dd, J = 4.4, 4.4 Hz, 1H), 1.53–1.33 (m, 3H), 
1.22–1.10 (m, 1H), 0.84 (s, 6H), 0.20 (s, 3H).  
5.3 Experimental Procedures and Analytical Data 
 
391 
13C-NMR (100 MHz, CDCl3): δ = 197.6 (Cq), 144.8 (Cq), 140.7 (CH), 139.6 (Cq), 136.3 (Cq), 131.4 (CH), 
130.5 (CH), 127.2 (CH), 126.6 (CH), 106.8 (CH), 50.5 (Cq), 50.5 (Cq), 45.6 (CH), 42.1 (CH), 35.4 (CH2), 
28.8 (CH2), 28.6 (CH2), 26.9 (CH3), 19.8 (CH3), 18.5 (CH3), 14.3 (CH3).  
IR (ATR): ṽ = 2951, 1684, 1602, 1518, 1395, 1239, 937, 909, 827, 728 cm−1.  
m.p.: 97–98 °C. 
MS (ESI) m/z (relative intensity): 667 (12) [2M+Na]+, 645 (3) [2M+H]+, 345 (35) [M+Na]+, 323 (100) 
[M+H]+.  




1H-NMR (400 MHz, CDCl3): δ = 7.97–7.92 (m, 2H), 7.75 (d, J = 1.7 Hz, 1H), 7.69 (d, 
J = 8.4 Hz, 1H), 7.55 (dd, J = 8.4, 2.1 Hz, 1H), 6.49 (dd, J = 2.5, 1.7 Hz, 1H), 4.03 (dd, 
J = 9.1, 8.7 Hz, 1H), 2.63 (s, 3H), 2.26 (ddt, J = 12.2, 8.7, 3.4 Hz, 1H), 1.89–1.77 (m, 
2H), 1.73 (dd, J = 12.2, 9.1 Hz, 1H), 1.61–1.54 (m, 2H), 1.43–1.32 (m, 1H), 0.93 (s, 
3H), 0.86 (s, 3H), 0.68 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 202.6 (Cq), 145.8 (Cq), 141.8 (CH), 141.6 (Cq), 138.4 (Cq), 130.5 (CH), 
126.8 (CH), 119.3 (CH), 115.3 (CH), 108.3 (CH), 50.7 (Cq), 48.6 (Cq), 46.5 (CH), 45.8 (CH), 39.7 (CH2), 
35.4 (CH2), 31.0 (CH3), 27.4 (CH2), 21.8 (CH3), 21.1 (CH3), 13.6 (CH3).  
IR (ATR): ṽ = 2952, 2878, 1682, 1605, 1577, 1390, 1247, 1043, 948, 749 cm−1.  
m.p.: 129–131 °C. 
MS (ESI) m/z (relative intensity): 667 (6) [2M+Na]+, 645 (2) [2M+H]+, 345 (37) [M+Na]+, 323 (100) 
[M+H]+.  









1H-NMR (400 MHz, CDCl3): δ = 7.97 (dd, J = 2.5, 0.7 Hz, 1H), 7.84 (d, J = 1.9 Hz, 
1H), 7.77 (d, J = 1.7 Hz, 1H), 7.61–7.56 (m, 2H), 6.51 (dd, J = 2.5, 1.7 Hz, 1H), 
4.25 (ddd, J = 11.6, 5.6, 2.3 Hz, 1H), 2.58 (s, 3H), 2.34–2.23 (m, 1H), 1.93–1.84 
(m, 1H), 1.81 (dd, J = 4.4, 4.4 Hz, 1H), 1.52 (dd, J = 13.3, 5.6 Hz, 1H), 1.47–1.39 
(m, 2H), 1.21–1.14 (m, 1H), 1.04 (s, 3H), 0.93 (s, 3H), 0.61 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 203.3 (Cq), 144.0 (Cq), 141.8 (CH), 141.1 (Cq), 139.7 (Cq), 129.4 (CH), 
126.9 (CH), 120.3 (CH), 115.8 (CH), 108.3 (CH), 51.4 (Cq), 50.6 (Cq), 45.6 (CH), 42.7 (CH), 35.4 (CH2), 
31.0 (CH3), 28.9 (CH2), 28.7 (CH2), 20.0 (CH3), 18.8 (CH3), 14.5 (CH3).  
IR (ATR): ṽ = 2938, 2882, 1683, 1603, 1389, 1247, 1038, 909, 828, 762 cm−1.  
m.p.: 118–120 °C. 
MS (EI) m/z (relative intensity): 322 (1) [M]+, 308 (7), 304 (10), 289 (8), 279 (14) [M–Ac]+, 213 (94), 
211 (100), 196 (42), 169 (16), 95 (10).  
HR-MS (EI): m/z calcd for C21H26N2O+ [M]+ 322.2040, found 322.2037. 
 
 
The general procedure M was followed using 1-[4-(1H-pyrazol-1-yl)phenyl]ethan-1-one (147j, 
93.1 mg, 0.50 mmol) and cis-1-bromo-4-(tert-butyl)cyclohexane (cis-136s, 312 mg, 1.50 mmol). 
After 16 h, purification by column chromatography (n-hexane/EtOAc 10:1 to 4:1) yielded ortho-
alkylated product cis-145js (31.2 mg, 19%) as a white solid, meta-alkylated product 146js 
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(16.5 mg, 10%) as a 1:1.3 mixture of cis- and trans-isomer as a colorless oil, and starting material 
147j (35.2 mg, 38%) as a white solid. 
 
1-{3-[cis-4-(tert-Butyl)cyclohexyl]-4-(1H-pyrazol-1-yl)phenyl}ethan-1-one (cis-145js) 
1H-NMR (400 MHz, CDCl3): δ = 8.24 (d, J = 2.0 Hz, 1H), 7.85 (dd, J = 8.2, 2.0 Hz, 1H), 
7.74 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 2.2 Hz, 1H), 7.36 (d, J = 8.2 Hz, 1H), 6.46 (dd, J = 
2.2, 2.0 Hz, 1H), 3.39–3.32 (m, 1H), 2.64 (s, 3H), 1.79–1.70 (m, 2H), 1.67–1.52 (m, 
4H), 1.38–1.24 (m, 2H), 1.08 (tt, J = 11.1, 3.8 Hz, 1H), 0.84 (s, 9H).  
13C-NMR (100 MHz, CDCl3): δ = 197.5 (Cq), 143.4 (Cq), 143.0 (Cq), 140.9 (CH), 136.6 (Cq), 130.8 (CH), 
129.2 (CH), 127.5 (CH), 126.5 (CH), 106.9 (CH), 46.6 (CH), 32.9 (Cq), 32.2 (CH), 29.9 (CH2), 27.7 (CH3), 
26.9 (CH3), 23.1 (CH2).  
IR (ATR): ṽ = 2934, 1678, 1596, 1420, 1393, 1359, 1260, 939, 826, 771 cm−1.  
m.p.: 98–99 °C. 
MS (EI) m/z (relative intensity): 324 (31) [M]+, 323 (100) [M–H]+, 309 (18) [M–Me]+, 267 (47) [M–
t-Bu]+, 250 (14), 225 (24) [M–t-Bu–Ac]+, 211 (21), 199 (11), 183 (6), 169 (10), 157 (5), 115 (4).  
HR-MS (EI): m/z calcd for C21H28N2O+ [M]+ 324.2196, found 324.2173. 
 
Mixture of 1-{2-[trans-4-(tert-Butyl)cyclohexyl]-4-(1H-pyrazol-1-yl)phenyl}ethan-1-one (trans-
146js) and 1-{2-[cis-4-(tert-Butyl)cyclohexyl]-4-(1H-pyrazol-1-yl)phenyl}ethan-1-one (cis-146js) 
1H-NMR (400 MHz, CDCl3, determined as 1:1.3 mixture of 
cis-146js and trans-146js): δ = 7.97 (d, J = 2.5 Hz, 1H, 
cis-isomer), 7.96 (d, J = 2.7 Hz, 1H, trans-isomer), 7.90 (d, J 
= 2.3 Hz, 1H, cis-isomer), 7.77 (d, J = 2.3 Hz, 1H, trans-
isomer), 7.76–7.73 (m, 2H), 7.64 (d, J = 8.4 Hz, 1H, cis-
isomer), 7.63 (d, J = 8.5 Hz, 1H, trans-isomer), 7.56 (dd, J = 8.4, 2.3 Hz, 1H, cis-isomer), 7.53 (dd, J 
= 8.5, 2.3 Hz, 1H, trans-isomer), 6.51–6.47 (m, 2H), 3.78–3.69 (m, 1H, cis-isomer), 3.17 (tt, J = 12.2, 
3.4 Hz, 1H, trans-isomer), 2.60 (s, 6H), 2.00–1.78 (m, 8H), 1.69–1.59 (m, 2H, cis-isomer), 1.57–1.45 
(m, 2H, trans-isomer), 1.40–1.28 (m, 2H, cis-isomer), 1.25–1.05 (m, 4H), 0.88 (s, 9H, cis-isomer), 
0.86 (s, 9H, trans-isomer). Some proton peaks could not be identified due to overlapping. 
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13C-NMR (100 MHz, CDCl3, determined as 1:1.3 mixture of cis-146js and trans-146js): δ = 202.6 (Cq 
of cis-isomer), 202.2 (Cq of trans-isomer), 149.6 (Cq of trans-isomer), 149.1 (Cq of cis-isomer), 142.0 
(Cq of trans-isomer), 141.8 (CH of cis-isomer), 141.8 (CH of trans-isomer), 141.5 (Cq of cis-isomer), 
137.0 (Cq of cis-isomer), 136.6 (Cq of trans-isomer), 130.2 (CH of cis-isomer), 130.0 (CH of trans-
isomer), 126.9 (CH of trans-isomer), 126.8 (CH of cis-isomer), 118.9 (CH of cis-isomer), 117.7 (CH 
of trans-isomer), 115.6 (CH of trans-isomer), 115.4 (CH of cis-isomer), 108.3 (CH of cis-isomer), 
108.3 (CH of trans-isomer), 48.0 (CH of trans-isomer), 46.1 (CH of cis-isomer), 40.1 (CH of trans-
isomer), 34.9 (CH2 of trans-isomer), 33.3 (CH of cis-isomer), 32.9 (Cq of cis-isomer), 32.6 (Cq of trans-
isomer), 31.1 (CH2 of cis-isomer), 30.7 (CH3 of trans-isomer), 30.6 (CH3 of cis-isomer), 27.8 (CH2 of 
trans-isomer), 27.8 (CH3 of cis- and trans-isomer), 23.4 (CH2 of cis-isomer).  
IR (ATR): ṽ = 2936, 2857, 1682, 1605, 1576, 1391, 1246, 1043, 945, 747 cm−1.  
MS (EI) m/z (relative intensity): 324 (5) [M]+, 309 (100) [M–Me]+, 306 (19), 291 (11), 267 (8) [M–t-
Bu]+, 249 (24), 235 (23), 222 (38), 209 (18), 195 (12), 183 (8), 157 (6), 115 (8).  
HR-MS (EI): m/z calcd for C21H28N2O+ [M]+ 324.2196, found 324.2195. 
 
 
The general procedure M was followed using 1-[4-(1H-pyrazol-1-yl)phenyl]ethan-1-one (147j, 
93.1 mg, 0.50 mmol) and trans-1-bromo-4-(tert-butyl)cyclohexane (trans-136s, 312 mg, 
1.50 mmol). After 16 h, purification by column chromatography (n-hexane/EtOAc 10:1) yielded 
ortho-alkylated product trans-145js (107 mg, 66%) as a white solid. 
 
1-{3-[trans-4-(tert-Butyl)cyclohexyl]-4-(1H-pyrazol-1-yl)phenyl}ethan-1-one (trans-145js) 
1H-NMR (400 MHz, CDCl3): δ = 8.03 (d, J = 2.0 Hz, 1H), 7.83 (dd, J = 8.2, 2.0 Hz, 
1H), 7.76 (d, J = 1.9 Hz, 1H), 7.59 (d, J = 2.2 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 
6.48 (dd, J = 2.2, 1.9 Hz, 1H), 2.64 (s, 3H), 2.58 (tt, J = 12.2, 3.2 Hz, 1H), 1.88–
1.79 (m, 4H), 1.56–1.43 (m, 2H), 1.14–0.92 (m, 3H), 0.84 (s, 9H). 
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13C-NMR (100 MHz, CDCl3): δ = 197.5 (Cq), 143.9 (Cq), 143.0 (Cq), 141.0 (CH), 137.2 (Cq), 131.0 (CH), 
127.7 (CH), 127.1 (CH), 126.6 (CH), 106.9 (CH), 47.8 (CH), 38.4 (CH), 34.6 (CH2), 32.6 (Cq), 27.7 (CH3), 
27.7 (CH2), 26.9 (CH3). 
IR (ATR): ṽ = 2920, 2854, 1690, 1601, 1390, 1224, 935, 824, 770, 624 cm−1.  
m.p.: 109–110 °C. 
MS (EI) m/z (relative intensity): 324 (34) [M]+, 323 (100) [M–H]+, 309 (19) [M–Me]+, 267 (46) [M–
t-Bu]+, 250 (14), 225 (25) [M–t-Bu–Ac]+, 211 (22), 199 (12), 169 (12).  
HR-MS (EI): m/z calcd for C21H28N2O+ [M]+ 324.2196, found 324.2175. 
 
5.3.6.2.2 Synthesis of Cyclometalated Ruthenium Complex 204 
 
An oven-dried pressure tube was charged with 3,5-dimethyl-1-phenyl-1H-pyrazole (147c, 172 mg, 
1.00 mmol), [RuCl2(p-cymene)]2 (306 mg, 0.50 mmol), KOAc (196 mg, 2.00 mmol), and KPF6 
(368 mg, 2.00 mmol). After evacuation and refilling with N2 for three times, MeCN (6.5 mL) was 
added and the tube was sealed. The reaction mixture was stirred at 120 °C. After 16 h, the reaction 
was cooled down to the ambient temperature. The crude mixture was loaded on an aluminium 
oxide (Al2O3, neutral, conditioned with CH2Cl2) column and eluted with MeCN/CH2Cl2 (1:1) using 
N2 instead of air. The pale green band was collected and the solvent was removed under reduced 
pressure. The complex was dissolved in MeCN (10 mL) and precipitated with Et2O, affording the 
desired complex 204 (391 mg, 67%) as a green solid. The complex 204 was transferred to the 
glovebox subsequently. Suitable crystals of 204 for X-ray crystallography were grown by slow 
crystallization from MeCN/Et2O (see X-Ray Crystallographic Analysis section).  
1H-NMR (300 MHz, MeCN-d3): δ = 7.95–7.90 (m, 1H), 7.45–7.40 (m, 1H), 7.00–6.89 (m, 2H), 6.08 
(s, 1H), 2.70 (s, 3H), 2.51 (s, 6H), 2.05 (s, 6H), 1.96 (s, 3H). 
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13C-NMR (100 MHz, MeCN-d3): δ = 166.3 (Cq), 152.9 (Cq), 148.7 (Cq), 141.1 (Cq), 139.9 (CH), 124.2 
(CH), 123.3 (Cq), 122.4 (Cq), 121.9 (CH), 112.6 (CH), 110.1 (CH), 15.1 (CH3), 14.7 (CH3), 4.36 (CH3), 
3.8 (CH3). 
19F-NMR (376 MHz, MeCN-d3): δ = (‒71.8)–(‒74.0) (m). 
31P-NMR (162 MHz, MeCN-d3): δ = ‒144.6 (hept, J = 708 Hz). 
IR (ATR): ṽ = 2274, 1546, 1460, 1436, 1419, 1032, 832, 737, 719, 556 cm–1.  
m.p.: >170 °C (decomp.) 
MS (ESI) m/z (relative intensity): 396 (100) [M‒MeCN‒PF6]+. 
HR-MS (ESI): m/z calcd for C17H20N5Ru+ [M‒MeCN‒PF6]+ 396.0761, found 396.0759. 
 
5.3.6.2.3 Catalytic C–H Alkylation with Cyclometalated Complex 204 
 
3,5-Dimethyl-1-phenyl-1H-pyrazole (147c, 86.2 mg, 0.50 mmol), complex 204 (14.5 mg, 25 µmol, 
5.0 mol %), MesCO2H (31, 24.6 mg, 150 µmol, 30 mol %) and K2CO3 (138 mg, 1.00 mmol) were 
placed in a pre-dried 25 mL Schlenk tube. The tube was evacuated and purged with N2 three times. 
Bromocyclohexane (136j, 123 mg, 0.75 mmol) and PhCMe3 (1.0 mL) were then added and the 
mixture was stirred at 120 °C. After 16 h, the resulting mixture was filtered through a pad of silica 
gel and washed with EtOAc. The filtrate was concentrated in vacuo. Purification of the residue by 
column chromatography on silica gel (n-hexane/EtOAc 30:1) yielded meta-alkylated product 146cj 
(89.5 mg, 70%) as a colorless oil. 
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In case of the reaction without MesCO2H (31), the reaction provided ortho-alkylated product 145cj 
(24.4 mg, 19%) as a colorless oil, meta-alkylated product 146cj (13.1 mg, 10%) as a colorless oil, 
and starting material 147c (34.4 mg, 38%) as a colorless oil.   
 
1-(2-Cyclohexylphenyl)-3,5-dimethyl-1H-pyrazole (145cj) 
1H-NMR (400 MHz, CDCl3): δ = 7.40–7.36 (m, 2H), 7.26–7.21 (m, 1H), 7.18–7.14 
(m, 1H), 5.95 (s, 1H), 2.29 (d, J = 1.1 Hz, 3H), 2.16 (tt, J = 12.0, 2.8 Hz, 1H), 2.04 
(d, J = 0.9 Hz, 3H), 1.82–1.61 (m, 5H), 1.44–1.29 (m, 2H), 1.24–1.14 (m, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 148.3 (Cq), 146.2 (Cq), 140.5 (Cq), 137.8 (Cq), 129.3 
(CH), 128.3 (CH), 127.3 (CH), 126.2 (CH), 104.9 (CH), 38.5 (CH), 34.1 (CH2), 26.9 (CH2), 26.2 (CH2), 
13.8 (CH3), 11.6 (CH3).  
IR (ATR): ṽ = 2924, 2851, 1555, 1498, 1448, 1028, 774, 754, 530 cm−1.  
MS (ESI) m/z (relative intensity): 277 (2) [M+Na]+, 255 (100) [M+H]+.  
HR-MS (ESI): m/z calcd for C17H23N2+ [M+H]+ 255.1856, found 255.1859. 
 
5.3.6.3 X-Ray Crystallographic Analysis 
A suitable crystal was selected and the crystal was mounted on a MITIGEN holder in NVH oil on a 
Bruker D8 Venture diffractometer. The crystal was kept at 100 or 300 K during data collection. 
Using Olex2,[137] the structure was solved with the XT[138] structure solution program using Intrinsic 
Phasing and refined with the XL[139] refinement package using Least Squares minimisation. 
 
 
Figure 55: Molecular structure of 145jj with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
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Crystal Data for C17H20N2O (M = 268.35 g/mol): monoclinic, space group P2/c (no. 13), a = 
20.7094(15) Å, b = 5.3605(4) Å, c = 27.2622(18) Å, β = 106.154(2)°, V = 2907.0(4) Å3, Z = 8, T = 
100.0 K, μ(MoKα) = 0.077 mm-1, Dcalc = 1.226 g/cm3, 56579 reflections measured (4.4° ≤ 2Θ ≤ 
57.528°), 7532 unique (Rint = 0.0559, Rsigma = 0.0337) which were used in all calculations. The final 
R1 was 0.0648 (I > 2σ(I)) and wR2 was 0.1690 (all data). 
 
Table 83: Crystal data and structure refinement for 145jj. 
Compound 145jj 
CCDC number 1979314 
Identification code 0700_CG_0m 
Empirical formula C17H20N2O 
Formula weight 268.35 
Temperature/K 100.0 
Crystal system monoclinic 












Crystal size/mm3 0.405 × 0.162 × 0.145 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.4 to 57.528 
Index ranges -28 ≤ h ≤ 27, -7 ≤ k ≤ 7, -36 ≤ l ≤ 36 
Reflections collected 56579 
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Independent reflections 7532 [Rint = 0.0559, Rsigma = 0.0337] 
Data/restraints/parameters 7532/0/363 
Goodness-of-fit on F2 1.122 
Final R indexes [I>=2σ (I)] R1 = 0.0648, wR2 = 0.1655 
Final R indexes [all data] R1 = 0.0709, wR2 = 0.1690 
Largest diff. peak/hole / e Å-3 0.45/-0.29 
 
Table 84: Selected bond lengths [Å] for 145jj. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C1 1.214(2) C4 C8 1.515(2) 
N1 N2 1.363(2) C5 C6 1.390(2) 
N1 C5 1.427(2) C6 C7 1.387(3) 
N1 C15 1.361(2) C8 C9 1.536(3) 
N2 C17 1.331(2) C8 C13 1.539(3) 
C1 C2 1.503(2) C9 C10 1.527(2) 
C1 C14 1.503(3) C10 C11 1.527(3) 
C2 C3 1.393(2) C11 C12 1.529(3) 
C2 C7 1.395(3) C12 C13 1.530(3) 
C3 C4 1.399(2) C15 C16 1.367(3) 
C4 C5 1.402(2) C16 C17 1.402(3) 
 
Table 85: Selected bond angles [°] for 145jj. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C5 120.98(15) C6 C5 N1 116.44(16) 
C15 N1 N2 111.92(15) C6 C5 C4 122.00(16) 
C15 N1 C5 126.38(15) C7 C6 C5 120.32(17) 
C17 N2 N1 103.99(15) C6 C7 C2 119.21(16) 
O1 C1 C2 120.17(17) C4 C8 C9 111.09(15) 
O1 C1 C14 121.75(17) C4 C8 C13 111.69(15) 
C2 C1 C14 118.07(16) C9 C8 C13 110.35(15) 
C3 C2 C1 118.47(16) C10 C9 C8 111.31(15) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C3 C2 C7 119.51(16) C11 C10 C9 111.27(15) 
C7 C2 C1 121.99(16) C10 C11 C12 110.86(16) 
C2 C3 C4 122.55(17) C11 C12 C13 111.47(16) 
C3 C4 C5 116.26(16) C12 C13 C8 110.97(15) 
C3 C4 C8 119.85(16) N1 C15 C16 106.98(16) 
C5 C4 C8 123.89(16) C15 C16 C17 104.77(16) 
C4 C5 N1 121.56(16) N2 C17 C16 112.33(16) 
 
 
Figure 56: Molecular structure of 145jj’ with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C23H30N2O (M = 350.49 g/mol): triclinic, space group P-1 (no. 2), a = 5.8157(4) Å, 
b = 10.5817(8) Å, c = 16.4884(12) Å, α = 79.072(3)°, β = 84.757(2)°, γ = 81.344(3)°, V = 
982.88(12) Å3, Z = 2, T = 100.01 K, μ(MoKα) = 0.072 mm-1, Dcalc = 1.184 g/cm3, 36020 reflections 
measured (5.042° ≤ 2Θ ≤ 57.588°), 5088 unique (Rint = 0.0191, Rsigma = 0.0142) which were used in 
all calculations. The final R1 was 0.0395 (I > 2σ(I)) and wR2 was 0.1053 (all data). 
 
Table 86: Crystal data and structure refinement for 145jj’. 
Compound 145jj’ 
CCDC number 1979313 
Identification code 0687_CG_0m 
Empirical formula C23H30N2O 
Formula weight 350.49 




Crystal system triclinic 












Crystal size/mm3 0.817 × 0.269 × 0.16 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.042 to 57.588 
Index ranges -7 ≤ h ≤ 7, -14 ≤ k ≤ 14, -22 ≤ l ≤ 22 
Reflections collected 36020 
Independent reflections 5088 [Rint = 0.0191, Rsigma = 0.0142] 
Data/restraints/parameters 5088/0/236 
Goodness-of-fit on F2 1.059 
Final R indexes [I>=2σ (I)] R1 = 0.0395, wR2 = 0.1044 
Final R indexes [all data] R1 = 0.0407, wR2 = 0.1053 
Largest diff. peak/hole / e Å-3 0.40/-0.25 
 
Table 87: Bond lengths [Å] for 145jj’. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C2 1.2196(11) C9 C10 1.5348(13) 
N1 N2 1.3537(11) C9 C14 1.5352(12) 
N1 C6 1.4326(11) C10 C11 1.5313(13) 
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Atom Atom Length/Å Atom Atom Length/Å 
N1 C21 1.3516(11) C11 C12 1.5273(14) 
N2 C23 1.3333(13) C12 C13 1.5263(14) 
C1 C2 1.5020(12) C13 C14 1.5282(12) 
C2 C3 1.5045(12) C15 C16 1.5364(13) 
C3 C4 1.3963(12) C15 C20 1.5359(13) 
C3 C8 1.3934(12) C16 C17 1.5339(13) 
C4 C5 1.4015(12) C17 C18 1.5254(14) 
C5 C6 1.4026(12) C18 C19 1.5208(15) 
C5 C15 1.5196(11) C19 C20 1.5319(13) 
C6 C7 1.4054(12) C21 C22 1.3716(13) 
C7 C8 1.3911(12) C22 C23 1.3967(14) 
C7 C9 1.5153(12)    
 
Table 88: Bond angles [°] for 145jj’. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C6 120.46(7) C7 C8 C3 121.68(8) 
C21 N1 N2 112.15(8) C7 C9 C10 111.30(7) 
C21 N1 C6 127.32(8) C7 C9 C14 110.43(7) 
C23 N2 N1 103.86(8) C10 C9 C14 110.53(7) 
O1 C2 C1 121.09(8) C11 C10 C9 111.04(8) 
O1 C2 C3 119.40(8) C12 C11 C10 111.30(8) 
C1 C2 C3 119.49(8) C13 C12 C11 110.34(8) 
C4 C3 C2 123.33(8) C12 C13 C14 111.18(8) 
C8 C3 C2 117.19(8) C13 C14 C9 112.24(8) 
C8 C3 C4 119.42(8) C5 C15 C16 110.95(7) 
C3 C4 C5 121.15(8) C5 C15 C20 111.40(7) 
C4 C5 C6 117.53(8) C20 C15 C16 110.98(7) 
C4 C5 C15 120.29(7) C17 C16 C15 112.20(8) 
C6 C5 C15 122.17(8) C18 C17 C16 111.59(8) 
C5 C6 N1 119.12(7) C19 C18 C17 110.59(8) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C5 C6 C7 122.69(8) C18 C19 C20 110.94(8) 
C7 C6 N1 118.19(7) C19 C20 C15 111.72(8) 
C6 C7 C9 122.69(8) N1 C21 C22 107.31(8) 
C8 C7 C6 117.50(8) C21 C22 C23 104.11(9) 
C8 C7 C9 119.79(8) N2 C23 C22 112.56(9) 
 
 
Figure 57: Molecular structure of endo-145jx with thermal ellipsoids at 50% probability level. 
The hydrogen atoms are omitted for clarity. 
 
Crystal Data for C21H26N2O (M = 322.44 g/mol): monoclinic, space group Cc (no. 9), a = 10.588(6) Å, 
b = 19.131(10) Å, c = 10.302(6) Å, β = 118.335(11)°, V = 1836.9(17) Å3, Z = 4, T = 300 K, μ(MoKα) = 
0.072 mm-1, Dcalc = 1.166 g/cm3, 35887 reflections measured (4.862° ≤ 2Θ ≤ 55.924°), 4332 
unique (Rint = 0.0350, Rsigma = 0.0234) which were used in all calculations. The final R1 was 0.0420 
(I > 2σ(I)) and wR2 was 0.1202 (all data). 
 
Table 89: Crystal data and structure refinement for endo-145jx. 
Compound endo-145jx 
CCDC number 2016734 
Identification code mo_1053_CG_0m 
Empirical formula C21H26N2O 
Formula weight 322.44 
Temperature/K 300 
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Crystal system monoclinic 












Crystal size/mm3 0.386 × 0.191 × 0.052 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.862 to 55.924 
Index ranges -13 ≤ h ≤ 13, -24 ≤ k ≤ 25, -13 ≤ l ≤ 13 
Reflections collected 35887 
Independent reflections 4332 [Rint = 0.0350, Rsigma = 0.0234] 
Data/restraints/parameters 4332/2/221 
Goodness-of-fit on F2 1.075 
Final R indexes [I>=2σ (I)] R1 = 0.0420, wR2 = 0.1132 
Final R indexes [all data] R1 = 0.0489, wR2 = 0.1202 
Largest diff. peak/hole / e Å-3 0.21/-0.18 
Flack parameter 0.1(4) 
 
Table 90: Bond lengths [Å] for endo-145jx. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C2 1.215(3) C9 C10 1.559(3) 
N1 N2 1.353(3) C9 C13 1.559(3) 
N1 C6 1.432(3) C10 C11 1.567(3) 
5.3 Experimental Procedures and Analytical Data 
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Atom Atom Length/Å Atom Atom Length/Å 
N1 C19 1.340(4) C10 C15 1.534(4) 
N2 C21 1.318(4) C10 C18 1.506(4) 
C1 C2 1.502(4) C11 C12 1.534(4) 
C2 C3 1.489(3) C11 C16 1.530(4) 
C3 C4 1.395(3) C11 C17 1.528(4) 
C3 C8 1.385(3) C12 C13 1.539(4) 
C4 C5 1.394(3) C12 C14 1.518(5) 
C5 C6 1.410(3) C14 C15 1.542(5) 
C5 C9 1.513(3) C19 C20 1.364(5) 
C6 C7 1.382(3) C20 C21 1.385(6) 
C7 C8 1.371(4)    
  
Table 91: Bond angles [°] for endo-145jx. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C6 120.5(2) C9 C10 C11 100.54(18) 
C19 N1 N2 112.1(2) C15 C10 C9 108.8(2) 
C19 N1 C6 126.9(2) C15 C10 C11 101.5(2) 
C21 N2 N1 104.4(3) C18 C10 C9 114.0(2) 
O1 C2 C1 120.7(2) C18 C10 C11 116.5(2) 
O1 C2 C3 121.1(2) C18 C10 C15 114.0(2) 
C3 C2 C1 118.3(2) C12 C11 C10 93.0(2) 
C4 C3 C2 119.4(2) C16 C11 C10 113.3(3) 
C8 C3 C2 121.2(2) C16 C11 C12 114.8(3) 
C8 C3 C4 119.3(2) C17 C11 C10 115.0(2) 
C5 C4 C3 122.8(2) C17 C11 C12 113.7(3) 
C4 C5 C6 115.57(19) C17 C11 C16 107.0(3) 
C4 C5 C9 123.3(2) C11 C12 C13 103.3(2) 
C6 C5 C9 121.14(19) C14 C12 C11 102.7(3) 
C5 C6 N1 122.2(2) C14 C12 C13 106.8(2) 
C7 C6 N1 115.9(2) C12 C13 C9 103.6(2) 
C7 C6 C5 121.9(2) C12 C14 C15 102.9(3) 
5 Experimental Part 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C8 C7 C6 120.7(2) C10 C15 C14 104.0(2) 
C7 C8 C3 119.6(2) N1 C19 C20 106.6(3) 
C5 C9 C10 116.03(17) C19 C20 C21 105.2(3) 
C5 C9 C13 117.54(19) N2 C21 C20 111.8(3) 
C13 C9 C10 101.97(19)     
 
 
Figure 58: Molecular structure of exo-146jx with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C21H26N2O (M = 322.44 g/mol): orthorhombic, space group Pbca (no. 61), a = 
18.2576(9) Å, b = 9.0892(4) Å, c = 21.3228(9) Å, V = 3538.5(3) Å3, Z = 8, T = 100.0 K, μ(MoKα) = 
0.074 mm-1, Dcalc = 1.211 g/cm3, 108209 reflections measured (3.82° ≤ 2Θ ≤ 59.25°), 4981 unique 
(Rint = 0.0595, Rsigma = 0.0246) which were used in all calculations. The final R1 was 0.0759 (I > 2σ(I)) 
and wR2 was 0.1690 (all data). 
 
Table 92: Crystal data and structure refinement for exo-146jx. 
Compound exo-146jx 
CCDC number 2016645 
Identification code mo_1036_CG_0m 
Empirical formula C21H26N2O 
Formula weight 322.44 




Crystal system orthorhombic 












Crystal size/mm3 0.409 × 0.367 × 0.307 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 3.82 to 59.25 
Index ranges -24 ≤ h ≤ 25, -12 ≤ k ≤ 12, -29 ≤ l ≤ 29 
Reflections collected 108209 
Independent reflections 4981 [Rint = 0.0595, Rsigma = 0.0246] 
Data/restraints/parameters 4981/252/354 
Goodness-of-fit on F2 1.203 
Final R indexes [I>=2σ (I)] R1 = 0.0759, wR2 = 0.1676 
Final R indexes [all data] R1 = 0.0789, wR2 = 0.1690 
Largest diff. peak/hole / e Å-3 0.44/-0.26 
 
Table 93: Selected bond lengths [Å] for exo-146jx. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C2 1.217(2) C9A C10A 1.558(4) 
N1 N2 1.368(3) C9A C13A 1.587(3) 
N1 C6A 1.396(3) C10A C11A 1.525(4) 
5 Experimental Part 
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Atom Atom Length/Å Atom Atom Length/Å 
N1 C19 1.354(3) C11A C12A 1.541(5) 
N2 C21 1.328(3) C11A C15A 1.544(4) 
C1 C2 1.511(3) C12A C13A 1.569(5) 
C2 C3A 1.529(3) C12A C17A 1.530(5) 
C3A C4A 1.415(3) C12A C18A 1.544(4) 
C3A C8A 1.398(3) C13A C14A 1.560(3) 
C4A C5A 1.396(3) C13A C16A 1.516(3) 
C4A C9A 1.521(3) C14A C15A 1.552(4) 
C5A C6A 1.394(3) C19 C20 1.369(3) 
C6A C7A 1.386(3) C20 C21 1.393(4) 
C7A C8A 1.386(3)    
 
Table 94: Selected bond angles [°] for exo-146jx. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C6A 120.4(2) C11A C10A C9A 103.5(2) 
C19 N1 N2 111.42(18) C10A C11A C12A 103.2(2) 
C19 N1 C6A 128.1(2) C10A C11A C15A 106.6(2) 
C21 N2 N1 104.2(2) C12A C11A C15A 102.6(2) 
O1 C2 C1 120.21(19) C11A C12A C13A 93.6(3) 
O1 C2 C3A 121.8(2) C11A C12A C18A 114.4(3) 
C1 C2 C3A 118.0(2) C17A C12A C11A 112.8(3) 
C4A C3A C2 124.5(3) C17A C12A C13A 114.6(2) 
C8A C3A C2 115.6(3) C17A C12A C18A 106.8(3) 
C8A C3A C4A 119.9(2) C18A C12A C13A 114.5(3) 
C3A C4A C9A 121.3(2) C12A C13A C9A 104.4(2) 
C5A C4A C3A 116.99(19) C14A C13A C9A 102.92(18) 
C5A C4A C9A 121.7(2) C14A C13A C12A 100.0(2) 
C6A C5A C4A 122.1(2) C16A C13A C9A 116.66(19) 
C5A C6A N1 117.5(3) C16A C13A C12A 117.2(2) 
C7A C6A N1 121.7(3) C16A C13A C14A 113.4(2) 
5.3 Experimental Procedures and Analytical Data 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C7A C6A C5A 120.8(2) C15A C14A C13A 102.73(19) 
C6A C7A C8A 117.7(2) C11A C15A C14A 103.7(2) 
C7A C8A C3A 122.4(2) N1 C19 C20 107.2(2) 
C4A C9A C10A 117.1(2) C19 C20 C21 104.8(2) 
C4A C9A C13A 119.31(18) N2 C21 C20 112.3(2) 
C10A C9A C13A 102.3(2)     
  
 
Figure 59: Molecular structure of endo-146jx with thermal ellipsoids at 50% probability level. 
The hydrogen atoms are omitted for clarity. 
 
Crystal Data for C21H26N2O (M = 322.44 g/mol): orthorhombic, space group Pbca (no. 61), a = 
18.2383(3) Å, b = 9.1329(2) Å, c = 21.4131(4) Å, V = 3566.75(12) Å3, Z = 8, T = 100.0 K, μ(CuKα) = 
0.573 mm-1, Dcalc = 1.201 g/cm3, 136327 reflections measured (8.258° ≤ 2Θ ≤ 159.994°), 3880 
unique (Rint = 0.0354, Rsigma = 0.0087) which were used in all calculations. The final R1 was 0.0524 
(I > 2σ(I)) and wR2 was 0.1295 (all data). 
 
Table 95: Crystal data and structure refinement for endo-146jx. 
Compound endo-146jx 
CCDC number 2016646 
Identification code 1041_Pbca 
Empirical formula C21H26N2O 
Formula weight 322.44 
Temperature/K 100.0 
5 Experimental Part 
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Crystal system orthorhombic 












Crystal size/mm3 0.26 × 0.247 × 0.197 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 8.258 to 159.994 
Index ranges -23 ≤ h ≤ 23, -11 ≤ k ≤ 11, -27 ≤ l ≤ 27 
Reflections collected 136327 
Independent reflections 3880 [Rint = 0.0354, Rsigma = 0.0087] 
Data/restraints/parameters 3880/60/287 
Goodness-of-fit on F2 1.138 
Final R indexes [I>=2σ (I)] R1 = 0.0524, wR2 = 0.1291 
Final R indexes [all data] R1 = 0.0531, wR2 = 0.1295 
Largest diff. peak/hole / e Å-3 0.31/-0.24 
 
Table 96: Selected bond lengths [Å] for endo-146jx. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C7 1.2166(19) C9 C10 1.568(2) 
N1 N2 1.365(2) C9 C14A 1.588(2) 
N1 C1 1.419(2) C10 C11A 1.562(3) 
N1 C19 1.363(2) C11A C12A 1.538(3) 
5.3 Experimental Procedures and Analytical Data 
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Atom Atom Length/Å Atom Atom Length/Å 
N2 C21 1.332(2) C11A C15A 1.556(3) 
C1 C2 1.391(2) C12A C13A 1.557(3) 
C1 C6 1.385(2) C13A C14A 1.543(3) 
C2 C3 1.397(2) C14A C15A 1.571(3) 
C3 C4 1.412(2) C14A C16 1.490(2) 
C3 C9 1.514(2) C15A C17A 1.531(3) 
C4 C5 1.396(2) C15A C18A 1.526(3) 
C4 C7 1.505(2) C19 C20 1.363(3) 
C5 C6 1.383(2) C20 C21 1.397(3) 
C7 C8 1.509(2)    
 
Table 97: Selected bond angles [°] for endo-146jx. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C1 120.35(13) C11A C10 C9 102.96(13) 
C19 N1 N2 111.27(14) C12A C11A C10 108.17(17) 
C19 N1 C1 128.28(14) C12A C11A C15A 102.42(18) 
C21 N2 N1 104.44(14) C15A C11A C10 102.76(15) 
C2 C1 N1 119.06(14) C11A C12A C13A 102.78(16) 
C6 C1 N1 120.49(14) C14A C13A C12A 104.05(15) 
C6 C1 C2 120.44(14) C13A C14A C9 109.29(15) 
C1 C2 C3 121.79(14) C13A C14A C15A 101.35(15) 
C2 C3 C4 117.61(13) C15A C14A C9 100.24(15) 
C2 C3 C9 120.51(13) C16 C14A C9 114.26(15) 
C4 C3 C9 121.84(13) C16 C14A C13A 113.31(17) 
C3 C4 C7 123.97(13) C16 C14A C15A 116.93(16) 
C5 C4 C3 119.47(14) C11A C15A C14A 93.20(14) 
C5 C4 C7 116.52(13) C17A C15A C11A 113.62(17) 
C6 C5 C4 122.23(15) C17A C15A C14A 113.88(18) 
C5 C6 C1 118.33(14) C18A C15A C11A 113.71(18) 
O1 C7 C4 121.79(15) C18A C15A C14A 115.15(18) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
O1 C7 C8 120.83(15) C18A C15A C17A 107.10(18) 
C4 C7 C8 117.36(14) N1 C19 C20 107.22(16) 
C3 C9 C10 117.07(13) C19 C20 C21 105.15(15) 
C3 C9 C14A 113.48(14) N2 C21 C20 111.92(17) 
C10 C9 C14A 102.80(13)     
 
 
Figure 60: Molecular structure of cis-145js with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C21H28N2O (M =324.45 g/mol): orthorhombic, space group Pna21 (no. 33), a = 
16.476(3) Å, b = 18.989(4) Å, c = 5.7847(9) Å, V = 1809.9(6) Å3, Z = 4, T = 100.0 K, μ(MoKα) = 0.073 
mm-1, Dcalc = 1.191 g/cm3, 130203 reflections measured (4.29° ≤ 2Θ ≤ 57.42°), 4675 unique (Rint 
= 0.0354, Rsigma = 0.0114) which were used in all calculations. The final R1 was 0.0296 (I > 2σ(I)) and 
wR2 was 0.0774 (all data).  
 
Table 98: Crystal data and structure refinement for cis-145js. 
Compound cis-145js 
CCDC number 2016647 
Identification code 1048_Pna21 
Empirical formula C21H28N2O 
Formula weight 324.45 
Temperature/K 100.0 
Crystal system orthorhombic 
5.3 Experimental Procedures and Analytical Data 
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Crystal size/mm3 0.384 × 0.19 × 0.038 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.29 to 57.42 
Index ranges -22 ≤ h ≤ 22, -25 ≤ k ≤ 25, -7 ≤ l ≤ 7 
Reflections collected 130203 
Independent reflections 4675 [Rint = 0.0354, Rsigma = 0.0114] 
Data/restraints/parameters 4675/1/221 
Goodness-of-fit on F2 1.040 
Final R indexes [I>=2σ (I)] R1 = 0.0296, wR2 = 0.0761 
Final R indexes [all data] R1 = 0.0308, wR2 = 0.0774 
Largest diff. peak/hole / e Å-3 0.22/-0.15 
Flack parameter -0.08(19) 
 
Table 99: Bond lengths [Å] for cis-145js. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C2 1.2190(18) C7 C18 1.3894(18) 
N1 N2 1.3637(16) C8 C9 1.533(2) 
N1 C6 1.4277(16) C8 C13 1.546(2) 
N1 C19 1.3601(17) C9 C10 1.5394(18) 
5 Experimental Part 
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Atom Atom Length/Å Atom Atom Length/Å 
N2 C21 1.3305(18) C10 C11 1.5307(18) 
C1 C2 1.501(2) C11 C12 1.5341(18) 
C2 C3 1.4988(18) C11 C14 1.5557(17) 
C3 C4 1.3937(18) C12 C13 1.528(2) 
C3 C18 1.4004(18) C14 C15 1.5342(18) 
C4 C5 1.3911(18) C14 C16 1.5357(19) 
C5 C6 1.3915(18) C14 C17 1.5319(19) 
C6 C7 1.4135(17) C19 C20 1.373(2) 
C7 C8 1.5241(18) C20 C21 1.407(2) 
 
Table 100: Bond angles [°] for cis-145js. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C6 120.79(11) C7 C8 C13 110.17(12) 
C19 N1 N2 112.21(11) C9 C8 C13 109.05(11) 
C19 N1 C6 126.99(12) C8 C9 C10 116.27(12) 
C21 N2 N1 103.96(12) C11 C10 C9 112.75(11) 
O1 C2 C1 120.92(13) C10 C11 C12 107.91(10) 
O1 C2 C3 120.01(13) C10 C11 C14 113.33(10) 
C3 C2 C1 119.07(12) C12 C11 C14 113.90(11) 
C4 C3 C2 122.61(12) C13 C12 C11 111.60(12) 
C4 C3 C18 119.37(12) C12 C13 C8 112.68(11) 
C18 C3 C2 118.01(12) C15 C14 C11 109.82(11) 
C5 C4 C3 119.40(12) C15 C14 C16 107.92(11) 
C4 C5 C6 120.13(12) C16 C14 C11 110.02(11) 
C5 C6 N1 117.22(11) C17 C14 C11 112.27(10) 
C5 C6 C7 121.87(11) C17 C14 C15 108.55(11) 
C7 C6 N1 120.91(11) C17 C14 C16 108.15(11) 
C6 C7 C8 121.26(11) C7 C18 C3 122.76(12) 
C18 C7 C6 116.18(12) N1 C19 C20 106.89(13) 
C18 C7 C8 122.48(11) C19 C20 C21 104.55(13) 
C7 C8 C9 116.23(12) N2 C21 C20 112.37(13) 




Figure 61: Molecular structure of trans-145js with thermal ellipsoids at 50% probability level. 
The hydrogen atoms are omitted for clarity. 
 
Crystal Data for C21H28N2O (M = 324.45 g/mol): triclinic, space group P-1 (no. 2), a = 5.9333(2) Å, 
b = 10.3005(3) Å, c = 16.2603(5) Å, α = 98.9640(10)°, β = 99.7430(10)°, γ = 91.3860(10)°, V = 
966.16(5) Å3, Z = 2, T = 300.0 K, μ(MoKα) = 0.068 mm-1, Dcalc = 1.115 g/cm3, 7889 reflections 
measured (5.104° ≤ 2Θ ≤ 55.832°), 7889 unique (Rint = ?, Rsigma = 0.0275) which were used in all 
calculations. The final R1 was 0.0670 (I > 2σ(I)) and wR2 was 0.1864 (all data). 
 
Table 101: Crystal data and structure refinement for trans-145js. 
Compound trans-145js 
CCDC number 2016735 
Identification code mo_1054_CG_0m_4 
Empirical formula C21H28N2O 
Formula weight 324.45 
Temperature/K 300.0 
Crystal system triclinic 















Crystal size/mm3 0.376 × 0.302 × 0.084 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.104 to 55.832 
Index ranges -7 ≤ h ≤ 7, -13 ≤ k ≤ 13, -21 ≤ l ≤ 21 
Reflections collected 7889 
Independent reflections 7889 [Rint = ?, Rsigma = 0.0275] 
Data/restraints/parameters 7889/0/222 
Goodness-of-fit on F2 1.074 
Final R indexes [I>=2σ (I)] R1 = 0.0670, wR2 = 0.1752 
Final R indexes [all data] R1 = 0.0850, wR2 = 0.1864 
Largest diff. peak/hole / e Å-3 0.27/-0.17 
 
Table 102: Bond lengths [Å] for trans-145js. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C2 1.189(4) C7 C18 1.384(3) 
N1 N2 1.343(3) C8 C9 1.514(3) 
N1 C6 1.427(3) C8 C13 1.517(3) 
N1 C19 1.351(3) C9 C10 1.527(3) 
N2 C21 1.333(4) C10 C11 1.528(3) 
C1 C2 1.484(4) C11 C12 1.519(3) 
C2 C3 1.490(3) C11 C14 1.560(2) 
C3 C4 1.390(3) C12 C13 1.527(3) 
C3 C18 1.385(3) C14 C15 1.531(3) 
C4 C5 1.371(3) C14 C16 1.521(3) 
C5 C6 1.387(3) C14 C17 1.536(3) 
C6 C7 1.396(3) C19 C20 1.353(4) 
5.3 Experimental Procedures and Analytical Data 
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Atom Atom Length/Å Atom Atom Length/Å 
C7 C8 1.518(2) C20 C21 1.368(5) 
 
Table 103: Bond angles [°] for trans-145js. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 N1 C6 120.08(18) C9 C8 C13 109.65(16) 
N2 N1 C19 112.0(2) C13 C8 C7 110.92(16) 
C19 N1 C6 127.9(2) C8 C9 C10 111.17(18) 
C21 N2 N1 103.2(3) C9 C10 C11 112.48(18) 
O1 C2 C1 119.8(3) C10 C11 C14 114.00(16) 
O1 C2 C3 120.8(3) C12 C11 C10 107.91(16) 
C1 C2 C3 119.4(3) C12 C11 C14 114.16(16) 
C4 C3 C2 122.1(2) C11 C12 C13 112.26(18) 
C18 C3 C2 118.7(2) C8 C13 C12 111.61(17) 
C18 C3 C4 119.1(2) C15 C14 C11 111.49(17) 
C5 C4 C3 119.49(19) C15 C14 C17 108.29(19) 
C4 C5 C6 120.5(2) C16 C14 C11 110.63(17) 
C5 C6 N1 118.02(18) C16 C14 C15 108.7(2) 
C5 C6 C7 121.44(19) C16 C14 C17 108.3(2) 
C7 C6 N1 120.52(17) C17 C14 C11 109.31(18) 
C6 C7 C8 122.51(17) C7 C18 C3 122.8(2) 
C18 C7 C6 116.55(17) N1 C19 C20 107.0(3) 
C18 C7 C8 120.80(17) C19 C20 C21 104.8(2) 
C9 C8 C7 113.61(17) N2 C21 C20 112.9(3) 
 




Figure 62: Molecular structure of 204 with thermal ellipsoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C19H23F6N6PRu (M = 581.47 g/mol): monoclinic, space group P21/n (no. 14), a = 
12.6946(6) Å, b = 12.8467(6) Å, c = 15.4440(9) Å, β = 96.350(2)°, V = 2503.2(2) Å3, Z = 4, T = 300 K, 
μ(MoKα) = 0.753 mm-1, Dcalc = 1.543 g/cm3, 54797 reflections measured (3.946° ≤ 2Θ ≤ 55.846°), 
5985 unique (Rint = 0.0233, Rsigma = 0.0138) which were used in all calculations. The final R1 was 
0.0299 (I > 2σ(I)) and wR2 was 0.0764 (all data). 
 
Table 104: Crystal data and structure refinement for 204. 
Compound 204 
CCDC number 2017186 
Identification code mo_1055_CG_0m 
Empirical formula C19H23F6N6PRu 
Formula weight 581.47 
Temperature/K 300 
Crystal system monoclinic 















Crystal size/mm3 0.369 × 0.338 × 0.128 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 3.946 to 55.846 
Index ranges -16 ≤ h ≤ 16, -16 ≤ k ≤ 16, -20 ≤ l ≤ 20 
Reflections collected 54797 
Independent reflections 5985 [Rint = 0.0233, Rsigma = 0.0138] 
Data/restraints/parameters 5985/6/359 
Goodness-of-fit on F2 1.187 
Final R indexes [I>=2σ (I)] R1 = 0.0299, wR2 = 0.0756 
Final R indexes [all data] R1 = 0.0314, wR2 = 0.0764 
Largest diff. peak/hole / e Å-3 0.37/-0.37 
 
Table 105: Selected bond lengths [Å] for 204. 
Atom Atom Length/Å Atom Atom Length/Å 
Ru1 N1 2.0616(18) C3 C4 1.383(4) 
Ru1 N3 2.0128(19) C4 C5 1.363(4) 
Ru1 N4 2.020(2) C5 C6 1.380(3) 
Ru1 N5 2.156(2) C7 C8 1.491(4) 
Ru1 N6 2.010(2) C8 C9 1.386(4) 
Ru1 C1 2.020(2) C9 C10 1.359(4) 
N1 N2 1.382(3) C10 C11 1.501(4) 
N1 C8 1.333(3) C12 C13 1.458(4) 
N2 C2 1.428(3) C14 C15 1.449(3) 
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Atom Atom Length/Å Atom Atom Length/Å 
N2 C10 1.359(3) C16 C17 1.449(4) 
N3 C12 1.127(3) C18 C19 1.463(4) 
N4 C14 1.133(3) P1B F1A 1.539(4) 
N5 C16 1.129(3) P1B F2A 1.571(4) 
N6 C18 1.123(3) P1B F3A 1.513(7) 
C1 C2 1.397(3) P1B F4A 1.542(4) 
C1 C6 1.400(3) P1B F5A 1.584(5) 
C2 C3 1.381(3) P1B F6A 1.557(6) 
 
Table 106: Selected bond angles [°] for 204. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N1 Ru1 N5 100.39(7) C10 C9 C8 108.1(2) 
N3 Ru1 N1 93.27(7) N2 C10 C11 124.8(3) 
N3 Ru1 N4 86.93(8) C9 C10 N2 106.5(2) 
N3 Ru1 N5 91.04(7) C9 C10 C11 128.7(3) 
N3 Ru1 C1 89.56(8) N3 C12 C13 178.7(3) 
N4 Ru1 N1 173.12(7) N4 C14 C15 178.6(3) 
N4 Ru1 N5 86.49(7) N5 C16 C17 179.3(3) 
N6 Ru1 N1 89.52(8) N6 C18 C19 178.9(4) 
N6 Ru1 N3 177.21(8) C2 C3 C4 118.8(2) 
N6 Ru1 N4 90.29(8) C5 C4 C3 120.3(2) 
N6 Ru1 N5 88.48(8) C4 C5 C6 120.2(2) 
N6 Ru1 C1 90.94(8) C5 C6 C1 122.1(2) 
C1 Ru1 N1 79.15(8) N1 C8 C7 122.5(2) 
C1 Ru1 N4 93.97(8) N1 C8 C9 109.1(2) 
C1 Ru1 N5 179.26(9) C9 C8 C7 128.5(2) 
N2 N1 Ru1 114.91(12) F1A P1B F2A 92.8(3) 
C8 N1 Ru1 138.28(17) F1A P1B F4A 90.4(4) 
C8 N1 N2 106.50(18) F1A P1B F5A 176.7(4) 
N1 N2 C2 115.17(17) F1A P1B F6A 80.3(4) 
C10 N2 N1 109.84(19) F2A P1B F5A 88.4(4) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C10 N2 C2 134.9(2) F3A P1B F1A 101.3(6) 
C12 N3 Ru1 173.41(19) F3A P1B F2A 89.9(5) 
C14 N4 Ru1 177.2(2) F3A P1B F4A 93.1(4) 
C16 N5 Ru1 173.7(2) F3A P1B F5A 81.7(5) 
C18 N6 Ru1 176.8(2) F3A P1B F6A 176.2(5) 
C2 C1 Ru1 116.00(15) F4A P1B F2A 175.1(5) 
C2 C1 C6 115.5(2) F4A P1B F5A 88.3(4) 
C6 C1 Ru1 128.49(17) F4A P1B F6A 90.4(4) 
C1 C2 N2 114.66(19) F6A P1B F2A 86.5(4) 
C3 C2 N2 122.3(2) F6A P1B F5A 96.7(5) 
C3 C2 C1 123.0(2)     
 
5.3.7 Photo-Induced Ruthenium-Catalyzed C–H Arylations at Room Temperature 
5.3.7.1 Characterization Data for 151 and 214 
2-(4'-Methoxy-3-methyl-[1,1'-biphenyl]-2-yl)pyridine (151a) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (46a, 176 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 7:1) yielded 151a (129 mg, 94%) as a viscous colorless 
oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.46 (ddd, J = 7.8, 7.7, 1.9 Hz, 
1H), 7.34 (dd, J = 7.6, 7.5 Hz, 1H), 7.28–7.23 (m, 2H), 7.09 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.99 (d, J 
= 8.8 Hz, 2H), 6.88 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 6.68 (d, J = 8.8 Hz, 2H), 3.73 (s, 3H), 2.17 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.8 (Cq), 158.0 (Cq), 148.9 (CH), 140.8 (Cq), 139.3 (Cq), 136.7 (Cq), 
135.7 (CH), 134.1 (Cq), 130.7 (CH), 129.0 (CH), 128.0 (CH), 127.6 (CH), 125.6 (CH), 121.2 (CH), 113.1 
(CH), 55.1 (CH3), 20.5 (CH3). 
IR (ATR): ṽ = 2954, 2835, 1609, 1585, 1511, 1458, 1244, 1178, 1029, 748 cm−1.  
MS (EI) m/z (relative intensity): 275 (48) [M]+, 274 (100) [M–H]+, 260 (24) [M–Me]+, 231 (20). 
5 Experimental Part 
 
422 
HR-MS (ESI): m/z calcd for C19H18NO+ [M+H]+ 276.1383, found 276.1381. 
The spectral data are in accordance with those reported in the literature.[41] 
 
2-(3,3'-Dimethyl-[1,1'-biphenyl]-2-yl)pyridine (151g) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 1-iodo-3-methylbenzene (46g, 164 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 15:1) yielded 151g (114 mg, 88%) as a viscous colorless 
oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.45 (ddd, J = 7.8, 7.7, 1.9 Hz, 
1H), 7.35 (dd, J = 7.6, 7.5 Hz, 1H), 7.30–7.25 (m, 2H), 7.09 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 7.03–6.98 
(m, 1H), 6.94–6.91 (m, 2H), 6.89 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 6.87–6.83 (m, 1H), 2.20 (s, 3H), 2.19 
(s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.7 (Cq), 148.7 (CH), 141.5 (Cq), 141.3 (Cq), 139.3 (Cq), 137.1 (Cq), 
136.6 (Cq), 135.6 (CH), 130.5 (CH), 129.3 (CH), 128.0 (CH), 127.5 (CH), 127.4 (CH), 126.9 (CH), 126.7 
(CH), 125.6 (CH), 121.2 (CH), 21.2 (CH3), 20.5 (CH3). 
IR (ATR): ṽ = 3058, 2920, 1584, 1562, 1459, 1423, 1024, 776, 746, 705 cm−1.  
MS (ESI) m/z (relative intensity): 282 (52) [M+Na]+, 260 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C19H18N+ [M+H]+ 260.1434, found 260.1428. 
The spectral data are in accordance with those reported in the literature.[143] 
 
2-(3'-Methoxy-3-methyl-[1,1'-biphenyl]-2-yl)pyridine (151h) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 1-iodo-3-methoxybenzene (46h, 176 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 7:1) yielded 151h (114 mg, 82%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.46 (ddd, J = 7.7, 7.6, 1.9 Hz, 
1H), 7.36 (dd, J = 7.9, 7.1 Hz, 1H), 7.31–7.27 (m, 2H), 7.10 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 7.07 (dd, J 
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= 8.2, 7.6 Hz, 1H), 6.90 (ddd, J = 7.7, 1.2, 1.1 Hz, 1H), 6.72 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 6.67 (ddd, 
J = 8.2, 2.6, 1.0 Hz, 1H), 6.59 (dd, J = 2.6, 1.6 Hz, 1H), 3.59 (s, 3H), 2.19 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.7 (Cq), 158.7 (Cq), 148.7 (CH), 143.0 (Cq), 141.0 (Cq), 139.2 (Cq), 
136.7 (Cq), 135.8 (CH), 129.5 (CH), 128.6 (CH), 128.0 (CH), 127.4 (CH), 125.6 (CH), 122.0 (CH), 121.3 
(CH), 114.6 (CH), 112.8 (CH), 55.0 (CH3), 20.4 (CH3). 
IR (ATR): ṽ = 2955, 1576, 1463, 1413, 1226, 1039, 778, 747, 702 cm−1.  
MS (EI) m/z (relative intensity): 275 (41) [M]+, 274 (100) [M–H]+, 258 (20), 231 (15). 
HR-MS (ESI): m/z calcd for C19H17NONa+ [M+Na]+ 298.1202, found 298.1207. 
The spectral data are in accordance with those reported in the literature.[143] 
 
2-(3'-Fluoro-3-methyl-[1,1'-biphenyl]-2-yl)pyridine (151i) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 1-fluoro-3-iodobenzene (46i, 167 mg, 0.75 mmol). 
After 24 h, purification by column chromatography (n-hexane/EtOAc 15:1) 
yielded 151i (73.3 mg, 56%) as a viscous colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.8, 1.1 Hz, 1H), 7.48 (ddd, J = 7.8, 7.7, 1.8 Hz, 
1H), 7.37 (dd, J = 7.6, 7.5 Hz, 1H), 7.31 (ddd, J = 7.6, 1.6, 0.8 Hz, 1H), 7.27–7.23 (m, 1H), 7.12 (ddd, 
J = 7.7, 4.9, 1.2 Hz, 1H), 7.11–7.04 (m, 1H), 6.91 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 6.85–6.78 (m, 3H), 
2.18 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 162.2 (d, 1JC–F = 245 Hz, Cq), 159.2 (Cq), 149.0 (CH), 143.9 (d, 3JC–F = 
8 Hz, Cq), 140.0 (d, 4JC–F = 2 Hz, Cq), 139.3 (Cq), 136.8 (Cq), 135.8 (CH), 129.8 (CH), 128.9 (d, 3JC–F = 
8 Hz, CH), 128.1 (CH), 127.4 (CH), 125.5 (CH), 125.4 (d, 4JC–F = 3 Hz, CH), 121.5 (CH), 116.5 (d, 2JC–F 
= 22 Hz, CH), 113.1 (d, 2JC–F = 21 Hz, CH), 20.4 (CH3). 
19F-NMR (376 MHz, CDCl3): δ = (–114.1)–(–114.2) (m). 
IR (ATR): ṽ = 3061, 1611, 1577, 1461, 1416, 1194, 1156, 874, 779, 699 cm−1.  
MS (ESI) m/z (relative intensity): 286 (67) [M+Na]+, 264 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C18H15FN+ [M+H]+ 264.1183, found 264.1184. 
The spectral data are in accordance with those reported in the literature.[143] 




The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 1-iodo-3-(trifluoromethyl)benzene (46j, 204 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 15:1) yielded 151j (80.2 mg, 51%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.48 (ddd, J = 7.8, 7.7, 1.8 Hz, 
1H), 7.41–7.31 (m, 4H), 7.30–7.22 (m, 3H), 7.11 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.89 (ddd, J = 7.8, 
1.2, 1.0 Hz, 1H), 2.20 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.0 (Cq), 149.1 (CH), 142.3 (Cq), 139.7 (Cq), 139.4 (Cq), 136.9 (Cq), 
135.9 (CH), 132.8 (CH), 130.0 (CH), 129.9 (q, 2JC–F = 32 Hz, Cq), 128.2 (CH), 128.0 (CH), 127.3 (CH), 
126.5 (q, 3JC–F = 4 Hz, CH), 125.5 (CH), 124.0 (q, 1JC–F = 272 Hz, Cq), 122.9 (q, 3JC–F = 4 Hz, CH), 121.5 
(CH), 20.4 (CH3). 
19F-NMR (376 MHz, CDCl3): δ = –62.8 (s). 
IR (ATR): ṽ = 3063, 1585, 1430, 1333, 1271, 1162, 1119, 1070, 783, 748 cm−1.  
MS (ESI) m/z (relative intensity): 336 (100) [M+Na]+, 314 (98) [M+H]+. 
HR-MS (ESI): m/z calcd for C19H14F3NNa+ [M+Na]+ 336.0971, found 336.0976. 
The spectral data are in accordance with those reported in the literature.[144] 
 
1-[3'-Methyl-2'-(pyridin-2-yl)-[1,1'-biphenyl]-3-yl]ethan-1-one (151k) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 1-(3-iodophenyl)ethan-1-one (46k, 185 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 3:1) yielded 151k (99.0 mg, 69%) as a yellow oil. 
1H-NMR (500 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.73 (ddd, J = 7.7, 1.6, 1.5 Hz, 
1H), 7.64 (dd, J = 1.6, 1.6 Hz, 1H), 7.46 (ddd, J = 7.8, 7.7, 1.9 Hz, 1H), 7.39 (dd, J = 7.6, 7.6 Hz, 1H), 
7.35–7.31 (m, 2H), 7.29 (ddd, J = 7.6, 1.5, 0.7 Hz, 1H), 7.25 (ddd, J = 7.7, 7.7, 0.5 Hz, 1H), 7.11 (ddd, 
J = 7.7, 4.9, 1.2 Hz, 1H), 6.90 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 2.41 (s, 3H), 2.19 (s, 3H). 
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13C-NMR (125 MHz, CDCl3): δ = 198.0 (Cq), 159.3 (Cq), 149.0 (CH), 141.9 (Cq), 140.1 (Cq), 139.3 (Cq), 
136.9 (Cq), 136.4 (Cq), 136.0 (CH), 134.1 (CH), 130.2 (CH), 129.9 (CH), 128.3 (CH), 128.0 (CH), 127.4 
(CH), 125.9 (CH), 125.6 (CH), 121.5 (CH), 26.6 (CH3), 20.4 (CH3). 
IR (ATR): ṽ = 3060, 1681, 1584, 1562, 1425, 1357, 1242, 782, 749, 698 cm−1.  
MS (EI) m/z (relative intensity): 287 (39) [M]+, 286 (100) [M–H]+, 244 (30) [M–Ac]+. 
HR-MS (ESI): m/z calcd for C20H18NO+ [M+H]+ 288.1383, found 288.1385. 
 
3'-Methyl-2'-(pyridin-2-yl)-[1,1'-biphenyl]-3-carbonitrile (151l) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 3-iodobenzonitrile (46l, 172 mg, 0.75 mmol) in 
DMA (2.0 mL). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 4:1) yielded 151l (68.0 mg, 50%) as a white solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.51 (ddd, J = 7.8, 7.7, 1.8 Hz, 
1H), 7.42–7.36 (m, 3H), 7.34 (ddd, J = 7.7, 1.6, 0.8 Hz, 1H), 7.29 (ddd, J = 7.9, 1.5, 1.5 Hz, 1H), 7.24–
7.19 (m, 2H), 7.13 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.91 (ddd, J = 7.8, 1.2, 1.0 Hz, 1H), 2.18 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 158.7 (Cq), 149.2 (CH), 142.9 (Cq), 139.3 (Cq), 138.9 (Cq), 137.0 (Cq), 
135.9 (CH), 134.0 (CH), 132.9 (CH), 130.3 (CH), 129.9 (CH), 128.4 (CH), 128.3 (CH), 127.2 (CH), 125.5 
(CH), 121.7 (CH), 118.7 (Cq), 111.8 (Cq), 20.4 (CH3). 
IR (ATR): ṽ = 2924, 2225, 1585, 1456, 1422, 1149, 1025, 785, 754, 699 cm−1.  
m.p.: 97–99 °C. 
MS (ESI) m/z (relative intensity): 563 (5) [2M+Na]+, 293 (100) [M+Na]+, 271 (74) [M+H]+. 
HR-MS (ESI): m/z calcd for C19H14N2Na+ [M+Na]+ 293.1049, found 293.1051. 
 
2-(2'-Methoxy-3-methyl-[1,1'-biphenyl]-2-yl)pyridine (151m) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 84.6 mg, 
0.50 mmol) and 1-iodo-2-methoxybenzene (46m, 176 mg, 0.75 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc 6:1) yielded 
151m (60.5 mg, 44%) as a light yellow oil. 
5 Experimental Part 
 
426 
1H-NMR (400 MHz, CDCl3): δ = 8.55 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.40 (ddd, J = 7.8, 7.7, 1.9 Hz, 
1H), 7.34 (dd, J = 7.6, 7.5 Hz, 1H), 7.29 (ddd, J = 7.6, 1.7, 0.7 Hz, 1H), 7.21 (ddd, J = 7.5, 1.7, 0.7 Hz, 
1H), 7.13 (ddd, J = 8.2, 7.4, 1.8 Hz, 1H), 7.05–7.01 (m, 1H), 7.01 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.94 
(d, J = 7.8 Hz, 1H), 6.78 (dd, J = 7.4, 7.4 Hz, 1H), 6.67 (d, J = 8.2 Hz, 1H), 3.54 (s, 3H), 2.22 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.5 (Cq), 156.2 (Cq), 148.4 (CH), 140.1 (Cq), 137.9 (Cq), 136.2 (Cq), 
135.0 (CH), 131.8 (CH), 130.5 (Cq), 129.5 (CH), 128.2 (CH), 128.1 (CH), 127.6 (CH), 124.8 (CH), 121.0 
(CH), 119.9 (CH), 110.1 (CH), 55.1 (CH3), 20.5 (CH3). 
IR (ATR): ṽ = 2930, 1583, 1496, 1462, 1419, 1238, 1126, 1024, 787, 745 cm−1.  
MS (ESI) m/z (relative intensity): 573 (27) [2M+Na]+, 298 (100) [M+Na]+, 276 (96) [M+H]+. 
HR-MS (ESI): m/z calcd for C19H17NONa+ [M+Na]+ 298.1202, found 298.1204. 
 
2-(3,3',5'-Trimethyl-[1,1'-biphenyl]-2-yl)pyridine (151n) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (46n, 174 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 15:1) yielded 151n (126 mg, 92%) as a white solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.8, 1.1 Hz, 1H), 7.46 (ddd, J = 7.8, 7.6, 1.8 Hz, 
1H), 7.34 (dd, J = 8.3, 6.7 Hz, 1H), 7.29–7.24 (m, 2H), 7.09 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 6.90 (ddd, 
J = 7.8, 1.2, 1.1 Hz, 1H), 6.76–6.74 (m, 1H), 6.70–6.68 (m, 2H), 2.18 (s, 3H), 2.15–2.14 (m, 6H). 
13C-NMR (100 MHz, CDCl3): δ = 159.8 (Cq), 148.6 (CH), 141.4 (Cq), 141.4 (Cq), 139.3 (Cq), 136.9 (Cq), 
136.6 (Cq), 135.6 (CH), 129.2 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 127.5 (CH), 125.6 (CH), 121.1 
(CH), 21.1 (CH3), 20.5 (CH3). 
IR (ATR): ṽ = 2917, 1583, 1562, 1460, 1426, 1025, 851, 784, 748, 704 cm−1.  
m.p.: 55–57 °C. 
MS (ESI) m/z (relative intensity): 569 (20) [2M+Na]+, 296 (100) [M+Na]+, 274 (90) [M+H]+. 
HR-MS (ESI): m/z calcd for C20H19NNa+ [M+Na]+ 296.1410, found 296.1412. 
The spectral data are in accordance with those reported in the literature.[46] 
 




The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 5-iodo-1H-indole (46o, 182 mg, 0.75 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc 2:1) yielded 
151o (128 mg, 90%) as a white solid. 
1H-NMR (400 MHz, DMSO-d6): δ = 10.96 (s, 1H), 8.58 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.50 (ddd, J = 
7.8, 7.7, 1.9 Hz, 1H), 7.36 (dd, J = 8.3, 6.8 Hz, 1H), 7.29–7.24 (m, 4H), 7.15 (ddd, J = 7.7, 4.9, 1.2 Hz, 
1H), 7.11 (ddd, J = 8.4, 0.9, 0.9 Hz, 1H), 6.89 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 6.69 (dd, J = 8.4, 1.7 Hz, 
1H), 6.28 (ddd, J = 3.0, 1.9, 0.9 Hz, 1H), 2.06 (s, 3H). 
13C-NMR (100 MHz, DMSO-d6): δ = 159.5 (Cq), 148.6 (CH), 142.0 (Cq), 139.5 (Cq), 135.9 (Cq), 135.8 
(CH), 134.4 (Cq), 132.0 (Cq), 128.2 (CH), 127.9 (CH), 127.7 (CH), 127.3 (Cq), 125.5 (CH), 125.3 (CH), 
122.9 (CH), 121.4 (CH), 120.7 (CH), 110.4 (CH), 101.2 (CH), 20.3 (CH3). 
IR (ATR): ṽ = 3137, 1592, 1454, 1420, 1316, 888, 766, 730 cm−1.  
m.p.: 189–191 °C. 
MS (ESI) m/z (relative intensity): 307 (15) [M+Na]+, 285 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C20H17N2+ [M+H]+ 285.1386, found 285.1388. 
 
2-(3',4'-Dimethoxy-3-methyl-[1,1'-biphenyl]-2-yl)pyridine (151p) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 4-iodo-1,2-dimethoxybenzene (46p, 198 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 3:1) yielded 151p (118 mg, 77%) as a white solid. 
1H-NMR (500 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.8, 1.1 Hz, 1H), 7.47 (ddd, J = 7.8, 7.7, 1.8 Hz, 
1H), 7.35 (dd, J = 7.6, 7.5 Hz, 1H), 7.30–7.26 (m, 2H), 7.11 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.88 (ddd, 
J = 7.8, 1.2, 1.1 Hz, 1H), 6.77 (dABd, J = 8.2, 2.0 Hz, 1H), 6.72 (dAB, J = 8.2 Hz, 1H), 6.48 (d, J = 2.0 Hz, 
1H), 3.82 (s, 3H), 3.56 (s, 3H), 2.17 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 160.0 (Cq), 148.7 (CH), 147.7 (Cq), 147.4 (Cq), 140.8 (Cq), 139.2 (Cq), 
136.7 (Cq), 136.0 (CH), 134.3 (Cq), 129.2 (CH), 128.1 (CH), 127.4 (CH), 125.6 (CH), 121.5 (CH), 121.3 
(CH), 113.3 (CH), 110.4 (CH), 55.7 (CH3), 55.5 (CH3), 20.4 (CH3). 
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IR (ATR): ṽ = 2933, 1584, 1512, 1462, 1247, 1138, 1024, 788, 748 cm−1.  
m.p.: 90–92 °C. 
MS (ESI) m/z (relative intensity): 633 (17) [2M+Na]+, 328 (100) [M+Na]+, 306 (79) [M+H]+. 
HR-MS (ESI): m/z calcd for C20H19NO2Na+ [M+Na]+ 328.1308, found 328.1308. 
 
2-[2-(Benzo[d][1,3]dioxol-5-yl)-6-methylphenyl]pyridine (151q) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 5-iodobenzo[d][1,3]dioxole (46q, 186 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 7:1) yielded 151q (102 mg, 70%) as a viscous colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.50 (ddd, J = 7.8, 7.7, 1.9 Hz, 
1H), 7.33 (dd, J = 7.6, 7.5 Hz, 1H), 7.27 (ddd, J = 7.6, 1.5, 0.7 Hz, 1H), 7.23 (ddd, J = 7.5, 1.5, 0.7 Hz, 
1H), 7.11 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.92 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 6.59 (dd, J = 6.3, 0.5 Hz, 
1H), 6.58 (s, 1H), 6.54–6.51 (m, 1H), 5.86 (s, 2H), 2.16 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.6 (Cq), 148.9 (CH), 146.9 (Cq), 146.0 (Cq), 140.8 (Cq), 139.3 (Cq), 
136.7 (Cq), 135.8 (CH), 135.7 (Cq), 129.2 (CH), 128.0 (CH), 127.5 (CH), 125.5 (CH), 123.2 (CH), 121.3 
(CH), 110.1 (CH), 107.6 (CH), 100.7 (CH2), 20.5 (CH3). 
IR (ATR): ṽ = 2892, 1584, 1459, 1337, 1223, 1036, 936, 784, 748, 638 cm−1.  
MS (ESI) m/z (relative intensity): 601 (5) [2M+Na]+, 312 (100) [M+Na]+, 290 (98) [M+H]+. 
HR-MS (ESI): m/z calcd for C19H15NO2Na+ [M+Na]+ 312.0995, found 312.0999. 
 
2,3,3-Trimethyl-5-[3-methyl-2-(pyridin-2-yl)phenyl]-3H-indole (151r) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 5-iodo-2,3,3-trimethyl-3H-indole (46r, 
214 mg, 0.75 mmol). After 24 h, purification by column 
chromatography (n-hexane/EtOAc 1:1) yielded 151r (83.7 mg, 51%) as 
a viscous dark yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.38–7.33 (m, 2H), 7.37 (ddd, J = 
7.8, 7.7, 1.9 Hz, 1H), 7.33–7.30 (m, 1H), 7.29 (ddd, J = 7.1, 1.7, 0.7 Hz, 1H), 7.17 (dd, J = 7.9, 1.8 Hz, 
5.3 Experimental Procedures and Analytical Data 
 
429 
1H), 7.04 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.82 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 6.77 (dd, J = 1.8, 0.6 Hz, 
1H), 2.20 (s, 6H), 1.03 (s, 6H). 
13C-NMR (100 MHz, CDCl3): δ = 187.9 (Cq), 159.9 (Cq), 151.9 (Cq), 148.6 (CH), 144.8 (Cq), 141.3 (Cq), 
139.4 (Cq), 138.6 (Cq), 136.7 (Cq), 135.7 (CH), 129.3 (CH), 128.6 (CH), 128.0 (CH), 127.4 (CH), 125.7 
(CH), 123.3 (CH), 121.1 (CH), 119.0 (CH), 53.2 (Cq), 22.9 (CH3), 20.4 (CH3), 15.4 (CH3). 
IR (ATR): ṽ = 2961, 1577, 1456, 1426, 1204, 1025, 834, 791, 749, 733 cm−1.  
MS (ESI) m/z (relative intensity): 675 (49) [2M+Na]+, 653 (17) [2M+H]+, 349 (47) [M+Na]+, 327 (100) 
[M+H]+. 




The general procedure N was followed using 2-(o-tolyl)pyridine 
(68e, 84.6 mg, 0.50 mmol) and (1R,2S,5R)-2-iso-propyl-5-
methylcyclohexyl 4-iodobenzoate (46s, 290 mg, 0.75 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc 
10:1) yielded 151s (94.6 mg, 44%) as a viscous colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.8, 1.1 Hz, 1H), 7.81 (d, J = 8.6 Hz, 2H), 7.47 (ddd, 
J = 7.8, 7.7, 1.8 Hz, 1H), 7.37 (dd, J = 7.6, 7.5 Hz, 1H), 7.32 (ddd, J = 7.6, 1.6, 0.8 Hz, 1H), 7.26 (ddd, 
J = 7.5, 1.6, 0.8 Hz, 1H), 7.15 (d, J = 8.6 Hz, 2H), 7.12 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 6.90 (ddd, J = 
7.8, 1.2, 1.1 Hz, 1H), 4.89 (ddd, J = 10.9, 10.9, 4.2 Hz, 1H), 2.19 (s, 3H), 2.09 (dddd, J = 12.1, 4.2, 
3.9, 1.6 Hz, 1H), 1.93 (heptd, J = 7.0, 2.7 Hz, 1H), 1.75–1.67 (m, 2H), 1.60–1.46 (m, 2H), 1.17–1.00 
(m, 2H), 0.97–0.84 (m, 1H), 0.91 (d, J = 6.6 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H), 0.77 (d, J = 7.0 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 166.0 (Cq), 159.1 (Cq), 149.0 (CH), 146.3 (Cq), 140.2 (Cq), 139.2 (Cq), 
136.9 (Cq), 135.9 (CH), 130.0 (CH), 129.5 (CH), 128.9 (CH), 128.6 (Cq), 128.1 (CH), 127.4 (CH), 125.5 
(CH), 121.5 (CH), 74.7 (CH), 47.2 (CH), 40.9 (CH2), 34.3 (CH2), 31.4 (CH), 26.4 (CH), 23.5 (CH2), 22.0 
(CH3), 20.8 (CH3), 20.4 (CH3), 16.4 (CH3). 
IR (ATR): ṽ = 2954, 2868, 1707, 1457, 1267, 1178, 1099, 767, 735, 702 cm−1.  
MS (ESI) m/z (relative intensity): 878 (24) [2M+Na]+, 856 (3) [2M+H]+, 450 (100) [M+Na]+, 428 (87) 
[M+H]+. 
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HR-MS (ESI): m/z calcd for C29H33NO2Na+ [M+Na]+ 450.2404, found 450.2407. 
 
9-[3'-Methyl-2'-(pyridin-2-yl)-[1,1'-biphenyl]-4-yl]-9H-carbazole (151t) 
The general procedure N was followed using 2-(o-tolyl)pyridine (68e, 
84.6 mg, 0.50 mmol) and 9-(4-iodophenyl)-9H-carbazole (46t, 
277 mg, 0.75 mmol). After 24 h, purification by column 
chromatography (n-hexane/EtOAc 7:1) yielded 151t (182 mg, 88%) as 
a white solid. 
1H-NMR (500 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 1.8, 1.1 Hz, 1H), 8.13 (ddd, J = 7.8, 1.0, 1.0 Hz, 
2H), 7.56 (ddd, J = 7.8, 7.7, 1.8 Hz, 1H), 7.44 (dd, J = 7.5, 7.4 Hz, 1H), 7.42–7.26 (m, 12H), 7.17 (ddd, 
J = 7.7, 4.9, 1.2 Hz, 1H), 7.02 (ddd, J = 7.8, 1.2, 1.1 Hz, 1H), 2.26 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 159.4 (Cq), 149.0 (CH), 140.9 (Cq), 140.7 (Cq), 140.4 (Cq), 139.5 (Cq), 
136.9 (Cq), 135.7 (CH), 135.7 (Cq), 131.0 (CH), 129.8 (CH), 128.2 (CH), 127.4 (CH), 126.1 (CH), 125.8 
(CH), 125.7 (CH), 123.3 (Cq), 121.5 (CH), 120.2 (CH), 119.8 (CH), 109.7 (CH), 20.5 (CH3). 
IR (ATR): ṽ = 3023, 1582, 1515, 1451, 1316, 1229, 841, 742, 719 cm−1.  
m.p.: 178–180 °C. 
MS (ESI) m/z (relative intensity): 843 (38) [2M+Na]+, 821 (4) [2M+H]+, 433 (57) [M+Na]+, 411 (100) 
[M+H]+. 
HR-MS (ESI): m/z calcd for C30H23N2+ [M+H]+ 411.1856, found 411.1858. 
 
2,7-Bis[3-methyl-2-(pyridin-2-yl)phenyl]-9H-fluorene (216a) 
The general procedure N was followed using 2-(o-tolyl)pyridine 
(68e, 186 mg, 1.10 mmol), 2,7-diiodo-9H-fluorene (215a, 
209 mg, 0.50 mmol) and K2CO3 (276 mg, 2.00 mmol). After 24 h, 
purification by column chromatography (n-hexane/EtOAc 2:1) 
yielded 216a (189 mg, 75%) as a pale yellow solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 5.0, 1.9, 1.0 Hz, 2H), 7.44 (dd, J = 8.0, 0.8 Hz, 2H), 7.41 
(ddd, J = 7.8, 7.7, 1.9 Hz, 2H), 7.37 (dd, J = 7.8, 7.2 Hz, 2H), 7.33–7.28 (m, 4H), 7.22 (dd, J = 1.7, 
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0.8 Hz, 2H), 7.06 (ddd, J = 7.7, 5.0, 1.2 Hz, 2H), 7.03 (dd, J = 8.0, 1.7 Hz, 2H), 6.90 (ddd, J = 7.8, 1.2, 
1.0 Hz, 2H), 3.60 (s, 2H), 2.19 (s, 6H). 
13C-NMR (100 MHz, CDCl3): δ = 159.7 (Cq), 148.8 (CH), 142.9 (Cq), 141.4 (Cq), 140.2 (Cq), 139.5 (Cq), 
139.4 (Cq), 136.7 (Cq), 135.7 (CH), 129.3 (CH), 128.4 (CH), 128.0 (CH), 127.6 (CH), 126.2 (CH), 125.6 
(CH), 121.2 (CH), 118.9 (CH), 36.7 (CH2), 20.5 (CH3). 
IR (ATR): ṽ = 2920, 1584, 1562, 1455, 1411, 1275, 1024, 826, 785, 746 cm−1.  
m.p.: 175–177 °C. 
MS (ESI) m/z (relative intensity): 1024 (30) [2M+Na]+, 1002 (48) [2M+H]+, 523 (29) [M+Na]+, 501 
(100) [M+H]+. 
HR-MS (ESI): m/z calcd for C37H29N2+ [M+H]+ 501.2325, found 501.2328. 
 
3,6-Bis[3-methyl-2-(pyridin-2-yl)phenyl]-9H-carbazole (216b) 
The general procedure N was followed using 2-(o-tolyl)pyridine 
(68e, 186 mg, 1.10 mmol), 3,6-diiodo-9H-carbazole (215b, 
210 mg, 0.50 mmol) and K2CO3 (276 mg, 2.00 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc 
1:1) yielded 216b (238 mg, 95%) as a white solid. 
1H-NMR (500 MHz, CDCl3): δ = 8.63 (ddd, J = 5.0, 1.9, 1.1 Hz, 2H), 8.39 (s, 1H), 7.73–7.71 (m, 2H), 
7.38 (dd, J = 7.5, 7.3 Hz, 2H), 7.37–7.34 (m, 2H), 7.35 (ddd, J = 7.7, 7.6, 1.9 Hz, 2H), 7.30 (ddd, J = 
7.3, 1.8, 0.8 Hz, 2H), 7.01 (ddd, J = 7.6, 5.0, 1.2 Hz, 2H), 6.98 (dABd, J = 8.4, 1.6 Hz, 2H), 6.96 (dABd, 
J = 8.4, 0.8 Hz, 2H), 6.89 (ddd, J = 7.7, 1.2, 1.1 Hz, 2H), 2.20 (s, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 159.9 (Cq), 148.7 (CH), 141.9 (Cq), 139.5 (Cq), 138.4 (Cq), 136.6 (Cq), 
135.7 (CH), 132.9 (Cq), 128.9 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 125.7 (CH), 122.9 (Cq), 121.1 
(CH), 121.0 (CH), 109.6 (CH), 20.6 (CH3). 
IR (ATR): ṽ = 3411, 3023, 1585, 1455, 1287, 1235, 1025, 784, 746, 618 cm−1.  
m.p.: 256–257 °C. 
MS (ESI) m/z (relative intensity): 1003 (17) [2M+H]+, 524 (37) [M+Na]+, 502 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C36H28N3+ [M+H]+ 502.2278, found 502.2279. 
 




The general procedure N was followed using 2-(o-tolyl)pyridine 
(68e, 279 mg, 1.65 mmol), tris(4-iodophenyl)amine (215c, 
312 mg, 0.50 mmol) and K2CO3 (415 mg, 3.00 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc 
1:1) yielded 216c (323 mg, 86%) as a off-white solid. 
1H-NMR (500 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 1.9, 1.1 Hz, 
3H), 7.47 (ddd, J = 7.8, 7.7, 1.9 Hz, 3H), 7.35 (dd, J = 8.4, 6.7 Hz, 
3H), 7.29–7.26 (m, 6H), 7.11 (ddd, J = 7.7, 4.9, 1.2 Hz, 3H), 6.89 (ddd, J = 7.8, 1.2, 1.1 Hz, 3H), 6.86 
(d, J = 8.6 Hz, 6H), 6.67 (d, J = 8.6 Hz, 6H), 2.19 (s, 9H). 
13C-NMR (125 MHz, CDCl3): δ = 159.7 (Cq), 148.7 (CH), 145.5 (Cq), 140.9 (Cq), 139.3 (Cq), 136.6 (Cq), 
135.9 (Cq), 135.5 (CH), 130.3 (CH), 129.2 (CH), 128.0 (CH), 127.2 (CH), 125.7 (CH), 122.9 (CH), 121.2 
(CH), 20.5 (CH3). 
IR (ATR): ṽ = 3028, 1584, 1506, 1458, 1318, 1269, 834, 785, 746, 580 cm−1.  
m.p.: >190 °C (decomp.). 
MS (ESI) m/z (relative intensity): 747 (80) [M+H]+, 374 (100) [M+2H]2+. 
HR-MS (ESI): m/z calcd for C54H43N4+ [M+H]+ 747.3482, found 747.3486. 
 
2-(3,4'-Dimethoxy-[1,1'-biphenyl]-2-yl)pyridine (151u) 
The general procedure N was followed using 2-(2-
methoxyphenyl)pyridine (68f, 92.7 mg, 0.50 mmol) and 1-iodo-4-
methoxybenzene (46a, 176 mg, 0.75 mmol). After 24 h, purification by 
column chromatography (n-hexane/EtOAc 2:1) yielded 151u (125 mg, 
86%) as a white solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.49 (ddd, J = 7.8, 7.7, 1.9 Hz, 
1H), 7.40 (dd, J = 8.3, 7.8 Hz, 1H), 7.08 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 7.04 (dd, J = 7.8, 1.0 Hz, 1H), 
7.02 (ddd, J = 7.8, 1.2, 1.0 Hz, 1H), 7.01 (d, J = 8.9 Hz, 2H), 6.98 (dd, J = 8.3, 1.0 Hz, 1H), 6.68 (d, J = 
8.9 Hz, 2H), 3.77 (s, 3H), 3.72 (s, 3H). 
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13C-NMR (100 MHz, CDCl3): δ = 158.1 (Cq), 157.2 (Cq), 157.0 (Cq), 148.8 (CH), 142.3 (Cq), 135.4 (CH), 
133.4 (Cq), 130.5 (CH), 129.0 (CH), 129.0 (Cq), 126.2 (CH), 122.4 (CH), 121.2 (CH), 113.0 (CH), 109.6 
(CH), 55.9 (CH3), 55.0 (CH3). 
IR (ATR): ṽ = 2935, 2835, 1586, 1514, 1463, 1242, 1174, 1121, 1021, 733 cm−1. 
m.p.: 111–112 °C.  
MS (ESI) m/z (relative intensity): 314 (16) [M+Na]+, 292 (100) [M+H]+, 236 (12). 
HR-MS (ESI): m/z calcd for C19H18NO2+ [M+H]+ 292.1332, found 292.1336. 
The spectral data are in accordance with those reported in the literature.[43] 
 
2-[4'-Methoxy-3-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]pyridine (151v) 
The general procedure N was followed using 2-[2-
(trifluoromethyl)phenyl]pyridine (68g, 112 mg, 0.50 mmol) and 1-iodo-4-
methoxybenzene (46a, 176 mg, 0.75 mmol). After 24 h, purification by 
column chromatography (n-hexane/EtOAc 10:1) yielded 151v (161 mg, 
97%) as a white solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.57 (ddd, J = 4.9, 1.8, 1.1 Hz, 1H), 7.78–7.74 (m, 1H), 7.60–7.52 (m, 
2H), 7.49 (ddd, J = 7.8, 7.7, 1.8 Hz, 1H), 7.12 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 7.02 (ddd, J = 7.8, 1.2, 
1.1 Hz, 1H), 6.97 (d, J = 8.9 Hz, 2H), 6.68 (d, J = 8.9 Hz, 2H), 3.73 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 158.4 (Cq), 156.8 (Cq), 148.4 (CH), 142.9 (Cq), 138.3 (q, 3JC–F = 2 Hz, 
Cq), 135.3 (CH), 133.6 (CH), 132.4 (Cq), 130.7 (CH), 129.2 (q, 2JC–F = 30 Hz, Cq), 128.2 (CH), 125.6 (q, 
5JC–F = 2 Hz, CH), 124.9 (q, 3JC–F = 5 Hz, CH), 124.0 (q, 1JC–F = 274 Hz, Cq), 122.0 (CH), 113.2 (CH), 55.1 
(CH3). 
19F-NMR (376 MHz, CDCl3): δ = –57.1 (s). 
IR (ATR): ṽ = 2934, 1609, 1517, 1445, 1323, 1247, 1166, 1119, 1025, 748 cm−1. 
m.p.: 83–85 °C.  
MS (ESI) m/z (relative intensity): 681 (3) [2M+Na]+, 352 (22) [M+Na]+, 330 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C19H15F3NO+ [M+H]+ 330.1100, found 330.1114. 
The spectral data are in accordance with those reported in the literature.[43] 




The general procedure N was followed using 2-(2,3-dimethylphenyl)-5-
methylpyridine (68h, 98.7 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene 
(46a, 176 mg, 0.75 mmol). After 24 h, purification by column 
chromatography (n-hexane/EtOAc 7:1) yielded 151w (127 mg, 84%) as a 
viscous colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.47 (ddd, J = 2.4, 0.8, 0.8 Hz, 1H), 7.26 (ddd, J = 8.0, 2.4, 0.8 Hz, 
1H), 7.23 (d, J = 7.8 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 6.96 (d, J = 8.8 Hz, 2H), 6.77 (dd, J = 8.0, 0.8 Hz, 
1H), 6.67 (d, J = 8.8 Hz, 2H), 3.73 (s, 3H), 2.35 (s, 3H), 2.30 (s, 3H), 2.03 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 157.8 (Cq), 157.3 (Cq), 149.1 (CH), 139.4 (Cq), 138.7 (Cq), 136.3 (CH), 
135.9 (Cq), 135.1 (Cq), 134.6 (Cq), 130.6 (CH), 130.3 (Cq), 129.4 (CH), 127.1 (CH), 125.1 (CH), 113.0 
(CH), 55.1 (CH3), 20.4 (CH3), 18.2 (CH3), 16.9 (CH3). 
IR (ATR): ṽ = 2924, 1609, 1514, 1465, 1242, 1176, 1030, 816, 574 cm−1.  
MS (EI) m/z (relative intensity): 303 (63) [M]+, 302 (100) [M–H]+, 288 (26) [M–Me]+, 258 (13), 244 
(9). 
HR-MS (ESI): m/z calcd for C21H22NO+ [M+H]+ 304.1696, found 304.1698. 
 
2-(4'-Methoxy-3-methyl-[1,1'-biphenyl]-2-yl)pyrimidine (151x) 
The general procedure N was followed using 2-(o-tolyl)pyrimidine (139d, 
85.1 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (46a, 176 mg, 
0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 5:1) yielded 151x (132 mg, 96%) as a white solid. 
1H-NMR (500 MHz, CDCl3): δ = 8.68 (d, J = 4.9 Hz, 2H), 7.36 (dd, J = 7.6, 7.6 Hz, 1H), 7.28–7.24 (m, 
2H), 7.09 (t, J = 4.9 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 6.69 (d, J = 8.7 Hz, 2H), 3.74 (s, 3H), 2.19 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 168.4 (Cq), 158.0 (Cq), 156.6 (CH), 140.5 (Cq), 138.2 (Cq), 135.9 (Cq), 
134.0 (Cq), 130.1 (CH), 129.0 (CH), 128.5 (CH), 127.6 (CH), 118.4 (CH), 113.2 (CH), 55.1 (CH3), 20.0 
(CH3). 
IR (ATR): ṽ = 2936, 1607, 1556, 1510, 1460, 1236, 1184, 1023, 848, 790 cm−1.  
m.p.: 109–110 °C. 
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MS (EI) m/z (relative intensity): 276 (100) [M]+, 275 (80) [M–H]+, 261 (41) [M–Me]+, 232 (22), 168 
(18). 
HR-MS (ESI): m/z calcd for C18H17N2O+ [M+H]+ 277.1335, found 277.1337. 
 
2-(3-Ethoxy-4'-methoxy-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (151y) 
The general procedure N was followed using 2-(2-ethoxyphenyl)-4,5-
dihydrooxazole (139k, 95.7 mg, 0.50 mmol) and 1-iodo-4-
methoxybenzene (46a, 176 mg, 0.75 mmol). After 24 h, purification by 
column chromatography (n-hexane/EtOAc 1:1) yielded 151y (112 mg, 
75%) as a white solid. 
1H-NMR (500 MHz, CDCl3): δ = 7.37 (d, J = 8.9 Hz, 2H), 7.37–7.34 (m, 1H), 6.96 (dd, J = 7.7, 0.9 Hz, 
1H), 6.89–6.86 (m, 1H), 6.90 (d, J = 8.9 Hz, 2H), 4.22 (t, J = 9.4 Hz, 2H), 4.10 (q, J = 7.0 Hz, 2H), 3.85 
(t, J = 9.4 Hz, 2H), 3.83 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 162.8 (Cq), 158.9 (Cq), 157.5 (Cq), 142.9 (Cq), 133.0 (Cq), 130.5 (CH), 
129.5 (CH), 121.9 (CH), 118.2 (Cq), 113.5 (CH), 110.6 (CH), 67.2 (CH2), 64.5 (CH2), 55.2 (CH3), 55.1 
(CH2), 14.7 (CH3). 
IR (ATR): ṽ = 2979, 1667, 1568, 1516, 1460, 1240, 1121, 1033, 939, 792 cm−1.  
m.p.: 88–90 °C. 
MS (ESI) m/z (relative intensity): 320 (35) [M+Na]+, 298 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C18H20NO3+ [M+H]+ 298.1438, found 298.1441. 
The spectral data are in accordance with those reported in the literature.[145] 
 
1-(3-Fluoro-4'-methoxy-[1,1'-biphenyl]-2-yl)-1H-pyrazole (151z) 
The general procedure N was followed using 1-(2-fluorophenyl)-1H-
pyrazole (147k, 81.1 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (46a, 
176 mg, 0.75 mmol). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 7:1) yielded 151z (124 mg, 93%) as a colorless oil. 
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1H-NMR (400 MHz, CDCl3): δ = 7.68 (dd, J = 1.9, 0.7 Hz, 1H), 7.44 (ddd, J = 8.2, 8.0, 5.4 Hz, 1H), 7.27 
(ddd, J = 8.0, 1.4, 1.3 Hz, 1H), 7.25 (ddd, J = 2.5, 0.7, 0.6 Hz, 1H), 7.20 (ddd, J = 9.5, 8.2, 1.4 Hz, 1H), 
7.00 (d, J = 8.9 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 6.29 (dd, J = 2.5, 1.9 Hz, 1H), 3.78 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.3 (Cq), 158.2 (d, 1JC–F = 252.0 Hz, Cq), 141.1 (Cq), 140.6 (CH), 
132.1 (CH), 129.9 (d, 3JC–F = 8.8 Hz, CH), 129.5 (d, 4JC–F = 2.5 Hz, Cq), 129.4 (CH), 126.8 (d, 2JC–F = 
12.4 Hz, Cq), 125.8 (d, 4JC–F = 3.5 Hz, CH), 114.9 (d, 2JC–F = 20.4 Hz, CH), 113.8 (CH), 106.5 (CH), 55.2 
(CH3). 
19F-NMR (376 MHz, CDCl3): δ = –122.3 (dd, J = 9.5, 5.4 Hz) 
IR (ATR): ṽ = 2837, 1608, 1515, 1467, 1242, 1180, 1095, 1023, 938, 743 cm−1.  
MS (ESI) m/z (relative intensity): 559 (5) [2M+Na]+, 291 (100) [M+Na]+, 269 (16) [M+H]+. 
HR-MS (ESI): m/z calcd for C16H13FN2ONa+ [M+Na]+ 291.0904, found 291.0906. 
 
4-Butyl-1-(3,4'-dimethoxy-[1,1'-biphenyl]-2-yl)-1H-1,2,3-triazole (151ab) 
The general procedure N was followed using 4-butyl-1-(2-
methoxyphenyl)-1H-1,2,3-triazole (139m, 116 mg, 0.50 mmol), 1-iodo-4-
methoxybenzene (46a, 352 mg, 1.50 mmol) and [Ru(OAc)2(p-cymene)] 
(181, 35.3 mg, 0.10 mmol, 20 mol %) in DMA (2.0 mL). After 24 h, 
purification by column chromatography (n-hexane/EtOAc 3:1) yielded 151ab (129 mg, 77%) as a 
white solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.48 (dd, J = 8.3, 7.8 Hz, 1H), 7.07 (dd, J = 7.8, 1.2 Hz, 1H), 7.03 (t, J 
= 0.7 Hz, 1H), 7.02 (dd, J = 8.3, 1.2 Hz, 1H), 6.99 (d, J = 8.8 Hz, 2H), 6.73 (d, J = 8.8 Hz, 2H), 3.80 (s, 
3H), 3.74 (s, 3H), 2.67 (t, J = 7.5 Hz, 2H), 1.60–1.51 (m, 2H), 1.28–1.17 (m, 2H), 0.86 (t, J = 7.3 Hz, 
3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.1 (Cq), 155.2 (Cq), 147.4 (Cq), 140.7 (Cq), 130.7 (CH), 129.7 (Cq), 
129.4 (CH), 124.5 (Cq), 123.7 (CH), 122.2 (CH), 113.6 (CH), 110.5 (CH), 56.2 (CH3), 55.1 (CH3), 31.4 
(CH2), 25.1 (CH2), 21.9 (CH2), 13.8 (CH3). 
IR (ATR): ṽ = 2932, 1610, 1516, 1471, 1244, 1176, 1122, 1021, 833, 790 cm−1.  
m.p.: 60–62 °C. 
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MS (EI) m/z (relative intensity): 337 (3) [M]+, 308 (59) [M–Et]+, 294 (40) [M–Pr]+, 278 (13) [M–Pr–
Me]+, 266 (100) [M–Bu–Me]+, 251 (61) [M–Bu–OMe]+, 236 (36), 223 (25), 155 (10), 139 (12), 127 
(12). 
HR-MS (EI): m/z calcd for C20H23N3O2+ [M]+ 337.1785, found 337.1791. 
The spectral data are in accordance with those reported in the literature.[145] 
 
9-iso-Propyl-6-(4'-methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-9H-purine (151ac) 
The general procedure N was followed using purine 123o (63.1 mg, 
0.25 mmol) and 1-iodo-4-methoxybenzene (46a, 87.8 mg, 0.38 mmol). 
After 24 h, purification by column chromatography (n-hexane/EtOAc 
3:2 to 1:1) yielded 151ac (50.1 mg, 56%) as a viscous light yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.85 (s, 1H), 7.97 (s, 1H), 7.52 (ddd, J = 1.9, 0.7, 0.7 Hz, 1H), 7.40 (d, 
J = 7.8 Hz, 1H), 7.33 (ddd, J = 7.8, 1.9, 0.7 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 6.65 (d, J = 8.8 Hz, 2H), 
4.89 (hept, J = 6.8 Hz, 1H), 3.71 (s, 3H), 2.44 (s, 3H), 1.62 (d, J = 6.8 Hz, 6H). 
13C-NMR (100 MHz, CDCl3): δ = 159.4 (Cq), 158.1 (Cq), 151.8 (CH), 151.1 (Cq), 141.9 (CH), 138.5 (Cq), 
136.5 (Cq), 134.1 (Cq), 133.7 (Cq), 132.6 (Cq), 131.3 (CH), 130.5 (CH), 130.4 (CH), 130.2 (CH), 113.2 
(CH), 55.1 (CH3), 47.2 (CH), 22.4 (CH3), 21.0 (CH3). 
IR (ATR): ṽ = 2977, 1576, 1494, 1329, 1242, 1177, 1037, 820, 734, 648 cm−1.  
MS (ESI) m/z (relative intensity): 739 (38) [2M+Na]+, 717 (5) [2M+H]+, 381 (24) [M+Na]+, 359 (100) 
[M+H]+. 
HR-MS (ESI): m/z calcd for C22H23N4O+ [M+H]+ 359.1866, found 359.1868. 
 
9-iso-Propyl-6-(4'-methoxy-[1,1'-biphenyl]-2-yl)-9H-purine (151ad) 
The general procedure N was followed using purine 123a (59.6 mg, 
0.25 mmol) and 1-iodo-4-methoxybenzene (46a, 87.8 mg, 0.38 mmol) 
in DMA (1.0 mL). After 24 h, purification by column chromatography 
(n-hexane/EtOAc 3:2) yielded monoarylated product 151ad (20.5 mg, 
24%) as a viscous yellow oil and diarylated product 151ad’ (65.0 mg, 58%) as a viscous colorless 
oil. 
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1H-NMR (400 MHz, CDCl3): δ = 8.84 (s, 1H), 7.99 (s, 1H), 7.76–7.73 (m, 1H), 7.55–7.43 (m, 3H), 7.08 
(d, J = 8.8 Hz, 2H), 6.67 (d, J = 8.8 Hz, 2H), 4.90 (hept, J = 6.8 Hz, 1H), 3.72 (s, 3H), 1.63 (d, J = 6.8 Hz, 
6H). 
13C-NMR (100 MHz, CDCl3): δ = 159.1 (Cq), 158.3 (Cq), 151.8 (CH), 151.2 (Cq), 142.0 (CH), 141.4 (Cq), 
134.3 (Cq), 133.8 (Cq), 132.7 (Cq), 131.0 (CH), 130.6 (CH), 130.3 (CH), 129.7 (CH), 126.9 (CH), 113.3 
(CH), 55.1 (CH3), 47.2 (CH), 22.5 (CH3). 
IR (ATR): ṽ = 2977, 1580, 1517, 1495, 1330, 1243, 1215, 1035, 833, 763 cm−1.  
MS (ESI) m/z (relative intensity): 367 (28) [M+Na]+, 345 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C21H21N4O+ [M+H]+ 345.1710, found 345.1713. 
 
6-(4,4''-Dimethoxy-[1,1':3',1''-terphenyl]-2'-yl)-9-iso-propyl-9H-purine (151ad’) 
1H-NMR (400 MHz, CDCl3): δ = 8.71 (s, 1H), 7.84 (s, 1H), 7.54 
(dd, J = 8.3, 7.3 Hz, 1H), 7.42 (d, J = 7.3 Hz, 1H), 7.42 (d, J = 
8.3 Hz, 1H), 7.03 (d, J = 8.8 Hz, 4H), 6.57 (d, J = 8.8 Hz, 4H), 4.78 
(hept, J = 6.8 Hz, 1H), 3.67 (s, 6H), 1.53 (d, J = 6.8 Hz, 6H). 
13C-NMR (100 MHz, CDCl3): δ = 159.4 (Cq), 158.1 (Cq), 151.2 (CH), 150.4 (Cq), 141.7 (CH), 141.6 (Cq), 
134.1 (Cq), 133.7 (Cq), 133.4 (Cq), 130.2 (CH), 129.0 (CH), 129.0 (CH), 112.9 (CH), 55.1 (CH3), 47.0 
(CH), 22.3 (CH3). 
IR (ATR): ṽ = 2977, 1609, 1592, 1513, 1455, 1330, 1244, 1176, 1031, 803 cm−1.  
MS (ESI) m/z (relative intensity): 923 (58) [2M+Na]+, 901 (9) [2M+H]+, 473 (60) [M+Na]+, 451 (100) 
[M+H]+. 










tetrahydrofuran-2-yl}-6-(4'-methoxy-[1,1'-biphenyl]-2-yl)-9H-purine (151ae)  
The general procedure N was followed using purine 123m 
(135 mg, 0.25 mmol) and 1-iodo-4-methoxybenzene (46a, 
87.8 mg, 0.38 mmol) in DMA (1.0 mL). After 24 h, 
purification by column chromatography (n-hexane/EtOAc 
5:1) yielded monoarylated product 151ae (24.4 mg, 15%) as 
a viscous colorless oil and diarylated product 151ae’ (109 mg, 58%) as a viscous colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.83 (s, 1H), 8.22 (s, 1H), 7.73 (ddd, J = 7.5, 1.1, 1.1 Hz, 1H), 7.55–
7.49 (m, 2H), 7.46 (ddd, J = 7.5, 5.8, 2.9 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.68 (d, J = 8.8 Hz, 2H), 
6.51 (dd, J = 7.2, 6.0 Hz, 1H), 4.63 (ddd, J = 5.9, 3.3, 3.2 Hz, 1H), 4.03 (ddd, J = 4.3, 3.3, 3.2 Hz, 1H), 
3.85 (dABd, J = 11.2, 4.3 Hz, 1H), 3.77 (dABd, J = 11.2, 3.3 Hz, 1H), 3.73 (s, 3H), 2.68 (ddd, J = 13.1, 
7.2, 5.9 Hz, 1H), 2.44 (ddd, J = 13.1, 6.0, 3.3 Hz, 1H), 0.92 (s, 9H), 0.89 (s, 9H), 0.11 (s, 6H), 0.06 (s, 
3H), 0.05 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.3 (Cq), 158.3 (Cq), 152.1 (CH), 151.1 (Cq), 142.8 (CH), 141.4 (Cq), 
134.2 (Cq), 133.7 (Cq), 132.8 (Cq), 131.0 (CH), 130.7 (CH), 130.3 (CH), 129.7 (CH), 126.9 (CH), 113.3 
(CH), 88.0 (CH), 84.3 (CH), 72.1 (CH), 62.9 (CH2), 55.1 (CH3), 41.0 (CH2), 25.9 (CH3), 25.8 (CH3), 18.4 
(Cq), 18.0 (Cq), –4.7 (CH3), –4.8 (CH3), –5.4 (CH3), –5.5 (CH3). 
IR (ATR): ṽ = 2929, 2857, 1581, 1252, 1109, 1032, 834, 778 cm−1.  
MS (ESI) m/z (relative intensity): 669 (84) [M+Na]+, 647 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C35H51N4O4Si2+ [M+H]+ 647.3443, found 647.3447. 




1H-NMR (400 MHz, CDCl3): δ = 8.71 (s, 1H), 8.07 (s, 1H), 7.53 
(dd, J = 7.8, 7.6 Hz, 1H), 7.42 (dd, J = 7.8, 1.3 Hz, 1H), 7.40 (dd, 
J = 7.6, 1.3 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 8.8 Hz, 
2H), 6.59 (d, J = 8.8 Hz, 2H), 6.57 (d, J = 8.8 Hz, 2H), 6.40 (dd, 
J = 7.4, 6.0 Hz, 1H), 4.54 (ddd, J = 5.7, 3.1, 3.1 Hz, 1H), 4.00 
(ddd, J = 4.1, 3.3, 3.1 Hz, 1H), 3.81 (dABd, J = 11.2, 4.1 Hz, 1H), 3.74 (dABd, J = 11.2, 3.3 Hz, 1H), 3.68 
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(s, 3H), 3.67 (s, 3H), 2.49 (ddd, J = 13.1, 7.4, 5.7 Hz, 1H), 2.37 (ddd, J = 13.1, 6.0, 3.1 Hz, 1H), 0.91 
(s, 9H), 0.89 (s, 9H), 0.10 (s, 6H), 0.05 (s, 3H), 0.04 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.4 (Cq), 158.1 (Cq), 158.1 (Cq), 151.5 (CH), 150.3 (Cq), 142.4 (CH), 
141.7 (Cq), 141.7 (Cq), 134.1 (Cq), 133.7 (Cq), 133.6 (Cq), 133.2 (Cq), 130.2 (CH), 130.1 (CH), 129.2 
(CH), 129.1 (CH), 129.0 (CH), 113.0 (CH), 112.9 (CH), 88.0 (CH), 84.1 (CH), 72.2 (CH), 62.9 (CH2), 
55.0 (CH3), 41.2 (CH2), 25.9 (CH3), 25.7 (CH3), 18.4 (Cq), 18.0 (Cq), –4.7 (CH3), –4.9 (CH3), –5.4 (CH3), 
–5.6 (CH3). 
IR (ATR): ṽ = 2929, 2857, 1610, 1579, 1513, 1245, 1113, 1031, 830, 777 cm−1.  
MS (ESI) m/z (relative intensity): 775 (100) [M+Na]+, 753 (49) [M+H]+. 
HR-MS (ESI): m/z calcd for C42H56N4O5Si2Na+ [M+Na]+ 775.3681, found 775.3679. 
The spectral data are in accordance with those reported in the literature.[109] 
 
Diethyl {{(3aR,4R,6R,6aR)-6-[6-(4'-methoxy-[1,1'-biphenyl]-2-yl)-9H-purin-9-yl]-2,2-dimethyl 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl}methyl} phosphate (151af) 
The general procedure N was followed using purine 123l 
(126 mg, 0.25 mmol) and 1-iodo-4-methoxybenzene (46a, 
87.8 mg, 0.38 mmol) in DMA (1.0 mL). After 24 h, 
purification by column chromatography (n-hexane/EtOAc 
3:7) yielded monoarylated product 151af (26.7 mg, 17%) 
as a viscous light yellow oil and diarylated product 151af’ 
(107 mg, 60%) as a viscous colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.86 (s, 1H), 8.09 (s, 1H), 7.72 (ddd, J = 7.5, 0.9, 0.9 Hz, 1H), 7.56–
7.50 (m, 2H), 7.47 (ddd, J = 7.5, 6.3, 2.4 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.69 (d, J = 8.8 Hz, 2H), 
6.18 (d, J = 2.7 Hz, 1H), 5.39 (dd, J = 6.3, 2.7 Hz, 1H), 5.09 (dd, J = 6.3, 3.2 Hz, 1H), 4.49 (dddd, J = 
4.9, 4.6, 3.2, 1.1 Hz, 1H), 4.27 (ddd, J = 11.1, 6.4, 4.6 Hz, 1H), 4.20 (ddd, J = 11.1, 7.0, 4.9 Hz, 1H), 
4.12–4.00 (m, 4H), 3.74 (s, 3H), 1.64 (s, 3H), 1.40 (s, 3H), 1.28 (td, J = 7.1, 1.0 Hz, 3H), 1.24 (td, J = 
7.1, 1.0 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.7 (Cq), 158.4 (Cq), 152.4 (CH), 150.8 (Cq), 143.2 (CH), 141.5 (Cq), 
133.9 (Cq), 133.6 (Cq), 132.8 (Cq), 131.0 (CH), 130.8 (CH), 130.2 (CH), 129.9 (CH), 126.9 (CH), 114.8 
(Cq), 113.4 (CH), 90.7 (CH), 84.9 (d, 3JC–P = 8 Hz, CH), 84.0 (CH), 81.2 (CH), 66.5 (d, 2JC–P = 6 Hz, CH2), 
5.3 Experimental Procedures and Analytical Data 
 
441 
64.1 (d, 2JC–P = 6 Hz, CH2), 64.1 (d, 2JC–P = 6 Hz, CH2), 55.1 (CH3), 27.2 (CH3), 25.3 (CH3), 16.1 (d, 3JC–P 
= 7 Hz, CH3). 
31P{1H}-NMR (162 MHz, CDCl3): δ = –1.0 (s). 
IR (ATR): ṽ = 2984, 1582, 1517, 1244, 1208, 1019, 834, 763, 728 cm−1.  
MS (ESI) m/z (relative intensity): 1243 (11) [2M+Na]+, 1221 (35) [2M+H]+, 633 (25) [M+Na]+, 611 
(100) [M+H]+. 
HR-MS (ESI): m/z calcd for C30H36N4O8P+ [M+H]+ 611.2265, found 611.2266. 
 
{(3aR,4R,6R,6aR)-6-[6-(4,4''-Dimethoxy-[1,1':3',1''-terphenyl]-2'-yl)-9H-purin-9-yl]-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl}methyl diethyl phosphate (151af’) 
1H-NMR (400 MHz, CDCl3): δ = 8.73 (s, 1H), 7.94 (s, 1H), 
7.53 (dd, J = 7.9, 7.4 Hz, 1H), 7.42 (dd, J = 7.9, 1.3 Hz, 1H), 
7.41 (dd, J = 7.4, 1.3 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 7.01 
(d, J = 8.8 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H), 6.58 (d, J = 8.8 Hz, 
2H), 6.07 (d, J = 2.7 Hz, 1H), 5.22 (dd, J = 6.3, 2.7 Hz, 1H), 
5.04 (dd, J = 6.3, 3.2 Hz, 1H), 4.43 (dddd, J = 4.9, 4.8, 3.2, 
1.0 Hz, 1H), 4.19 (ddd, J = 11.4, 6.7, 4.9 Hz, 1H), 4.14–4.01 (m, 5H), 3.68 (s, 6H), 1.61 (s, 3H), 1.37 
(s, 3H), 1.27 (td, J = 7.1, 1.0 Hz, 3H), 1.25 (td, J = 7.1, 1.0 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 159.9 (Cq), 158.2 (Cq), 158.1 (Cq), 151.7 (CH), 150.0 (Cq), 143.0 (CH), 
141.7 (Cq), 141.6 (Cq), 134.1 (Cq), 133.5 (Cq), 133.4 (Cq), 132.9 (Cq), 130.1 (CH), 130.1 (CH), 129.1 
(CH), 129.1 (CH), 114.7 (Cq), 113.0 (CH), 112.9 (CH), 90.5 (CH), 84.7 (d, 3JC–P = 8 Hz, CH), 83.9 (CH), 
81.1 (CH), 66.3 (d, 2JC–P = 6 Hz, CH2), 64.1 (d, 2JC–P = 6 Hz, CH2), 55.0 (CH3), 27.1 (CH3), 25.3 (CH3), 
16.0 (d, 3JC–P = 6 Hz, CH3). 
31P{1H}-NMR (162 MHz, CDCl3): δ = –1.0 (s). 
IR (ATR): ṽ = 2985, 1580, 1514, 1245, 1024, 835, 803, 732 cm−1.  
MS (ESI) m/z (relative intensity): 739 (100) [M+Na]+, 717 (19) [M+H]+. 
HR-MS (ESI): m/z calcd for C37H41N4O9PNa+ [M+Na]+ 739.2503, found 739.2501. 
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5.3.7.2 Photo-Induced Ruthenium-Catalyzed C–H Arylation of Ketimine 135z 
1-(3,4'-Dimethoxy-[1,1'-biphenyl]-2-yl)ethan-1-one (217) 
Ketimine 135z (158 mg, 0.50 mmol), [Ru(OAc)2(p-cymene)] (181, 
17.7 mg, 50.0 μmol, 10 mol %) and K2CO3 (138 mg, 1.00 mmol) were 
placed in a 10 mL vial. The vial was capped with a septum and wrapped 
with parafilm. The vial was evacuated and purged with N2 three times. 1-Iodo-4-methoxybenzene 
(46a, 176 mg, 0.75 mmol) and 1,4-dioxane (2.0 mL) were then added and the mixture was stirred 
under visible light irradiation (2 × Kessil A360N, temperature was maintained between 30 °C and 
35 °C) for 24 h. At ambient temperature, HCl (2 N, 3.0 mL) was added, and the resulting mixture 
was stirred for an additional 3 h, and then extracted with EtOAc (3 × 20 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification of the residue by column 
chromatography (SiO2, n-hexane/EtOAc 7:1) yielded ortho-arylated product 217 (58.4 mg, 46%) as 
a light yellow solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.36 (dd, J = 8.4, 7.7 Hz, 1H), 7.27 (d, J = 8.8 Hz, 2H), 6.95 (dd, J = 
7.7, 0.9 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 6.91 (dd, J = 8.4, 0.9 Hz, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 2.14 
(s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 205.2 (Cq), 159.2 (Cq), 155.5 (Cq), 139.6 (Cq), 132.0 (Cq), 131.1 (Cq), 
130.0 (CH), 129.8 (CH), 122.2 (CH), 113.9 (CH), 109.5 (CH), 55.9 (CH3), 55.2 (CH3), 32.4 (CH3). 
IR (ATR): ṽ = 2938, 1687, 1566, 1514, 1462, 1247, 1176, 1020, 834, 795 cm−1.  
m.p.: 127–129 °C. 
MS (ESI) m/z (relative intensity): 535 (13) [2M+Na]+, 404 (27), 279 (100) [M+Na]+, 257 (11) [M+H]+, 
148 (31). 
HR-MS (ESI): m/z calcd for C16H16O3Na+ [M+Na]+ 279.0992, found 279.0994. 
The spectral data are in accordance with those reported in the literature.[146] 
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5.3.7.3 Photo-Induced C–H Arylation by Ruthenacycle 218 
 
2-(o-Tolyl)pyridine (68e, 84.6 mg, 0.50 mmol), ruthenacycle 218 (28.9 mg, 50.0 μmol, 10 mol %), 
KOAc (9.8 mg, 0.10 mmol, 20 mol %) and K2CO3 (138 mg, 1.00 mmol) were placed in a 10 mL vial. 
The vial was capped with a septum and wrapped with parafilm. The vial was evacuated and purged 
with N2 three times. 1-Iodo-4-methoxybenzene (46a, 176 mg, 0.75 mmol) and 1,4-dioxane 
(2.0 mL) were then added and the mixture was stirred under visible light irradiation (2 × Kessil 
A360N, temperature was maintained between 30 °C and 35 °C). After 24 h, the resulting mixture 
was filtered through a pad of silica gel and washed with EtOAc. The filtrate was concentrated in 
vacuo. Purification of the residue by column chromatography (SiO2, n-hexane/EtOAc 7:1) yielded 
ortho-arylated product 151a (145 mg, 96%) as a viscous colorless oil. 
In case of the reaction without KOAc, the reaction provided the arylated product 151a (32.3 mg, 
21%) as a viscous colorless oil. 
 
5.3.7.4 X-Ray Crystallographic Analysis 
A suitable crystal was selected and the crystal was mounted on a MITIGEN holder in NVH oil on a 
Bruker D8 Venture diffractometer. The crystal was kept at 100 or 150 K during data collection. 
Using Olex2,[137] the structure was solved with the XT[138] structure solution program using Intrinsic 
Phasing and refined with the XL[139] refinement package using Least Squares minimisation. 
 




Figure 63: Molecular structure of 151o with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C20H16N2 (M = 284.35 g/mol): orthorhombic, space group Pca21 (no. 29), a = 
15.2112(6) Å, b = 8.9415(4) Å, c = 22.0568(12) Å, V = 3000.0(2) Å3, Z = 8, T = 150.04 K, μ(MoKα) = 
0.074 mm-1, Dcalc = 1.259 g/cm3, 48106 reflections measured (4.556° ≤ 2Θ ≤ 57.456°), 7738 
unique (Rint = 0.0299, Rsigma = 0.0205) which were used in all calculations. The final R1 was 0.0434 
(I > 2σ(I)) and wR2 was 0.1161 (all data). 
 
Table 107: Crystal data and structure refinement for 151o. 
Compound 151o 
CCDC number 1968604 
Identification code 0764_CG_Pca21 
Empirical formula C20H16N2 
Formula weight 284.35 
Temperature/K 150.04 
Crystal system orthorhombic 















Crystal size/mm3 0.418 × 0.311 × 0.126 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.556 to 57.456 
Index ranges -20 ≤ h ≤ 19, -12 ≤ k ≤ 12, -29 ≤ l ≤ 29 
Reflections collected 48106 
Independent reflections 7738 [Rint = 0.0299, Rsigma = 0.0205] 
Data/restraints/parameters 7738/1/405 
Goodness-of-fit on F2 1.063 
Final R indexes [I>=2σ (I)] R1 = 0.0434, wR2 = 0.1138 
Final R indexes [all data] R1 = 0.0460, wR2 = 0.1161 
Largest diff. peak/hole / e Å-3 0.30/-0.27 
Flack parameter -0.1(6) 
 
Table 108: Bond lengths [Å] for 151o. 
Atom Atom Length/Å Atom Atom Length/Å 
N1 C1 1.375(3) C7 C8 1.497(3) 
N1 C20 1.378(3) C7 C13 1.413(3) 
N2 C8 1.346(3) C8 C9 1.388(3) 
N2 C12 1.345(3) C9 C10 1.385(3) 
C1 C2 1.360(3) C10 C11 1.385(3) 
C2 C3 1.437(3) C11 C12 1.383(4) 
C3 C4 1.401(3) C13 C14 1.389(3) 
C3 C20 1.418(3) C13 C17 1.512(3) 
C4 C5 1.391(3) C14 C15 1.385(4) 
C5 C6 1.490(3) C15 C16 1.386(4) 
C5 C18 1.415(3) C18 C19 1.389(3) 
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Atom Atom Length/Å Atom Atom Length/Å 
C6 C7 1.408(3) C19 C20 1.395(3) 
C6 C16 1.393(3)    
 
Table 109: Bond angles [°] for 151o. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 N1 C20 108.50(19) N2 C8 C9 122.3(2) 
C12 N2 C8 117.4(2) C9 C8 C7 119.9(2) 
C2 C1 N1 110.4(2) C10 C9 C8 119.4(2) 
C1 C2 C3 106.9(2) C11 C10 C9 118.7(2) 
C4 C3 C2 134.3(2) C12 C11 C10 118.4(2) 
C4 C3 C20 119.2(2) N2 C12 C11 123.7(2) 
C20 C3 C2 106.47(19) C7 C13 C17 122.4(2) 
C5 C4 C3 119.8(2) C14 C13 C7 118.8(2) 
C4 C5 C6 120.93(19) C14 C13 C17 118.8(2) 
C4 C5 C18 119.6(2) C15 C14 C13 121.2(2) 
C18 C5 C6 119.4(2) C14 C15 C16 119.9(2) 
C7 C6 C5 122.82(19) C15 C16 C6 120.8(2) 
C16 C6 C5 118.1(2) C19 C18 C5 121.8(2) 
C16 C6 C7 119.0(2) C18 C19 C20 117.8(2) 
C6 C7 C8 120.4(2) N1 C20 C3 107.7(2) 
C6 C7 C13 120.2(2) N1 C20 C19 130.6(2) 
C13 C7 C8 119.3(2) C19 C20 C3 121.6(2) 
N2 C8 C7 117.79(19)     
 




Figure 64: Molecular structure of 151t with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C30H22N2 (M = 410.49 g/mol): triclinic, space group P-1 (no. 2), a = 8.0802(7) Å, b = 
9.6205(6) Å, c = 15.0324(11) Å, α = 105.143(4)°, β = 91.497(3)°, γ = 110.285(3)°, V = 
1049.19(14) Å3, Z = 2, T = 100.0 K, μ(MoKα) = 0.076 mm-1, Dcalc = 1.299 g/cm3, 54130 reflections 
measured (4.714° ≤ 2Θ ≤ 61.172°), 6426 unique (Rint = 0.0207, Rsigma = 0.0113) which were used in 
all calculations. The final R1 was 0.0412 (I > 2σ(I)) and wR2 was 0.1124 (all data). 
 
Table 110: Crystal data and structure refinement for 151t. 
Compound 151t 
CCDC number 1968602 
Identification code 0773_CG_0m 
Empirical formula C30H22N2 
Formula weight 410.49 
Temperature/K 100.0 
Crystal system triclinic 















Crystal size/mm3 0.497 × 0.38 × 0.311 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.714 to 61.172 
Index ranges -11 ≤ h ≤ 11, -11 ≤ k ≤ 13, -21 ≤ l ≤ 21 
Reflections collected 54130 
Independent reflections 6426 [Rint = 0.0207, Rsigma = 0.0113] 
Data/restraints/parameters 6426/0/290 
Goodness-of-fit on F2 1.032 
Final R indexes [I>=2σ (I)] R1 = 0.0412, wR2 = 0.1107 
Final R indexes [all data] R1 = 0.0430, wR2 = 0.1124 
Largest diff. peak/hole / e Å-3 0.41/-0.24 
 
Table 111: Bond lengths [Å] for 151t. 
Atom Atom Length/Å Atom Atom Length/Å 
N1 C1 1.3952(11) C13 C30 1.3980(11) 
N1 C4 1.3969(11) C14 C15 1.3918(11) 
N1 C13 1.4143(10) C15 C16 1.3968(12) 
N2 C19 1.3440(11) C16 C17 1.4865(11) 
N2 C23 1.3421(12) C16 C29 1.4001(11) 
C1 C2 1.4092(11) C17 C18 1.4072(12) 
C1 C12 1.3929(12) C17 C27 1.3976(12) 
C2 C3 1.4433(12) C18 C19 1.4947(12) 
C2 C9 1.3959(12) C18 C24 1.4059(11) 
C3 C4 1.4105(12) C19 C20 1.3966(12) 
C3 C8 1.3980(12) C20 C21 1.3872(13) 
C4 C5 1.3935(12) C21 C22 1.3873(14) 
C5 C6 1.3889(12) C22 C23 1.3854(13) 
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Atom Atom Length/Å Atom Atom Length/Å 
C6 C7 1.4010(14) C24 C25 1.3961(13) 
C7 C8 1.3858(14) C24 C28 1.5068(13) 
C9 C10 1.3871(13) C25 C26 1.3888(14) 
C10 C11 1.4043(13) C26 C27 1.3890(12) 
C11 C12 1.3905(12) C29 C30 1.3890(11) 
C13 C14 1.3941(11)    
 
Table 112: Bond angles [°] for 151t. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 N1 C4 108.37(7) C15 C14 C13 119.96(8) 
C1 N1 C13 126.14(7) C14 C15 C16 120.94(8) 
C4 N1 C13 125.09(7) C15 C16 C17 120.58(7) 
C23 N2 C19 117.42(8) C15 C16 C29 118.55(8) 
N1 C1 C2 108.97(7) C29 C16 C17 120.87(7) 
C12 C1 N1 129.22(8) C18 C17 C16 120.52(7) 
C12 C1 C2 121.80(8) C27 C17 C16 119.72(8) 
C1 C2 C3 106.89(7) C27 C17 C18 119.75(8) 
C9 C2 C1 119.55(8) C17 C18 C19 119.00(7) 
C9 C2 C3 133.55(8) C24 C18 C17 120.19(8) 
C4 C3 C2 106.96(7) C24 C18 C19 120.80(8) 
C8 C3 C2 133.46(8) N2 C19 C18 117.08(7) 
C8 C3 C4 119.55(8) N2 C19 C20 122.34(8) 
N1 C4 C3 108.81(7) C20 C19 C18 120.53(8) 
C5 C4 N1 129.16(8) C21 C20 C19 119.21(8) 
C5 C4 C3 121.96(8) C20 C21 C22 118.80(9) 
C6 C5 C4 117.38(9) C23 C22 C21 118.15(8) 
C5 C6 C7 121.36(9) N2 C23 C22 124.05(9) 
C8 C7 C6 121.02(8) C18 C24 C28 121.08(8) 
C7 C8 C3 118.70(9) C25 C24 C18 118.70(8) 
C10 C9 C2 119.16(8) C25 C24 C28 120.23(8) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C9 C10 C11 120.49(8) C26 C25 C24 121.27(8) 
C12 C11 C10 121.37(9) C25 C26 C27 119.98(8) 
C11 C12 C1 117.59(8) C26 C27 C17 120.10(9) 
C14 C13 N1 119.99(7) C30 C29 C16 120.87(8) 
C14 C13 C30 119.64(7) C29 C30 C13 120.00(7) 
C30 C13 N1 120.36(7)     
 
 
Figure 65: Molecular structure of 216b with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity.  
 
Crystal Data for C37Cl2H29N3 (M = 586.53 g/mol): monoclinic, space group P21/n (no. 14), a = 
8.3699(11) Å, b = 13.291(3) Å, c = 27.082(3) Å, β = 90.799(7)°, V = 3012.4(8) Å3, Z = 4, T = 100.0 K, 
μ(MoKα) = 0.247 mm-1, Dcalc = 1.293 g/cm3, 99832 reflections measured (5.074° ≤ 2Θ ≤ 59.19°), 
8420 unique (Rint = 0.0300, Rsigma = 0.0153) which were used in all calculations. The final R1 was 
0.0438 (I > 2σ(I)) and wR2 was 0.1151 (all data). 
 
Table 113: Crystal data and structure refinement for 216b. 
Compound 216b 
CCDC number 1968605 
Identification code mo_0856_CG_0m 
Empirical formula C37Cl2H29N3 
Formula weight 586.53 
Temperature/K 100.0 
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Crystal system monoclinic 












Crystal size/mm3 0.401 × 0.105 × 0.068 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.074 to 59.19 
Index ranges -11 ≤ h ≤ 11, -18 ≤ k ≤ 18, -36 ≤ l ≤ 37 
Reflections collected 99832 
Independent reflections 8420 [Rint = 0.0300, Rsigma = 0.0153] 
Data/restraints/parameters 8420/0/359 
Goodness-of-fit on F2 1.029 
Final R indexes [I>=2σ (I)] R1 = 0.0438, wR2 = 0.1092 
Final R indexes [all data] R1 = 0.0518, wR2 = 0.1151 
Largest diff. peak/hole / e Å-3 0.38/-0.25 
 
Table 114: Bond lengths [Å] for 216b. 
Atom Atom Length/Å Atom Atom Length/Å 
N1 C1 1.3865(13) C12 C13 1.3809(19) 
N1 C4 1.3839(13) C13 C14 1.3822(18) 
N2 C25 1.3426(14) C15 C16 1.3906(18) 
N2 C29 1.3387(16) C15 C19 1.5081(18) 
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Atom Atom Length/Å Atom Atom Length/Å 
N3 C10 1.3413(14) C16 C17 1.384(2) 
N3 C14 1.3428(15) C17 C18 1.3877(17) 
C1 C2 1.4178(14) C21 C22 1.3926(14) 
C1 C36 1.3938(14) C22 C23 1.4926(14) 
C2 C3 1.4449(14) C22 C35 1.4057(15) 
C2 C21 1.3957(14) C23 C24 1.4034(15) 
C3 C4 1.4143(14) C23 C33 1.4011(15) 
C3 C20 1.3951(14) C24 C25 1.4917(15) 
C4 C5 1.3957(14) C24 C30 1.4077(15) 
C5 C6 1.3846(15) C25 C26 1.3925(15) 
C6 C7 1.4097(15) C26 C27 1.3807(18) 
C7 C8 1.4920(14) C27 C28 1.3798(19) 
C7 C20 1.3905(14) C28 C29 1.3806(18) 
C8 C9 1.3988(15) C30 C31 1.3941(17) 
C8 C18 1.3991(15) C30 C34 1.5071(17) 
C9 C10 1.4915(15) C31 C32 1.3862(18) 
C9 C15 1.4054(15) C32 C33 1.3891(16) 
C10 C11 1.3911(15) C35 C36 1.3869(15) 
C11 C12 1.3866(17)    
 
Table 115: Bond angles [°] for 216b. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C4 N1 C1 108.68(9) C9 C15 C19 120.39(11) 
C29 N2 C25 117.28(10) C16 C15 C9 118.64(11) 
C10 N3 C14 117.44(10) C16 C15 C19 120.96(11) 
N1 C1 C2 108.94(9) C17 C16 C15 121.01(11) 
N1 C1 C36 130.21(10) C16 C17 C18 120.15(11) 
C36 C1 C2 120.81(9) C17 C18 C8 120.33(11) 
C1 C2 C3 106.60(9) C7 C20 C3 119.18(9) 
C21 C2 C1 120.12(9) C22 C21 C2 119.33(9) 
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Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C21 C2 C3 133.17(9) C21 C22 C23 119.78(9) 
C4 C3 C2 106.47(9) C21 C22 C35 119.56(9) 
C20 C3 C2 133.42(9) C35 C22 C23 120.52(9) 
C20 C3 C4 120.10(9) C24 C23 C22 121.73(9) 
N1 C4 C3 109.26(9) C33 C23 C22 118.57(10) 
N1 C4 C5 129.60(10) C33 C23 C24 119.63(10) 
C5 C4 C3 121.13(9) C23 C24 C25 119.84(9) 
C6 C5 C4 117.72(9) C23 C24 C30 120.11(10) 
C5 C6 C7 122.07(9) C30 C24 C25 120.05(10) 
C6 C7 C8 119.67(9) N2 C25 C24 116.84(9) 
C20 C7 C6 119.78(9) N2 C25 C26 122.47(10) 
C20 C7 C8 120.51(9) C26 C25 C24 120.69(10) 
C9 C8 C7 121.29(9) C27 C26 C25 119.06(11) 
C9 C8 C18 118.98(10) C28 C27 C26 118.89(11) 
C18 C8 C7 119.72(10) C27 C28 C29 118.40(12) 
C8 C9 C10 120.19(9) N2 C29 C28 123.87(12) 
C8 C9 C15 120.85(10) C24 C30 C34 121.00(11) 
C15 C9 C10 118.97(10) C31 C30 C24 118.94(11) 
N3 C10 C9 115.86(9) C31 C30 C34 120.05(11) 
N3 C10 C11 122.62(10) C32 C31 C30 121.13(11) 
C11 C10 C9 121.50(10) C31 C32 C33 120.04(11) 
C12 C11 C10 118.82(11) C32 C33 C23 120.13(11) 
C13 C12 C11 119.07(11) C36 C35 C22 122.20(10) 
C12 C13 C14 118.31(11) C35 C36 C1 117.93(9) 
N3 C14 C13 123.70(11)     
 




Figure 66: Molecular structure of 217 with thermal ellipoids at 50% probability level. The 
hydrogen atoms are omitted for clarity. 
 
Crystal Data for C16H16O3 (M = 256.29 g/mol): monoclinic, space group P21/c (no. 14), a = 
7.9023(5) Å, b = 17.4162(12) Å, c = 10.1964(7) Å, β = 110.822(2)°, V = 1311.66(15) Å3, Z = 4, T = 
100.0 K, μ(MoKα) = 0.089 mm-1, Dcalc = 1.298 g/cm3, 26466 reflections measured (4.678° ≤ 2Θ ≤ 
57.442°), 3377 unique (Rint = 0.0225, Rsigma = 0.0127) which were used in all calculations. The final 
R1 was 0.0418 (I > 2σ(I)) and wR2 was 0.1093 (all data). 
 
Table 116: Crystal data and structure refinement for 217. 
Compound 217 
CCDC number 1979317 
Identification code mo_0859_CG_0m 
Empirical formula C16H16O3 
Formula weight 256.29 
Temperature/K 100.0 
Crystal system monoclinic 















Crystal size/mm3 0.337 × 0.214 × 0.153 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.678 to 57.442 
Index ranges -10 ≤ h ≤ 10, -23 ≤ k ≤ 23, -13 ≤ l ≤ 13 
Reflections collected 26466 
Independent reflections 3377 [Rint = 0.0225, Rsigma = 0.0127] 
Data/restraints/parameters 3377/0/175 
Goodness-of-fit on F2 1.053 
Final R indexes [I>=2σ (I)] R1 = 0.0418, wR2 = 0.1058 
Final R indexes [all data] R1 = 0.0461, wR2 = 0.1093 
Largest diff. peak/hole / e Å-3 0.96/-0.20 
 
Table 117: Bond lengths [Å] for 217. 
Atom Atom Length/Å Atom Atom Length/Å 
O1 C1 1.3673(13) C4 C7 1.4862(15) 
O1 C15 1.4269(14) C5 C6 1.3906(16) 
O2 C9 1.3657(14) C7 C8 1.4033(15) 
O2 C16 1.4313(13) C7 C12 1.4032(15) 
O3 C13 1.2140(13) C8 C9 1.4053(14) 
C1 C2 1.3973(15) C8 C13 1.5093(14) 
C1 C6 1.3900(15) C9 C10 1.3945(15) 
C2 C3 1.3841(15) C10 C11 1.3865(18) 
C3 C4 1.4034(14) C11 C12 1.3837(17) 
C4 C5 1.3947(15) C13 C14 1.5069(15) 
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Table 118: Bond angles [°] for 217. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C1 O1 C15 117.16(9) C12 C7 C8 118.91(10) 
C9 O2 C16 117.64(9) C7 C8 C9 119.60(9) 
O1 C1 C2 115.67(9) C7 C8 C13 121.25(9) 
O1 C1 C6 124.33(10) C9 C8 C13 119.09(9) 
C6 C1 C2 119.99(10) O2 C9 C8 115.57(9) 
C3 C2 C1 120.12(10) O2 C9 C10 123.48(10) 
C2 C3 C4 121.00(10) C10 C9 C8 120.91(10) 
C3 C4 C7 122.38(9) C11 C10 C9 118.81(11) 
C5 C4 C3 117.69(10) C12 C11 C10 121.22(10) 
C5 C4 C7 119.86(9) C11 C12 C7 120.52(11) 
C6 C5 C4 122.11(10) O3 C13 C8 120.05(10) 
C1 C6 C5 119.08(10) O3 C13 C14 121.23(10) 
C8 C7 C4 122.87(9) C14 C13 C8 118.72(9) 
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